PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	FARLOW, M; GRACON, SI; HERSHEY, LA; LEWIS, KW; SADOWSKY, CH; DOLANURENO, J				FARLOW, M; GRACON, SI; HERSHEY, LA; LEWIS, KW; SADOWSKY, CH; DOLANURENO, J			A CONTROLLED TRIAL OF TACRINE IN ALZHEIMERS-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SENILE DEMENTIA; DOUBLE-BLIND; TETRAHYDROAMINOACRIDINE; LECITHIN; PHYSOSTIGMINE; MULTICENTER; PREVALENCE; MEMORY; SCALE; THA	Objective.-To compare efficacy and safety of tacrine hydrochloride with placebo in patients with probable Alzheimer's disease. Design.-A 12-week, double-blind, placebo-controlled, parallel-group study. Setting.-Outpatients at 23 centers. Patients.-Men and women with probable Alzheimer's disease, at least 50 years old, mildly to moderately impaired, without other significant medical conditions. Interventions.-In the initial 6 weeks, patients received placebo, 20 mg/d of tacrine, or 40 mg/d of tacrine. In the second 6 weeks, half received the same treatment and half increased tacrine dose: those receiving placebo increased to 20 mg/d, those receiving 20 mg/d increased to 40 mg/d, and those receiving 40 mg/d increased to 80 mg/d. Primary Outcome Measures.-Alzheimer's Disease Assessment Scale (ADAS) cognitive component and clinician-rated Clinical Global impression of Change (CGIC). Results.-Four hundred sixty-eight patients entered. After 12 weeks, dose-related improvement was significant on the ADAS cognitive (P=.014), clinician-rated CGIC (P=.014), and caregiver-rated CGIC (P=.006). Comparison of 80 mg/d with placebo showed significant improvement on the ADAS cognitive (P=.015), clinician-rated CGIC (P=.016), and caregiver-rated CGIC (P=.028). Significant effects appeared as early as 6 weeks on the ADAS cognitive and caregiver-rated CGIC. Among patients receiving 80 mg/d of tacrine, 51% achieved a four-point or greater improvement of the ADAS cognitive component after 12 weeks of treatment. Reversible asymptomatic transaminase elevations greater than three times normal occurred in 25% of patients. Other treatment-related events included nausea and/or vomiting (8%), diarrhea (5%), abdominal pain (4%), dyspepsia (3%), and rash (3%). Conclusions.-These results confirm the efficacy and safety of tacrine in some patients with Alzheimer's disease. After 12 weeks, the magnitude of the treatment effect is clinically important and recognized by the physician and caregiver. Liver toxicity is reversible and easily detected by weekly alanine aminotransferase determinations.	PARKE DAVIS WARNER LAMBERT CO,CLIN RES DEPT,ANN ARBOR,MI; PARKE DAVIS WARNER LAMBERT CO,DEPT BIOSTAT,ANN ARBOR,MI; SUNY BUFFALO,VET AFFAIRS MED CTR,DEPT NEUROL,BUFFALO,NY 14260; W PALM BEACH NEUROL GRP,W PALM BEACH,FL	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; US Department of Veterans Affairs; Veterans Health Administration (VHA)	FARLOW, M (corresponding author), INDIANA UNIV,MED CTR,SCH MED,CTR ALZHEIMERS DIS & RELATED DISORDERS,EMERSON HALL,ROOM 125,INDIANAPOLIS,IN 46202, USA.		Hershey, Linda Ann/H-7934-2019	Hershey, Linda/0000-0001-5090-6634				ALLARD P, 1990, EUR NEUROL, V30, P181, DOI 10.1159/000117341; Alzheimer A., 1907, ALLGEMEINE Z PSYCHIA, V64, P146, DOI DOI 10.1002/CA.980080612; ARMSTRONG DM, 1989, NEUROSCIENCE, V31, P663, DOI 10.1016/0306-4522(89)90431-4; CHATELLIER G, 1990, BRIT MED J, V300, P495, DOI 10.1136/bmj.300.6723.495; DAVIES B, 1989, LANCET, V2, P163; DAVIES P, 1976, LANCET, V2, P1043; DAVIS KL, 1982, AM J PSYCHIAT, V139, P1421; DAVIS KL, 1987, AM J PSYCHIAT, V144, P468; DAVIS KL, IN PRESS N ENGL J ME; DEJONG R, 1989, CLIN THER, V11, P545; EAGGER SA, 1991, LANCET, V337, P989, DOI 10.1016/0140-6736(91)92656-M; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GAUTHIER S, 1990, NEW ENGL J MED, V322, P1272, DOI 10.1056/NEJM199005033221804; GIACOBINI E, 1989, ALZHEIMERS DISEASE R, P1121; KATZMAN R, 1986, NEW ENGL J MED, V314, P964, DOI 10.1056/NEJM198604103141506; KAYE WH, 1982, BIOL PSYCHIAT, V17, P275; KRAMERGINSBERG E, 1988, PSYCHOPHARMACOL BULL, V24, P458; LITTLE A, 1985, J NEUROL NEUROSUR PS, V48, P736, DOI 10.1136/jnnp.48.8.736; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MOHS RC, 1985, AM J PSYCHIAT, V142, P28; MOLLOY DW, 1991, CAN MED ASSOC J, V144, P29; PLUM F, 1979, NATURE, V279, P372, DOI 10.1038/279372a0; REISBERG B, 1982, AM J PSYCHIAT, V139, P1136; ROSEN WG, 1980, ANN NEUROL, V7, P486, DOI 10.1002/ana.410070516; ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356; SCHOENBERG BS, 1985, ARCH NEUROL-CHICAGO, V42, P740, DOI 10.1001/archneur.1985.04210090004002; SULKAVA R, 1985, NEUROLOGY, V35, P1025, DOI 10.1212/WNL.35.7.1025; SUMMERS WK, 1981, BIOL PSYCHIAT, V16, P145; SUMMERS WK, 1986, NEW ENGL J MED, V315, P1241, DOI 10.1056/NEJM198611133152001; TARIOT P, 1988, J AM GERIATR SOC, V36, P582; WALSH JS, 1990, ANN INTERN MED, V113, P429, DOI 10.7326/0003-4819-113-6-429; ZUBENKO GS, 1991, ARCH NEUROL-CHICAGO, V48, P619, DOI 10.1001/archneur.1991.00530180075020; 1976, ECDEU ASSESSMENT MAN, P218; 1989, 1989 ADV COMM M ROCK, P227	34	623	629	1	26	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1992	268	18					2523	2529		10.1001/jama.268.18.2523	http://dx.doi.org/10.1001/jama.268.18.2523			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW616	1404819				2022-12-28	WOS:A1992JW61600023
J	DAVIS, KL; THAL, LJ; GAMZU, ER; DAVIS, CS; WOOLSON, RF; GRACON, SI; DRACHMAN, DA; SCHNEIDER, LS; WHITEHOUSE, PJ; HOOVER, TM; MORRIS, JC; KAWAS, CH; KNOPMAN, DS; EARL, NL; KUMAR, V; DOODY, RS				DAVIS, KL; THAL, LJ; GAMZU, ER; DAVIS, CS; WOOLSON, RF; GRACON, SI; DRACHMAN, DA; SCHNEIDER, LS; WHITEHOUSE, PJ; HOOVER, TM; MORRIS, JC; KAWAS, CH; KNOPMAN, DS; EARL, NL; KUMAR, V; DOODY, RS			A DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY OF TACRINE FOR ALZHEIMERS-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ORAL PHYSOSTIGMINE; SENILE DEMENTIA; LECITHIN; MEMORY; TETRAHYDROAMINOACRIDINE; THA	Background. In Alzheimer's disease, there is a marked decline in the function of cholinergic neurons in the brain. However, studies of treatment with cholinesterase inhibitors have produced conflicting results. We conducted a multicenter trial to evaluate whether the cholinesterase inhibitor tacrine (1,2,3,4-tetrahydro-9-acridinamine monohydrochloride monohydrate) could improve cognition in patients with Alzheimer's disease. Methods. Of 632 eligible patients with probable Alzheimer's disease, 215 improved while receiving tacrine during a preliminary crossover phase to determine responsiveness and the best dose. The 215 patients were randomly assigned to receive either placebo or their best dose of tacrine (10 or 20 mg four times a day) in a six-week, double-blind trial. The primary measures of efficacy were the cognitive subscale of the Alzheimer's Disease Assessment Scale and the Clinical Global Impression of Change scale; the secondary measures included the Mini-Mental State Examination and the assessment of the activities of daily living. Results. At the end of the six-week trial, the patients receiving tacrine had a mean adjusted cognitive-subscale score of 30.3 (Alzheimer's Disease Assessment Scale) as compared with 32.7 in patients receiving placebo. This represents a smaller decline (by 2.4 points) in cognitive performance in the tacrine group (P<0.001). There were no differences between the groups in their global-rating scores. The tacrine group had a significantly smaller decline in the activities of daily living. The results of the Mini-Mental State Examination favored tacrine, but the differences were small and not statistically significant (a score of 16.0 with tacrine vs. 15.3 with placebo; P = 0.08). Gastrointestinal symptoms, elevation of aminotransferase levels, and headache were the most frequent side effects; all could be reversed by reducing the dose or discontinuing treatment. Conclusions. In this short-term study in patients with Alzheimer's disease who were selected for apparent responsiveness to tacrine, treatment with tacrine resulted in a statistically significant reduction in the decline of cognitive function, although this reduction was not large enough to be detected by the study physicians' global assessments of the patients.			DAVIS, KL (corresponding author), MT SINAI MED CTR, 1 GUSTAVE LEVY PL, NEW YORK, NY 10029 USA.		Morris, John C/A-1686-2012	Kawas, Claudia/0000-0001-9577-230X	NCRR NIH HHS [RR-36, M01-RR-30] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		CHATELLIER G, 1990, BRIT MED J, V300, P495, DOI 10.1136/bmj.300.6723.495; DAVIS KL, 1982, AM J PSYCHIAT, V139, P1421; DAWSON RM, 1989, NEUROSCI LETT, V100, P227, DOI 10.1016/0304-3940(89)90689-7; DEJONG R, 1989, CLIN THER, V11, P545; DRACHMAN DA, 1974, ARCH NEUROL-CHICAGO, V30, P113, DOI 10.1001/archneur.1974.00490320001001; EAGGER SA, 1991, LANCET, V337, P989, DOI 10.1016/0140-6736(91)92656-M; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GAUTHIER S, 1990, NEW ENGL J MED, V322, P1272, DOI 10.1056/NEJM199005033221804; Guy W., 1976, ASSESSMENT MANUAL PS, P218, DOI DOI 10.1186/1471-244X-7-7; KAYE WH, 1982, BIOL PSYCHIAT, V17, P275; KRAMERGINSBERG E, 1988, PSYCHOPHARMACOL BULL, V24, P458; LANDIS JR, 1978, INT STAT REV, V46, P237, DOI 10.2307/1402373; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MOHS RC, 1985, AM J PSYCHIAT, V142, P28; NIELSEN JA, 1989, EUR J PHARMACOL, V173, P53, DOI 10.1016/0014-2999(89)90008-3; RELMAN AS, 1991, NEW ENGL J MED, V324, P349, DOI 10.1056/NEJM199101313240525; ROSEN WG, 1980, ANN NEUROL, V7, P486, DOI 10.1002/ana.410070516; ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356; SIMS NR, 1983, ALZHEIMERS DISEASE, P88; SUMMERS WK, 1981, BIOL PSYCHIAT, V16, P145; SUMMERS WK, 1986, NEW ENGL J MED, V315, P1241, DOI 10.1056/NEJM198611133152001; THAL LJ, 1983, ANN NEUROL, V13, P491, DOI 10.1002/ana.410130504	23	591	599	0	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 29	1992	327	18					1253	1259		10.1056/NEJM199210293271801	http://dx.doi.org/10.1056/NEJM199210293271801			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV259	1406817	Green Published			2022-12-28	WOS:A1992JV25900001
J	GALZI, JL; DEVILLERSTHIERY, A; HUSSY, N; BERTRAND, S; CHANGEUX, JP; BERTRAND, D				GALZI, JL; DEVILLERSTHIERY, A; HUSSY, N; BERTRAND, S; CHANGEUX, JP; BERTRAND, D			MUTATIONS IN THE CHANNEL DOMAIN OF A NEURONAL NICOTINIC RECEPTOR CONVERT ION SELECTIVITY FROM CATIONIC TO ANIONIC	NATURE			English	Article							INHIBITORY GLYCINE RECEPTOR; AFFINITY BINDING-SITE; ACETYLCHOLINE-RECEPTOR; H-3 CHLORPROMAZINE; AMINO-ACIDS; NONCOMPETITIVE BLOCKERS; FUNCTIONAL EXPRESSION; DELTA-SUBUNIT; LIGAND; TRANSPORT	Introduction by site-directed mutagenesis of three amino acids from the MII segment of glycine or gamma-aminobutyric acid (GABA(A)) receptors into the MII segment of alpha7 nicotinic receptor was sufficient to convert a cation-selective channel into an anion-selective channel gated by acetylcholine. A critical mutation was the insertion of an uncharged residue at the amino-terminal end of MII, stressing the importance of protein geometrical constraints on ion selectivity.	CTR MED UNIV GENEVA,FAC MED,DEPT PHYSIOL,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva	GALZI, JL (corresponding author), INST PASTEUR,CNRS,UNITE RECH ASSOCIEE D1284,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE.							ARENA JP, 1992, J CELL BIOCH S E, V16, P226; ASCHER P, 1983, SINGLE CHANNEL RECOR, P401; BERTRAND D, 1992, P NATL ACAD SCI USA, V89, P1261, DOI 10.1073/pnas.89.4.1261; Bertrand D, 1991, METHODS NEUROSCIENCE, V4, P174; BERTRAND D, IN PRESS NEUROSCI LE; BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; BORMANN J, 1987, J PHYSIOL-LONDON, V385, P243, DOI 10.1113/jphysiol.1987.sp016493; CHARNET P, 1990, NEURON, V4, P87, DOI 10.1016/0896-6273(90)90445-L; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; CURUTCHET P, 1992, BIOCHEM BIOPH RES CO, V182, P1089, DOI 10.1016/0006-291X(92)91843-F; DEVILLERSTHIERY A, IN PRESS NEUROREPORT; FRANCIOLINI F, 1990, BIOCHIM BIOPHYS ACTA, V1031, P247, DOI 10.1016/0304-4157(90)90009-2; GALZI JL, 1991, P NATL ACAD SCI USA, V88, P5051, DOI 10.1073/pnas.88.11.5051; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; GIRAUDAT J, 1986, P NATL ACAD SCI USA, V83, P2719, DOI 10.1073/pnas.83.8.2719; GIRAUDAT J, 1987, BIOCHEMISTRY-US, V26, P2410, DOI 10.1021/bi00383a003; GRENNINGLOH G, 1990, NEURON, V4, P963, DOI 10.1016/0896-6273(90)90149-A; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; HEIDMANN T, 1979, EUR J BIOCHEM, V94, P281, DOI 10.1111/j.1432-1033.1979.tb12894.x; HODGKIN AL, 1951, BIOL REV, V26, P339, DOI 10.1111/j.1469-185X.1951.tb01204.x; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HUCHO F, 1986, FEBS LETT, V205, P137, DOI 10.1016/0014-5793(86)80881-X; IMOTO K, 1986, NATURE, V324, P670, DOI 10.1038/324670a0; IMOTO K, 1991, FEBS LETT, V289, P193, DOI 10.1016/0014-5793(91)81068-J; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; KARLIN A, 1991, HARVEY LECT, V85, P71; KATZ B, 1957, J PHYSIOL-LONDON, V138, P63, DOI 10.1113/jphysiol.1957.sp005838; KEHOE J, 1972, J PHYSIOL-LONDON, V225, P85, DOI 10.1113/jphysiol.1972.sp009930; KONNO T, 1991, P ROY SOC B-BIOL SCI, V244, P69, DOI 10.1098/rspb.1991.0053; LANGOSCH D, 1991, BIOCHIM BIOPHYS ACTA, V1063, P36, DOI 10.1016/0005-2736(91)90350-H; LEONARD RJ, 1988, SCIENCE, V242, P1578, DOI 10.1126/science.2462281; LO DC, 1991, NEURON, V6, P31, DOI 10.1016/0896-6273(91)90119-K; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; MILEDI R, 1982, PROC R SOC SER B-BIO, V215, P491, DOI 10.1098/rspb.1982.0056; MILEDI R, 1984, J PHYSIOL-LONDON, V357, P173, DOI 10.1113/jphysiol.1984.sp015495; MULLE C, 1992, NEURON, V8, P135, DOI 10.1016/0896-6273(92)90115-T; NEUBIG RR, 1982, BIOCHEMISTRY-US, V21, P3460, DOI 10.1021/bi00257a032; NEWLAND CF, 1991, J PHYSIOL-LONDON, V432, P203, DOI 10.1113/jphysiol.1991.sp018382; PULLMAN A, 1991, CHEM REV, V91, P793, DOI 10.1021/cr00005a008; REVAH F, 1990, P NATL ACAD SCI USA, V87, P4675, DOI 10.1073/pnas.87.12.4675; REVAH F, 1991, NATURE, V353, P846, DOI 10.1038/353846a0; SAKMANN B, 1980, NATURE, V286, P71, DOI 10.1038/286071a0; SCHOEPFER R, 1990, NEURON, V5, P35, DOI 10.1016/0896-6273(90)90031-A; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SEEBURG PH, 1990, COLD SH Q B, V55, P29; TAUC L, 1962, J NEUROPHYSIOL, V25, P236, DOI 10.1152/jn.1962.25.2.236; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; UNWIN N, 1988, J CELL BIOL, V107, P1123, DOI 10.1083/jcb.107.3.1123; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; VERNINO S, 1992, NEURON, V8, P127, DOI 10.1016/0896-6273(92)90114-S; VERNINO S, 1992, J CELL BIOCH E S, V16, P217	52	344	357	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 8	1992	359	6395					500	505		10.1038/359500a0	http://dx.doi.org/10.1038/359500a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR859	1383829				2022-12-28	WOS:A1992JR85900049
J	SEUBERT, P; VIGOPELFREY, C; ESCH, F; LEE, M; DOVEY, H; DAVIS, D; SINHA, S; SCHLOSSMACHER, M; WHALEY, J; SWINDLEHURST, C; MCCORMACK, R; WOLFERT, R; SELKOE, D; LIEBERBURG, I; SCHENK, D				SEUBERT, P; VIGOPELFREY, C; ESCH, F; LEE, M; DOVEY, H; DAVIS, D; SINHA, S; SCHLOSSMACHER, M; WHALEY, J; SWINDLEHURST, C; MCCORMACK, R; WOLFERT, R; SELKOE, D; LIEBERBURG, I; SCHENK, D			ISOLATION AND QUANTIFICATION OF SOLUBLE ALZHEIMERS BETA-PEPTIDE FROM BIOLOGICAL-FLUIDS	NATURE			English	Article							AMYLOID PRECURSOR PROTEIN; DISEASE; MUTATION; GENE; CLEAVAGE; CELLS	CEREBRAL deposition of the beta-amyloid peptide (A-beta) is an invariant feature of Alzheimer's disease. Since the original isolation and characterization of A-beta (ref. 1) and the subsequent cloning of its precursor protein2-5, no direct evidence for the actual production of discrete A-beta has been reported6-11. Here we investigate whether A-beta is present in human biological fluids using antibodies specific for an epitope within A-beta that spans the site of normal constitutive cleavage12,13. These antibodies were used to construct a sandwich-type enzyme-linked immunosorbent assay that detects A-beta in cerebrospinal fluid, plasma and conditioned medium of human mixed-brain cells grown in vitro (see also ref. 14). By affinity chromatography, we have purified and sequenced A-beta and a novel A-beta fragment from human cerebrospinal fluid and conditioned medium of human mixed-brain cell cultures. These findings demonstrate that A-beta is produced and released both in vivo and in vitro. These observations offer new opportunities for developing diagnostic tests for Alzheimer's disease and therapeutic strategies aimed at reducing the cerebral deposition of A-beta.	ATHENA NEUROSCI INC, 800F GATEWAY BLVD, San Francisco, CA 94080 USA; HARVARD UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, PROGRAM NEUROSCI, BOSTON, MA 02115 USA; HYBRITECH INC, SAN DIEGO, CA 92196 USA; BRIGHAM & WOMENS HOSP, CTR NEUROL DIS, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital				Schlossmacher, Michael/0000-0002-0394-0300				ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; HYMAN BT, 1992, J NEUROPATH EXP NEUR, V51, P76, DOI 10.1097/00005072-199201000-00009; JOACHIM CL, 1988, BRAIN RES, V474, P100, DOI 10.1016/0006-8993(88)90673-7; JOHNSTONE EM, 1991, MOL BRAIN RES, V10, P299, DOI 10.1016/0169-328X(91)90088-F; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; MORI H, 1992, J BIOL CHEM, V267, P17082; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NORDSTEDT C, 1991, P NATL ACAD SCI USA, V88, P8910, DOI 10.1073/pnas.88.20.8910; OI VT, 1990, METHODS CELLULAR IMM; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; PRELLI F, 1988, J NEUROCHEM, V51, P648, DOI 10.1111/j.1471-4159.1988.tb01087.x; TAMAOKA A, 1992, P NATL ACAD SCI USA, V89, P1345, DOI 10.1073/pnas.89.4.1345; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; WANG RW, 1984, J IMMUNOL METHODS, V18, P157; ZAGORSKI MG, 1992, BIOCHEMISTRY-US, V31, P5621, DOI 10.1021/bi00139a028	27	1641	1793	1	87	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 24	1992	359	6393					325	327		10.1038/359325a0	http://dx.doi.org/10.1038/359325a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP503	1406936				2022-12-28	WOS:A1992JP50300058
J	VANDENENGH, G; SACHS, R; TRASK, BJ				VANDENENGH, G; SACHS, R; TRASK, BJ			ESTIMATING GENOMIC DISTANCE FROM DNA-SEQUENCE LOCATION IN CELL-NUCLEI BY A RANDOM-WALK MODEL	SCIENCE			English	Article							HUNTINGTON DISEASE GENE; INSITU HYBRIDIZATION; COSMID CLONES; INTERPHASE; RESOLUTION; SERIATION; REGION	The folding of chromatin in interphase cell nuclei was studied by fluorescent in situ hybridization with pairs of unique DNA sequence probes. The sites of DNA sequences separated by 100 to 2000 kilobase pairs (kbp) are distributed in interphase chromatin according to a random walk model. This model provides the basis for calculating the spacing of sequences along the linear DNA molecule from interphase distance measurements. An interphase mapping strategy based on this model was tested with 13 probes from a 4-megabase pair (Mbp) region of chromosome 4 containing the Huntington disease locus. The results confirmed the locations of the probes and showed that the remaining gap in the published maps of this region is negligible in size. Interphase distance measurements should facilitate construction of chromosome maps with an average marker density of one per 100 kbp, approximately ten times greater than that achieved by hybridization to metaphase chromosomes.	UNIV WASHINGTON,SCH MED,DEPT MOLEC BIOTECHNOL GJ-10,SEATTLE,WA 98195; UNIV CALIF BERKELEY,DEPT MATH,BERKELEY,CA 94720; LAWRENCE LIVERMORE NATL LAB,DIV BIOMED SCI,CTR HUMAN GENOME,LIVERMORE,CA 94550	University of Washington; University of Washington Seattle; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Livermore National Laboratory					NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000256] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00256] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BATES GP, 1990, AM J HUM GENET, V46, P762; BATES GP, 1991, AM J HUM GENET, V49, P7; BUCAN M, 1990, GENOMICS, V6, P1; BUETOW KH, 1987, AM J HUM GENET, V41, P180; BUETOW KH, 1987, AM J HUM GENET, V41, P189; CANTOR CR, 1980, BIOPHYSICAL CHEM 3, pCH18; CHUMAKOV IM, 1992, NAT GENET, V1, P222, DOI 10.1038/ng0692-222; Doi M., 1988, THEORY POLYM DYNAMIC; FEYNMAN RP, 1963, FEYNMAN LECTURES PHY, pCH6; LAWRENCE JB, 1990, SCIENCE, V249, P928, DOI 10.1126/science.2203143; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LIN CS, 1991, SOMAT CELL MOLEC GEN, V17, P481, DOI 10.1007/BF01233172; MONTANARO V, 1991, AM J HUM GENET, V48, P183; TRASK B, 1989, GENOMICS, V5, P710, DOI 10.1016/0888-7543(89)90112-2; TRASK BJ, 1991, METHOD CELL BIOL, V35, P3; TRASK BJ, 1991, AM J HUM GENET, V48, P1; TRASK BJ, UNPUB; TRASK BJ, IN PRESS GENOMICS; TRASK BJ, 1992, IN PRESS GENOMICS, V13, P455; WHALEY WL, 1991, SOMAT CELL MOLEC GEN, V17, P83, DOI 10.1007/BF01233207	20	218	236	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 4	1992	257	5075					1410	1412		10.1126/science.1388286	http://dx.doi.org/10.1126/science.1388286			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL612	1388286				2022-12-28	WOS:A1992JL61200037
J	DOIG, CM				DOIG, CM			ABC OF COLORECTAL DISEASES - PEDIATRIC PROBLEMS .2.	BRITISH MEDICAL JOURNAL			English	Article											DOIG, CM (corresponding author), UNIV MANCHESTER,BOOTH HALL CHILDRENS HOSP,MANCHESTER M13 9PL,LANCS,ENGLAND.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 29	1992	305	6852					511	513		10.1136/bmj.305.6852.511	http://dx.doi.org/10.1136/bmj.305.6852.511			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL609	1392999	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992JL60900023
J	AVNI, A; ANDERSON, JD; HOLLAND, N; ROCHAIX, JD; GROMETELHANAN, Z; EDELMAN, M				AVNI, A; ANDERSON, JD; HOLLAND, N; ROCHAIX, JD; GROMETELHANAN, Z; EDELMAN, M			TENTOXIN SENSITIVITY OF CHLOROPLASTS DETERMINED BY CODON-83 OF BETA-SUBUNIT OF PROTON-ATPASE	SCIENCE			English	Article							CHLAMYDOMONAS-REINHARDTII; RHODOSPIRILLUM-RUBRUM; COUPLING FACTOR-1; ESCHERICHIA-COLI; ATPB GENE; POLYPHENOL OXIDASE; H+-ATPASE; SYNTHASE; NICOTIANA; F1-ATPASE	Tentoxin is a naturally occurring phytotoxic peptide that causes seedling chlorosis and arrests growth in sensitive plants and algae. In vitro, it inhibits activity of the beta-subunit of the plastid proton-adenosine triphosphatase (ATPase) from sensitive species. Plastid atpB genes from six closely related, tentoxin-sensitive or -resistant Nicotiana species differ at codon 83, according to their response to the toxin: glutamate correlated with resistance and aspartate correlated with sensitivity. The genetic relevance of this site was confirmed in Chlamydomonas reinhardtii by chloroplast transformation. The alga, normally tentoxin-resistant, was rendered tentoxin-sensitive by mutagenesis of its plastid atpB gene at codon 83. Codon 83 may represent a critical site on the beta-subunit that does not compete with nucleotide binding or other catalytic activities.	WEIZMANN INST SCI,DEPT PLANT GENET,IL-76100 REHOVOT,ISRAEL; UNIV GENEVA,DEPT MOLEC BIOL,CH-1211 GENEVA,SWITZERLAND; WEIZMANN INST SCI,DEPT BIOCHEM,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science; University of Geneva; Weizmann Institute of Science			Rochaix, Jean-David/ABC-5243-2020					ALSHAWI MK, 1988, J BIOL CHEM, V263, P19633; ARNTZEN CJ, 1972, BIOCHIM BIOPHYS ACTA, V283, P539, DOI 10.1016/0005-2728(72)90273-3; AVITAL S, 1991, J BIOL CHEM, V266, P7067; AVIV D, 1980, THEOR APPL GENET, V56, P145, DOI 10.1007/BF00286675; AVNI A, 1991, J BIOL CHEM, V266, P7317; AVNI A, 1991, MOL GEN GENET, V225, P273, DOI 10.1007/BF00269859; AVNI A, UNPUB; AVRON M, 1960, BIOCHIM BIOPHYS ACTA, V40, P257, DOI 10.1016/0006-3002(60)91350-0; BENNETT J, 1976, PHYTOCHEMISTRY, V15, P263, DOI 10.1016/S0031-9422(00)89000-7; BOYNTON JE, 1988, SCIENCE, V240, P1534, DOI 10.1126/science.2897716; BURK LG, 1978, J HERED, V69, P117, DOI 10.1093/oxfordjournals.jhered.a108892; Clayton R. K., 1963, BACTERIAL PHOTOSYNTH, P495; DURBIN RD, 1977, PHYTOPATHOLOGY, V67, P602, DOI 10.1094/Phyto-67-602; FLICK CE, 1982, J HERED, V73, P264, DOI 10.1093/oxfordjournals.jhered.a109636; FLUHR R, 1981, MOL GEN GENET, V181, P484, DOI 10.1007/BF00428740; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GALUN E, 1982, METHODS CHLOROPLAST, P139; GROMETELHANAN Z, 1985, J BIOL CHEM, V260, P2635; GROMETELHANAN Z, 1986, METHOD ENZYMOL, V126, P528; HOLLAND NB, UNPUB; JAGENDORF AT, 1991, CELL CULTURE SOMAT B, V7, P225; KLOTZ MG, 1988, PHYSIOL PLANTARUM, V74, P575, DOI 10.1111/j.1399-3054.1988.tb02021.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAX AR, 1986, PHYSIOL PLANTARUM, V66, P384, DOI 10.1111/j.1399-3054.1986.tb05939.x; LEMAIRE C, 1988, P NATL ACAD SCI USA, V85, P1344, DOI 10.1073/pnas.85.5.1344; MEYER WL, 1974, BIOCHEM BIOPH RES CO, V56, P234, DOI 10.1016/S0006-291X(74)80339-6; OHAD I, 1967, J CELL BIOL, V35, P521, DOI 10.1083/jcb.35.3.521; PARSONAGE D, 1988, J BIOL CHEM, V263, P4740; RICHTER ML, 1986, J BIOL CHEM, V261, P2109; ROBERTSON D, 1989, J BIOL CHEM, V264, P2331; Rochaix J. D., 1988, PLANT MOL BIOL PRACT, P253; SANGER F, 1981, SCIENCE, V214, P1205, DOI 10.1126/science.7302589; SELMAN BR, 1978, BIOCHIM BIOPHYS ACTA, V502, P29, DOI 10.1016/0005-2728(78)90128-7; SHINOZAKI K, 1983, GENE, V24, P147; STEELE JA, 1977, BIOCHIM BIOPHYS ACTA, V459, P347, DOI 10.1016/0005-2728(77)90036-6; STEELE JA, 1976, P NATL ACAD SCI USA, V73, P2245, DOI 10.1073/pnas.73.7.2245; STEELE JA, 1978, BIOCHIM BIOPHYS ACTA, V501, P72, DOI 10.1016/0005-2728(78)90096-8; TEMPLETON GE, 1972, MICROB TOXINS, V8, P160; VAUGHN KC, 1984, PHYSIOL PLANTARUM, V60, P257, DOI 10.1111/j.1399-3054.1984.tb04574.x; VAUGHN KC, 1981, PHYSIOL PLANTARUM, V53, P421, DOI 10.1111/j.1399-3054.1981.tb02725.x; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; WALLACH D, 1972, BIOCHIM BIOPHYS ACTA, V267, P124; WOESSNER JP, 1986, GENE, V44, P17; WOESSNER JP, 1984, PLANT MOL BIOL, V3, P177, DOI 10.1007/BF00016065; ZUMBRUNN G, 1989, TECHNIQUE, V1, P204; 1991, EMBL DATA LIBRARY RE	46	67	73	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 28	1992	257	5074					1245	1247		10.1126/science.1387730	http://dx.doi.org/10.1126/science.1387730			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1387730				2022-12-28	WOS:A1992JL05000023
J	MASLOV, DA; SIMPSON, L				MASLOV, DA; SIMPSON, L			THE POLARITY OF EDITING WITHIN A MULTIPLE GRNA-MEDIATED DOMAIN IS DUE TO FORMATION OF ANCHORS FOR UPSTREAM GRNAS BY DOWNSTREAM EDITING	CELL			English	Article							KINETOPLAST DNA MINICIRCLES; LEISHMANIA-TARENTOLAE; GUIDE RNAS; CRITHIDIA-FASCICULATA; MESSENGER-RNAS; CYTOCHROME-OXIDASE; SEQUENCE CLASSES; SUBUNIT-III; MITOCHONDRIA; REPLICATION	Seventeen kinetoplast minicircle-encoded and nine maxicircle-encoded gRNA genes have been identified. Six overlapping minicircle-encoded gRNAs mediate editing for the 5'-pan-edited MURF4 gene and two for the 5-edited COIII gene. The pan-edited RPS12 mRNA is edited by seven minicircle-encoded gRNAs and one maxicircle-encoded gRNA. The 3'-most gRNA in each domain forms an anchor with unedited mRNA, whereas upstream gRNAs form anchors only with edited mRNA, thereby explaining the observed 3' to 5' polarity of editing within an editing domain. We suggest that a role of G-U base pairs is to allow breathing of the edited mRNA-gRNA hybrid and formation of the upstream anchor hybrid.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles	MASLOV, DA (corresponding author), UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI009102, R01AI009102] Funding Source: NIH RePORTER; NIAID NIH HHS [AI09102] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM JM, 1988, CELL, V55, P267, DOI 10.1016/0092-8674(88)90049-9; BENNE R, 1989, BIOCHIM BIOPHYS ACTA, V1007, P131, DOI 10.1016/0167-4781(89)90031-6; BHAT GJ, 1990, CELL, V61, P885, DOI 10.1016/0092-8674(90)90199-O; BHAT GJ, 1991, MOL BIOCHEM PARASIT, V48, P139, DOI 10.1016/0166-6851(91)90110-R; BIRKENMEYER L, 1986, J BIOL CHEM, V261, P2362; BLUM B, 1991, CELL, V65, P543, DOI 10.1016/0092-8674(91)90087-F; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BLUM B, 1990, CELL, V62, P391, DOI 10.1016/0092-8674(90)90375-O; BRALY P, 1974, J PROTOZOOL, V21, P782, DOI 10.1111/j.1550-7408.1974.tb03752.x; DECKER CJ, 1990, CELL, V61, P1001, DOI 10.1016/0092-8674(90)90065-M; GOMEZEICHELMANN MC, 1988, MOL BIOCHEM PARASIT, V27, P143, DOI 10.1016/0166-6851(88)90034-5; HOLBROOK SR, 1991, NATURE, V353, P579, DOI 10.1038/353579a0; KIDANE GZ, 1984, GENE, V27, P265, DOI 10.1016/0378-1119(84)90071-4; KOSLOWSKY DJ, 1991, CELL, V67, P537, DOI 10.1016/0092-8674(91)90528-7; MASLOV DA, 1992, MOL CELL BIOL, V12, P56, DOI 10.1128/MCB.12.1.56; MUHICH ML, 1985, NUCLEIC ACIDS RES, V13, P3241, DOI 10.1093/nar/13.9.3241; MUHICH ML, 1986, NUCLEIC ACIDS RES, V14, P5531, DOI 10.1093/nar/14.13.5531; PARKER RC, 1977, P NATL ACAD SCI USA, V74, P851, DOI 10.1073/pnas.74.3.851; Parrot L., 1939, Arch Inst Pasteur Alger, V17, P231; POLLARD VW, 1990, CELL, V63, P783, DOI 10.1016/0092-8674(90)90144-4; RAY DS, 1989, MOL CELL BIOL, V9, P1365, DOI 10.1128/MCB.9.3.1365; RAY DS, 1987, PLASMID, V17, P177, DOI 10.1016/0147-619X(87)90026-6; RYAN KA, 1988, ANNU REV MICROBIOL, V42, P339, DOI 10.1146/annurev.mi.42.100188.002011; Sambrook J, 1989, MOL CLONING LABORATO; SHAW JM, 1988, CELL, V53, P401, DOI 10.1016/0092-8674(88)90160-2; SIMPSON L, 1970, J PROTOZOOL, V17, P511, DOI 10.1111/j.1550-7408.1970.tb04719.x; SIMPSON L, 1989, CELL, V57, P355, DOI 10.1016/0092-8674(89)90911-2; SIMPSON L, 1990, SCIENCE, V250, P512, DOI 10.1126/science.1700474; SIMPSON L, 1978, CELL, V14, P169, DOI 10.1016/0092-8674(78)90311-2; SIMPSON L, 1987, ANNU REV MICROBIOL, V41, P363, DOI 10.1146/annurev.mi.41.100187.002051; SIMPSON L, 1974, BIOCHIM BIOPHYS ACTA, V349, P161, DOI 10.1016/0005-2787(74)90077-X; SIMPSON L, 1979, P NATL ACAD SCI USA, V76, P1585, DOI 10.1073/pnas.76.4.1585; SOUZA AE, 1992, MOL CELL BIOL, V12, P2100, DOI 10.1128/MCB.12.5.2100; STUART K, 1991, ANNU REV MICROBIOL, V45, P327, DOI 10.1146/annurev.mi.45.100191.001551; STURM NR, 1992, CELL, V70, P469, DOI 10.1016/0092-8674(92)90171-8; STURM NR, 1990, CELL, V61, P879, DOI 10.1016/0092-8674(90)90198-N; STURM NR, 1990, CELL, V61, P871, DOI 10.1016/0092-8674(90)90197-M; STURM NR, 1991, NUCLEIC ACIDS RES, V19, P6277, DOI 10.1093/nar/19.22.6277; TRAGER W, 1957, J PROTOZOOL, V4, P269, DOI 10.1111/j.1550-7408.1957.tb02519.x; VANDERSPEK H, 1990, EMBO J, V9, P257, DOI 10.1002/j.1460-2075.1990.tb08103.x	40	128	129	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 7	1992	70	3					459	467		10.1016/0092-8674(92)90170-H	http://dx.doi.org/10.1016/0092-8674(92)90170-H			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1379519	Bronze			2022-12-28	WOS:A1992JH12400011
J	BEGENT, RHJ				BEGENT, RHJ			CURRENT ISSUES IN CANCER .12. COLORECTAL-CANCER	BRITISH MEDICAL JOURNAL			English	Article							ADJUVANT THERAPY; RANDOMIZED TRIAL; CARCINOMA; FLUOROURACIL; LEVAMISOLE				BEGENT, RHJ (corresponding author), ROYAL FREE HOSP,SCH MED,DEPT CLIN ONCOL,LONDON NW3 2PF,ENGLAND.							AITKEN WS, 1992, NEW ENGL J MED, V326, P658; ARNAUD JP, 1989, BRIT J SURG, V76, P284, DOI 10.1002/bjs.1800760322; AUGUST DA, 1984, CANCER METAST REV, V3, P303, DOI 10.1007/BF00051457; BEGENT RHJ, 1986, BRIT J SURG, V73, P64, DOI 10.1002/bjs.1800730126; BEGENT RHJ, 1989, CANCER SURV, V8, P108; BLAIR SD, 1991, BRIT J CANCER, V61, P891; BUYSE M, 1988, JAMA-J AM MED ASSOC, V259, P3571; BYRNE M, 1992, BRIT MED J, V304, P1523, DOI 10.1136/bmj.304.6841.1523; CHANG AE, 1987, ANN SURG, V206, P685, DOI 10.1097/00000658-198712000-00001; DARBY CR, 1992, BRIT J SURG, V79, P206, DOI 10.1002/bjs.1800790305; GLIMELIUS B, 1991, EUR J CANCER       S, V2, pS82; HARDCASTLE JD, 1983, LANCET, V2, P1; HOULSTON RS, 1990, BRIT MED J, V301, P18; KROOK JE, 1991, NEW ENGL J MED, V324, P709, DOI 10.1056/NEJM199103143241101; LOKICH JJ, 1989, J CLIN ONCOL, V7, P425, DOI 10.1200/JCO.1989.7.4.425; MCARDLE CS, 1991, BRIT MED J, V302, P1501, DOI 10.1136/bmj.302.6791.1501; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; MOERTEL CG, 1909, MAY P AM ASS CLIN ON, P457; PIEDBOIS P, 1992, MAY P AM SOC CLIN ON, P1026; POON MA, 1989, J CLIN ONCOL, V7, P1407, DOI 10.1200/JCO.1989.7.10.1407; SCHNALL SF, 1991, SEMIN ONCOL, V18, P560; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; TAYLOR I, 1985, BRIT J SURG, V72, P359, DOI 10.1002/bjs.1800720509; WINDLE R, 1987, BRIT J SURG, V74, P569, DOI 10.1002/bjs.1800740707; 1990, CANCER COLON RECTUM; 1990, JAMA-J AM MED ASSOC, V264, P1444	26	8	8	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1992	305	6847					246	249		10.1136/bmj.305.6847.246	http://dx.doi.org/10.1136/bmj.305.6847.246			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG112	1382766	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992JG11200035
J	HASLER, J				HASLER, J			PARTNERS IN PRACTICE .1. THE PRIMARY HEALTH-CARE TEAM - HISTORY AND CONTRACTUAL FARCES	BRITISH MEDICAL JOURNAL			English	Article							NURSES				HASLER, J (corresponding author), JOHN RADCLIFFE HOSP,MED SCH OFF,OXFORD OX3 9DU,ENGLAND.							Anderson S, 1979, J R Coll Gen Pract, V29, P352; DRURY VWM, 1990, NEW PRACTICE MANAGER; FOWLER G, 1988, NURESE FAMILY PRACTI; Hasler J C, 1972, Br Med J, V1, P232; HASLER JC, 1968, BRIT MED J, V3, P734, DOI 10.1136/bmj.3.5620.734; HASLER JC, 1991, HDB PRACTICE MANAGEM; HOCKEY L, 1966, FEELING PULSE; JACKA SM, 1976, TREATMENT ROOM NURSI; KUENSSBERG EV, 1991, TEAM PRIMARY CARE RO; MACKINNON M, 1989, BRIT MED J, V299, P552, DOI 10.1136/bmj.299.6698.552; MARSH GN, 1967, BRIT MED J, V1, P489, DOI 10.1136/bmj.1.5538.489; MARSH GN, 1991, OXFORD GP SERIES, V21, P40; MARSH GN, 1991, EFFICIENT CARE GENER, P11; PEARSON R, 1988, ASTHMA CARE GENERAL; PINSENT R J, 1961, Br Med J, V1, P123; PRITCHARD P, 1981, J R COLL GEN PRACT, V17; SALISBURY C, 1991, BRIT J GEN PRACT, V41, P398; SMITH JW, 1967, BRIT MED J, V4, P672, DOI 10.1136/bmj.4.5580.672; SWIFT G, 1964, BRIT MED J, V1, P1697, DOI 10.1136/bmj.1.5399.1697; THORN PA, 1973, BRIT MED J, V2, P534, DOI 10.1136/bmj.2.5865.534; 1965, PRESENT STATE FUTURE, P40	21	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1992	305	6847					232	234		10.1136/bmj.305.6847.232	http://dx.doi.org/10.1136/bmj.305.6847.232			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG112	1392831	Bronze, Green Submitted, Green Published			2022-12-28	WOS:A1992JG11200029
J	HELENIUS, A				HELENIUS, A			UNPACKING THE INCOMING INFLUENZA-VIRUS	CELL			English	Review							AMANTADINE; PROTEIN; VIRIONS				HELENIUS, A (corresponding author), YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510, USA.							BUKRINSKAYA AG, 1982, J GEN VIROL, V60, P49, DOI 10.1099/0022-1317-60-1-49; HAY AJ, 1985, EMBO J, V4, P3021, DOI 10.1002/j.1460-2075.1985.tb04038.x; HOLSINGER LJ, 1991, VIROLOGY, V183, P32, DOI 10.1016/0042-6822(91)90115-R; LAMB RA, 1985, CELL, V40, P627, DOI 10.1016/0092-8674(85)90211-9; LAMB RA, 1989, VIRUSES, V6, P1; MARTIN K, 1991, CELL, V67, P117, DOI 10.1016/0092-8674(91)90576-K; MARTIN K, 1991, J VIROL, V65, P232, DOI 10.1128/JVI.65.1.232-244.1991; MATLIN KS, 1981, J CELL BIOL, V91, P601, DOI 10.1083/jcb.91.3.601; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; SKEHEL JJ, 1977, J GEN VIROL, V38, P97; SUGRUE RJ, 1990, EMBO J, V9, P3469, DOI 10.1002/j.1460-2075.1990.tb07555.x; SUGRUE RJ, 1991, VIROLOGY, V180, P617, DOI 10.1016/0042-6822(91)90075-M; WENGLER G, 1987, ARCH VIROL, V94, P1, DOI 10.1007/BF01313721; ZEBEDEE SL, 1988, J VIROL, V62, P2762, DOI 10.1128/JVI.62.8.2762-2772.1988; ZHIRNOV OP, 1990, VIROLOGY, V176, P274, DOI 10.1016/0042-6822(90)90253-N	15	267	296	2	21	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 15	1992	69	4					577	578		10.1016/0092-8674(92)90219-3	http://dx.doi.org/10.1016/0092-8674(92)90219-3			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HV089	1375129				2022-12-28	WOS:A1992HV08900002
J	JARMAN, B; HIRSCH, S; WHITE, P; DRISCOLL, R				JARMAN, B; HIRSCH, S; WHITE, P; DRISCOLL, R			PREDICTING PSYCHIATRIC ADMISSION RATES	BRITISH MEDICAL JOURNAL			English	Article							UNDERPRIVILEGED AREAS; INPATIENT CARE; SCHIZOPHRENIA	Objective - To determine the numbers of actual and expected psychiatric admissions for the residents of the district health authorities of England and to develop a model to indicate which social, health status, and service provision factors best explain the variation of the actual from the expected psychiatric admissions; to use this model to predict psychiatric admissions for district health authorities as an aid to resource allocation. Design - The actual psychiatric admissions for district health authority residents were extracted from data of the 1986 Mental Health Enquiry. Expected admissions were calculated using the age, sex, and marital status structure of each district health authority and the national psychiatric admission rates related to age, sex, and marital status. Standardised psychiatric admission ratios were calculated as the ratios of the numbers of actual to expected psychiatric admissions. A wide range of social, health status, and service provision data were used as the explanatory variables in regression analyses to determine which combination of factors best explained the variation between districts of standardised psychiatric admission ratios. Setting - The 168652 psychiatric admissions recorded for the 1986 Mental Health Enquiry, after exclusion of mental handicap and psychogeriatric admissions. Results - The actual number of psychiatric admissions varied from 79% above to 54% below the expected number of admissions from age, sex, and marital status for the districts of England. The most powerful variables to explain this variation were the rate of notification of drug misusers, standardised mortality ratios, and levels of illegitimacy in each district. A complex. model was developed which could be used to predict district psychiatric admissions as an aid to resource allocation. A simpler model was also developed (which was less powerful than the more complex model) based on the under-privileged area score. One advantage of this model was that it could be used at the level of electoral wards as well as district health authorities.	CHARING CROSS & WESTMINSTER MED SCH,DEPT PSYCHIAT,LONDON W6 8RP,ENGLAND; ST MARYS HOSP,SCH MED,DEPT GEN PRACTICE,LONDON NW8 8EG,ENGLAND	Imperial College London; Imperial College London			White, Patrick/AAN-7799-2020	White, Patrick/0000-0002-2047-8787				BUGLASS D, 1980, REGISTER SOCIAL MED; BURKE AW, 1976, BRIT J PSYCHIAT, V128, P534, DOI 10.1192/bjp.128.6.534; CHORNICROFT G, 1991, BRIT J PSYCHIAT, V158, P475; COOPER JE, 1987, BRIT J PSYCHIAT, V151, P619, DOI 10.1192/bjp.151.5.619; Durkheim E., 1952, SUICIDE; Faris Robert E.L, 1939, MENTAL DISORDERS URB; Goldberg D., 1983, INT J REHABIL RES, V6, P127, DOI [10.1097/00004356-198303000-00021, DOI 10.1097/00004356-198303000-00021]; GOODMAN AB, 1983, AM J PSYCHIAT, V140, P166; JARMAN B, 1984, BRIT MED J, V289, P1587, DOI 10.1136/bmj.289.6458.1587; JARMAN B, 1983, BRIT MED J, V286, P1705, DOI 10.1136/bmj.286.6379.1705; JARMAN B, 1985, MED ANN, P224; MILLER GH, 1986, CAN J PSYCHIAT, V31, P424, DOI 10.1177/070674378603100508; ODEGAARD O, 1932, ACTA PSYCHIATRICA S, V4; PLATT S, 1985, PSYCHOL MED, V15, P113, DOI 10.1017/S0033291700020973; RICHMAN A, 1984, PSYCHOL MED, V14, P175, DOI 10.1017/S0033291700003184; SAINSBURY P, 1955, SUICIDE; SHEPHERD M, 1957, MAUDSLEY MONOGRAPH, V3; Townsend P., 1986, INEQUALITIES HLTH NO; 1983, INFORMATION NOTE DEP, V2; 1990, HLTH PERSONAL SOCIAL; 1976, SHARING RESOURCES HL; 1986, INPATIENT STATISTICS; 1988, PSYCHIATRIC BEDS RES; 1988, REV RESOURCE ALLOCAT	24	88	88	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 2	1992	304	6835					1146	1151		10.1136/bmj.304.6835.1146	http://dx.doi.org/10.1136/bmj.304.6835.1146			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HT232	1392792	Green Published, Bronze			2022-12-28	WOS:A1992HT23200020
J	GIESE, KP; MARTINI, R; LEMKE, G; SORIANO, P; SCHACHNER, M				GIESE, KP; MARTINI, R; LEMKE, G; SORIANO, P; SCHACHNER, M			MOUSE P(0) GENE DISRUPTION LEADS TO HYPOMYELINATION, ABNORMAL EXPRESSION OF RECOGNITION MOLECULES, AND DEGENERATION OF MYELIN AND AXONS	CELL			English	Article							CELL-ADHESION MOLECULES; IMMUNOELECTRON MICROSCOPIC LOCALIZATION; L3 CARBOHYDRATE STRUCTURES; PERIPHERAL NERVOUS-SYSTEM; N-CAM; SCIATIC-NERVE; SCHWANN-CELLS; PROTEIN-ZERO; IMMUNOGLOBULIN SUPERFAMILY; MONOCLONAL-ANTIBODIES	We have used homologous recombination in embryonic stem cells to generate mice carrying a mutation in the gene encoding P0, an immunoglobulin-related recognition molecule and the major protein of peripheral nervous system myelin. These mice are deficient in normal motor coordination and exhibit tremors and occasional convulsions. Axons in their peripheral nerves are severely hypomyelinated and a subset of myelin-like figures and axons degenerate. The mutation leads to an abnormal regulation of some, but not all, molecules involved in myelination. These results demonstrate that P0 is essential for the normal spiraling, compaction, and maintenance of the peripheral myelin sheath and the continued integrity of associated axons. They further suggest that this protein conveys a signal that regulates Schwann cell gene expression.	SALK INST BIOL STUDIES, MOLEC NEUROBIOL LAB, LA JOLLA, CA 92037 USA; BAYLOR COLL MED, INST MOLEC GENET, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA	Salk Institute; Baylor College of Medicine; Howard Hughes Medical Institute	GIESE, KP (corresponding author), SWISS FED INST TECHNOL, DEPT NEUROBIOL, CH-8093 ZURICH, SWITZERLAND.		Soriano, Philippe M/E-5797-2015; Giese, Karl P/A-3112-2011	Soriano, Philippe M/0000-0002-0427-926X; Giese, Karl P/0000-0003-4503-7344; Martini, Rudolf/0000-0002-5463-5592	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024875, R01HD025326, R37HD025326] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 24875, HD 25326] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ATASHI JR, 1992, NEURON, V8, P831, DOI 10.1016/0896-6273(92)90197-L; BIXBY JL, 1990, J CELL BIOL, V111, P2725, DOI 10.1083/jcb.111.6.2725; BOLLENSEN E, 1987, NEUROSCI LETT, V82, P77, DOI 10.1016/0304-3940(87)90174-1; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CERVELLO M, 1991, P NATL ACAD SCI USA, V88, P10548, DOI 10.1073/pnas.88.23.10548; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; DURSO D, 1990, NEURON, V4, P449, DOI 10.1016/0896-6273(90)90057-M; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FAHRIG T, 1990, EUR J NEUROSCI, V2, P153, DOI 10.1111/j.1460-9568.1990.tb00407.x; FAISSNER A, 1985, EMBO J, V4, P3105, DOI 10.1002/j.1460-2075.1985.tb04052.x; FAISSNER A, 1990, NEURON, V5, P627, DOI 10.1016/0896-6273(90)90217-4; FILBIN MT, 1990, NATURE, V344, P871, DOI 10.1038/344871a0; FREI T, 1992, J CELL BIOL, V118, P177, DOI 10.1083/jcb.118.1.177; GREENFIELD S, 1973, J NEUROCHEM, V20, P1207, DOI 10.1111/j.1471-4159.1973.tb00089.x; HASTY P, 1991, MOL CELL BIOL, V11, P4509, DOI 10.1128/MCB.11.9.4509; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; ISHAQUE A, 1980, CAN J BIOCHEM CELL B, V58, P913, DOI 10.1139/o80-125; JESSEN KR, 1990, DEVELOPMENT, V109, P91; KADMON G, 1990, J CELL BIOL, V110, P209, DOI 10.1083/jcb.110.1.209; KADMON G, 1990, J CELL BIOL, V110, P193, DOI 10.1083/jcb.110.1.193; KOGAN SC, 1987, NEW ENGL J MED, V317, P985, DOI 10.1056/NEJM198710153171603; KRUSE J, 1984, NATURE, V311, P153, DOI 10.1038/311153a0; KUCHERER A, 1987, J CELL BIOL, V104, P1597, DOI 10.1083/jcb.104.6.1597; KUHN R, 1990, J NEUROSCI, V10, P205; LAI C, 1987, P NATL ACAD SCI USA, V84, P4337, DOI 10.1073/pnas.84.12.4337; LEMKE G, 1988, NEURON, V1, P73, DOI 10.1016/0896-6273(88)90211-5; LEMKE G, 1988, NEURON, V1, P535, DOI 10.1016/0896-6273(88)90103-1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTINI R, 1991, J NEUROSCI RES, V28, P261, DOI 10.1002/jnr.490280214; MARTINI R, 1990, J NEUROCYTOL, V19, P601, DOI 10.1007/BF01257247; MARTINI R, 1986, J CELL BIOL, V103, P2439, DOI 10.1083/jcb.103.6.2439; MARTINI R, 1988, DEV BIOL, V129, P330, DOI 10.1016/0012-1606(88)90380-6; MARTINI R, 1988, J CELL BIOL, V106, P1735, DOI 10.1083/jcb.106.5.1735; MESSING A, 1992, NEURON, V8, P507, DOI 10.1016/0896-6273(92)90279-M; MIRSKY R, 1986, J NEUROCYTOL, V15, P799, DOI 10.1007/BF01625196; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; NEUMANN H, 1990, THESIS U WURZBURG GE; NIEKE J, 1985, DIFFERENTIATION, V30, P141, DOI 10.1111/j.1432-0436.1985.tb00525.x; NORONHA AB, 1986, BRAIN RES, V385, P237, DOI 10.1016/0006-8993(86)91069-3; OWENS GC, 1991, DEVELOPMENT, V112, P639; Palay S. L., 1974, CEREBELLAR CORTEX CY; POLLERBERG GE, 1987, CELL TISSUE RES, V250, P227, DOI 10.1007/BF00214676; POLTORAK M, 1987, J CELL BIOL, V105, P1893, DOI 10.1083/jcb.105.4.1893; POTTER NT, 1988, J NEUROIMMUNOL, V18, P49, DOI 10.1016/0165-5728(88)90134-8; PUCKETT C, 1987, J NEUROSCI RES, V18, P511, DOI 10.1002/jnr.490180402; RATHJEN FG, 1984, EMBO J, V3, P1; REICHARDT LF, 1990, COLD SPRING HARB SYM, V55, P341; SCHACHNER M, 1991, NERVE GROWTH CONE, P237; Schachner M., 1990, SEMIN NEUROSCI, V2, P497; SCHNEIDERSCHAULIES J, 1990, J NEUROSCI RES, V27, P286, DOI 10.1002/jnr.490270307; SCHUCH U, 1989, NEURON, V3, P13, DOI 10.1016/0896-6273(89)90111-6; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SWASH M, 1991, CLIN NEUROLOGY, P1177; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TRAPP BD, 1981, J CELL BIOL, V90, P1, DOI 10.1083/jcb.90.1.1; VONBOHLEN, 1992, IN PRESS EUR J NEURO; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YOU KH, 1991, GENOMICS, V9, P751, DOI 10.1016/0888-7543(91)90370-T; ZIMMER A, 1992, ANNU REV NEUROSCI, V15, P115, DOI 10.1146/annurev.neuro.15.1.115	63	430	431	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 13	1992	71	4					565	576		10.1016/0092-8674(92)90591-Y	http://dx.doi.org/10.1016/0092-8674(92)90591-Y			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JY676	1384988				2022-12-28	WOS:A1992JY67600005
J	GRABOYS, TB; BIEGELSEN, B; LAMPERT, S; BLATT, CM; LOWN, B				GRABOYS, TB; BIEGELSEN, B; LAMPERT, S; BLATT, CM; LOWN, B			RESULTS OF A 2ND-OPINION TRIAL AMONG PATIENTS RECOMMENDED FOR CORONARY ANGIOGRAPHY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MYOCARDIAL-INFARCTION; ARTERY DISEASE; BYPASS-SURGERY; DEATH; SURVIVAL; RISK	Objective.-To assess the feasibility of carrying out a second-opinion trial for patients urged to undergo coronary angiography and to assess the long-range out-come of such patients denied that procedure, and the criteria evolved for reaching such a conclusion. Design.-A case series of patients referred for a second opinion as to the need for coronary angiography. Patients were followed up by questionnaire, telephone call, and center visits. Setting.-Cardiovascular referral center and teaching hospital in Boston, Mass. Patients.-One hundred seventy-one patients with coronary artery disease (144 men, average age 60 years; range, 36 to 88 years). Three patients became unavailable for follow-up during a mean of 46.5 months. Outcome Measures.-Concordant-discordant outcome as to the second opinion, cardiac events, invasive interventions, quality of life questionnaire, and level of symptoms. Results.-One hundred thirty-four (80%) of the 168 patients were judged not to require angiography; it was recommended in six. In 28 (16%) recommendation was deferred pending further studies. At a mean follow-up of 46.5 months among the 168 patients, there were seven cardiac deaths (annualized cardiac mortality of 1.1%); 19 patients experienced a new myocardial infarction (2.7% annualized rate), while 27 patients (4.3%) were judged to have developed unstable angina. Twenty-six patients (1 5.4%) ultimately underwent either coronary bypass or angioplasty. Conclusions.-In a large fraction of medically stable patients with coronary disease who are urged to undergo coronary angiography, the procedure can be safely deferred. While there may be a limitation in terms of generalizing this experience to all patients with coronary disease, we reasonably conclude that an estimated 50% of coronary angiography currently being undertaken in the United States is unnecessary, or at least could be postponed.	BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health	GRABOYS, TB (corresponding author), LOWN CARDIOVASC CTR, 21 LONGWOOD AVE, BROOKLINE, MA 02146 USA.							ALDERMAN EL, 1990, CIRCULATION, V82, P1629, DOI 10.1161/01.CIR.82.5.1629; AMBROSE JA, 1988, J AM COLL CARDIOL, V12, P56, DOI 10.1016/0735-1097(88)90356-7; BONOW RO, 1984, NEW ENGL J MED, V311, P1339, DOI 10.1056/NEJM198411223112103; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; FISHER L, 1984, NEW ENGL J MED, V310, P750; FISHER L, 1983, CIRCULATION, V68, P939, DOI 10.1161/01.CIR.68.5.939; GRABOYS TB, 1987, JAMA-J AM MED ASSOC, V258, P1611, DOI 10.1001/jama.258.12.1611; HUEB W, 1989, AM J CARDIOL, V63, P155, DOI 10.1016/0002-9149(89)90277-4; KELLY P, 1990, J AM COLL CARDIOL, V15, P267, DOI 10.1016/S0735-1097(10)80046-4; KIRKLIN JW, 1989, CIRCULATION, V79, P81; LITTLE WC, 1988, CIRCULATION, V78, P1157, DOI 10.1161/01.CIR.78.5.1157; MCINTOSH HD, 1989, J AM COLL CARDIOL, V14, P24, DOI 10.1016/0735-1097(89)90048-X; MCINTOSH HD, 1987, JAMA-J AM MED ASSOC, V258, P1644, DOI 10.1001/jama.258.12.1644; NICOD PH, 1989, CIRCULATION, V80, P410; OCONNOR GT, 1991, JAMA-J AM MED ASSOC, V266, P803, DOI 10.1001/jama.266.6.803; PARISI AF, 1992, NEW ENGL J MED, V326, P10, DOI 10.1056/NEJM199201023260102; PODRID PJ, 1981, NEW ENGL J MED, V305, P1111, DOI 10.1056/NEJM198111053051903; Preston T A, 1989, Int J Technol Assess Health Care, V5, P431; ROGERS WJ, 1990, CIRCULATION, V81, P1457, DOI 10.1161/01.CIR.81.5.1457; Sleight P, 1990, Circulation, V81, P1707; SULLIVAN MJ, 1989, CARDIOLOGY, V6, P62; TGOPOL EJ, 1992, J AM COLL CARDIOL, V19, P138; WINSLOW CM, 1988, JAMA-J AM MED ASSOC, V260, P505, DOI 10.1001/jama.260.4.505; 1992, DATA NATIONAOL CTR H; 1992, LANCET, V339, P782	25	73	70	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1992	268	18					2537	2540		10.1001/jama.268.18.2537	http://dx.doi.org/10.1001/jama.268.18.2537			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW616	1404821				2022-12-28	WOS:A1992JW61600025
J	COOPER, SJ; KELLY, CB; KING, DJ				COOPER, SJ; KELLY, CB; KING, DJ			5-HYDROXYINDOLEACETIC ACID IN CEREBROSPINAL-FLUID AND PREDICTION OF SUICIDAL-BEHAVIOR IN SCHIZOPHRENIA	LANCET			English	Note							MONOAMINE METABOLITES; CSF; 5-HIAA	Low concentrations of the serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA) in cerebrospinal fluid (CSF) are associated with suicidal behaviour in patients with depressive illness, but studies of the relation between CSF 5-HIAA and suicide in schizophrenia have been inconclusive and have not included long-term follow-up. In a prospective study, we measured 5-HIAA in CSF taken from 30 schizophrenic patients in a drug-free state, and followed these patients for 11 years. 10 patients made suicide attempts during follow-up. Suicide attempters had significantly lower concentrations of CSF 5-HIAA at initial evaluation than non-attempters (mean [SE] 6.7 [2.2] vs 23.6 [5.6] ng/ml, p < 0.05). Our findings provide further evidence of the relation between serotoninergic dysfunction and suicide, and suggest a role for drugs with serotoninergic effects in schizophrenia.	QUEENS UNIV BELFAST, DEPT THERAPEUT & PHARMACOL, BELFAST BT9 7BL, ANTRIM, NORTH IRELAND; HOLYWELL HOSP, ANTRIM, NORTH IRELAND	Queens University Belfast	COOPER, SJ (corresponding author), QUEENS UNIV BELFAST, DEPT MENTAL HLTH, 97 LISBURN RD, BELFAST BT9 7BL, ANTRIM, NORTH IRELAND.							ASBERG M, 1976, ARCH GEN PSYCHIAT, V33, P1193; BANKI CM, 1984, J AFFECT DISORDERS, V6, P341, DOI 10.1016/S0165-0327(84)80012-9; DRAKE RE, 1985, COMPR PSYCHIAT, V26, P90, DOI 10.1016/0010-440X(85)90053-7; FEIGHNER JP, 1972, ARCH GEN PSYCHIAT, V26, P57, DOI 10.1001/archpsyc.1972.01750190059011; LEMUS CZ, 1990, BIOL PSYCHIAT, V27, P923, DOI 10.1016/0006-3223(90)90475-H; NINAN PT, 1984, AM J PSYCHIAT, V141, P566; ROY A, 1989, ARCH GEN PSYCHIAT, V46, P609; ROY A, 1985, PSYCHOL MED, V15, P335, DOI 10.1017/S0033291700023618; TRASKMAN L, 1981, ARCH GEN PSYCHIAT, V38, P631; VANPRAAG HM, 1983, LANCET, V2, P977	10	84	85	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 17	1992	340	8825					940	941		10.1016/0140-6736(92)92819-2	http://dx.doi.org/10.1016/0140-6736(92)92819-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT823	1383659				2022-12-28	WOS:A1992JT82300005
J	TATE, ME; ENNEKING, D				TATE, ME; ENNEKING, D			A MESS OF RED POTTAGE	NATURE			English	Editorial Material											TATE, ME (corresponding author), UNIV ADELAIDE,WAITE AGR RES INST,DEPT PLANT SCI,GLEN OSMOND,SA 5064,AUSTRALIA.							BARULINA H, 1930, T PRIKL BOT GENET S, V40, P302; Candolle AD, 1886, ORIGIN CULTIVATED PL; COKE LA, 1992, PLANT VAR SEEDS, V5, P1; DANCKWORTT PW, 1935, Z UNTERSUCHUNG LEBEN, V69, P458; HARPER JA, 1962, POULTRY SCI, V41, P1968, DOI 10.3382/ps.0411968; Hegi, 1925, ILLUSTRIERTE FLORA M; RESSLER C, 1969, J AM CHEM SOC, V91, P2758, DOI 10.1021/ja01038a058; 1959, FAO TABULATED INFORM, P297	8	36	36	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 1	1992	359	6394					357	358		10.1038/359357a0	http://dx.doi.org/10.1038/359357a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JQ624	1406942				2022-12-28	WOS:A1992JQ62400023
J	HUNT, AJ; DAVIES, PM; MCMANUS, TJ; WEATHERBURN, P; HICKSON, FCI; CHRISTOFINIS, G; COXON, APM; SUTHERLAND, S				HUNT, AJ; DAVIES, PM; MCMANUS, TJ; WEATHERBURN, P; HICKSON, FCI; CHRISTOFINIS, G; COXON, APM; SUTHERLAND, S			HIV-INFECTION IN A COHORT OF HOMOSEXUAL AND BISEXUAL MEN	BRITISH MEDICAL JOURNAL			English	Article							SEXUAL-BEHAVIOR; GONORRHEA		UNIV ESSEX,DEPT SOCIOL,COLCHESTER CO4 3SQ,ESSEX,ENGLAND; UNIV LONDON KINGS COLL HOSP,DEPT GENITOURINARY MED,LONDON SE5 8RX,ENGLAND; DULWICH HOSP,PUBL HLTH LAB SERV,LONDON SE22 8PT,ENGLAND	University of Essex; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; Public Health England	HUNT, AJ (corresponding author), S BANK UNIV,DEPT SOCIAL SCI,LONDON SE1 0AA,ENGLAND.		Weatherburn, Peter/AAC-2701-2019	Weatherburn, Peter/0000-0002-4950-6163				ADIB SM, 1991, AIDS, V5, P757, DOI 10.1097/00002030-199106000-00018; CARNE CA, 1987, LANCET, V1, P656; DAVIES PM, 1990, LONGITUDINAL STUDY S; STALL RD, 1988, AM PSYCHOL, V43, P878, DOI 10.1037/0003-066X.43.11.878; WAUGH MA, 1991, LANCET, V337, P375, DOI 10.1016/0140-6736(91)91017-O	5	17	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 5	1992	305	6853					561	562		10.1136/bmj.305.6853.561	http://dx.doi.org/10.1136/bmj.305.6853.561			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM495	1393036	Green Submitted, Bronze, Green Published			2022-12-28	WOS:A1992JM49500018
J	WAKSMAN, G; KOMINOS, D; ROBERTSON, SC; PANT, N; BALTIMORE, D; BIRGE, RB; COWBURN, D; HANAFUSA, H; MAYER, BJ; OVERDUIN, M; RESH, MD; RIOS, CB; SILVERMAN, L; KURIYAN, J				WAKSMAN, G; KOMINOS, D; ROBERTSON, SC; PANT, N; BALTIMORE, D; BIRGE, RB; COWBURN, D; HANAFUSA, H; MAYER, BJ; OVERDUIN, M; RESH, MD; RIOS, CB; SILVERMAN, L; KURIYAN, J			CRYSTAL-STRUCTURE OF THE PHOSPHOTYROSINE RECOGNITION DOMAIN SH2 OF V-SRC COMPLEXED WITH TYROSINE-PHOSPHORYLATED PEPTIDES	NATURE			English	Article							PANCREATIC TRYPSIN-INHIBITOR; PHOSPHOLIPASE-C; EGF RECEPTOR; SIGNAL TRANSDUCTION; TRANSFORMING GENE; ATOMIC-STRUCTURE; KINASE-ACTIVITY; X-RAY; PROTEIN; VIRUS	Three-dimensional structures of complexes of the SH2 domain of the v-src oncogene product with two phosphotyrosyl peptides have been determined by X-ray crystallography at resolutions of 1.5 and 2.0 angstrom, respectively. A central antiparallel beta-sheet in the structure is flanked by two alpha-helices, with peptide binding mediated by the sheet, intervening loops and one of the helices. The specific recognition of phosphotyrosine involves amino-aromatic interactions between lysine and arginine side chains and the ring system in addition to hydrogen-bonding interactions with the phosphate.	ROCKEFELLER UNIV, 1230 YORK AVE, NEW YORK, NY 10021 USA; HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA; SLOAN KETTERING MEM CANC CTR, DEPT CELL BIOL & GENET, NEW YORK, NY 10021 USA	Rockefeller University; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center			Cowburn, David/A-8448-2008; Overduin, Michael/AAG-3632-2020	Overduin, Michael/0000-0002-3114-6585; Cowburn, David/0000-0001-6770-7172; Resh, Marilyn/0000-0001-6118-9466				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BRANDEN C, 1991, INTRO PROTEIN STRUCT, P1; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1988, XPLOR VERSION 2 2 MA; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; CZERNILOFSKY AP, 1983, NATURE, V301, P736, DOI 10.1038/301736b0; DEAKYNE CA, 1985, J AM CHEM SOC, V107, P44; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GREGORY RJ, 1987, MOL CELL BIOL, V7, P2119, DOI 10.1128/MCB.7.6.2119; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HODEL A, IN PRESS ACTA CRYS A; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEVINSON AD, 1978, CELL, V15, P561, DOI 10.1016/0092-8674(78)90024-7; LEVITT M, 1988, J MOL BIOL, V201, P751, DOI 10.1016/0022-2836(88)90471-8; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; OVERDUIN M, IN PRESS CELL; OVERDUIN M, IN PRESS P NATN ACAD; PERUTZ MF, 1986, J AM CHEM SOC, V108, P1064, DOI 10.1021/ja00265a036; QUIOCHO FA, 1964, P NATL ACAD SCI USA, V52, P833, DOI 10.1073/pnas.52.3.833; RINGE D, 1983, P NATL ACAD SCI-BIOL, V80, P3879, DOI 10.1073/pnas.80.13.3879; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; RUSSELL RB, 1992, FEBS LETT, V304, P15, DOI 10.1016/0014-5793(92)80579-6; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TUCHSEN E, 1987, BIOCHEMISTRY-US, V26, P1918, DOI 10.1021/bi00381a020; ULHAQUE M, ACTA CRYSTALLOGR B, V26, P1528; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WEIS WI, 1990, J MOL BIOL, V212, P737, DOI 10.1016/0022-2836(90)90234-D; WLODAWER A, 1984, J MOL BIOL, V180, P301, DOI 10.1016/S0022-2836(84)80006-6	59	636	661	2	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 20	1992	358	6388					646	653		10.1038/358646a0	http://dx.doi.org/10.1038/358646a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ882	1379696				2022-12-28	WOS:A1992JJ88200046
J	TEMPLE, JMF; SYKES, AM				TEMPLE, JMF; SYKES, AM			ASTHMA AND OPEN CAST MINING	BRITISH MEDICAL JOURNAL			English	Article									UNIV COLL SWANSEA,SWANSEA SA2 8PP,W GLAM,WALES	Swansea University								KIRN TF, 1988, JAMA-J AM MED ASSOC, V260, P455; LLOYD OL, 1978, LANCET, V1, P318; NEWHOUSE ML, 1965, BRIT J IND MED, V22, P261; WILLIAMS SM, 1992, BRIT MED J, V304, P1359, DOI 10.1136/bmj.304.6838.1359; 1985, OFFICIAL J EUROPEAN, V175, P40	5	25	25	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 15	1992	305	6850					396	397		10.1136/bmj.305.6850.396	http://dx.doi.org/10.1136/bmj.305.6850.396			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK314	1392920	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JK31400015
J	DANIELS, DL; PLUNKETT, G; BURLAND, V; BLATTNER, FR				DANIELS, DL; PLUNKETT, G; BURLAND, V; BLATTNER, FR			ANALYSIS OF THE ESCHERICHIA-COLI GENOME - DNA-SEQUENCE OF THE REGION FROM 84.5 TO 86.5 MINUTES	SCIENCE			English	Article							DETERMINE ANTIGENIC SPECIFICITY; COMPLETE NUCLEOTIDE-SEQUENCE; DEPENDENT RNA HELICASE; GROUP-D SALMONELLAE; SACCHAROMYCES-CEREVISIAE; GENE-CLUSTER; MOLECULAR CHARACTERIZATION; TRANSCRIPTIONAL ACTIVITY; POSITIVE REGULATOR; BACILLUS-SUBTILIS	The DNA sequence of 91.4 kilobases of the Escherichia coli K-12 genome, spanning the region between rrnC at 84.5 minutes and rrnA at 86.5 minutes on the genetic map (85 to 87 percent on the physical map), is described. Analysis of this sequence identified 82 potential coding regions (open reading frames) covering 84 percent of the sequenced interval. The arrangement of these open reading frames, together with the consensus promoter sequences and terminator-like sequences found by computer searches, made it possible to assign them to proposed transcriptional units. More than half the open reading frames correlated with known genes or functions suggested by similarity to other sequences. Those remaining encode still unidentified proteins. The sequenced region also contains several RNA genes and two types of repeated sequence elements were found. Intergenic regions include three "gray holes," 0.6 to 0.8 kilobases, with no recognizable functions.			DANIELS, DL (corresponding author), UNIV WISCONSIN, GENET LAB, 445 HENRY MALL, MADISON, WI 53706 USA.		Plunkett, Guy/B-8058-2009	Plunkett, Guy/0000-0003-1422-469X	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000301] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00301] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ADAMS CW, 1988, J BACTERIOL, V170, P203, DOI 10.1128/jb.170.1.203-212.1988; AIBA H, 1984, NUCLEIC ACIDS RES, V12, P9427, DOI 10.1093/nar/12.24.9427; Bachmann B. J., 1987, ESCHERICHIA COLI SAL, V2, P807; Bachmann B.J., 1987, ESCHERICHIA COLI SAL, P1190; BACHMANN BJ, 1990, MICROBIOL REV, V54, P130, DOI 10.1128/MMBR.54.2.130-197.1990; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BARTLETT DH, 1988, J BACTERIOL, V170, P1575, DOI 10.1128/jb.170.4.1575-1581.1988; BERLYN M, COMMUNICATION; BOELKER M, 1989, EMBO (European Molecular Biology Organization) Journal, V8, P2403; BOYD J, 1990, UNPUB; CASHEL M, COMMUNICATION; CHRISTMAN MF, 1989, P NATL ACAD SCI USA, V86, P3484, DOI 10.1073/pnas.86.10.3484; Church George, COMMUNICATION, V207; COPPOLA G, 1991, GENE, V97, P21, DOI 10.1016/0378-1119(91)90005-V; Daniels D L, 1983, Cold Spring Harb Symp Quant Biol, V47 Pt 2, P1009; DANIELS DL, 1990, BACTERIAL CHROMOSOME, P43; DANIELS DL, 1990, NUCLEIC ACIDS RES, V18, P2649, DOI 10.1093/nar/18.9.2649; DANIELS DL, 1987, NATURE, V325, P831, DOI 10.1038/325831a0; DANIELS DL, 1990, STRUCTURE METHODS, V1, P29; DERETIC V, 1987, NUCLEIC ACIDS RES, V15, P4567, DOI 10.1093/nar/15.11.4567; DHILLON N, 1989, MOL MICROBIOL, V3, P1405, DOI 10.1111/j.1365-2958.1989.tb00123.x; DISTLER J, 1987, NUCLEIC ACIDS RES, V15, P8041, DOI 10.1093/nar/15.19.8041; DORER DR, 1990, NUCLEIC ACIDS RES, V18, P5489, DOI 10.1093/nar/18.18.5489; DUNN JJ, 1981, J MOL BIOL, V148, P303, DOI 10.1016/0022-2836(81)90178-9; ENDO F, 1989, J BIOL CHEM, V264, P4476; GILCHRIST CA, 1987, NUCLEIC ACIDS RES, V15, P465, DOI 10.1093/nar/15.2.465; GOLDMAN RC, 1986, J BIOL CHEM, V261, P5831; GOSS TJ, 1985, MOL GEN GENET, V201, P308, DOI 10.1007/BF00425676; GRIBSKOV M, 1984, NUCLEIC ACIDS RES, V12, P539, DOI 10.1093/nar/12.1Part2.539; HAGSTROM R, COMMUNICATION; HAY B, 1988, CELL, V55, P577, DOI 10.1016/0092-8674(88)90216-4; HENIKOFF S, 1988, P NATL ACAD SCI USA, V85, P6602, DOI 10.1073/pnas.85.18.6602; HENIKOFF SJC, 1990, METHOD ENZYMOL, V183, P111; HENNER DJ, 1988, J BACTERIOL, V170, P5102, DOI 10.1128/jb.170.11.5102-5109.1988; HIRATSUKA J, 1989, MOL GEN GENET, V217, P185, DOI 10.1007/BF02464880; HLOCH P, 1990, NUCLEIC ACIDS RES, V18, P3045, DOI 10.1093/nar/18.10.3045; HOFFMANN W, 1985, J BIOL CHEM, V260, P1831; HONORE N, 1990, NUCLEIC ACIDS RES, V18, P653, DOI 10.1093/nar/18.3.653; HULTON CSJ, 1991, MOL MICROBIOL, V5, P825, DOI 10.1111/j.1365-2958.1991.tb00755.x; IGGO R, 1990, NUCLEIC ACIDS RES, V18, P5413, DOI 10.1093/nar/18.18.5413; IKEDA M, 1990, NUCLEIC ACIDS RES, V18, P1058, DOI 10.1093/nar/18.4.1058; KALMAN M, 1991, NEW BIOL, V3, P886; KOBAYASHI T, 1985, J BIOCHEM-TOKYO, V98, P1017, DOI 10.1093/oxfordjournals.jbchem.a135347; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KROGER M, 1991, NUCLEIC ACIDS RES, V19, P2023, DOI 10.1093/nar/19.suppl.2023; KROGER M, 1989, NUCLEIC ACIDS RES S, V17, P283; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; LAWTHER RP, 1981, P NATL ACAD SCI-BIOL, V78, P922, DOI 10.1073/pnas.78.2.922; LEROY P, 1989, CELL, V57, P549, DOI 10.1016/0092-8674(89)90125-6; LEVENE SD, 1983, J BIOMOL STRUCT DYN, V1, P429, DOI 10.1080/07391102.1983.10507452; LINDER P, 1988, NUCLEIC ACIDS RES, V16, P10359, DOI 10.1093/nar/16.21.10359; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MAGIURE M, COMMUNICATION; MATSUMOTO Y, 1986, J BACTERIOL, V166, P945, DOI 10.1128/jb.166.3.945-958.1986; MAXON ME, 1990, P NATL ACAD SCI USA, V87, P7076, DOI 10.1073/pnas.87.18.7076; MAXON ME, 1989, P NATL ACAD SCI USA, V86, P85, DOI 10.1073/pnas.86.1.85; MEIERDIETER U, 1992, J BIOL CHEM, V267, P746; MEIGHEN EA, 1991, MICROBIOL REV, V55, P123, DOI 10.1128/MMBR.55.1.123-142.1991; MOYLE H, 1991, J BACTERIOL, V173, P1944, DOI 10.1128/jb.173.6.1944-1950.1991; MUROOKA Y, 1990, J BACTERIOL, V172, P2131, DOI 10.1128/jb.172.4.2131-2140.1990; NAKAHIGASHI K, 1990, NUCLEIC ACIDS RES, V18, P6439, DOI 10.1093/nar/18.21.6439; NIELSEN PJ, 1985, NUCLEIC ACIDS RES, V13, P6867, DOI 10.1093/nar/13.19.6867; NIKAIDO H, 1987, ESCHERICHIA COLI SAL, P7; NISHI K, 1988, NATURE, V336, P496, DOI 10.1038/336496a0; NISHI K, 1989, NATURE, V340, P246, DOI 10.1038/340246a0; OHTA M, 1991, MOL MICROBIOL, V5, P1853, DOI 10.1111/j.1365-2958.1991.tb00809.x; OHTAKE Y, 1988, AGR BIOL CHEM TOKYO, V52, P2753, DOI 10.1080/00021369.1988.10869126; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; OLSON C H, 1991, Methods (Orlando), V3, P27, DOI 10.1016/S1046-2023(05)80160-4; OSTROWSKI J, 1987, J BIOL CHEM, V262, P5999; PARK MH, 1976, J BACTERIOL, V126, P1096, DOI 10.1128/JB.126.3.1096-1103.1976; PEGUES JC, 1990, J BACTERIOL, V172, P4652, DOI 10.1128/jb.172.8.4652-4660.1990; PINKHAM JL, 1983, NUCLEIC ACIDS RES, V11, P3531, DOI 10.1093/nar/11.11.3531; REHEMTULLA A, 1986, J BACTERIOL, V166, P651, DOI 10.1128/jb.166.2.651-657.1986; ROTHMEL RK, 1990, J BACTERIOL, V172, P922, DOI 10.1128/jb.172.2.922-931.1990; RUDD KE, 1991, NUCLEIC ACIDS RES, V19, P637, DOI 10.1093/nar/19.3.637; RUDD KE, 1992, SHORT COURSE BACTERI; SANGER F, 1977, NATURE, V265, P687, DOI 10.1038/265687a0; SANGER F, 1982, J MOL BIOL, V162, P729, DOI 10.1016/0022-2836(82)90546-0; SASARMAN A, 1988, J BACTERIOL, V170, P1575; SEOL W, 1991, P NATL ACAD SCI USA, V88, P3802, DOI 10.1073/pnas.88.9.3802; SERAPHIN B, 1989, NATURE, V337, P84, DOI 10.1038/337084a0; SHARMA RC, 1983, J BACTERIOL, V154, P743, DOI 10.1128/JB.154.2.743-747.1983; SHARMA RC, 1987, MUTAT RES, V184, P23, DOI 10.1016/0167-8817(87)90032-0; SHARPLES GJ, 1990, NUCLEIC ACIDS RES, V18, P6503, DOI 10.1093/nar/18.22.6503; SHAVLIK J, 1990, 988 U WISC COMP SCI; SMITH CL, 1987, SCIENCE, V236, P1448, DOI 10.1126/science.3296194; SOPHIANOPOULOU V, 1989, MOL MICROBIOL, V3, P705, DOI 10.1111/j.1365-2958.1989.tb00219.x; SPARROW CP, 1983, J BIOL CHEM, V258, P9963; SPYROU G, 1991, J BACTERIOL, V173, P3673, DOI 10.1128/JB.173.12.3673-3679.1991; STADEN R, 1982, NUCLEIC ACIDS RES, V10, P141, DOI 10.1093/nar/10.1.141; STAINTHORPE AC, 1990, GENE, V91, P27, DOI 10.1016/0378-1119(90)90158-N; STEIN C, 1989, J BIOL CHEM, V264, P1252; STRAGIER P, 1983, J MOL BIOL, V168, P333, DOI 10.1016/S0022-2836(83)80022-9; SUTCLIFFE JG, 1979, COLD SPRING HARB SYM, V43, P77, DOI 10.1101/SQB.1979.043.01.013; SUZUKI M, 1991, J BACTERIOL, V173, P1690, DOI 10.1128/jb.173.5.1690-1695.1991; SWARTZMAN E, 1990, J BACTERIOL, V172, P6797, DOI 10.1128/jb.172.12.6797-6802.1990; SWARTZMAN E, 1990, J BIOL CHEM, V265, P3513; TAKAGI M, 1990, J BACTERIOL, V172, P411, DOI 10.1128/JB.172.1.411-418.1990; TOONE WM, 1991, J BACTERIOL, V173, P3291, DOI 10.1128/jb.173.11.3291-3302.1991; VANDENBOL M, 1989, GENE, V83, P153, DOI 10.1016/0378-1119(89)90413-7; VERMA N, 1989, J BACTERIOL, V171, P5694, DOI 10.1128/jb.171.10.5694-5701.1989; WASSARMAN DA, 1991, NATURE, V349, P463, DOI 10.1038/349463a0; WEBSTER TD, 1988, NUCLEIC ACIDS RES, V16, P8192, DOI 10.1093/nar/16.16.8192; WEK RC, 1986, J BIOL CHEM, V261, P2441; YAMADA T, 1978, J BACTERIOL, V133, P536, DOI 10.1128/JB.133.2.536-541.1978; YAMAMOTO Y, 1986, J BIOCHEM-TOKYO, V99, P1579, DOI 10.1093/oxfordjournals.jbchem.a135631; YANG Y, 1990, BACTERIAL CHROMOSOME, P211	108	235	319	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 7	1992	257	5071					771	778		10.1126/science.1379743	http://dx.doi.org/10.1126/science.1379743			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG851	1379743				2022-12-28	WOS:A1992JG85100027
J	DAVIES, PH; FRANKLYN, JA; SHEPPARD, MC				DAVIES, PH; FRANKLYN, JA; SHEPPARD, MC			TREATMENT OF AMIODARONE INDUCED THYROTOXICOSIS WITH CARBIMAZOLE ALONE AND CONTINUATION OF AMIODARONE	BRITISH MEDICAL JOURNAL			English	Article							INDUCED HYPERTHYROIDISM				DAVIES, PH (corresponding author), UNIV BIRMINGHAM,QUEEN ELIZABETH HOSP,DEPT MED,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND.							GAMMAGE MD, 1987, Q J MED, V283, P83; MARTINO E, 1987, HORM RES, V26, P158, DOI 10.1159/000180696; MEHRA A, 1991, AM HEART J, V122, P1160, DOI 10.1016/0002-8703(91)90488-4; REICHERT LJM, 1989, BRIT MED J, V298, P1547, DOI 10.1136/bmj.298.6687.1547; WIMPFHEIMER C, 1982, BRIT MED J, V284, P1835, DOI 10.1136/bmj.284.6332.1835-a	5	23	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1992	305	6847					224	225		10.1136/bmj.305.6847.224	http://dx.doi.org/10.1136/bmj.305.6847.224			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG112	1392826	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992JG11200023
J	DEWIND, CM				DEWIND, CM			A TALE OF ONE CITY	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1992	305	6847					260	260		10.1136/bmj.305.6847.260	http://dx.doi.org/10.1136/bmj.305.6847.260			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG112	1392851	Green Submitted, Bronze, Green Published			2022-12-28	WOS:A1992JG11200070
J	FFYTCHE, TJ; BRANDT, F; CERCHEZ, J; STOICESCU, S; STINGL, P; FILITIS, M				FFYTCHE, TJ; BRANDT, F; CERCHEZ, J; STOICESCU, S; STINGL, P; FILITIS, M			OCULAR COMPLICATIONS OBSERVED IN LEPROSY PATIENTS IN ROMANIA	BRITISH MEDICAL JOURNAL			English	Article									EYE CLIN HOSP,BUCHAREST,ROMANIA		FFYTCHE, TJ (corresponding author), ST THOMAS HOSP,LONDON SE1 7EH,ENGLAND.							BORTHEN L, 1902, BLINDENVERHALTNISSE; COURTRIGHT P, 1988, PREVENTION BLINDNESS; FFYTCHE TJ, 1983, LEPROSY REV, V54, P271; GIBSON J B G, 1950, Med J Aust, V1, P8; Hobbs H E, 1971, Lepr Rev, V42, P131; LOWE J, 1955, P ROY SOC MED, V48, P107, DOI 10.1177/003591575504800210; PENDERGAST JJ, 1940, ARCH OPHTHALMOL-CHIC, V23, P112; SHIELDS JA, 1974, AM J OPHTHALMOL, V77, P880, DOI 10.1016/0002-9394(74)90393-6; SUZUKI T, 1980, Folia Ophthalmologica Japonica, V31, P1719; WANGSPA S, 1976, T ASIA PACIFIC ACADE, V5, P153	10	5	5	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1992	305	6847					240	242		10.1136/bmj.305.6847.240	http://dx.doi.org/10.1136/bmj.305.6847.240			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG112	1392833	Bronze, Green Submitted, Green Published			2022-12-28	WOS:A1992JG11200031
J	SHI, YF; GLYNN, JM; GUILBERT, LJ; COTTER, TG; BISSONNETTE, RP; GREEN, DR				SHI, YF; GLYNN, JM; GUILBERT, LJ; COTTER, TG; BISSONNETTE, RP; GREEN, DR			ROLE FOR C-MYC IN ACTIVATION-INDUCED APOPTOTIC CELL-DEATH IN T-CELL HYBRIDOMAS	SCIENCE			English	Article							GENE-EXPRESSION; MACROMOLECULAR-SYNTHESIS; DNA FRAGMENTATION; SUICIDE PROGRAM; IL-2 ADDICTION; PROTEIN; ANTISENSE; GROWTH; THYMOCYTES; INHIBITION	Immature T cells and some T cell hybridomas undergo apoptotic cell death when activated through the T cell receptor complex, a phenomenon that is probably related to antigen induced negative selection of developing T cells. This activation-induced apoptosis depends on active protein and RNA synthesis in the dying cells, although none of the genes required for this process have previously been identified. Antisense oligonucleotides corresponding to c-myc block the constitutive expression of c-Myc protein in T cell hybridomas and interfere with all aspects of activation-induced apoptosis without affecting lymphokine production in these cells. These data indicate that c-myc expression is a necessary component of activation-induced apoptosis.	LA JOLLA INST ALLERGY & IMMUNOL,LA JOLLA,CA 92037; UNIV ALBERTA,DEPT IMMUNOL,EDMONTON T6G 2H7,ALBERTA,CANADA; ST PATRICKS COLL,DEPT BIOL,MAYNOOTH,KILDARE,IRELAND	La Jolla Institute for Immunology; University of Alberta; Maynooth University			Green, Douglas R/N-8083-2018; Shi, Yufang/AAE-4431-2020	Green, Douglas R/0000-0002-7332-1417; Shi, Yufang/0000-0001-8964-319X; Cotter, Thomas/0000-0003-4626-5613	NIAID NIH HHS [AI31591] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031591] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altman A, 1990, Adv Immunol, V48, P227, DOI 10.1016/S0065-2776(08)60756-7; ASKEW DS, 1991, ONCOGENE, V6, P1915; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BURSCH W, 1990, BIOCHEM CELL BIOL, V68, P1071, DOI 10.1139/o90-160; COHEN JJ, 1984, J IMMUNOL, V132, P38; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COTTER TG, 1992, CANCER RES, V52, P997; DEGOLS G, 1991, NUCLEIC ACIDS RES, V19, P945, DOI 10.1093/nar/19.4.945; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; FOTEDAR A, 1985, J IMMUNOL, V135, P3028; HARELBELLAN A, 1988, J IMMUNOL, V140, P2431; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; IWATA M, 1991, EUR J IMMUNOL, V21, P643, DOI 10.1002/eji.1830210316; KADDURAHDAOUK R, 1987, GENE DEV, V1, P347, DOI 10.1101/gad.1.4.347; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; Kerr J.F.R., 1987, P93; KERR JFR, 1980, INT REV CYTOL, V68, P251; MCCONKEY DJ, 1990, ARCH BIOCHEM BIOPHYS, V278, P284, DOI 10.1016/0003-9861(90)90261-V; MCMANAWAY ME, 1990, LANCET, V335, P808, DOI 10.1016/0140-6736(90)90934-W; MORRIS RG, 1984, AM J PATHOL, V115, P426; ODAKA C, 1990, J IMMUNOL, V144, P2096; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; PALLAVICINI MG, 1990, J CELL PHYSIOL, V143, P372, DOI 10.1002/jcp.1041430223; PENDERGAST GC, 1991, CELL, V65, P395; PULLEN AM, 1989, IMMUNOL REV, V107, P125, DOI 10.1111/j.1600-065X.1989.tb00006.x; REED JC, 1990, P NATL ACAD SCI USA, V87, P3660, DOI 10.1073/pnas.87.10.3660; REIGEL JS, 1990, J IMMUNOL, V144, P3611; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; Shi Y. G., UNPUB; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; SHI YF, 1990, J IMMUNOL, V144, P3326; SHI YF, 1991, J IMMUNOL, V146, P3340; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SWAT W, 1991, J IMMUNOL METHODS, V137, P79, DOI 10.1016/0022-1759(91)90396-W; UCKER DS, 1989, J IMMUNOL, V143, P3461; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WATERS CM, 1991, ONCOGENE, V6, P797; WURM FM, 1986, P NATL ACAD SCI USA, V83, P5414, DOI 10.1073/pnas.83.15.5414; WYLLIE AH, 1987, BRIT J CANCER, V56, P251, DOI 10.1038/bjc.1987.186; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YUH YS, 1989, J BIOL CHEM, V264, P10904; ZACHARCHUK CM, 1990, J IMMUNOL, V145, P4037	48	756	774	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 10	1992	257	5067					212	214		10.1126/science.1378649	http://dx.doi.org/10.1126/science.1378649			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC585	1378649				2022-12-28	WOS:A1992JC58500028
J	CLIPSTONE, NA; CRABTREE, GR				CLIPSTONE, NA; CRABTREE, GR			IDENTIFICATION OF CALCINEURIN AS A KEY SIGNALING ENZYME IN LYMPHOCYTE-T ACTIVATION	NATURE			English	Article							CYCLOSPORINE-A; EXPRESSION; BINDING; GENE; CYCLOPHILIN; PHOSPHATASE; CALMODULIN; PROTEINS; ENHANCER; CLONING	THE immunosuppressive drugs cyclosporin A (CsA) and FK506 both interfere with a Ca2+-sensitive T-cell signal transduction pathway 1-4, thereby preventing the activation of specific transcription factors (such as NF-AT and NF-IL2A) 1,5-7 involved in lymphokine gene expression. CsA and FK506 seem to act by interaction with their cognate intracellular receptors 8-10, cyclophilin and FKBP, respectively (see ref. 11 for review). The Ca2+/calmodulin-regulated phosphatase calcineurin is a major target of drug-isomerase complexes in vitro 12. We have therefore tested the hypothesis that this interaction is responsible for the in vivo effects of CsA/FK506. We report here that overexpression of calcineurin in Jurkat cells renders them more resistant to the effects of CsA and FK506 and augments both NFAT- and NFIL2A-dependent transcription. These results identify calcineurin as a key enzyme in the T-cell signal transduction cascade and provide biological evidence to support the notion that the interaction of drug-isomerase complexes with calcineurin underlies the molecular basis of CsA/FK506-mediated immunosuppression.			CLIPSTONE, NA (corresponding author), STANFORD UNIV,MED CTR,SCH MED,HOWARD HUGHES MED INST,BECKMAN CTR MOLEC & GENET MED,STANFORD,CA 94305, USA.							BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FLANAGAN WM, 1992, J BIOL CHEM, V267, P399; GUERINI D, 1989, P NATL ACAD SCI USA, V86, P9183, DOI 10.1073/pnas.86.23.9183; GUNTER KC, 1989, J IMMUNOL, V142, P3286; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; KAY JE, 1989, CELL IMMUNOL, V124, P175, DOI 10.1016/0008-8749(89)90121-4; KINCAID RL, 1990, J BIOL CHEM, V265, P11312; KINCAID RL, 1987, NATURE, V330, P176, DOI 10.1038/330176a0; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; LIN CS, 1991, CELL IMMUNOL, V133, P269, DOI 10.1016/0008-8749(91)90103-I; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LUI J, 1992, BIOCHEMISTRY-US, V31, P3896; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MCPARTLIN AE, 1991, BIOCHIM BIOPHYS ACTA, V1088, P308, DOI 10.1016/0167-4781(91)90069-X; MERAT DL, 1985, J BIOL CHEM, V260, P1053; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; RANDAK C, 1990, EMBO J, V9, P2529, DOI 10.1002/j.1460-2075.1990.tb07433.x; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; TROPSCHUG M, 1989, NATURE, V342, P953, DOI 10.1038/342953a0	23	1499	1560	2	36	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 25	1992	357	6380					695	697		10.1038/357695a0	http://dx.doi.org/10.1038/357695a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA430	1377362				2022-12-28	WOS:A1992JA43000073
J	ISOM, LL; DEJONGH, KS; PATTON, DE; REBER, BFX; OFFORD, J; CHARBONNEAU, H; WALSH, K; GOLDIN, AL; CATTERALL, WA				ISOM, LL; DEJONGH, KS; PATTON, DE; REBER, BFX; OFFORD, J; CHARBONNEAU, H; WALSH, K; GOLDIN, AL; CATTERALL, WA			PRIMARY STRUCTURE AND FUNCTIONAL EXPRESSION OF THE BETA-1-SUBUNIT OF THE RAT-BRAIN SODIUM-CHANNEL	SCIENCE			English	Article							AMINO-ACID SEQUENCE; PURIFIED CALCIUM CHANNELS; SITE-DIRECTED ANTIBODIES; ALPHA-SUBUNIT; XENOPUS-OOCYTES; ELECTROPHORUS-ELECTRICUS; BIOCHEMICAL-PROPERTIES; SAXITOXIN RECEPTOR; BINDING-PROTEIN; BETA-2 SUBUNITS	Voltage-sensitive sodium channels are responsible for the initiation and propagation of the action potential and therefore are important for neuronal excitability. Complementary DNA clones encoding the beta-1 subunit of the rat brain sodium channel were isolated by a combination of polymerase chain reaction and library screening techniques. The deduced primary structure indicates that the beta-1 subunit is a 22,851 -dalton protein that contains a single putative transmembrane domain and four potential extracellular N-linked glycosylation sites, consistent with biochemical data. Northern blot analysis reveals a 1400-nucleotide messenger RNA in rat brain, heart, skeletal muscle, and spinal cord. Coexpression of beta-1 subunits with alpha-subunits increases the size of the peak sodium current, accelerates its inactivation, and shifts the voltage dependence of inactivation to more negative membrane potentials. These results indicate that the beta-1 subunit is crucial in the assembly, expression, and functional modulation of the heterotrimeric complex of the rat brain sodium channel.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195; UNIV CALIF IRVINE,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of California System; University of California Irvine; University of Washington; University of Washington Seattle			Goldin, Alan/A-8385-2015	Goldin, Alan/0000-0001-7159-0288; Offord, James/0000-0003-4180-0146; Isom, Lori/0000-0002-9479-6729	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026729, R01NS025704, R01NS015751] Funding Source: NIH RePORTER; NINDS NIH HHS [NS25704, NS15751, NS26729] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; AGNEW WS, 1980, BIOCHEM BIOPH RES CO, V92, P860, DOI 10.1016/0006-291X(80)90782-2; AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; DEJONGH KS, 1989, P NATL ACAD SCI USA, V86, P8585; DEJONGH KS, 1990, J BIOL CHEM, V265, P14738; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GOLDIN AL, 1986, P NATL ACAD SCI USA, V83, P7503, DOI 10.1073/pnas.83.19.7503; GORDON D, 1988, BIOCHEMISTRY-US, V27, P7032, DOI 10.1021/bi00418a054; GORDON D, 1987, P NATL ACAD SCI USA, V84, P8682, DOI 10.1073/pnas.84.23.8682; HARTSHORNE RP, 1984, J BIOL CHEM, V259, P1667; HARTSHORNE RP, 1981, P NATL ACAD SCI-BIOL, V78, P4620, DOI 10.1073/pnas.78.7.4620; HARTSHORNE RP, 1982, J BIOL CHEM, V257, P3888; Hille B, 1984, IONIC CHANNELS EXCIT; JOHO RH, 1990, MOL BRAIN RES, V7, P105, DOI 10.1016/0169-328X(90)90087-T; KAYANO T, 1988, FEBS LETT, V228, P187, DOI 10.1016/0014-5793(88)80614-8; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRAFTE DS, 1990, J GEN PHYSIOL, V96, P689, DOI 10.1085/jgp.96.4.689; KRANER SD, 1985, J BIOL CHEM, V260, P6341; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; LOMBET A, 1984, EUR J BIOCHEM, V141, P651, DOI 10.1111/j.1432-1033.1984.tb08241.x; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MESSNER DJ, 1986, J BIOL CHEM, V261, P211; MESSNER DJ, 1986, J BIOL CHEM, V261, P4882; MESSNER DJ, 1985, J BIOL CHEM, V260, P597; MILLER JA, 1983, BIOCHEMISTRY-US, V22, P462, DOI 10.1021/bi00271a032; NODA M, 1986, NATURE, V322, P826, DOI 10.1038/322826a0; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; PATTON DE, 1991, NEURON, V7, P637, DOI 10.1016/0896-6273(91)90376-B; REBER BFX, 1987, J BIOL CHEM, V262, P11369; SCHEUER T, 1990, SCIENCE, V247, P854, DOI 10.1126/science.2154850; SCHMIDT JW, 1987, J BIOL CHEM, V262, P13713; SCHMIDT JW, 1986, CELL, V46, P437, DOI 10.1016/0092-8674(86)90664-1; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; SUTKOWSKI EM, 1990, J BIOL CHEM, V265, P12393; SUZUKI H, 1988, FEBS LETT, V228, P195, DOI 10.1016/0014-5793(88)80615-X; WEST JW, 1992, NEURON, V8, P59, DOI 10.1016/0896-6273(92)90108-P	39	609	622	1	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 8	1992	256	5058					839	842		10.1126/science.1375395	http://dx.doi.org/10.1126/science.1375395			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT235	1375395				2022-12-28	WOS:A1992HT23500046
J	ARMITAGE, RJ; FANSLOW, WC; STROCKBINE, L; SATO, TA; CLIFFORD, KN; MACDUFF, BM; ANDERSON, DM; GIMPEL, SD; DAVISSMITH, T; MALISZEWSKI, CR; CLARK, EA; SMITH, CA; GRABSTEIN, KH; COSMAN, D; SPRIGGS, MK				ARMITAGE, RJ; FANSLOW, WC; STROCKBINE, L; SATO, TA; CLIFFORD, KN; MACDUFF, BM; ANDERSON, DM; GIMPEL, SD; DAVISSMITH, T; MALISZEWSKI, CR; CLARK, EA; SMITH, CA; GRABSTEIN, KH; COSMAN, D; SPRIGGS, MK			MOLECULAR AND BIOLOGICAL CHARACTERIZATION OF A MURINE LIGAND FOR CD40	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; GROWTH-FACTOR RECEPTOR; HUMAN B-CELLS; MONOCLONAL-ANTIBODY; CARCINOMA ANTIGEN; GENE-TRANSFER; ACTIVATION; EXPRESSION; CLONING; DIFFERENTIATION	THE CD40 surface molecule is a 277-amino-acid glycoprotein expressed on B lymphocytes, epithelial cells and some carcinoma cell lines. Monoclonal antibodies against CD40 mediate a variety of effects on B lymphocytes, including induction of intercellular adhesion 1,2, short- and long-term proliferation 3-5, differentiation 6,7 and enhanced tyrosine phosphorylation of proteins 8. In addition, germinal centre centrocytes are prevented from undergoing apoptosis by activation through CD40 and receptor for antigen 9. These data indicate that CD40 could be a receptor for an unknown ligand with important functions in B-cell development and activation. This hypothesis is strengthened by the homology of the extracellular region of the CD40 molecule 10 with a family of cell-surface glycoproteins 11,12 that includes the receptors for nerve growth factor 13,14 and tumour necrosis factor 11,15,16. Here we report the cloning of a ligand for CD40 that is expressed on the cell surface of activated T cells and mediates B-cell proliferation in the absence of co-stimulus, as well as IgE production in the presence of interleukin-4.	IMMUNEX RES & DEV CORP,DEPT MOLEC BIOL,SEATTLE,WA 98101; IMMUNEX RES & DEV CORP,DEPT BIOCHEM,SEATTLE,WA 98101; UNIV WASHINGTON,DEPT MICROBIOL SC42,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	ARMITAGE, RJ (corresponding author), IMMUNEX RES & DEV CORP,DEPT IMMUNOL,51 UNIV ST,SEATTLE,WA 98101, USA.			Clark, Edward A/0000-0001-8061-5475				BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; BARRETT TB, 1991, J IMMUNOL, V146, P1722; BRAESCHANDERSEN S, 1989, J IMMUNOL, V142, P562; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; COFFMAN RL, 1988, IMMUNOL REV, V102, P5, DOI 10.1111/j.1600-065X.1988.tb00739.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FANSLOW WC, IN PRESS J IMMUN; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; PAULIE S, 1989, J IMMUNOL, V142, P590; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SMITH CA, 1991, BIOCHEM BIOPH RES CO, V176, P335, DOI 10.1016/0006-291X(91)90929-2; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SPRIGGS MK, 1990, J BIOL CHEM, V265, P22499; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; THOMAS G, 1988, ANNU REV PHYSIOL, V50, P323; UCKUN FM, 1991, J BIOL CHEM, V266, P17478; VALLE A, 1989, EUR J IMMUNOL, V19, P1463, DOI 10.1002/eji.1830190818; ZHANG K, 1991, J IMMUNOL, V146, P1836	25	1050	1157	1	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 7	1992	357	6373					80	82		10.1038/357080a0	http://dx.doi.org/10.1038/357080a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT229	1374165				2022-12-28	WOS:A1992HT22900063
J	RICHMOND, PW; MCCABE, M; DAVIES, JP; THOMAS, DM				RICHMOND, PW; MCCABE, M; DAVIES, JP; THOMAS, DM			PERFORATION OF GLOVES IN AN ACCIDENT AND EMERGENCY DEPARTMENT	BRITISH MEDICAL JOURNAL			English	Article							RISK				RICHMOND, PW (corresponding author), CARDIFF ROYAL INFIRM,DEPT ACCID & EMERGENCY,CARDIFF CF2 1SZ,S GLAM,WALES.							BROUGH SJ, 1988, BRIT J SURG, V75, P317, DOI 10.1002/bjs.1800750408; CHAN P, 1989, BRIT J SURG, V76, P1208, DOI 10.1002/bjs.1800761129; Church J, 1980, J Hosp Infect, V1, P84, DOI 10.1016/0195-6701(80)90036-5; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; HUSSAIN SA, 1988, BRIT J SURG, V75, P314, DOI 10.1002/bjs.1800750407	5	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1992	304	6831					879	880		10.1136/bmj.304.6831.879	http://dx.doi.org/10.1136/bmj.304.6831.879			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM835	1392748	Green Published, Bronze			2022-12-28	WOS:A1992HM83500025
J	EZEKOWITZ, MD; BRIDGERS, SL; JAMES, KE; CARLINER, NH; COLLING, CL; GORNICK, CC; KRAUSESTEINRAUF, H; KURTZKE, JF; NAZARIAN, SM; RADFORD, MJ; RICKLES, FR; SHABETAI, R; DEYKIN, D				EZEKOWITZ, MD; BRIDGERS, SL; JAMES, KE; CARLINER, NH; COLLING, CL; GORNICK, CC; KRAUSESTEINRAUF, H; KURTZKE, JF; NAZARIAN, SM; RADFORD, MJ; RICKLES, FR; SHABETAI, R; DEYKIN, D			WARFARIN IN THE PREVENTION OF STROKE ASSOCIATED WITH NONRHEUMATIC ATRIAL-FIBRILLATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FRAMINGHAM; POPULATION	Background. Nonrheumatic atrial fibrillation is common among the elderly and is associated with an increased risk of stroke. We investigated whether anticoagulation with warfarin would reduce this risk. Methods. We conducted a randomized, double-blind, placebo-controlled study to evaluate low-intensity anticoagulation with warfarin (prothrombin-time ratio, 1.2 to 1.5) in 571 men with chronic nonrheumatic atrial fibrillation; 525 patients had not previously had a cerebral infarction, whereas 46 patients had previously had such an event. The primary end point was cerebral infarction; secondary end points were cerebral hemorrhage and death. Results. Among the patients with no history of stroke, cerebral infarction occurred in 19 of the 265 patients in the placebo group during an average follow-up of 1.7 years (4.3 percent per year) and in 4 of the 260 patients in the warfarin group during an average follow-up of 1.8 years (0.9 percent per year). The reduction in risk with warfarin therapy was 0.79 (95 percent confidence interval, 0.52 to 0.90; P = 0.001). The annual event rate among the 228 patients over 70 years of age was 4.8 percent in the placebo group and 0.9 percent in the warfarin group (risk reduction, 0.79; P = 0.02). The only cerebral hemorrhage occurred in a 73-year-old patient in the warfarin group. Other major hemorrhages, all gastrointestinal, occurred in 10 patients: 4 in the placebo group, for a rate of 0.9 percent per year, and 6 in the warfarin group, for a rate of 1.3 percent per year. There were 37 deaths that were not preceded by a cerebral end point - 22 in the placebo group and 15 in the warfarin group (risk reduction, 0.31; P = 0.19). Cerebral infarction was more common among patients with a history of cerebral infarction (9.3 percent per year in the placebo group and 6.1 percent per year in the warfarin group) than among those without such a history. Conclusions. Low-intensity anticoagulation with warfarin prevented cerebral infarction in patients with nonrheumatic atrial fibrillation without producing an excess risk of major hemorrhage. This benefit extended to patients over 70 years of age.			EZEKOWITZ, MD (corresponding author), YALE UNIV,DEPT VET AFFAIRS MED CTR,SCH MED,CARDIOVASC SECT,111B,CLIN CAMPUS,950 CAMPBELL AVE,W HAVEN,CT 06516, USA.		Ezekowitz, Michael/AAJ-2543-2021	Radford, Martha/0000-0001-7503-9557				ANSELLJE, 1992, NEW ENGL J MED, V326, P68; BRAND FN, 1985, JAMA-J AM MED ASSOC, V254, P3449, DOI 10.1001/jama.254.24.3449; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; DIXON WJ, 1988, BMDP STATISTICAL SOF, P700; HISS RG, 1962, CIRCULATION, V25, P947, DOI 10.1161/01.CIR.25.6.947; HULL R, 1982, NEW ENGL J MED, V307, P1676, DOI 10.1056/NEJM198212303072704; KANNEL WB, 1982, NEW ENGL J MED, V306, P1018, DOI 10.1056/NEJM198204293061703; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KITCHIN AH, 1977, BRIT HEART J, V39, P889, DOI 10.1136/hrt.39.8.889; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P340; KOPECKY SL, 1987, NEW ENGL J MED, V317, P669, DOI 10.1056/NEJM198709103171104; PETERSEN P, 1989, LANCET, V1, P175; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; TURPIE AGG, 1988, LANCET, V1, P1242; WOLF PA, 1978, NEUROLOGY, V28, P973, DOI 10.1212/WNL.28.10.973; 1990, STROKE, V21, P538; 1991, CIRCULATION, V84, P527; 1990, NEW ENGL J MED, V322, P863; 1990, NEW ENGL J MED, V323, P1505	19	1092	1112	1	23	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 12	1992	327	20					1406	1412		10.1056/NEJM199211123272002	http://dx.doi.org/10.1056/NEJM199211123272002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX479	1406859				2022-12-28	WOS:A1992JX47900002
J	ENGLAND, MR; GORDON, G; SALEM, M; CHERNOW, B				ENGLAND, MR; GORDON, G; SALEM, M; CHERNOW, B			MAGNESIUM ADMINISTRATION AND DYSRHYTHMIAS AFTER CARDIAC-SURGERY - A PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED TRIAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; HYPERKALEMIC CARDIOPLEGIC SOLUTIONS; REFRACTORY POTASSIUM REPLETION; INTRACELLULAR FREE MAGNESIUM; SERUM MAGNESIUM; HYPOMAGNESEMIA; CALCIUM; ARRHYTHMIAS; HEART; PRESERVATION	Objective.-To determine whether magnesium administration is effective in reducing postoperative morbidity and mortality after cardiac surgery. Design.-Randomized, double-blind, placebo-controlled trial. Setting.-A tertiary acute-care 500-bed university teaching hospital. Patients.-Over a 6-month period, 100 patients electively scheduled for cardiac surgery involving cardiopulmonary bypass were studied. Interventions.-Fifty patients were randomized to receive an intravenous infusion of magnesium chloride, 2 g, and 50 patients received placebo intraoperatively after the termination of cardiopulmonary bypass. Results.-Magnesium-treated patients had a significantly decreased frequency (P<.04) of postoperative ventricular dysrhythmias (eight [16%] of 50) compared with placebo-treated patients (17 [34%] of 50). Patients who were normomagnesemic postoperatively had new supraventricular dysrhythmias less frequently (P<.03) than patients who were hypomagnesemic postoperatively (eight [17%] of 48 vs 19 [37%] of 52). Compared with placebo-treated patients, magnesium-treated patients had significantly higher (P<.02) postoperative cardiac indices in the intensive care unit (2.8+/-0.1 vs 2.5+/-0.1 L/min per m2). Patients with postoperative total and ultrafilterable hypomagnesemia had postoperative ventricular dysrhythmias (P<.04) and required prolonged mechanical ventilatory support (P<.01) more frequently than patients without postoperative hypomagnesemia. Conclusions.-Total and ultrafilterable hypomagnesemia are prevalent findings in cardiac surgery patients, and postoperative hypomagnesemia is strongly associated with clinically important morbidity. Magnesium administration decreased the frequency of postoperative ventricular dysrhythmias and increased the stroke volume and thereby cardiac index in the early postoperative period.	SINAI HOSP BALTIMORE,DEPT MED,BELVEDERE AVE & GREENSPRING,BALTIMORE,MD 21215; TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DEPT ANESTHESIA,DIV CARDIAC ANESTHESIA,BOSTON,MA 02111; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT ANESTHESIOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT CRIT CARE MED,BALTIMORE,MD 21205	Sinai Hospital of Baltimore; Tufts Medical Center; Tufts University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University								ABRAHAM AS, 1987, ARCH INTERN MED, V147, P753, DOI 10.1001/archinte.147.4.753; Aglio L S, 1991, J Cardiothorac Vasc Anesth, V5, P201, DOI 10.1016/1053-0770(91)90274-W; ALTURA BM, 1984, DRUGS, V28, P120, DOI 10.2165/00003495-198400281-00013; Calverley R K, 1973, Can Anaesth Soc J, V20, P499; CHERNOW B, 1989, CHEST, V95, P391, DOI 10.1378/chest.95.2.391; CHERNOW B, 1989, CIRC SHOCK, V27, P323; CHRYSANT SG, 1988, CARDIOLOGY, V75, P81, DOI 10.1159/000174354; DCOSTA M, 1983, CLIN CHEM, V29, P519; DECARLI C, 1986, AM J CARDIOL, V57, P956, DOI 10.1016/0002-9149(86)90738-1; DUNNETT J, 1978, J MOL CELL CARDIOL, V10, P487, DOI 10.1016/0022-2828(78)90369-3; DYCKNER T, 1980, ACTA MED SCAND, V207, P59; FLATMAN PW, 1981, J PHYSIOL-LONDON, V315, P421, DOI 10.1113/jphysiol.1981.sp013756; FLINK EB, 1981, ARCH INTERN MED, V141, P441, DOI 10.1001/archinte.141.4.441; GEFFIN GA, 1989, J THORAC CARDIOV SUR, V98, P239; GUPTA RK, 1984, ANNU REV BIOPHYS BIO, V13, P221; HARRIS MNE, 1988, BRIT J ANAESTH, V60, P779, DOI 10.1093/bja/60.7.779; HEARSE DJ, 1978, J THORAC CARDIOV SUR, V75, P877; HECKER BR, 1985, AM J CARDIOL, V55, P61, DOI 10.1016/0002-9149(85)90300-5; HOLDEN MP, 1972, THORAX, V27, P212, DOI 10.1136/thx.27.2.212; HOLDEN MP, 1982, NUTR HEART DIS, P273; HOLLIFIELD JW, 1987, AM J MED, V82, P30, DOI 10.1016/0002-9343(87)90130-6; ISERI LT, 1989, MAGNESIUM, V8, P299; ISERI LT, 1985, AM HEART J, V110, P789, DOI 10.1016/0002-8703(85)90458-2; KULICK DL, 1988, AM HEART J, V115, P367, DOI 10.1016/0002-8703(88)90483-8; KUPFER S, 1965, J CLIN INVEST, V44, P1132, DOI 10.1172/JCI105220; LIEBSCHER G, 1992, CRIT CARE MED, V20, P5105; MANN CK, 1956, ANAL CHEM, V28, P201; MATSUDA H, 1987, NATURE, V325, P156, DOI 10.1038/325156a0; MOLLOY DW, 1984, AM REV RESPIR DIS, V129, P497; MUNOZ R, 1991, CRIT CARE MED, V19, pS48; NISHIO A, 1988, J PHARMACOL EXP THER, V246, P859; POLIMENI PI, 1972, RECENT ADV STUDIES C, V4, P217; QUAMME GA, 1983, REV PHYSIOL BIOCH P, V97, P69, DOI 10.1007/BFb0035346; RASMUSSEN HS, 1987, CLIN CARDIOL, V10, P351, DOI 10.1002/clc.4960100610; RESNICK LM, 1984, P NATL ACAD SCI-BIOL, V81, P6511, DOI 10.1073/pnas.81.20.6511; REYNOLDS TR, 1989, ANN THORAC SURG, V47, P907, DOI 10.1016/0003-4975(89)90033-7; SALEM M, 1991, ARCH INTERN MED, V151, P2185, DOI 10.1001/archinte.151.11.2185; SALEM M, 1991, CRIT CARE CLIN, V7, P225, DOI 10.1016/S0749-0704(18)30334-8; SCHEINMAN MM, 1969, CIRCULATION, V34, P235; SCHWIEGER I, 1989, ANESTHESIOLOGY, V71, pA1162; SEELIG M, 1989, AM J CARDIOL, V63, pG4, DOI 10.1016/0002-9149(89)90213-0; SHATTOCK MJ, 1987, J AM COLL NUTR, V6, P27; SHEN AC, 1972, AM J PATHOL, V67, P417; SHINE KI, 1975, AM J PHYSIOL, V228, P1545, DOI 10.1152/ajplegacy.1975.228.5.1545; STEINBERG SF, 1986, J PHARMACOL EXP THER, V237, P764; TURLAPATY PDMV, 1980, SCIENCE, V208, P198, DOI 10.1126/science.7361117; TURNIER E, 1972, J THORAC CARDIOV SUR, V64, P694; WHANG R, 1990, JAMA-J AM MED ASSOC, V263, P3063, DOI 10.1001/jama.263.22.3063; WHANG R, 1982, J AM COLL NUTR, V1, P317; WHANG R, 1984, ARCH INTERN MED, V144, P1794; WHANG R, 1985, ARCH INTERN MED, V145, P1686; WHITE RE, 1988, SCIENCE, V239, P778, DOI 10.1126/science.2448878; WHITE RE, 1989, BIOCHEM PHARMACOL, V38, P859, DOI 10.1016/0006-2952(89)90272-4; ZALOGA GP, 1987, CRIT CARE MED, V15, P813, DOI 10.1097/00003246-198709000-00002	54	181	185	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 4	1992	268	17					2395	2402		10.1001/jama.268.17.2395	http://dx.doi.org/10.1001/jama.268.17.2395			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV694	1404796				2022-12-28	WOS:A1992JV69400025
J	HANDEL, N; SILVERSTEIN, MJ; GAMAGAMI, P; JENSEN, JA; COLLINS, A				HANDEL, N; SILVERSTEIN, MJ; GAMAGAMI, P; JENSEN, JA; COLLINS, A			FACTORS AFFECTING MAMMOGRAPHIC VISUALIZATION OF THE BREAST AFTER AUGMENTATION MAMMAPLASTY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CANCER; MAMMOPLASTY; IMPLANTS; PROSTHESES; MORTALITY; DIAGNOSIS; LESIONS; BIOPSY	Objective.-To measure the effect of various parameters on mammographic visualization of the breast after augmentation mammaplasty. Design.-Preoperative and postoperative mammography was performed in patients undergoing augmentation mammaplasty. The area of breast tissue visualized on each film was measured. Changes in the area visualized were correlated with a variety of different parameters. Setting.-The Breast Center, Van Nuys, Calif, a free-standing multidisciplinary breast diagnostic and treatment facility. Patients.-The 68 women (126 breasts) represent a consecutive sample of patients undergoing augmentation mammaplasty for whom preoperative and postoperative mammograms were available. Main Outcome Measures.-Area visualized was correlated with degree of capsular contracture, implant position, type of mammography, preoperative breast size, implant size, and implant type. Results.-The major factor affecting mammography is capsular contracture. Little or no capsular contracture results in a 30% reduction in the area visualized; moderate or severe contracture results in a 50% reduction. Other important factors include implant position (improved visualization with implant beneath pectoral muscle) and type of mammography performed (slightly more tissue seen with displacement technique). Very small preoperative breast size yields increased visualization. Implant size and type have little or no effect. Conclusions.-In most women with breast implants, there is a decrease in measurable breast tissue on the postaugmentation mammogram. Capsular contracture and implant position exert a profound effect; type of mammography performed and preoperative breast size are also significant.			HANDEL, N (corresponding author), BREAST CTR,14624 SHERMAN WAY,VAN NUYS,CA 91405, USA.			Jensen, Jay/0000-0002-2369-8291				BAKER JL, 1975, OCT AESTH BREAST S S; BEISANG AA, 1991, PLAST RECONSTR SURG, V87, P855; BORGEN PI, 1991, AM SURGEON, V57, P8; CATHCART RS, 1989, ANN PLAS SURG, V22, P533, DOI 10.1097/00000637-198906000-00011; DERSHAW DD, 1989, RADIOLOGY, V170, P69, DOI 10.1148/radiology.170.1.2909122; DOUGLAS KP, 1991, SOUTH MED J, V84, P49, DOI 10.1097/00007611-199101000-00013; EKLUND GW, 1988, AM J ROENTGENOL, V151, P469, DOI 10.2214/ajr.151.3.469; ERSEK RA, 1991, PLAST RECONSTR SURG, V87, P879, DOI 10.1097/00006534-199105000-00012; GALLAGER HS, 1971, CANCER, V28, P1505, DOI 10.1002/1097-0142(197112)28:6<1505::AID-CNCR2820280624>3.0.CO;2-W; GRACE GT, 1990, ANN PLAS SURG, V25, P119, DOI 10.1097/00000637-199008000-00008; GUMUCIO CA, 1989, PLAST RECONSTR SURG, V84, P772, DOI 10.1097/00006534-198911000-00008; HAYES H, 1988, PLAST RECONSTR SURG, V82, P1, DOI 10.1097/00006534-198882010-00001; HERMAN S, 1984, PLAST RECONSTR SURG, V73, P411, DOI 10.1097/00006534-198403000-00012; HESTER TR, 1990, PLASTIC RECONSTRUCTI, P131; Hester TR, 1988, PERSPECT PLAST SURG, V2, P135; LEIBMAN AJ, 1990, RADIOLOGY, V174, P195, DOI 10.1148/radiology.174.1.2152981; LEIS HP, 1989, BREAST CANCER CONSER, P3; LEIS HP, 1986, SURGERY BREAST DIAGN, P100; LITTLE G, 1980, PLAST RECONSTR SURG, V65, P30, DOI 10.1097/00006534-198001000-00006; McCurdy JA, 1990, AM J COSMETIC SURG, V7, P235; MELMED EP, 1988, PLAST RECONSTR SURG, V82, P285, DOI 10.1097/00006534-198808000-00013; MITNICK JS, 1989, SURG GYNECOL OBSTET, V168, P30; MONSEES BS, 1991, PERSPECT PLAST SURG, V5, P103; RINTALA AE, 1974, PLAST RECONSTR SURG, V54, P390, DOI 10.1097/00006534-197410000-00002; SCHWARTZ GF, 1978, CANCER, V41, P1147, DOI 10.1002/1097-0142(197803)41:3<1147::AID-CNCR2820410352>3.0.CO;2-9; SHAPIRO S, 1982, JNCI-J NATL CANCER I, V69, P349; SILVERSTEIN MJ, 1988, ARCH SURG-CHICAGO, V123, P681; SILVERSTEIN MJ, 1992, EUR J CANCER, V28A, P635, DOI 10.1016/S0959-8049(05)80115-7; SILVERSTEIN MJ, 1989, RADIOLOGY, V171, P633, DOI 10.1148/radiology.171.3.2717734; SILVERSTEIN MJ, 1987, CANCER, V59, P715, DOI 10.1002/1097-0142(19870215)59:4<715::AID-CNCR2820590409>3.0.CO;2-C; SILVERSTEIN MJ, 1990, PLAST RECONSTR SURG, V86, P1126, DOI 10.1097/00006534-199012000-00014; STRAX P, 1990, CANCER, V66, P1136; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; VANA J, 1981, CANCER, V48, P1043, DOI 10.1002/1097-0142(19810815)48:4<1043::AID-CNCR2820480432>3.0.CO;2-K; Walt A J, 1990, Bull Am Coll Surg, V75, P6; WERTHEIMER MD, 1986, JAMA-J AM MED ASSOC, V255, P1311, DOI 10.1001/jama.255.10.1311; Whidden PG, 1986, TRANSPLANT IMPLANT T, V3, P43	37	72	73	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1992	268	14					1913	1917		10.1001/jama.268.14.1913	http://dx.doi.org/10.1001/jama.268.14.1913			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR439	1404718				2022-12-28	WOS:A1992JR43900043
J	RESNICK, JL; BIXLER, LS; CHENG, LZ; DONOVAN, PJ				RESNICK, JL; BIXLER, LS; CHENG, LZ; DONOVAN, PJ			LONG-TERM PROLIFERATION OF MOUSE PRIMORDIAL GERM-CELLS IN CULTURE	NATURE			English	Article							DIFFERENTIATION INHIBITING ACTIVITY; EMBRYOS; GROWTH	PRIMORDIAL germ cells(PGCs) are first identifiable as a population of about eight alkaline phosphatase-positive cells in the 7.0 days postcoitum mouse embryo1. During the next 6 days of development they proliferate to give rise to the 25,000 cells that will establish the meiotic population2. Steel factor is required for PGC survival both in vivo3 and in vitro4,5 and together with leukaemia inhibitory factor stimulates PGC proliferation in vitro6. In feeder-dependent culture, PGCs will proliferate for up to 7 days, but their numbers eventually decline and their proliferative capacity is only a fraction of that seen in vivo6,7. Here we report a further factor that stimulates PGC proliferation in vitro, basic fibroblast growth factor (bFGF). Furthermore, bFGF, in the presence of steel factor and leukaemia inhibitory factor, stimulates long-term proliferation of PGCs, leading to the derivation of large colonies of cells. These embryonic germ cells resemble embryonic stem cells, pluripotent cells derived from preimplantation embryos, or feeder-dependent embryonal carcinoma cells, pluripotent stem cells of PGC-derived tumours (teratomas and teratocarcinomas)8. To our knowledge, these results provide the first system for long-term culture of PGCs.	NCI,FREDERICK CANC RES & DEV CTR,PRI DYNCORP,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	RESNICK, JL (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MAMMALIAN GENET LAB,POB B,FREDERICK,MD 21702, USA.							BENNETT DOROTHEA, 1956, J MORPH, V98, P199, DOI 10.1002/jmor.1050980202; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; DONOVAN PJ, 1986, CELL, V44, P831, DOI 10.1016/0092-8674(86)90005-X; FOX N, 1981, DEV BIOL, V83, P391, DOI 10.1016/0012-1606(81)90487-5; GINSBURG M, 1990, DEVELOPMENT, V110, P521; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; KOOPMAN P, 1984, EXP CELL RES, V154, P233, DOI 10.1016/0014-4827(84)90683-9; MARTIN GR, 1983, TERATOCARCINOMA STEM, P635; MATSUI Y, 1991, NATURE, V353, P750, DOI 10.1038/353750a0; MATSUI Y, 1992, CELL, V70, P841, DOI 10.1016/0092-8674(92)90317-6; RATHJEN PD, 1990, CELL, V62, P1105, DOI 10.1016/0092-8674(90)90387-T; RATHJEN PD, 1990, GENE DEV, V4, P2308, DOI 10.1101/gad.4.12b.2308; STEVENS LC, 1967, J NATL CANCER I, V38, P549; STEVENS LC, 1961, J NATL CANCER I, V27, P443; TAM PPL, 1981, J EMBRYOL EXP MORPH, V64, P133; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299	16	680	767	1	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 8	1992	359	6395					550	551		10.1038/359550a0	http://dx.doi.org/10.1038/359550a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR859	1383830				2022-12-28	WOS:A1992JR85900064
J	CLARKE, AR; MAANDAG, ER; VANROON, M; VANDERLUGT, NMT; VANDERVALK, M; HOOPER, ML; BERNS, A; RIELE, HT				CLARKE, AR; MAANDAG, ER; VANROON, M; VANDERLUGT, NMT; VANDERVALK, M; HOOPER, ML; BERNS, A; RIELE, HT			REQUIREMENT FOR A FUNCTIONAL RB-1 GENE IN MURINE DEVELOPMENT	NATURE			English	Article							EMBRYONIC STEM-CELLS; LEUKEMIA INHIBITORY FACTOR; MOUSE PGK-1 GENE; RETINOBLASTOMA GENE; ALTERED EXPRESSION; DIFFERENTIATION; DISRUPTION; CARCINOMA; MUTATIONS; SARCOMAS	HUMAN retinoblastomas can occur both as hereditary and as sporadic cases. Knudson's proposal1 that they result from two mutational events, of which one is present in the germ line in hereditary cases, has been confirmed by more recent molecular analysis, which has shown both events to involve loss or mutational inactivation of the same gene, RB-1 (ref. 2). RB-1 heterozygosity also predisposes to osteosarcoma, and RB-1 allele losses are seen in sporadic lung, breast, prostate and bladder carcinomas3-7. RB-1 is expressed in most, if not all, tissues and codes for a nuclear phosphoprotein which becomes hypophosphorylated in the G0 growth arrest state and in the G1 phase of the cell cycle2. To gain a further insight ino the role of RB-1 we and other groups8,9 have generated mice carrying an inactivated allele of the homologous gene, Rb-1 (ref. 10), by gene targeting". We report here that young heterozygous mice do not appear abnormal and do not develop retinoblastoma at a detectable frequency. However, homozygous mutant embryos fail to reach term and show a number of abnormalities in neural and haematopoietic development. Broadly similar results are reported by the other groups8,9.	UNIV EDINBURGH, DEPT PATHOL, CANC RES, CAMPAIGN LABS, EDINBURGH EH8 9YL, MIDLOTHIAN, SCOTLAND; UNIV EDINBURGH, AFRC, CTR GENOME RES, EDINBURGH EH8 9YL, MIDLOTHIAN, SCOTLAND; UNIV AMSTERDAM, DEPT BIOCHEM, AMSTERDAM, NETHERLANDS; NETHERLANDS CANC INST, DIV MOLEC GENET, 1066 CX AMSTERDAM, NETHERLANDS	University of Edinburgh; University of Edinburgh; University of Amsterdam; Netherlands Cancer Institute			Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Clarke, Alan/0000-0002-4281-426X				ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; CANCE WG, 1990, NEW ENGL J MED, V323, P1457, DOI 10.1056/NEJM199011223232105; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; COLBEREGARAPIN F, 1979, P NATL ACAD SCI USA, V76, P3755, DOI 10.1073/pnas.76.8.3755; DIVE C, IN PRESS FRONTIERS P; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KASTER KR, 1983, NUCLEIC ACIDS RES, V11, P6895, DOI 10.1093/nar/11.19.6895; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MOORE GE, 1967, J AMER MED ASSOC, V199, P519, DOI 10.1001/jama.199.8.519; MOREAU JF, 1988, NATURE, V336, P690, DOI 10.1038/336690a0; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; SHEW JY, 1989, ONCOGENE RES, V4, P205; SMITH AG, 1987, DEV BIOL, V121, P1, DOI 10.1016/0012-1606(87)90132-1; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; STRATTON MR, 1989, BRIT J CANCER, V60, P202, DOI 10.1038/bjc.1989.251; SZEKELY L, 1992, CELL GROWTH DIFFER, V3, P149; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; VANDERLUGT N, 1991, GENE, V105, P263, DOI 10.1016/0378-1119(91)90161-4; WEINBERG RA, 1990, TRENDS BIOCHEM SCI, V15, P199, DOI 10.1016/0968-0004(90)90162-5; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; YOKOTA J, 1988, ONCOGENE, V3, P471	30	913	927	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 24	1992	359	6393					328	330		10.1038/359328a0	http://dx.doi.org/10.1038/359328a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP503	1406937				2022-12-28	WOS:A1992JP50300059
J	HANDYSIDE, AH; LESKO, JG; TARIN, JJ; WINSTON, RML; HUGHES, MR				HANDYSIDE, AH; LESKO, JG; TARIN, JJ; WINSTON, RML; HUGHES, MR			BIRTH OF A NORMAL GIRL AFTER INVITRO FERTILIZATION AND PREIMPLANTATION DIAGNOSTIC TESTING FOR CYSTIC-FIBROSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GENETIC DIAGNOSIS; HUMAN OOCYTES; AMPLIFICATION; DNA; PREGNANCIES; MUTATION	Background. Cystic fibrosis is a common, severe autosomal recessive disease caused in a majority of cases by a three-nucleotide deletion (DELTA-F508) in the cystic fibrosis transmembrane regulator gene. Current methods of prenatal diagnosis involve chorionic-villus sampling or amniocentesis. In vitro fertilization and diagnosis during embryonic development before implantation would allow only unaffected embryos to be selected for transfer to the uterus, thereby avoiding the need to terminate a pregnancy. Methods. Preimplantation diagnosis of cystic fibrosis was attempted in the cases of three couples, both members of which carried the DELTA-F508 deletion. In vitro fertilization techniques were used to recover oocytes from each woman and fertilize them with her husband's sperm. Three days after insemination, embryos in the cleavage stage underwent biopsy and removal of one or two cells for DNA amplification and analysis. Results. Only two oocytes from one woman were fertilized normally; DNA analysis of one of the embryos failed and cystic fibrosis was diagnosed in the other (i.e., it was homozygous for DELTA-F508), so neither was transferred. The oocytes of each of the other two women produced noncarrier, carrier, and affected embryos. Both couples chose to have one noncarrier embryo and one carrier embryo transferred. One woman became pregnant and gave birth to a girl free of the deletion in both chromosomes. Conclusions. Preimplantation diagnosis of the DELTA-F508 deletion causing cystic fibrosis is possible through in vitro fertilization, biopsy of a cleavage-stage embryo, and amplification of DNA from single embryonic cells. This approach should be equally applicable to other single-gene diseases in which the defect has been identified. Analysis of a series of pregnancies, however, will be required to assess the method adequately.	BAYLOR COLL MED,INST MOLEC GENET,1 BAYLOR PLAZA,HOUSTON,TX 77030; BAYLOR COLL MED,CTR REPROD MED & SURG,HOUSTON,TX 77030; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,INST OBSTET & GYNAECOL,LONDON W12 0HS,ENGLAND; METHODIST HOSP,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Imperial College London; The Methodist Hospital System; The Methodist Hospital - Houston				Tarin, Juan/0000-0002-4436-5162				Boat T.J., 1989, METABOLIC BASIS INHE, P2649; COUTELLE C, 1989, BRIT MED J, V299, P22, DOI 10.1136/bmj.299.6690.22; Cystic Fibrosis Genetic Anal Consortium, 1990, AM J HUM GENET, V47, P354; DAWSON KJ, 1991, LANCET, V337, P1543, DOI 10.1016/0140-6736(91)93232-X; DIMITRY ES, 1991, FERTIL STERIL, V55, P934; HANDYSIDE AH, 1990, NATURE, V344, P768, DOI 10.1038/344768a0; HANDYSIDE AH, 1991, PREIMPLANTATION GENETICS, P75; HANDYSIDE AH, 1992, CURR OBSTET GYNECOL, V2, P85; HARDY K, 1990, HUM REPROD, V5, P708, DOI 10.1093/oxfordjournals.humrep.a137173; HARDY K, 1992, ARCH PATHOL LAB MED, V116, P388; LESKO J, 1991, AM J HUM GENET, V49, P223; MONK M, 1990, LANCET, V335, P985, DOI 10.1016/0140-6736(90)91060-N; PENKETH R, 1987, BAILLIERE CLIN OB GY, V1, P747, DOI 10.1016/S0950-3552(87)80015-9; PERGAMENT E, 1991, PRENATAL DIAG, V11, P493, DOI 10.1002/pd.1970110803; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS J, 1990, AM J HUM GENET, V46, P395; RUTHERFORD AJ, 1988, BRIT MED J, V296, P1765, DOI 10.1136/bmj.296.6639.1765; STROM CM, 1990, LANCET, V336, P306, DOI 10.1016/0140-6736(90)91835-X; TARIN JJ, IN PRESS FERTIL STER	19	410	421	0	41	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 24	1992	327	13					905	909		10.1056/NEJM199209243271301	http://dx.doi.org/10.1056/NEJM199209243271301			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP014	1381054	Bronze			2022-12-28	WOS:A1992JP01400001
J	KOFF, A; GIORDANO, A; DESAI, D; YAMASHITA, K; HARPER, JW; ELLEDGE, S; NISHIMOTO, T; MORGAN, DO; FRANZA, BR; ROBERTS, JM				KOFF, A; GIORDANO, A; DESAI, D; YAMASHITA, K; HARPER, JW; ELLEDGE, S; NISHIMOTO, T; MORGAN, DO; FRANZA, BR; ROBERTS, JM			FORMATION AND ACTIVATION OF A CYCLIN E-CDK2 COMPLEX DURING THE G(1)-PHASE OF THE HUMAN CELL-CYCLE	SCIENCE			English	Article							CLN FUNCTION; YEAST; GENE	Human cyclin E, originally identified on the basis of its ability to function as a G1 cyclin in budding yeast, associated with a cell cycle-regulated protein kinase in human cells. The cyclin E-associated kinase activity peaked during G1, before the appearance of cyclin A, and was diminished during exit from the cell cycle after differentiation or serum withdrawal. The major cyclin E-associated kinase in human cells was Cdk2 (cyclin-dependent kinase 2). The abundance of the cyclin E protein and the cyclin E-Cdk2 complex was maximal in G1 cells. These results provide further evidence that in all eukaryotes assembly of a cyclin-Cdk complex is an important step in the biochemical pathway that controls cell proliferation during G1.	COLD SPRING HARBOR LAB, FREEMAN LAB CANC CELL BIOL, COLD SPRING HARBOR, NY 11724 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; KYUSHU UNIV, GRAD SCH MED SCI, DEPT MOLEC BIOL, FUKUOKA 812, JAPAN; BAYLOR COLL MED, VERNA & MARRS MCLEAN DEPT BIOCHEM, HOUSTON, TX 77030 USA	Cold Spring Harbor Laboratory; University of California System; University of California San Francisco; Kyushu University; Baylor College of Medicine	KOFF, A (corresponding author), FRED HUTCHINSON CANC RES CTR, DEPT BASIC SCI, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA.		Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X; Morgan, David/0000-0001-8753-4416; Harper, Jeffrey/0000-0002-6944-7236				DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FRANZA BR, UNPUB; GARRELS JI, 1989, J BIOL CHEM, V264, P5823; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, UNPUB; LAHUE EE, 1991, GENE DEV, V5, P2166, DOI 10.1101/gad.5.12a.2166; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MARRACCINO RL, 1992, MOL BIOL CELL, V3, P389, DOI 10.1091/mbc.3.4.389; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; OHTSUBO M, UNPUB; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	20	1023	1058	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 18	1992	257	5077					1689	1694		10.1126/science.1388288	http://dx.doi.org/10.1126/science.1388288			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN501	1388288				2022-12-28	WOS:A1992JN50100033
J	ROSS, S; GODDEN, D; MCMURRAY, D; DOUGLAS, A; OLDMAN, D; FRIEND, J; LEGGE, J; DOUGLAS, G				ROSS, S; GODDEN, D; MCMURRAY, D; DOUGLAS, A; OLDMAN, D; FRIEND, J; LEGGE, J; DOUGLAS, G			SOCIAL EFFECTS OF WHEEZE IN CHILDHOOD - A 25-YEAR FOLLOW-UP	BRITISH MEDICAL JOURNAL			English	Article							ADULT LIFE; ASTHMA; MORBIDITY; CHILDREN; ILLNESS; COUGH; AGE	Objectives-To determine the outcome of childhood wheeze in terms of education, employment, housing, and social class. Design-25 year follow up study. Setting-Community study based at the department of thoracic medicine, Aberdeen Royal Infirmary. Participants-Three groups of subjects who had been identified in a random community survey in 1964: those who had had asthma in childhood (n=97), those who had wheezed only in the presence of upper respiratory tract infections (n = 132), and a comparison group who had had no respiratory symptoms as children (n=131). Subjects were aged 34 to 40 years at the time of the current study. Main outcome measures-Interview and questionnaire data on education, employment, housing and social class, ventilatory function, and peak flow rate. Results-Pulmonary function testing showed that only the "asthmatic" group had airways obstruction; this group showed greater peak flow variation than the "wheezy" group, which did not differ from the comparison group. The asthmatic subjects were more likely to have experienced respiratory problems during their school years and associated with their work. Despite these problems, educational attainment, employment, housing, and eventual social class were similar for all three groups. Conclusion-Childhood wheeze did not adversely affect education, employment, housing, or social class in this population.	ABERDEEN ROYAL INFIRM,DEPT THORAC MED,ABERDEEN AB9 2ZB,SCOTLAND; UNIV ABERDEEN,DEPT SOCIOL,ABERDEEN AB9 2ZD,SCOTLAND	University of Aberdeen; University of Aberdeen								ANDERSON HR, 1989, THORAX, V44, P614, DOI 10.1136/thx.44.8.614; ANDERSON HR, 1983, ARCH DIS CHILD, V58, P777, DOI 10.1136/adc.58.10.777; BRITTEN N, 1987, BRIT MED J, V294, P1317, DOI 10.1136/bmj.294.6583.1317; DAWSON B, 1969, LANCET, V1, P827; GOLDTHORPE JH, 1987, SOCIAL MOBILITY CLAS, P39; HIGGINS BG, 1989, AM REV RESPIR DIS, V140, P1368, DOI 10.1164/ajrccm/140.5.1368; KELLY WJW, 1987, BRIT MED J, V294, P1059, DOI 10.1136/bmj.294.6579.1059; KELLY WJW, 1988, AM REV RESPIR DIS, V138, P26, DOI 10.1164/ajrccm/138.1.26; MARTIN AJ, 1980, BRIT MED J, V280, P1397, DOI 10.1136/bmj.280.6229.1397; MARTIN AJ, 1982, BMJ-BRIT MED J, V284, P380, DOI 10.1136/bmj.284.6313.380; MCCARTHY P, 1985, J EPIDEMIOL COMMUN H, V39, P15, DOI 10.1136/jech.39.1.15; MITCHELL RG, 1973, ARCH DIS CHILD, V48, P467, DOI 10.1136/adc.48.6.467; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; NOCON A, 1989, SOCIAL IMPACT ASTHMA; ROBERTSON CF, 1991, BMJ-BRIT MED J, V302, P1116, DOI 10.1136/bmj.302.6785.1116; SIBBALD B, 1992, THORAX, V47, P19, DOI 10.1136/thx.47.1.19; SPEIGHT ANP, 1983, BRIT MED J, V286, P1253, DOI 10.1136/bmj.286.6373.1253; STRACHAN DP, 1986, FAM PRACT, V3, P137, DOI 10.1093/fampra/3.3.137; STRACHAN DP, 1988, BMJ-BRIT MED J, V296, P890, DOI 10.1136/bmj.296.6626.890; 1989, GRAMPIAN Q EC RE WIN, P17	20	27	27	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 5	1992	305	6853					545	548		10.1136/bmj.305.6853.545	http://dx.doi.org/10.1136/bmj.305.6853.545			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM495	1393032	Bronze, Green Submitted, Green Published			2022-12-28	WOS:A1992JM49500014
J	BURNASHEV, N; SCHOEPFER, R; MONYER, H; RUPPERSBERG, JP; GUNTHER, W; SEEBURG, PH; SAKMANN, B				BURNASHEV, N; SCHOEPFER, R; MONYER, H; RUPPERSBERG, JP; GUNTHER, W; SEEBURG, PH; SAKMANN, B			CONTROL BY ASPARAGINE RESIDUES OF CALCIUM PERMEABILITY AND MAGNESIUM BLOCKADE IN THE NMDA RECEPTOR	SCIENCE			English	Article							MOUSE CENTRAL NEURONS; SPINAL-CORD NEURONS; GLUTAMATE-ACTIVATED CHANNELS; VOLTAGE-DEPENDENT BLOCK; LONG-TERM POTENTIATION; CENTRAL-NERVOUS-SYSTEM; D-ASPARTATE RESPONSES; AMINO-ACID RECEPTORS; MOLECULAR-CLONING; DIVALENT-CATIONS	The N-methyl-D-aspartate (NMDA) receptor forms a cation-selective channel with a high calcium permeability and sensitivity to channel block by extracellular magnesium. These properties, which are believed to be important for the induction of long-term changes in synaptic strength, are imparted by asparagine residues in a putative channel-forming segment of the protein, transmembrane 2 (TM2). In the NR1 subunit, replacement of this asparagine by a glutamine residue decreases calcium permeability of the channel and slightly reduces magnesium block. The same substitution in NR2 subunits strongly reduces magnesium block and increases the magnesium permeability but barely affects calcium permeability. These asparagines are in a position homologous to the site in the TM2 region (Q/R site) of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors that is occupied by either glutamine (Q) or arginine (R) and that controls divalent cation permeability of the AMPA receptor channel. Hence AMPA and NMDA receptor channels contain common structural motifs in their TM2 segments that are responsible for some of their ion selectivity and conductance properties.	MAX PLANCK INST MED RES, ZELLPHYSIOL ABT, JAHNSTR 29, W-6900 HEIDELBERG 1, GERMANY; UNIV HEIDELBERG, CTR MOLEC BIOL, W-6900 HEIDELBERG, GERMANY	Max Planck Society; Ruprecht Karls University Heidelberg			Burnashev, Nail/G-4056-2013	Monyer, Hannah/0000-0002-9332-5749				ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOI DW, 1988, J NEUROSCI, V8, P185; CHOL D, 1987, J NEUROSCI, V7, P369; CHOL DW, 1988, NEURON, V1, P623; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; DINGLEDINE R, 1988, CRIT REV NEUROBIOL, V4, P1; GIBB AJ, IN PRESS J PHYSL LON; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MAYER ML, 1985, J PHYSIOL-LONDON, V361, P65, DOI 10.1113/jphysiol.1985.sp015633; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; PRITCHETT DB, 1989, SCIENCE, V245, P1389, DOI 10.1126/science.2551039; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; UNWIN N, 1988, J CELL BIOL, V107, P1123, DOI 10.1083/jcb.107.3.1123; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; VILLARROEL A, IN PRESS P R SOC L B	36	346	351	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 4	1992	257	5075					1415	1419		10.1126/science.1382314	http://dx.doi.org/10.1126/science.1382314			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL612	1382314				2022-12-28	WOS:A1992JL61200039
J	HADDOW, JE; PALOMAKI, GE; KNIGHT, GJ; WILLIAMS, J; PULKKINEN, A; CANICK, JA; SALLER, DN; BOWERS, GB				HADDOW, JE; PALOMAKI, GE; KNIGHT, GJ; WILLIAMS, J; PULKKINEN, A; CANICK, JA; SALLER, DN; BOWERS, GB			PRENATAL SCREENING FOR DOWNS-SYNDROME WITH USE OF MATERNAL SERUM MARKERS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALPHA-FETOPROTEIN; UNCONJUGATED ESTRIOL; 2ND TRIMESTER; PREGNANCY; ABNORMALITIES; AGE	Background. Approximately 35 percent of all cases of Down's syndrome in fetuses can be detected by measuring maternal serum alpha-fetoprotein during the second trimester in the general population of pregnant women. Recent case-control studies indicate that this detection rate could be approximately doubled by measuring serum levels of unconjugated estriol and chorionic gonadotropin, which are abnormally low and abnormally high, respectively, in women carrying fetuses affected by Down's syndrome. Methods. We prospectively screened 25,207 women and adolescents in the second trimester of pregnancy and assigned each a risk of fetal Down's syndrome with an algorithm that took into account measurements of all three serum markers in combination with maternal age. On this basis, 1661 subjects (6.6 percent) were initially assigned a second-trimester risk of fetal Down's syndrome of at least 1 in 190, and 962 (3.8 percent) were offered amniocentesis for chromosomal analysis after verification of gestational age. Gestational age was determined on the basis of the first day of the last menstrual period or, when available, by ultrasonography. Results. Among the 760 women and adolescents who chose amniocentesis, 20 cases of fetal Down's syndrome were detected, along with 7 other chromosomal disorders. There was 1 additional case of Down's syndrome among the 202 women who chose not to have amniocentesis. The rate of detection of fetal Down's syndrome was thus 58 percent (21 of 36 expected cases), and the frequency of identifying a fetus with Down's syndrome in women undergoing amniocentesis was 1 per 38 amniocenteses (95 percent confidence interval, 1 in 25 to 1 in 62). Conclusions. Measuring serum alpha-fetoprotein, chorionic gonadotropin, and estriol is more effective in screening for fetal Down's syndrome than measuring maternal serum alpha-fetoprotein alone. Such an expanded protocol can readily be incorporated into existing prenatal screening programs.	WOMEN & INFANTS HOSP RHODE ISL,PROVIDENCE,RI 02908; BROWN UNIV,PROVIDENCE,RI 02912	Women & Infants Hospital Rhode Island; Brown University	HADDOW, JE (corresponding author), FDN BLOOD RES,POB 190,SCARBOROUGH,ME 04070, USA.				PHS HHS [MCJ-251003-06] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BOGART MH, 1987, PRENATAL DIAG, V7, P623, DOI 10.1002/pd.1970070904; CANICK JA, 1988, BRIT J OBSTET GYNAEC, V95, P330, DOI 10.1111/j.1471-0528.1988.tb06601.x; CANICK JA, 1990, J CLIN IMMUNOASSAY, V13, P30; CANICK JA, 1990, PRENATAL DIAG, V10, P546, DOI 10.1002/pd.1970100813; CUCKLE HS, 1987, BRIT J OBSTET GYNAEC, V94, P274, DOI 10.1111/j.1471-0528.1987.tb02369.x; CUCKLE HS, 1984, LANCET, V1, P926; CUCKLE HS, 1987, BRIT J OBSTET GYNAEC, V94, P387, DOI 10.1111/j.1471-0528.1987.tb03115.x; CUCKLE HS, 1990, PRENATAL DIAGNOSIS P, P67; DIMAIO MS, 1987, NEW ENGL J MED, V317, P342, DOI 10.1056/NEJM198708063170603; HOOK EB, 1981, TRISOMY, V21, P3; KNIGHT GJ, 1987, METHODS CLIN CHEM, P459; MERKATZ IR, 1984, AM J OBSTET GYNECOL, V148, P886, DOI 10.1016/0002-9378(84)90530-1; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883; WALD NJ, 1987, BAILLIERE CLIN OB GY, V1, P649, DOI 10.1016/S0950-3552(87)80010-X; 1989, AM J OBSTET GYNECOL, V160, P575; 1990, VITAL STATISTICS US, V1, P89	16	384	395	1	20	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 27	1992	327	9					588	593		10.1056/NEJM199208273270902	http://dx.doi.org/10.1056/NEJM199208273270902			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK204	1379344				2022-12-28	WOS:A1992JK20400002
J	ALI, A; RUDGE, P				ALI, A; RUDGE, P			MYELOPATHY ASSOCIATED WITH HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE-1 IN A WHITE EUROPEAN NATIVE TO ENGLAND	BRITISH MEDICAL JOURNAL			English	Article							TROPICAL SPASTIC PARAPARESIS; UNITED-KINGDOM		UCL NATL HOSP NEUROL & NEUROSURG, QUEEN SQ, LONDON WC1N 3BG, ENGLAND; CLIN RES CTR, HARROW HA1 3UJ, MIDDX, ENGLAND	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust								ARAUJO ADQ, 1992, J NEUROL NEUROSUR PS, V55, P153, DOI 10.1136/jnnp.55.2.153; CRUICKSHANK JK, 1989, BRAIN, V112, P1057, DOI 10.1093/brain/112.4.1057; LUGARESI A, 1991, ACTA NEUROL SCAND, V184, P186; RUDGE P, 1991, J NEUROL NEUROSUR PS, V54, P689, DOI 10.1136/jnnp.54.8.689; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	5	2	2	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 22	1992	305	6851					453	453		10.1136/bmj.305.6851.453	http://dx.doi.org/10.1136/bmj.305.6851.453			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK680	1392959	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992JK68000023
J	TAI, PKK; ALBERS, MW; CHANG, H; FABER, LE; SCHREIBER, SL				TAI, PKK; ALBERS, MW; CHANG, H; FABER, LE; SCHREIBER, SL			ASSOCIATION OF A 59-KILODALTON IMMUNOPHILIN WITH THE GLUCOCORTICOID RECEPTOR COMPLEX	SCIENCE			English	Article							UTERINE PROGESTIN RECEPTOR; HEAT-SHOCK PROTEINS; STEROID-RECEPTORS; BINDING-PROTEIN; COMMON; COMPONENT; DNA; CONTAINS; EXISTS	Immunophilins, a family of proteins that exhibit rotamase (peptidyl-prolyl cis-trans isomerase) activity in vitro, are expressed in many organisms and most some immunophilins can mediate the immunosuppressive actions of FK506, rapamycin, and cyclosporin A, the physiological role of the unligated proteins is not known. A 59-kilodalton member of the FK506- and rapamycin-binding class was found to associate in the absence of these drugs with two heat shock proteins (hsp90 and hsp70) and the glucocorticoid receptor (GR). Together, these proteins make up the inactive GR, thus biochemically linking two families of proteins proposed to be involved in protein folding assembly as well as two potent immunosuppressive modalities.	HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138; MED COLL OHIO,DEPT OBSTET & GYNECOL,TOLEDO,OH 43699	Harvard University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R03HD028034] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041881] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038627, R37GM038627] Funding Source: NIH RePORTER; NICHD NIH HHS [HD28034] Funding Source: Medline; NIDDK NIH HHS [DK41881] Funding Source: Medline; NIGMS NIH HHS [GM-38627] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; CATELLI MG, 1985, EMBO J, V4, P3131, DOI 10.1002/j.1460-2075.1985.tb04055.x; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; DENIS M, 1987, J BIOL CHEM, V262, P11803; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DONNELLY JG, 1990, CLIN CHEM, V36, P1034; FRETZ H, 1991, J AM CHEM SOC, V113, P1409, DOI 10.1021/ja00004a051; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; GALAT A, 1992, BIOCHEMISTRY-US, V31, P2427, DOI 10.1021/bi00123a031; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HUITSCH T, 1991, P NATL ACAD SCI USA, V88, P6229; JOAB I, 1984, NATURE, V308, P850, DOI 10.1038/308850a0; KOST SL, 1989, MOL CELL BIOL, V9, P3829, DOI 10.1128/MCB.9.9.3829; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAKAO K, 1985, CAN J BIOCHEM CELL B, V63, P33, DOI 10.1139/o85-005; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; PRATT WB, 1987, J CELL BIOCHEM, V35, P51, DOI 10.1002/jcb.240350105; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; REXIN M, 1991, J BIOL CHEM, V266, P24601; RIEHL RM, 1985, BIOCHEMISTRY-US, V24, P6586, DOI 10.1021/bi00344a042; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; SANCHEZ ER, 1990, J BIOL CHEM, V265, P22067; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SCHUH S, 1985, J BIOL CHEM, V260, P4292; SMITH DF, 1990, J BIOL CHEM, V265, P3996; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; TAI PC, UNPUB; TAI PKK, 1985, CAN J BIOCHEM CELL B, V63, P41, DOI 10.1139/o85-006; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; YEM AW, 1992, J BIOL CHEM, V267, P2868	38	300	318	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 29	1992	256	5061					1315	1318		10.1126/science.1376003	http://dx.doi.org/10.1126/science.1376003			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW135	1376003				2022-12-28	WOS:A1992HW13500032
J	ARNOLD, E; JACOBOMOLINA, A; NANNI, RG; WILLIAMS, RL; LU, XD; DING, JP; CLARK, AD; ZHANG, AQ; FERRIS, AL; CLARK, P; HIZI, A; HUGHES, SH				ARNOLD, E; JACOBOMOLINA, A; NANNI, RG; WILLIAMS, RL; LU, XD; DING, JP; CLARK, AD; ZHANG, AQ; FERRIS, AL; CLARK, P; HIZI, A; HUGHES, SH			STRUCTURE OF HIV-1 REVERSE-TRANSCRIPTASE DNA COMPLEX AT 7-A RESOLUTION SHOWING ACTIVE-SITE LOCATIONS	NATURE			English	Article							NUCLEOTIDE-SEQUENCE; AIDS VIRUS; REPLICATION; INHIBITION	AIDS, caused by human immunodeficiency virus (HIV), is one of the world's most serious health problems, with current protocols being inadequate for either prevention or successful long-term treatment. In retroviruses such as HIV, the enzyme reverse transcriptase copies the single-stranded RNA genome into double-stranded DNA that is then integrated into the chromosomes of infected cells. Reverse transcriptase is the target of the most widely used treatments for AIDS, 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxyinosine (ddI), but resistant strains of HIV-1 arise in patients after a relatively short time 1,2. There are several non-nucleoside inhibitors of HIV-1 reverse transcriptase 3-6, but resistance to such agents also develops rapidly 7. We report here the structure at 7 angstrom resolution of a ternary complex of the HIV-1 reverse transcriptase heterodimer, a monoclonal antibody Fab fragment 8, and a duplex DNA template-primer. The double-stranded DNA binds in a groove on the surface of the enzyme. The electron density near one end of the DNA matches well with the known structure of the HIV-1 reverse transcriptase RNase H domain 12. At the opposite end of the DNA, a mercurated derivative of UTP has been localized by difference Fourier methods, allowing tentative identification of the polymerase nucleoside triphosphate binding site. We also determined the structure of the reverse transcriptase/Fab complex in the absence of template-primer to compare the bound and free forms of the enzyme. The presence of DNA correlates with movement of protein electron density in the vicinity of the putative template-primer binding groove. These results have important implications for developing improved inhibitors of reverse transcriptase for the treatment of AIDS.	RUTGERS STATE UNIV,DEPT CHEM,PISCATAWAY,NJ 08854; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702; PROGRAM RESOURCES INC,FREDERICK,MD 21702; TEL AVIV UNIV,SACKLER SCH MED,DEPT CELL BIOL & HISTOL,IL-69978 TEL AVIV,ISRAEL	Rutgers State University New Brunswick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Tel Aviv University; Sackler Faculty of Medicine	ARNOLD, E (corresponding author), CTR ADV BIOTECHNOL & MED,679 HOES LANE,PISCATAWAY,NJ 08854, USA.			Williams, Roger/0000-0001-7754-4207				BABA M, 1991, P NATL ACAD SCI USA, V88, P2356, DOI 10.1073/pnas.88.6.2356; CAMBILLAU C, 1987, J MOL GRAPHICS, V5, P174, DOI 10.1016/0263-7855(87)80024-3; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; FERRIS AL, 1990, VIROLOGY, V175, P456, DOI 10.1016/0042-6822(90)90430-Y; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; FURFINE ES, 1991, J BIOL CHEM, V266, P406; GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863; HIZI A, 1992, J BIOL CHEM, V267, P1293; JACOBOMOLINA A, 1991, P NATL ACAD SCI USA, V88, P10895, DOI 10.1073/pnas.88.23.10895; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; NAKAMURA H, 1991, P NATL ACAD SCI USA, V88, P11535, DOI 10.1073/pnas.88.24.11535; NUNBERG JH, 1991, J VIROL, V65, P4887, DOI 10.1128/JVI.65.9.4887-4892.1991; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SANCHEZPESCADOR R, 1985, SCIENCE, V227, P484, DOI 10.1126/science.2578227; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4; WANG BC, 1985, METHOD ENZYMOL, V115, P90; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648	22	173	180	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 7	1992	357	6373					85	89		10.1038/357085a0	http://dx.doi.org/10.1038/357085a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT229	1374166				2022-12-28	WOS:A1992HT22900065
J	SINGH, BM; JACKSON, DMA; WILLS, R; DAVIES, J; WISE, PH				SINGH, BM; JACKSON, DMA; WILLS, R; DAVIES, J; WISE, PH			DELAYED DIAGNOSIS IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS	BRITISH MEDICAL JOURNAL			English	Article											SINGH, BM (corresponding author), CHARING CROSS HOSP,DEPT ENDOCRINOL,LONDON W6 8RF,ENGLAND.							Hillson R M, 1985, Diabet Med, V2, P383; JACKSON DMA, 1991, DIABETIC MED, V8, P971, DOI 10.1111/j.1464-5491.1991.tb01540.x; KNUIMAN MW, 1986, DIABETES, V35, P1332, DOI 10.2337/diabetes.35.12.1332; MINCU I, 1970, MED INTERNAT, V304, P1331; 1990, WHO TECH REP SER, P646	5	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 2	1992	304	6835					1154	1155		10.1136/bmj.304.6835.1154	http://dx.doi.org/10.1136/bmj.304.6835.1154			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT232	1392794	Green Published, Bronze			2022-12-28	WOS:A1992HT23200022
J	FANTL, WJ; ESCOBEDO, JA; MARTIN, GA; TURCK, CW; DELROSARIO, M; MCCORMICK, F; WILLIAMS, LT				FANTL, WJ; ESCOBEDO, JA; MARTIN, GA; TURCK, CW; DELROSARIO, M; MCCORMICK, F; WILLIAMS, LT			DISTINCT PHOSPHOTYROSINES ON A GROWTH-FACTOR RECEPTOR BIND TO SPECIFIC MOLECULES THAT MEDIATE DIFFERENT SIGNALING PATHWAYS	CELL			English	Article							PROTEIN-TYROSINE KINASES; PHOSPHOLIPASE-C-GAMMA; FACTOR-I RECEPTOR; GTPASE-ACTIVATING PROTEIN; GAP-ASSOCIATED PROTEINS; PDGF BETA-RECEPTOR; PHOSPHATIDYLINOSITOL KINASE; ONCOGENE PRODUCT; PHOSPHORYLATION; TRANSDUCTION	The receptor for platelet-derived growth factor (PDGF) binds two proteins containing SH2 domains, GTPase activating protein (GAP) and phosphatidylinositol 3-kinase (Pl3-kinase). The sites on the receptor that mediate this interaction were identified by using phosphotyrosine-containing peptides representing receptor sequences to block specifically binding of either Pl3-kinase or GAP. These results suggested that Pl3-kinase binds two phosphotyrosine residues, each located in a 5 aa motif with an essential methionine at the fourth position C-terminal to the tyrosine. Point mutations at these sites caused a selective elimination of Pl3-kinase binding and loss of PDGF-stimulated DNA synthesis. Mutation of the binding site for GAP prevented the receptor from associating with or phosphorylating GAP, but had no effect on Pl3-kinase binding and little effect on DNA synthesis. Therefore, GAP and Pl3-kinase interact with the receptor by binding to different phosphotyrosine-containing sequence motifs.	CETUS CORP, EMERYVILLE, CA 94608 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	FANTL, WJ (corresponding author), UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA.				NCI NIH HHS [CA51992-01] Funding Source: Medline; NHLBI NIH HHS [R01 HL-32898] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA051992] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032898] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COHEN B, 1990, P NATL ACAD SCI USA, V87, P4458, DOI 10.1073/pnas.87.12.4458; COUGHLIN SR, 1989, SCIENCE, V243, P1191; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EK B, 1982, J BIOL CHEM, V257, P486; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; ESCOBEDO JA, 1988, J BIOL CHEM, V263, P1482; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NISHIMURA J, 1982, P NATL ACAD SCI-BIOL, V79, P4303, DOI 10.1073/pnas.79.14.4303; PAWSON T, 1988, ONCOGENE, V3, P491; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SEVERINSSON L, 1990, MOL CELL BIOL, V10, P801, DOI 10.1128/MCB.10.2.801; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; Summers MD, 1987, MANUAL METHODS BACUL; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TURCK CW, 1992, IN PRESS PEPTIDE RES; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	46	630	703	0	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 1	1992	69	3					413	423		10.1016/0092-8674(92)90444-H	http://dx.doi.org/10.1016/0092-8674(92)90444-H			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HT078	1374684				2022-12-28	WOS:A1992HT07800005
J	SIMMONS, HE; RHOADES, MM; GOLDBERG, MA				SIMMONS, HE; RHOADES, MM; GOLDBERG, MA			COMPREHENSIVE HEALTH-CARE REFORM AND MANAGED COMPETITION	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											SIMMONS, HE (corresponding author), NATL LEADERSHIP COALIT HLTH CARE REFORM,WASHINGTON,DC 20004, USA.								0	16	16	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 19	1992	327	21					1525	1528		10.1056/NEJM199211193272113	http://dx.doi.org/10.1056/NEJM199211193272113			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY165	1406886				2022-12-28	WOS:A1992JY16500013
J	STIMMEL, B				STIMMEL, B			THE CRISIS IN PRIMARY CARE AND THE ROLE OF MEDICAL-SCHOOLS - DEFINING THE ISSUES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTERNAL-MEDICINE; FAMILY MEDICINE; STUDENTS; SPECIALTY; CHOICE; EDUCATION				STIMMEL, B (corresponding author), CUNY MT SINAI SCH MED,1 GUSTAVE L LEVY PL,BOX 1255,NEW YORK,NY 10029, USA.							ALLEN SS, 1987, J MED EDUC, V62, P911; Altman L. K., 1990, NY TIMES A, P1; BREARLEY WD, 1982, J MED EDUC, V57, P449; CAMPOSOUTCALT D, 1989, ACAD MED, V64, P610, DOI 10.1097/00001888-198910000-00013; COOKE M, 1989, NEW ENGL J MED, V321, P1334, DOI 10.1056/NEJM198911093211911; FREUDENHEIM M, 1990, NY TIMES        0205, pA1; FREUDENHEIM M, 1990, NY TIMES        1125, P32; GEYMAN JP, 1986, JAMA-J AM MED ASSOC, V255, P2631, DOI 10.1001/jama.255.19.2631; GRAETTINGER JS, 1988, ANN INTERN MED, V108, P101, DOI 10.7326/0003-4819-108-1-101; HOLOWEIKO M, 1990, MED EC          1112, P2; JAECKY RK, 1991, ACAD MED, V66, P756; KASSEBAUM DG, 1992, ACAD MED, V67, P217, DOI 10.1097/00001888-199203000-00018; KLETKE PR, 1987, ANN INTERN MED, V107, P93, DOI 10.7326/0003-4819-107-1-93; LARKIN H, 1990, AM MED NEWS     1116, P9; LEWIS CE, 1991, ANN INTERN MED, V114, P1, DOI 10.7326/0003-4819-114-1-1; MCCARTY DJ, 1987, NEW ENGL J MED, V317, P567, DOI 10.1056/NEJM198708273170909; MELLRATH S, 1991, AM WORLD NEWS   0218, P1; NESS R, 1989, ACAD MED, V64, P588, DOI 10.1097/00001888-198910000-00009; PEAR R, 1991, NY TIMES        0813, pA14; PEAR R, 1991, NY TIMES        1118, pA1; PETERSDORF RG, 1989, J GEN INTERN MED, V4, P527, DOI 10.1007/BF02599554; PETERSDORF RG, 1991, ACAD MED, V66, P61, DOI 10.1097/00001888-199102000-00001; PHILLIPS TJ, 1978, JAMA-J AM MED ASSOC, V240, P1736; PRASHKER MJ, 1991, ANN INTERN MED, V115, P715, DOI 10.7326/0003-4819-115-9-715; REINHARDT UE, 1981, AM J PUBLIC HEALTH, V71, P1149, DOI 10.2105/AJPH.71.10.1149; SCHWARTZ RW, 1989, ACAD MED, V64, P606, DOI 10.1097/00001888-198910000-00012; STIMMEL B, 1978, NEW ENGL J MED, V299, P227, DOI 10.1056/NEJM197808032990504; STIMMEL B, 1977, J MED EDUC, V52, P484; SWANSON AG, 1990, JUN NEW YORK STAT CO; WAGONER NE, 1990, 101ST ANN M ASS AM M; 1990, 1990 NAT BOARD MED E; 1980, HRA81651 US DEP HLTH; 1991, SUPPLYING PHYSICIANS; 1991, FUNCTIONS STRUCTURE; 1982, JAMA-J AM MED ASSOC, V248, P3274; 1990, FACTS APPLICANTS MAT; 1990, JAMA-J AM MED ASSOC, V264, P823; 1986, AMA MED SCH ALUMNI 1; 1980, CHARACTERISTICS 1989; 1980, LCME QUESTIONNAIRE 2; 1980, JAMA-J AM MED ASSOC, V244, P2831; 1989, NRMP DATA; 1990, AAMC GRADUATION QUES; 1991, NRMP DATA	44	41	41	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 21	1992	268	15					2060	2065		10.1001/jama.268.15.2060	http://dx.doi.org/10.1001/jama.268.15.2060			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT520	1404743				2022-12-28	WOS:A1992JT52000030
J	GHO, M; MCDONALD, K; GANETZKY, B; SAXTON, WM				GHO, M; MCDONALD, K; GANETZKY, B; SAXTON, WM			EFFECTS OF KINESIN MUTATIONS ON NEURONAL FUNCTIONS	SCIENCE			English	Article							TRANSMITTER RELEASE; AXONAL-TRANSPORT; HEAVY-CHAIN; C-ELEGANS; DROSOPHILA; SQUID; MICROTUBULES; IDENTIFICATION; MOTILITY; PROTEINS	Kinesin is believed to generate force for the movement of organelles in anterograde axonal transport. The identification of genes that encode kinesin-like proteins suggests that other motors may provide anterograde force instead of or in addition to kinesin. To gain insight into the specific functions of kinesin, the effects of mutations in the kinesin heavy chain gene (khc) on the physiology and ultrastructure of Drosophila larval neurons were studied. Mutations in khc impair both action potential propagation in axons and neurotransmitter release at nerve terminals but have no apparent effect on the concentration of synaptic vesicles in nerve terminal cytoplasm. Thus kinesin is required in vivo for normal neuronal function and may be active in the transport of ion channels and components of the synaptic release machinery to their appropriate cellular locations. Kinesin appears not to be required for the anterograde transport of synaptic vesicles or their components.	UNIV WISCONSIN,GENET LAB,MADISON,WI 53706; UNIV COLORADO,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80309; INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405	University of Wisconsin System; University of Wisconsin Madison; University of Colorado System; University of Colorado Boulder; Indiana University System; Indiana University Bloomington					NIGMS NIH HHS [R01 GM046295, R01 GM046295-09] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046295] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGUSTINE GJ, 1985, J PHYSIOL-LONDON, V367, P163, DOI 10.1113/jphysiol.1985.sp015819; BRADY ST, 1990, P NATL ACAD SCI USA, V87, P1061, DOI 10.1073/pnas.87.3.1061; BRADY ST, 1991, NEURON, V7, P521, DOI 10.1016/0896-6273(91)90365-7; BRISMAR T, 1987, P NATL ACAD SCI USA, V84, P1459, DOI 10.1073/pnas.84.5.1459; Goldstein L S, 1991, Trends Cell Biol, V1, P93, DOI 10.1016/0962-8924(91)90036-9; GYOEVA FK, 1991, NATURE, V353, P445, DOI 10.1038/353445a0; HALL DH, 1991, CELL, V65, P837, DOI 10.1016/0092-8674(91)90391-B; HEUSER JE, 1979, J CELL BIOL, V81, P275, DOI 10.1083/jcb.81.2.275; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; JAN LY, 1976, J PHYSIOL-LONDON, V262, P189, DOI 10.1113/jphysiol.1976.sp011592; JOHANSEN J, 1989, J NEUROSCI, V9, P710; MCDONALD K, 1984, J ULTRA MOL STRUCT R, V86, P107, DOI 10.1016/S0022-5320(84)80051-9; OTSUKA AJ, 1991, NEURON, V6, P113, DOI 10.1016/0896-6273(91)90126-K; SAXTON WM, 1991, CELL, V64, P1093, DOI 10.1016/0092-8674(91)90264-Y; STEWART RJ, 1991, P NATL ACAD SCI USA, V88, P8470, DOI 10.1073/pnas.88.19.8470; VALE RD, 1990, CELL, V60, P883, DOI 10.1016/0092-8674(90)90334-B; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1985, CELL, V43, P623, DOI 10.1016/0092-8674(85)90234-X; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; WONDERLIN WF, 1991, P NATL ACAD SCI USA, V88, P4391, DOI 10.1073/pnas.88.10.4391; WU CF, 1978, P NATL ACAD SCI USA, V75, P4047, DOI 10.1073/pnas.75.8.4047; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	22	107	108	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 9	1992	258	5080					313	316		10.1126/science.1384131	http://dx.doi.org/10.1126/science.1384131			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR860	1384131	Green Accepted			2022-12-28	WOS:A1992JR86000039
J	BIX, M; RAULET, D				BIX, M; RAULET, D			INEFFICIENT POSITIVE SELECTION OF T-CELLS DIRECTED BY HEMATOPOIETIC-CELLS	NATURE			English	Article							THYMUS	SUCCESSFUL intrathymic differentiation of alpha-beta-TCR+ T cells depends on positive selection of CD4+CD8+ thymocytes by thymic major histocompatibility complex (MHC) molecules1-9. Positive selection allows the maturation of only those T cells capable of restricted antigen recognition in the context of the hosts' MHC alleles. Studies of normal or T-cell receptor-transgenic mice engrafted with MHC-different bone marrow or thymuses support the conclusion that positive selection is directed by MHC molecules expressed on non-haematopoietic cells, presumably thymic epithelial cells1-3,8-10. Here we present contrary evidence that class I MHC molecules expressed by haematopoietic cell types direct positive selection of CD8+ T cells, though at a reduced rate compared with positive selection directed by thymic epithelial cells. The identity of cell types that direct positive selection bears directly on mechanistic models of the process, including the idea that thymic epithelial cell MHC molecules uniquely present specialized peptides that mediate positive selection, and the notion that thymic epithelial cells express unique differentiation-inducing cell surface molecules.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV IMMUNOL,489 LIFE SCI ADDIT,BERKELEY,CA 94720	University of California System; University of California Berkeley				Raulet, David/0000-0002-1257-8649; Bix, Mark/0000-0003-4617-0497				BEVAN MJ, 1978, IMMUNOL REV, V42, P3, DOI 10.1111/j.1600-065X.1978.tb00256.x; SPRENT J, 1978, J EXP MED, V147, P1159, DOI 10.1084/jem.147.4.1159; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882	3	142	144	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 24	1992	359	6393					330	333		10.1038/359330a0	http://dx.doi.org/10.1038/359330a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP503	1406938				2022-12-28	WOS:A1992JP50300060
J	STEIN, PL; LEE, HM; RICH, S; SORIANO, P				STEIN, PL; LEE, HM; RICH, S; SORIANO, P			PP59(FYN) MUTANT MICE DISPLAY DIFFERENTIAL SIGNALING IN THYMOCYTES AND PERIPHERAL T-CELLS	CELL			English	Article							PROTEIN-TYROSINE KINASE; ANTIGEN RECEPTOR; SRC FAMILY; STAPHYLOCOCCAL-ENTEROTOXIN; TOLERANCE INDUCTION; STEM-CELLS; STIMULATION; ACTIVATION; PROTOONCOGENE; ASSOCIATION	We have generated mutant mice that do not express pp59fyn, a nonreceptor protein tyrosine kinase related to pp60src, by homologous recombination in embryonic stem cells. fyn- mice did not display an overt phenotype. Because fyn is associated with the T cell receptor (TCR), thymocyte and T cell signaling was analyzed in the mutant background. Cross-linking of TCR-CD3 in thymocytes led to markedly reduced calcium fluxes and abrogated proliferation, whereas mature splenic T cells retained largely normal proliferation despite depressed calcium movements and IL-2 production. Similarly, proliferation induced by Thy-1 cross-linking was reduced in thymocytes but not in splenic T cells. fyn- thymocytes were impaired at a late stage of maturation and showed limited clonal deletion to the Mls-1a self-superantigen but not to staphylococcal enterotoxin A. These results implicate fyn as a critical component in TCR signaling in thymocytes and, potentially, in the process that determines T cell repertoire in the adult mouse.	BAYLOR COLL MED, DEPT NEUROL & PSYCHIAT, HOUSTON, TX 77030 USA; BAYLOR COLL MED, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute	STEIN, PL (corresponding author), BAYLOR COLL MED, INST MOLEC GENET, HOUSTON, TX 77030 USA.		Soriano, Philippe M/E-5797-2015	Soriano, Philippe M/0000-0002-0427-926X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD025326, R01HD025326, R01HD024875] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021420] Funding Source: NIH RePORTER; NIAID NIH HHS [AI21420] Funding Source: Medline; NICHD NIH HHS [HD25326, HD24875] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALARCON B, 1991, EMBO J, V10, P903, DOI 10.1002/j.1460-2075.1991.tb08023.x; Altman A, 1990, Adv Immunol, V48, P227, DOI 10.1016/S0065-2776(08)60756-7; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BLACKMAN MA, 1990, NATURE, V345, P540, DOI 10.1038/345540a0; BOLEN JB, 1991, CELL GROWTH DIFFER, V2, P409; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; COOKE M P, 1989, New Biologist, V1, P66; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; FINKEL TH, 1989, J IMMUNOL, V142, P3006; GAJEWSKI TF, 1990, J IMMUNOL, V144, P4110; GUIDOS CJ, 1990, J EXP MED, V172, P835, DOI 10.1084/jem.172.3.835; HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; JONES LA, 1990, SCIENCE, V250, P1726, DOI 10.1126/science.2125368; JUNE CH, 1990, J IMMUNOL, V144, P1591; KISIELOW P, 1991, IMMUNOL REV, V122, P69, DOI 10.1111/j.1600-065X.1991.tb00597.x; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEE HM, 1991, J IMMUNOL, V147, P1127; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LEVY JB, 1989, MOL CELL BIOL, V9, P3332, DOI 10.1128/MCB.9.8.3332; LIU H, 1991, P NATL ACAD SCI USA, V88, P8705, DOI 10.1073/pnas.88.19.8705; MACDONALD HR, 1988, J EXP MED, V167, P2005, DOI 10.1084/jem.167.6.2005; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; RAO A, 1991, CRIT REV IMMUNOL, V10, P495; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUGIE K, 1991, P NATL ACAD SCI USA, V88, P9132, DOI 10.1073/pnas.88.20.9132; SUSSMAN JJ, 1988, NATURE, V334, P625, DOI 10.1038/334625a0; SUSSMAN JJ, 1988, J IMMUNOL, V140, P2520; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TAKIMOTO H, 1990, EUR J IMMUNOL, V20, P617, DOI 10.1002/eji.1830200323; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THOMAS PM, 1992, J BIOL CHEM, V267, P12317; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X	47	563	570	1	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 4	1992	70	5					741	750		10.1016/0092-8674(92)90308-Y	http://dx.doi.org/10.1016/0092-8674(92)90308-Y			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JL663	1387588				2022-12-28	WOS:A1992JL66300006
J	HENDRICK, DJ; SIZER, KE				HENDRICK, DJ; SIZER, KE			BREATHING COAL-MINES AND SURFACE ASPHYXIATION FROM STYTHE (BLACK DAMP)	BRITISH MEDICAL JOURNAL			English	Article									WARDELL ARMSTRONG MIN ENGINEERS,NEWCASTLE TYNE,ENGLAND		HENDRICK, DJ (corresponding author), UNIV NEWCASTLE UPON TYNE,NEWCASTLE GEN HOSP,CHEST UNIT,NEWCASTLE TYNE NE4 6BE,ENGLAND.							BAXTER PJ, 1989, BRIT MED J, V298, P1437, DOI 10.1136/bmj.298.6685.1437; BLACK D, 1987, JOURNAL         0330, P9; GRAHAM JI, 1913, T I MINING ENG, V55, P294; MOSS KN, 1927, GASES DUST HEAT MINE, P19; SNOWDON M, 1987, EVENING CHRONIC 0328, P1; 1987, SUNDAY SUN      0329, P6; 1987, JOURNAL         0328, P1; 1987, EVENING CHRONIC 0619, P12	8	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 29	1992	305	6852					509	510		10.1136/bmj.305.6852.509	http://dx.doi.org/10.1136/bmj.305.6852.509			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL609	1392998	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JL60900022
J	EYSENCK, HJ				EYSENCK, HJ			PSYCHOSOCIAL FACTORS, CANCER, AND ISCHEMIC-HEART-DISEASE	BRITISH MEDICAL JOURNAL			English	Article							PERSONALITY; PREDICTOR; STRESS				EYSENCK, HJ (corresponding author), UNIV LONDON,INST PSYCHIAT,LONDON SE5 8AF,ENGLAND.							EYSENCK H J, 1991, Integrative Physiological and Behavioral Science, V26, P309, DOI 10.1007/BF02691067; Eysenck H.J., 1991, ADULT EPQ R; EYSENCK HJ, 1990, PERCEPT MOTOR SKILL, V71, P216; EYSENCK HJ, 1991, BEHAV RES THER, V29, P17, DOI 10.1016/S0005-7967(09)80003-X; EYSENCK HJ, 1991, PSYCHOL INQ, V2, P320; GROSSARTHMATICE.R, 1991, PSYCHOL REP, V65, P1027; GROSSARTHMATICEK R, 1991, PSYCHOL REP, V68, P1083, DOI 10.2466/PR0.68.4.1083-1087; GROSSARTHMATICEK R, 1988, PERS INDIV DIFFER, V9, P479, DOI 10.1016/0191-8869(88)90125-0; GROSSHANS EM, 1990, J AM ACAD DERMATOL, V23, P153, DOI 10.1016/S0190-9622(08)81224-8; KISSEN DM, 1992, J PSYCHOSOM RES, V6, P123; PELOSI AJ, 1992, BRIT MED J, V303, P1295; QUANDERBLAZNIK J, 1991, PERS INDIV DIFFER, V12, P125, DOI 10.1016/0191-8869(91)90095-S; SCHMALE AH, 1971, SOC SCI MED, V5, P95, DOI 10.1016/0037-7856(71)90090-4; SCHMITZ PG, 1992, PERS INDIV DIFFER, V13, P683, DOI 10.1016/0191-8869(92)90239-L; SPIEGEL D, 1989, LANCET, V2, P888; VETTER H, 1991, PSYCHOL INQ, V2, P322; Vetter H, 1991, PSYCHOL INQ, V2, P286	17	18	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 22	1992	305	6851					457	459		10.1136/bmj.305.6851.457	http://dx.doi.org/10.1136/bmj.305.6851.457			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JK680	1392961	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992JK68000025
J	EGAN, M; FLOTTE, T; AFIONE, S; SOLOW, R; ZEITLIN, PL; CARTER, BJ; GUGGINO, WB				EGAN, M; FLOTTE, T; AFIONE, S; SOLOW, R; ZEITLIN, PL; CARTER, BJ; GUGGINO, WB			DEFECTIVE REGULATION OF OUTWARDLY RECTIFYING CL- CHANNELS BY PROTEIN KINASE-A CORRECTED BY INSERTION OF CFTR	NATURE			English	Article							CYSTIC-FIBROSIS GENE; CHLORIDE CHANNELS; EPITHELIAL-CELLS; EXPRESSION; CONDUCTANCE; ACTIVATION; DISEASE	CYSTIC fibrosis (CF) is a lethal genetic disease resulting in a reduced Cl- permeability1, increased mucous sulphation2, increased Na+ absorption3 and defective acidification of lysosomal vesicles4. The CF gene encodes a protein (the cystic fibrosis transmembrane conductance regulator, CFTR5) that can function as a low-conductance Cl- channel with a linear current-voltage relationship whose regulation is defective in CF patients6-8. Larger conductance, outwardly rectifying Cl- channels are also defective in CF and fail to activate when exposed either to cyclic AMP-dependent protein kinase A or to protein kinase C9-13. The role of the outwardly rectifying Cl- channel in CF has been questioned14. We report here that expression of recombinant CF genes using adeno-associated virus vectors in CF bronchial epithelial cells corrects defective Cl- secretion, that it induces the appearance of small, linear conductance Cl- channels, and restores protein kinase A activation of outwardly rectifying Cl- channels. These results re-establish an involvement of outwardly rectifying Cl- channels in CF and suggest that CFTR regulates more than one conductance pathway in airway tissues.	JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,BALTIMORE,MD 21205; NIDDKD,MOLEC & CELLULAR BIOL LAB,BETHESDA,MD	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)				Zeitlin, Pamela/0000-0002-2719-1834				ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BEAR CE, 1991, J BIOL CHEM, V266, P19142; BRIDGES RJ, 1989, AM J PHYSIOL, V256, pC902, DOI 10.1152/ajpcell.1989.256.4.C902; CHEN JH, 1989, SCIENCE, V243, P657, DOI 10.1126/science.2464852; CHENG PW, 1989, J CLIN INVEST, V84, P68, DOI 10.1172/JCI114171; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; FLOTTE T, 1991, PEDIATR PULM, V6, P247; FLOTTE TR, IN PRESS AM J RESPIR; FRIZZELL RA, 1987, TRENDS NEUROSCI, V10, P190, DOI 10.1016/0166-2236(87)90144-5; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; LI M, 1989, SCIENCE, V244, P1353, DOI 10.1126/science.2472006; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; SCHOUMACHER RA, 1987, NATURE, V330, P752, DOI 10.1038/330752a0; TRAPNELL BC, 1991, J BIOL CHEM, V266, P10319; WARD CL, 1991, P NATL ACAD SCI USA, V88, P5277, DOI 10.1073/pnas.88.12.5277; WELSH MJ, 1989, J CLIN INVEST, V84, P2002, DOI 10.1172/JCI114391; ZEITLIN PL, 1992, P NATL ACAD SCI USA, V89, P344, DOI 10.1073/pnas.89.1.344; ZEITLIN PL, 1991, AM J RESP CELL MOL, V4, P313, DOI 10.1165/ajrcmb/4.4.313	25	401	410	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 13	1992	358	6387					581	584		10.1038/358581a0	http://dx.doi.org/10.1038/358581a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH829	1380129				2022-12-28	WOS:A1992JH82900059
J	PRIMIG, M; SOCKANATHAN, S; AUER, H; NASMYTH, K				PRIMIG, M; SOCKANATHAN, S; AUER, H; NASMYTH, K			ANATOMY OF A TRANSCRIPTION FACTOR IMPORTANT FOR THE START OF THE CELL-CYCLE IN SACCHAROMYCES-CEREVISIAE	NATURE			English	Article							YEAST HO GENE; FISSION YEAST; BUDDING YEAST; DNA; POLYMERASE; EXPRESSION; PROTEINS; SEQUENCE; SWI4; ACTIVATION	ENTRY of yeast cells into the mitotic cell cycle (Start) involves a form of the CDC28 kinase that associates with G1-specific cyclins encoded by CLN1 and CLN2 (ref. 1). The onset of Start may be triggered by the activation of CLN1 and CLN2 transcription in late G1 (ref. 2). SWI4 and SWI6 are components of a factor (SBF) that binds the CACGAAAA (SCB) promoter elements3-5 responsible for activation in late G1 of the HO endonuclease, CLN1 and CLN2 genes6,7. A related factor (MBF) containing SWI6 and a 120K protein8 binds to the ACGCGTNA (MCB) promoter elements responsible for late G1-specific transcription of DNA replication genes9-12. Nothing is known about how these heteromeric proteins bind DNA. We show here that SWI4 contains a novel DNA-binding domain at its N terminus that alone binds specifically to SCBs and a C-terminal domain that binds to SWI6. SWI4's DNA-binding domain is similar to an N-terminal domain of the cdc10 protein that is a component of an MBF-like factor from Schizosaccharomyces pombe13 and is required for Start14,15. An involvement of this kind of DNA-binding domain in transcriptional controls at Start may therefore be a conserved feature of eukaryotic cells.			PRIMIG, M (corresponding author), INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.		Primig, Michael/G-3175-2013; Auer, Herbert/AAV-2332-2020	Primig, Michael/0000-0002-2061-0119; Nasmyth, Kim/0000-0001-7030-4403				ANDREWS BJ, 1989, NATURE, V342, P803; AVES SJ, 1985, EMBO J, V4, P457, DOI 10.1002/j.1460-2075.1985.tb03651.x; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; BREEDEN L, 1991, GENE DEV, V5, P1183, DOI 10.1101/gad.5.7.1183; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIRICK L, 1992, NATURE, V357, P508, DOI 10.1038/357508a0; GORDON CB, 1991, P NATL ACAD SCI USA, V88, P6058, DOI 10.1073/pnas.88.14.6058; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWNDES NF, 1992, NATURE, V355, P449, DOI 10.1038/355449a0; LOWNDES NF, 1991, NATURE, V350, P247, DOI 10.1038/350247a0; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MCINTOSH EM, 1991, MOL CELL BIOL, V11, P329, DOI 10.1128/MCB.11.1.329; MOLL T, IN PRESS J CELL SCI; NASMYTH K, 1985, CELL, V42, P213, DOI 10.1016/S0092-8674(85)80117-3; NASMYTH K, 1991, CELL, V66, P995, DOI 10.1016/0092-8674(91)90444-4; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; PIZZAGALLI A, 1988, P NATL ACAD SCI USA, V85, P3772, DOI 10.1073/pnas.85.11.3772; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; SOCKANATHAN S, 1991, THESIS U CAMBRIDGE; STILLMAN DJ, 1988, EMBO J, V7, P485, DOI 10.1002/j.1460-2075.1988.tb02836.x; STURM R, 1987, GENE DEV, V1, P1147, DOI 10.1101/gad.1.10.1147; TABA MRM, 1991, GENE DEV, V5, P2000, DOI 10.1101/gad.5.11.2000; THOMPSON CC, 1991, SCIENCE, V253, P726; VANDERWERF S, 1986, P NATL ACAD SCI USA, V83, P2330; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	28	108	109	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 13	1992	358	6387					593	597		10.1038/358593a0	http://dx.doi.org/10.1038/358593a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH829	1386897	Bronze			2022-12-28	WOS:A1992JH82900063
J	DEYO, RA; RAINVILLE, J; KENT, DL				DEYO, RA; RAINVILLE, J; KENT, DL			WHAT CAN THE HISTORY AND PHYSICAL-EXAMINATION TELL US ABOUT LOW-BACK-PAIN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANKYLOSING-SPONDYLITIS; LUMBAR SPINE; SIGNS; DISK; RELIABILITY; SYMPTOMS; SCIATICA; QUANTIFICATION; OSTEOMYELITIS; EPIDEMIOLOGY		UNIV WASHINGTON, DEPT MED, BACK PAIN OUTCOME ASSESSMENT TEAM, JD-23, SEATTLE, WA 98195 USA; VET AFFAIRS MED CTR, HLTH SERV RES & DEV FIELD PROGRAM, SEATTLE, WA USA; UNIV WASHINGTON, DEPT HLTH SERV, SEATTLE, WA 98195 USA; TUFTS UNIV, SCH MED, DEPT REHABIL MED, BOSTON, MA 02111 USA	University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle; Tufts University					AHRQ HHS [HS-06344] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ALPERS BJ, 1953, MED CLIN N AM, P503, DOI 10.1016/S0025-7125(16)35026-X; ARONSON HA, 1963, J BONE JOINT SURG AM, V45, P311, DOI 10.2106/00004623-196345020-00009; BAKER AS, 1975, NEW ENGL J MED, V293, P463, DOI 10.1056/NEJM197509042931001; BAUER RL, 1987, ARCH INTERN MED, V147, P1437, DOI 10.1001/archinte.147.8.1437; BLOWER PW, 1984, ANN RHEUM DIS, V43, P192, DOI 10.1136/ard.43.2.192; BLOWER PW, 1981, SPINE, V6, P175, DOI 10.1097/00007632-198103000-00013; BODEN SD, 1990, J BONE JOINT SURG AM, V72A, P403, DOI 10.2106/00004623-199072030-00013; BREKKAN A, 1983, CLIN RADIOL, V34, P321, DOI 10.1016/S0009-9260(83)80349-3; BRIEG A, 1979, SPINE, V4, P242; BURNAM MA, 1988, MED CARE, V26, P775, DOI 10.1097/00005650-198808000-00004; CALIN A, 1977, JAMA-J AM MED ASSOC, V237, P2613, DOI 10.1001/jama.237.24.2613; CALIN A, 1980, SPINE, V5, P201, DOI 10.1097/00007632-198003000-00016; CARTER ET, 1979, ARTHRITIS RHEUM, V22, P365, DOI 10.1002/art.1780220408; CHANDRASEKAR PH, 1990, ARCH INTERN MED, V150, P1125, DOI 10.1001/archinte.1990.00390170147041; CHARNLEY J, 1951, LANCET, V260, P186; CYPRESS BK, 1983, AM J PUBLIC HEALTH, V73, P389, DOI 10.2105/AJPH.73.4.389; DEYO RA, 1987, SPINE, V12, P264, DOI 10.1097/00007632-198704000-00013; DEYO RA, 1986, J GEN INTERN MED, V1, P328, DOI 10.1007/BF02596214; DEYO RA, 1988, J GEN INTERN MED, V3, P230, DOI 10.1007/BF02596337; DEYO RA, 1989, ANN INTERN MED, V111, P865, DOI 10.7326/0003-4819-111-11-865; DEYO RA, 1990, ANN INTERN MED, V112, P598, DOI 10.7326/0003-4819-112-8-598; GATCHEL RJ, 1986, SPINE, V11, P36, DOI 10.1097/00007632-198601000-00010; GEHWEILER JA, 1983, AM J ROENTGENOL, V140, P109, DOI 10.2214/ajr.140.1.109; GRAN JT, 1985, CLIN RHEUMATOL, V4, P161, DOI 10.1007/BF02032287; HAKELIUS A, 1972, ACTA ORTHOP SCAND, V43, P239, DOI 10.3109/17453677208991262; HAKELIUS A, 1972, ACTA ORTHOP SCAND, V43, P234, DOI 10.3109/17453677208991261; HAWKES CH, 1978, J NEUROL SCI, V38, P337, DOI 10.1016/0022-510X(78)90140-5; HAWKINS BR, 1981, ARTHRITIS RHEUM, V24, P743, DOI 10.1002/art.1780240524; HOEHLER FK, 1982, RHEUMATOL REHABIL, V21, P21, DOI 10.1093/rheumatology/21.1.21; HSIEH CY, 1983, PHYS THER, V63, P1429, DOI 10.1093/ptj/63.9.1429; HUDGINS WR, 1979, J OCCUP ENVIRON MED, V21, P407; Keegan JJ, 1943, ARCH NEURO PSYCHIATR, V50, P67, DOI 10.1001/archneurpsyc.1943.02290190077006; KORBON GA, 1987, SPINE, V12, P787, DOI 10.1097/00007632-198710000-00014; KORTELAINEN P, 1985, SPINE, V10, P88, DOI 10.1097/00007632-198501000-00014; KOSTELJANETZ M, 1988, SPINE, V13, P393, DOI 10.1097/00007632-198804000-00003; KOSTELJANETZ M, 1984, ACTA NEUROCHIR, V73, P67, DOI 10.1007/BF01401785; KOSTUIK JP, 1986, J BONE JOINT SURG AM, V68A, P386, DOI 10.2106/00004623-198668030-00011; LIANG M, 1982, ARCH INTERN MED, V142, P1108, DOI 10.1001/archinte.142.6.1108; MAYER TG, 1984, SPINE, V9, P588, DOI 10.1097/00007632-198409000-00009; MCCOMBE PF, 1989, SPINE, V14, P908, DOI 10.1097/00007632-198909000-00002; MOLL JMH, 1972, ANN RHEUM DIS, V31, P1, DOI 10.1136/ard.31.1.1; MORRIS EW, 1986, SPINE, V11, P436, DOI 10.1097/00007632-198606000-00007; NACHEMSON A L, 1976, Spine, V1, P59, DOI 10.1097/00007632-197603000-00009; OLAOIRE SA, 1981, BRIT MED J, V282, P1852, DOI 10.1136/bmj.282.6279.1852; POTTER NA, 1985, PHYS THER, V65, P1671, DOI 10.1093/ptj/65.11.1671; RAE P S, 1984, Journal of the Royal College of Surgeons of Edinburgh, V29, P281; REYNOLDS P M G, 1975, Rheumatology and Rehabilitation, V14, P180, DOI 10.1093/rheumatology/14.3.180; RUCKER L, 1986, ARCH INTERN MED, V146, P729, DOI 10.1001/archinte.146.4.729; RUSSELL AS, 1981, ARTHRITIS RHEUM, V24, P1575, DOI 10.1002/art.1780241219; SAPICO FL, 1979, REV INFECT DIS, V1, P754; SCAVONE JG, 1981, AM J ROENTGENOL, V136, P715, DOI 10.2214/ajr.136.4.715; SCHWARTZ RS, 1990, AUST NZ J MED, V20, P116, DOI 10.1111/j.1445-5994.1990.tb01286.x; SHIQING X, 1987, J BONE JOINT SURG AM, V69, P517; SPANGFORT EV, 1972, ACTA ORTHOP SCAND, P1; Spitzer WO, 1987, SPINE, V12, pS16; TAY ECK, 1979, J BONE JOINT SURG BR, V61, P43, DOI 10.1302/0301-620X.61B1.154521; TURNER JA, 1992, SPINE, V17, P1, DOI 10.1097/00007632-199201000-00001; VANDERLINDEN S, 1984, ARTHRITIS RHEUM, V27, P361; WADDELL G, 1980, SPINE, V5, P117, DOI 10.1097/00007632-198003000-00005; WADDELL G, 1982, BMJ-BRIT MED J, V284, P1519, DOI 10.1136/bmj.284.6328.1519; WALDVOGEL FA, 1980, NEW ENGL J MED, V303, P360, DOI 10.1056/NEJM198008143030703; WALSH NE, 1988, OCCUP MED, V3, P109; WHITE AA, 1982, SPINE, V7, P141, DOI 10.1097/00007632-198203000-00009; WIESEL SW, 1984, SPINE, V9, P549, DOI 10.1097/00007632-198409000-00003	64	605	625	3	42	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1992	268	6					760	765		10.1001/jama.268.6.760	http://dx.doi.org/10.1001/jama.268.6.760			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG666	1386391				2022-12-28	WOS:A1992JG66600018
J	STURM, NR; MASLOV, DA; BLUM, B; SIMPSON, L				STURM, NR; MASLOV, DA; BLUM, B; SIMPSON, L			GENERATION OF UNEXPECTED EDITING PATTERNS IN LEISHMANIA TARENTOLAE MITOCHONDRIAL MESSENGER-RNAS - MISEDITING PRODUCED BY MISGUIDING	CELL			English	Article							ENCODE GUIDE RNAS; CYTOCHROME-OXIDASE; SUBUNIT-III; MINICIRCLES; MOLECULES; REGION; GENES; GRNA	We have analyzed the generation of unexpected patterns of RNA editing, i.e., those not following a strict 3' to 5' progression, which occur in junction regions between fully edited and preedited sequences. Evidence is presented that these patterns are generated by misediting due to specific events of misguiding. Misediting can occur through the interaction of inappropriate gRNAs with mRNAs or appropriate gRNAs in an incorrect fashion. Four possible mechanisms for the generation of misedited sequences are presented. Chimeric molecules have been detected in steady-state mitochondrial RNAs that are composed of misguiding gRNAs covalently linked to mRNAs at misediting sites by the 3' oligo(U) tail. We propose that misediting within junction regions can be corrected by appropriately acting gRNAs.	UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles					NIAID NIH HHS [AI-09102] Funding Source: Medline; NIGMS NIH HHS [GM-07104] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009102, R37AI009102] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM JM, 1988, CELL, V55, P267, DOI 10.1016/0092-8674(88)90049-9; BAKALARA N, 1989, J BIOL CHEM, V264, P18679; BENNE R, 1989, BIOCHIM BIOPHYS ACTA, V1007, P131, DOI 10.1016/0167-4781(89)90031-6; BLUM B, 1991, CELL, V65, P543, DOI 10.1016/0092-8674(91)90087-F; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BRALY P, 1974, J PROTOZOOL, V21, P782, DOI 10.1111/j.1550-7408.1974.tb03752.x; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; DECKER CJ, 1990, CELL, V61, P1001, DOI 10.1016/0092-8674(90)90065-M; FEAGIN JE, 1990, J BIOL CHEM, V265, P1; HARRIS ME, 1992, CELL, V68, P1091, DOI 10.1016/0092-8674(92)90080-V; KOSLOWSKY DJ, 1991, CELL, V67, P537, DOI 10.1016/0092-8674(91)90528-7; KOSLOWSKY DJ, 1992, NATURE, V356, P807, DOI 10.1038/356807a0; MASLOV DA, 1992, MOL CELL BIOL, V12, P56, DOI 10.1128/MCB.12.1.56; MASLOV DA, 1992, CELL, V70, P459, DOI 10.1016/0092-8674(92)90170-H; POLLARD VW, 1990, CELL, V63, P783, DOI 10.1016/0092-8674(90)90144-4; SIMPSON L, 1970, J PROTOZOOL, V17, P511, DOI 10.1111/j.1550-7408.1970.tb04719.x; SIMPSON L, 1989, CELL, V57, P355, DOI 10.1016/0092-8674(89)90911-2; SIMPSON L, 1990, SCIENCE, V250, P512, DOI 10.1126/science.1700474; SIMPSON L, 1978, CELL, V14, P169, DOI 10.1016/0092-8674(78)90311-2; STURM NR, 1990, CELL, V61, P879, DOI 10.1016/0092-8674(90)90198-N; STURM NR, 1990, CELL, V61, P871, DOI 10.1016/0092-8674(90)90197-M; STURM NR, 1991, NUCLEIC ACIDS RES, V19, P6277, DOI 10.1093/nar/19.22.6277; VANDERSPEK H, 1991, EMBO J, V10, P1217, DOI 10.1002/j.1460-2075.1991.tb08063.x	23	62	63	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 7	1992	70	3					469	476		10.1016/0092-8674(92)90171-8	http://dx.doi.org/10.1016/0092-8674(92)90171-8			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1379520				2022-12-28	WOS:A1992JH12400012
J	KARJALAINEN, J; MARTIN, JM; KNIP, M; ILONEN, J; ROBINSON, BH; SAVILAHTI, E; AKERBLOM, HK; DOSCH, HM				KARJALAINEN, J; MARTIN, JM; KNIP, M; ILONEN, J; ROBINSON, BH; SAVILAHTI, E; AKERBLOM, HK; DOSCH, HM			A BOVINE ALBUMIN PEPTIDE AS A POSSIBLE TRIGGER OF INSULIN-DEPENDENT DIABETES-MELLITUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ISLET CELL ANTIBODIES; SERUM-ALBUMIN; NOD MICE; BB-RAT; IDDM; CHILDREN; AUTOANTIBODIES; SUSCEPTIBILITY; DESTRUCTION; CHILDHOOD	Background. Cow's milk has been implicated as a possible trigger of the autoimmune response that destroys pancreatic beta cells in genetically susceptible hosts, thus causing diabetes mellitus. Studies in animals have suggested that bovine serum albumin (BSA) is the milk protein responsible, and an albumin peptide containing 17 amino acids (ABBOS) may be the reactive epitope. Antibodies to this peptide react with p69, a beta-cell surface protein that may represent the target antigen for milk-induced beta-cell-specific immunity. Methods. We used immunoassays and Western blot analysis to analyze anti-BSA antibodies in the serum of 142 children with insulin-dependent diabetes mellitus, 79 healthy children, and 300 adult blood donors. Anti-ABBOS antibodies were measured in 44 diabetic patients at the time of diagnosis, three to four months later, and one to two years later. Results. All the diabetic patients had elevated serum concentrations of IgG anti-BSA antibodies (but not of antibodies to other milk proteins), the bulk of which were specific for ABBOS. The mean (+/-SE) concentration was 8.5+/-0.2 kilofluorescence units (kfU) per microliter, as compared with 1.3+/-0.1 kfU per microliter in the healthy children. IgA antibodies were elevated as well, but not IgM antibodies. The antibody concentrations declined after diagnosis, reaching normal levels in most patients within one to two years. The initial decline involved anti-ABBOS-specific antibodies almost exclusively. Much lower serum concentrations of anti-BSA antibodies were found in all 379 control subjects, but only 2.5 percent of them had small amounts of ABBOS-specific IgG. Conclusions. Patients with insulin-dependent diabetes mellitus have immunity to cow's-milk albumin, with antibodies to an albumin peptide that are capable of reacting with a beta-cell-specific surface protein. Such antibodies could participate in the development of islet dysfunction.	UNIV TORONTO,HOSP SICK CHILDREN,DEPT PEDIAT & IMMUNOL,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV OULU,DEPT PEDIAT,SF-90100 OULU 10,FINLAND; UNIV OULU,DEPT MED MICROBIOL,SF-90100 OULU 10,FINLAND; UNIV TURKU,DEPT VIROL,SF-20500 TURKU 50,FINLAND; UNIV HELSINKI,CHILDRENS HOSP,DEPT PEDIAT 1,SF-00100 HELSINKI 10,FINLAND; UNIV HELSINKI,CHILDRENS HOSP,DEPT PEDIAT 2,SF-00100 HELSINKI 10,FINLAND	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Oulu; University of Oulu; University of Turku; University of Helsinki; University of Helsinki			Knip, Mikael/AAL-3773-2020	Knip, Mikael/0000-0003-0474-0033				BAISCH JM, 1990, NEW ENGL J MED, V322, P1836, DOI 10.1056/NEJM199006283222602; BARNETT AH, 1981, DIABETOLOGIA, V20, P87, DOI 10.1007/BF00262007; BEPPU H, 1987, DIABETES RES CLIN EX, V6, P67; BRUINING GJ, 1984, DIABETOLOGIA, V26, P24; DANEMAN D, 1987, DIABETES RES CLIN EX, V5, P93; DOSCH HM, 1992, PEDIAT AD E, V21, P202; DOSCH HM, 1988, PANDEX S PCFIA, P5; DRASH AL, 1990, SCHWEIZ MED WSCHR, V120, P39; ELLIOTT RB, 1984, DIABETOLOGIA, V26, P297, DOI 10.1007/BF00283653; ELLIOTT RB, 1988, DIABETOLOGIA, V31, P62; GLERUM M, 1989, DIABETES RES CLIN EX, V10, P103; GORSUCH AN, 1981, LANCET, V2, P1363; HANENBERG H, 1989, DIABETOLOGIA, V32, P126, DOI 10.1007/BF00505185; HUSBY S, 1985, INT ARCH ALLER A IMM, V77, P416, DOI 10.1159/000233819; IHM SH, 1990, DIABETES, V39, P1273, DOI 10.2337/diabetes.39.10.1273; ILONEN J, 1988, TISSUE ANTIGENS, V32, P139, DOI 10.1111/j.1399-0039.1988.tb01649.x; KARJALAINEN J, 1989, NEW ENGL J MED, V320, P881, DOI 10.1056/NEJM198904063201401; KARJALAINEN J, 1988, DIABETOLOGIA, V31, P129, DOI 10.1007/BF00276844; KARJALAINEN JK, 1990, DIABETES, V39, P1144, DOI 10.2337/diabetes.39.9.1144; KOLB H, 1988, DIABETOLOGIA, V31, P189, DOI 10.1007/BF00290583; MACKENZIE T, 1989, J EXP MED, V169, P407, DOI 10.1084/jem.169.2.407; MARTIN JM, 1991, ANN MED, V23, P447, DOI 10.3109/07853899109148088; MIGLIORESAMOUR D, 1988, EXPERIENTIA, V44, P188, DOI 10.1007/BF01941703; NERUP J, 1988, DIABETES CARE, V11, P16; PAGANO G, 1987, DIABETES, V36, P859, DOI 10.2337/diabetes.36.7.859; POCECCO M, 1991, HORM RES, V35, P67; REIJONEN H, 1991, DIABETES, V40, P1640, DOI 10.2337/diabetes.40.12.1640; SAVILAHTI E, 1988, DIABETES RES CLIN EX, V7, P137; SCOTT FW, 1990, AM J CLIN NUTR, V51, P489; SCOTT FW, 1989, DIABETES 1988, P763; TARN AC, 1988, LANCET, V1, P845; THIVOLET C, 1988, DIABETOLOGIA, V31, P741, DOI 10.1007/BF00274776; TODD JA, 1991, NATURE, V351, P542, DOI 10.1038/351542a0; VIRTANEN SM, 1991, DIABETES CARE, V14, P415, DOI 10.2337/diacare.14.5.415; WALTER MA, 1991, J EXP MED, V174, P335, DOI 10.1084/jem.174.2.335; YOKOTA A, 1990, DIABETES RES CLIN PR, V9, P211, DOI 10.1016/0168-8227(90)90047-W	36	366	373	2	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 30	1992	327	5					302	307		10.1056/NEJM199207303270502	http://dx.doi.org/10.1056/NEJM199207303270502			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF655	1377788				2022-12-28	WOS:A1992JF65500002
J	ROGERS, WJ; EPSTEIN, AE; ARCINIEGAS, JG; CROSSLEY, GH; DAILEY, SM; KAY, GN; LITTLE, RE; MACLEAN, WAH; PAPAPIETRO, SE; PLUMB, VJ; SILBER, S; BAKER, AR; CARLISLE, K; COHEN, N; COX, M; THOMAS, C; LEVSON, L; VONHAGEL, D; WALTON, AE; PRATT, CM; MAHMARIAN, J; MORRIS, G; CAPONE, RJ; BERGER, EE; CHMIELEWSKI, C; GORKIN, L; KHAN, AH; KORR, K; HANDSHAW, K; CONNOLLY, E; FITZPATRICK, D; CAMERON, T; WYSE, DG; DUFF, HJ; MITCHELL, LB; GILLIS, AM; WARNICA, JW; SHELDON, RS; LESOWAY, NR; KELLEN, J; HALE, C; INKSTER, M; BRODSKY, M; WOLFF, L; ALLEN, B; ZELMAN, R; THOMAS, G; CAUDILLO, G; TAKEDA, D; SHERWOOD, C; RANAZZI, R; RAPAPORT, E; DOHRMANN, ML; RASKIN, S; DREW, DW; SOMELOFSKI, CA; DANFORTH, JW; HUI, PY; JOHNSON, MR; LABARCA, JR; WALDO, AL; CARLSON, MD; ADLER, DS; HOLLAND, JB; BUCHTER, CM; BAHLER, RC; PAMELIA, FX; JOSEPHSON, RA; HENTHORN, RW; ZUELGARAY, JG; WOOD, K; REDMON, P; VARGAS, MA; VARGO, L; SCHALLER, SE; KOBUS, CE; CHOBAN, NL; BIGGER, JT; GREENBERG, HM; GREGORY, JJ; HOCHMAN, JS; RADOSLOVICH, G; STEINBERG, JS; ROTHBART, ST; CASE, R; DWYER, EM; SQUATRITO, A; KELLY, M; CAMPION, JM; TORMEY, D; ANTHONY, R; CALLAGHAN, E; CHAPNICK, M; RIPLEY, B; FONTANA, C; SCHLANT, RC; ARENSBERG, D; CORSO, JA; HURST, JW; MORRIS, DC; SHERMAN, SW; SILVERMAN, BD; SILVERMAN, ME; ROBERTS, JS; BALLOU, SK; JEFFRIES, VD; BRACKNEY, BA; SEALS, AA; HARTLEY, J; BAKER, RM; GILMOUR, KE; BAKER, SB; HOWARD, J; KATZ, RJ; BESCH, GA; BRILL, D; DIBIANCO, R; DONOHUE, D; FISHER, G; FRANCIS, C; FRIEDMAN, D; GOLDBERG, D; GOLDBERG, S; KOSS, G; LARCA, L; LEONARD, R; LINDGREN, K; RONAN, J; ROSENBLATT, A; ROSING, D; ROSS, A; ROTSZTAIN, A; SHAWL, F; SINDERSON, T; STEVENSON, R; TINKER, B; VARGHESE, J; YACKEE, J; BIGHAM, H; FRANKLIN, W; GOLD, R; GRAHAM, G; GROSSBERG, D; HOARE, R; LEVY, W; MAHMOOD, T; TANNENBAUM, E; TULLNER, W; EISENHOWER, E; GERACI, T; WILHELMSEN, L; BERGSTRAND, R; FREDLUND, BO; SIGURDSSON, A; SIVERTSSON, R; SWEDBERG, K; HOULTZ, B; WIKLUND, I; SCHLYTER, G; HEDELIN, G; LEIJON, M; MORGANROTH, J; CARVER, J; HOROWITZ, L; KUTALEK, S; PAPA, L; SANDBERG, J; VICTOR, M; CESARE, S; VRABEL, C; TALARICO, K; LUHMANN, S; PALAZZO, D; GOLDSTEIN, S; GOLDBERG, AD; FRUMIN, H; WESTVEER, D; DEBUTLIER, M; SCHAIRER, J; STOMEL, R; FRANK, DM; JARANDILLA, R; DAVEY, D; HASSE, C; SHINNEY, S; MORLEDGE, JH; FARNHAM, DJ; HINDERACKER, PH; MUSSER, WE; DEVRIES, K; KUSHNER, JA; RAO, R; PETERSON, DT; MCCAULEY, CS; BERGEN, TS; BOWMAN, KO; GILLMAN, A; FULLER, L; OBRIEN, J; MORLEDGE, J; DEMARIA, AN; KUO, CS; KAMMERLING, JM; CORUM, J; THIEMANN, M; SCHRODT, R; PETERS, R; SUTTON, F; GOTTLIEB, S; PAPUCHIS, G; MATTIONI, T; TODD, L; CUSACK, C; SCHECK, J; HUANG, SKS; ALPERT, JS; GORE, JM; RYAN, M; COLLETTWILLEY, P; CHAHINE, RA; SEQUEIRA, RF; LOWERY, MH; DELGADO, LM; CORREA, JL; LASO, LJ; HODGES, M; SALERNO, D; ANDERSON, B; COLLINS, R; DENES, P; DUNBAR, D; GRANRUD, G; HAUGLAND, J; HESSION, W; MCBRIDE, J; GORNICK, C; SIMONSON, J; TOLINS, M; ETTINGER, A; PETERSON, S; SLIVKEN, R; GRIMALDI, L; ROY, D; THEROUX, P; LEMERY, R; MORISSETTE, D; BEAUDOIN, D; GIRARD, L; LAVALLEE, E; MCANULTY, JH; REINHART, SE; MAURICE, G; MURPHY, ES; KRON, J; MARCHANT, C; BOXER, J; PRINCEHOUSE, L; SINNER, K; BEANLANDS, D; DAVIES, R; GREEN, M; WILLIAMS, W; BAIRD, MJ; GARRARD, L; HEAL, S; HASPECT, A; BORTHWICK, J; MAROIS, L; WOODEND, K; AKIYAMA, T; HOOD, WB; EASLEY, R; RYAN, G; KENIEN, G; PATT, M; KAZIERAD, D; GOLDFARB, A; BUTLER, LL; KELLER, ML; STANLEY, P; PEEBLES, J; SYROCKI, D; LAVIN, D; DENES, P; SCHOENBERGER, JA; LIEBSON, PR; STAMATO, NJ; PETROPULOS, AT; BUCKINGHAM, TA; REMIJAS, T; KOCOUREK, J; JANKO, K; BARKER, AH; ANDERSON, JL; FOWLES, RE; KEITH, TB; WILLIAMS, CB; MORENO, FL; DORAN, EN; FOWLER, B; SUMMERS, K; WHITE, C; OHARA, G; ROULEAU, JL; PLANTE, S; VINCENT, C; BOUCHARD, D; ZOBLE, RG; OTERO, JE; BUGNI, WJ; SCHWARTZ, KM; SHETTIGAR, UR; BREWINGTON, JA; UMBERGER, J; COHEN, JD; BJERREGAARD, P; HAMILTON, WP; GARNER, M; ANDERSON, S; ELSHERIF, N; URSELL, SN; GABOR, GE; IBRAHIM, B; ASSADI, M; BREZSNYAK, ML; PORTER, AV; STANIORSKI, A; WOOSLEY, RL; RODEN, DM; CAMPBELL, WB; ECHT, DS; LEE, JT; MURRAY, KT; SPELL, JD; BONHOTAL, ST; JARED, LL; THOMAS, TI; GOLDNER, F; RICHARDSON, DW; ROMHILT, DW; ELLENBOGEN, KA; BANE, BB; FIELDS, J; SHRADER, S; POWELL, E; CHAFFIN, CF; WELLS, A; CONWAY, KT; PLATIA, EV; ODONOGHUE, S; TRACY, CM; ALI, N; BOWEN, P; BROOKS, KM; OETGEN, W; WESTON, LT; CARSON, P; OBIASMANNO, D; HARRISON, J; SAYLOR, A; POWELL, S; HAAKENSON, CM; SATHER, MR; MALONE, LA; HALLSTROM, AP; MCBRIDE, R; GREENE, HL; BROOKS, MM; LEDINGHAM, R; REYNOLDSHAERTLE, RA; HUTHER, M; SCHOLZ, M; MORRIS, M; FRIEDMAN, LM; SCHRON, E; VERTER, J; JENNINGS, C; PROSCHAN, M; BRISTOW, JD; DEMETS, DL; FISCH, C; NIES, AS; RUSKIN, J; STRAUSS, H; WALTERS, L				ROGERS, WJ; EPSTEIN, AE; ARCINIEGAS, JG; CROSSLEY, GH; DAILEY, SM; KAY, GN; LITTLE, RE; MACLEAN, WAH; PAPAPIETRO, SE; PLUMB, VJ; SILBER, S; BAKER, AR; CARLISLE, K; COHEN, N; COX, M; THOMAS, C; LEVSON, L; VONHAGEL, D; WALTON, AE; PRATT, CM; MAHMARIAN, J; MORRIS, G; CAPONE, RJ; BERGER, EE; CHMIELEWSKI, C; GORKIN, L; KHAN, AH; KORR, K; HANDSHAW, K; CONNOLLY, E; FITZPATRICK, D; CAMERON, T; WYSE, DG; DUFF, HJ; MITCHELL, LB; GILLIS, AM; WARNICA, JW; SHELDON, RS; LESOWAY, NR; KELLEN, J; HALE, C; INKSTER, M; BRODSKY, M; WOLFF, L; ALLEN, B; ZELMAN, R; THOMAS, G; CAUDILLO, G; TAKEDA, D; SHERWOOD, C; RANAZZI, R; RAPAPORT, E; DOHRMANN, ML; RASKIN, S; DREW, DW; SOMELOFSKI, CA; DANFORTH, JW; HUI, PY; JOHNSON, MR; LABARCA, JR; WALDO, AL; CARLSON, MD; ADLER, DS; HOLLAND, JB; BUCHTER, CM; BAHLER, RC; PAMELIA, FX; JOSEPHSON, RA; HENTHORN, RW; ZUELGARAY, JG; WOOD, K; REDMON, P; VARGAS, MA; VARGO, L; SCHALLER, SE; KOBUS, CE; CHOBAN, NL; BIGGER, JT; GREENBERG, HM; GREGORY, JJ; HOCHMAN, JS; RADOSLOVICH, G; STEINBERG, JS; ROTHBART, ST; CASE, R; DWYER, EM; SQUATRITO, A; KELLY, M; CAMPION, JM; TORMEY, D; ANTHONY, R; CALLAGHAN, E; CHAPNICK, M; RIPLEY, B; FONTANA, C; SCHLANT, RC; ARENSBERG, D; CORSO, JA; HURST, JW; MORRIS, DC; SHERMAN, SW; SILVERMAN, BD; SILVERMAN, ME; ROBERTS, JS; BALLOU, SK; JEFFRIES, VD; BRACKNEY, BA; SEALS, AA; HARTLEY, J; BAKER, RM; GILMOUR, KE; BAKER, SB; HOWARD, J; KATZ, RJ; BESCH, GA; BRILL, D; DIBIANCO, R; DONOHUE, D; FISHER, G; FRANCIS, C; FRIEDMAN, D; GOLDBERG, D; GOLDBERG, S; KOSS, G; LARCA, L; LEONARD, R; LINDGREN, K; RONAN, J; ROSENBLATT, A; ROSING, D; ROSS, A; ROTSZTAIN, A; SHAWL, F; SINDERSON, T; STEVENSON, R; TINKER, B; VARGHESE, J; YACKEE, J; BIGHAM, H; FRANKLIN, W; GOLD, R; GRAHAM, G; GROSSBERG, D; HOARE, R; LEVY, W; MAHMOOD, T; TANNENBAUM, E; TULLNER, W; EISENHOWER, E; GERACI, T; WILHELMSEN, L; BERGSTRAND, R; FREDLUND, BO; SIGURDSSON, A; SIVERTSSON, R; SWEDBERG, K; HOULTZ, B; WIKLUND, I; SCHLYTER, G; HEDELIN, G; LEIJON, M; MORGANROTH, J; CARVER, J; HOROWITZ, L; KUTALEK, S; PAPA, L; SANDBERG, J; VICTOR, M; CESARE, S; VRABEL, C; TALARICO, K; LUHMANN, S; PALAZZO, D; GOLDSTEIN, S; GOLDBERG, AD; FRUMIN, H; WESTVEER, D; DEBUTLIER, M; SCHAIRER, J; STOMEL, R; FRANK, DM; JARANDILLA, R; DAVEY, D; HASSE, C; SHINNEY, S; MORLEDGE, JH; FARNHAM, DJ; HINDERACKER, PH; MUSSER, WE; DEVRIES, K; KUSHNER, JA; RAO, R; PETERSON, DT; MCCAULEY, CS; BERGEN, TS; BOWMAN, KO; GILLMAN, A; FULLER, L; OBRIEN, J; MORLEDGE, J; DEMARIA, AN; KUO, CS; KAMMERLING, JM; CORUM, J; THIEMANN, M; SCHRODT, R; PETERS, R; SUTTON, F; GOTTLIEB, S; PAPUCHIS, G; MATTIONI, T; TODD, L; CUSACK, C; SCHECK, J; HUANG, SKS; ALPERT, JS; GORE, JM; RYAN, M; COLLETTWILLEY, P; CHAHINE, RA; SEQUEIRA, RF; LOWERY, MH; DELGADO, LM; CORREA, JL; LASO, LJ; HODGES, M; SALERNO, D; ANDERSON, B; COLLINS, R; DENES, P; DUNBAR, D; GRANRUD, G; HAUGLAND, J; HESSION, W; MCBRIDE, J; GORNICK, C; SIMONSON, J; TOLINS, M; ETTINGER, A; PETERSON, S; SLIVKEN, R; GRIMALDI, L; ROY, D; THEROUX, P; LEMERY, R; MORISSETTE, D; BEAUDOIN, D; GIRARD, L; LAVALLEE, E; MCANULTY, JH; REINHART, SE; MAURICE, G; MURPHY, ES; KRON, J; MARCHANT, C; BOXER, J; PRINCEHOUSE, L; SINNER, K; BEANLANDS, D; DAVIES, R; GREEN, M; WILLIAMS, W; BAIRD, MJ; GARRARD, L; HEAL, S; HASPECT, A; BORTHWICK, J; MAROIS, L; WOODEND, K; AKIYAMA, T; HOOD, WB; EASLEY, R; RYAN, G; KENIEN, G; PATT, M; KAZIERAD, D; GOLDFARB, A; BUTLER, LL; KELLER, ML; STANLEY, P; PEEBLES, J; SYROCKI, D; LAVIN, D; DENES, P; SCHOENBERGER, JA; LIEBSON, PR; STAMATO, NJ; PETROPULOS, AT; BUCKINGHAM, TA; REMIJAS, T; KOCOUREK, J; JANKO, K; BARKER, AH; ANDERSON, JL; FOWLES, RE; KEITH, TB; WILLIAMS, CB; MORENO, FL; DORAN, EN; FOWLER, B; SUMMERS, K; WHITE, C; OHARA, G; ROULEAU, JL; PLANTE, S; VINCENT, C; BOUCHARD, D; ZOBLE, RG; OTERO, JE; BUGNI, WJ; SCHWARTZ, KM; SHETTIGAR, UR; BREWINGTON, JA; UMBERGER, J; COHEN, JD; BJERREGAARD, P; HAMILTON, WP; GARNER, M; ANDERSON, S; ELSHERIF, N; URSELL, SN; GABOR, GE; IBRAHIM, B; ASSADI, M; BREZSNYAK, ML; PORTER, AV; STANIORSKI, A; WOOSLEY, RL; RODEN, DM; CAMPBELL, WB; ECHT, DS; LEE, JT; MURRAY, KT; SPELL, JD; BONHOTAL, ST; JARED, LL; THOMAS, TI; GOLDNER, F; RICHARDSON, DW; ROMHILT, DW; ELLENBOGEN, KA; BANE, BB; FIELDS, J; SHRADER, S; POWELL, E; CHAFFIN, CF; WELLS, A; CONWAY, KT; PLATIA, EV; ODONOGHUE, S; TRACY, CM; ALI, N; BOWEN, P; BROOKS, KM; OETGEN, W; WESTON, LT; CARSON, P; OBIASMANNO, D; HARRISON, J; SAYLOR, A; POWELL, S; HAAKENSON, CM; SATHER, MR; MALONE, LA; HALLSTROM, AP; MCBRIDE, R; GREENE, HL; BROOKS, MM; LEDINGHAM, R; REYNOLDSHAERTLE, RA; HUTHER, M; SCHOLZ, M; MORRIS, M; FRIEDMAN, LM; SCHRON, E; VERTER, J; JENNINGS, C; PROSCHAN, M; BRISTOW, JD; DEMETS, DL; FISCH, C; NIES, AS; RUSKIN, J; STRAUSS, H; WALTERS, L			EFFECT OF THE ANTIARRHYTHMIC AGENT MORICIZINE ON SURVIVAL AFTER MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ARRHYTHMIA SUPPRESSION TRIAL; VENTRICULAR ARRHYTHMIAS; STIMULATION; MORTALITY	Background. The Cardiac Arrhythmia Suppression Trial (CAST) tested the hypothesis that the suppression of asymptomatic or mildly symptomatic ventricular premature depolarizations in survivors of myocardial infarction would decrease the number of deaths from ventricular arrhythmias and improve overall survival. The second CAST study (CAST-II) tested this hypothesis with a comparison of moricizine and placebo. Methods. CAST-II was divided into two blinded, randomized phases: an early, 14-day exposure phase that evaluated the risk of starting treatment with moricizine after myocardial infarction (1325 patients), and a long-term phase that evaluated the effect of moricizine on survival after myocardial infarction in patients whose ventricular premature depolarizations were either adequately suppressed by moricizine (1155 patients) or only partially suppressed (219 patients). Results. CAST-II was stopped early because the first 14-day period of treatment with moricizine after a myocardial infarction was associated with excess mortality (17 of 665 patients died or had cardiac arrests), as compared with no treatment or placebo (3 of 660 patients died or had cardiac arrests); and estimates of conditional power indicated that it was highly unlikely (<8 percent chance) that a survival benefit from moricizine could be observed if the trial were completed. At the completion of the long-term phase, there were 49 deaths or cardiac arrests due to arrhythmias in patients assigned to moricizine, and 42 in patients assigned to placebo (adjusted P = 0.40). Conclusions. As with the antiarrhythmic agents used in CAST-I (flecainide and encainide), the use of moricizine in CAST-II to suppress asymptomatic or mildly symptomatic ventricular premature depolarizations to try to reduce mortality after myocardial infarction is not only ineffective but also harmful.	UNIV ALABAMA, BIRMINGHAM, AL 35294 USA; BAYLOR COLL MED, HOUSTON, TX 77030 USA; BROWN UNIV, CTR AFFILIATED HOSP, PROVIDENCE, RI 02912 USA; UNIV CALGARY, CALGARY T2N 1N4, ALBERTA, CANADA; UNIV CALIF IRVINE, IRVINE MED CTR, ORANGE, CA 92668 USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO AFFILIATED HOSP, SAN FRANCISCO, CA 94143 USA; CASE WESTERN RESERVE UNIV, CLEVELAND, OH 44106 USA; UNIV MARYLAND, BALTIMORE, MD 21201 USA; UNIV MASSACHUSETTS, AMHERST, MA 01003 USA; UNIV MIAMI, CORAL GABLES, FL 33124 USA; UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA; MONTREAL HEART INST, MONTREAL H1T 1C8, QUEBEC, CANADA; OREGON HLTH SCI UNIV, PORTLAND, OR 97201 USA; UNIV OTTAWA, OTTAWA K1N 6N5, ONTARIO, CANADA; UNIV ROCHESTER, ROCHESTER, NY 14627 USA; RUSH PRESBYTERIAN ST LUKES MED CTR, CHICAGO, IL 60612 USA; SALT LAKE CLIN RES FDN, SALT LAKE CITY, UT USA; UNIV SHERBROOKE, CHU, SHERBROOKE J1K 2R1, QUEBEC, CANADA; UNIV S FLORIDA, TAMPA, FL 33620 USA; ST LOUIS UNIV, ST LOUIS, MO 63103 USA; SUNY HLTH SCI CTR BROOKLYN, BROOKLYN, NY USA; VANDERBILT UNIV, NASHVILLE, TN 37240 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, RICHMOND, VA 23298 USA; WASHINGTON HOSP CTR, WASHINGTON, DC 20010 USA; UNIV WASHINGTON, CTR COORDINATING, SEATTLE, WA 98195 USA; NHLBI, DIV EPIDEMIOL & CLIN APPLICAT, CLIN TRIALS BRANCH, PROGRAM OFF, BETHESDA, MD 20892 USA; INDIANA UNIV, SCH MED, KRANNERT INST CARDIOL, INDIANAPOLIS, IN 46202 USA; COLUMBIA UNIV, AFFILIATED HOSP, NEW YORK, NY 10027 USA; EMORY UNIV, SCH MED, ATLANTA, GA 30322 USA; UNIV FLORIDA, JACKSONVILLE, FL USA; GEORGE WASHINGTON UNIV, MED CTR, WASHINGTON, DC 20037 USA; GOTHENBURG UNIV, S-41124 GOTHENBURG, SWEDEN; HAHNEMANN UNIV, PHILADELPHIA, PA 19102 USA; HENRY FORD HOSP, DETROIT, MI 48202 USA; JACKSON FDN MED EDUC & RES, MADISON, WI USA; UNIV KENTUCKY, LEXINGTON, KY 40506 USA; UNIV WISCONSIN, MADISON, WI 53706 USA; UNIV COLORADO, SCH MED, BOULDER, CO 80309 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; DUKE UNIV, MED CTR, DURHAM, NC 27710 USA; GEORGETOWN UNIV, KENNEDY INST ETH, WASHINGTON, DC 20057 USA; VET AFFAIRS MED CTR, COOPERAT STUDIES PROGRAM, CTR CLIN RES PHARM COORDINAT, CTR DRUG DISTRIBUT, ALBUQUERQUE, NM USA	University of Alabama System; University of Alabama Birmingham; Baylor College of Medicine; Brown University; University of Calgary; University of California System; University of California Irvine; University of California System; University of California San Francisco; Case Western Reserve University; University System of Maryland; University of Maryland Baltimore; University of Massachusetts System; University of Massachusetts Amherst; University of Miami; University of Minnesota System; University of Minnesota Twin Cities; Universite de Montreal; Oregon Health & Science University; University of Ottawa; University of Rochester; Rush University; University of Sherbrooke; State University System of Florida; University of South Florida; Saint Louis University; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Vanderbilt University; Virginia Commonwealth University; MedStar Washington Hospital Center; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Indiana University System; Indiana University-Purdue University Indianapolis; Columbia University; Emory University; State University System of Florida; University of Florida; George Washington University; University of Gothenburg; Drexel University; Henry Ford Health System; Henry Ford Hospital; University of Kentucky; University of Wisconsin System; University of Wisconsin Madison; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder; Harvard University; Harvard Medical School; Duke University; Georgetown University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	ROGERS, WJ (corresponding author), CARDIAC ARRHYTHMIA SUPRESS TRIAL, CTR COORDINATING CTR, 1107 NE 45TH ST, RM 505, SEATTLE, WA 98105 USA.		Woosley, Raymond/AAE-4874-2020; Bjerregaard, Peter/ABD-8894-2020; Roden, Dan/ABD-5412-2021; Ellenbogen, Kenneth/AAJ-3992-2021; Grimaldi, Luigi/L-2614-2019; Swedberg, Karl/B-2475-2008	Woosley, Raymond/0000-0002-2588-328X; Bjerregaard, Peter/0000-0001-7153-8447; Patt, Mitchell/0000-0001-9696-4477				[Anonymous], 1989, NEW ENGL J MED, V321, P406; [Anonymous], 1988, AM J CARDIOL, V61, P501; BIGGER JT, 1984, CIRCULATION, V69, P250, DOI 10.1161/01.CIR.69.2.250; BURKART F, 1990, J AM COLL CARDIOL, V16, P1711, DOI 10.1016/0735-1097(90)90324-I; CAIRNS JA, 1991, CIRCULATION, V84, P550, DOI 10.1161/01.CIR.84.2.550; COX DR, 1974, THEORETICAL STAT, P179; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; FRIEDMAN L, 1986, CIRCULATION, V73, P59; FURBERG CD, 1983, AM J CARDIOL, V52, pC32, DOI 10.1016/0002-9149(83)90629-X; GREENE HL, 1989, AM J CARDIOL, V63, P1, DOI 10.1016/0002-9149(89)91065-5; GREENE HL, 1992, J AM COLL CARDIOL, V19, P894, DOI 10.1016/0735-1097(92)90267-Q; HALLSTROM AP, 1991, STAT MED, V10, P1621, DOI 10.1002/sim.4780101013; Impact Research Group, 1984, J AM COLL CARDIOL, V4, P1148; KIM SG, 1987, CIRCULATION, V76, P1, DOI 10.1161/01.CIR.76.1.1; Lan KKG, 1982, COMMUN STATIST C, V1, P207, DOI DOI 10.1080/07474948208836014; MORGANROTH J, 1991, CIRCULATION, V84, P1977, DOI 10.1161/01.CIR.84.5.1977; MORGANROTH J, 1990, AM J CARDIOL, V65, P40, DOI 10.1016/0002-9149(90)90023-T; MUKHARJI J, 1984, AM J CARDIOL, V54, P31, DOI 10.1016/0002-9149(84)90299-6; PAWITAN Y, 1990, STAT MED, V9, P1081, DOI 10.1002/sim.4780090915; VLAY SC, 1985, AM HEART J, V110, P904, DOI 10.1016/0002-8703(85)90485-5; WILBER DJ, 1988, NEW ENGL J MED, V318, P19, DOI 10.1056/NEJM198801073180105; 1985, FUNDAMENTALS CLIN TR, P213; 1984, POSTGRAD MED J, V60, P98	23	732	755	3	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 23	1992	327	4					227	233						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE381	1377359				2022-12-28	WOS:A1992JE38100003
J	CHUNG, J; KUO, CJ; CRABTREE, GR; BLENIS, J				CHUNG, J; KUO, CJ; CRABTREE, GR; BLENIS, J			RAPAMYCIN FKBP SPECIFICALLY BLOCKS GROWTH-DEPENDENT ACTIVATION OF AND SIGNALING BY THE 70 KD S6 PROTEIN-KINASES	CELL			English	Article							PEPTIDYL-PROLYL ISOMERASE; RIBOSOMAL PROTEIN-S6; IMMUNOSUPPRESSANT FK506; MACROLIDES FK-506; DISTINCT; PHOSPHORYLATION; IMMUNOPHILIN; S6-KINASE; HOMOLOGS; CHICKEN	The macrolide rapamycin blocks cell cycle progression in yeast and various animal cells by an unknown mechanism. We demonstrate that rapamycin blocks the phosphorylation and activation of the 70 kd S6 protein kinases (pp70S6K) in a variety of animal cells. The structurally related drug FK506 had no effect on pp70S6K activation but at high concentrations reversed the rapamycin-induced block, confirming the requirement for the rapamycin and FK506 receptor, FKBP. Rapamycin also interfered with signaling by these S6 kinases, blocking serum-stimulated S6 phosphorylation and delaying entry of Swiss 3T3 cells into S phase. Neither rapamycin nor FK506 blocked activation of a distinct family of S6 kinases (RSKs) or the MAP kinases. These studies identify a rapamycin-sensitive signaling pathway, argue for a ubiquitous role for FKBPs in signal transduction, indicate that FK506-FKBP-calcineurin complexes do not interfere with pp70S6K signaling, and show that in fibroblasts pp70S6K, not RSK, is the physiological S6 kinase.	STANFORD UNIV,MED CTR,SCH MED,BECKMAN CTR,MOLEC & GENET MED UNIT,STANFORD,CA 94305	Stanford University	CHUNG, J (corresponding author), HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115, USA.				NATIONAL CANCER INSTITUTE [R37CA039612, R01CA046595, R01CA039612, R37CA046595] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033942] Funding Source: NIH RePORTER; NCI NIH HHS [CA-46595, CA-39612] Funding Source: Medline; NHLBI NIH HHS [HLB-33942] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDRES JL, 1989, J BIOL CHEM, V264, P151; BALLOU LM, 1988, J BIOL CHEM, V263, P1188; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BLENIS J, 1985, P NATL ACAD SCI USA, V82, P7621, DOI 10.1073/pnas.82.22.7621; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; BLENIS J, 1991, CANCER CELL-MON REV, V3, P445; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; CHANG JY, 1991, TRENDS PHARMACOL SCI, V12, P218, DOI 10.1016/0165-6147(91)90555-7; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; CHUNG JK, 1991, MOL CELL BIOL, V11, P1868, DOI 10.1128/MCB.11.4.1868; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; DUMONT FJ, 1990, J IMMUNOL, V144, P251; ERIKSON E, 1989, J BIOL CHEM, V264, P13711; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; JOHNSON SP, 1987, MOL CELL BIOL, V7, P1338, DOI 10.1128/MCB.7.4.1338; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; JURIVICH DA, 1991, J CELL PHYSIOL, V148, P252, DOI 10.1002/jcp.1041480210; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; KUO CJ, 1991, EMBO J, V10, P2231, DOI 10.1002/j.1460-2075.1991.tb07759.x; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MCKEON F, 1991, CELL, V66, P823, DOI 10.1016/0092-8674(91)90426-Y; MORRIS RE, 1991, IMMUNOL TODAY, V12, P137; OLIVIER AR, 1990, J BIOL CHEM, V265, P22460; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SWEET LJ, 1990, MOL CELL BIOL, V10, P2787, DOI 10.1128/MCB.10.6.2787; TERAO K, 1970, BIOCHEM BIOPH RES CO, V38, P80, DOI 10.1016/0006-291X(70)91086-7; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	44	1071	1100	2	30	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 26	1992	69	7					1227	1236		10.1016/0092-8674(92)90643-Q	http://dx.doi.org/10.1016/0092-8674(92)90643-Q			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JA431	1377606				2022-12-28	WOS:A1992JA43100016
J	FUJITA, N; BABA, T; TOMIYAMA, T; KODAMA, T; KAKO, N				FUJITA, N; BABA, T; TOMIYAMA, T; KODAMA, T; KAKO, N			HYPERINSULINEMIA AND BLOOD-PRESSURE IN PATIENTS WITH INSULINOMA	BRITISH MEDICAL JOURNAL			English	Article							HYPERTENSION		HIROSAKI UNIV,DEPT INTERNAL MED 3,HIROSAKI,AOMORI 036,JAPAN; HIROSAKI UNIV,DEPT SURG 1,HIROSAKI,AOMORI 036,JAPAN	Hirosaki University; Hirosaki University								FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; MODAN M, 1985, J CLIN INVEST, V75, P809, DOI 10.1172/JCI111776; ROWE JW, 1981, DIABETES, V30, P219, DOI 10.2337/diab.30.3.219; SKOTT P, 1989, DIABETOLOGIA, V32, P694; ZAVARONI I, 1989, NEW ENGL J MED, V320, P702, DOI 10.1056/NEJM198903163201105	5	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 2	1992	304	6835					1157	1157		10.1136/bmj.304.6835.1157	http://dx.doi.org/10.1136/bmj.304.6835.1157			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT232	1392796	Green Published, Bronze			2022-12-28	WOS:A1992HT23200025
J	CARTER, HB; PEARSON, JD; METTER, J; BRANT, LJ; CHAN, DW; ANDRES, R; FOZARD, JL; WALSH, PC				CARTER, HB; PEARSON, JD; METTER, J; BRANT, LJ; CHAN, DW; ANDRES, R; FOZARD, JL; WALSH, PC			LONGITUDINAL EVALUATION OF PROSTATE-SPECIFIC ANTIGEN LEVELS IN MEN WITH AND WITHOUT PROSTATE DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RADICAL PROSTATECTOMY; TREATED PATIENTS; ADENOCARCINOMA; HYPERPLASIA; CANCER; DIAGNOSIS	Objective. - To evaluate longitudinal changes in prostate-specific antigen (PSA) levels in men with and without prostate disease. Design. - Case-control study of men with and without prostate disease who were participants in a prospective aging study. Setting. - Gerontology Research Center of the National institute on Aging; the Baltimore (Md) Longitudinal Study of Aging. Patients. - Sixteen men with no prostate disease (control group), 20 men with a histologic diagnosis of benign prostatic hyperplasia (BPH), and 18 men with a histologic diagnosis of prostate cancer. Outcome Measures. - Multiple PSA and androgen determinations on serum samples obtained from 7 to 25 years prior to histologic diagnosis or exclusion of prostate disease. Results. - Changes in androgen levels with age did not differ between groups. Control subjects did not show a significant change in PSA levels with age. There was a significant difference in the age-adjusted rate of change in PSA levels between groups (prostate cancer > BPH > control; P < .01). At 5 years before diagnosis when PSA levels did not differ between subjects with BPH and prostate cancer, rate of change in PSA levels (0.75-mu-g/L per year) was significantly greater in subjects with prostate cancer compared with control subjects and subjects with BPH. Also, rate of change in PSA levels distinguished subjects with prostate cancer from subjects with BPH and control subjects with a specificity of 90% and 100%, respectively. Conclusions. - The most significant factor affecting serum PSA levels with age is the development of prostate disease. Rate of change in PSA levels may be a sensitive and specific early clinical marker for the development of prostate cancer.	JOHNS HOPKINS UNIV HOSP,SCH MED,JAMES BUCHANAN BRADY UROL INST,DEPT LAB MED,BALTIMORE,MD 21205; NIA,GERONTOL RES CTR,CLIN PHYSIOL LAB,BETHESDA,MD 20892; NIA,GERONTOL RES CTR,LONGITUDINAL STUDIES BRANCH,BETHESDA,MD 20892	Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	CARTER, HB (corresponding author), JOHNS HOPKINS UNIV HOSP,SCH MED,JAMES BUCHANAN BRADY UROL INST,DEPT UROL,403 MARBURG,BALTIMORE,MD 21205, USA.		Chan, Doris/O-1227-2014; Fozard, James Leonard/B-3660-2009	Chan, Doris/0000-0002-4990-986X; 	NCI NIH HHS [P50 CA058236] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058236] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARRIGHI HM, 1990, PROSTATE, V16, P253, DOI 10.1002/pros.2990160309; BERRY SJ, 1984, J UROLOGY, V132, P474, DOI 10.1016/S0022-5347(17)49698-4; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; COONER WH, 1990, J UROLOGY, V143, P1146, DOI 10.1016/S0022-5347(17)40211-4; GUESS HA, 1990, PROSTATE, V17, P241, DOI 10.1002/pros.2990170308; HUDSON MA, 1989, J UROLOGY, V142, P1011, DOI 10.1016/S0022-5347(17)38972-3; KYPRIANOU N, 1991, ENDOCRINE DEPENDENT, P69; LINDSTROM MJ, 1988, J AM STAT ASSOC, V83, P1014; MEYER JS, 1982, J UROLOGY, V128, P1353, DOI 10.1016/S0022-5347(17)53506-5; OESTERLING JE, 1988, J UROLOGY, V139, P766, DOI 10.1016/S0022-5347(17)42630-9; PEARSON JD, 1991, P SOC STAT, P580; ROSNER B, 1986, FUNDAMENTALS BIOSTAT, P79; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501; STAMEY TA, 1989, J UROLOGY, V141, P1088, DOI 10.1016/S0022-5347(17)41177-3; STAMEY TA, 1989, J UROLOGY, V141, P1076, DOI 10.1016/S0022-5347(17)41175-X; WANG MC, 1979, INVEST UROL, V17, P159; WEBER JP, 1989, J UROLOGY, V141, P987, DOI 10.1016/S0022-5347(17)41083-4; [No title captured]; 1987, NIH882789 PUBL	19	851	888	0	33	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 22	1992	267	16					2215	2220		10.1001/jama.267.16.2215	http://dx.doi.org/10.1001/jama.267.16.2215			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN841	1372942	Green Accepted			2022-12-28	WOS:A1992HN84100032
J	PRESTON, GM; CARROLL, TP; GUGGINO, WB; AGRE, P				PRESTON, GM; CARROLL, TP; GUGGINO, WB; AGRE, P			APPEARANCE OF WATER CHANNELS IN XENOPUS OOCYTES EXPRESSING RED-CELL CHIP28 PROTEIN	SCIENCE			English	Article							MAJOR INTRINSIC PROTEIN; MEMBRANE; TRANSCRIPTION; INVITRO; KIDNEY; SP6	Water rapidly crosses the plasma membrane of red blood cells (RBCs) and renal tubules through specialized channels. Although selective for water, the molecular structure of these channels is unknown. The CHIP28 protein is an abundant integral membrane protein in mammalian RBCs and renal proximal tubules and belongs to a family of membrane proteins with unknown functions. Oocytes from Xenopus laevis microinjected with in vitro-transcribed CHIP28 RNA exhibited increased osmotic water permeability; this was reversibly inhibited by mercuric chloride, a known inhibitor of water channels. Therefore it is likely that CHIP28 is a functional unit of membrane water channels.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT CELL BIOL ANAT, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PHYSIOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048268, R37HL048268, R01HL033991] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032753, R37DK032753] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER ME, 1990, CELL, V60, P185, DOI 10.1016/0092-8674(90)90731-S; BROWN D, 1989, AM J PHYSIOL, V256, pF1, DOI 10.1152/ajprenal.1989.256.1.F1; CUTTING GR, 1991, P NATL ACAD SCI USA, V88, P2673, DOI 10.1073/pnas.88.7.2673; DAVIS J, 1982, J BIOL CHEM, V257, P5816; DEMPSTER JA, 1991, PFLUG ARCH EUR J PHY, V419, P249, DOI 10.1007/BF00371103; DENKER BM, 1988, J BIOL CHEM, V263, P15634; FISCHBARG J, 1990, P NATL ACAD SCI USA, V87, P3244, DOI 10.1073/pnas.87.8.3244; GORIN MB, 1984, CELL, V39, P49, DOI 10.1016/0092-8674(84)90190-9; GUERRERO FD, 1990, PLANT MOL BIOL, V15, P11, DOI 10.1007/BF00017720; HANDLER JS, 1988, AM J PHYSIOL, V255, pF375, DOI 10.1152/ajprenal.1988.255.3.F375; HARRIS HW, 1991, J CLIN INVEST, V88, P1, DOI 10.1172/JCI115263; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LU L, 1990, BIOPHYS J, V57, P1117, DOI 10.1016/S0006-3495(90)82632-1; MACEY RI, 1984, AM J PHYSIOL, V246, pC195, DOI 10.1152/ajpcell.1984.246.3.C195; PAO GM, 1991, MOL MICROBIOL, V5, P33, DOI 10.1111/j.1365-2958.1991.tb01823.x; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; Sambrook J, 1989, MOL CLONING LABORATO; SMITH BL, 1991, J BIOL CHEM, V266, P6407; SOLOMON AK, 1983, ANN NY ACAD SCI, V414, P97, DOI 10.1111/j.1749-6632.1983.tb31678.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI ST, 1991, BIOCHEMISTRY-US, V30, P2087, DOI 10.1021/bi00222a013; VANHOEK AN, 1991, J BIOL CHEM, V266, P16633; VERKMAN AS, 1989, AM J PHYSIOL, V257, pC837, DOI 10.1152/ajpcell.1989.257.5.C837; VERKMAN AS, 1988, NATURE, V333, P268, DOI 10.1038/333268a0; WISTOW GJ, 1991, TRENDS BIOCHEM SCI, V16, P170, DOI 10.1016/0968-0004(91)90065-4; YISRAELI JK, 1989, METHOD ENZYMOL, V180, P42; ZAMPIGHI GA, 1989, J CELL BIOL, V108, P2255, DOI 10.1083/jcb.108.6.2255; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P589, DOI 10.1021/bi00117a041; ZHANG R, 1990, J BIOL CHEM, V265, P15375; ZHANG R, 1991, J CLIN INVEST, V88, P1553, DOI 10.1172/JCI115466; [No title captured]; [No title captured]	33	1635	1767	9	251	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 17	1992	256	5055					385	387		10.1126/science.256.5055.385	http://dx.doi.org/10.1126/science.256.5055.385			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP032	1373524				2022-12-28	WOS:A1992HP03200039
J	XIE, QW; CHO, HJ; CALAYCAY, J; MUMFORD, RA; SWIDEREK, KM; LEE, TD; DING, AH; TROSO, T; NATHAN, C				XIE, QW; CHO, HJ; CALAYCAY, J; MUMFORD, RA; SWIDEREK, KM; LEE, TD; DING, AH; TROSO, T; NATHAN, C			CLONING AND CHARACTERIZATION OF INDUCIBLE NITRIC-OXIDE SYNTHASE FROM MOUSE MACROPHAGES	SCIENCE			English	Article							L-ARGININE; CALMODULIN; CYTOSOL	Nitric oxide (NO) conveys a variety of messages between cells, including signals for vasorelaxation, neurotransmission, and cytotoxicity. In some endothelial cells and neurons, a constitutive NO synthase is activated transiently by agonists that elevate intracellular calcium concentrations and promote the binding of calmodulin. In contrast, in macrophages, NO synthase activity appears slowly after exposure of the cells to cytokines and bacterial products, is sustained, and functions independently of calcium and calmodulin. A monospecific antibody was used to clone complementary DNA that encoded two isoforms of NO synthase from immunologically activated mouse macrophages. Liquid chromatography-mass spectrometry was used to confirm most of the amino acid sequence. Macrophage NO synthase differs extensively from cerebellar NO synthase. The macrophage enzyme is immunologically induced at the transcriptional level and closely resembles the enzyme in cytokine-treated tumor cells and inflammatory neutrophils.	CORNELL UNIV, MED CTR,COLL MED,DEPT MED,DIV HEMATOL ONCOL, BEATRICE & SAMUEL A SEAVER LAB, NEW YORK, NY 10021 USA; MERCK SHARP & DOHME LTD, DEPT BIOCHEM & MOLEC BIOL, RAHWAY, NJ 07065 USA; CITY HOPE NATL MED CTR, BECKMAN RES INT, DIV IMMUNOL, DUARTE, CA 91010 USA	Cornell University; Merck & Company; City of Hope; Beckman Research Institute of City of Hope					NCI NIH HHS [CA43610] Funding Source: Medline; NIAID NIH HHS [AI30165] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043610] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030165, R29AI030165] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMBER IJ, 1988, J LEUKOCYTE BIOL, V44, P58, DOI 10.1002/jlb.44.1.58; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BUSSE R, 1990, FEBS LETT, V265, P133, DOI 10.1016/0014-5793(90)80902-U; ELLISTON KO, UNPUB SCIENCE; HIBBS JB, 1990, INT CONGR SER, V897, P189; IGNARRO LJ, 1991, BIOCHEM PHARMACOL, V41, P485, DOI 10.1016/0006-2952(91)90618-F; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAMAS S, 1991, AM J PHYSIOL, V261, pC634, DOI 10.1152/ajpcell.1991.261.4.C634; LEE TD, 1990, BIOMED ENVIRON MASS, V19, P639, DOI 10.1002/bms.1200191103; MCLUCKEY SA, 1991, ANAL CHEM, V63, P375, DOI 10.1021/ac00004a015; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PORTER TD, 1991, TRENDS BIOCHEM SCI, V16, P154, DOI 10.1016/0968-0004(91)90059-5; STUEHR DJ, 1989, BIOCHEM BIOPH RES CO, V161, P420, DOI 10.1016/0006-291X(89)92615-6; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, IN PRESS ADV ENZYMOL; XIE Q, UNPUB; XIE QW, IN PRESS CELLULAR MO; YUI Y, 1991, J BIOL CHEM, V266, P12544	22	1849	1899	0	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 10	1992	256	5054					225	228		10.1126/science.1373522	http://dx.doi.org/10.1126/science.1373522			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM896	1373522				2022-12-28	WOS:A1992HM89600030
J	CHEN, L; HUANG, LYM				CHEN, L; HUANG, LYM			PROTEIN-KINASE-C REDUCES MG2+ BLOCK OF NMDA-RECEPTOR CHANNELS AS A MECHANISM OF MODULATION	NATURE			English	Article							LONG-TERM POTENTIATION; MOUSE CENTRAL NEURONS; ASPARTATE-ACTIVATED CHANNELS; DIVALENT-CATIONS; CELLS; EXPRESSION; INHIBITION; INDUCTION; RESPONSES; CURRENTS	THF roles of N-methyl-D-aspartate (NMDA) receptors and protein kinase C (PKC) are critical in generating and maintaining a variety of sustained neuronal responses. In the nociceptive (pain-sensing) system, tissue injury or repetitive stimulation of small-diameter afferent fibres triggers a dramatic increase in discharge (wind-up) or prolonged depolarization of spinal cord neurons. This central sensitization can neither be induced nor maintained when NMDA receptor channels are blocked 1,2. In the trigeminal subnucleus caudalis (a centre for processing nociceptive information from the orofacial areas 3), a mu-opioid receptor agonist causes a sustained increase in NMDA-activated currents by activating intracellular PKC 4. There is also evidence that PKC enhances NMDA-receptor-mediated glutamate responses 4-7 and regulates long-term potentiation of synaptic transmission 8-14. Despite the importance of NMDA-receptors and PKC, the mechanism by which PKC alters the NMDA response has remained unclear. Here we examine the actions of intracellularly applied PKC on NMDA-activated currents in isolated trigeminal neurons. We find that PKC potentiates the NMDA response by increasing the probability of channel openings and by reducing the voltage-dependent Mg2+ block of NMDA-receptor channels.	UNIV TEXAS, MED BRANCH, INST MARINE BIOMED, GALVESTON, TX 77550 USA; UNIV TEXAS, MED BRANCH, DEPT PHYSIOL & BIOPHYS, GALVESTON, TX 77550 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston								ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; ASCHER P, 1988, J PHYSIOL-LONDON, V399, P207; Bell R M, 1986, Methods Enzymol, V124, P353; CHEN L, 1991, NEURON, V7, P319, DOI 10.1016/0896-6273(91)90270-A; CULLCANDY SG, 1987, NATURE, V325, P525, DOI 10.1038/325525a0; DICKENSON AH, 1990, TRENDS PHARMACOL SCI, V11, P307, DOI 10.1016/0165-6147(90)90228-Z; DUBNER R, 1991, A REV NEUROSCI, V44, P293; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FORSYTHE ID, 1988, J PHYSIOL-LONDON, V396, P515, DOI 10.1113/jphysiol.1988.sp016975; GERBER G, 1989, J NEUROSCI, V9, P3606; Goldberg M, 1976, KIDNEY, P344; GU YP, 1991, NEURON, V6, P777, DOI 10.1016/0896-6273(91)90174-X; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HU GY, 1987, NATURE, V328, P426, DOI 10.1038/328426a0; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; KELSO SR, IN PRESS J PHYSL LON; LEGENDRE P, 1990, J PHYSIOL-LONDON, V429, P429, DOI 10.1113/jphysiol.1990.sp018266; LESTER RAJ, 1990, NATURE, V346, P565, DOI 10.1038/346565a0; LINDEN DJ, 1989, BRAIN RES REV, V14, P279, DOI 10.1016/0165-0173(89)90004-0; MACDERMOTT AB, 1986, J NEUROSCI, V7, P3230; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MULLER D, 1988, SCIENCE, V242, P1694, DOI 10.1126/science.2904701; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; PITZER KS, 1974, J AM CHEM SOC, V96, P5701, DOI 10.1021/ja00825a004; RANE SG, 1989, NEURON, V3, P239, DOI 10.1016/0896-6273(89)90037-8; YAMAMOTO D, 1988, J PHYSIOL-LONDON, V400, P691, DOI 10.1113/jphysiol.1988.sp017144	32	817	852	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 9	1992	356	6369					521	523		10.1038/356521a0	http://dx.doi.org/10.1038/356521a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HN231	1373227				2022-12-28	WOS:A1992HN23100058
J	JUDGE, K; SOLOMON, M; MILLER, D; PHILO, G				JUDGE, K; SOLOMON, M; MILLER, D; PHILO, G			PUBLIC-OPINION, THE NHS, AND THE MEDIA - CHANGING PATTERNS AND PERSPECTIVES	BRITISH MEDICAL JOURNAL			English	Article									UNIV GLASGOW,MEDIA GRP,GLASGOW G12 8QQ,SCOTLAND; KINGS FUND INST,LONDON NW1 7NF,ENGLAND	University of Glasgow			Miller, David/C-4803-2015	Miller, David/0000-0003-2408-845X				BLENDON RJ, 1989, HEALTH AFFAIR, V8, P52, DOI 10.1377/hlthaff.8.4.52; BLENDON RJ, 1991, HEALTH AFFAIR, V10, P166, DOI 10.1377/hlthaff.10.2.166; BOSANQUET N, 1988, BRIT SOCIAL ATTITUDE; JAJICHTOTH C, 1990, HEALTH AFFAIR, V9, P149, DOI 10.1377/hlthaff.9.4.149; JAJICHTOTH C, 1991, HEALTH AFFAIR, V10, P170, DOI 10.1377/hlthaff.10.2.170; Klein R, 1985, Health Aff (Millwood), V4, P41, DOI 10.1377/hlthaff.4.1.41; PRESCOTTCLARKE P, 1988, FOCUS HLTH CARE SURV; SCHUMAN H, 1981, QUESTIONS ANSWERS AT; SIGELMAN L, 1989, SURVEY RES METHODS R; SOLOMON M, 1991, HLTH CARE UK, P73; TAYLORGOOBY P, 1990, BRIT SOCIAL ATTITUDE; 1991, NHS OUTPATIENT SERVI; 1991, FUTURE NHS BRIT PUBL	13	11	11	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1992	304	6831					892	895		10.1136/bmj.304.6831.892	http://dx.doi.org/10.1136/bmj.304.6831.892			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM835	1392757	Green Published, Bronze			2022-12-28	WOS:A1992HM83500036
J	WIGGINS, S; WHYTE, P; HUGGINS, M; ADAM, S; THEILMANN, J; BLOCH, M; SHEPS, SB; SCHECHTER, MT; HAYDEN, MR				WIGGINS, S; WHYTE, P; HUGGINS, M; ADAM, S; THEILMANN, J; BLOCH, M; SHEPS, SB; SCHECHTER, MT; HAYDEN, MR			THE PSYCHOLOGICAL CONSEQUENCES OF PREDICTIVE TESTING FOR HUNTINGTONS-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LINKED DNA MARKERS; GENE	Background. Advances in molecular genetics have led to the development of tests that can predict the risk of inheriting the genes for several adult-onset diseases. However, the psychological consequences of such testing are not well understood. Methods. The 135 participants in the Canadian program of genetic testing to predict the risk of Huntington's disease were followed prospectively in three groups according to their test results: the increased-risk group (37 participants), the decreased-risk group (58 participants), and the group with no change in risk (the no-change group) (40 participants). All the participants received counseling before and after testing. Standard measures of psychological distress (the General Severity Index of the Symptom Check List 90-R), depression (the Beck Depression Inventory), and well-being (the General Well-Being Scale) were administered before genetic testing and again at intervals of 7 to 10 days, 6 months, and 12 months after the participants received their test results. Results. At each follow-up assessment, the decreased-risk group had lower scores for distress than before testing (P<0.001). The increased-risk group showed no significant change from base line on any follow-up measure, but over the year of study there were small linear declines (P<0.023) for distress and depression. The no-change group had scores lower than at base line on the index of general well-being at each follow-up (P less-than-or-equal-to 0.045). At the 12-month follow-up, both the increased-risk group and the decreased-risk group had lower scores for depression and higher scores for well-being than the no-change group (P less-than-or-equal-to 0.049). Conclusions. Predictive testing for Huntington's disease has potential benefits for the psychological health of persons who receive results that indicate either an increase or a decrease in the risk of inheriting the gene for the disease.	UNIV BRITISH COLUMBIA,DEPT MED GENET,RM 416,2125 E MALL,VANCOUVER V6T 1Z4,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT HLTH CARE & EPIDEMIOL,VANCOUVER V6T 1W5,BC,CANADA	University of British Columbia; University of British Columbia			Hayden, Michael R/D-8581-2011	Hayden, Michael R/0000-0001-5159-1419; Adam, Shelin/0000-0002-4401-6157; Schechter, Martin/0000-0001-6063-2155				BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BLOCH M, 1992, AM J MED GENET, V42, P499, DOI 10.1002/ajmg.1320420416; BRANDT J, 1989, JAMA-J AM MED ASSOC, V261, P3108, DOI 10.1001/jama.261.21.3108; CRAUFURD D, 1989, LANCET, V2, P603; DEROGATIS LR, 1983, SCL90R ADM SCORING P; DUPUY H, 1969, PSYCHOL EXAMINATION; FOLSTEIN SE, 1983, NEUROBEH TOXICOL TER, V5, P605; FOX S, 1989, AM J MED GENET, V32, P211, DOI 10.1002/ajmg.1320320214; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; HAYDEN MR, 1988, AM J HUM GENET, V43, P689; HUGGINS M, 1992, AM J MED GENET, V42, P508, DOI 10.1002/ajmg.1320420417; KESSLER S, 1987, AM J MED GENET, V26, P259, DOI 10.1002/ajmg.1320260204; KESSLER S, 1987, AM J ORTHOPSYCHIAT, V57, P212, DOI 10.1111/j.1939-0025.1987.tb03531.x; SKRAASTAD MI, 1991, AM J MED GENET, V38, P217; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; WARE JE, 1979, R19873HEW RAND REP; WINER BJ, 1971, STATISTICAL PRINCIPL, P177	18	338	338	0	17	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 12	1992	327	20					1401	1405		10.1056/NEJM199211123272001	http://dx.doi.org/10.1056/NEJM199211123272001			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JX479	1406858	Bronze			2022-12-28	WOS:A1992JX47900001
J	BREO, DL				BREO, DL			A FEW WORDS OF ADVICE FROM A WOMAN OF LETTERS - LANDERS,ANN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1992	268	14					1930	1931		10.1001/jama.268.14.1930	http://dx.doi.org/10.1001/jama.268.14.1930			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR439	1404723				2022-12-28	WOS:A1992JR43900048
J	PARKE, TJ; STEVENS, JE; RICE, ASC; GREENAWAY, CL; BRAY, RJ; SMITH, PJ; WALDMANN, CS; VERGHESE, C				PARKE, TJ; STEVENS, JE; RICE, ASC; GREENAWAY, CL; BRAY, RJ; SMITH, PJ; WALDMANN, CS; VERGHESE, C			METABOLIC-ACIDOSIS AND FATAL MYOCARDIAL FAILURE AFTER PROPOFOL INFUSION IN CHILDREN - 5 CASE-REPORTS	BRITISH MEDICAL JOURNAL			English	Article							SEDATION; MIDAZOLAM	Objective-To examine the possible contribution of sedation with propofol in the deaths of children who were intubated and required intensive care. Design - Case note review. Setting-Three intensive care units. Subjects-Five children with upper respiratory tract infections aged between 4 weeks and 6 years. Results-Four patients had laryngotracheobronchitis and one had bronchiolitis. All were sedated with propofol. The clinical course in all five cases was remarkably similar: an increasing metabolic acidosis was associated with brady-arrhythmia and progressive myocardial failure, which did not respond to resuscitative measures. All children developed lipaemic serum after starting propofol. These features are not usually associated with respiratory tract infections. No evidence was found of viral myocarditis, which was considered as a possible cause of death. Conclusion-Although the exact cause of death in these children could not be defined, propofol may have been a contributing factor.	JOHN RADCLIFFE HOSP,NUFFIELD DEPT ANAESTHET,OXFORD OX3 9DU,ENGLAND; JOHN RADCLIFFE HOSP,DEPT PAEDIAT,OXFORD OX3 9DU,ENGLAND; ROYAL VICTORIA INFIRM,DEPT ANAESTHET,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND; ROYAL VICTORIA INFIRM,DEPT CHILD HLTH,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND; ROYAL BERKSHIRE HOSP,DEPT ANAESTHET,READING RG1 5AN,BERKS,ENGLAND	University of Oxford; University of Oxford; Newcastle University - UK; Newcastle University - UK; Royal Berkshire Hospital			Waldmann, Christoph/F-3386-2017; Rice, Andrew/I-7501-2012	Waldmann, Christoph/0000-0003-3388-7579; 				AITKENHEAD AR, 1989, LANCET, V2, P704, DOI 10.1016/S0140-6736(89)90770-8; BEDRICK AD, 1988, AM J DIS CHILD, V142, P135, DOI 10.1001/archpedi.1988.02150020033021; BELLER JP, 1988, BRIT J ANAESTH, V61, P583, DOI 10.1093/bja/61.5.583; CLAEYS MA, 1988, BRIT J ANAESTH, V60, P3, DOI 10.1093/bja/60.1.3; COOK GC, 1989, CURR OPIN INFECT DIS, V2, P65, DOI 10.1097/00001432-198902010-00014; EDDELSTON JM, 1991, INTENS CARE MED, V17, P424; Guyton A.C., 1991, TXB MED PHYSL, P754; HARRIS CE, 1990, ANAESTHESIA, V45, P366, DOI 10.1111/j.1365-2044.1990.tb14777.x; KAUFFMAN RE, 1991, J PEDIATR-US, V119, P588, DOI 10.1016/S0022-3476(05)82409-6; MARSH B, 1991, BRIT J ANAESTH, V67, P41, DOI 10.1093/bja/67.1.41; MATTHEWS AJ, 1991, CARE CRITICALLY ILL, V8, P34; NORRESLET J, 1990, CRIT CARE MED, V18, P890, DOI 10.1097/00003246-199008000-00022; RODGERS EM, 1991, BRIT J ANAESTH, V67, P505, DOI 10.1093/bja/67.4.505-b; SHORT SM, 1991, ANAESTHESIA, V46, P783, DOI 10.1111/j.1365-2044.1991.tb09781.x; TROTTER C, 1992, ANAESTHESIA, V47, P340, DOI 10.1111/j.1365-2044.1992.tb02178.x; WEATHERALL DJ, 1987, OXFORD TXB MED, V13, P197; 1992, BRIT NATIONAL FORMUL, P450	17	354	361	1	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 12	1992	305	6854					613	616		10.1136/bmj.305.6854.613	http://dx.doi.org/10.1136/bmj.305.6854.613			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN698	1393073	Green Submitted, Bronze, Green Published			2022-12-28	WOS:A1992JN69800016
J	YANAGISAWAMIWA, A; UCHIDA, Y; NAKAMURA, F; TOMARU, T; KIDO, H; KAMIJO, T; SUGIMOTO, T; KAJI, K; UTSUYAMA, M; KURASHIMA, C; ITO, H				YANAGISAWAMIWA, A; UCHIDA, Y; NAKAMURA, F; TOMARU, T; KIDO, H; KAMIJO, T; SUGIMOTO, T; KAJI, K; UTSUYAMA, M; KURASHIMA, C; ITO, H			SALVAGE OF INFARCTED MYOCARDIUM BY ANGIOGENIC ACTION OF BASIC FIBROBLAST GROWTH-FACTOR	SCIENCE			English	Article							CORONARY COLLATERAL VESSELS; DNA-SYNTHESIS; FUNCTIONAL-SIGNIFICANCE; EXTRACELLULAR-MATRIX; CARDIAC MYOCYTES; HEPARIN; CIRCULATION; HEART; ARTERY; LOCALIZATION	Coronary collateral vessels reduce damage to ischemic myocardium after coronary obstruction. Factors that stimulate collateral formation are expected to have ameliorating effects on myocardial infarction. In a canine experimental myocardial infarct model, intracoronary injection of basic fibroblast growth factor (bFGF) improved cardiac systolic function and reduced infarct size. Treatment with bFGF increased the number of arterioles and capillaries in the infarct. Thus, the angiogenic action of bFGF might lead to a reduction in infarct size. The application of bFGF might bring about a therapeutic modality for the salvage of infarcted myocardium.	TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL, ENDOCRINOL & METAB SECT, ITABASHI KU, TOKYO 173, JAPAN; TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL, DEPT PATHOL, ITABASHI KU, TOKYO 173, JAPAN; TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL, DEPT BIOCHEM ISOTOPES, ITABASHI KU, TOKYO 173, JAPAN		YANAGISAWAMIWA, A (corresponding author), UNIV TOKYO, FAC MED, DEPT INTERNAL MED, 7-3-1 HONGO, BUNKYO KU, TOKYO 113, JAPAN.							BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CASSCELLS W, 1990, J CLIN INVEST, V85, P433, DOI 10.1172/JCI114456; COLLE JP, 1982, ARCH MAL COEUR VAISS, V75, P395; DAMORE PA, 1987, ANNU REV PHYSIOL, V49, P453; FLANAGAN MF, 1991, CIRC RES, V68, P1458, DOI 10.1161/01.RES.68.5.1458; FLAUMENHAFT R, 1989, J CELL PHYSIOL, V140, P75, DOI 10.1002/jcp.1041400110; FLAUMENHAFT R, 1990, J CELL BIOL, V111, P1651, DOI 10.1083/jcb.111.4.1651; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FUJITA M, 1991, AM HEART J, V122, P409, DOI 10.1016/0002-8703(91)90993-R; FUJITA M, 1988, CIRCULATION, V77, P1022, DOI 10.1161/01.CIR.77.5.1022; GOSPODAROWICZ D, 1989, J INVEST DERMATOL, V93, pS39, DOI 10.1111/1523-1747.ep12580907; GREGG DE, 1974, CIRC RES, V35, P335, DOI 10.1161/01.RES.35.3.335; HABIB GB, 1991, CIRCULATION, V83, P739, DOI 10.1161/01.CIR.83.3.739; KARDAMI E, 1989, J CELL BIOL, V109, P1865, DOI 10.1083/jcb.109.4.1865; KIDO H, 1991, J JPN COLL ANGIOL, V31, P753; KUMAR S, 1983, LANCET, V2, P364; LEVIN DC, 1974, CIRCULATION, V50, P831, DOI 10.1161/01.CIR.50.4.831; LINDNER V, 1991, CIRC RES, V68, P106, DOI 10.1161/01.RES.68.1.106; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; MOHRI M, 1989, CIRC RES, V64, P287, DOI 10.1161/01.RES.64.2.287; PASYK S, 1982, AM J PHYSIOL, V242, P1031; PIEK JJ, 1988, J AM COLL CARDIOL, V11, P1290, DOI 10.1016/0735-1097(88)90294-X; QUINKLER W, 1989, EUR J BIOCHEM, V181, P67, DOI 10.1111/j.1432-1033.1989.tb14694.x; RAKUSAN K, 1985, CIRC RES, V57, P393, DOI 10.1161/01.RES.57.3.393; SABRI MN, 1991, AM HEART J, V121, P876, DOI 10.1016/0002-8703(91)90202-S; SASAKI H, 1989, J BIOL CHEM, V264, P17606; SCHAPER W, 1990, J AM COLL CARDIOL, V15, P513, DOI 10.1016/0735-1097(90)90618-Y; SCHAPER W, 1978, BASIC RES CARDIOL, V73, P584, DOI 10.1007/BF01906796; SCHAPER W, 1988, PROG CARDIOVASC DIS, V31, P57, DOI 10.1016/0033-0620(88)90011-4; SCHAPER W, 1971, CIRC RES, V28, P671, DOI 10.1161/01.RES.28.6.671; SCHWARZ F, 1978, AM HEART J, V95, P570, DOI 10.1016/0002-8703(78)90298-3; THOMPSON JA, 1989, P NATL ACAD SCI USA, V86, P7928, DOI 10.1073/pnas.86.20.7928; THOMPSON JA, 1988, SCIENCE, V241, P1349, DOI 10.1126/science.2457952; UNGER EF, 1990, CIRCULATION, V82, P1449, DOI 10.1161/01.CIR.82.4.1449; WEINER HL, 1989, P NATL ACAD SCI USA, V86, P2683, DOI 10.1073/pnas.86.8.2683; YANAGISAWAMIWA A, UNPUB	36	433	469	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 4	1992	257	5075					1401	1403		10.1126/science.1382313	http://dx.doi.org/10.1126/science.1382313			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL612	1382313				2022-12-28	WOS:A1992JL61200034
J	TSARFATY, I; RESAU, JH; SHEN, RL; KEYDAR, I; FALETTO, DL; VANDEWOUDE, GF				TSARFATY, I; RESAU, JH; SHEN, RL; KEYDAR, I; FALETTO, DL; VANDEWOUDE, GF			THE MET PROTOONCOGENE RECEPTOR AND LUMEN FORMATION	SCIENCE			English	Article							HEPATOCYTE GROWTH-FACTOR; C-MET; SCATTER FACTOR; MOLECULAR-CLONING; KINASE-ACTIVITY; CELL-LINE; EXPRESSION; PROTOONCOGENE; IDENTIFICATION; ACTIVATION	The met proto-oncogene product (Met) and its ligand, hepatocyte growth factor/scatter factor (HGF/SF), have been implicated in cell mitogenic response, cell motility, and the promotion of the ordered spatial arrangement of tissue. By means of confocal laser-scanning microscopy, it was shown that Met is expressed in cells bordering lumen-like structures that resemble ducts in the human mammary cell line T47D. In human breast tissue biopsies, Met staining was intense in normal cells bordering mammary ducts but was reduced in adjacent tumor tissue. Met staining in lumen-forming organs colocalizes with staining of antibody to phosphotyrosine, which suggests that the Met receptor and its substrates may be activated in lumen structures or ducts. HGF/SF treatment of human epithelial carcinoma cell lines resulted in the formation of lumen-like structures in vitro. Reduced expression of Met could be related to the extent ot tumor cell differentiation.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702; NCI,DIV CANC ETIOL,MOLEC ONCOL LAB,BETHESDA,MD 20892; UNIV MARYLAND,SCH MED,DEPT PATHOL,BALTIMORE,MD 21201; TEL AVIV UNIV,DEPT CELL RES & IMMUNOL,IL-69978 TEL AVIV,ISRAEL	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Maryland; University of Maryland Baltimore; Tel Aviv University			Shen, Rulong/E-4079-2011	Tsarfaty, Ilan/0000-0002-5230-7093	PHS HHS [N01-C0-74101] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BASLER K, 1989, SCIENCE, V243, P931, DOI 10.1126/science.2493159; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; Bissell M. J., 1987, The mammary gland. Development, regulation, and function., P97; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BOWTELL DDL, 1989, CELL, V56, P931, DOI 10.1016/0092-8674(89)90626-0; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; DIRENZO MF, 1991, ONCOGENE, V6, P1997; FALETTO DL, 1992, ONCOGENE, V7, P1149; FALETTO DL, UNPUB; Freshney RI, 1987, CULTURE ANIMAL CELLS, P57; GERARDI E, 1991, CANCER CELLS, V3, P227; GIORDANO S, 1989, ONCOGENE, V4, P1383; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; KEYDAR I, 1979, EUR J CANCER, V15, P659, DOI 10.1016/0014-2964(79)90139-7; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, ONCOGENE, V6, P501; Naldini L., 1991, EMBO J, V10, P2876; PADAWER J, 1968, Journal of the Royal Microscopical Society, V88, P305; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; ROSEN EM, 1991, CELL GROWTH DIFFER, V2, P603; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; STREULI CH, 1991, J CELL BIOL, V115, P1383, DOI 10.1083/jcb.115.5.1383; TAJIMA H, 1991, FEBS LETT, V291, P229, DOI 10.1016/0014-5793(91)81291-F; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; TSARFATY I, UNPUB; VANDEWOUDE GF, 1992, JPN J CANCER RES, V83; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001	35	251	263	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 28	1992	257	5074					1258	1261		10.1126/science.1387731	http://dx.doi.org/10.1126/science.1387731			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1387731				2022-12-28	WOS:A1992JL05000027
J	BURSTIN, HR; LIPSITZ, SR; BRENNAN, TA				BURSTIN, HR; LIPSITZ, SR; BRENNAN, TA			SOCIOECONOMIC-STATUS AND RISK FOR SUBSTANDARD MEDICAL-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADVERSE EVENTS; HOSPITALIZED-PATIENTS; HEALTH-INSURANCE; PREVENTIVE CARE; HEART-DISEASE; MASSACHUSETTS; AGE; PATTERNS; ACCESS; BOSTON	Objective.-To assess whether the socioeconomic status of the patient was associated with the risk of adverse events, defined as medical injuries caused by medical management, and the proportion of these events that resulted from substandard care. Setting.-51 hospitals in New York State. Methods.-Rates of medical injury and substandard care by gender, race, income, and payer status were developed from reviews of 30195 medical records in New York in 1984. We evaluated these socioeconomic parameters in a multivariate analysis, while controlling for hospital-level factors. Results.-We found that uninsured patients (odds ratio, 2.35; 95% confidence interval, 1.40 to 3.95) were at greater risk for substandard care. The characteristics of the hospitals to which patients were admitted did not affect this result. Race, gender, and income were not independently associated with risk for medical injury or substandard care in multivariate analyses. Conclusion.-Our findings suggest that the uninsured are at greater risk for suffering medical injury due to substandard medical care.	BRIGHAM & WOMENS HOSP,DIV GEN MED,75 FRANCIS ST,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health								AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BENNETT CL, 1991, CANCER, V67, P2633, DOI 10.1002/1097-0142(19910515)67:10<2633::AID-CNCR2820671039>3.0.CO;2-9; BINDMAN AB, 1990, JAMA-J AM MED ASSOC, V264, P2899, DOI 10.1001/jama.264.22.2899; BLENDON RJ, 1989, JAMA-J AM MED ASSOC, V261, P278, DOI 10.1001/jama.261.2.278; BOMBARDIER C, 1977, NEW ENGL J MED, V297, P699, DOI 10.1056/NEJM197709292971305; BRAVEMAN P, 1989, NEW ENGL J MED, V321, P508, DOI 10.1056/NEJM198908243210805; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BRENNAN TA, 1991, JAMA-J AM MED ASSOC, V265, P3265, DOI 10.1001/jama.265.24.3265; BRENNAN TA, 1991, JUST DOCTORING MED E; GOULD JB, 1989, NEW ENGL J MED, V321, P233, DOI 10.1056/NEJM198907273210406; GREENBERGER NJ, 1991, BRIT MED J, V303, P1216, DOI 10.1136/bmj.303.6812.1216; GREENFIELD S, 1987, JAMA-J AM MED ASSOC, V257, P2766, DOI 10.1001/jama.257.20.2766; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; HELLER TA, 1984, J AM GERIATR SOC, V32, P782, DOI 10.1111/j.1532-5415.1984.tb06297.x; KJELLSTRAND CM, 1988, ARCH INTERN MED, V148, P1305; LAMMER EJ, 1989, JAMA-J AM MED ASSOC, V261, P1757, DOI 10.1001/jama.261.12.1757; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; LURIE N, 1984, NEW ENGL J MED, V311, P480, DOI 10.1056/NEJM198408163110735; LURIE N, 1987, AM J PUBLIC HEALTH, V77, P801, DOI 10.2105/AJPH.77.7.801; SHAH BV, 1981, SESUDAAN STANDARD ER; SHAH BV, 1984, RTI LOGIT PROCEDURE; SHAPIRO MF, 1986, ANN INTERN MED, V104, P246, DOI 10.7326/0003-4819-104-2-246; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; WEISSMAN J, 1989, JAMA-J AM MED ASSOC, V261, P3572, DOI 10.1001/jama.261.24.3572; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; WENNEKER MB, 1990, JAMA-J AM MED ASSOC, V264, P1255, DOI 10.1001/jama.264.10.1255; WISE PH, 1985, NEW ENGL J MED, V313, P360, DOI 10.1056/NEJM198508083130605; WOOLHANDLER S, 1988, JAMA-J AM MED ASSOC, V259, P2872; YERGAN J, 1987, MED CARE, V25, P592, DOI 10.1097/00005650-198707000-00003; 1985, STATEWIDE PLANNING R; 1985, AM HOSPITAL ASS GUID; 1984, 1984 SOURCEBOOK ZIP	32	193	192	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 4	1992	268	17					2383	2387		10.1001/jama.268.17.2383	http://dx.doi.org/10.1001/jama.268.17.2383			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JV694	1404794				2022-12-28	WOS:A1992JV69400023
J	GUYATT, G				GUYATT, G			EVIDENCE-BASED MEDICINE - A NEW APPROACH TO TEACHING THE PRACTICE OF MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CRITICAL-APPRAISAL; CONTROLLED TRIAL; GUIDELINES; CURRICULUM; ACCESS; CARE				GUYATT, G (corresponding author), MCMASTER UNIV,HLTH SCI CTR,ROOM 3W10,1200 MAIN ST W,HAMILTON L8N 3Z5,ONTARIO,CANADA.							[Anonymous], 1981, Can Med Assoc J, V124, P703; AUDET AM, 1990, ANN INTERN MED, V113, P709, DOI 10.7326/0003-4819-113-9-709; BENNETT KJ, 1987, JAMA-J AM MED ASSOC, V257, P2451, DOI 10.1001/jama.257.18.2451; BULPITT CJ, 1987, LANCET, V1, P494; CAMPBELL EJM, 1987, LANCET, V1, P849; CARTER WB, 1982, MED CARE, V20, P550, DOI 10.1097/00005650-198206000-00002; CASSEL EJ, 1982, NEW ENGL J MED, V306, P639, DOI 10.1056/NEJM198203183061104; CHALMERS I, 1983, BIRTH-ISS PERINAT C, V10, P151; Chalmers I, 1989, EFFECTIVE CARE PREGN; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P2239, DOI 10.1001/jama.263.16.2239; Ehrenkranz R.A., 1992, EFFECTIVE CARE NEWBO; ENDE J, 1989, J GEN INTERN MED, V4, P23, DOI 10.1007/BF02596485; FEINSTEIN AR, 1970, NEW ENGL J MED, V283, P847, DOI 10.1056/NEJM197010152831605; GODFREY K, 1985, NEW ENGL J MED, V313, P1629, DOI 10.1056/NEJM198512263132604; GREENFIELD S, 1985, ANN INTERN MED, V102, P520, DOI 10.7326/0003-4819-102-4-520; Guyatt GH., 1991, ACP J CLUB, V114, pA; HART YM, 1990, LANCET, V336, P1271, DOI 10.1016/0140-6736(90)92960-P; HAYNES RB, 1990, ANN INTERN MED, V112, P78, DOI 10.7326/0003-4819-112-1-78; HAYNES RB, 1986, ANN INTERN MED, V105, P810, DOI 10.7326/0003-4819-105-5-810; HAYNES RB, 1990, ANN INTERN MED, V113, P69, DOI 10.7326/0003-4819-113-1-69; HAYNES RB, 1991, ACP J CLUB, V114, pA18; KITCHENS JM, 1989, J GEN INTERN MED, V4, P384, DOI 10.1007/BF02599686; Kuhn T.S., 1970, STRUCTURE SCI REVOLU, P174; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; LARSEN ML, 1990, NEW ENGL J MED, V323, P1021, DOI 10.1056/NEJM199010113231503; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; LIGHT D, 1979, J HEALTH SOC BEHAV, V20, P310, DOI 10.2307/2955407; LINDBERG DAB, 1989, METHOD INFORM MED, V28, P202; MCKIBBON KA, 1992, 5TH P ANN S COMP APP, P73; MULROW CD, 1987, ANN INTERN MED, V106, P485, DOI 10.7326/0003-4819-106-3-485; NIERENBERG AA, 1988, JAMA-J AM MED ASSOC, V259, P1699, DOI 10.1001/jama.259.11.1699; OXMAN AD, 1988, CAN MED ASSOC J, V138, P697; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P173; SHIN J, 1991, CLIN RES, V39, pA143; 1981, CAN MED ASSOC J, V124, P1156; 1991, LANCET, V337, P1235	37	2656	2813	7	190	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 4	1992	268	17					2420	2425		10.1001/jama.1992.03490170092032	http://dx.doi.org/10.1001/jama.1992.03490170092032			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV694	1404801				2022-12-28	WOS:A1992JV69400030
J	GILL, DR; HYDE, SC; HIGGINS, CF; VALVERDE, MA; MINTENIG, GM; SEPULVEDA, FV				GILL, DR; HYDE, SC; HIGGINS, CF; VALVERDE, MA; MINTENIG, GM; SEPULVEDA, FV			SEPARATION OF DRUG TRANSPORT AND CHLORIDE CHANNEL FUNCTIONS OF THE HUMAN MULTIDRUG RESISTANCE P-GLYCOPROTEIN	CELL			English	Article							NUCLEOTIDE-BINDING FOLD; CYSTIC-FIBROSIS; ATP-BINDING; ADENYLATE KINASE; DEPENDENT TRANSPORT; STRUCTURAL MODEL; EPITHELIAL-CELLS; ESCHERICHIA-COLI; R-DOMAIN; EXPRESSION	The human multidrug resistance P-glycoprotein is an active transporter that pumps cytotoxic drugs out of cells. Expression of P-glycoprotein is also associated with a volume-activated chloride channel. Here we address the relationship between these two functions. Drug transport requires ATP hydrolysis while, in contrast, ATP binding is sufficient to enable activation of the chloride channel. The chloride channel and drug transport activities of P-glycoprotein appear to reflect two distinct functional states of the protein that can be interconverted by changes in tonicity. Transportable drugs prevent channel activation but have no effect on channel activity once it has been preactivated by hypotonicity. The transport and channel functions of P-glycoprotein have been separated by directed mutations in the nucleotide-binding domains of the protein. These data provide further evidence that P-glycoprotein is bifunctional with both transport and channel activities. Implications for the design of chemotherapeutic drugs and for the function of the related cystic fibrosis gene product, CFTR, are discussed.	AFRC,INST ANIM PHYSIOL & GENET RES,CAMBRIDGE CB2 4AT,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	GILL, DR (corresponding author), UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,IMPERIAL CANC RES FUND LABS,OXFORD OX3 9DU,ENGLAND.			Sepulveda Valenzuela, Francisco Leandro/0000-0003-0022-6598; Gill, Deborah/0000-0002-5264-054X; Valverde, Miguel A./0000-0002-6961-3361; Hyde, Stephen/0000-0002-8877-4005				ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ARCECI RJ, 1988, P NATL ACAD SCI USA, V85, P4350, DOI 10.1073/pnas.85.12.4350; ASHCROFT FM, 1989, J PHYSIOL-LONDON, V416, P349, DOI 10.1113/jphysiol.1989.sp017765; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BAAS F, 1990, CANCER RES, V50, P5392; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; CANOGAUCI DF, 1990, BIOCHEM BIOPH RES CO, V167, P48, DOI 10.1016/0006-291X(90)91728-B; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CORDONCARDO C, 1990, J HISTOCHEM CYTOCHEM, V38, P1277, DOI 10.1177/38.9.1974900; CORNWELL MM, 1987, FASEB J, V1, P51, DOI 10.1096/fasebj.1.1.2886389; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; DIAZ M, 1992, UNPUB EUR J PHYSL; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GARBOCZI DN, 1990, J BIOL CHEM, V265, P14632; GOTTESMAN MM, 1988, TRENDS PHARMACOL SCI, V9, P54, DOI 10.1016/0165-6147(88)90117-4; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; HAMADA H, 1988, J BIOL CHEM, V263, P1454; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; HOFFMANN EK, 1989, PHYSIOL REV, V69, P315, DOI 10.1152/physrev.1989.69.2.315; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8445; MCNAUGHTON PA, 1986, NATURE, V322, P261, DOI 10.1038/322261a0; MIMMACK ML, 1989, P NATL ACAD SCI USA, V86, P8257, DOI 10.1073/pnas.86.21.8257; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; MOOS C, 1960, ARCH BIOCHEM BIOPHYS, V88, P183, DOI 10.1016/0003-9861(60)90220-4; OBRIEN JA, 1991, BIOCHIM BIOPHYS ACTA, V1070, P501, DOI 10.1016/0005-2736(91)90093-N; OKADA Y, 1989, NEWS PHYSIOL SCI, V4, P238; PASTAN I, 1988, P NATL ACAD SCI USA, V85, P4486, DOI 10.1073/pnas.85.12.4486; REINSTEIN J, 1990, BIOCHEMISTRY-US, V29, P7451, DOI 10.1021/bi00484a014; REINSTEIN J, 1988, BIOCHEMISTRY-US, V27, P4712, DOI 10.1021/bi00413a020; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RONINSON IB, 1990, PEDIATR PULM, V5, P138; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SHEN DW, 1986, SCIENCE, V232, P643, DOI 10.1126/science.3457471; SHEPPARD DN, 1991, J PHYSIOL-LONDON, V433, P663, DOI 10.1113/jphysiol.1991.sp018449; SHIMABUKU AM, 1992, J BIOL CHEM, V267, P4305; SMITH JS, 1985, NATURE, V316, P446, DOI 10.1038/316446a0; SOLC CK, 1991, AM J PHYSIOL, V261, pC658, DOI 10.1152/ajpcell.1991.261.4.C658; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; SUZUKI S, 1990, J PHYSIOL-LONDON, V421, P645, DOI 10.1113/jphysiol.1990.sp017967; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; TIAN G, 1990, BIOCHEMISTRY-US, V29, P4296, DOI 10.1021/bi00470a006; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111; YOUNT RG, 1971, BIOCHEMISTRY-US, V10, P2490, DOI 10.1021/bi00789a010	55	366	371	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 2	1992	71	1					23	32		10.1016/0092-8674(92)90263-C	http://dx.doi.org/10.1016/0092-8674(92)90263-C			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1382860				2022-12-28	WOS:A1992JQ62300004
J	NELSON, RJ; ZIEGELHOFFER, T; NICOLET, C; WERNERWASHBURNE, M; CRAIG, EA				NELSON, RJ; ZIEGELHOFFER, T; NICOLET, C; WERNERWASHBURNE, M; CRAIG, EA			THE TRANSLATION MACHINERY AND 70 KD HEAT-SHOCK PROTEIN COOPERATE IN PROTEIN-SYNTHESIS	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; HSP70 FAMILY; YEAST; MEMBER; TRANSLOCATION; MITOCHONDRIA; SEQUENCE; CLONING; MUTANT; GENES	The function of the yeast SSB 70 kd heatshock proteins (hsp70s) was investigated by a variety of approaches. The SSB hsp70s (Ssb1/2p) are associated with translating ribosomes. This association is disrupted by puromycin, suggesting that Ssb1/2p may bind directly to the nascent polypeptide. Mutant ssb1 ssb2 strains grow slowly, contain a low number of translating ribosomes, and are hypersensitive to several inhibitors of protein synthesis. The slow growth phenotype of ssb1 ssb2 mutants is suppressed by increased copy number of a gene encoding a novel translation elongation factor 1alpha (EF-1alpha)-like protein. We suggest that cytosolic hsp70 aids in the passage of the nascent polypeptide chain through the ribosome in a manner analogous to the role played by organelle-localized hsp70 in the transport of proteins across membranes.	UNIV WISCONSIN,PROGRAM CELLULAR & MOLEC BIOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	NELSON, RJ (corresponding author), UNIV WISCONSIN,DEPT BIOMOLEC CHEM,MADISON,WI 53706, USA.							BAYLISS FT, 1971, SCIENCE, V174, P1339, DOI 10.1126/science.174.4016.1339; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BLOBEL G, 1971, P NATL ACAD SCI USA, V68, P390, DOI 10.1073/pnas.68.2.390; BLOBEL G, 1970, J CELL BIOL, V45, P130, DOI 10.1083/jcb.45.1.130; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CARTER CJ, 1980, EUR J BIOCHEM, V107, P173, DOI 10.1111/j.1432-1033.1980.tb04638.x; CRAIG EA, 1985, MOL CELL BIOL, V5, P3517, DOI 10.1128/MCB.5.12.3517; CRAIG EA, 1989, MOL CELL BIOL, V9, P3000, DOI 10.1128/MCB.9.7.3000; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; CULBERTSON MR, 1982, GENETICS, V102, P361; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; ENGMAN DM, 1989, MOL CELL BIOL, V9, P5163, DOI 10.1128/MCB.9.11.5163; FORCHHAMMER J, 1971, J MOL BIOL, V55, P563, DOI 10.1016/0022-2836(71)90337-8; FRIED HM, 1981, P NATL ACAD SCI-BIOL, V78, P238, DOI 10.1073/pnas.78.1.238; Gale E.F., 1981, MOL BASIS ANTIBIOTIC, Vsecond; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GONZALEZ A, 1978, BIOCHIM BIOPHYS ACTA, V521, P459, DOI 10.1016/0005-2787(78)90287-3; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; Hawthorne D C, 1974, Curr Top Microbiol Immunol, V64, P1; HEMMINGS BA, 1981, P NATL ACAD SCI-BIOL, V78, P435, DOI 10.1073/pnas.78.1.435; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KITAKAWA M, 1990, NUCLEIC ACIDS RES, V18, P1521, DOI 10.1093/nar/18.6.1521; LEUSTEK T, 1989, P NATL ACAD SCI USA, V86, P7805, DOI 10.1073/pnas.86.20.7805; MALKIN LI, 1967, J MOL BIOL, V26, P329, DOI 10.1016/0022-2836(67)90301-4; Maniatis T., 1982, MOL CLONING; MARSHALL JS, 1990, P NATL ACAD SCI USA, V87, P374, DOI 10.1073/pnas.87.1.374; MASUREKAR M, 1981, J MOL BIOL, V147, P381, DOI 10.1016/0022-2836(81)90490-3; MILLIGAN RA, 1986, NATURE, V319, P693, DOI 10.1038/319693a0; MIZZEN LA, 1989, J BIOL CHEM, V264, P20664; NAGATA S, 1984, EMBO J, V3, P1825, DOI 10.1002/j.1460-2075.1984.tb02053.x; NGUYEN TH, 1991, P NATL ACAD SCI USA, V88, P1565, DOI 10.1073/pnas.88.4.1565; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SMITH JD, 1965, J MOL BIOL, V13, P617, DOI 10.1016/S0022-2836(65)80130-9; STOCKLEIN W, 1981, FEBS LETT, V136, P265, DOI 10.1016/0014-5793(81)80632-1; Surguchovs AP, 1984, PHYSICOCHEMICAL BIOL, V4, P147; VANHOLDE KE, 1974, RIBOSOMES, P53; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WETTSTEIN FO, 1964, BIOCHIM BIOPHYS ACTA, V87, P525, DOI 10.1016/0926-6550(64)90131-8	47	448	473	1	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 2	1992	71	1					97	105		10.1016/0092-8674(92)90269-I	http://dx.doi.org/10.1016/0092-8674(92)90269-I			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1394434				2022-12-28	WOS:A1992JQ62300010
J	WEETMAN, AP; TANDON, N; MORGAN, BP				WEETMAN, AP; TANDON, N; MORGAN, BP			ANTITHYROID DRUGS AND RELEASE OF INFLAMMATORY MEDIATORS BY COMPLEMENT-ATTACKED THYROID-CELLS	LANCET			English	Article							GRAVES-DISEASE; HASHIMOTOS THYROIDITIS; MEMBRANE ATTACK; GROWTH-FACTOR; T-CELLS; INTERLEUKIN-6; LYMPHOCYTES; METHIMAZOLE; SURFACE	Thyroid cells are exposed to complement attack in Graves' disease and Hashimoto's thyroiditis, but are resistant to killing by homologous complement. We have examined the effects of sublethal complement attack on thyroid cells in vitro. Extracellular reactive oxygen metabolites were produced and prostaglandin E2, interleukin-1-alpha, and interleukin-6 were released after complement attack. Cells pretreated with interferon-gamma and interleukin-1-alpha, which increase expression of CD59, were more resistant to these effects of complement. Conversely, blockade of CD59 with monoclonal antibody increased complement-mediated oxygen radical production and release of prostaglandin E2, interleukin-1-alpha, and interleukin-6. The antithyroid drugs methimazole and propylthiouracil abolished or reduced oxygen radical production by complement-attacked thyroid cells and reduced cytokine release. These results suggest that sublethal complement attack in autoimmune thyroid diseases exacerbates tissue injury by causing thyroid cells to release potent phlogistic mediators, although some degree of protection may be afforded in vivo by cytokine-mediated upregulation of CD59. Antithyroid drugs, concentrated within thyroid cells, will prevent the release of these inflammatory molecules, which may in turn explain the amelioration of thyroiditis and remission of Graves' disease after such treatment.	UNIV WALES COLL MED,DEPT MED BIOCHEM,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University	WEETMAN, AP (corresponding author), UNIV SHEFFIELD,NO GEN HOSP,CTR CLIN SCI,DEPT MED,SHEFFIELD S5 7AU,ENGLAND.			Morgan, Paul/0000-0003-4075-7676	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; ALLEN EM, 1986, AM J MED SCI, V29, P267; BANGA JP, 1991, AUTOIMMUNITY, V8, P335, DOI 10.3109/08916939109007642; BELLUR S, 1990, ENDOCRINOLOGY, V127, P1526, DOI 10.1210/endo-127-3-1526; BROWN TR, 1991, J CLIN INVEST, V88, P106, DOI 10.1172/JCI115265; GRUBECKLOEBENSTEIN B, 1989, CLIN EXP IMMUNOL, V77, P324; JANSSON R, 1985, BRIT MED J, V290, P11, DOI 10.1136/bmj.290.6461.11; KALDERON AE, 1977, AM J MED, V63, P729, DOI 10.1016/0002-9343(77)90159-0; KASAI K, 1987, LIFE SCI, V41, P241, DOI 10.1016/0024-3205(87)90499-1; KHOURY EL, 1984, J EXP MED, V159, P577, DOI 10.1084/jem.159.2.577; KHOURY EL, 1981, CLIN EXP IMMUNOL, V45, P316; MARCHANT B, 1972, J CLIN ENDOCR METAB, V34, P847, DOI 10.1210/jcem-34-5-847; MARGOLICK JB, 1988, CLIN IMMUNOL IMMUNOP, V47, P208, DOI 10.1016/0090-1229(88)90073-6; MCGREGOR AM, 1982, BRIT MED J, V284, P1750, DOI 10.1136/bmj.284.6331.1750; MCGREGOR AM, 1980, BRIT MED J, V281, P968, DOI 10.1136/bmj.281.6246.968; MCLACHLAN SM, 1986, CLIN ENDOCRINOL, V24, P223, DOI 10.1111/j.1365-2265.1986.tb00766.x; MORGAN BP, 1989, BIOCHEM J, V264, P1; OLEESKY DA, 1985, CLIN ENDOCRINOL, V25, P623; ROMALDINI JH, 1986, J ENDOCRINOL INVEST, V9, P233, DOI 10.1007/BF03348107; ROMALDINI JH, 1983, J CLIN ENDOCR METAB, V57, P563, DOI 10.1210/jcem-57-3-563; TANDON N, 1992, IMMUNOLOGY, V75, P372; TOTTERMAN TH, 1987, NEW ENGL J MED, V316, P15, DOI 10.1056/NEJM198701013160104; VOLPE R, 1987, NEW ENGL J MED, V316, P44, DOI 10.1056/NEJM198701013160109; WEETMAN AP, 1990, J ENDOCRINOL, V127, P357, DOI 10.1677/joe.0.1270357; WEETMAN AP, 1990, CLIN EXP IMMUNOL, V82, P69; WEETMAN AP, 1982, CLIN EXP IMMUNOL, V48, P196; WEETMAN AP, 1989, CLIN EXP IMMUNOL, V77, P25; WEETMAN AP, 1984, CLIN ENDOCRINOL, V21, P163, DOI 10.1111/j.1365-2265.1984.tb03456.x; WERNER SC, 1972, NEW ENGL J MED, V287, P421, DOI 10.1056/NEJM197208312870901; WOOD LC, 1979, J CLIN INVEST, V64, P1429, DOI 10.1172/JCI109601; YOUNG RJ, 1976, J CLIN PATHOL, V29, P398, DOI 10.1136/jcp.29.5.398; ZHENG RQH, 1991, CLIN EXP IMMUNOL, V83, P314	32	83	84	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 12	1992	340	8820					633	636						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM851	1381035				2022-12-28	WOS:A1992JM85100004
J	LOWENSTEIN, CJ; SNYDER, SH				LOWENSTEIN, CJ; SNYDER, SH			NITRIC-OXIDE, A NOVEL BIOLOGIC MESSENGER	CELL			English	Article							SYNTHASE; GLUTAMATE		JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT,BALTIMORE,MD 21205	Johns Hopkins University	LOWENSTEIN, CJ (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205, USA.			Lowenstein, Charles/0000-0003-0485-7514				BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRUNE B, 1990, ARCH BIOCHEM BIOPHYS, V279, P286, DOI 10.1016/0003-9861(90)90493-I; BURNETT AL, 1992, SCIENCE, V257, P401, DOI 10.1126/science.1378650; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; KOTS AY, 1992, FEBS LETT, V300, P9, DOI 10.1016/0014-5793(92)80153-8; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LWOENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MCMILLAN K, 1992, IN PRESS P NATL ACAD; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; NOWICKI JP, 1991, EUR J PHARMACOL, V204, P339, DOI 10.1016/0014-2999(91)90862-K; POU S, 1992, IN PRESS J BIOL CHEM; VERMA A, 1992, IN PRESS SCIENCE; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; ZHANG J, 1992, IN PRESS P NATL ACAD	24	732	768	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 4	1992	70	5					705	707		10.1016/0092-8674(92)90301-R	http://dx.doi.org/10.1016/0092-8674(92)90301-R			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JL663	1381285				2022-12-28	WOS:A1992JL66300001
J	HART, J; GORDON, B				HART, J; GORDON, B			NEURAL SUBSYSTEMS FOR OBJECT KNOWLEDGE	NATURE			English	Article							OPTIC APHASIA; LANGUAGE; IMPAIRMENT; CATEGORIES; SYSTEMS; MEMORY; VISION	CRITICAL issues in the cognitive neuroscience of language are whether there are multiple systems for the representation of meaning, perhaps organized by processing system (such as vision or language1-6), and whether further subsystems are distinguishable within these larger ones. We describe here a patient (K.R.) with cerebral damage whose pattern of acquired deficits offers direct evidence for a major division between visually based and language-based higher-level representations, and for processing subsystems within language. K.R. could not name animals regardless of the type of presentation (auditory or visual), but had no difficulty naming other living things and objects. When asked to describe verbally the physical attributes of animals (for example, 'what colour is an elephant?'), she was strikingly impaired. Nevertheless, she could distinguish the correct physical attributes of animals when they were presented visually (she could distinguish animals that were correctly coloured from those that were not). Her knowledge of other animal properties was completely intact, regardless of input stimulus. To explain this selective deficit, these data mandate the existence of two distinct representations of such properties in normal individuals, one visually based and one language-based. Furthermore, these data establish that knowledge of physical attributes is strictly segregated from knowledge of other properties in the language system.	JOHNS HOPKINS UNIV HOSP, DEPT PSYCHOL, DIV COGNIT NEUROL NEUROPSYCHOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV HOSP, CTR EPILEPSY, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV HOSP, ZANVYL KRIEGER MIND BRAIN INST, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	HART, J (corresponding author), JOHNS HOPKINS UNIV HOSP, DEPT NEUROL, BALTIMORE, MD 21205 USA.			Hart, John/0000-0003-3919-8125				BEAUVOIS MF, 1982, PHILOS T R SOC B, V298, P35, DOI 10.1098/rstb.1982.0070; CARAMAZZA A, 1990, COGNITIVE NEUROPSYCH, V7, P161, DOI 10.1080/02643299008253441; COUGHLAN AK, 1981, J NEUROL NEUROSUR PS, V44, P1079, DOI 10.1136/jnnp.44.12.1079; DAMASIO AR, 1989, COGNITION, V33, P25, DOI 10.1016/0010-0277(89)90005-X; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; Goodglass H., 1983, REVISED BOSTON NAMIN; Goodglass H., 1983, ASSESSMENT APHASIA R, V2nd; HART J, 1990, ANN NEUROL, V27, P226, DOI 10.1002/ana.410270303; LINDE J, 1982, J EXP PSYCHOL LEARN, V8, P584; MCCARTHY RA, 1988, NATURE, V334, P428, DOI 10.1038/334428a0; MESULAM MM, 1990, ANN NEUROL, V28, P597, DOI 10.1002/ana.410280502; OGDEN JA, 1985, BRAIN, V108, P1009, DOI 10.1093/brain/108.4.1009; Paivio, 1986, MENTAL REPRESENTATIO; Paivio A, 1971, IMAGERY VERBAL PROCE; RAPCSAK SZ, 1989, NEUROPSYCHOLOGIA, V27, P1031, DOI 10.1016/0028-3932(89)90183-8; RIDDOCH MJ, 1987, COGN NEUROPSYCHOL, V4, P131, DOI 10.1080/02643298708252038; RIDDOCH MJ, 1988, COGNITIVE NEUROPSYCH, V5, P143; ROSCH E, 1975, J EXP PSYCHOL GEN, V104, P192, DOI 10.1037/0096-3445.104.3.192; SARTORI G, 1988, COGNITIVE NEUROPSYCH, V5, P105, DOI 10.1080/02643298808252928; SHALLICE T, 1988, COGNITIVE NEUROPSYCH, V5, P133, DOI 10.1080/02643298808252929; SHALLICE T, 1988, NEUROPSYCHOLOGY MENT, P269; Shallice T., 1987, COGNITIVE NEUROPSYCH, P111; SILVERI MC, 1988, COGNITIVE NEUROPSYCH, V5, P677, DOI 10.1080/02643298808253278; SILVERI MC, 1991, NEUROLOGY, V41, P545, DOI 10.1212/WNL.41.4.545; SNODGRASS JG, 1980, J EXP PSYCHOL-HUM L, V6, P174, DOI 10.1037/0278-7393.6.2.174; STEWART F, 1992, Q J EXP PSYCHOL-A, V44, P261, DOI 10.1080/02724989243000037; WARRINGTON EK, 1984, BRAIN, V107, P829, DOI 10.1093/brain/107.3.829; WARRINGTON EK, 1987, BRAIN, V110, P1273, DOI 10.1093/brain/110.5.1273; WARRINGTON EK, 1983, BRAIN, V106, P859, DOI 10.1093/brain/106.4.859; ZIMLER J, 1983, J EXP PSYCHOL LEARN, V9, P269, DOI 10.1037/0278-7393.9.2.269	30	223	225	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 3	1992	359	6390					60	64		10.1038/359060a0	http://dx.doi.org/10.1038/359060a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL662	1381810				2022-12-28	WOS:A1992JL66200053
J	DENNING, GM; ANDERSON, MP; AMARA, JF; MARSHALL, J; SMITH, AE; WELSH, MJ				DENNING, GM; ANDERSON, MP; AMARA, JF; MARSHALL, J; SMITH, AE; WELSH, MJ			PROCESSING OF MUTANT CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR IS TEMPERATURE-SENSITIVE	NATURE			English	Article							CFTR CHLORIDE CHANNEL; INTRACELLULAR-TRANSPORT; R-DOMAIN; GENE; IDENTIFICATION; EXPRESSION; CELLS; PHOSPHORYLATION; EXERCISE	CYSTIC fibrosis transmembrane conductance regulator (CFTR) is a plasma membrane Cl- channel regulated by cyclic AMP-dependent phosphorylation and by intracellular ATP1-7. Mutations in CFTR cause cystic fibrosis8-10 partly through loss of cAMP-regulated Cl- permeability from the plasma membrane of affected epithelia11,12. The most common mutation in cystic fibrosis is deletion of phenylalanine at residue 508 (CFTR-DELTA-F508) (ref. 10). Studies on the biosynthesis13,14 and localization15 of CFTR-DELTA-F508 indicate that the mutant protein is not processed correctly and, as a result, is not delivered to the plasma membrane. These conclusions are consistent with earlier functional studies which failed to detect cAMP-stimulated Cl- channels in cells expressing CFTR-DELTA-F508 (refs 16, 17). Chloride channel activity was detected, however, when CFTR-DELTA-F508 was expressed in Xenopus oocytes18, Vero cells19 and Sf9 insect cells20. Because oocytes and Sf9 cells are typically maintained at lower temperatures than mammalian cells, and because processing of nascent proteins can be sensitive to temperature21, we tested the effect of temperature on the processing of CFTR-DELTA-F508. Here we show that the processing of CFTR-DELTA-F508 reverts towards that of wild-type as the incubation temperature is reduced. When the processing defect is corrected, cAMP-regulated Cl- channels appear in the plasma membrane. These results reconcile previous contradictory observations and suggest that the mutant most commonly associated with cystic fibrosis is temperature-sensitive.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; GENZYME CORP,FRAMINGHAM,MA 01701	Howard Hughes Medical Institute; University of Iowa; Sanofi-Aventis; Genzyme Corporation	DENNING, GM (corresponding author), UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED,IOWA CITY,IA 52242, USA.		Denning, Gerene M/D-1077-2009	Denning, Gerene/0000-0002-2334-993X; Anderson, Matthew/0000-0003-4602-1811; Marshall, John/0000-0003-1361-2869; Welsh, Michael/0000-0002-1646-6206				ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BEAR C E, 1992, Biophysical Journal, V61, pA127; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; BOAT TF, 1989, METABOLIC BASIS INHE, V6, P2649; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; DALEMANS W, 1991, NATURE, V354, P52; DEAL EC, 1979, J APPL PHYSIOL, V46, P484, DOI 10.1152/jappl.1979.46.3.484; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; GILBERT IA, 1987, J APPL PHYSIOL, V63, P1681, DOI 10.1152/jappl.1987.63.4.1681; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MACHAMER CE, 1988, J BIOL CHEM, V263, P5955; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0	25	1066	1095	0	72	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 27	1992	358	6389					761	764		10.1038/358761a0	http://dx.doi.org/10.1038/358761a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JK699	1380673				2022-12-28	WOS:A1992JK69900055
J	BIRKHEAD, JS				BIRKHEAD, JS			TIME DELAYS IN PROVISION OF THROMBOLYTIC TREATMENT IN 6 DISTRICT HOSPITALS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE MYOCARDIAL-INFARCTION; SYMPTOMS; THERAPY	Objective-To measure the delays between onset of symptoms and admission to hospital and provision of thrombolysis in patients with possible acute myocardial infarction. Design-Observational study of patients admitted with suspected myocardial infarction during six months. Setting- Six district general hospitals in Britain. Subjects-1934 patients admitted with suspected myocardial infarction. Main outcome measures-Route of admission to hospital and time to admission and thrombolysis. Results-Patients who made emergency calls did so sooner after onset of symptoms than those who called their doctor (median time 40 (95% confidence interval 30 to 52) minutes v 70 (60 to 90) minutes). General practitioners took a median of 20 (20 to 25) minutes to visit patients, rising to 30 (20 to 30) minutes during 0800-1200. The median time from call to arrival in hospital was 41 (38 to 47) minutes for patients who called an ambulance from home and 90 (90 to 94) minutes for those who contacted their doctor. The median time from arrival at hospital to thrombolysis was 80 (75 to 85) minutes for patients who were treated in the cardiac care unit and 31 (25 to 35) minutes for those treated in the accident and emergency department. Conclusion-The time from onset of symptoms to thrombolysis could be reduced substantially by more effective use of emergency services and faster provision of thrombolysis in accident and emergency departments.			BIRKHEAD, JS (corresponding author), NORTHAMPTON GEN HOSP, DEPT MED, NORTHAMPTON NN1 5BD, ENGLAND.							[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, Lancet, V1, P397; CAMERON M, 1975, BRIT MED J, V1, P384, DOI 10.1136/bmj.1.5954.384; COLLING A, 1976, BRIT MED J, V2, P1169, DOI 10.1136/bmj.2.6045.1169; EMERSON PA, 1989, Q J MED, V70, P213; KENNEDY JW, 1989, AM J CARDIOL, V64, pA8, DOI 10.1016/0002-9149(89)90922-3; KEREIAKES DJ, 1990, AM HEART J, V120, P773, DOI 10.1016/0002-8703(90)90192-Z; KOREN G, 1985, NEW ENGL J MED, V313, P1384, DOI 10.1056/NEJM198511283132204; LEIZOROVICZ A, 1988, EUR HEART J, V9, P118; MATHEY DG, 1985, J AM COLL CARDIOL, V6, P518, DOI 10.1016/S0735-1097(85)80107-8; PANTRIDG.JF, 1967, LANCET, V2, P271; PARRY G, 1991, BRIT HEART J, V66, P39; PELL ACH, 1992, BMJ-BRIT MED J, V304, P83, DOI 10.1136/bmj.304.6819.83; RAWLES JM, 1990, EUR HEART J, V11, P643, DOI 10.1093/oxfordjournals.eurheartj.a059770; RAWLES JM, 1989, ABERDEEN POSTGRAD ME, V23, P1; ROWLEY JM, 1992, BRIT HEART J, V67, P255; SCHROEDER JS, 1978, AM J MED, V64, P742, DOI 10.1016/0002-9343(78)90512-0; SHARKEY SW, 1989, JAMA-J AM MED ASSOC, V262, P3171, DOI 10.1001/jama.262.22.3171; SMYLLIE HC, 1972, BRIT MED J, V1, P34, DOI 10.1136/bmj.1.5791.34; WILCOX RG, 1988, LANCET, V2, P525; 1987, LANCET, V1, P871	21	109	109	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 22	1992	305	6851					445	448		10.1136/bmj.305.6851.445	http://dx.doi.org/10.1136/bmj.305.6851.445			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK680	1392956	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992JK68000020
J	LINDQUIST, M; EDWARDS, IR				LINDQUIST, M; EDWARDS, IR			ENDOCRINE ADVERSE-EFFECTS OF OMEPRAZOLE	BRITISH MEDICAL JOURNAL			English	Article							GYNECOMASTIA; THERAPY				LINDQUIST, M (corresponding author), WHO,COLLABORATING CTR INT DRUG MONITORING,BOX 26,S-75103 UPPSALA,SWEDEN.							CONVENS C, 1991, LANCET, V338, P1153, DOI 10.1016/0140-6736(91)92018-W; GUGLER R, 1984, LANCET, V1, P969; JENSEN JC, 1986, BRIT J CLIN PHARMACO, V21, P328, DOI 10.1111/j.1365-2125.1986.tb05199.x; SANTUCCI L, 1991, NEW ENGL J MED, V324, P635	4	46	47	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 22	1992	305	6851					451	452		10.1136/bmj.305.6851.451	http://dx.doi.org/10.1136/bmj.305.6851.451			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK680	1392958	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JK68000022
J	TEASDALE, S				TEASDALE, S			PARTNERS IN PRACTICE - MANAGEMENT AND ADMINISTRATION .5.	BRITISH MEDICAL JOURNAL			English	Article											TEASDALE, S (corresponding author), LINCOLNSHIRE MED AUDIT ADVISORY GRP,LINCOLN LN4 2JE,ENGLAND.							DRURY M, 1989, NEW PRACTICE MANAGER; 1987, CMND249; 1989, CMND849; 1989, CMND555	4	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 22	1992	305	6851					454	456		10.1136/bmj.305.6851.454	http://dx.doi.org/10.1136/bmj.305.6851.454			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK680	1392960	Bronze, Green Submitted, Green Published			2022-12-28	WOS:A1992JK68000024
J	CICCHETTI, P; MAYER, BJ; THIEL, G; BALTIMORE, D				CICCHETTI, P; MAYER, BJ; THIEL, G; BALTIMORE, D			IDENTIFICATION OF A PROTEIN THAT BINDS TO THE SH3 REGION OF ABI AND IS SIMILAR TO BCR AND GAP-RHO	SCIENCE			English	Article							C-ABL; SIGNAL TRANSDUCTION; REGULATORY DOMAIN; TRANSFORMATION; HOMOLOGY; LEUKEMIA	A Src homology 3 (SH3) region is a sequence of approximately 50 amino acids found in many nonreceptor tyrosine kinases and other proteins. Deletion of the SH3 region from the protein encoded by the c-abl proto-oncogene activates the protein's transforming capacity, thereby suggesting the participation of the SH3 region in the negative regulation of transformation. A complementary DNA was isolated that encoded a protein, 3BP-1, to which the SH3 region of Abl bound with high specificity and to which SH3 regions from other proteins bound differentially. The sequence of the 3BP-1 protein is similar to that of a COOH-terminal segment of Bcr and to guanosine triphosphatase-activating protein (GAP)-rho, which suggests that it might have GAP activity for Ras-related proteins. The 3BP-1 protein may therefore be a mediator of SH3 function in transformation inhibition and may link tyrosine kinases to Ras-related proteins.	ROCKEFELLER UNIV,NEW YORK,NY 10021	Rockefeller University					NCI NIH HHS [CA51462, CA 08875] Funding Source: Medline; PHS HHS [A107233] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051462, F32CA008875] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHENEVERT J, 1992, NATURE, V356, P77, DOI 10.1038/356077a0; CICCHETTI P, UNPUB; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; FRY M J, 1992, Current Biology, V2, P78, DOI 10.1016/0960-9822(92)90207-Q; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HIRAI J, 1990, MOL CELL BIOL, V10, P1307; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PEAR WS, UNPUB; Potts W M, 1988, Oncogene Res, V3, P343; PRYWES R, 1985, J VIROL, V54, P123, DOI 10.1128/JVI.54.1.123-132.1985; PRYWES R, 1983, CELL, V34, P569, DOI 10.1016/0092-8674(83)90389-6; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SINGH H, 1989, BIOTECHNIQUES, V7, P252	27	513	537	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 7	1992	257	5071					803	806		10.1126/science.1379745	http://dx.doi.org/10.1126/science.1379745			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG851	1379745				2022-12-28	WOS:A1992JG85100037
J	PYLE, AM; MURPHY, FL; CECH, TR				PYLE, AM; MURPHY, FL; CECH, TR			RNA SUBSTRATE BINDING-SITE IN THE CATALYTIC CORE OF THE TETRAHYMENA RIBOZYME	NATURE			English	Article							CIRCULARIZED INTERVENING SEQUENCE; GROUP-I INTRON; RIBOSOMAL-RNA; ACTIVE-SITE; PRE-RRNA; OLIGONUCLEOTIDE; SPECIFICITY; CLEAVAGE; ENZYME; COMPLEMENTARY	In catalysis by group I introns, the helix (P1) containing the RNA cleavage site must be positioned next to the guanosine binding site. We have identified a conserved adenine in the catalytic core that contributes to the stability of this arrangement and propose that it accepts a hydrogen bond from a specific 2'-OH in P1. Such base-backbone tertiary interactions may be generally important to the organization of RNA tertiary structure.	UNIV COLORADO, HOWARD HUGHES MED INST, BOULDER, CO 80309 USA; UNIV COLORADO, DEPT CHEM & BIOCHEM, BOULDER, CO 80309 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder								BARFOD ET, 1989, MOL CELL BIOL, V9, P3657, DOI 10.1128/MCB.9.9.3657; BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; BEVILACQUA PC, 1991, BIOCHEMISTRY-US, V30, P10632, DOI 10.1021/bi00108a005; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; CURTISS LA, 1978, J AM CHEM SOC, V100, P79, DOI 10.1021/ja00469a013; DAVIES RW, 1982, NATURE, V300, P719, DOI 10.1038/300719a0; DOCKBREGEON AC, 1989, J MOL BIOL, V209, P459, DOI 10.1016/0022-2836(89)90010-7; DOUDNA JA, 1989, P NATL ACAD SCI USA, V86, P7402, DOI 10.1073/pnas.86.19.7402; DOUDNA JA, 1989, NATURE, V339, P519, DOI 10.1038/339519a0; FORSTER AC, 1990, SCIENCE, V249, P783, DOI 10.1126/science.1697102; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; GUSCHLBAUER W, 1980, NUCLEIC ACIDS RES, V8, P1421, DOI 10.1093/nar/8.6.1421; HERSCHLAG D, 1992, BIOCHEMISTRY-US, V31, P1386, DOI 10.1021/bi00120a015; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; HOLBROOK SR, 1991, NATURE, V353, P579, DOI 10.1038/353579a0; HUANG JF, 1989, J AM CHEM SOC, V111, P6909, DOI 10.1021/ja00200a003; INOUE T, 1985, P NATL ACAD SCI USA, V82, P648, DOI 10.1073/pnas.82.3.648; JANIK B, 1972, BIOCHEM BIOPH RES CO, V46, P1153, DOI 10.1016/S0006-291X(72)80095-0; KIM SH, 1987, P NATL ACAD SCI USA, V84, P8788, DOI 10.1073/pnas.84.24.8788; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LATHAM JA, 1989, SCIENCE, V245, P276, DOI 10.1126/science.2501870; MICHEL F, 1990, NATURE, V347, P578, DOI 10.1038/347578a0; MICHEL F, 1982, BIOCHIMIE, V64, P867, DOI 10.1016/S0300-9084(82)80349-0; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MOAZED D, 1986, J MOL BIOL, V187, P399, DOI 10.1016/0022-2836(86)90441-9; MURRAYRUST P, 1983, J AM CHEM SOC, V105, P3206, DOI 10.1021/ja00348a041; PACE NR, 1990, J BIOL CHEM, V265, P3587; PIEKEN WA, 1991, SCIENCE, V253, P314, DOI 10.1126/science.1857967; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; QUIGLEY GJ, 1976, SCIENCE, V194, P796, DOI 10.1126/science.790568; SUGIMOTO N, 1989, CHEM LETT, P2223, DOI 10.1246/cl.1989.2223; SUGIMOTO N, 1988, BIOCHEMISTRY-US, V27, P6384, DOI 10.1021/bi00417a029; SULLIVAN FX, 1985, CELL, V42, P639, DOI 10.1016/0092-8674(85)90121-7; TAKAHASHI LH, 1989, J AM CHEM SOC, V111, P3368, DOI 10.1021/ja00191a039; WARING RB, 1986, NATURE, V321, P133, DOI 10.1038/321133a0; WEEKS KM, 1991, CELL, V66, P577, DOI 10.1016/0092-8674(81)90020-9; WILLIAMS DM, 1992, P NATL ACAD SCI USA, V89, P918, DOI 10.1073/pnas.89.3.918; WILLIAMSON CL, 1987, J BIOL CHEM, V262, P14672; WITHERS SG, 1988, ACS SYM SER, V374, P59; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	45	204	209	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 9	1992	358	6382					123	131		10.1038/358123a0	http://dx.doi.org/10.1038/358123a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC583	1377367				2022-12-28	WOS:A1992JC58300042
J	HAHN, WC; MENU, E; BOTHWELL, ALM; SIMS, PJ; BIERER, BE				HAHN, WC; MENU, E; BOTHWELL, ALM; SIMS, PJ; BIERER, BE			OVERLAPPING BUT NONIDENTICAL BINDING-SITES ON CD2 FOR CD58 AND A 2ND LIGAND CD59	SCIENCE			English	Article							T-CELL ACTIVATION; THYMIC EPITHELIAL-CELLS; MEMBRANE-PROTEIN; SURFACE LIGAND; RECEPTOR CD2; LFA-3; COMPLEMENT; ANTIGEN; EXPRESSION; MOLECULES	The interaction of the T cell glycoprotein CD2 with one ligand, CD58, contributes to T cell function. We have identified CD59, a glycoprotein with complement-inhibitory function, as a second physiological ligand for CD2. Antibodies to CD59 inhibit CD2-dependent T cell activation in murine T cell hybridomas expressing human CD2. In an in vitro binding assay with purified CD58 and CD59, CD2+ cells bind not only immobilized CD58 but also CD59. With two complementary approaches, it was demonstrated that the binding sites on CD2 for CD58 and CD59 are overlapping but nonidentical. These observations suggest that direct interactions between CD2 and both CD58 and CD59 contribute to T cell activation and adhesion.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02115; OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,OKLAHOMA CITY,OK 73104; OKLAHOMA STATE UNIV,HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,OKLAHOMA CITY,OK 73104; BRIGHAM & WOMENS HOSP,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06510	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Oklahoma Medical Research Foundation; Oklahoma State University System; Oklahoma State University Center for Health Sciences; Oklahoma State University - Stillwater; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Yale University			MENU, Elisabeth/B-2886-2010	MENU, Elisabeth/0000-0001-8844-9328; Bierer, Barbara/0000-0001-6448-8170	NHLBI NIH HHS [HL36061] Funding Source: Medline; NIAID NIH HHS [AI28554] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036061, R37HL036061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI028554, R01AI028554] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERNARD A, 1987, J IMMUNOL, V139, P18; BIERER BE, 1988, P NATL ACAD SCI USA, V85, P1194, DOI 10.1073/pnas.85.4.1194; BIERER BE, 1989, ANNU REV IMMUNOL, V7, P579, DOI 10.1146/annurev.immunol.7.1.579; DAVIES A, 1989, J EXP MED, V170, P637, DOI 10.1084/jem.170.3.637; DECKERT M, 1992, J IMMUNOL, V148, P672; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DRISCOLL PC, 1991, NATURE, V353, P762, DOI 10.1038/353762a0; GILLIS S, 1978, J IMMUNOL, V120, P2027; GROUX H, 1989, J IMMUNOL, V142, P3013; HAHN W, UNPUB; HAHN WC, 1991, J IMMUNOL, V147, P14; HAHN WC, IN PRESS P NATL ACAD; HARADA R, 1990, J IMMUNOL, V144, P1823; HOLGUIN MH, 1989, J CLIN INVEST, V84, P7, DOI 10.1172/JCI114172; HUNIG T, 1987, NATURE, V326, P298, DOI 10.1038/326298a0; KORTY PE, 1991, J IMMUNOL, V146, P4092; LE PT, 1990, J IMMUNOL, V144, P4541; MCMICHAEL AJ, 1987, LEUKOCYTE TYPING 3; OKADA H, 1989, BIOCHEM BIOPH RES CO, V162, P1553, DOI 10.1016/0006-291X(89)90852-8; PETERSON A, 1987, NATURE, V329, P842, DOI 10.1038/329842a0; ROLLINS SA, 1990, J IMMUNOL, V144, P3478; ROSENSTEIN Y, 1991, NATURE, V354, P233, DOI 10.1038/354233a0; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SELVARAJ P, 1987, NATURE, V326, P400, DOI 10.1038/326400a0; SHAW S, 1986, NATURE, V323, P262, DOI 10.1038/323262a0; SIMS PJ, 1982, P NATL ACAD SCI USA, V264, P19228; SLECKMAN BP, 1987, NATURE, V328, P351, DOI 10.1038/328351a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; TAKAI Y, 1987, P NATL ACAD SCI USA, V84, P6864, DOI 10.1073/pnas.84.19.6864; VOLLGER LW, 1987, J IMMUNOL, V138, P358; WEBB DSA, 1990, SCIENCE, V249, P1295, DOI 10.1126/science.1697984; WHITLOW MB, 1990, CELL IMMUNOL, V126, P176, DOI 10.1016/0008-8749(90)90310-N; WOLFF HL, 1990, J IMMUNOL, V144, P1215	37	179	183	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 26	1992	256	5065					1805	1807		10.1126/science.1377404	http://dx.doi.org/10.1126/science.1377404			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA434	1377404				2022-12-28	WOS:A1992JA43400032
J	HENRICH, JB				HENRICH, JB			THE POSTMENOPAUSAL ESTROGEN BREAST-CANCER CONTROVERSY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							REPLACEMENT THERAPY; EXOGENOUS ESTROGENS; WOMENS HEALTH; HORMONE USE; RISK; EPIDEMIOLOGY; ASSOCIATION; MORTALITY	Objective.-To provide an overview of the postmenopausal estrogen/breast cancer controversy emphasizing the sources of disagreement in the literature and their clinical and research implications. Data Source and Selection.-A MEDLINE search of the English-language literature and a review of bibliographies of meta-analyses describing the association between postmenopausal estrogen use and breast cancer risk. Data Extraction.-Twenty-four original articles and three meta-analyses were reviewed. In addition, five studies that attempted to minimize detection bias were reviewed to assess the potential role of this bias on risk estimates. Data Synthesis.-Among the original articles, risk estimates ranged from a protective to an adverse effect in women who ever used estrogens; no consistent quantitative effects of estrogens on breast cancer risk were found. In the meta-analyses, summary risk estimates were not significantly elevated in women who ever used estrogen. Findings from European-based studies may account for the increased risk associated with increasing duration of use reported in one meta-analysis. In studies that controlled for detection bias, risk estimates were 1 or less in the ever-used category; there was no consistent effect across other categories of use. Conclusion.-These findings do not support an overall increased risk of breast cancer in women who ever used postmenopausal estrogens or a conclusive or consistent effect across other measures of use. Cross-national differences in estrogen use and inequalities in breast cancer detection between estrogen users and nonusers may account for the increased risk estimates reported in some studies. Newer estrogen and progestin-opposed regimens need to be evaluated further.	YALE UNIV,SCH MED,DEPT MED,NEW HAVEN,CT 06510	Yale University								BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; BERGKVIST L, 1989, AM J EPIDEMIOL, V130, P221, DOI 10.1093/oxfordjournals.aje.a115328; BRINTON LA, 1986, BRIT J CANCER, V54, P825, DOI 10.1038/bjc.1986.246; BROWNSON RC, 1988, ARCH INTERN MED, V148, P140, DOI 10.1001/archinte.148.1.140; BURING JE, 1987, AM J EPIDEMIOL, V125, P939, DOI 10.1093/oxfordjournals.aje.a114632; COLDITZ GA, 1990, JAMA-J AM MED ASSOC, V264, P2648, DOI 10.1001/jama.264.20.2648; DUPONT WD, 1991, ARCH INTERN MED, V151, P67, DOI 10.1001/archinte.151.1.67; DUPONT WD, 1989, CANCER-AM CANCER SOC, V63, P948, DOI 10.1002/1097-0142(19890301)63:5<948::AID-CNCR2820630527>3.0.CO;2-U; EWERTZ M, 1988, INT J CANCER, V42, P832, DOI 10.1002/ijc.2910420606; GAMBRELL RD, 1983, OBSTET GYNECOL, V62, P435; HEALY B, 1991, JAMA-J AM MED ASSOC, V266, P566, DOI 10.1001/jama.266.4.566; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; HENDERSON IC, 1991, CANCER SOC NEWSLETTE, V2, P1; HIATT RA, 1984, CANCER, V54, P139, DOI 10.1002/1097-0142(19840701)54:1<139::AID-CNCR2820540128>3.0.CO;2-X; HOOVER R, 1981, J NATL CANCER I, V67, P815; HORWITZ RI, 1984, AM J MED, V76, P192, DOI 10.1016/0002-9343(84)90773-3; HULKA BS, 1982, AM J OBSTET GYNECOL, V143, P638, DOI 10.1016/0002-9378(82)90108-9; HUNT K, 1987, BRIT J OBSTET GYNAEC, V94, P620, DOI 10.1111/j.1471-0528.1987.tb03166.x; KAUFMAN DW, 1984, JAMA-J AM MED ASSOC, V252, P63, DOI 10.1001/jama.252.1.63; KAUFMAN DW, 1991, AM J EPIDEMIOL, V134, P1375, DOI 10.1093/oxfordjournals.aje.a116041; KELSEY JL, 1988, CANCER RES, V48, P5615; KELSEY JL, 1981, JNCI-J NATL CANCER I, V67, P327; LIPPMAN ME, 1986, BREAST CANCER RES TR, V7, P59, DOI 10.1007/BF01806790; MILLS PK, 1989, CANCER, V64, P591, DOI 10.1002/1097-0142(19890801)64:3<591::AID-CNCR2820640305>3.0.CO;2-U; NOMURA AMY, 1986, INT J CANCER, V37, P49, DOI 10.1002/ijc.2910370109; PALCA J, 1991, SCIENCE, V254, P792, DOI 10.1126/science.1948061; PALMER JR, 1991, AM J EPIDEMIOL, V134, P1386, DOI 10.1093/oxfordjournals.aje.a116042; ROHAN TE, 1988, MED J AUSTRALIA, V148, P217; ROSS RK, 1980, JAMA-J AM MED ASSOC, V243, P1635, DOI 10.1001/jama.243.16.1635; SHERMAN B, 1983, CANCER, V51, P1527, DOI 10.1002/1097-0142(19830415)51:8<1527::AID-CNCR2820510828>3.0.CO;2-T; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; THOMAS DB, 1982, JNCI-J NATL CANCER I, V69, P1017; WINGO PA, 1987, JAMA-J AM MED ASSOC, V257, P209, DOI 10.1001/jama.257.2.209	34	54	54	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1992	268	14					1900	1902		10.1001/jama.268.14.1900	http://dx.doi.org/10.1001/jama.268.14.1900			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR439	1404715				2022-12-28	WOS:A1992JR43900040
J	HORTOBAGYI, GN				HORTOBAGYI, GN			DIAGNOSTIC BREAST IMAGING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											HORTOBAGYI, GN (corresponding author), TEXAS MED CTR,MD ANDERSON CANC CTR,HOUSTON,TX 77025, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1992	268	14					1926	1926						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR439	1404721				2022-12-28	WOS:A1992JR43900047
J	OLSSON, S; EDWARDS, IR				OLSSON, S; EDWARDS, IR			TACHYCARDIA DURING CISAPRIDE TREATMENT	BRITISH MEDICAL JOURNAL			English	Article							METOCLOPRAMIDE				OLSSON, S (corresponding author), WHO,COLLABORATING CTR INT DRUG MONITORING,BOX 26,S-75103 UPPSALA,SWEDEN.							BEVACQUA BK, 1988, ANESTHESIOLOGY, V68, P124, DOI 10.1097/00000542-198801000-00021; CHERON G, 1991, PRESSE MED, V20, P1138; MCCALLUM RW, 1988, DRUGS, V36, P652, DOI 10.2165/00003495-198836060-00002; SHAKLAI M, 1974, BRIT MED J, V2, P385, DOI 10.1136/bmj.2.5915.385-a	4	77	78	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 26	1992	305	6856					748	749		10.1136/bmj.305.6856.748-a	http://dx.doi.org/10.1136/bmj.305.6856.748-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ520	1384896	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JQ52000023
J	LEE, EYHP; CHANG, CY; HU, NP; WANG, YCJ; LAI, CC; HERRUP, K; LEE, WH; BRADLEY, A				LEE, EYHP; CHANG, CY; HU, NP; WANG, YCJ; LAI, CC; HERRUP, K; LEE, WH; BRADLEY, A			MICE DEFICIENT FOR RB ARE NONVIABLE AND SHOW DEFECTS IN NEUROGENESIS AND HEMATOPOIESIS	NATURE			English	Article							RETINOBLASTOMA GENE-PRODUCT; LARGE T-ANTIGEN; CELL-CYCLE; SUSCEPTIBILITY GENE; TRANSCRIPTION FACTOR; MOUSE EMBRYO; ENCODED PROTEIN; CARCINOMA-CELLS; STEM-CELLS; BINDING	The retinoblastoma gene, a prototypic tumour-suppressor gene, encodes a nuclear phosphoprotein (Rb). To understand better the role of Rb in development and in tumorigenesis, mice with an insertional mutation in exon 20 of the Rb-1 locus were generated. Homozygous mutants die before the 16th embryonic day with multiple defects. The haematopoietic system is abnormal; there is a significant increase in the number of immature nucleated erythrocytes. In the nervous system, ectopic mitoses and massive cell death are found, particularly in the hindbrain. All spinal ganglion cells die, but the neural retina is unaffected. Transfer of the human retinoblastoma (RB) mini-transgene into the mutant mice corrects the developmental defects. Thus, Rb is essential for normal mouse development.	UNIV TEXAS, HLTH SCI CTR, INST BIOTECHNOL, SAN ANTONIO, TX 78284 USA; CASE WESTERN RESERVE UNIV, SCH MED, ALZHEIMER RES LAB, CLEVELAND, OH 44106 USA; BAYLOR COLL MED, INST MOLEC GENET, HOUSTON, TX 77030 USA	University of Texas System; University of Texas Health San Antonio; Case Western Reserve University; Baylor College of Medicine	LEE, EYHP (corresponding author), UNIV TEXAS, HLTH SCI CTR, CTR MOLEC MED, SAN ANTONIO, TX 78284 USA.		; Herrup, Karl/C-5313-2014	Bradley, Allan/0000-0002-2349-8839; Herrup, Karl/0000-0001-7786-5844				ABRAMSON DH, 1984, OPHTHALMOLOGY, V91, P1351; ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DRYJA TP, 1986, P NATL ACAD SCI USA, V83, P7391, DOI 10.1073/pnas.83.19.7391; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GOODRICH DW, 1992, CANCER RES, V52, P1968; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; Knudson A G Jr, 1989, Birth Defects Orig Artic Ser, V25, P15; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEE EYHP, 1991, PROG CLIN BIOL RES, V362, P221; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEE WH, 1990, TUMOUR SUPPRESSOR GE, P159; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MOORE MAS, 1970, BRIT J HAEMATOL, V18, P279, DOI 10.1111/j.1365-2141.1970.tb01443.x; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; VOGEL F, 1979, HUM GENET, V52, P1; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XU HJ, 1989, ONCOGENE, V4, P807	49	1150	1170	0	13	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 24	1992	359	6393					288	294		10.1038/359288a0	http://dx.doi.org/10.1038/359288a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP503	1406932				2022-12-28	WOS:A1992JP50300045
J	LAYBOURN, PJ; KADONAGA, JT				LAYBOURN, PJ; KADONAGA, JT			THRESHOLD PHENOMENA AND LONG-DISTANCE ACTIVATION OF TRANSCRIPTION BY RNA POLYMERASE-II	SCIENCE			English	Article							GAL4 DERIVATIVES; HYPERSENSITIVE SITES; INVITRO; GENE; NUCLEOSOME; PROTEINS	To explore the underlying mechanisms by which genes are regulated in eukaryotes, long-distance transcriptional activation and threshold effects were reconstituted in vitro. Long-range activation of transcription by GAL4-VP16 protein located 1300 base pairs upstream of the RNA start site was dependent on packaging of the template into histone H1-containing chromatin. A transcriptional threshold effect by GAL4-VP16 was observed with repressed chromatin templates but not naked DNA templates. The experimental data with the chromatin templates were similar to the theoretical activation profile that is predicted if the action of each DNA bound protomer of GAL4-VP16 were independent and additive in terms of free energy.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR MOLEC GENET, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego								BULGER MD, UNPUB; CAREY M, 1990, SCIENCE, V247, P710, DOI 10.1126/science.2405489; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; Croston G.E., 1991, Protein Expression and Purification, V2, P162, DOI 10.1016/1046-5928(91)90066-R; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; CROSTON GE, UNPUB; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HOUGH PVC, 1982, J MOL BIOL, V160, P375, DOI 10.1016/0022-2836(82)90183-8; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KORNBERG RD, 1991, CELL, V67, P833, DOI 10.1016/0092-8674(91)90354-2; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LAYBOURN PJ, UNPUB; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1992, J BIOL CHEM, V267, P679; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SERFLING E, 1985, TRENDS GENET, V1, P224, DOI 10.1016/0168-9525(85)90088-5; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; SINHA SN, 1982, NUCLEIC ACIDS RES, V10, P5533, DOI 10.1093/nar/10.18.5533; STJOHNSTON D, 1992, CELL, V68, P201; TAMAKA RT, 1991, P NATL ACAD SCI USA, V88, P1024; van Holde KE., 1989, SPRINGER SERIES MOL; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WOLFFE A P, 1990, New Biologist, V2, P211; ZAWEL L, IN PRESS PROG NUCLEI	36	96	97	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 18	1992	257	5077					1682	1685		10.1126/science.1388287	http://dx.doi.org/10.1126/science.1388287			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN501	1388287				2022-12-28	WOS:A1992JN50100031
J	PRINGLE, M				PRINGLE, M			PARTNERS IN PRACTICE - THE DEVELOPING PRIMARY CARE PARTNERSHIP	BRITISH MEDICAL JOURNAL			English	Article											PRINGLE, M (corresponding author), UNIV NOTTINGHAM,DEPT GEN PRACTICE,NOTTINGHAM NG7 2UH,ENGLAND.								0	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 12	1992	305	6854					624	626		10.1136/bmj.305.6854.624	http://dx.doi.org/10.1136/bmj.305.6854.624			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN698	1393078	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JN69800021
J	EDWARDS, FA; GIBB, AJ; COLQUHOUN, D				EDWARDS, FA; GIBB, AJ; COLQUHOUN, D			ATP RECEPTOR-MEDIATED SYNAPTIC CURRENTS IN THE CENTRAL-NERVOUS-SYSTEM	NATURE			English	Article							ADENOSINE-TRIPHOSPHATE; HIPPOCAMPAL SLICES; DORSAL HORN; NEURONS; CHANNELS; RELEASE; CELLS	UNTIL now, the only well documented, fast excitatory neurotransmitter in the brain has been glutamate. Although there is evidence for adenosine 5'-triphosphate (ATP) acting as a transmitter in the peripheral nervous system1-4, suggestions for such a role in the central nervous system1,5-11 have so far not been supported by any direct evidence. Here we report the recording of evoked and miniature synaptic currents in the rat medial habenula. The fast rise time of the currents showed that they were mediated by a ligand-activated ion channel rather than a second messenger system, thus limiting the known transmitter candidates. Evidence was found for the presence on the cells of glutamate, gamma-aminobutyric acid, acetylcholine and ATP receptors, but not for 5-hydroxytryptamine (5HT3) or glycine receptors. The evoked currents were unaffected by blockers of glutamate, gamma-aminobutyric acid or acetylcholine receptors but were blocked by the ATP receptor-blocker, suramin and the desensitizing ATP receptor-agonist alpha,beta-methylene-ATP. Our evidence identifies for the first time synaptic currents in the brain, mediated directly by ATP receptors.	UNIV LONDON UNIV COLL,DEPT PHARMACOL,LONDON WC1E 6BT,ENGLAND	University of London; University College London			Edwards, Frances/AAE-1755-2019; Gibb, Alasdair/AAL-1605-2020; Colquhoun, David/C-1664-2008	Colquhoun, David/0000-0002-4263-017X; Gibb, Alasdair/0000-0002-2145-1615	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEAN BP, 1992, TRENDS PHARMACOL SCI, V13, P87, DOI 10.1016/0165-6147(92)90032-2; BURNSTOCK G, 1985, GEN PHARMACOL, V16, P433, DOI 10.1016/0306-3623(85)90001-1; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; EVANS RJ, 1992, NATURE, V357, P503, DOI 10.1038/357503a0; FIEBER LA, 1991, J PHYSIOL-LONDON, V434, P239, DOI 10.1113/jphysiol.1991.sp018467; FYFFE REW, 1984, P NATL ACAD SCI-BIOL, V81, P6890, DOI 10.1073/pnas.81.21.6890; HOYLE CHV, 1991, ADENOSINE NERVOUS SY, pCH3; INOUE K, 1992, NEUROSCI LETT, V134, P215, DOI 10.1016/0304-3940(92)90520-H; JAHR CE, 1983, NATURE, V304, P730, DOI 10.1038/304730a0; KRISHTAL OA, 1988, NEUROSCIENCE, V27, P995, DOI 10.1016/0306-4522(88)90203-5; NAKAZAWA K, 1991, J PHYSIOL-LONDON, V434, P647, DOI 10.1113/jphysiol.1991.sp018491; NEUHAUS R, 1991, J NEUROSCI, V11, P3984; PHILLIS JW, 1974, CAN J PHYSIOL PHARM, V52, P1226, DOI 10.1139/y74-162; POTTER P, 1980, NEUROSCIENCE, V5, P1351, DOI 10.1016/0306-4522(80)90207-9; RICHARDSON PJ, 1986, BIOCHEM SOC T, V14, P1250, DOI 10.1042/bst0141250; SALTER MW, 1985, NEUROSCIENCE, V15, P815, DOI 10.1016/0306-4522(85)90080-6; SCHUBERT P, 1979, BRAIN RES, V168, P419, DOI 10.1016/0006-8993(79)90186-0; SILINSKY EM, 1992, BRIT J PHARMACOL, V106, P762, DOI 10.1111/j.1476-5381.1992.tb14408.x; TOKUNAGA A, 1978, BRAIN RES, V150, P600, DOI 10.1016/0006-8993(78)90823-5; TSCHOPL M, 1992, EUR J PHARMACOL, V213, P71, DOI 10.1016/0014-2999(92)90234-U; WHITE TD, 1978, J NEUROCHEM, V30, P329, DOI 10.1111/j.1471-4159.1978.tb06534.x; WIERASZKO A, 1989, BRAIN RES, V491, P356, DOI 10.1016/0006-8993(89)90070-X; WIERASZKO A, 1989, BRAIN RES, V485, P244, DOI 10.1016/0006-8993(89)90567-2; WILLIAMS M, 1987, PSYCHOPHARMACOLOGY 3, pCH30	24	729	738	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 10	1992	359	6391					144	147		10.1038/359144a0	http://dx.doi.org/10.1038/359144a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM494	1381811				2022-12-28	WOS:A1992JM49400051
J	JONES, DJ				JONES, DJ			ABC OF COLORECTAL DISEASES - PRURITUS ANI	BRITISH MEDICAL JOURNAL			English	Article											JONES, DJ (corresponding author), HOPE HOSP,GEN SURG,SALFORD M6 8HD,LANCS,ENGLAND.			Jones, David/0000-0001-5743-8562					0	11	11	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 5	1992	305	6853					575	577		10.1136/bmj.305.6853.575	http://dx.doi.org/10.1136/bmj.305.6853.575			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM495	1393040	Bronze, Green Submitted, Green Published			2022-12-28	WOS:A1992JM49500024
J	WAKABAYASHI, I; SAKAMOTO, K; YOSHIMOTO, S; MASUI, H				WAKABAYASHI, I; SAKAMOTO, K; YOSHIMOTO, S; MASUI, H			RELATION OF SERUM SIALIC-ACID TO LIPID CONCENTRATIONS	BRITISH MEDICAL JOURNAL			English	Article											WAKABAYASHI, I (corresponding author), HYOGO MED UNIV,DEPT HYG,1-1 MUKOGAWA CHO,NISHINOMIYA,HYOGO 663,JAPAN.							COMB DG, 1960, J BIOL CHEM, V235, P2529; LINDBERG G, 1991, BRIT MED J, V303, P1306, DOI 10.1136/bmj.303.6813.1306; LINDBERG G, 1991, BRIT MED J, V302, P143, DOI 10.1136/bmj.302.6769.143; RADHAKRISHNAMURTHY B, 1976, LAB INVEST, V34, P159; SHVARTZ OLS, 1971, PROBLEMY ENDOKRINOLO, V17, P37	5	35	35	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 5	1992	305	6853					562	563		10.1136/bmj.305.6853.562	http://dx.doi.org/10.1136/bmj.305.6853.562			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM495	1393037	Green Published, Green Submitted			2022-12-28	WOS:A1992JM49500019
J	JOSEPH, CA; WATSON, JM; FERN, KJ				JOSEPH, CA; WATSON, JM; FERN, KJ			BCG IMMUNIZATION IN ENGLAND AND WALES - A SURVEY OF POLICY AND PRACTICE IN SCHOOLCHILDREN AND NEONATES	BRITISH MEDICAL JOURNAL			English	Article							VACCINATION; TUBERCULOSIS	Objective-To determine the policy and practice of district health authorities in England and Wales for BCG immunisation in schoolchildren and neonates. Design-Self completion postal questionnaire survey. Participants-District immunisation coordinators. Setting-199 district health authorities in England and Wales. Results-Questionnaires were received from 186 districts, a response rate of 94%. Considerable uniformity was observed in many aspects of BCG immunisation policy and practice but some important variations were found. 15 districts no longer carry out a routine schools programme. 148 districts offer BCG to selected groups of neonates and five to all neonates, but 31 districts do not offer BCG to this age group. The recommended action in response to different levels of tuberculin sensitivity in schoolchildren and neonates varied among districts. Conclusions-Despite the recommendations of the Joint Committee on Vaccination and Immunisation some districts do not offer BCG immunisation to neonates at high risk of tuberculosis and there are important variations in other aspects of BCG policy.			JOSEPH, CA (corresponding author), PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,RESP DIS SECT,LONDON NW9 KEQ,ENGLAND.							CITRON KM, 1990, BRIT MED J, V301, P1275, DOI 10.1136/bmj.301.6763.1275; CUNDALL DB, 1988, ARCH DIS CHILD, V63, P964, DOI 10.1136/adc.63.8.964; CURTIS HM, 1984, LANCET, V1, P145; Dean A. G., 1990, EPI INFO VERSION 5 W; FRANKENBERG RA, 1991, J PUBLIC HEALTH MED, V13, P209, DOI 10.1093/oxfordjournals.pubmed.a042620; MILLER CL, 1984, BRIT MED J, V288, P564, DOI 10.1136/bmj.288.6416.564; PACKE GE, 1988, ARCH DIS CHILD, V63, P277, DOI 10.1136/adc.63.3.277; RODRIGUES LC, 1991, J EPIDEMIOL COMMUN H, V45, P78, DOI 10.1136/jech.45.1.78; SPRINGETT VH, 1990, THORAX, V45, P83, DOI 10.1136/thx.45.2.83; SUTHERLAND I, 1989, J EPIDEMIOL COMMUN H, V43, P15, DOI 10.1136/jech.43.1.15; Watson J M, 1991, CDR (Lond Engl Rev), V1, pR13; 1985, BMJ, V291, P658; IN PRESS IMMUNISATIO; 1974, COMMUNICABLE DISEASE; 1927, ANNUAL REPORT; 1985, SCH BCG VACCINATION	16	25	25	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 29	1992	305	6852					495	498		10.1136/bmj.305.6852.495	http://dx.doi.org/10.1136/bmj.305.6852.495			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL609	1392994	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JL60900015
J	VANOORTMARSSEN, GJ; HABBEMA, JDF; VANBALLEGOOIJEN, M				VANOORTMARSSEN, GJ; HABBEMA, JDF; VANBALLEGOOIJEN, M			PREDICTING MORTALITY FROM CERVICAL-CANCER AFTER NEGATIVE SMEAR TEST-RESULTS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To assess the relative protection against death from cervical cancer after two or more negative smear test results and compare it with the protection against invasive cancer estimated by an International Agency for Research on Cancer (IARC) working group in an analysis of data from 10 large screening programmes. Design-Comparison of risk of death from cervical cancer after two or more negative smear results with the risk in unscreened women by using a model constructed with data from the British Columbia screening programme. Main outcome measures - Mortality from and incidence of invasive cancer. Results-In women with two negative smear results estimates of protection against cervical cancer were about 50% higher when lethal invasive cancer was used as the criterion rather than all invasive cancer. This difference was due to these women being more likely to attend for further tests at which invasive cancer could be detected: screen detected cancer has a better prognosis than clinically diagnosed cancer. Screening intervals could be longer than three years: screening women aged 35-64 every five years was predicted to result in a 90% reduction in mortality from cervical cancer. Conclusion-Because protection from mortality is higher than protection from disease and because of the high costs and negative side effects of frequent screening, screening intervals should be longer than three years.			VANOORTMARSSEN, GJ (corresponding author), ERASMUS UNIV,FAC MED,DEPT PUBL HLTH & SOCIAL MED,POB 1738,3000 DR ROTTERDAM,NETHERLANDS.							BOYES DA, 1982, CLIN INVEST MED, V5, P1; ELLIOTT PM, 1989, BRIT MED J, V298, P288, DOI 10.1136/bmj.298.6669.288; GUSTAFSSON L, 1989, BRIT J CANCER, V60, P132, DOI 10.1038/bjc.1989.236; HABBEMA JDF, 1988, COSTS EFFECTS MASS S; HAKAMA M, 1986, SCREENING CANCER UTE; HAKULINEN T, 1983, ANN CLIN RES, V13, P50; KOOPMANSCHAP MA, 1990, SOC SCI MED, V10, P1081; VANBALLEGOOIJEN M, 1990, EUR J CANCER, V26, P941, DOI 10.1016/0277-5379(90)90615-Z; VANDERGRAAF Y, 1987, THESIS KATHOLIEKE U; VANOORTMARSSEN GJ, 1991, BRIT J CANCER, V64, P559, DOI 10.1038/bjc.1991.350; 1986, BMJ, V293, P659; 1980, SURVIVAL CANCER PATI	12	31	31	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 22	1992	305	6851					449	451		10.1136/bmj.305.6851.449	http://dx.doi.org/10.1136/bmj.305.6851.449			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK680	1392957	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992JK68000021
J	VICTOR, CR				VICTOR, CR			HEALTH-STATUS OF THE TEMPORARILY HOMELESS POPULATION AND RESIDENTS OF NORTH-WEST-THAMES REGION	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To survey the health status of the temporarily homeless population of North West Thames region and make comparisons with regional residents. Design-Direct interview with standardised questionnaires. Setting-Temporarily homeless people resident in hotels in the London boroughs in the North West Thames region and a random sample of regional residents. Subjects-137 hotels thought to be providing accommodation to homeless people selected at random from a list of 295. 113 (82%) participated in the study, and 319 (61%) of 522 homeless people approached participated. The study was restricted to adults aged 16 and over selected at random. Results-The homeless population was predominantly female (195/319; 61%), young (229 (72%) aged 16-34), and poor, 54% (172/319) receiving income support. 207 subjects (65%) had dependent children aged 16 and under. Rates of acute illness among homeless people (32 cases; 10%) were similar to those reported by regional residents. The prevalence of longstanding limiting illness (108 cases; 34%) was similar to that for regional residents, but the prevalence of mental morbidity was twice that for the region as a whole (145 cases (45%) v 1485 (18%)). Utilisation of general practitioner services, accident and emergency departments, and inpatient admission was much higher by the homeless population than by regional residents. General practitioner registration rates were above 90% for the homeless sample. Conclusions-Survey data provide empirical evidence about the nature and characteristics of the temporarily homeless population. The high service utilisation recorded may, in part, have resulted from the higher morbidity in this sample of homeless people. The concentration of homeless people into specific locations may suggest that additional funding should be provided to the district which provides care to this group. However, such funding should not necessarily be used for additional acute care but should be used to purchase appropriate services which meet the health needs of this very young, poor and vulnerable group.			VICTOR, CR (corresponding author), PARKSIDE DIST HLTH AUTHOR,DEPT PUBL HLTH,PUBL HLTH RES UNIT,LONDON W2 1PF,ENGLAND.			Victor, Christina/0000-0002-4213-3974				BLACK M, 1991, 4 KINGS FUND I OCC P; CONNELLY J, 1990, PUBLIC HLTH, V109, P13; VICTOR CR, 1989, BRIT MED J, V299, P725, DOI 10.1136/bmj.299.6701.725; 1991, WORKING GROUP HOMELE; 1991, OPCS SS911 OFF POP C	5	29	29	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 15	1992	305	6850					387	391		10.1136/bmj.305.6850.387	http://dx.doi.org/10.1136/bmj.305.6850.387			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK314	1392918	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JK31400012
J	HARDMAN, TC; DUBREY, SW; LESLIE, DG; HAFIZ, M; NOBLE, MI; LANT, AF				HARDMAN, TC; DUBREY, SW; LESLIE, DG; HAFIZ, M; NOBLE, MI; LANT, AF			ERYTHROCYTE SODIUM-LITHIUM COUNTERTRANSPORT AND BLOOD-PRESSURE IN IDENTICAL TWIN PAIRS DISCORDANT FOR INSULIN-DEPENDENT DIABETES	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RED-CELLS; ESSENTIAL-HYPERTENSION; MELLITUS; CHILDREN; NEPHROPATHY; EXCHANGE	Objective-To investigate whether insulin dependent diabetes is responsible for the abnormal behaviour of the carrier in sodium-lithium countertransport and whether the diabetic state is associated with rise in blood pressure. Design-Case-control study. Setting-London teaching hospital. Subjects-44 twin pairs discordant for insulin dependent diabetes living in United Kingdom and 44 healthy control subjects matched for age, sex, and body mass index. None of the twin pairs or the controls had evidence of microalbuminuria. Main outcome measures-Sodium-lithium countertransport activity in erythrocytes and arterial blood pressure. Results-The mean (95% confidence interval) sodium-lithium countertransport activity (mmol Li per litre of red blood cells per h) of the diabetic twins (0.291 (0.244 to 0.338)) was similar to that of their non-diabetic cotwins (0.247 (0.204 to 0.290)); both values were significantly higher than that of the controls (0.187 (0.157 to 0.216), p<0.05). In addition, systolic blood pressure was higher in those twins with diabetes (127 (122 to 133) mm Hg) than in the non-diabetic cotwins (122 (117 to 127) mm Hg; p<0.01). There were no significant differences in mean diastolic blood pressure between any of the groups studied. Conclusions-The raised erythrocyte sodium-lithium countertransport activity in the diabetic twins compared with the controls seems to be inherited rather than a consequence of overt diabetes. The higher systolic blood pressure in diabetic twins than non-diabetic cotwins indicates that insulin dependent diabetes does exert a small influence on systolic blood pressure.	WESTMINSTER MED SCH & HOSP, CHARING CROSS & WESTMINSTER MED SCH, ACAD UNIT CARDIOVASC MED, LONDON SW1P 2AP, ENGLAND	Imperial College London			Leslie, Richard/AAF-6977-2020	Leslie, Richard/0000-0002-1786-1531; Hardman, Tim/0000-0002-1417-9019	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARNETT AH, 1981, DIABETOLOGIA, V20, P87, DOI 10.1007/BF00262007; CANESSA M, 1980, NEW ENGL J MED, V302, P772, DOI 10.1056/NEJM198004033021403; CANESSA M, 1989, METHOD ENZYMOL, V173, P176; CARR S, 1990, NEW ENGL J MED, V322, P500, DOI 10.1056/NEJM199002223220803; EILERS RJ, 1967, AM J CLIN PATHOL, V47, P212, DOI 10.1093/ajcp/47.2.212; FERRARI P, 1990, J HYPERTENS, V8, P491, DOI 10.1097/00004872-199006000-00001; FOYLE WJ, 1991, J HYPERTENS, V9, P713, DOI 10.1097/00004872-199108000-00004; HALKIN A, 1991, CLIN SCI, V81, P223, DOI 10.1042/cs0810223; HUNT SC, 1991, HYPERTENSION, V17, P1; IBSEN KK, 1983, ACTA PAEDIATR SCAND, V72, P191, DOI 10.1111/j.1651-2227.1983.tb09695.x; JENSEN JS, 1990, DIABETOLOGIA, V33, P619, DOI 10.1007/BF00400206; KROLEWSKI AS, 1988, NEW ENGL J MED, V318, P140, DOI 10.1056/NEJM198801213180303; LAURENZI M, 1989, HYPERTENSION, V13, P408, DOI 10.1161/01.HYP.13.5.408; LEWITTER FI, 1985, AM J HUM GENET S, V36, pS172; MANGILI R, 1988, NEW ENGL J MED, V318, P146, DOI 10.1056/NEJM198801213180304; MATHIESEN ER, 1985, DIABETES, V34, P1301, DOI 10.2337/diabetes.34.12.1301; ROWE DJF, 1990, ANN CLIN BIOCHEM, V27, P297, DOI 10.1177/000456329002700404; RUTHERFORD PA, 1992, CLIN SCI, V82, P341, DOI 10.1042/cs0820341; RUTHERFORD PA, 1990, CLIN SCI, V79, P365, DOI 10.1042/cs0790365; SCHIEKEN RM, 1989, AM J CARDIOL, V64, P1333, DOI 10.1016/0002-9149(89)90577-8; SMITH JB, 1986, CLIN CHIM ACTA, V157, P317, DOI 10.1016/0009-8981(86)90308-6; SMITH JB, 1982, CLIN CHIM ACTA, V122, P327, DOI 10.1016/0009-8981(82)90135-8; TARN AC, 1986, DIABETOLOGIA, V29, P275, DOI 10.1007/BF00452062; TREVISAN M, 1981, CLIN CHIM ACTA, V116, P319, DOI 10.1016/0009-8981(81)90051-6; TURNER ST, 1989, HYPERTENSION, V13, P378, DOI 10.1161/01.HYP.13.4.378; WALKER JD, 1990, BMJ-BRIT MED J, V301, P633; WEDER AB, 1986, J HYPERTENS, V4, pS373; 1980, DIABETES, V28, P1039; 1979, WHO TECH REP SER, V628	29	27	27	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 25	1992	305	6847					215	219		10.1136/bmj.305.6847.215	http://dx.doi.org/10.1136/bmj.305.6847.215			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG112	1392822	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992JG11200019
J	MINAKAMI, H; TAKAHASHI, T; IZUMI, A; ITOI, H; TAMADA, T				MINAKAMI, H; TAKAHASHI, T; IZUMI, A; ITOI, H; TAMADA, T			ENLARGEMENT OF THE SALIVARY-GLAND AFTER RITODRINE TREATMENT IN PREGNANT-WOMEN	BRITISH MEDICAL JOURNAL			English	Article							PRETERM				MINAKAMI, H (corresponding author), JICHI MED SCH,DEPT OBSTET & GYNAECOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN.		MINAKAMI, HISANORI/D-6477-2012					BARDEN TP, 1980, OBSTET GYNECOL, V56, P1; MCPHERSON MA, 1978, BIOCHEM J, V176, P855, DOI 10.1042/bj1760855; MCPHERSON MA, 1986, LANCET, V2, P1007; RUSH RW, 1976, BRIT MED J, V2, P965, DOI 10.1136/bmj.2.6042.965; SELYE H, 1961, SCIENCE, V133, P44, DOI 10.1126/science.133.3445.44	5	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 27	1992	304	6843					1668	1668		10.1136/bmj.304.6843.1668	http://dx.doi.org/10.1136/bmj.304.6843.1668			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB939	1378771	Green Published, Bronze			2022-12-28	WOS:A1992JB93900022
J	BRAYDEN, JE; NELSON, MT				BRAYDEN, JE; NELSON, MT			REGULATION OF ARTERIAL TONE BY ACTIVATION OF CALCIUM-DEPENDENT POTASSIUM CHANNELS	SCIENCE			English	Article							SMOOTH-MUSCLE CELLS; SENSITIVE K+ CHANNELS; RABBIT PORTAL-VEIN; SKELETAL-MUSCLE; CEREBRAL-ARTERIES; PRESSURE; DEPOLARIZATION; ENDOTHELIUM; CONDUCTANCE; VESSELS	Blood pressure and tissue perfusion are controlled in part by the level of intrinsic (myogenic) vascular tone. However, many of the molecular determinants of this response are unknown. Evidence is now presented that the degree of myogenic tone is regulated in part by the activation of large-conductance calcium-activated potassium channels in arterial smooth muscle. Tetraethylammonium ion (TEA+) and charybdotoxin (CTX), at concentrations that block calcium-activated potassium channels in smooth muscle cells isolated from cerebral arteries, depolarized and constricted pressurized cerebral arteries with myogenic tone. Both TEA+ and CTX had little effect on arteries when intracellular calcium was reduced by lowering intravascular pressure or by blocking calcium channels. Elevation of intravascular pressure through membrane depolarization and an increase in intracellular calcium may activate calcium-activated potassium channels. Thus, these channels may serve as a negative feedback pathway to control the degree of membrane depolarization and vasoconstriction.	UNIV VERMONT,VERMONT CTR VASC RES,COLCHESTER,VT 05446	University of Vermont	BRAYDEN, JE (corresponding author), UNIV VERMONT,DEPT PHARMACOL,MED RES FACIL,55A S PK DR,COLCHESTER,VT 05446, USA.			Nelson, Mark/0000-0002-6608-8784	NHLBI NIH HHS [HL 35911, HL 44455] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL035911, R01HL044455, R01HL035911] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRETT JN, 1982, J PHYSIOL-LONDON, V331, P211, DOI 10.1113/jphysiol.1982.sp014370; Bayliss WM, 1902, J PHYSIOL-LONDON, V28, P220; BEECH DJ, 1989, J PHYSIOL-LONDON, V418, P293, DOI 10.1113/jphysiol.1989.sp017841; BENHAM CD, 1986, J PHYSIOL-LONDON, V371, P45, DOI 10.1113/jphysiol.1986.sp015961; BLATZ AL, 1986, NATURE, V323, P718, DOI 10.1038/323718a0; BLATZ AL, 1987, TRENDS NEUROSCI, V10, P463, DOI 10.1016/0166-2236(87)90101-9; BRAYDEN JE, 1989, J CEREBR BLOOD F MET, V9, P256, DOI 10.1038/jcbfm.1989.42; BRAYDEN JE, 1991, CIRCULATION S2, V84, P406; CARL A, 1989, AM J PHYSIOL, V257, pC470, DOI 10.1152/ajpcell.1989.257.3.C470; COLE WC, 1989, AM J PHYSIOL, V257, pC481, DOI 10.1152/ajpcell.1989.257.3.C481; DULING BR, 1981, AM J PHYSIOL, V241, pH108, DOI 10.1152/ajpheart.1981.241.1.H108; GALVEZ A, 1990, J BIOL CHEM, V265, P11083; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARDER DR, 1987, CIRC RES, V60, P102, DOI 10.1161/01.RES.60.1.102; HARDER DR, 1987, AM J PHYSIOL, V253, pF778, DOI 10.1152/ajprenal.1987.253.4.F778; HARDER DR, 1984, CIRC RES, V55, P197, DOI 10.1161/01.RES.55.2.197; HU SL, 1989, J GEN PHYSIOL, V94, P849, DOI 10.1085/jgp.94.5.849; INOUE R, 1985, PFLUG ARCH EUR J PHY, V405, P173, DOI 10.1007/BF00582557; JOHNSON PC, 1986, CIRC RES, V59, P483, DOI 10.1161/01.RES.59.5.483; KOVACS RJ, 1991, AM J PHYSIOL, V261, pH604, DOI 10.1152/ajpheart.1991.261.2.H604; KUME H, 1991, AM J PHYSIOL, V261, pC1204, DOI 10.1152/ajpcell.1991.261.6.C1204; LANGTON PD, 1991, AM J PHYSIOL, V260, pH927, DOI 10.1152/ajpheart.1991.260.3.H927; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; MCCARRON JG, 1991, AM J PHYSIOL, V261, pH287, DOI 10.1152/ajpheart.1991.261.2.H287; MEININGER GA, 1991, AM J PHYSIOL, V261, pH950, DOI 10.1152/ajpheart.1991.261.3.H950; MILLER C, 1985, NATURE, V313, P316, DOI 10.1038/313316a0; NELSON MT, 1988, NATURE, V336, P382, DOI 10.1038/336382a0; NELSON MT, 1990, AM J PHYSIOL, V259, pC3; NELSON MT, 1990, NATURE, V344, P770, DOI 10.1038/344770a0; OGDEN DC, 1985, PROC R SOC SER B-BIO, V225, P329, DOI 10.1098/rspb.1985.0065; OSOL G, 1985, AM J PHYSIOL, V249, pH914, DOI 10.1152/ajpheart.1985.249.5.H914; OSOL G, 1986, ESSENTIAL HYPERTENSI, P107; QUAST U, 1989, TRENDS PHARMACOL SCI, V10, P431, DOI 10.1016/S0165-6147(89)80003-3; QUAYLE JM, 1990, BIOPHYS J, V57, pA301; QUAYLE JM, 1988, J PHYSIOL-LONDON, V405, P677, DOI 10.1113/jphysiol.1988.sp017355; RUBANYI GM, 1988, AM J PHYSIOL, V255, pH783, DOI 10.1152/ajpheart.1988.255.4.H783; SINGER JJ, 1987, PFLUG ARCH EUR J PHY, V408, P98, DOI 10.1007/BF00581337; STANDEN NB, 1989, SCIENCE, V245, P177, DOI 10.1126/science.2501869; TORO L, 1991, J BIOENERG BIOMEMBR, V23, P561, DOI 10.1007/BF00785811; TORO L, 1990, AM J PHYSIOL, V258, pH912, DOI 10.1152/ajpheart.1990.258.3.H912; WORLEY JF, 1991, AM J PHYSIOL, V261, pH1951, DOI 10.1152/ajpheart.1991.261.6.H1951	41	825	840	1	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 24	1992	256	5056					532	535		10.1126/science.1373909	http://dx.doi.org/10.1126/science.1373909			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ187	1373909				2022-12-28	WOS:A1992HQ18700067
J	HAMILTON, KK; KIM, PMH; DOETSCH, PW				HAMILTON, KK; KIM, PMH; DOETSCH, PW			A EUKARYOTIC DNA GLYCOSYLASE LYASE RECOGNIZING ULTRAVIOLET LIGHT-INDUCED PYRIMIDINE DIMERS	NATURE			English	Article							COLI ENDONUCLEASE-IV; SACCHAROMYCES-CEREVISIAE; MICROCOCCUS-LUTEUS; REPAIR; BACTERIOPHAGE-T4; MECHANISM; CLEAVAGE; ENZYME; PHOTOLYASE; INVITRO	CYCLOBUTANE pyrimidine dimers (CPDs) are the predominant product of photodamage in DNA after exposure of cells to ultraviolet light 1,2 and are cytotoxic, mutagenic and carcinogenic in a variety of cellular and animal systems 3-5. In prokaryotes, enzymes and protein complexes have been characterized that remove or reverse CPDs in DNA 6-8. Micrococcus luteus and T4 phage-infected Escherichia coli contain a specific N-glycosylase/apurinic-apyrimidinic lyase that catalyses a two-step DNA incision process at sites of CPDs, thus initiating base excision repair of these lesions 7,9-12. It is we established that CPDs are recognized and removed from eukaryotic DNA by excision repair processes but very little information exists concerning the nature of the proteins involved in CPD recognition and DNA incision events 7,12,13. We report here that an enzyme functionally similar to the prokaryotic N-glycosylase/apurinic-apyrimidinic lyases exists in Saccharomyces cerevisiae. To our knowledge, this is the first time such an activity has been found in a eukaryote and is also the first example of an organism having both direct reversal and base excision repair pathways for the removal of CPDs from DNA.	EMORY UNIV,SCH MED,ROLLINS RES CTR,DEPT BIOCHEM,ATLANTA,GA 30322	Emory University								[Anonymous], 1985, DNA REPAIR; BAILLY V, 1989, BIOCHEM J, V259, P761, DOI 10.1042/bj2590761; BANKMANN M, 1992, NATURE, V355, P555, DOI 10.1038/355555a0; BEKKER ML, 1980, J BACTERIOL, V142, P322, DOI 10.1128/JB.142.1.322-324.1980; COOHILL TP, 1987, PHOTOCHEM PHOTOBIOL, V46, P1043, DOI 10.1111/j.1751-1097.1987.tb04891.x; DODSON ML, 1989, MUTAT RES, V218, P49, DOI 10.1016/0921-8777(89)90011-6; DOETSCH PW, 1986, BIOCHEMISTRY-US, V25, P2212, DOI 10.1021/bi00356a054; DOWD DR, 1990, J BIOL CHEM, V265, P3424; Friedberg E C, 1980, Methods Enzymol, V65, P191; FRIEDBERG EC, 1988, MICROBIOL REV, V52, P70, DOI 10.1128/MMBR.52.1.70-102.1988; FRIEDBERG EC, 1981, J SUPRAMOL STR CELL, V16, P91, DOI 10.1002/jsscb.1981.380160109; GORDON LK, 1980, J BIOL CHEM, V255, P2047; GOSSETT J, 1988, BIOCHEMISTRY-US, V27, P2629, DOI 10.1021/bi00407a054; GRAFSTROM RH, 1982, J BIOL CHEM, V257, P13465; Harm W, 1980, BIOL EFFECTS ULTRAVI; HART RW, 1975, MOL MECHANISMS REPAI, P719; HASEGAWA SL, 1991, NUCLEIC ACIDS RES, V19, P4915, DOI 10.1093/nar/19.18.4915; HASELTINE WA, 1980, NATURE, V285, P634, DOI 10.1038/285634a0; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; LEVIN JD, 1988, J BIOL CHEM, V263, P8066; Maxam A M, 1980, Methods Enzymol, V65, P499; MAZUMDER A, 1989, J AM CHEM SOC, V111, P8029, DOI 10.1021/ja00202a062; PATRICK MH, 1976, PHOTOCHEM PHOTOBIOL, V24, P507, DOI 10.1111/j.1751-1097.1976.tb06867.x; PATRICK MH, 1977, PHOTOCHEM PHOTOBIOL, V25, P357, DOI 10.1111/j.1751-1097.1977.tb07355.x; PAYNE G, 1987, BIOCHEMISTRY-US, V26, P7121, DOI 10.1021/bi00396a038; PRAKASH L, 1977, MUTAT RES, V45, P13, DOI 10.1016/0027-5107(77)90038-0; RADANY EH, 1980, NATURE, V286, P182, DOI 10.1038/286182a0; RADANY EH, 1982, J VIROL, V41, P88, DOI 10.1128/JVI.41.1.88-96.1982; REYNOLDS RJ, 1981, J BACTERIOL, V146, P692, DOI 10.1128/JB.146.2.692-704.1981; SANCAR A, 1984, J BIOL CHEM, V259, P6028; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SANCAR GB, 1990, MUTAT RES, V236, P147, DOI 10.1016/0921-8777(90)90002-M; SEAWALL PC, J VIROL, V35, P790; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; WALDSTEIN EA, 1979, P NATL ACAD SCI USA, V76, P3746, DOI 10.1073/pnas.76.8.3746; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120	36	38	38	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 23	1992	356	6371					725	728		10.1038/356725a0	http://dx.doi.org/10.1038/356725a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ146	1373868				2022-12-28	WOS:A1992HQ14600066
J	CERRETTI, DP; KOZLOSKY, CJ; MOSLEY, B; NELSON, N; VANNESS, K; GREENSTREET, TA; MARCH, CJ; KRONHEIM, SR; DRUCK, T; CANNIZZARO, LA; HUEBNER, K; BLACK, RA				CERRETTI, DP; KOZLOSKY, CJ; MOSLEY, B; NELSON, N; VANNESS, K; GREENSTREET, TA; MARCH, CJ; KRONHEIM, SR; DRUCK, T; CANNIZZARO, LA; HUEBNER, K; BLACK, RA			MOLECULAR-CLONING OF THE INTERLEUKIN-1-BETA CONVERTING ENZYME	SCIENCE			English	Article							ACUTE MYELOBLASTIC-LEUKEMIA; GRANULOCYTE-MACROPHAGE; SEQUENCE; EXPRESSION; RECEPTOR; CELLS; PRECURSOR; PROLIFERATION; SPECIFICITY; STIMULATION	Interleukin-1-beta (IL-1-beta) mediates a wide range of immune and inflammatory responses. The active cytokine is generated by proteolytic cleavage of an inactive precursor. A complementary DNA encoding a protease that carries out this cleavage has been cloned. Recombinant expression in COS-7 cells enabled the cells to process precursor IL-1-beta to the mature form. Sequence analysis indicated that the enzyme itself may undergo proteolytic processing. The gene encoding the protease was mapped to chromosomal band 11q23, a site frequently involved in rearrangement in human cancers.	THOMAS JEFFERSON UNIV, JEFFERSON CANC INST, PHILADELPHIA, PA 19107 USA	Jefferson University	CERRETTI, DP (corresponding author), IMMUNEX CORP, 51 UNIV ST, SEATTLE, WA 98101 USA.							AURON PE, 1987, J IMMUNOL, V138, P1447; AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; BLACK RA, 1988, J BIOL CHEM, V263, P9437; BRADBURY D, 1990, LEUKEMIA, V4, P44; CANNIZZARO LA, 1990, GENOMICS, V6, P197, DOI 10.1016/0888-7543(90)90557-B; CERRETTI DP, 1986, P NATL ACAD SCI USA, V83, P3223, DOI 10.1073/pnas.83.10.3223; CERRETTI DP, UNPUB; COSMAN D, 1984, NATURE, V312, P768, DOI 10.1038/312768a0; COZZOLINO F, 1990, INT J CANCER, V46, P902, DOI 10.1002/ijc.2910460525; COZZOLINO F, 1989, P NATL ACAD SCI USA, V86, P2369, DOI 10.1073/pnas.86.7.2369; DELWEL R, 1989, BLOOD, V74, P586; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIGIOVINE FS, 1990, IMMUNOL TODAY, V11, P13; DINARELLO CA, 1991, BLOOD, V77, P1627; DINARELLO CA, 1991, IMMUNOL TODAY, V12, P404, DOI 10.1016/0167-5699(91)90142-G; DOWER SK, 1992, CHEM IMMUNOL, V51, P33; DRUCK T, UNPUB; ESTROV Z, 1991, BLOOD, V78, P1476; FANSLOW WC, 1990, SCIENCE, V248, P739, DOI 10.1126/science.2139736; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HAZUDA DJ, 1990, J BIOL CHEM, V265, P6318; HOWARD AD, 1991, J IMMUNOL, V147, P2964; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRONHEIM SR, UNPUB; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CC, 1990, PCR PROTOCOLS GUIDE, P46; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; NETT MA, UNPUB; RAMBALDI A, 1991, BLOOD, V78, P3248; RAY CA, IN PRESS CELL; SAKAI K, 1987, J EXP MED, V166, P1597, DOI 10.1084/jem.166.5.1597; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; TRENT JM, 1989, CYTOGENET CELL GENET, V51, P533, DOI 10.1159/000132807	41	994	1052	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 3	1992	256	5053					97	100		10.1126/science.1373520	http://dx.doi.org/10.1126/science.1373520			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL822	1373520				2022-12-28	WOS:A1992HL82200035
J	BREARLEY, S				BREARLEY, S			LEADING FOR HEALTH - MANPOWER	BRITISH MEDICAL JOURNAL			English	Article											BREARLEY, S (corresponding author), WHIPPS CROSS HOSP & CHEST CLIN,LONDON E11 1NR,ENGLAND.							Allen, 1988, DOCTORS THEIR CAREER; BEECHAM L, 1991, BMJ, V303, P1140; BULSTRODE C, 1991, BRIT MED J, V303, P255, DOI 10.1136/bmj.303.6796.255; SCHIEBER GJ, 1990, OECD SOCIAL POLICY S; 1991, JUNIOR DOCTORS NEW D; 1991, MED MANPOWER EUROPE; 1991, PATIENTS CHARTER; 1987, HOSPITAL MED STAFFIN; 1991, LEADING HLTH BMA AGE; 1991, INAPPROPRIATE DUTIES; 1989, CMND555; 1987, PROJECT 2000 FINAL P	12	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1992	304	6830					832	834		10.1136/bmj.304.6830.832	http://dx.doi.org/10.1136/bmj.304.6830.832			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL827	1392716	Green Published, Bronze			2022-12-28	WOS:A1992HL82700031
J	YKIJARVINEN, H; KAUPPILA, M; KUJANSUU, E; LAHTI, J; MARJANEN, T; NISKANEN, L; RAJALA, S; RYYSY, L; SALO, S; SEPPALA, P; TULOKAS, T; VIIKARI, J; KARJALAINEN, J; TASKINEN, MR				YKIJARVINEN, H; KAUPPILA, M; KUJANSUU, E; LAHTI, J; MARJANEN, T; NISKANEN, L; RAJALA, S; RYYSY, L; SALO, S; SEPPALA, P; TULOKAS, T; VIIKARI, J; KARJALAINEN, J; TASKINEN, MR			COMPARISON OF INSULIN REGIMENS IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES-MELLITUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ORAL HYPOGLYCEMIC AGENTS; SULFONYLUREA THERAPY; PLASMA-LIPOPROTEIN; SECONDARY FAILURE; METABOLISM; HYPERGLYCEMIA; GLIBENCLAMIDE; TRIGLYCERIDE; COMBINATION; GLUCOSE	Background. Insulin is widely used to improve metabolic control in patients with non-insulin-dependent diabetes mellitus (NIDDM), but there is no consensus about the optimal regimen of insulin treatment. Methods. We treated 153 patients with NIDDM for three months with five regimens: (1) oral hypoglycemic drug therapy plus NPH insulin given at 7 a.m. (the morning-NPH group), (2) oral hypoglycemic drug therapy plus NPH insulin given at 9 p.m. (the evening-NPH group), (3) NPH and regular insulin (ratio, 70 units to 30 units) given before breakfast and dinner (the two-insulin-injection group), (4) NPH insulin at 9 p.m. and regular insulin before meals (the multiple-insulin-injection group), and (5) continued oral hypoglycemic drug therapy (the control group). Results. The mean (+/-SE) value for glycosylated hemoglobin decreased similarly in all four insulin-treatment groups (1.7+/-0.3, 1.9+/-0.2, 1.8+/-0.3, and 1.6+/-0.3 percent, respectively). The decrease was significantly greater in these four groups than in the control group (0.5+/-0.2 percent; P<0.001 vs. all insulin-treated groups). Weight gain was significantly less (1.2+/-0.5 kg) in the evening-NPH group than in the other insulin-treatment groups (2.2+/-0.5 kg in the morning-NPH group, 1.8+/-0.5 kg in the two-insulin-injection group, and 2.9+/-O.5 kg in the multiple-injection group; P<0.05). In addition, the increment in the mean diurnal serum free insulin concentration was 50 to 65 percent smaller in the evening-NPH group than in the other insulin-treatment groups. Subjective well-being improved significantly more in the insulin-treatment groups than in the control group (P<0.001). Conclusions. In patients with NIDDM who are receiving oral hypoglycemic drug therapy, the addition of NPH insulin in the evening improves glycemic control in a manner similar to combination therapy with NPH insulin in the morning, a two-insulin-injection regimen, or a multiple-insulin-injection regimen, but induces less weight gain and hyperinsulinemia. The data thus suggest that patients with NIDDM do not benefit from multiple insulin injections and that nocturnal insulin administration appears preferable to daytime administration.	UNIV TURKU,DEPT MED,SF-20500 TURKU 50,FINLAND; UNIV HELSINKI,DEPT MED 3,SF-00290 HELSINKI 29,FINLAND; HATANPAA HOSP,TAMPERE,FINLAND; KUOPIO CITY HOSP,KUOPIO,FINLAND; AANEKOSKI HLTH CTR,AANEKOSKI,FINLAND; KYMENLAAKSO CENT HOSP,KOTKA,FINLAND; LAPPI CENT HOSP,ROVANIEMI,FINLAND; UNIV OULU,DEPT PEDIAT,SF-90100 OULU 10,FINLAND	University of Turku; University of Helsinki; University of Oulu	YKIJARVINEN, H (corresponding author), UNIV HELSINKI,DEPT MED 2,HAARTMANINKATU 4,SF-00290 HELSINKI 29,FINLAND.		Taskinen, Marja-Riitta/AAN-5432-2020	Taskinen, Marja-Riitta/0000-0002-6229-3588				AGARDH CD, 1982, DIABETES CARE, V5, P322, DOI 10.2337/diacare.5.3.322; ANDREWS WJ, 1984, DIABETES, V33, P634, DOI 10.2337/diabetes.33.7.634; BERGER M, 1982, DIABETES CARE, V5, P77, DOI 10.2337/diacare.5.2.77; BONIFACIO E, 1988, J IMMUNOL METHODS, V106, P83, DOI 10.1016/0022-1759(88)90274-8; BOOTH DA, 1968, PHYSIOL BEHAV, V3, P439, DOI 10.1016/0031-9384(68)90075-9; DIXON WJ, 1983, BMDP STATISTICAL SOF; FIRTH RG, 1986, J CLIN INVEST, V77, P1525, DOI 10.1172/JCI112467; GERICH JE, 1989, NEW ENGL J MED, V321, P1231; GROOP L, 1989, DIABETOLOGIA, V32, P599; GUTNIAK M, 1987, DIABETES CARE, V10, P545, DOI 10.2337/diacare.10.5.545; HAMILTON BPM, 1990, AM J KIDNEY DIS, V16, P20; KNOWLER WC, 1981, AM J EPIDEMIOL, V113, P144, DOI 10.1093/oxfordjournals.aje.a113079; KUZUYA H, 1977, DIABETES, V26, P22, DOI 10.2337/diabetes.26.1.22; LEBOVITZ HE, 1990, DIABETES CARE, V13, P667, DOI 10.2337/diacare.13.6.667; LINDSTROM T, 1990, ATHEROSCLEROSIS, V81, P137, DOI 10.1016/0021-9150(90)90020-J; LINS PE, 1988, ACTA MED SCAND, V223, P171; LOTZ N, 1988, KLIN WOCHENSCHR, V66, P1079, DOI 10.1007/BF01711922; OSEI K, 1984, AM J MED, V77, P1002, DOI 10.1016/0002-9343(84)90179-7; PAISEY R, 1978, DIABETOLOGIA, V15, P81, DOI 10.1007/BF00422249; PFEIFER MA, 1983, DIABETES, V32, P525, DOI 10.2337/diabetes.32.6.525; RIDDLE MC, 1985, LANCET, V1, P192, DOI 10.1016/S0140-6736(85)92029-X; SANE T, 1992, J INTERN MED, V231, P253, DOI 10.1111/j.1365-2796.1992.tb00532.x; SCHADE DS, 1987, JAMA-J AM MED ASSOC, V257, P2441, DOI 10.1001/jama.257.18.2441; STENMAN S, 1988, DIABETOLOGIA, V31, P206, DOI 10.1007/BF00290586; STENMAN UH, 1984, J CHROMATOGR, V297, P327, DOI 10.1016/S0021-9673(01)89052-X; TASKINEN MR, 1988, ARTERIOSCLEROSIS, V8, P168, DOI 10.1161/01.ATV.8.2.168; TAVES DR, 1974, CLIN PHARMACOL THER, V15, P443; YKIJARVINEN H, 1990, DIABETOLOGIA, V33, P579, DOI 10.1007/BF00400200	28	271	274	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 12	1992	327	20					1426	1433		10.1056/NEJM199211123272005	http://dx.doi.org/10.1056/NEJM199211123272005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX479	1406860				2022-12-28	WOS:A1992JX47900005
J	VERITY, CM; ROSS, EM; GOLDING, J				VERITY, CM; ROSS, EM; GOLDING, J			EPILEPSY IN THE 1ST 10 YEARS OF LIFE - FINDINGS OF THE CHILD HEALTH AND EDUCATION STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CONVULSIVE DISORDERS; FEBRILE CONVULSIONS; UNPROVOKED SEIZURE; NATIONAL COHORT; RISK-FACTORS; FOLLOW-UP; RECURRENCE; POPULATION; PREVALENCE; PROGNOSIS	Objectives-To identify children with afebrile seizures in a national cohort, classify the seizures, and document progress in the first 10 years of life. Design-Population based birth cohort study. Setting-The child health and education study, which includes 16004 neonatal survivors (98.5% of infants born in the United Kingdom during one week of April 1970). Subjects-14676 children for whom relevant information was available. Main outcome measures-Responses to parental and general practitioner questionnaires and hospital records at 5 and 10 years after birth. Results-84 children (42 boys, 42 girls) had had one or more afebrile seizure (incidence 5.7/1000). 63 children (31 boys, 32 girls) had epilepsy (incidence 4.3/1000). 49 of 55 children had a second seizure within a year of the first. The commonest seizure types were tonic-clonic (42) and complex partial (25). A greater proportion of children with complex partial seizures had recurrences. Children who had infantile spasms or a mixed seizure disorder had a poor outcome. All six children who died had symptomatic seizures in the first year, but seizures were not the direct cause of death. Conclusions-The results of this study are probably representative of seizure patterns in the general population. Outcome after seizures is determined more by the underlying disease than by the seizures themselves.	UNIV LONDON KINGS COLL HOSP, DEPT COMMUNITY PAEDIAT, LONDON SE5 8RX, ENGLAND; UNIV BRISTOL, INST CHILD HLTH, DEPT PAEDIAT & PERINATAL, BRISTOL BS8 1TH, AVON, ENGLAND	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; University of Bristol	VERITY, CM (corresponding author), ADDENBROOKES HOSP, DEPT PAEDIAT, CAMBRIDGE CB2 2QQ, ENGLAND.			Golding, Jean/0000-0003-2826-3307				ANNEGERS JF, 1979, EPILEPSIA, V20, P729, DOI 10.1111/j.1528-1157.1979.tb04857.x; ANNEGERS JF, 1986, EPILEPSIA, V27, P43, DOI 10.1111/j.1528-1157.1986.tb03499.x; [Anonymous], 1981, Epilepsia, V22, P489; BERG AT, 1991, NEUROLOGY, V41, P965, DOI 10.1212/WNL.41.7.965; CAVAZZUTI GB, 1984, DEV MED CHILD NEUROL, V26, P425; CHADWICK D, 1991, J NEUROL NEUROSUR PS, V54, P385, DOI 10.1136/jnnp.54.5.385; CHAMBERLAIN R, 1978, BRIT BIRTHS 1970, V1; CHEVRIE JJ, 1979, EPILEPSIA, V20, P643, DOI 10.1111/j.1528-1157.1979.tb04848.x; CHEVRIE JJ, 1978, EPILEPSIA, V19, P67; COOPER JE, 1965, BRIT MED J, V1, P1020, DOI 10.1136/bmj.1.5441.1020; ELLENBERG JH, 1984, ANN NEUROL, V15, P127, DOI 10.1002/ana.410150204; FALCONER MA, 1964, ARCH NEUROL-CHICAGO, V10, P233, DOI 10.1001/archneur.1964.00460150003001; GOODRIDGE DMG, 1983, BRIT MED J, V287, P645, DOI 10.1136/bmj.287.6393.645; GOODRIDGE DMG, 1983, BMJ-BRIT MED J, V287, P641, DOI 10.1136/bmj.287.6393.641; HART YM, 1990, LANCET, V336, P1271, DOI 10.1016/0140-6736(90)92960-P; HAUSER WA, 1990, NEUROLOGY, V40, P1163, DOI 10.1212/WNL.40.8.1163; NELSON KB, 1976, NEW ENGL J MED, V295, P1029, DOI 10.1056/NEJM197611042951901; ROCCA WA, 1987, ANN NEUROL, V21, P22, DOI 10.1002/ana.410210106; ROCCA WA, 1987, NEUROLOGY, V37, P1315, DOI 10.1212/WNL.37.8.1315; ROSS EM, 1980, BRIT MED J, V280, P207, DOI 10.1136/bmj.280.6209.207; SANDER JWAS, 1987, J NEUROL NEUROSUR PS, V50, P829, DOI 10.1136/jnnp.50.7.829; SHORVON SD, 1984, J NEUROL NEUROSUR PS, V47, P1157, DOI 10.1136/jnnp.47.11.1157; SILLANPAA M, 1973, ACTA PAEDIATR SC   S, V273, P1; TAYLOR DC, 1971, EPILEPSIA, V12, P33, DOI 10.1111/j.1528-1157.1971.tb03913.x; VANDENBERG BJ, 1969, PEDIATR RES, V3, P298, DOI 10.1203/00006450-196907000-00005; VERITY CM, 1985, BRIT MED J, V290, P1307, DOI 10.1136/bmj.290.6478.1307; VERITY CM, 1985, BMJ-BRIT MED J, V290, P1311, DOI 10.1136/bmj.290.6478.1311; VERITY CM, 1991, BMJ-BRIT MED J, V303, P1373, DOI 10.1136/bmj.303.6814.1373	28	60	61	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 10	1992	305	6858					857	861		10.1136/bmj.305.6858.857	http://dx.doi.org/10.1136/bmj.305.6858.857			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT777	1384897	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992JT77700022
J	JEUNEMAITRE, X; SOUBRIER, F; KOTELEVTSEV, YV; LIFTON, RP; WILLIAMS, CS; CHARRU, A; HUNT, SC; HOPKINS, PN; WILLIAMS, RR; LALOUEL, JM; CORVOL, P				JEUNEMAITRE, X; SOUBRIER, F; KOTELEVTSEV, YV; LIFTON, RP; WILLIAMS, CS; CHARRU, A; HUNT, SC; HOPKINS, PN; WILLIAMS, RR; LALOUEL, JM; CORVOL, P			MOLECULAR-BASIS OF HUMAN HYPERTENSION - ROLE OF ANGIOTENSINOGEN	CELL			English	Article							BLOOD-PRESSURE; MESSENGER-RNA; RENIN GENE; LINKAGE; RAT; SYSTEM; IDENTIFICATION; POLYMORPHISMS; SUBSTRATE; FAMILIES	Essential hypertension is a common human disease believed to result from the interplay of multiple genetic and environmental determinants. In genetic studies of two large panels of hypertensive sibships from widely separated geographical areas, we obtained evidence of genetic linkage between the angiotensinogen gene (AGT) and hypertension, demonstrated association of AGT molecular variants with the disease, and found significant differences in plasma concentrations of angiotensinogen among hypertensive subjects with different AGT genotypes. The corroboration and replication afforded by these results support the interpretation that molecular variants of AGT constitute inherited predispositions to essential hypertension in humans.	UNIV UTAH, HLTH SCI CTR, ECCLES INST HUMAN GENET, DEPT HUMAN GENET, SALT LAKE CITY, UT 84112 USA; COLL FRANCE, INSERM U36, F-75005 PARIS, FRANCE; BRIGHAM & WOMENS HOSP, DIV ENDOCRINE HYPERTENS, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; UNIV UTAH, HLTH SCI CTR, CARDIOVASC GENET RES CLIN, SALT LAKE CITY, UT 84112 USA	Utah System of Higher Education; University of Utah; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Utah System of Higher Education; University of Utah	JEUNEMAITRE, X (corresponding author), UNIV UTAH, HLTH SCI CTR, ECCLES INST HUMAN GENET, HOWARD HUGHES MED INST, SALT LAKE CITY, UT 84112 USA.		JEUNEMAITRE, Xavier/AAQ-4853-2021; Williams, christopher S/A-1186-2009; Kotelevtsev, Yuri V/R-1772-2016	JEUNEMAITRE, Xavier/0000-0001-5925-381X; Kotelevtsev, Yuri/0000-0002-7255-7794; Williams, Christopher/0000-0002-1541-579X	NHLBI NIH HHS [HL45325, HL24855] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024855, R01HL045325] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNAL JF, 1991, AM J MED, V90, P17, DOI 10.1016/0002-9343(91)90501-N; BACHMANN J, 1991, J STEROID BIOCHEM, V40, P511, DOI 10.1016/0960-0760(91)90270-F; BISHOP DT, 1990, AM J HUM GENET, V46, P254; BLACKWELDER W C, 1985, Genetic Epidemiology, V2, P85, DOI 10.1002/gepi.1370020109; BROWN AJ, 1981, AM J PHYSIOL, V241, pH381, DOI 10.1152/ajpheart.1981.241.3.H381; CAIN MD, 1971, J CLIN ENDOCR METAB, V33, P671, DOI 10.1210/jcem-33-4-671; CAMPBELL DJ, 1986, J CLIN INVEST, V78, P31, DOI 10.1172/JCI112566; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; CLAUSER E, 1989, AM J HYPERTENS, V2, P403, DOI 10.1093/ajh/2.5.403; CORVOL P, 1989, CLIN EXP HYPERTENS A, V11, P1053, DOI 10.3109/10641968909035391; CUDWORTH AG, 1975, BRIT MED J, V3, P133, DOI 10.1136/bmj.3.5976.133; DAUSSET J, 1990, GENOMICS, V6, P575, DOI 10.1016/0888-7543(90)90491-C; DENG YL, 1992, NAT GENET, V1, P267, DOI 10.1038/ng0792-267; FASOLA AF, 1968, J APPL PHYSIOL, V25, P410, DOI 10.1152/jappl.1968.25.4.410; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; FUKAMIZU A, 1990, J BIOL CHEM, V265, P7576; GAILLARD I, 1989, DNA-J MOLEC CELL BIO, V8, P87, DOI 10.1089/dna.1.1989.8.87; GARDES J, 1982, HYPERTENSION, V4, P185, DOI 10.1161/01.HYP.4.2.185; GOULD AB, 1971, CARDIOVASC RES, V5, P86, DOI 10.1093/cvr/5.1.86; Hall JE, 1990, HYPERTENSION PATHOPH, P1105; HATA A, 1990, NUCLEIC ACIDS RES, V18, P5407, DOI 10.1093/nar/18.18.5407; HILBERT P, 1991, NATURE, V353, P521, DOI 10.1038/353521a0; HODGE S E, 1984, Genetic Epidemiology, V1, P109, DOI 10.1002/gepi.1370010203; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; JEUNEMAITRE X, 1992, HUM GENET, V88, P301; JEUNEMAITRE X, 1992, NAT GENET, V1, P72, DOI 10.1038/ng0492-72; KIMURA S, 1992, EMBO J, V11, P821, DOI 10.1002/j.1460-2075.1992.tb05119.x; KOTELEVTSEV YV, 1991, NUCLEIC ACIDS RES, V19, P6978, DOI 10.1093/nar/19.24.6978; KUNAPULI SP, 1986, NUCLEIC ACIDS RES, V14, P7509, DOI 10.1093/nar/14.18.7509; KURTZ TW, 1990, J CLIN INVEST, V85, P1328, DOI 10.1172/JCI114572; LALOUEL JM, 1990, DRUGS AFFECTING LIPI, V10, P11; LANDER ES, 1989, GENETICS, V121, P185; LANDER ES, 1986, COLD SPRING HARB SYM, V51, P49, DOI 10.1101/SQB.1986.051.01.007; LANGE K, 1986, ANN HUM GENET, V50, P283, DOI 10.1111/j.1469-1809.1986.tb01049.x; LATHROP GM, 1991, HDB STATISTICS, V8, P81; LIFTON RP, 1992, NATURE, V355, P262, DOI 10.1038/355262a0; MENARD J, 1991, HYPERTENSION, V18, P705, DOI 10.1161/01.HYP.18.5.705; MENARD J, 1973, ENDOCRINOLOGY, V92, P1382, DOI 10.1210/endo-92-5-1382; MULLINS JJ, 1990, NATURE, V344, P541, DOI 10.1038/344541a0; OHKUBO H, 1990, P NATL ACAD SCI USA, V87, P5153, DOI 10.1073/pnas.87.13.5153; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PLOUIN PF, 1989, PRESSE MED, V18, P917; PRATT RE, 1989, AM J PHYSIOL, V256, pF469, DOI 10.1152/ajprenal.1989.256.3.F469; RAPP JP, 1989, SCIENCE, V243, P542, DOI 10.1126/science.2563177; RISCH N, 1990, AM J HUM GENET, V46, P242; ROCCELLA EJ, 1985, HYPERTENSION, V7, P457; Sealey JE, 1990, HYPERTENSION PATHOPH, P1287; SOUBRIER F, 1990, HYPERTENSION, V16, P712, DOI 10.1161/01.HYP.16.6.712; SUAREZ BK, 1984, AM J MED GENET, V18, P135, DOI 10.1002/ajmg.1320180117; SUAREZ BK, 1978, ANN HUM GENET, V42, P87, DOI 10.1111/j.1469-1809.1978.tb00933.x; TEWKSBURY DA, 1990, HYPERTENSION PATHOPH, P1197; WALKER WG, 1979, HYPERTENSION, V1, P287, DOI 10.1161/01.HYP.1.3.287; WARD R, 1990, HYPERTENSION PATHOPH, P81; WATT GCM, 1992, J HYPERTENS, V10, P473, DOI 10.1097/00004872-199205000-00011; WHITE R, 1987, ADV HUM GENET, V16, P121; WILLIAMS RR, 1988, JAMA-J AM MED ASSOC, V259, P3579, DOI 10.1001/jama.259.24.3579; WILLIAMS RR, 1989, HYPERTENSION, V14, P610, DOI 10.1161/01.HYP.14.6.610; YONGUE BG, 1991, HYPERTENSION, V17, P485, DOI 10.1161/01.HYP.17.4.485	58	1612	1687	0	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 2	1992	71	1					169	180		10.1016/0092-8674(92)90275-H	http://dx.doi.org/10.1016/0092-8674(92)90275-H			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1394429				2022-12-28	WOS:A1992JQ62300016
J	JACKS, T; FAZELI, A; SCHMITT, EM; BRONSON, RT; GOODELL, MA; WEINBERG, RA				JACKS, T; FAZELI, A; SCHMITT, EM; BRONSON, RT; GOODELL, MA; WEINBERG, RA			EFFECTS OF AN RB MUTATION IN THE MOUSE	NATURE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; HUMAN PROSTATE CARCINOMA; SV40-TRANSFORMED CELLS; ENCODED PROTEIN; T-ANTIGEN; PRODUCT; EXPRESSION; TUMORS; CANCER; PHOSPHORYLATION	The retinoblastoma gene is mutated in several types of human cancer and is the best characterized of the tumour-suppressor genes. A mouse strain has been constructed in which one allele of Rb is disrupted. These heterozygous animals are not predisposed to retinoblastoma, but some display pituitary tumours arising from cells in which the wild-type Rb allele is absent. Embryos homozygous for the mutation die between days 14 and 15 of gestation, exhibiting neuronal cell death and defective erythropoiesis.	MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02139; TUFTS UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02111; TUFTS UNIV,SCH VET MED,BOSTON,MA 02111	Massachusetts Institute of Technology (MIT); Whitehead Institute; Tufts University; Tufts University	JACKS, T (corresponding author), MIT,DEPT BIOL,CTR CANC RES,CAMBRIDGE,MA 02139, USA.			Goodell, Margaret A./0000-0003-1111-2932				ABRAMSON DH, 1984, OPHTHALMOLOGY, V91, P1351; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BRONSTEIN I, 1992, BIOTECHNIQUES, V12, P748; BUCHKOVICH K, 1989, CELL, V46, P447; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HENSEL CH, 1990, CANCER RES, V50, P3067; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATSUNAGA E, 1980, HUM GENET, V56, P127; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; TANG A, 1988, SCIENCE, V241, P1797; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VARLEY JM, 1989, ONCOGENE, V4, P725; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WINDLE JJ, 1990, NATURE, V343, P665, DOI 10.1038/343665a0; WONG PMC, 1986, P NATL ACAD SCI USA, V83, P3851, DOI 10.1073/pnas.83.11.3851; YOKOTA J, 1988, ONCOGENE, V3, P471	46	1541	1590	0	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 24	1992	359	6393					295	300		10.1038/359295a0	http://dx.doi.org/10.1038/359295a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP503	1406933				2022-12-28	WOS:A1992JP50300046
J	MATSUI, Y; ZSEBO, K; HOGAN, BLM				MATSUI, Y; ZSEBO, K; HOGAN, BLM			DERIVATION OF PLURIPOTENTIAL EMBRYONIC STEM-CELLS FROM MURINE PRIMORDIAL GERM-CELLS IN CULTURE	CELL			English	Article							GROWTH-FACTOR; DIFFERENTIATION; PROLIFERATION	Steel factor (SF) and LIF (leukemia inhibitory factor) synergistically promote the proliferation and survival of mouse primordial germ cells (PGCs), but only for a limited time period in culture. We show here that addition of bFGF to cultures in the presence of membrane-associated SF and LIF enhances the growth of PGCs and allows their continued proliferation beyond the time when they normally stop dividing in vivo. They form colonies of densely packed, alkaline phosphatase-positive, SSEA-1-positive cells resembling undifferentiated embryonic stem (ES) cells in morphology. These cultures can be maintained on feeder layers for at least 20 passages, and under appropriate conditions give rise to embryoid bodies and to multiple differentiated cell phenotypes in monolayer culture and in tumors in nude mice. PGC-derived ES cells can also contribute to chimeras when injected into host blasto-cysts. The long-term culture of PGCs and their reprogramming to pluripotential ES cells has important implications for germ cell biology and the induction of teratocarcinomas.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT CELL BIOL,NASHVILLE,TN 37232; AMGEN INC,AMGEN CTR,THOUSAND OAKS,CA 91320	Vanderbilt University; Amgen				Matsui, Yasuhisa/0000-0001-7026-6355				BOGLER O, 1990, P NATL ACAD SCI USA, V87, P6368, DOI 10.1073/pnas.87.16.6368; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; DONOVAN PJ, 1986, CELL, V44, P831, DOI 10.1016/0092-8674(86)90005-X; FFRENCHCONSTANT C, 1991, DEVELOPMENT, V113, P1365; GINSBURG M, 1990, DEVELOPMENT, V110, P521; GODIN I, 1991, DEVELOPMENT, V113, P1451; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; LAWSON KA, 1992, CIBA F S, V165; MANN JR, 1990, CELL, V62, P251, DOI 10.1016/0092-8674(90)90363-J; MANOVA K, 1991, DEV BIOL, V146, P312, DOI 10.1016/0012-1606(91)90233-S; MATSUI Y, 1991, NATURE, V353, P750, DOI 10.1038/353750a0; MINTZ B, 1957, J EXP ZOOL, V134, P207, DOI 10.1002/jez.1401340202; NOBLE M, 1988, NATURE, V333, P560, DOI 10.1038/333560a0; NOGUCHI T, 1982, J NATL CANCER I, V69, P907; RAFF MC, 1988, NATURE, V333, P562, DOI 10.1038/333562a0; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; SOLTER D, 1975, TERATOMAS DIFFERENTI; SORIANO P, 1986, CELL, V46, P19, DOI 10.1016/0092-8674(86)90856-1; STEVENS LC, 1961, J NATL CANCER I, V27, P443; Stevens LC, 1983, COLD SPRING HARB C C, P23; SURANI MA, 1990, DEVELOPMENT S, V110, P89; TAM PPL, 1981, J EMBRYOL EXP MORPH, V64, P133; TOKSOZ D, 1992, IN PRESS P NATL ACAD, V89	24	962	1159	0	44	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 4	1992	70	5					841	847		10.1016/0092-8674(92)90317-6	http://dx.doi.org/10.1016/0092-8674(92)90317-6			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JL663	1381289				2022-12-28	WOS:A1992JL66300015
J	KHAW, KT; SNEYD, MJ; COMPSTON, J				KHAW, KT; SNEYD, MJ; COMPSTON, J			BONE-DENSITY PARATHYROID-HORMONE AND 25-HYDROXYVITAMIN-D CONCENTRATIONS IN MIDDLE-AGED WOMEN	BRITISH MEDICAL JOURNAL			English	Article							VITAMIN-D STATUS; HIP FRACTURE; POSTMENOPAUSAL OSTEOPOROSIS; PROXIMAL FEMUR; PHYSICAL-ACTIVITY; DIETARY CALCIUM; CALCITRIOL; SECRETION; RISK; 25-HYDROXYCHOLECALCIFEROL	Objective-To examine the relation between bone density and indices of calcium metabolism including parathyroid hormone and 25-hydroxyvitamin D concentrations in middle aged women. Design-A cross sectional study. Setting and subjects-138 women volunteers aged 45-65 with no known osteoporosis and unselected for disease status recruited for a dietary assessment study from the community using general practice registers. Volunteer rate was 20%. Main outcome measure-Bone mineral density measured with dual energy x ray absorptiometry. Results-Bone density at the lumbar spine and neck and trochanteric regions of the femur was inversely related to serum intact parathyroid hormone concentrations and positively related to serum 25-hydroxyvitamin D concentrations. These associations were independent of possible confounding factors, including age, body mass index, cigarette smoking habit, menopausal status, and use of diuretics and postmenopausal hormone replacement therapy. These associations were apparent throughout the whole distribution of bone density and 25-hydroxyvitamin D and parathyroid hormone concentrations within the normal range, suggesting a physiological relation. Conclusions-The findings are consistent with the hypothesis that parathyroid hormone and 25-hydroxyvitamin D concentrations influence bone density in middle aged women. Findings from this study together with other work suggest that the role of vitamin D in osteoporosis should not be neglected. The associations with parathyroid hormone also indicate plausible biological mechanisms. The roughly 5-10% difference in bone density between top and bottom tertiles of serum 25-hydroxyvitamin D concentrations, though not large in magnitude, may have considerable public health implications in terms of prevention of osteoporosis and its sequelae, fractures.			KHAW, KT (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,SCH CLIN MED,CLIN GERONTOL UNIT,CAMBRIDGE CB2 2QQ,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AIKEN JM, 1973, NATURE, V241, P59; ALOIA JF, 1988, AM J MED, V84, P401, DOI 10.1016/0002-9343(88)90259-8; BAKER MR, 1979, BRIT MED J, V1, P589, DOI 10.1136/bmj.1.6163.589; BOYCE WJ, 1985, LANCET, V1, P150; CALVO MS, 1991, J CLIN ENDOCR METAB, V72, P69, DOI 10.1210/jcem-72-1-69; CALVO MS, 1990, J CLIN ENDOCR METAB, V70, P1334, DOI 10.1210/jcem-70-5-1334; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; FRAME B, 1978, ANN INTERN MED, V89, P966, DOI 10.7326/0003-4819-89-6-966; GALLAGHER JC, 1989, P SOC EXP BIOL MED, V191, P287; GLOTH FM, 1991, J AM GERIATR SOC, V39, P137, DOI 10.1111/j.1532-5415.1991.tb01615.x; Gregory F., 1990, DIETARY NUTR SURVEY; HOLBROOK TL, 1988, LANCET, V2, P1046, DOI 10.1016/S0140-6736(88)90065-7; HOLICK MF, 1985, ANN NY ACAD SCI, V453, P1, DOI 10.1111/j.1749-6632.1985.tb11793.x; HUI SL, 1988, J CLIN INVEST, V81, P1804, DOI 10.1172/JCI113523; JACOBSEN SJ, 1991, AM J EPIDEMIOL, V133, P996, DOI 10.1093/oxfordjournals.aje.a115819; KRALL EA, 1989, NEW ENGL J MED, V321, P1777, DOI 10.1056/NEJM198912283212602; LAU E, 1988, BRIT MED J, V297, P1441, DOI 10.1136/bmj.297.6661.1441; LAW MR, 1991, BMJ-BRIT MED J, V303, P453, DOI 10.1136/bmj.303.6800.453; LINDALL AW, 1983, J CLIN ENDOCR METAB, V57, P1007, DOI 10.1210/jcem-57-5-1007; LIPS P, 1987, AM J CLIN NUTR, V46, P1005, DOI 10.1093/ajcn/46.6.1005; LIPS P, 1988, J CLIN ENDOCR METAB, V67, P644, DOI 10.1210/jcem-67-4-644; LUND B, 1975, LANCET, V2, P300; MAZESS RB, 1989, P SOC EXP BIOL MED, V191, P261; OTT SM, 1989, ANN INTERN MED, V110, P267, DOI 10.7326/0003-4819-110-4-267; PARFITT AM, 1982, AM J CLIN NUTR, V36, P1014, DOI 10.1093/ajcn/36.5.1014; PARFITT AM, 1988, DRUGS, V36, P513, DOI 10.2165/00003495-198836050-00001; PREECE MA, 1974, CLIN CHIM ACTA, V54, P235, DOI 10.1016/0009-8981(74)90241-1; RAISZ LG, 1988, NEW ENGL J MED, V318, P818; RIGGS BL, 1983, AM J MED, V75, P889; ROSE G, 1981, BMJ-BRIT MED J, V282, P1847, DOI 10.1136/bmj.282.6279.1847; SCRAGG R, IN PRESS ANN EPIDEMI; SILVERBERG SJ, 1989, NEW ENGL J MED, V320, P277, DOI 10.1056/NEJM198902023200503; STEVENSON JC, 1982, BRIT MED J, V285, P585, DOI 10.1136/bmj.285.6342.585; TSAI KS, 1989, J CLIN ENDOCR METAB, V69, P1024, DOI 10.1210/jcem-69-5-1024; TSAI KS, 1984, J CLIN INVEST, V73, P1668, DOI 10.1172/JCI111373; VILLAREAL DT, 1991, J CLIN ENDOCR METAB, V72, P628, DOI 10.1210/jcem-72-3-628; WASNICH RD, 1985, AM J OBSTET GYNECOL, V153, P745, DOI 10.1016/0002-9378(85)90338-2; WICKHAM CAC, 1989, BMJ-BRIT MED J, V299, P889, DOI 10.1136/bmj.299.6704.889; 1991, FORTIFICATION YELLOW, V40	40	186	192	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1992	305	6848					273	277		10.1136/bmj.305.6848.273	http://dx.doi.org/10.1136/bmj.305.6848.273			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG740	1392857	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JG74000014
J	ROBERTS, I; MARSHALL, R; NORTON, R				ROBERTS, I; MARSHALL, R; NORTON, R			CHILD PEDESTRIAN MORTALITY AND TRAFFIC VOLUME IN NEW-ZEALAND	BRITISH MEDICAL JOURNAL			English	Article											ROBERTS, I (corresponding author), UNIV AUCKLAND,INJURY PREVENT RES CTR,DEPT COMMUNITY HLTH,AUCKLAND,NEW ZEALAND.			Marshall, Roger/0000-0001-8278-167X				FROME EL, 1983, BIOMETRICS, V39, P665, DOI 10.2307/2531094; READ RC, 1990, BRIT MED J, V300, P761, DOI 10.1136/bmj.300.6727.761; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; 1990, MORTALITY DEMOGRAPHI; 1990, NZ OFFICIAL YB 1990	5	27	27	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1992	305	6848					283	283		10.1136/bmj.305.6848.283	http://dx.doi.org/10.1136/bmj.305.6848.283			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG740	1392860	Bronze, Green Submitted, Green Published			2022-12-28	WOS:A1992JG74000017
J	RYAN, M				RYAN, M			RUSSIAN REPORT - PERSPECTIVES ON STRIKES BY HEALTH-CARE STAFF	BRITISH MEDICAL JOURNAL			English	Article											RYAN, M (corresponding author), UNIV COLL SWANSEA,CTR RUSSIAN & E EUROPEAN STUDIES,SWANSEA SA2 8PP,W GLAM,WALES.							KOLESNOKOV A, 1992, MOSCOW NEWS WEE 0503, P4; MANUCHAROVA Y, 1992, IZVESTIYA       0513, P2; NARZIKULOV R, 1992, MOSCOW NEWS WEE 0510; SEMENOV A, 1992, MEDITSINSKAYA G 0501, P2; 1992, MOSKOVSKIE NOVO 0510, P2	5	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1992	305	6848					298	299		10.1136/bmj.305.6848.298	http://dx.doi.org/10.1136/bmj.305.6848.298			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG740	1392864	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JG74000025
J	RANDALL, T; MUIR, J; MANT, D				RANDALL, T; MUIR, J; MANT, D			CHOOSING THE PREVENTIVE WORKLOAD IN GENERAL-PRACTICE - PRACTICAL APPLICATION OF THE CORONARY-PREVENTION-GROUP GUIDELINES AND DUNDEE CORONARY RISK-DISK	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine the workload implications for general practice of the Coronary Prevention Group and British Heart Foundation action plan for preventing heart disease. Design-Computer simulation of plan, including calculation of Dundee risk scores, with data from OXCHECK trial. Subjects-4759 patients aged 35-64 who had health checks during 1989-91. Main outcome measure-Effect of using different risk scores as thresholds on workload and coverage of patients at known risk. Thresholds of 6-20 were used for cholesterol screening (nearset) and 4-16 for special care (preset). Results-On the basis of workload a nearset of 8 and preset of 12 would be reasonable. This implies cholesterol measurement in 1794 (37.7%) patients and special care in 1074 (22.6%). However, many patients with single risk factors were not allocated to special care at these thresholds: 11 (37.9%) patients with cholesterol concentrations greater-than-or-equal-to 10 mmol/l, 21 (33.9%) with systolic pressure greater-than-or-equal-to 180 mm Hg, and 213 (40.7%) heavy smokers (>20 cigarettes/day) were missed. The distribution of scores was similar in those at established clinical risk, those with family history of heart disease, and others. Conclusion-The guidelines may help to make best use of resources within specific age-sex groups but sound protocols for unifactorial risk assessment and modification remain essential.	UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,OXFORD OX4 1SX,ENGLAND	Radcliffe Infirmary; University of Oxford			Mant, David CA/C-7763-2009					MANN JI, 1988, BRIT MED J, V296, P1702, DOI 10.1136/bmj.296.6638.1702; Scientific Steering Committee on behalf of the Simon Broome Register Group, 1991, BMJ, V303, P893; TUNSTALLPEDOE H, 1991, BRIT MED J, V303, P744, DOI 10.1136/bmj.303.6805.744; 1991, BMJ, V303, P748; 1980, EUR HEART J, V1, P73; 1989, BMJ; 1991, BMJ, V302, P1057	7	10	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1992	305	6847					227	231		10.1136/bmj.305.6847.227	http://dx.doi.org/10.1136/bmj.305.6847.227			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG112	1392829	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JG11200027
J	DAVIES, M; RAYMAN, G; DAY, J				DAVIES, M; RAYMAN, G; DAY, J			INCREASED INCIDENCE OF CORONARY-DISEASE IN PEOPLE WITH IMPAIRED GLUCOSE-TOLERANCE - LINK WITH INCREASED LIPOPROTEIN(A) CONCENTRATIONS	BRITISH MEDICAL JOURNAL			English	Article											DAVIES, M (corresponding author), IPSWICH DIABET CTR,IPSWICH IP4 5PD,SUFFOLK,ENGLAND.			Davies, Melanie/0000-0002-9987-9371				FULLER JH, 1980, LANCET, V1, P1374; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; SCHRIEWER H, 1984, J CLIN CHEM CLIN BIO, V22, P591; SCOTT J, 1991, BRIT MED J, V303, P663, DOI 10.1136/bmj.303.6804.663; ZIMMET P, 1989, DIABETIC MED, V6, P728, DOI 10.1111/j.1464-5491.1989.tb01266.x	5	19	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 20	1992	304	6842					1610	1611		10.1136/bmj.304.6842.1610	http://dx.doi.org/10.1136/bmj.304.6842.1610			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA436	1385748	Green Published, Bronze			2022-12-28	WOS:A1992JA43600023
J	ROE, TF; COATES, TD; THOMAS, DW; MILLER, JH; GILSANZ, V				ROE, TF; COATES, TD; THOMAS, DW; MILLER, JH; GILSANZ, V			BRIEF REPORT - TREATMENT OF CHRONIC INFLAMMATORY BOWEL-DISEASE IN GLYCOGEN-STORAGE-DISEASE TYPE-IB WITH COLONY-STIMULATING FACTORS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							CROHNS-DISEASE; NEUTROPENIA; DEFECT; LEUKOCYTES; CHEMOTAXIS; SYSTEM; SHUNT		CHILDRENS HOSP LOS ANGELES,DIV NUCL RADIOL,LOS ANGELES,CA; CHILDRENS HOSP LOS ANGELES,DIV DIAGNOST RADIOL,LOS ANGELES,CA; UNIV SO CALIF,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT RADIOL,LOS ANGELES,CA 90033; CHILDRENS HOSP LOS ANGELES,DIV HEMATOL & ONCOL,LOS ANGELES,CA; CHILDRENS HOSP LOS ANGELES,DIV GASTROENTEROL & NUTR,LOS ANGELES,CA	Children's Hospital Los Angeles; Children's Hospital Los Angeles; University of Southern California; University of Southern California; Children's Hospital Los Angeles; Children's Hospital Los Angeles	ROE, TF (corresponding author), CHILDRENS HOSP LOS ANGELES,DIV ENDOCRINOL & METAB,4650 SUNSET BLVD,LOS ANGELES,CA 90027, USA.		Coates, Thomas/AAN-3556-2020	Coates, Thomas/0000-0001-9878-6029	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023547] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-23547] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMBRUSO DR, 1985, AM J DIS CHILD, V139, P691, DOI 10.1001/archpedi.1985.02140090053027; AMENT ME, 1973, NEW ENGL J MED, V288, P382, DOI 10.1056/NEJM197302222880802; ANDERSON DC, 1981, J INFECT DIS, V143, P447, DOI 10.1093/infdis/143.3.447; BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BEAUDET AL, 1980, J PEDIATR-US, V97, P906, DOI 10.1016/S0022-3476(80)80418-5; COATES TD, 1985, COMPUT METH PROG BIO, V21, P195, DOI 10.1016/0169-2607(85)90004-5; CORBEEL L, 1983, EUR J PEDIATR, V140, P273, DOI 10.1007/BF00443375; COUPER R, 1991, GASTROENTEROLOGY, V100, P549, DOI 10.1016/0016-5085(91)90229-E; DIROCCO M, 1984, J INHERIT METAB DIS, V7, P151, DOI 10.1007/BF01805597; GAHR M, 1983, EUR J PEDIATR, V140, P329, DOI 10.1007/BF00442674; GEELHOED GW, 1973, J PEDIATR SURG, V8, P379, DOI 10.1016/0022-3468(73)90105-X; KOVEN NL, 1986, PEDIATR RES, V20, P438, DOI 10.1203/00006450-198605000-00012; LANGE AJ, 1980, J BIOL CHEM, V255, P8381; MCCABE ERB, 1980, J PEDIATR-US, V97, P944, DOI 10.1016/S0022-3476(80)80428-8; NARISAWA K, 1978, BIOCHEM BIOPH RES CO, V83, P1360, DOI 10.1016/0006-291X(78)91371-2; NUSSLE D, 1983, PEDIATR RES, V17, P425; PROLLA JC, 1964, ANN INTERN MED, V61, P1084, DOI 10.7326/0003-4819-61-6-1084; ROE TF, 1986, J PEDIATR-US, V109, P55, DOI 10.1016/S0022-3476(86)80572-8; SANDERSON IR, 1991, J INHERIT METAB DIS, V14, P771, DOI 10.1007/BF01799948; SCHAUB J, 1983, EUR J PEDIATR, V140, P283, DOI 10.1007/BF00442664; SCHROTEN H, 1991, J PEDIATR-US, V119, P748, DOI 10.1016/S0022-3476(05)80290-2; SEGER R, 1984, PEDIATR RES, V18, P297, DOI 10.1203/00006450-198403000-00019; STEIN DT, 1983, GASTROENTEROLOGY, V84, P388; THOMAS DW, 1983, J PEDIATR GASTR NUTR, V2, P491, DOI 10.1097/00005176-198302030-00017; VANNIER JP, 1982, ARCH FR PEDIATR, V39, P367; WANG WC, 1991, LEUKEMIA, V5, P347; WENDEL U, 1987, J PEDIATR-US, V110, P166, DOI 10.1016/S0022-3476(87)80329-3	27	91	94	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 18	1992	326	25					1666	1669		10.1056/NEJM199206183262504	http://dx.doi.org/10.1056/NEJM199206183262504			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY628	1375344				2022-12-28	WOS:A1992HY62800004
J	PARK, JW; MEHROTRA, B; BARNETT, BO; BARON, AD; VENOOK, AP				PARK, JW; MEHROTRA, B; BARNETT, BO; BARON, AD; VENOOK, AP			THE SWEET SYNDROME DURING THERAPY WITH GRANULOCYTE COLONY-STIMULATING FACTOR	ANNALS OF INTERNAL MEDICINE			English	Note						SWEETS SYNDROME; GRANULOCYTE COLONY-STIMULATING FACTOR; NEUTROPENIA; BREAST NEOPLASMS; LEUKOPENIA	MALIGNANCY	A 41-year-old woman with recently diagnosed breast cancer developed the Sweet syndrome during therapy with granulocyte colony-stimulating factor (G-CSF; filgrastim). This patient developed leukopenia during neoadjuvant combination chemotherapy and was subsequently treated with G-CSF. After a brisk recovery of her neutrophil count, the patient developed fever and an erythematous plaque on her thigh, followed by additional lesions. Examination of a skin biopsy specimen confirmed the diagnosis of the Sweet syndrome. The lesions resolved rapidly in the absence of further G-CSF therapy. To our knowledge, this the first unequivocal, biopsy-proven case of the Sweet syndrome to occur during G-CSF therapy. This case suggests that endogenous G-CSF may be involved in the pathogenesis of the Sweet syndrome.	UNIV CALIF SAN FRANCISCO, DIV HEMATOL ONCOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT DERMATOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	PARK, JW (corresponding author), UNIV CALIF SAN FRANCISCO, CTR AMBULATORY CARE A502, HEMATOL ONCOL CLIN, 400 PARNASSUS AVE, SAN FRANCISCO, CA 94143 USA.							COHEN PR, 1987, AM J MED, V82, P1220, DOI 10.1016/0002-9343(87)90229-4; COHEN PR, 1988, J CLIN ONCOL, V6, P1887, DOI 10.1200/JCO.1988.6.12.1887; COHEN PR, 1989, ANN INTERN MED, V110, P573, DOI 10.7326/0003-4819-110-7-573_2; DREICER R, 1989, ANN INTERN MED, V111, P91, DOI 10.7326/0003-4819-111-1-91_2; GLASPY JA, 1988, ANN INTERN MED, V109, P789, DOI 10.7326/0003-4819-109-10-789; KEMMETT D, 1990, J AM ACAD DERMATOL, V23, P503, DOI 10.1016/0190-9622(90)70250-L; MEULDERS Q, 1989, AM J MED, V86, P138, DOI 10.1016/0002-9343(89)90252-0; NEGRIN RS, 1989, ANN INTERN MED, V110, P976, DOI 10.7326/0003-4819-110-12-976; ROSS HJ, 1991, CANCER, V68, P441, DOI 10.1002/1097-0142(19910715)68:2<441::AID-CNCR2820680239>3.0.CO;2-4; SWEET RD, 1964, BRIT J DERMATOL, V76, P349, DOI 10.1111/j.1365-2133.1964.tb14541.x; WAKEFIELD PE, 1990, J AM ACAD DERMATOL, V23, P903, DOI 10.1016/0190-9622(90)70313-7	11	108	108	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1992	116	12	1				996	998		10.7326/0003-4819-116-12-996	http://dx.doi.org/10.7326/0003-4819-116-12-996			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY793	1375012				2022-12-28	WOS:A1992HY79300008
J	HART, IR; SAINI, A				HART, IR; SAINI, A			BIOLOGY OF TUMOR-METASTASIS	LANCET			English	Article							ANGIOGENESIS; RECEPTORS; MELANOMA; CELLS; GENE				HART, IR (corresponding author), IMPERIAL CANC RES FUND,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.							ALBELDA SM, 1990, CANCER RES, V50, P6757; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIDLER IJ, 1977, SCIENCE, V197, P893, DOI 10.1126/science.887927; FOLKMAN J, 1983, SCIENCE, V221, P719, DOI 10.1126/science.6192498; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOULDS L, 1954, CANCER RES, V14, P327; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HART IR, 1989, BIOCHIM BIOPHYS ACTA, V989, P65, DOI 10.1016/0304-419X(89)90035-8; HART IR, 1989, CURR OPIN IMMUNOL, V1, P900, DOI 10.1016/0952-7915(89)90068-X; HUMPHRIES MJ, 1986, SCIENCE, V233, P467, DOI 10.1126/science.3726541; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LLOTA LA, 1991, CELL, V64, P327; MAHADEVAN V, 1991, BRIT J CANCER, V63, P889, DOI 10.1038/bjc.1991.195; MAHADEVAN V, 1990, ACTA ONCOL, V29, P97, DOI 10.3109/02841869009089997; MATSUSHITA Y, 1991, CLIN EXP METASTAS, V9, P283, DOI 10.1007/BF01753731; ROSEN EM, 1991, CELL GROWTH DIFFER, V2, P603; SHIMOYAMA Y, 1991, CANCER LETT, V57, P131, DOI 10.1016/0304-3835(91)90206-W; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STOKER M, 1991, BICHIM BIOPHYS ACTA, V1072, P88; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101	26	339	351	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 13	1992	339	8807					1453	1457		10.1016/0140-6736(92)92039-I	http://dx.doi.org/10.1016/0140-6736(92)92039-I			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY317	1376386				2022-12-28	WOS:A1992HY31700012
J	TORPEY, N; WYLIE, CC; HEASMAN, J				TORPEY, N; WYLIE, CC; HEASMAN, J			FUNCTION OF MATERNAL CYTOKERATIN IN XENOPUS DEVELOPMENT	NATURE			English	Article							HUMAN KERATIN-18; OOCYTES; EMBRYOS; CELLS; EXPRESSION; LAEVIS; ORGANIZATION; DEGRADATION; CLONING; MOUSE	INTERMEDIATE filaments are ubiquitous in eukaryotic cells, but their functions are poorly understood. The Xenopus oocyte contains both messenger RNA and protein products of cytokeratin and vimentin genes 1-5 in non-overlapping arrays. The cytokeratin filaments contain dimers of the type I (acidic) subunit XLK3a(19), and the type II (basic) subunit XCK1(8), polymerized to form a cortical network. These are homologues of the human simple epithelial keratins 19 and 8, respectively. After the first few cell cycles following fertilization these filaments become restricted to the superficial cells of the blastula. We have depleted the oocyte's store of the type II cytokeratin mRNA by injecting antisense oligodeoxynucleotides (oligos) and studied the effect on embryonic development. As zygotic transcription does not commence until the late blastula stage 6, there are at least 9 hours in which to see the effect of loss of function of this mRNA. We report here that the cytokeratin filaments become depleted in the cortical cells of the embryo. As a result, there is a loss of the 'compacted' epithelial surface of the blastula, an inability to close a wounded surface and defective gastrulation.	WELLCOME CANC RES CAMPAIGN,INST CANC & DEV BIOL,TENNIS COURT RD,CAMBRIDGE CB2 1QR,ENGLAND; DEPT ZOOL,CAMBRIDGE CB2 3ED,ENGLAND						Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; DAGLE JM, 1990, NUCLEIC ACIDS RES, V18, P4751, DOI 10.1093/nar/18.16.4751; DOMENJOUD L, 1988, EXP CELL RES, V179, P352, DOI 10.1016/0014-4827(88)90274-1; FRANZ JK, 1986, P NATL ACAD SCI USA, V83, P6475, DOI 10.1073/pnas.83.17.6475; GURDON JB, 1985, CELL, V41, P913, DOI 10.1016/S0092-8674(85)80072-6; HERMANN H, 1989, DEVELOPMENT, V105, P279; HOLWILL S, 1987, DEVELOPMENT, V100, P735; KLYMKOWSKY MW, 1987, DEVELOPMENT, V100, P543; KLYMKOWSKY MW, 1989, DEV BIOL, V134, P479, DOI 10.1016/0012-1606(89)90121-8; KNAPP AC, 1989, CELL, V59, P67, DOI 10.1016/0092-8674(89)90870-2; KULESH DA, 1988, MOL CELL BIOL, V8, P1540, DOI 10.1128/MCB.8.4.1540; KULESH DA, 1989, MOL CELL BIOL, V9, P1553, DOI 10.1128/MCB.9.4.1553; LANE EB, 1992, NATURE, V356, P244, DOI 10.1038/356244a0; LU X, 1990, CELL, V62, P681, DOI 10.1016/0092-8674(90)90114-T; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; Sambrook J, 1989, MOL CLONING LABORATO; TANG P, 1988, DEVELOPMENT, V103, P279; TORPEY NP, 1992, J CELL SCI, V101, P151; TORPEY NP, 1990, DEVELOPMENT, V110, P1185; VASSAR R, 1991, CELL, V64, P365, DOI 10.1016/0092-8674(91)90645-F	20	71	71	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1992	357	6377					413	415		10.1038/357413a0	http://dx.doi.org/10.1038/357413a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX172	1375708				2022-12-28	WOS:A1992HX17200066
J	OLD, P; MONTGOMERY, J				OLD, P; MONTGOMERY, J			LAW, COERCION, AND THE PUBLIC-HEALTH	BRITISH MEDICAL JOURNAL			English	Article							AIDS		UNIV SOUTHAMPTON,FAC LAW,SOUTHAMPTON SO9 5NH,HANTS,ENGLAND	University of Southampton	OLD, P (corresponding author), WESTERN HOSP,DEPT PUBL HLTH,SOUTHAMPTON SO9 4WQ,ENGLAND.		Montgomery, Jonathan/G-6034-2014	Montgomery, Jonathan/0000-0002-4592-0930				Brahams D., 1987, New Law Journal, V137, P749; DELAMONTE T, 1991, BRIT MED J, V303, P540; GRAY JAM, 1981, J MED ETHICS, V7, P146, DOI 10.1136/jme.7.3.146; OSBORN JE, 1988, NEW ENGL J MED, V318, P444, DOI 10.1056/NEJM198802183180710; PORTER R, 1986, BRIT MED J, V293, P1589, DOI 10.1136/bmj.293.6562.1589; 1989, REV LAW INFECTIOUS D; 1985, BMJ, V291, P1102	7	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1992	304	6831					891	892		10.1136/bmj.304.6831.891	http://dx.doi.org/10.1136/bmj.304.6831.891			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HM835	1392756	Green Published, Bronze			2022-12-28	WOS:A1992HM83500035
J	STRACHAN, DP; ANDERSON, HR				STRACHAN, DP; ANDERSON, HR			TRENDS IN HOSPITAL ADMISSION RATES FOR ASTHMA IN CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE; HEALTH				STRACHAN, DP (corresponding author), ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.							ANDERSON HR, 1989, THORAX, V44, P614, DOI 10.1136/thx.44.8.614; ANDERSON HR, 1989, ARCH DIS CHILD, V64, P172, DOI 10.1136/adc.64.1.172; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; Burr ML, 1989, ARCH DIS CHILD, V64, P1118; HILL R, 1989, BRIT MED J, V299, P898, DOI 10.1136/bmj.299.6704.898	5	73	73	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1992	304	6830					819	820		10.1136/bmj.304.6830.819	http://dx.doi.org/10.1136/bmj.304.6830.819			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL827	1392711	Green Published, Bronze			2022-12-28	WOS:A1992HL82700023
J	MUST, A; JACQUES, PF; DALLAL, GE; BAJEMA, CJ; DIETZ, WH				MUST, A; JACQUES, PF; DALLAL, GE; BAJEMA, CJ; DIETZ, WH			LONG-TERM MORBIDITY AND MORTALITY OF OVERWEIGHT ADOLESCENTS - A FOLLOW-UP OF THE HARVARD GROWTH STUDY OF 1922 TO 1935	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARDIOVASCULAR-DISEASE; SERUM-LIPIDS; RISK FACTOR; OBESITY; WOMEN; WEIGHT; LIPOPROTEINS; CHILDREN; HEALTH; DEATH	Background. Overweight in adults is associated with increased morbidity and mortality. In contrast, the long-term effect of overweight in adolescence on morbidity and mortality is not known. Methods. We studied the relation between overweight and morbidity and mortality in 508 lean or overweight adolescents 13 to 18 years old who participated in the Harvard Growth Study of 1922 to 1935. Overweight adolescents were defined as those with a body-mass index that on two occasions was greater than the 75th percentile in subjects of the same age and sex in a large national survey. Lean adolescents were defined as those with a body-mass index between the 25th and 50th percentiles. Subjects who were still alive were interviewed in 1988 to obtain information about their medical history, weight, functional capacity, and other risk factors. For those who had died, information on the cause of death was obtained from death certificates. Results. Overweight in adolescent subjects was associated with an increased risk of mortality from all causes and disease-specific mortality among men, but not among women. The relative risks among men were 1.8 (95 percent confidence interval, 1.2 to 2.7; P = 0.004) for mortality from all causes and 2.3 (95 percent confidence interval, 1.4 to 4.1; P = 0.002) for mortality from coronary heart disease. The risk of morbidity from coronary heart disease and atherosclerosis was increased among men and women who had been overweight in adolescence. The risk of colorectal cancer and gout was increased among men and the risk of arthritis was increased among women who had been overweight in adolescence. Overweight in adolescence was a more powerful predictor of these risks than overweight in adulthood. Conclusions. Overweight in adolescence predicted a broad range of adverse health effects that were independent of adult weight after 55 years of follow-up.	GRAND VALLEY STATE UNIV, ALLENDALE, MI USA; TUFTS UNIV, USDA, HUMAN NUTR RES CTR, DIV BIOSTAT, BOSTON, MA 02111 USA; NEW ENGLAND MED CTR, BOSTON, MA 02111 USA	Grand Valley State University; Tufts University; United States Department of Agriculture (USDA); Tufts Medical Center	MUST, A (corresponding author), TUFTS UNIV, USDA, HUMAN NUTR RES CTR, EPIDEMIOL PROGRAM, 711 WASHINGTON ST, BOSTON, MA 02111 USA.							ABRAHAM S, 1971, HSMHA HEALTH REP, V86, P273, DOI 10.2307/4594149; USA Pooling Project Research Group, 1978, Journal of Chronic Diseases, V31, P201; COLDITZ GA, 1990, AM J EPIDEMIOL, V132, P501, DOI 10.1093/oxfordjournals.aje.a115686; COMSTOCK GW, 1986, AM J EPIDEMIOL, V124, P180, DOI 10.1093/oxfordjournals.aje.a114376; CRONK CE, 1982, AM J CLIN NUTR, V35, P347, DOI 10.1093/ajcn/35.2.347; DAVIS MA, 1990, SEMIN ARTHRITIS RHEU, V20, P34, DOI 10.1016/0049-0172(90)90045-H; DEARBORN WF, 1938, MONOGR SOC RES CHILD, V3; DEUTSCH MI, 1985, ANN HUM BIOL, V12, P275, DOI 10.1080/03014468500007781; DIXON WJ, 1988, BMDP STATISTICAL SOF; DONAHUE RP, 1985, AM J EPIDEMIOL, V122, P458, DOI 10.1093/oxfordjournals.aje.a114127; FELSON DT, 1990, SEMIN ARTHRITIS RHEU, V20, P42, DOI 10.1016/0049-0172(90)90046-I; HARTZ AJ, 1986, J CHRON DIS, V39, P311, DOI 10.1016/0021-9681(86)90053-6; HAUST M D, 1990, Pediatric Pathology, V10, P253; HENRY RR, 1986, DIABETES, V35, P155, DOI 10.2337/diabetes.35.2.155; HOFFMANS MDAF, 1988, J CLIN EPIDEMIOL, V41, P749, DOI 10.1016/0895-4356(88)90161-8; HOFFMANS MDAF, 1989, J CLIN EPIDEMIOL, V42, P513, DOI 10.1016/0895-4356(89)90147-9; KANNEL WB, 1984, J AM COLL NUTR, V3, P139; KATZ S, 1983, NEW ENGL J MED, V309, P1218, DOI 10.1056/NEJM198311173092005; LAPIDUS L, 1984, BMJ-BRIT MED J, V289, P1257, DOI 10.1136/bmj.289.6454.1257; LAPIDUS L, 1990, BRIT MED J, V10, P253; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MANSON JE, 1989, AM J EPIDEMIOL, V130, P833; MOSSBERG HO, 1989, LANCET, V2, P491; MUELLER WH, 1982, SOC SCI MED, V16, P191, DOI 10.1016/0277-9536(82)90022-3; PAFFENBARGER RS, 1973, AM J EPIDEMIOL, V97, P314, DOI 10.1093/oxfordjournals.aje.a121511; PAFFENBARGER RS, 1969, AM J EPIDEMIOL, V90, P527, DOI 10.1093/oxfordjournals.aje.a121099; SCOTT EC, 1982, HUM BIOL, V54, P501; SORENSEN TIA, 1977, J CHRON DIS, V30, P359, DOI 10.1016/0021-9681(77)90030-3; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; VANITALLIE TB, 1979, AM J CLIN NUTR, V32, P2723, DOI 10.1093/ajcn/32.12.2723; VOORS AW, 1982, ARTERIOSCLEROSIS, V2, P346, DOI 10.1161/01.ATV.2.4.346; WAALER HT, 1984, ACTA MED SCAND, P1; WEBBER LS, 1983, J CHRON DIS, V36, P647, DOI 10.1016/0021-9681(83)90081-4; WEBBER LS, 1991, AM J EPIDEMIOL, V133, P884, DOI 10.1093/oxfordjournals.aje.a115968; WEINSIER RL, 1985, HYPERTENSION, V7, P578, DOI 10.1161/01.HYP.7.4.578; WILLETT W, 1989, NATURE, V338, P389, DOI 10.1038/338389a0; WILLETT W, 1990, MONOGRAPHS EPIDEMIOL, V15, P231; WYLIE CM, 1984, J AM GERIATR SOC, V32, P670, DOI 10.1111/j.1532-5415.1984.tb02258.x; 1990, NUTRITION YOUR HLTH; 1990, SAS STAT USERS GUIDE; 1980, INT CLASSIFICATION D; 1990, DHHS PHS901148 PUBL; 1990, NATIONAL HLTH NUTRIT, V3	44	1586	1641	1	64	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 5	1992	327	19					1350	1355		10.1056/NEJM199211053271904	http://dx.doi.org/10.1056/NEJM199211053271904			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW077	1406836				2022-12-28	WOS:A1992JW07700004
J	WANG, KY; HODGES, M				WANG, KY; HODGES, M			THE PREMATURE VENTRICULAR COMPLEX AS A DIAGNOSTIC-AID	ANNALS OF INTERNAL MEDICINE			English	Review						EXTRASYSTOLE; PREMATURE VENTRICULAR COMPLEX; CORONARY DISEASE; ELECTROCARDIOGRAPHY	MYOCARDIAL-INFARCTION; POSTEXTRASYSTOLIC POTENTIATION; DYSFUNCTION; MORTALITY; PREDICTOR; SURGERY; BEATS	Premature ventricular complexes (PVCs) can provide clues to the physical or electrocardiographic diagnosis through the associated compensatory pause, the break in the regularity of the rhythm, or the morphology of the PVC itself. A PVC may allow visualization of the P wave or of atrial flutter waves that would otherwise be obscured in the electrocardiogram. It can also be useful in distinguishing an S3 gallop from an S4 gallop. The compensatory pause that follows a PVC may allow normal conduction of the next QRS complex in a patient with a rate-dependent intraventricular conduction defect, and this normalized QRS complex may contain important diagnostic findings. A PVC can also reveal a myocardial infarct pattern when the sinus complex fails to do so. Although the need to treat PVCs is currently being de-emphasized, their diagnostic utility should not be overlooked.	UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	WANG, KY (corresponding author), HENNEPIN CTY MED CTR, DEPT MED, DIV CARDIOL, 701 PK AVE S, MINNEAPOLIS, MN 55415 USA.							[Anonymous], 1989, NEW ENGL J MED, V321, P406; [Anonymous], 1973, JAMA, V223, P1116; ANTTONEN V M, 1962, Acta Med Scand Suppl, V387, P1; BECKER LC, 1986, J AM COLL CARDIOL, V7, P580, DOI 10.1016/S0735-1097(86)80468-5; BIGGER JT, 1984, CIRCULATION, V69, P250, DOI 10.1161/01.CIR.69.2.250; BISTENI A, 1961, BRIT HEART J, V23, P521; BROCKENBROUGH E, 1961, CIRCULATION, V23, P189, DOI 10.1161/01.CIR.23.2.189; COHN KE, 1967, CIRCULATION, V36, P372, DOI 10.1161/01.CIR.36.3.372; CONNOLLY SJ, 1992, AM J CARDIOL, V69, P308, DOI 10.1016/0002-9149(92)90225-N; DASH H, 1983, AM J CARDIOL, V52, P458, DOI 10.1016/0002-9149(83)90007-3; Dressler W, 1943, AM J MED SCI, V206, P361, DOI 10.1097/00000441-194320630-00011; GOLDMAN L, 1983, ANN INTERN MED, V98, P504, DOI 10.7326/0003-4819-98-4-504; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; HADA Y, 1982, CIRCULATION, V65, P617, DOI 10.1161/01.CIR.65.3.617; HILL JC, 1969, AM HEART J, V78, P194, DOI 10.1016/0002-8703(69)90008-8; KILLIP T, 1967, AM J CARDIOL, V20, P457, DOI 10.1016/0002-9149(67)90023-9; LEE DCS, 1982, NEW ENGL J MED, V306, P699, DOI 10.1056/NEJM198203253061202; NESTO RW, 1982, AM J CARDIOL, V50, P39, DOI 10.1016/0002-9149(82)90006-6; POPIO KA, 1977, AM J CARDIOL, V39, P944, DOI 10.1016/S0002-9149(77)80206-3; RILEY CP, 1973, AM HEART J, V86, P598, DOI 10.1016/0002-8703(73)90336-0; Ross J Jr, 1968, Circulation, V38, P61; RUBERMAN W, 1977, NEW ENGL J MED, V297, P750, DOI 10.1056/NEJM197710062971404	22	19	23	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1992	117	9					766	770		10.7326/0003-4819-117-9-766	http://dx.doi.org/10.7326/0003-4819-117-9-766			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV424	1384411				2022-12-28	WOS:A1992JV42400010
J	TIENARI, PJ; WIKSTROM, J; SAJANTILA, A; PALO, J; PELTONEN, L				TIENARI, PJ; WIKSTROM, J; SAJANTILA, A; PALO, J; PELTONEN, L			GENETIC SUSCEPTIBILITY TO MULTIPLE-SCLEROSIS LINKED TO MYELIN BASIC-PROTEIN GENE	LANCET			English	Article							LENGTH POLYMORPHISM; DNA; AMPLIFICATION; TRANSCRIPTION; POLYMERASE; CRITERIA; MOUSE; RISK; MRI	Genetic factors have been implicated in the aetiology of multiple sclerosis (MS), but the genes conferring susceptibility to MS have not been identified. We carried out genetic linkage and association analyses by studying polymorphism of the myelin basic protein (MBP) gene on chromosome 18, a candidate gene for MS, in 21 MS families, 51 additional unrelated patients with definite MS, and 85 controls. All subjects were Finnish, and 14 of the families were from an area with an exceptional familial clustering of MS. Magnetic resonance imaging (MRI) was used to examine subclinical disease in symptom-free family members. In the association analysis, the allele frequencies between MS patients and controls differed significantly, p = 0.000049), the difference being attributable mainly to a higher frequency of a 1.27 kb allele among patients. In the linkage analysis, based on an autosomal dominant model and penetrance 0.05, a maximum LOD score of 3.42 (theta = 0.00) was obtained when patients with optic neuritis and their symptom-free siblings with abnormal MRI findings were classified as "affected". When these subjects were classified as "unknown" the maximum LOD scores ranged from 2.99 to 3.25 (theta = 0.00). The results suggest that in this population genetic predisposition to MS is closely linked to the MBP gene and that polymorphism at the MBP locus or an adjacent locus has a role in the aetiology of MS.	UNIV HELSINKI,DEPT NEUROL,SF-00100 HELSINKI 10,FINLAND	University of Helsinki	TIENARI, PJ (corresponding author), NATL PUBL HLTH INST,DEPT HUMAN MOLEC GENET,MANNERHEIMINTIE 166,SF-00300 HELSINKI,FINLAND.		Sajantila, Antti/AAY-9084-2021; Tienari, Pentti J/A-4893-2012	Sajantila, Antti/0000-0003-4117-5248				Alvord EC, 1984, EXPT ALLERGIC ENCEPH; BOYLAN KB, 1990, GENOMICS, V6, P16, DOI 10.1016/0888-7543(90)90443-X; BOYLAN KB, 1987, AM J HUM GENET, V40, P387; BOYLAN KB, 1990, ANN NEUROL, V27, P291, DOI 10.1002/ana.410270311; COMPSTON A, 1986, P56; EBERS GC, 1982, LANCET, V2, P88; FAZEKAS F, 1988, NEUROLOGY, V38, P1822, DOI 10.1212/WNL.38.12.1822; FUJINAMI RS, 1985, SCIENCE, V230, P1043, DOI 10.1126/science.2414848; KAMHOLZ J, 1987, AM J HUM GENET, V40, P365; KASAI K, 1990, J FORENSIC SCI, V35, P1196; KINNUNEN E, 1983, ACTA NEUROL SCAND, V67, P255, DOI 10.1111/j.1600-0404.1983.tb04574.x; KURTZKE JF, 1983, MULTIPLE SCLEROSIS P, P47; MCDONALD WI, 1986, J NEUROL NEUROSUR PS, V49, P434; MCFARLAND HF, 1989, CLIN IMMUNOL IMMUNOP, V50, pS96, DOI 10.1016/0090-1229(89)90116-5; NEVANLINNA HR, 1972, HEREDITAS-GENETISK A, V71, P195; OKANO H, 1988, EMBO J, V7, P77, DOI 10.1002/j.1460-2075.1988.tb02785.x; Ott J., 1991, ANAL HUMAN GENETIC L; PATY DW, 1988, NEUROLOGY, V38, P180, DOI 10.1212/WNL.38.2.180; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; RIZZO JF, 1988, NEUROLOGY, V38, P185, DOI 10.1212/WNL.38.2.185; ROACH A, 1985, CELL, V42, P149, DOI 10.1016/S0092-8674(85)80110-0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAJANTILA A, 1992, AM J HUM GENET, V50, P816; Sambrook J., 1989, MOL CLONING; SANDBERG-WOLLHEIM M, 1990, Annals of Neurology, V27, P386, DOI 10.1002/ana.410270406; TIENARI PJ, IN PRESS J NEUROL NE; VISSCHER BR, 1979, NEUROLOGY, V29, P1354, DOI 10.1212/WNL.29.10.1354; WIKSTROM J, 1975, ACTA NEUROL SCAND, V51, P173, DOI 10.1111/j.1600-0404.1975.tb07598.x; WIKSTROM J, 1984, Neuroepidemiology, V3, P74, DOI 10.1159/000110844	29	141	141	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 24	1992	340	8826					987	991		10.1016/0140-6736(92)93007-A	http://dx.doi.org/10.1016/0140-6736(92)93007-A			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV014	1383661				2022-12-28	WOS:A1992JV01400001
J	ALCAMI, A; SMITH, GL				ALCAMI, A; SMITH, GL			A SOLUBLE RECEPTOR FOR INTERLEUKIN-1-BETA ENCODED BY VACCINIA VIRUS - A NOVEL MECHANISM OF VIRUS MODULATION OF THE HOST RESPONSE TO INFECTION	CELL			English	Article							TUMOR-NECROSIS-FACTOR; INVERTED TERMINAL REPEAT; IL-1 RECEPTOR; BIOLOGICAL CHARACTERIZATION; IMMUNOGLOBULIN SUPERFAMILY; NUCLEOTIDE-SEQUENCE; B-CELLS; ANTAGONIST; EXPRESSION; BINDING	Vaccinia virus gene B15R is shown to encode an abundant, secretory glycoprotein that functions as a soluble interleukin-1 (IL-1) receptor. This IL-1 receptor has novel specificity since, in contrast with cellular counterparts, it binds only IL-1beta and not IL-1alpha or the natural competitor IL-1 receptor antagonist. The vaccinia IL-1beta receptor is secreted when expressed in a baculovirus system and competitively inhibited binding of IL-1beta to the natural receptor on T cells. Deletion of B15R from vaccinia virus accelerated the appearance of symptoms of illness and mortality in intranasally infected mice, suggesting that the blockade of IL-1beta by vaccinia virus can diminish the systemic acute phase response to infection and modulate the severity of the disease. The IL-1beta binding activity is present in other orthopoxviruses.			ALCAMI, A (corresponding author), UNIV OXFORD, SIR WILLIAM DUNN SCH PATHOL, OXFORD OX1 3RE, ENGLAND.		Alcami, Antonio/F-8512-2015; Smith, Geoffrey L/G-2894-2012	Alcami, Antonio/0000-0002-3333-6016; Smith, Geoffrey L/0000-0002-3730-9955	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGUADO B, 1992, CELL, V73; ALEXANDER HR, 1991, J EXP MED, V173, P1029, DOI 10.1084/jem.173.4.1029; BENJAMIN D, 1990, J BIOL CHEM, V265, P9943; BREDER CD, 1988, SCIENCE, V240, P321, DOI 10.1126/science.3258444; BROWN M, 1977, J GEN VIROL, V36, P361, DOI 10.1099/0022-1317-36-2-361; BULLER RML, 1991, MICROBIOL REV, V55, P80, DOI 10.1128/MMBR.55.1.80-122.1991; BUSBRIDGE NJ, 1989, BIOCHEM BIOPH RES CO, V162, P591, DOI 10.1016/0006-291X(89)92351-6; CARTER DB, 1990, NATURE, V344, P633, DOI 10.1038/344633a0; DIGIOVINE FS, 1990, IMMUNOL TODAY, V11, P13; DINARELLO CA, 1989, ADV IMMUNOL, V44, P153, DOI 10.1016/S0065-2776(08)60642-2; DINARELLO CA, 1991, IMMUNOL TODAY, V12, P404, DOI 10.1016/0167-5699(91)90142-G; DINARELLO CA, 1988, FASEB J, V2, P108, DOI 10.1096/fasebj.2.2.3277884; DOWER SK, 1985, J EXP MED, V162, P501, DOI 10.1084/jem.162.2.501; DOWER SK, 1989, J IMMUNOL, V142, P4314; DOWER SK, 1987, IMMUNOL TODAY, V8, P46, DOI 10.1016/0167-5699(87)90238-6; DRIPPS DJ, 1991, J BIOL CHEM, V266, P20311; DUFF GW, 1983, NATURE, V304, P449, DOI 10.1038/304449a0; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; ESPOSITO J, 1981, J VIROL METHODS, V2, P175, DOI 10.1016/0166-0934(81)90036-7; FALKNER FG, 1990, J VIROL, V64, P3108, DOI 10.1128/JVI.64.6.3108-3111.1990; FANSLOW WC, 1990, SCIENCE, V248, P739, DOI 10.1126/science.2139736; GERSHENWALD JE, 1990, P NATL ACAD SCI USA, V87, P4966, DOI 10.1073/pnas.87.13.4966; GINSBERG HS, 1989, P NATL ACAD SCI USA, V86, P3823, DOI 10.1073/pnas.86.10.3823; GIRI JG, 1990, J BIOL CHEM, V265, P17416; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; GOODING LR, 1988, CELL, V53, P341, DOI 10.1016/0092-8674(88)90154-7; GRANOWITZ EV, 1991, J BIOL CHEM, V266, P14147; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HAZUDA DJ, 1988, J BIOL CHEM, V263, P8473; HOWARD ST, 1991, VIROLOGY, V180, P633, DOI 10.1016/0042-6822(91)90077-O; HSU DH, 1990, SCIENCE, V250, P830, DOI 10.1126/science.2173142; HUGHES SJ, 1991, J BIOL CHEM, V266, P20103; IKUTA K, 1980, J GEN VIROL, V47, P227, DOI 10.1099/0022-1317-47-1-227; ISAACS SN, 1990, VIROLOGY, V178, P626, DOI 10.1016/0042-6822(90)90367-Z; Jezek Z, 1988, HUMAN MONKEYPOX; KATSUURA G, 1988, BIOCHEM BIOPH RES CO, V156, P61, DOI 10.1016/S0006-291X(88)80805-2; KENT RK, 1988, THESIS U CAMBRIDGE C; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARRICK JW, 1989, IMMUNOL TODAY, V10, P61, DOI 10.1016/0167-5699(89)90308-3; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MACDONALD HR, 1985, J IMMUNOL, V135, P3944; Mackett M., 1985, DNA CLONING PRACTICA, P191; MCINTYRE KW, 1991, J EXP MED, V173, P931, DOI 10.1084/jem.173.4.931; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MOORE JB, 1992, EMBO J, V11, P1973, DOI 10.1002/j.1460-2075.1992.tb05251.x; MOSS B, 1990, ANNU REV BIOCHEM, V59, P661, DOI 10.1146/annurev.biochem.59.1.661; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEURATH AR, 1992, J EXP MED, V175, P461, DOI 10.1084/jem.175.2.461; OHLSSON K, 1990, NATURE, V348, P550, DOI 10.1038/348550a0; PERKUS ME, 1991, VIROLOGY, V180, P406, DOI 10.1016/0042-6822(91)90047-F; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; ROMANCZUK H, 1992, P NATL ACAD SCI USA, V89, P3159, DOI 10.1073/pnas.89.7.3159; Sambrook J, 1989, MOL CLONING LABORATO; SHIELDS J, 1991, CLIN BIOTECHNOL, V3, P81; SIMS JE, 1989, P NATL ACAD SCI USA, V86, P8946, DOI 10.1073/pnas.86.22.8946; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SMITH CA, 1991, BIOCHEM BIOPH RES CO, V176, P335, DOI 10.1016/0006-291X(91)90929-2; SMITH GL, 1991, J GEN VIROL, V72, P511, DOI 10.1099/0022-1317-72-3-511; SMITH GL, 1991, J GEN VIROL, V72, P1349, DOI 10.1099/0022-1317-72-6-1349; SPRIGGS MK, 1992, CELL, V71, P145, DOI 10.1016/0092-8674(92)90273-F; SYMONS J A, 1990, Cytokine, V2, P190, DOI 10.1016/1043-4666(90)90015-L; SYMONS JA, 1991, J EXP MED, V174, P1251, DOI 10.1084/jem.174.5.1251; SYMONS JA, 1990, FEBS LETT, V272, P133, DOI 10.1016/0014-5793(90)80466-V; TAGA T, 1987, J EXP MED, V166, P967, DOI 10.1084/jem.166.4.967; TRAKTMAN P, 1990, CURR TOP MICROBIOL, V163, P93; Turner G S, 1967, J Gen Virol, V1, P399, DOI 10.1099/0022-1317-1-3-399; TURNER PC, 1990, CURR TOP MICROBIOL, V163, P125; UEDA Y, 1972, VIROLOGY, V49, P794, DOI 10.1016/0042-6822(72)90535-1; UEDA Y, 1990, VIROLOGY, V177, P588, DOI 10.1016/0042-6822(90)90524-U; UEHARA A, 1987, BIOCHEM BIOPH RES CO, V146, P1286, DOI 10.1016/0006-291X(87)90788-1; UPTON C, 1991, VIROLOGY, V184, P370, DOI 10.1016/0042-6822(91)90853-4; URDAL DL, 1988, J BIOL CHEM, V263, P2870; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WILLIAMSON JD, 1990, J GEN VIROL, V71, P2761, DOI 10.1099/0022-1317-71-11-2761; ZUIDEMA D, 1990, J GEN VIROL, V71, P2201, DOI 10.1099/0022-1317-71-10-2201; [No title captured]	78	425	439	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 2	1992	71	1					153	167		10.1016/0092-8674(92)90274-G	http://dx.doi.org/10.1016/0092-8674(92)90274-G			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1394428				2022-12-28	WOS:A1992JQ62300015
J	CLARK, DJ; FELSENFELD, G				CLARK, DJ; FELSENFELD, G			A NUCLEOSOME CORE IS TRANSFERRED OUT OF THE PATH OF A TRANSCRIBING POLYMERASE	CELL			English	Article							RNA-POLYMERASE; TRANSCRIPTIONALLY COMPETENT; CHROMATIN STRUCTURE; DNA-TEMPLATE; II INVITRO; 5S RNA; INITIATION; HISTONES; DISPLACEMENT; ELONGATION	We have determined the fate of a nucleosome core on transcription. A nucleosome core was assembled on a short DNA fragment and ligated into a plasmid containing a promoter and terminators for SP6 RNA polymerase. The nucleosome core was stable in the absence of transcription. The distribution of nucleosome cores after transcription was examined. The histone octamer was displaced from its original site and reformed a nucleosome core at a new site within the same plasmid molecule, with some preference for the untranscribed region behind the promoter. These observations eliminate several models that have been proposed for transcription through a nucleosome core. Our results suggest that a nucleosome core in the path of a transcribing polymerase is displaced by transfer to the closest acceptor DNA.			CLARK, DJ (corresponding author), NIH,MOLEC BIOL LAB,BETHESDA,MD 20892, USA.							BERG OG, 1982, TRENDS BIOCHEM SCI, V7, P52, DOI 10.1016/0968-0004(82)90075-5; BJORKROTH B, 1988, CHROMOSOMA, V96, P333, DOI 10.1007/BF00330699; BONNEANDREA C, 1990, NATURE, V343, P719, DOI 10.1038/343719a0; CAMERON V, 1977, BIOCHEMISTRY-US, V16, P5120, DOI 10.1021/bi00642a027; CARON F, 1981, J MOL BIOL, V146, P513, DOI 10.1016/0022-2836(81)90045-0; CLARK DJ, 1991, EMBO J, V10, P387, DOI 10.1002/j.1460-2075.1991.tb07960.x; DEBERNARDIN W, 1986, J MOL BIOL, V191, P469, DOI 10.1016/0022-2836(86)90142-7; EICKBUSH TH, 1978, BIOCHEMISTRY-US, V17, P4955, DOI 10.1021/bi00616a016; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FELTS SJ, 1990, MOL CELL BIOL, V10, P2390, DOI 10.1128/MCB.10.5.2390; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; HAYES JJ, 1990, P NATL ACAD SCI USA, V87, P7405, DOI 10.1073/pnas.87.19.7405; HOROWITZ DS, 1984, J MOL BIOL, V173, P75, DOI 10.1016/0022-2836(84)90404-2; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; KIROV N, 1992, EMBO J, V11, P1941, DOI 10.1002/j.1460-2075.1992.tb05247.x; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; KNEZETIC JA, 1988, MOL CELL BIOL, V8, P3114, DOI 10.1128/MCB.8.8.3114; KORNBERG RD, 1991, CELL, V67, P833, DOI 10.1016/0092-8674(91)90354-2; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; LORCH Y, 1988, CELL, V55, P743, DOI 10.1016/0092-8674(88)90128-6; LOSA R, 1987, CELL, V50, P801, DOI 10.1016/0092-8674(87)90338-2; McKnight S L, 1978, Cold Spring Harb Symp Quant Biol, V42 Pt 2, P741; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MORSE RH, 1989, EMBO J, V8, P2343, DOI 10.1002/j.1460-2075.1989.tb08362.x; MORSE RH, 1992, TRENDS BIOCHEM SCI, V17, P23, DOI 10.1016/0968-0004(92)90422-6; NACHEVA GA, 1989, CELL, V58, P27, DOI 10.1016/0092-8674(89)90399-1; ONEILL TE, 1992, J MOL BIOL, V223, P67, DOI 10.1016/0022-2836(92)90716-W; PFAFFLE P, 1990, J BIOL CHEM, V265, P16830; RHODES D, 1985, EMBO J, V4, P3473, DOI 10.1002/j.1460-2075.1985.tb04106.x; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; RUUSALA T, 1992, P NATL ACAD SCI USA, V89, P4903, DOI 10.1073/pnas.89.11.4903; SHORE D, 1983, J MOL BIOL, V170, P957, DOI 10.1016/S0022-2836(83)80198-3; SPADAFORA C, 1979, EUR J BIOCHEM, V100, P225, DOI 10.1111/j.1432-1033.1979.tb02053.x; STEIN A, 1979, J MOL BIOL, V130, P103, DOI 10.1016/0022-2836(79)90421-2; TENHEGGELERBORDIER B, 1992, EMBO J, V11, P667, DOI 10.1002/j.1460-2075.1992.tb05098.x; THOMA F, 1991, TRENDS GENET, V7, P175, DOI 10.1016/0168-9525(91)90429-T; THOMAS JO, 1975, P NATL ACAD SCI USA, V72, P2626, DOI 10.1073/pnas.72.7.2626; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; VOORDOUW G, 1978, NATURE, V273, P446, DOI 10.1038/273446a0; WILLIAMSON P, 1978, BIOCHEMISTRY-US, V17, P5695, DOI 10.1021/bi00619a015; WOLFFE A, 1992, CHROMATIN STRUCTURE; WOLFFE AP, 1989, P NATL ACAD SCI USA, V86, P9817, DOI 10.1073/pnas.86.24.9817; WOLFFE AP, 1986, CELL, V44, P381, DOI 10.1016/0092-8674(86)90459-9; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8	48	132	133	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 2	1992	71	1					11	22		10.1016/0092-8674(92)90262-B	http://dx.doi.org/10.1016/0092-8674(92)90262-B			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1394427				2022-12-28	WOS:A1992JQ62300003
J	MATSUMURA, K; TOME, FMS; COLLIN, H; AZIBI, K; CHAOUCH, M; KAPLAN, JC; FARDEAU, M; CAMPBELL, KP				MATSUMURA, K; TOME, FMS; COLLIN, H; AZIBI, K; CHAOUCH, M; KAPLAN, JC; FARDEAU, M; CAMPBELL, KP			DEFICIENCY OF THE 50K DYSTROPHIN-ASSOCIATED GLYCOPROTEIN IN SEVERE CHILDHOOD AUTOSOMAL RECESSIVE MUSCULAR-DYSTROPHY	NATURE			English	Article							SKELETAL-MUSCLE; COMPLEX; PROTEIN	X-LINKED recessive Duchenne muscular dystrophy (DMD) is caused by the absence of dystrophin, a membrane cytoskeletal protein1,2. Dystrophin is associated with a large oligomeric complex of sarcolemmal glycoproteins3-10. The dystrophin-glycoprotein complex has been proposed to span the sarcolemma to provide a link between the subsarcolemmal cytoskeleton and the extracellular matrix component, laminin7,9. In DMD, the absence of dystrophin leads to a large reduction in all of the dystrophin-associated proteins4,9,10. We have investigated the possibility that a deficiency of a dystrophin-associated protein could be the cause of severe childhood autosomal recessive muscular dystrophy (SCARMD) with a DMD-like phenotype11-14. Here we report the specific deficiency of the 50K dystrophin-associated glycoprotein (M(r) 50,000) in sarcolemma of SCARMD patients. Therefore, the loss of this glycoprotein is a common denominator of the pathological process leading to muscle cell necrosis in two forms of muscular dystrophy, DMD and SCARMD.	UNIV IOWA, COLL MED, HOWARD HUGHES MED INST, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA; INSERM, U153, F-75005 PARIS, FRANCE; HOP BOLOGHINE, BIOL LAB, ALGIERS, ALGERIA; HOP BEN AKNOUN, SERV NEUROL, ALGIERS, ALGERIA; INST COCHIN GENET MOLEC, INSERM, U129, F-75014 PARIS, FRANCE	Howard Hughes Medical Institute; University of Iowa; University of Iowa; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)				Campbell, Kevin/0000-0003-2066-5889				BENHAMIDA M, 1992, J NEUROL SCI, V107, P60; BENJELLOUNDELLAGI S, 1990, NEUROLOGY, V40, P1903; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; HAMIDA MB, 1983, MUSCLE NERVE, V6, P469, DOI 10.1002/mus.880060702; HEMMINGS L, 1992, J CELL BIOL, V116, P1369, DOI 10.1083/jcb.116.6.1369; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; Khurana T S, 1991, Neuromuscul Disord, V1, P185, DOI 10.1016/0960-8966(91)90023-L; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; LOVE DR, 1989, NATURE, V339, P55, DOI 10.1038/339055a0; McKusick V. A. E., 1991, MENDELIAN INHERITANC; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; OHLENDIECK K, IN PRESS NEUROLOGY	17	256	258	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 24	1992	359	6393					320	322		10.1038/359320a0	http://dx.doi.org/10.1038/359320a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP503	1406935				2022-12-28	WOS:A1992JP50300056
J	OSIPCHUK, Y; CAHALAN, M				OSIPCHUK, Y; CAHALAN, M			CELL-TO-CELL SPREAD OF CALCIUM SIGNALS MEDIATED BY ATP RECEPTORS IN MAST-CELLS	NATURE			English	Article							MECHANICAL STIMULATION; G-PROTEINS; SECRETION; CA-2+; OSCILLATIONS; IONOPHORES; GLUTAMATE; GRANULES; MEMBRANE; WAVES	RAT basophilic leukaemia cells, like mast cells from which they are derived, have surface Fc-epsilon receptors that trigger secretion of inflammatory mediators when crosslinked. Both GTP-binding proteins and a rise in cytosolic calcium concentration ([Ca2+]i) are implicated in the secretory mechanism1-5. Here we use a video-imaging technique to report that transient rises in [Ca2+]i initiated in an individual cell can spread from cell to cell in a wave-like pattern by means of a secreted intermediate, in the absence of gap-junctional communication. We find that the leukaemia cells, peritoneal mast cells and mucosal mast cells have cell-surface P2-type purinergic receptors that can trigger similar [Ca2+]i transients. We provide evidence that ATP is rapidly released, and that it can amplify [Ca2+]i signals and initial secretory responses during antigen-stimulation of rat basophilic leukaemia cells.			OSIPCHUK, Y (corresponding author), UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92717, USA.							ALI H, 1989, J IMMUNOL, V143, P2626; ALMERS W, 1985, FEBS LETT, V192, P13, DOI 10.1016/0014-5793(85)80033-8; ALTER SC, 1989, BIOCHIM BIOPHYS ACTA, V991, P426, DOI 10.1016/0304-4165(89)90068-8; BORN GVR, 1984, J PHYSIOL-LONDON, V354, P419, DOI 10.1113/jphysiol.1984.sp015385; BROIDE DH, 1988, J IMMUNOL, V141, P4298; BURNSTOCK G, 1990, ANN NY ACAD SCI, V603, P1; CHAKRAVARTY N, 1980, ACTA PHARMACOL TOX, V47, P223; CHARLES AC, 1991, NEURON, V6, P983, DOI 10.1016/0896-6273(91)90238-U; CHEEK TR, 1989, J CELL BIOL, V109, P1219, DOI 10.1083/jcb.109.3.1219; COCHRANE DE, 1974, P NATL ACAD SCI USA, V71, P408, DOI 10.1073/pnas.71.2.408; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; DEMATTEIS MA, 1991, J BIOL CHEM, V266, P10452; DUBYAK GR, 1990, ANN NY ACAD SCI, V603, P227; FERNANDEZ JM, 1984, NATURE, V312, P453, DOI 10.1038/312453a0; GRISSMER S, 1992, J GEN PHYSIOL, V99, P63, DOI 10.1085/jgp.99.1.63; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOWELL TW, 1987, J CELL BIOL, V105, P191, DOI 10.1083/jcb.105.1.191; JOHNSON RG, 1980, FEBS LETT, V120, P75, DOI 10.1016/0014-5793(80)81050-7; LEFF P, 1990, BRIT J PHARMACOL, V101, P645, DOI 10.1111/j.1476-5381.1990.tb14134.x; LEVISCHAFFER F, 1985, J IMMUNOL, V135, P3454; MCCLOSKEY MA, 1990, J GEN PHYSIOL, V95, P205, DOI 10.1085/jgp.95.2.205; MILLARD PJ, 1989, J BIOL CHEM, V264, P19730; NEHER E, 1988, J PHYSIOL-LONDON, V395, P193, DOI 10.1113/jphysiol.1988.sp016914; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; SANDERSON MJ, 1990, CELL REGUL, V1, P585, DOI 10.1091/mbc.1.8.585; TATHAM PER, 1988, EUR J PHARMACOL, V147, P13, DOI 10.1016/0014-2999(88)90628-0; TATHAM PER, 1990, J GEN PHYSIOL, V95, P459, DOI 10.1085/jgp.95.3.459; UVNAS B, 1974, LIFE SCI, V14, P2355, DOI 10.1016/0024-3205(74)90131-3; WOLDEMUSSIE E, 1986, J IMMUNOL, V137, P1674	29	338	343	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 17	1992	359	6392					241	244		10.1038/359241a0	http://dx.doi.org/10.1038/359241a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN944	1388246				2022-12-28	WOS:A1992JN94400063
J	ROBERTSON, DA; TUNBRIDGE, FKE; JOHN, WG; HOME, PD; ALBERTI, KGMM				ROBERTSON, DA; TUNBRIDGE, FKE; JOHN, WG; HOME, PD; ALBERTI, KGMM			LESSON OF THE WEEK - DIAGNOSTIC CONFUSION IN DIABETES WITH PERSISTENCE OF FETAL HEMOGLOBIN	BRITISH MEDICAL JOURNAL			English	Article							GLYCOSYLATED HEMOGLOBIN; AFFINITY-CHROMATOGRAPHY; MELLITUS; GLUCOSE	Persistence of fetal haemoglobin falsely increases estimates of haemoglobin A1 concentration by charge dependent methods and is not detected by routine electrophoresis. Diagnosis of diabetes should not be based solely on HbA1 concentration	ROYAL LONDON HOSP,DEPT CLIN BIOCHEM,LONDON E1 1BB,ENGLAND	Barts Health NHS Trust; Royal London Hospital	ROBERTSON, DA (corresponding author), UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT MED,NEWCASTLE TYNE NE2 4HH,ENGLAND.							AKINMOKUN A, IN PRESS DIABETES RE; ALBERTI KGMM, 1988, DIABETIC MED, V5, P275, DOI 10.1111/j.1464-5491.1988.tb00984.x; BETKE K, 1959, NATURE, V184, P1877, DOI 10.1038/1841877a0; DAVIS RE, 1978, LANCET, V2, P350; EBERENTZLHOMME C, 1984, DIABETOLOGIA, V27, P596, DOI 10.1007/BF00276975; ENGBAEK F, 1989, CLIN CHEM, V35, P93; FLUCKINGER R, 1976, FEBS LETT, V7, P356; FORREST RD, 1987, DIABETIC MED, V4, P254, DOI 10.1111/j.1464-5491.1987.tb00875.x; GEBHART SSP, 1991, ARCH INTERN MED, V151, P1133, DOI 10.1001/archinte.151.6.1133; Hadden D R, 1984, Diabet Med, V1, P91; JOHN WG, 1992, DIABETIC MED, V9, P15, DOI 10.1111/j.1464-5491.1992.tb01708.x; JOHN WG, 1985, ANN CLIN BIOCHEM, V22, P79, DOI 10.1177/000456328502200108; JOHN WG, 1987, ANN CLIN BICH S1, V24, P158; KLENK DC, 1982, CLIN CHEM, V28, P2088; LEHMANN H, 1974, MANS HAEMOGLOBINS, P273; LITTLE RR, 1988, DIABETES, V37, P60, DOI 10.2337/diabetes.37.1.60; MENARD L, 1980, CLIN CHEM, V26, P1598; MIYOSHI K, 1988, BLOOD, V72, P1854; MULLIS P, 1989, DIABETOLOGIA, V32, P227, DOI 10.1007/BF00285288; PAISEY RB, 1984, BRIT MED J, V289, P279, DOI 10.1136/bmj.289.6440.279; PEMBREY ME, 1973, LANCET, V1, P1350; PHILLIPS HM, 1988, PEDIATR RES, V23, P595, DOI 10.1203/00006450-198806000-00013; STACIEWICZ J, 1980, HEPATOGASTROENTEROLO, V27, P152; WEATHERALL DJ, 1975, BRIT J HAEMATOL, V29, P191, DOI 10.1111/j.1365-2141.1975.tb01813.x; YATSCOFF RW, 1983, CLIN CHEM, V29, P543; 1985, DIABETES MELLITUS, P10	26	12	12	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 12	1992	305	6854					635	637		10.1136/bmj.305.6854.635	http://dx.doi.org/10.1136/bmj.305.6854.635			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN698	1382771	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JN69800025
J	SLEVIN, ML				SLEVIN, ML			CURRENT ISSUES IN CANCER - QUALITY-OF-LIFE - PHILOSOPHICAL QUESTION OR CLINICAL REALITY	BRITISH MEDICAL JOURNAL			English	Article							ADVANCED BREAST-CANCER; OF-LIFE; CHEMOTHERAPY; MASTECTOMY; RESECTION; CARCINOMA; SURVIVAL; THERAPY				SLEVIN, ML (corresponding author), ST BARTHOLOMEWS HOSP,IMPERIAL CANC RES FUND,DEPT MED ONCOL,LONDON EC1A 7BE,ENGLAND.							Aaronson N K, 1988, Recent Results Cancer Res, V111, P231; BECKMANN J, 1983, DAN MED BULL, V30, P10; BRINKLEY D, 1985, BRIT MED J, V291, P685, DOI 10.1136/bmj.291.6497.685; BUHL K, 1990, EUR J SURG ONCOL, V16, P404; CASSILETH BR, 1991, NEW ENGL J MED, V324, P1180, DOI 10.1056/NEJM199104253241706; COATES A, 1987, NEW ENGL J MED, V317, P1490, DOI 10.1056/NEJM198712103172402; DEHAES JCJM, 1990, BRIT J CANCER, V62, P1034, DOI 10.1038/bjc.1990.434; GELBER RD, 1991, ANN INTERN MED, V114, P621, DOI 10.7326/0003-4819-114-8-621; GLIMELIUS B, 1989, EUR J CANCER CLIN ON, V25, P829, DOI 10.1016/0277-5379(89)90128-4; GOUGH IR, 1981, CLIN ONCOL, V7, P5; GREER S, 1992, BRIT MED J, V304, P675, DOI 10.1136/bmj.304.6828.675; Harris J., 1985, VALUE LIFE INTRO MED, P87; KAASA S, 1988, ACTA ONCOL, V27, P335, DOI 10.3109/02841868809093551; KIEBERT GM, 1991, J CLIN ONCOL, V9, P1059, DOI 10.1200/JCO.1991.9.6.1059; MAGUIRE P, 1989, BRIT J CANCER, V60, P437, DOI 10.1038/bjc.1989.301; MAGUIRE P, 1988, BRIT MED J, V297, P907, DOI 10.1136/bmj.297.6653.907; PRIESTMAN TJ, 1976, LANCET, V1, P899; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; SLEVIN ML, 1988, BRIT J CANCER, V57, P109, DOI 10.1038/bjc.1988.20; SLEVIN ML, 1991, BR J CANC S8, V63, P11; SPIEGEL D, 1989, LANCET, V2, P888; STEINBERG MD, 1985, AM J PSYCHIAT, V142, P34; TAYLOR SE, 1985, CANCER, V55, P2506, DOI 10.1002/1097-0142(19850515)55:10<2506::AID-CNCR2820551033>3.0.CO;2-0; WOLBERG WH, 1989, CANCER-AM CANCER SOC, V63, P1645, DOI 10.1002/1097-0142(19890415)63:8<1645::AID-CNCR2820630835>3.0.CO;2-8; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	25	65	66	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 22	1992	305	6851					466	469		10.1136/bmj.305.6851.466	http://dx.doi.org/10.1136/bmj.305.6851.466			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JK680	1392964	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992JK68000030
J	COAST, J				COAST, J			REPROCESSING DATA TO FORM QALYS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TRANS-URETHRAL RESECTION; PROSTATISM	Objectives-To determine whether reprocessing data from published sources into quality adjusted life years (QALYs), as recommended in The QALY Toolkit, is a useful method of helping purchasing authorities to determine the most cost effective pattern of care to buy for their populations. Setting-United Kingdom. Design-The method was tested for six elective surgical conditions; data from published studies were reprocessed into the Rosser index, to obtain values for change in quality of life. These were then used to form QALYs. A small validation exercise was carried out. Main outcome measures-QALYs formed from the Rosser index. Results-Published data could not be found for three interventions (cataract surgery, inguinal hernia repair, varicose vein surgery). For the remainder (prostatectomy, hip replacement, and knee replacement) data were found which could be reprocessed to form QALYs, though it was often hard to compare data from different studies and many assumptions had to be made. Conclusion-The value of QALY results obtained by this method is questionable, given the large number of assumptions which had to be made. For many interventions published data are unlikely to be available.			COAST, J (corresponding author), UNIV BRISTOL, DEPT EPIDEMIOL & PUBL HLTH MED, HLTH CARE EVALUAT UNIT, BRISTOL B58 2PR, ENGLAND.			Coast, Joanna/0000-0002-3537-5166				BALL AJ, 1981, BRIT J UROL, V53, P613, DOI 10.1111/j.1464-410X.1981.tb03273.x; BARRY MJ, 1988, JAMA-J AM MED ASSOC, V259, P3010, DOI 10.1001/jama.259.20.3010; BERNTHPETERSEN P, 1985, ACTA OPHTHALMOL, V63, P1; BRYAN S, 1991, HEALTH POLICY, V18, P169, DOI 10.1016/0168-8510(91)90098-I; CARRHILL RA, 1991, BRIT MED J, V303, P699, DOI 10.1136/bmj.303.6804.699; CHILTON CP, 1978, BRIT J UROL, V50, P542, DOI 10.1111/j.1464-410X.1978.tb06208.x; DIXON AK, 1991, BRIT MED J, V302, P79, DOI 10.1136/bmj.302.6768.79; DOBBS HS, 1980, J BONE JOINT SURG BR, V62, P168, DOI 10.1302/0301-620X.62B2.7364829; DONALDSON C, 1991, BRIT MED J, V303, P1529, DOI 10.1136/bmj.303.6816.1529; DONOVAN J, 1991, EPIDEMIOLOGICALLY BA; EFTEKHAR N, 1971, CLIN ORTHOP RELAT R, P93; FOWLER FJ, 1988, JAMA-J AM MED ASSOC, V259, P3018, DOI 10.1001/jama.259.20.3018; FRANKEL S, 1991, J EPIDEMIOL COMMUN H, V45, P257, DOI 10.1136/jech.45.4.257; FRANKEL SJ, 1990, 2 HLTH CAR EV UN; Gudex C, 1990, Health Trends, V22, P103; Gudex C, 1988, QALY TOOLKIT; GUDEX C, 1986, QALYS THEIR USE HLTH; Kaplan R.M., 1982, HEALTH PSYCHOL, V1, P61, DOI [DOI 10.1037/0278-6133.1.1.61, 10.1037/0278-6133.1.1.61]; KNUTSON K, 1986, J BONE JOINT SURG BR, V68, P795, DOI 10.1302/0301-620X.68B5.3782249; LIANG MH, 1984, ARTHRITIS RHEUM, V27, P522, DOI 10.1002/art.1780270507; McPherson Klim, 1990, CHALLENGES MED PRACT, P19; Parsonage M, 1992, Health Econ, V1, P71, DOI 10.1002/hec.4730010110; PATERSON M, 1991, MEASURING HLTH PRACT, P157; ROOS NP, 1989, NEW ENGL J MED, V320, P1120, DOI 10.1056/NEJM198904273201705; ROSSER R, 1978, INT J EPIDEMIOL, V7, P347, DOI 10.1093/ije/7.4.347; Torrance GW, 1987, METHODS EC EVALUATIO; Willard A, 1988, MAPPING MORAL DOMAIN, P225; WILLIAMS A, 1985, BRIT MED J, V291, P326, DOI 10.1136/bmj.291.6491.326; Woodward R, 1983, J Med Syst, V7, P481, DOI 10.1007/BF00995179; 1990, SOCIAL TRENDS, V20; [No title captured]	31	41	41	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 11	1992	305	6845					87	90		10.1136/bmj.305.6845.87	http://dx.doi.org/10.1136/bmj.305.6845.87			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD850	1379096	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JD85000022
J	BIRD, A				BIRD, A			THE ESSENTIALS OF DNA METHYLATION	CELL			English	Review							CHROMATIN STRUCTURE; CYTOSINE METHYLATION; DENOVO METHYLATION; CPG ISLANDS; GLOBIN GENE; CELL-LINES; EXPRESSION; PROMOTER; BINDING				BIRD, A (corresponding author), UNIV EDINBURGH,INST CELL & MOLEC BIOL,KINGS BLDG,EDINBURGH EH9 3JR,MIDLOTHIAN,SCOTLAND.			Bird, Adrian/0000-0002-8600-0372				ANTEQUERA F, 1989, CELL, V58, P509, DOI 10.1016/0092-8674(89)90431-5; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; BESTOR TH, 1990, PHILOS T ROY SOC B, V326, P179, DOI 10.1098/rstb.1990.0002; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; COOPER DN, 1989, HUM GENET, V83, P181, DOI 10.1007/BF00286715; ENVER T, 1988, GENE DEV, V2, P698, DOI 10.1101/gad.2.6.698; GOUNARI F, 1987, GENE DEV, V1, P899, DOI 10.1101/gad.1.9.899; GREEN PM, 1990, NUCLEIC ACIDS RES, V18, P3227, DOI 10.1093/nar/18.11.3227; HSIEH CL, 1992, EMBO J, V11, P315, DOI 10.1002/j.1460-2075.1992.tb05054.x; JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117; JONES PA, 1992, BIOESSAYS, V14, P33, DOI 10.1002/bies.950140107; LEVINE A, 1991, P NATL ACAD SCI USA, V88, P6515, DOI 10.1073/pnas.88.15.6515; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MURRAY EJ, 1987, EMBO J, V6, P2329, DOI 10.1002/j.1460-2075.1987.tb02508.x; PAROUSH Z, 1990, CELL, V63, P1229, DOI 10.1016/0092-8674(90)90418-E; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; RIGGS AD, 1992, TRENDS GENET, V8, P169, DOI 10.1016/0168-9525(92)90219-T; SNELLER MC, 1987, J IMMUNOL, V138, P3505; SULLIVAN CH, 1989, MOL CELL BIOL, V9, P3132, DOI 10.1128/MCB.9.7.3132; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; WEIH F, 1991, EMBO J, V10, P2559, DOI 10.1002/j.1460-2075.1991.tb07796.x; YISRAELI J, 1986, CELL, V46, P409, DOI 10.1016/0092-8674(86)90661-6	29	899	947	6	82	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 10	1992	70	1					5	8		10.1016/0092-8674(92)90526-I	http://dx.doi.org/10.1016/0092-8674(92)90526-I			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JC957	1377983				2022-12-28	WOS:A1992JC95700002
J	LIESCHKE, GJ; BURGESS, AW				LIESCHKE, GJ; BURGESS, AW			DRUG-THERAPY - GRANULOCYTE COLONY-STIMULATING FACTOR AND GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTOR .2.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							BONE-MARROW TRANSPLANTATION; HUMAN-IMMUNODEFICIENCY-VIRUS; HIGH-DOSE CHEMOTHERAPY; NON-HODGKINS-LYMPHOMA; NONHEMATOPOIETIC TUMOR-CELLS; ACUTE MYELOBLASTIC-LEUKEMIA; RECOMBINANT GM-CSF; MYELODYSPLASTIC SYNDROMES; APLASTIC-ANEMIA; CYCLIC NEUTROPENIA				LIESCHKE, GJ (corresponding author), ROYAL MELBOURNE HOSP, LUDWIG INST CANC RES, MELBOURNE TUMOUR BIOL BRANCH, PARKVILLE, VIC 3050, AUSTRALIA.			Lieschke, Graham/0000-0003-0325-798X				ANTIN JH, 1988, BLOOD, V72, P705; ASANO S, 1990, JPN J MED, V3, P317; BALDWIN GC, 1988, P NATL ACAD SCI USA, V85, P2763, DOI 10.1073/pnas.85.8.2763; BALDWIN GC, 1989, BLOOD, V73, P1033; BARLOGIE B, 1990, BLOOD, V76, P677, DOI 10.1182/blood.V76.4.677.bloodjournal764677; BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x; BERDEL WE, 1989, BLOOD, V73, P80; BLAZAR BR, 1989, BLOOD, V73, P849; BRANDT SJ, 1988, NEW ENGL J MED, V318, P869, DOI 10.1056/NEJM198804073181401; BRONCHUD MH, 1989, BRIT J CANCER, V60, P121, DOI 10.1038/bjc.1989.234; BUCHNER T, 1991, BLOOD, V78, P1190; BUDEL LM, 1989, BLOOD, V74, P2668; CAMITTA BM, 1982, NEW ENGL J MED, V306, P645, DOI 10.1056/NEJM198203183061105; CHAMPLIN RE, 1989, BLOOD, V73, P694; CRAWFORD J, 1992, NEW ENGL J MED, V326, P270; DALE DC, 1990, BLOOD S, V76, P139; DEVRIES EGE, 1991, CANCER RES, V51, P116; ESTEY EH, 1990, BLOOD, V75, P1766; Faulds D, 1992, Pharmacoeconomics, V1, P231; FINLEY RS, 1991, CANCER, V67, P2727, DOI 10.1002/1097-0142(19910515)67:10+<2727::AID-CNCR2820671710>3.0.CO;2-V; FREUND MRF, 1990, LANCET, V336, P313, DOI 10.1016/0140-6736(90)91849-6; GANSER A, 1989, BLOOD, V73, P31; GERHARTZ HH, 1989, BONE MARROW TRANSPL, V4, P36; GIANNI AM, 1989, LANCET, V2, P580; GIANNI AM, 1990, J CLIN ONCOL, V8, P768, DOI 10.1200/JCO.1990.8.5.768; GLASPY J, 1991, BLOOD S, V78, P7; GROOPMAN JE, 1987, NEW ENGL J MED, V317, P593, DOI 10.1056/NEJM198709033171003; GULATI SC, 1992, ANN INTERN MED, V116, P177, DOI 10.7326/0003-4819-116-3-177; HAMMER SM, 1990, BLOOD, V75, P1215; HAMMOND WP, 1989, NEW ENGL J MED, V320, P1306, DOI 10.1056/NEJM198905183202003; HERRMANN F, 1989, LEUKEMIA, V3, P335; HERRMANN F, 1990, AM J MED, V88, P619, DOI 10.1016/0002-9343(90)90528-L; HO AD, 1990, CANCER, V66, P423, DOI 10.1002/1097-0142(19900801)66:3<423::AID-CNCR2820660304>3.0.CO;2-V; JAKUBOWSKI AA, 1989, NEW ENGL J MED, V320, P38, DOI 10.1056/NEJM198901053200107; KLAUSMANN M, 1991, LUNG CANCER S1, V7, P141; KOJIMA S, 1991, BLOOD, V77, P937; KOTAKE T, 1991, CANCER CHEMOTH PHARM, V27, P253, DOI 10.1007/BF00685108; MASAOKA T, 1989, EXP HEMATOL, V17, P1047; MASAOKA T, 1990, JPN J MED, V3, P233; MEMPEL K, 1991, BLOOD, V77, P1919; MIGLIACCIO AR, 1990, BLOOD, V75, P1951; MILES SA, 1990, BLOOD, V75, P2137; MIZUNO Y, 1990, PEDIATR HEMAT ONCOL, V7, P377, DOI 10.3109/08880019009033415; MOTOJI T, 1989, EXP HEMATOL, V17, P56; NEGRIN RS, 1989, ANN INTERN MED, V110, P976, DOI 10.7326/0003-4819-110-12-976; NEGRIN RS, 1990, BLOOD, V76, P36; NEIDHART J, 1989, J CLIN ONCOL, V7, P1685, DOI 10.1200/JCO.1989.7.11.1685; NEMUNAITIS J, 1991, BLOOD, V77, P2065; NEMUNAITIS J, 1988, BLOOD, V72, P834; NISSEN C, 1988, BLOOD, V72, P2045; OHNO R, 1990, NEW ENGL J MED, V323, P871, DOI 10.1056/NEJM199009273231304; PERNO CF, 1989, J EXP MED, V169, P933, DOI 10.1084/jem.169.3.933; PETERS WP, 1991, BLOOD CELL GROWTH FACTORS : THEIR PRESENT AND FUTURE USE IN HEMATOLOGY AND ONCOLOGY, P31; PLUDA JM, 1990, BLOOD, V76, P463; POWLES R, 1990, LANCET, V336, P1417, DOI 10.1016/0140-6736(90)93111-2; ROSENFELD CS, 1991, EXP HEMATOL, V19, P273; RUFF MR, 1986, P NATL ACAD SCI USA, V83, P6613, DOI 10.1073/pnas.83.17.6613; SCHUSTER MW, 1990, BLOOD S, V76, P318; SCHUSTER MW, 1990, BLOOD S, V76, P47; SHERIDAN WP, 1992, LANCET, V339, P640, DOI 10.1016/0140-6736(92)90795-5; SHERIDAN WP, 1989, LANCET, V2, P891; STEIN RS, 1992, NEW ENGL J MED, V326, P269; STEWARD WP, 1990, BRIT J CANCER, V61, P749, DOI 10.1038/bjc.1990.167; Takahashi S, 1991, Rinsho Ketsueki, V32, P221; TAYLOR, 1990, J CLIN ONCOL, V8, P567, DOI 10.1200/JCO.1990.8.3.567; TAYLOR KM, 1989, J CLIN ONCOL, V7, P1791, DOI 10.1200/JCO.1989.7.12.1791; Ueda K, 1991, Rinsho Ketsueki, V32, P212; VADHANRAJ S, 1988, NEW ENGL J MED, V319, P1628, DOI 10.1056/NEJM198812223192503; VADHANRAJ S, 1987, NEW ENGL J MED, V317, P1545, DOI 10.1056/NEJM198712173172501; VELLENGA E, 1987, BLOOD, V69, P1771; WELTE K, 1987, J EXP MED, V165, P941, DOI 10.1084/jem.165.4.941; YOSHIDA T, 1990, CANCER, V66, P1904, DOI 10.1002/1097-0142(19901101)66:9<1904::AID-CNCR2820660908>3.0.CO;2-V	72	459	470	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 9	1992	327	2					99	106						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC214	1376442				2022-12-28	WOS:A1992JC21400007
J	LASKY, LA; SINGER, MS; DOWBENKO, D; IMAI, Y; HENZEL, WJ; GRIMLEY, C; FENNIE, C; GILLETT, N; WATSON, SR; ROSEN, SD				LASKY, LA; SINGER, MS; DOWBENKO, D; IMAI, Y; HENZEL, WJ; GRIMLEY, C; FENNIE, C; GILLETT, N; WATSON, SR; ROSEN, SD			AN ENDOTHELIAL LIGAND FOR L-SELECTIN IS A NOVEL MUCIN-LIKE MOLECULE	CELL			English	Article							NODE HOMING RECEPTOR; CELL-ADHESION; LYMPH-NODES; VASCULAR ADDRESSIN; SPERM RECEPTOR; MEL-14 ANTIGEN; LECTIN DOMAIN; SIALIC-ACID; CARBOHYDRATE; LYMPHOCYTES	The adhesive interaction between circulating lymphocytes and the high endothelial venules (HEV) of lymph nodes (LN) is mediated by lymphocyte L-selectin, a member of the selectin family of cell adhesion proteins. Previous work has identified a sulfated 50 kd glycoprotein (Sgp50) as an HEV ligand for L-selectin. We now report the purification of this glycoprotein and the utilization of the derived N-terminal amino acid sequence to clone a cDNA. The predicted sequence reveals a novel, mucin-like molecule containing two serine/threonine-rich domains. The mRNA encoding this glycoprotein is preferentially expressed in LN. Antibodies against predicted peptides immunoprecipitate Sgp50 and stain the apical surface of LN HEV. These results thus define a tissue-specific mucin-like endothelial glycoprotein that appears to function as a scaffold that presents carbohydrates to the L-selectin lectin domain.	GENENTECH INC, DEPT SAFETY EVALUAT, San Francisco, CA 94080 USA; GENENTECH INC, DEPT PROT CHEM, San Francisco, CA 94080 USA; UNIV CALIF SAN FRANCISCO, DEPT ANAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, PROGRAM IMMUNOL, SAN FRANCISCO, CA 94143 USA	Roche Holding; Genentech; Roche Holding; Genentech; University of California System; University of California San Francisco; University of California System; University of California San Francisco	LASKY, LA (corresponding author), GENENTECH INC, DEPT IMMUNOBIOL, 460 POINT SAN BRUNO BLVD, San Francisco, CA 94080 USA.		Imai, Yasuyuki/E-8701-2010	Imai, Yasuyuki/0000-0002-8937-0221; Henzel, William/0000-0003-2940-3797	NIGMS NIH HHS [GM23547] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023547, R37GM023547] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARGATZE RF, 1987, J EXP MED, V166, P1125, DOI 10.1084/jem.166.4.1125; BARGATZE RF, 1990, J CELL BIOCHEM, V42, P219, DOI 10.1002/jcb.240420405; BERG EL, 1991, J CELL BIOL, V114, P343, DOI 10.1083/jcb.114.2.343; BERG EL, 1989, IMMUNOL REV, V108, P5, DOI 10.1111/j.1600-065X.1989.tb00010.x; BEVILACQUA M, 1991, CELL, V67, P233, DOI 10.1016/0092-8674(91)90174-W; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BOWEN BR, 1990, J CELL BIOL, V110, P147, DOI 10.1083/jcb.110.1.147; BOWEN BR, 1989, J CELL BIOL, V109, P421, DOI 10.1083/jcb.109.1.421; BUTCHER EC, 1980, EUR J IMMUNOL, V10, P556, DOI 10.1002/eji.1830100713; BUTCHER EC, 1986, CURR TOP MICROBIOL, V128, P85; BUTCHER EC, 1990, AM J PATHOL, V136, P3; CAMERINI D, 1989, NATURE, V342, P78, DOI 10.1038/342078a0; CARAS IW, 1991, CELL BIOL INT REP, V15, P815, DOI 10.1016/0309-1651(91)90035-H; CARRAWAY K L, 1991, Glycobiology, V1, P131, DOI 10.1093/glycob/1.2.131; CORRAL L, 1990, BIOCHEM BIOPH RES CO, V172, P1349, DOI 10.1016/0006-291X(90)91598-M; CUMMING D A, 1991, Glycobiology, V1, P115, DOI 10.1093/glycob/1.2.115; CYSTER J, 1990, EUR J IMMUNOL, V20, P875, DOI 10.1002/eji.1830200424; CYSTER JG, 1991, EMBO J, V10, P893, DOI 10.1002/j.1460-2075.1991.tb08022.x; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FINERMOORE J, 1984, P NATL ACAD SCI-BIOL, V81, P155, DOI 10.1073/pnas.81.1.155; FLORMAN HM, 1985, CELL, V41, P313, DOI 10.1016/0092-8674(85)90084-4; FUKUDA M, 1991, Glycobiology, V1, P347, DOI 10.1093/glycob/1.4.347; GALLATIN M, 1986, CELL, V44, P673, DOI 10.1016/0092-8674(86)90832-9; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; GEOFFROY JS, 1989, J CELL BIOL, V109, P2463, DOI 10.1083/jcb.109.5.2463; GUM JR, 1991, J BIOL CHEM, V266, P22733; HAFFAR OK, 1988, J CELL BIOL, V107, P1677, DOI 10.1083/jcb.107.5.1677; HALLMANN R, 1991, BIOCHEM BIOPH RES CO, V174, P236, DOI 10.1016/0006-291X(91)90511-5; HAMANN A, 1991, EUR J IMMUNOL, V21, P2925, DOI 10.1002/eji.1830211205; HARDING SE, 1989, ADV CARBOHYD CHEM BI, V47, P345; HARLOW E, 1988, ANTIBODIES LABORATOR; HENDRIKS HR, 1987, EUR J IMMUNOL, V17, P1691, DOI 10.1002/eji.1830171203; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; IMAI Y, 1990, J CELL BIOL, V111, P1225, DOI 10.1083/jcb.111.3.1225; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; JUTILA MA, 1989, J IMMUNOL, V143, P3318; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LEE YC, 1989, CIBA F S, V145, P80; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LEWINSOHN DM, 1987, J IMMUNOL, V138, P4313; LEY K, 1991, BLOOD, V77, P2553; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MEBIUS RE, 1991, J CELL BIOL, V115, P85, DOI 10.1083/jcb.115.1.85; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; PORCHET N, 1991, AM REV RESPIR DIS, V144, pS15, DOI 10.1164/ajrccm/144.3_pt_2.S15; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; Rosen SD, 1989, CURR OPIN CELL BIOL, V1, P913, DOI 10.1016/0955-0674(89)90058-6; ROSEN SD, 1985, SCIENCE, V228, P1005, DOI 10.1126/science.4001928; ROSEN SD, 1989, J IMMUNOL, V142, P1895; ROTHLEIN R, 1991, J IMMUNOL, V147, P3788; Sambrook J, 1989, MOL CLONING LABORATO; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SHARON N, 1989, LECTINS; SHER BT, 1988, ADV CANCER RES, V51, P361, DOI 10.1016/S0065-230X(08)60226-2; SHERBLOM AP, 1980, J BIOL CHEM, V255, P2051; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SIEGELMAN MH, 1990, CELL, V61, P611, DOI 10.1016/0092-8674(90)90473-R; SIMMONS DL, 1992, J IMMUNOL, V148, P267; SPERTINI O, 1991, J IMMUNOL, V147, P2565; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STOOLMAN LM, 1989, J CLIN INVEST, V84, P1196, DOI 10.1172/JCI114285; STOOLMAN LM, 1983, J CELL BIOL, V96, P722, DOI 10.1083/jcb.96.3.722; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; STOOLMAN LM, 1987, BLOOD, V70, P1842; STOOLMAN LM, 1984, J CELL BIOL, V99, P1535, DOI 10.1083/jcb.99.4.1535; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; STREETER PR, 1988, NATURE, V331, P41, DOI 10.1038/331041a0; TEDDER TF, 1989, J EXP MED, V170, P123, DOI 10.1084/jem.170.1.123; TIEMEYER M, 1991, P NATL ACAD SCI USA, V88, P1138, DOI 10.1073/pnas.88.4.1138; TRUE DD, 1990, J CELL BIOL, V111, P2757, DOI 10.1083/jcb.111.6.2757; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WASSARMAN PM, 1990, DEVELOPMENT, V108, P1; WATSON SR, 1990, J CELL BIOL, V110, P2221, DOI 10.1083/jcb.110.6.2221; WATSON SR, 1991, NATURE, V349, P164, DOI 10.1038/349164a0; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; WILLIAMS AF, 1991, NATURE, V352, P473, DOI 10.1038/352473a0; WOODRUFF JJ, 1987, ANNU REV IMMUNOL, V5, P201, DOI 10.1146/annurev.immunol.5.1.201; YEDNOCK TA, 1987, J CELL BIOL, V104, P713, DOI 10.1083/jcb.104.3.713; YEDNOCK TA, 1989, ADV IMMUNOL, V44, P313, DOI 10.1016/S0065-2776(08)60645-8; YEDNOCK TA, 1987, J CELL BIOL, V104, P725, DOI 10.1083/jcb.104.3.725; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	93	634	662	1	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 12	1992	69	6					927	938		10.1016/0092-8674(92)90612-G	http://dx.doi.org/10.1016/0092-8674(92)90612-G			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HY792	1376638				2022-12-28	WOS:A1992HY79200005
J	JAN, LY; JAN, YN; HUGHES, H				JAN, LY; JAN, YN; HUGHES, H			TRACING THE ROOTS OF ION CHANNELS	CELL			English	Review							PROTEIN		UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	JAN, LY (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT PHYSIOL,SAN FRANCISCO,CA 94143, USA.			Jan, Lily/0000-0003-3938-8498; Jan, Yuh Nung/0000-0003-1367-6299				ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; HIGGINS C, 1989, NATURE, V341, P103, DOI 10.1038/341103a0; Hille B., 1991, IONIC CHANNELS EXCIT; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KO CH, 1991, MOL CELL BIOL, V11, P4266, DOI 10.1128/MCB.11.8.4266; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; RAYMOND M, 1992, SCIENCE, V256, P232, DOI 10.1126/science.1348873; SCHULTZ JE, 1992, SCIENCE, V255, P600, DOI 10.1126/science.1371017; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SWENSON RP, 1981, NATURE, V291, P427, DOI 10.1038/291427a0; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0	21	202	206	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 29	1992	69	5					715	718		10.1016/0092-8674(92)90280-P	http://dx.doi.org/10.1016/0092-8674(92)90280-P			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1375539				2022-12-28	WOS:A1992HW83800001
J	BEATH, SV; BOXALL, EH; WATSON, RM; TARLOW, MJ; KELLY, DA				BEATH, SV; BOXALL, EH; WATSON, RM; TARLOW, MJ; KELLY, DA			LESSON OF THE WEEK - FULMINANT HEPATITIS-B IN INFANTS BORN TO ANTI-HBE HEPATITIS-B CARRIER MOTHERS	BRITISH MEDICAL JOURNAL			English	Article							PREVENTION; INFECTION; VACCINE		E BIRMINGHAM DIST GEN HOSP,REG VIRUS LAB,BIRMINGHAM B9 5ST,W MIDLANDS,ENGLAND; WEXHAM PARK HOSP,SLOUGH,BERKS,ENGLAND; UNIV BIRMINGHAM,DEPT PAEDIAT & CHILD HLTH,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham	BEATH, SV (corresponding author), CHILDRENS HOSP,LIVER UNIT,LADYWOOD MIDDLEWAY,BIRMINGHAM B16 8ET,W MIDLANDS,ENGLAND.							BARIN F, 1982, LANCET, V1, P251; BROOK MG, 1989, Q J MED, V71, P313; DEINHARDT F, 1985, J MED VIROL, V17, P209, DOI 10.1002/jmv.1890170302; EWING CI, 1985, ARCH DIS CHILD, V60, P265, DOI 10.1136/adc.60.3.265; Maynard JE, 1988, VIRAL HEPATITIS LIVE, P967; POLAKOFF S, 1982, BRIT MED J, V285, P1294, DOI 10.1136/bmj.285.6351.1294; WEN YM, 1990, CLIN EXP IMMUNOL, V79, P83; WHEELEY SM, 1990, J MED VIROL, V30, P113, DOI 10.1002/jmv.1890300207; 1990, IMMUNISATION INFECTI, P105	9	27	27	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 2	1992	304	6835					1169	1170		10.1136/bmj.304.6835.1169	http://dx.doi.org/10.1136/bmj.304.6835.1169			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT232	1392798	Bronze, Green Published			2022-12-28	WOS:A1992HT23200031
J	CRAWFORD, ED; SCHUTZ, MJ; CLEJAN, S; DRAGO, J; RESNICK, MI; CHODAK, GW; GOMELLA, LG; AUSTENFELD, M; STONE, NN; MILES, BJ; THOMSON, R				CRAWFORD, ED; SCHUTZ, MJ; CLEJAN, S; DRAGO, J; RESNICK, MI; CHODAK, GW; GOMELLA, LG; AUSTENFELD, M; STONE, NN; MILES, BJ; THOMSON, R			THE EFFECT OF DIGITAL RECTAL EXAMINATION ON PROSTATE-SPECIFIC ANTIGEN LEVELS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							CANCER; MARKER	Objective. - To identify the effect of digital rectal examination (DRE) on serum prostate-specific antigen (PSA) levels. Design. - A prospective trial before and after DRE. Setting. - Multicenter outpatient screening program. Patients. - A total of 2754 healthy men aged 40 years and older who presented to a prostate cancer screening program and consented to two phlebotomies. Main Outcome Measure. - Changes in serum PSA levels after DRE. Results. - Patients were divided into four groups based on their initial serum PSA levels. The levels were chosen based on previous studies that showed different incidences of prostate cancer within these groups. The two groups with the lowest initial PSA values (0.1 through 4-mu-g/L and 4.1 through 10-mu-g/L) were found to have statistically insignificant changes in the serum PSA levels after DRE. The group with initial PSA levels of 10.1 through 20-mu-g/L had increases in serum PSA values that showed a trend toward statistical significance. The group with initial PSA levels of greater than 20-mu-g/L had statistically significant increases in serum PSA values after DRE. The alterations in serum PSA levels in the two groups with the highest PSA values were not clinically important as the patients' clinical treatment was not altered. Conclusions. - No clinically important effects on serum PSA levels were noted after DRE.	UNIV COLORADO,HLTH SCI CTR,DIV UROL,DENVER,CO 80262; TULANE UNIV,SCH MED,NEW ORLEANS,LA 70112; OHIO STATE UNIV,COLUMBUS,OH 43210; CASE WESTERN RESERVE UNIV,CLEVELAND,OH 44106; UNIV CHICAGO,CHICAGO,IL 60637; THOMAS JEFFERSON UNIV,PHILADELPHIA,PA 19107; UNIV KANSAS,MED CTR,KANSAS CITY,KS 66103; CUNY MT SINAI SCH MED,NEW YORK,NY 10029; HENRY FORD HOSP,DETROIT,MI 48202	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Tulane University; University System of Ohio; Ohio State University; Case Western Reserve University; University of Chicago; Jefferson University; University of Kansas; University of Kansas Medical Center; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Henry Ford Health System; Henry Ford Hospital			Stone, Nelson N./R-3951-2019	Stone, Nelson N./0000-0001-6233-1209				BRAWER MK, 1990, UROL CLIN N AM, V17, P759; BRAWER MK, 1988, ARCH PATHOL LAB MED, V112, P1110; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; COONER WH, 1991, MONOGR UROL, V12, P3; DALTON DL, 1989, UROLOGY, V33, P465, DOI 10.1016/0090-4295(89)90131-3; HUDSON MA, 1989, J UROLOGY, V142, P1011, DOI 10.1016/S0022-5347(17)38972-3; OESTERLING JE, 1988, J UROLOGY, V139, P766, DOI 10.1016/S0022-5347(17)42630-9; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501; STONE N N, 1991, Journal of Urology, V145, p250A; WANG MC, 1981, PROSTATE, V2, P89, DOI 10.1002/pros.2990020109	10	78	82	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 22	1992	267	16					2227	2228		10.1001/jama.267.16.2227	http://dx.doi.org/10.1001/jama.267.16.2227			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN841	1372943				2022-12-28	WOS:A1992HN84100034
J	SCOTT, AIF; FREEMAN, CPL				SCOTT, AIF; FREEMAN, CPL			EDINBURGH PRIMARY CARE DEPRESSION STUDY - TREATMENT OUTCOME, PATIENT SATISFACTION, AND COST AFTER 16 WEEKS	BRITISH MEDICAL JOURNAL			English	Article							NATURALISTIC FOLLOW-UP; GENERAL-PRACTICE; COGNITIVE THERAPY; CONTROLLED TRIAL; AMITRIPTYLINE; PHARMACOTHERAPY; COMBINATION; ILLNESS; PLACEBO	Objective-To compare the clinical efficacy, patient satisfaction, and cost of three specialist treatments for depressive illness with routine care by general practitioners in primary care. Design-Prospective, randomised allocation to amitriptyline prescribed by a psychiatrist, cognitive behaviour therapy from a clinical psychologist, counselling and case work by a social worker, or routine care by a general practitioner. Subjects and setting-121 patients aged between 18 and 65 years suffering depressive illness (without psychotic features) meeting the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Third Edition for major depressive episode in 14 primary care practices in southern Edinburgh. Main outcome measures-Standard observer rating of depression at outset and after four and 16 weeks. Numbers of patients recovered at four and 16 weeks. Total length and cost of therapist contact. Structured evaluation of treatment by patients at 16 weeks. Results-Marked improvement in depressive symptoms occurred in all treatment groups over 16 weeks. Any clinical advantages of specialist treatments over routine general practitioner care were small, but specialist treatment involved at least four times as much therapist contact and cost at least twice as much as routine general practitioner care. Psychological treatments, especially social work counselling, were most positively evaluated by patients. Conclusions-The additional costs associated with specialist treatments of new episodes of mild to moderate depressive illness presenting in primary care were not commensurate with their clinical superiority over routine general practitioner care. A proper cost-benefit analysis requires information about the ability of specialist treatment to prevent future episodes of depression.			SCOTT, AIF (corresponding author), UNIV EDINBURGH,ROYAL EDINBURGH HOSP,DEPT PSYCHIAT,EDINBURGH EH10 5HF,SCOTLAND.							BECK AT, 1979, COGNITIVE THERAPY DE; BLACKBURN IM, 1986, J AFFECT DISORDERS, V10, P67, DOI 10.1016/0165-0327(86)90050-9; BLACKBURN IM, 1981, BRIT J PSYCHIAT, V139, P181, DOI 10.1192/bjp.139.3.181; BLASHKI TG, 1971, BMJ-BRIT MED J, V1, P133, DOI 10.1136/bmj.1.5741.133; Brown G., 1978, SOCIAL ORIGINS DEPRE; Buchan IC, 1973, TIME STUDY CONSULTAT; COOPER B, 1973, PSYCHOL MED, V3, P421, DOI 10.1017/S0033291700054234; CORNEY RH, 1984, PSYCHOL MED S, V6; ELKIN I, 1989, ARCH GEN PSYCHIAT, V46, P971; GLEN AIM, 1984, PSYCHOL MED, V14, P37, DOI 10.1017/S0033291700003068; GOLDBERG DP, 1970, BMJ-BRIT MED J, V2, P439, DOI 10.1136/bmj.2.5707.439; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; JOHNSON DAW, 1973, BRIT MED J, V2, P18, DOI 10.1136/bmj.2.5857.18; LADER M, 1975, ROY SOC HEALTH J, V95, P304, DOI 10.1177/146642407509500615; ORMEL J, 1990, PSYCHOL MED, V20, P909, DOI 10.1017/S0033291700036606; PAYKEL ES, 1988, J AFFECT DISORDERS, V14, P83, DOI 10.1016/0165-0327(88)90075-4; PORTER AMW, 1970, BMJ-BRIT MED J, V1, P773, DOI 10.1136/bmj.1.5699.773; SHEPHERD M, 1981, PSYCHIATRIC ILLNESS; SIMONS AD, 1986, ARCH GEN PSYCHIAT, V43, P43; SIRELING LI, 1985, BRIT J PSYCHIAT, V147, P119, DOI 10.1192/bjp.147.2.119; TEASDALE JD, 1984, BRIT J PSYCHIAT, V144, P400, DOI 10.1192/bjp.144.4.400; THOMSON J, 1982, PSYCHOL MED, V12, P741, DOI 10.1017/S0033291700049047; TRETHOWAN WH, 1975, BRIT MED J, V3, P749, DOI 10.1136/bmj.3.5986.749; TYRER P, 1978, BRIT MED J, V2, P1008, DOI 10.1136/bmj.2.6143.1008; Watson J M, 1981, Health Bull (Edinb), V39, P112; 1980, DIAGNOSTIC STATISTIC; 1988, BRIT NATIONAL FORMUL, P123; 1985, DE801 OP U; 1989, 647 U KENT PERS SOC	29	155	157	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1992	304	6831					883	887		10.1136/bmj.304.6831.883	http://dx.doi.org/10.1136/bmj.304.6831.883			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HM835	1392754	Green Published, Bronze			2022-12-28	WOS:A1992HM83500031
J	NEWTON, J; ECCLES, M; HUTCHINSON, A				NEWTON, J; ECCLES, M; HUTCHINSON, A			COMMUNICATION BETWEEN GENERAL-PRACTITIONERS AND CONSULTANTS - WHAT SHOULD THEIR LETTERS CONTAIN	BRITISH MEDICAL JOURNAL			English	Article							WRITTEN COMMUNICATION	Objective - To canvass the views of all general practitioners and consultants working in Newcastle upon Tyne on the content of referral letters and replies, the feasibility of standardising certain aspects of referral letters, and the use of communications data for audit purposes. Design - A postal questionnaire was sent to all general practitioners and consultants in Newcastle upon Tyne in May 1991. Questions were asked about the clinical and administrative content of letters, the utility of standard categories to state the reason for referral, the idea of using letters for feedback purposes, and communications as a potential topic for professionally led audit. Setting - Area served by Newcastle upon Tyne Family Health Services Authority and District Health Authority. Results - Replies were received from 274 (77%) doctors (115 general practitioners and 159 consultants). A majority (225; 82%) were in favour of items defined as "always important" forming a minimum requirement for referral letters and for consultants' replies. Using standardised categories to state the reason for referral was not endorsed: 102 (89%) general practitioners and 132 (83%) consultants preferred referrers to use their own words. Using referral communications to provide feedback was less popular with consultants (54; 34%) than general practitioners (72; 63%). Finally, a majority of doctors (179; 65%) were in favour of using written communications as a topic for professionally led audit. Conclusions - A high degree of consensus exists among clinicians about the content of referral communications. Although doctors may still reject the concept of standardised communications, they have unambiguously endorsed a standard for communication that they can aspire to, and they are prepared to use it as a yardstick for their actual performance.			NEWTON, J (corresponding author), UNIV NEWCASTLE UPON TYNE,CTR HLTH SERV RES,NEWCASTLE TYNE NE2 4AA,ENGLAND.		Eccles, Martin P/AAD-4029-2020					Doleman F, 1987, FAM PRACT, V4, P176; FLETCHER CM, 1972, COMMUNICATION MED; HART JT, 1985, EXCHANGE LETT; KENTISH R, 1987, J ROY COLL GEN PRACT, V37, P162; LEONARD I, 1990, J ROY SOC MED, V83, P241, DOI 10.1177/014107689008300413; MARINKER M, 1988, BRIT MED J, V297, P461, DOI 10.1136/bmj.297.6646.461; ROLAND MO, 1991, BRIT MED J, V302, P1124, DOI 10.1136/bmj.302.6785.1124; SCAFFARDI RA, 1989, J ROY COLL GEN PRACT, V39, P375; WESTERMAN RF, 1990, BRIT J GEN PRACT, V40, P445; Young D W, 1985, Eff Health Care, V2, P225; 1990, FRAMEWORK INFORMATIO	11	105	105	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1992	304	6830					821	824		10.1136/bmj.304.6830.821	http://dx.doi.org/10.1136/bmj.304.6830.821			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL827	1392712	Bronze, Green Published			2022-12-28	WOS:A1992HL82700024
J	BRANDJES, DPM; HEIJBOER, H; BULLER, HR; DERIJK, M; JAGT, H; TENCATE, JW				BRANDJES, DPM; HEIJBOER, H; BULLER, HR; DERIJK, M; JAGT, H; TENCATE, JW			ACENOCOUMAROL AND HEPARIN COMPARED WITH ACENOCOUMAROL ALONE IN THE INITIAL TREATMENT OF PROXIMAL-VEIN THROMBOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VENOUS THROMBOSIS; ANTICOAGULANT-THERAPY; PULMONARY-EMBOLISM; MANAGEMENT; DIAGNOSIS; WARFARIN	Background. In most countries, heparin is used in the initial treatment of patients with deep-vein thrombosis. Well-designed studies establishing the efficacy of heparin therapy are lacking, however. Treatment with acenocoumarol alone, according to the hypothesis that high dosages of oral anticoagulants obviate the need for heparin, is considered an effective alternative in some countries. Methods. In a randomized, double-blind study we compared the efficacy and safety of continuous intravenous heparin plus acenocoumarol with the efficacy and safety of acenocoumarol alone in the initial treatment of outpatients with proximal-vein thrombosis. The principal study end point was a confirmed symptomatic extension or recurrence of venous thromboembolism during six months of follow-up. In addition, we assessed asymptomatic extension or pulmonary embolism by repeating venography and lung scanning after the first week of treatment. The incidence of major bleeding was determined during three months of follow-up. Results. The study was terminated early by the Data Safety and Monitoring Committee because of an excess of symptomatic events in the group that received acenocoumarol alone (in 12 of 60 patients [20 percent], as compared with 4 of 60 patients [6.7 percent] in the combined-therapy group by intention-to-treat analysis; P = 0.058). Asymptomatic extension of venous thrombosis was observed in 39.6 percent of the patients in the acenocoumarol group and in 8.2 percent of patients treated with heparin plus acenocoumarol (P<0.001). Major bleeding complications were infrequent and comparable in the two groups. Conclusions. Patients with proximal-vein thrombosis require initial treatment with full-dose heparin, which can safely be combined with acenocoumarol therapy.	UNIV AMSTERDAM, ACAD MED CTR, CTR HAEMOSTASIS THROMBOSIS ATHEROSCLEROSIS & INFLA, 1105 AZ AMSTERDAM, NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam	BRANDJES, DPM (corresponding author), SLOTERVAART HOSP, DEPT MED, LOUWESWEG 6, 1066 EC AMSTERDAM, NETHERLANDS.							BAUER G, 1946, LANCET, V250, P447; COON WW, 1972, ARCH SURG-CHICAGO, V105, P209; Fisher RA, 1934, STAT METHODS RES WOR, V5; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; GALLUS A, 1986, LANCET, V2, P1293; GALLUS AS, 1989, SEMIN THROMB HEMOST, V15, P99, DOI 10.1055/s-2007-1002692; GITEL SN, 1979, J LAB CLIN MED, V94, P481; HIRSH J, 1991, NEW ENGL J MED, V324, P1565; HIRSH J, 1987, HEMOSTASIS THROMBOSI, P1266; HULL R, 1982, NEW ENGL J MED, V307, P1676, DOI 10.1056/NEJM198212303072704; HULL RD, 1985, CHEST, V88, P819, DOI 10.1378/chest.88.6.819; HULL RD, 1990, NEW ENGL J MED, V322, P1260, DOI 10.1056/NEJM199005033221802; HULL RD, 1986, NEW ENGL J MED, V315, P1109, DOI 10.1056/NEJM198610303151801; HULL RD, 1983, CIRCULATION, V67, P901, DOI 10.1161/01.CIR.67.4.901; HYERS TM, 1989, CHEST, V95, pS37, DOI 10.1378/chest.95.2.37S; Lensing A W, 1986, Ned Tijdschr Geneeskd, V130, P1434; MARDER VJ, 1977, J LAB CLIN MED, V89, P1018; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134; ROOKE TW, 1986, MAYO CLIN PROC, V61, P198, DOI 10.1016/S0025-6196(12)61849-7; WEITZ JI, 1990, J CLIN INVEST, V86, P385, DOI 10.1172/JCI114723; WESSLER S, 1959, CIRCULATION, V20, P864, DOI 10.1161/01.CIR.20.5.864	21	382	389	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 19	1992	327	21					1485	1489		10.1056/NEJM199211193272103	http://dx.doi.org/10.1056/NEJM199211193272103			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY165	1406880				2022-12-28	WOS:A1992JY16500003
J	SWEDLOW, A; JOHNSON, G; SMITHLINE, N; MILSTEIN, A				SWEDLOW, A; JOHNSON, G; SMITHLINE, N; MILSTEIN, A			INCREASED COSTS AND RATES OF USE IN THE CALIFORNIA WORKERS COMPENSATION SYSTEM AS A RESULT OF SELF-REFERRAL BY PHYSICIANS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background. There is widespread concern that ownership by physicians of testing or treatment facilities to which they refer patients leads to overuse of such facilities. We determined the patterns of use of three services - physical therapy, psychiatric evaluation, and magnetic resonance imaging (MRI) - among physicians treating patients whose care was covered under workers' compensation. We then compared the rates of use among physicians who referred patients to facilities of which they were owners (self-referral group) with the rates among physicians who referred patients to independent facilities (independent-referral group). Methods. We used a large data base to analyze claims under workers' compensation in California from October 1, 1990, through June 30, 1991, to determine the frequency and cost of these three selected services and determined whether the referring physicians were practicing self-referral or independent referral. We evaluated the cost per case for all three services, measured the frequency with which physical therapy was initiated, and evaluated the medical appropriateness of MRI. Results. We found that physical therapy was initiated 2.3 times more often by the physicians in the self-referral group (68 percent) than by those in the independent-referral group (30 percent; P<0.01). The mean cost per case for physical therapy was significantly lower in the self-referral group ($404+/-102) than in the independent-referral group ($440+/-167; P<0.01). The mean cost of psychiatric evaluation services was significantly higher in the self-referral group than in the independent-referral group (psychometric testing, $1,165+/-728 vs. $870+/-482; P<0.01; psychiatric evaluation reports, $2,056+/-1,063 vs. $1,680+/-578; P<0.01). The total cost per case of psychiatric evaluation services was 26.3 percent higher in the self referral group ($3,222+/-1,451) than in the independent-referral group ($2,550+/-742; P<0.01). Of all the MRI scans requested by the self-referring physicians, 38 percent were found to be medically inappropriate, as compared with 28 percent of those requested by physicians in the independent-referral group (P<0.05). There was no significant difference in the cost per case between the two groups. Conclusions. This study demonstrates that self-referral increases the cost of medical care covered by workers' compensation for each of the three types of service studied.	WILLIAM MERCER INC,NATL MED AUDIT UNIT,3 EMBARCADERO CTR,SUITE 1250,SAN FRANCISCO,CA 94111; CURRENT HLTH CONCEPTS,SAUSALITO,CA									DYCKMAN Z, 1992, IMPACT PHYSICIAN JOI; HILLMAN BJ, 1990, NEW ENGL J MED, V323, P1604, DOI 10.1056/NEJM199012063232306; IGLEHART JK, 1991, NEW ENGL J MED, V325, P1820, DOI 10.1056/NEJM199112193252523; JONES M, 1991, MED FEES 1990; LEAPE LL, 1989, NEW ENGL J MED, V321, P653, DOI 10.1056/NEJM198909073211006; MITCHELL JM, 1991, JOINT VENTURES HLTH, V2; MORREIM EH, 1990, J MED PHILOS, V15, P425, DOI 10.1093/jmp/15.4.425; RELMAN AS, 1985, NEW ENGL J MED, V313, P749, DOI 10.1056/NEJM198509193131209; RELMAN AS, 1992, ATLANTIC MONTHLY MAR, P99; SCHNEIDER K, 1986, NEW ICD9CM AMBULATOR; Smithline N, 1990, J Ambul Care Manage, V13, P47; Waldholz Michael, 1989, WALL STREET J   0301, P1; 1989, FINANCIAL ARRANGEMEN; 1992, NY TIMES        0624, pA12; 1992, JAMA-J AM MED ASSOC, V267, P2366; 1991, FED REGISTER, V56, P35952	16	95	95	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 19	1992	327	21					1502	1506		10.1056/NEJM199211193272107	http://dx.doi.org/10.1056/NEJM199211193272107			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY165	1406882				2022-12-28	WOS:A1992JY16500007
J	LIPSHULTZ, SE; ORAV, EJ; SANDERS, SP; HALE, AR; MCINTOSH, K; COLAN, SD				LIPSHULTZ, SE; ORAV, EJ; SANDERS, SP; HALE, AR; MCINTOSH, K; COLAN, SD			CARDIAC STRUCTURE AND FUNCTION IN CHILDREN WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION TREATED WITH ZIDOVUDINE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SYSTOLIC WALL STRESS; MITOCHONDRIAL-DNA; HIV-INFECTION; AIDS PATIENTS; RAT HEARTS; MYOPATHY; THERAPY; DYSFUNCTION; HYPERTROPHY; MECHANICS	Background. Abnormalities of cardiac structure and function are common in children infected with the human immunodeficiency virus (HIV). It is unclear, however, whether these abnormalities are attributable to the disease itself, associated infections, or possible cardiotoxic effects of the most commonly used treatment, zidovudine. Methods. We performed echocardiography in 24 children with symptomatic HIV infection immediately before they started zidovudine therapy and a mean of 1.32 years after therapy began. Sixteen of these children were also studied a mean of 1.26 years before starting zidovudine treatment. Comparison groups included 27 age-matched children with symptomatic HIV infection who had not received zidovudine and 191 normal children. Results. As compared with the normal children, the children treated with zidovudine had progressive left ventricular dilatation and an increase in ventricular-wall stress at end-systole (a measure of ventricular afterload); dilatation and stress were significantly elevated both before and during zidovudine treatment. The ratio of ventricular thickness to internal dimension was below normal before zidovudine treatment began (P<0.001). After treatment with zidovudine, however, overall left ventricular mass was increased (P = 0.02), as was peak wall stress (a stimulus to ventricular hypertrophy) (P = 0.01). Ventricular contractility remained normal, but fractional shortening of the left ventricle was decreased (P = 0.004). No statistically significant differences were detected at follow-up in any of these measurements between HIV-infected children treated with zidovudine and those not so treated. Conclusions. Progressive left ventricular dilatation occurred in children with symptomatic HIV infection. Compensatory hypertrophy also occurred but was inadequate to maintain peak systolic wall stress within the normal range. The progressive elevation of ventricular afterload due to dilatation resulted in depressed ventricular performance, but intrinsic ventricular contractility remained normal. Zidovudine did not appear to worsen or ameliorate these cardiac changes.	CHILDRENS HOSP MED CTR,DIV INFECT DIS,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; BOSTON CITY HOSP,DEPT PEDIAT,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02118	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Boston Medical Center; Boston University	LIPSHULTZ, SE (corresponding author), CHILDRENS HOSP MED CTR,DEPT CARDIOL,300 LONGWOOD AVE,BOSTON,MA 02115, USA.		Colan, Steven/ABB-4580-2020	Sanders, Stephen/0000-0003-3521-4044	NCRR NIH HHS [5M01RR02172] Funding Source: Medline; NHLBI NIH HHS [R01HL48012-01] Funding Source: Medline; NIAID NIH HHS [U01AI25934] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002172] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048012] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI025934] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALDEN PB, 1987, NUTRITION HEART DISE, V2, P71; ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5; CALDWELL B, 1991, 7TH P INT C AIDS FLO, V2, P362; COHEN AJ, 1990, AIDS, V4, P807, DOI 10.1097/00002030-199008000-00014; COLAN SD, 1987, J AM COLL CARDIOL, V9, P776, DOI 10.1016/S0735-1097(87)80232-2; COLAN SD, 1984, J AM COLL CARDIOL, V4, P715, DOI 10.1016/S0735-1097(84)80397-6; COLAN SD, 1987, J AM COLL CARDIOL, V10, P1085, DOI 10.1016/S0735-1097(87)80350-9; COLAN SD, 1992, J AM COLL CARDIOL, V19, P619, DOI 10.1016/S0735-1097(10)80282-7; CONNOR E, 1991, SEMIN PEDIATR INFECT, V2, P285; COOPER HL, 1985, MOL CELL BIOL, V5, P972, DOI 10.1128/MCB.5.5.972; DALAKAS M, 1990, NEW ENGL J MED, V323, P994; DALAKAS MC, 1991, NEW ENGL J MED, V325, P1487, DOI 10.1056/NEJM199111213252107; DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602; DEVEREUX RB, 1986, AM J CARDIOL, V57, P450, DOI 10.1016/0002-9149(86)90771-X; DEYTON LR, 1989, NEW ENGL J MED, V321, P1246, DOI 10.1056/NEJM198911023211806; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; GLANTZ S, 1990, PRIMER APPL REGRESSI, P294; GREENE MG, 1991, HARRIET LANE HDB, P42; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; HERSKOWITZ A, 1992, ANN INTERN MED, V116, P311, DOI 10.7326/0003-4819-116-4-311; HSIA J, 1991, CIRCULATION S2, V84, P3; LAMPERTH L, 1991, LAB INVEST, V65, P742; LEWIS W, 1991, LAB INVEST, V65, P228; Lewis W, 1992, Cardiovasc Pathol, V1, P53, DOI 10.1016/1054-8807(92)90007-B; LIPSHULTZ SE, 1990, CIRCULATION, V82, P118; LIPSHULTZ SE, 1990, AM J CARDIOL, V66, P246, DOI 10.1016/0002-9149(90)90603-X; LIPSHULTZ SE, 1989, AM J CARDIOL, V63, P1489, DOI 10.1016/0002-9149(89)90014-3; LIPSHULTZ SE, 1989, PEDIATR RES, V25, pA183; LIPSHULTZ SE, 1989, CIRCULATION S2, V80, P322; LIPSHULTZ SE, 1991, CIRCULATION, V84, P660; MCKINNEY RE, 1991, NEW ENGL J MED, V324, P1018, DOI 10.1056/NEJM199104113241503; MHIRI C, 1991, ANN NEUROL, V29, P606, DOI 10.1002/ana.410290607; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; SALGO M, 1991, CARDIOMYOPATHY CONGE; SCHUNKERT H, 1991, P NATL ACAD SCI USA, V88, P11480, DOI 10.1073/pnas.88.24.11480; SIMPSON DM, 1991, AIDS, V5, P917, DOI 10.1097/00002030-199108000-00001; SIMPSON MV, 1989, BIOCHEM PHARMACOL, V38, P1033, DOI 10.1016/0006-2952(89)90245-1; STEIN KM, 1991, AM J CARDIOL, V68, P1091, DOI 10.1016/0002-9149(91)90502-C; WALTER EB, 1991, J PEDIATR-US, V119, P152, DOI 10.1016/S0022-3476(05)81057-1; WHARTON JM, 1987, AM J MED, V83, P571, DOI 10.1016/0002-9343(87)90774-1; WILKINS CE, 1989, TEX HEART I J, V16, P44; Zar JH., 1999, BIOSTAT ANAL; 1987, MMWR MORB MORTAL WKL, V36, P225	43	79	79	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 29	1992	327	18					1260	1265		10.1056/NEJM199210293271802	http://dx.doi.org/10.1056/NEJM199210293271802			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV259	1406818	Bronze			2022-12-28	WOS:A1992JV25900002
J	TOMPKINS, LS				TOMPKINS, LS			CURRENT CONCEPTS - THE USE OF MOLECULAR METHODS IN INFECTIOUS-DISEASES	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PROSTHETIC-VALVE ENDOCARDITIS; SHOCK-LIKE SYNDROME; BACILLARY ANGIOMATOSIS; STAPHYLOCOCCUS-EPIDERMIDIS; PELIOSIS HEPATIS; OUTBREAK; STRAINS; FEVER; DNA; ELECTROPHORESIS		STANFORD UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305	Stanford University	TOMPKINS, LS (corresponding author), STANFORD UNIV,MED CTR,DEPT MED INFECT DIS,H1537-J,STANFORD,CA 94305, USA.							ANDERSON BE, 1992, J CLIN MICROBIOL, V30, P775, DOI 10.1128/JCM.30.4.775-780.1992; CHEN K, 1989, FEMS MICROBIOL LETT, V57, P19, DOI 10.1016/S0378-1097(97)00476-X; EISENSTEIN BI, 1990, NEW ENGL J MED, V322, P178; ELWELL LP, 1978, ANTIMICROB AGENTS CH, V13, P312, DOI 10.1128/AAC.13.2.312; GRIMONT F, 1986, ANN INST PASTEUR MIC, V137B, P165, DOI 10.1016/S0769-2609(86)80105-3; HOLMBERG SD, 1984, J CLIN MICROBIOL, V19, P100, DOI 10.1128/JCM.19.2.100-104.1984; LEBOIT PE, 1990, ARCH DERMATOL, V126, P808, DOI 10.1001/archderm.126.6.808; LEBOIT PE, 1989, AM J SURG PATHOL, V13, P909, DOI 10.1097/00000478-198911000-00001; LEE SC, 1984, MOL GEN GENET, V194, P173, DOI 10.1007/BF00383513; LIANG TJ, 1991, NEW ENGL J MED, V324, P1705, DOI 10.1056/NEJM199106133242405; LOCKSLEY RM, 1982, ANN INTERN MED, V97, P317, DOI 10.7326/0003-4819-97-3-317; LOUTIT JS, 1991, J CLIN MICROBIOL, V29, P2897, DOI 10.1128/JCM.29.12.2897-2900.1991; LOUTIT JS, 1992, 1992 INT S LEG ORL; LOWRY PW, 1991, NEW ENGL J MED, V324, P109, DOI 10.1056/NEJM199101103240207; MAYER L W, 1988, Clinical Microbiology Reviews, V1, P228; MICKELSEN PA, 1985, J INFECT DIS, V152, P50, DOI 10.1093/infdis/152.1.50; MUSSER JM, 1991, P NATL ACAD SCI USA, V88, P2668, DOI 10.1073/pnas.88.7.2668; OMATA M, 1991, NEW ENGL J MED, V324, P1699, DOI 10.1056/NEJM199106133242404; PARISI JT, 1980, J INFECT DIS, V141, P637, DOI 10.1093/infdis/141.5.637; PATTON CM, 1991, J CLIN MICROBIOL, V29, P680, DOI 10.1128/JCM.29.4.680-688.1991; PERKOCHA LA, 1990, NEW ENGL J MED, V323, P1581, DOI 10.1056/NEJM199012063232302; REGNERY RL, 1992, J CLIN MICROBIOL, V30, P265, DOI 10.1128/JCM.30.2.265-274.1992; RELMAN DA, 1992, NEW ENGL J MED, V327, P293, DOI 10.1056/NEJM199207303270501; RELMAN DA, 1991, NEW ENGL J MED, V324, P1514; RELMAN DA, 1990, NEW ENGL J MED, V323, P1573, DOI 10.1056/NEJM199012063232301; SADOWSKI PL, 1979, ANTIMICROB AGENTS CH, V15, P616, DOI 10.1128/AAC.15.4.616; SCHABERG DR, 1981, J CLIN MICROBIOL, V13, P1105, DOI 10.1128/JCM.13.6.1105-1108.1981; SELANDER RK, 1986, INFECT IMMUN, V52, P213, DOI 10.1128/IAI.52.1.213-222.1986; SELANDER RK, 1986, APPL ENVIRON MICROB, V51, P873, DOI 10.1128/AEM.51.5.873-884.1986; SLATER LN, 1990, NEW ENGL J MED, V323, P1587, DOI 10.1056/NEJM199012063232303; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STARNBACH MN, 1989, J CLIN MICROBIOL, V27, P1257, DOI 10.1128/JCM.27.6.1257-1261.1989; STEVENS DL, 1989, NEW ENGL J MED, V321, P1, DOI 10.1056/NEJM198907063210101; STOLER MH, 1983, AM J CLIN PATHOL, V80, P714, DOI 10.1093/ajcp/80.5.714; STOUT JE, 1992, NEW ENGL J MED, V326, P151, DOI 10.1056/NEJM199201163260302; TAYLOR DN, 1982, NEW ENGL J MED, V306, P1249, DOI 10.1056/NEJM198205273062101; TENOVER F C, 1988, Clinical Microbiology Reviews, V1, P82; Tompkins L S, 1989, Curr Clin Top Infect Dis, V10, P174; TOMPKINS LS, 1987, J CLIN MICROBIOL, V25, P1875, DOI 10.1128/JCM.25.10.1875-1880.1987; TOMPKINS LS, 1988, NEW ENGL J MED, V318, P530, DOI 10.1056/NEJM198803033180902; TOMPKINS LS, 1980, J INFECT DIS, V141, P625, DOI 10.1093/infdis/141.5.625; TOMPKINS LS, 1986, J INFECT DIS, V154, P156, DOI 10.1093/infdis/154.1.156; WACHSMUTH K, 1986, REV INFECT DIS, V8, P682; WILSON KH, 1991, LANCET, V338, P474, DOI 10.1016/0140-6736(91)90545-Z; 1991, MMWR MORB MORTAL WKL, V40, P21	45	72	73	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 29	1992	327	18					1290	1297						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV259	1406820				2022-12-28	WOS:A1992JV25900008
J	LINDEMANN, F; SCHLIMOK, G; DIRSCHEDL, P; WITTE, J; RIETHMULLER, G				LINDEMANN, F; SCHLIMOK, G; DIRSCHEDL, P; WITTE, J; RIETHMULLER, G			PROGNOSTIC-SIGNIFICANCE OF MICROMETASTATIC TUMOR-CELLS IN BONE-MARROW OF COLORECTAL-CANCER PATIENTS	LANCET			English	Article							LARGE BOWEL-CANCER; MONOCLONAL-ANTIBODIES; MULTIVARIATE-ANALYSIS; MICRO-METASTESES; BREAST-CANCER; RECTAL-CANCER; CARCINOMA; CYTOKERATIN; METASTASES; EXPRESSION	Much of the information recorded at the time of surgery for malignant disease has been used, alone or in combination, to indicate the outlook for that patient, including probability of metastasis. However, direct evidence of tumour seeding in distant organs at that time is not available. An immunocytochemical assay for the epithelial cytokeratin protein (CK18) may fill this gap since it is a feature of epithelial cells but would not normally be in bone marrow. We looked for disseminated tumour cells preoperatively in bone marrow from 88 patients with radically resected colorectal carcinomas. Smears for 28 (32%) patients were positive for cells of epithelial origin, which were absent from aspirates taken from 102 controls with non-malignant disease. The prognostic value was assessed in a follow-up study with a median observation time of 35 (12-58) months. Patients who had bone marrow tumour cells in the aspirate showed a significantly shorter disease-free survival than those without tumour cells (p = 0.0084). In a Cox regression model multivariate analysis demonstrated that the finding of tumour cells in bone marrow is an independent, significant (p = 0.0035) determinant of relapse. Although the skeleton is not a preferred site of overt metastasis in colorectal cancer the demonstration of tumour cells in bone marrow has to be taken as evidence of the general disseminative capability of an individual tumour.	UNIV MUNICH, INST IMMUNOL, W-8000 MUNICH 2, GERMANY; UNIV MUNICH, INST MED INFORMAT BIOMETRY & EPIDEMIOL, W-8000 MUNICH 2, GERMANY; ZENT KLINIKUM, MED CLIN 2, W-8900 AUGSBURG, GERMANY	University of Munich; University of Munich	LINDEMANN, F (corresponding author), ZENT KLINIKUM, ALLGEMEIN & ABDOMINALCHIRURG KLIN, DEPT GEN SURG, STENGLINSTR 2, W-8900 AUGSBURG, GERMANY.							BONNHEIM DC, 1986, AM J SURG, V151, P457, DOI 10.1016/0002-9610(86)90102-9; BURKHARDT R, 1980, B CANCER, V67, P291; CHAPUIS PH, 1985, BRIT J SURG, V72, P698, DOI 10.1002/bjs.1800720909; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; COTE RJ, 1991, J CLIN ONCOL, V9, P1749, DOI 10.1200/JCO.1991.9.10.1749; COX DR, 1972, J R STAT SOC B, V34, P187; DEBUS E, 1984, AM J PATHOL, V114, P121; FIELDING LP, 1986, LANCET, V2, P904; FREEDMAN LS, 1984, LANCET, V2, P733; HERMANEK P, 1989, DIS COLON RECTUM, V32, P593, DOI 10.1007/BF02554180; JASS JR, 1986, HISTOPATHOLOGY, V10, P437, DOI 10.1111/j.1365-2559.1986.tb02497.x; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KILLION JJ, 1989, SEMIN ONCOL, V16, P106; KNAPP AC, 1989, CELL, V59, P67, DOI 10.1016/0092-8674(89)90870-2; MANSI JL, 1987, BRIT MED J, V295, P1093, DOI 10.1136/bmj.295.6606.1093; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; Paget S, 1989, LANCET, V8, P98, DOI [DOI 10.1016/S0140-6736(00)49915-0, 10.1016/S0140-6736(00)49915-0]; PANTEL K, 1991, CANCER RES, V51, P4712; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; RIETHMULLER G, 1989, PROGR IMMUNOLOGY, V7, P1079; Schlimok G, 1990, Semin Cancer Biol, V1, P207; SCHLIMOK G, 1987, P NATL ACAD SCI USA, V84, P8672, DOI 10.1073/pnas.84.23.8672; SCHLIMOK G, 1990, J CLIN ONCOL, V8, P831, DOI 10.1200/JCO.1990.8.5.831; SCHLIMOK G, 1985, BLUT, V51, P203; SCHMITZMOORMANN P, 1987, J CANCER RES CLIN, V113, P586, DOI 10.1007/BF00390871; TALBOT RW, 1989, EUR J SURG ONCOL, V15, P449; WEISS L, 1986, J PATHOL, V150, P195, DOI 10.1002/path.1711500308; WELCH JP, 1979, ANN SURG, V189, P496; WIGGERS T, 1988, CANCER, V61, P386, DOI 10.1002/1097-0142(19880115)61:2<386::AID-CNCR2820610231>3.0.CO;2-J; ZETTER BR, 1990, NEW ENGL J MED, V322, P605; 1991, JAMA-J AM MED ASSOC, V264, P1444	31	506	517	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 19	1992	340	8821					685	689		10.1016/0140-6736(92)92230-D	http://dx.doi.org/10.1016/0140-6736(92)92230-D			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN780	1381801				2022-12-28	WOS:A1992JN78000002
J	SIEGERT, W; AGTHE, A; GRIESSER, H; SCHWERDTFEGER, R; BRITTINGER, G; ENGELHARD, M; KUSE, R; TIEMANN, M; LENNERT, K; HUHN, D				SIEGERT, W; AGTHE, A; GRIESSER, H; SCHWERDTFEGER, R; BRITTINGER, G; ENGELHARD, M; KUSE, R; TIEMANN, M; LENNERT, K; HUHN, D			TREATMENT OF ANGIOIMMUNOBLASTIC LYMPHADENOPATHY (AILD)-TYPE T-CELL LYMPHOMA USING PREDNISONE WITH OR WITHOUT THE COPBLAM/IMVP-16 REGIMEN - A MULTICENTER STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						CEREBROVASCULAR DISORDERS; HEPARINOID; ENOXAPARIN; HEPARIN; THROMBOEMBOLISM	ANGIO-IMMUNOBLASTIC LYMPHADENOPATHY; LYMPHOPROLIFERATIVE DISORDERS; CHROMOSOMAL-ABNORMALITIES; COMBINATION CHEMOTHERAPY; REARRANGEMENT; FEATURES; DISEASE	Objective: To describe the clinical course of patients with angioimmunoblastic lymphadenopathy (AILD)-type lymphoma with a sequential treatment with prednisone and COPBLAM/IMVP-16. Design: A multicenter, prospective, nonrandomized trial. Setting: University medical centers and community hospitals. Patients: Sixty-seven patients were registered, 28 were excluded, and 39 patients were evaluable for response (median age, 59 years; range, 25 to 82 years) (stages I and II, 10%; stages III and IV, 90%; B symptoms, 74%). Measurements: Response, survival, and relapse. Intervention: Patients initially received prednisone and no further treatment if a complete remission was achieved. Relapsing or refractory patients were treated with COPBLAM/IMVP-16. Patients with life-threatening tumor progression or extension received COPBLAM/IMVP-16 initially. Treatments were chosen in accordance with tumor extension and response to prednisone. Treatment modalities were not compared. Results: Twenty-eight patients received primary prednisone, 18 received secondary prednisone, and 11 received primary chemotherapy. The complete response rates (with 95% CIs) were 29% (CI, 12% to 46%), 56% (CI, 33% to 79%), and 64% (CI, 36% to 92%), respectively. The median observation time of surviving patients was 28 months (range, 7 to 53). The median overall survival time was 15 months. The probabilities (with 95% CIs) of overall survival, event-free survival, and relapse at 36 months were 40.5% (CI, 24% to 56%), 32.3% (CI, 17% to 47%), and 34.6% (CI, 14% to 56%), respectively. At the time of evaluation, 22 of 39 patients had died, 7 of noninfectious complications and 14 of infections. Conclusions: Prednisone with or without COPBLAM/IMVP-16 treatment in AILD-type lymphoma leads to complete remissions in about half of the patients and in long-term, disease free survival for one third.	UNIV KIEL, INST PATHOL, W-2300 KIEL 1, GERMANY; UNIV ESSEN GESAMTHSCH, MED KLIN, W-4300 ESSEN 1, GERMANY; ALLGEMEINES KRANKENHAUS ST GEORG, W-2000 HAMBURG 1, GERMANY	University of Kiel; University of Duisburg Essen; Asklepios Klinik St. Georg	SIEGERT, W (corresponding author), FREE UNIV BERLIN, KLINIKUM RUDOLF VIRCHOW, STANDORT CHARLOTTENBURG, SPANDAUER DAMM 130, W-1000 BERLIN 19, GERMANY.		Agthe, Alexander/A-3003-2011					ARCHIMBAUD E, 1987, CANCER-AM CANCER SOC, V59, P208, DOI 10.1002/1097-0142(19870115)59:2<208::AID-CNCR2820590205>3.0.CO;2-7; AZEVEDO SJ, 1985, AM J HEMATOL, V20, P301, DOI 10.1002/ajh.2830200314; CABANILLAS F, 1982, BLOOD, V60, P693; ENGELHARD M, 1991, ANN ONCOL, V2, P177, DOI 10.1093/annonc/2.suppl_2.177; FELLER AC, 1988, AM J PATHOL, V133, P549; FRIZZERA G, 1975, AM J MED, V59, P803, DOI 10.1016/0002-9343(75)90466-0; FRIZZERA G, 1989, LEUKEMIA, V3, P1; GANESAN TS, 1987, BRIT J CANCER, V55, P437, DOI 10.1038/bjc.1987.86; GODDESALZ E, 1987, LEUKEMIA RES, V11, P181, DOI 10.1016/0145-2126(87)90024-5; GRIESSER H, 1986, J CLIN INVEST, V78, P1179, DOI 10.1172/JCI112700; GRIESSER H, 1989, BLOOD, V73, P1402; KANEKO Y, 1988, BLOOD, V72, P413; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LAURENCE J, 1982, ANN INTERN MED, V97, P190, DOI 10.7326/0003-4819-97-2-190; LENNERT K, 1973, LEUKAMIEN MALIGNE LY, P281; Lennert K, 1990, HISTOPATHOLOGIE NONH; LUKES RJ, 1975, NEW ENGL J MED, V292, P1, DOI 10.1056/NEJM197501022920101; NATHWANI BN, 1978, CANCER, V41, P578, DOI 10.1002/1097-0142(197802)41:2<578::AID-CNCR2820410226>3.0.CO;2-8; PANGALIS GA, 1983, CANCER-AM CANCER SOC, V52, P318, DOI 10.1002/1097-0142(19830715)52:2<318::AID-CNCR2820520221>3.0.CO;2-G; RADASZKIEWICZ T, 1975, DEUT MED WOCHENSCHR, V100, P1157, DOI 10.1055/s-0028-1106350; SCHAUER PK, 1981, CANCER, V48, P2493, DOI 10.1002/1097-0142(19811201)48:11<2493::AID-CNCR2820481124>3.0.CO;2-T; SCHLEGELBERGER B, 1990, CANCER GENET CYTOGEN, V50, P15, DOI 10.1016/0165-4608(90)90233-Z; SIEGERT W, 1989, BLOOD S, V74, pA280; SUCHI T, 1987, J CLIN PATHOL, V40, P995, DOI 10.1136/jcp.40.9.995; TOBINAI K, 1988, BLOOD, V72, P1000; WEISS LM, 1986, AM J PATHOL, V122, P392	27	89	92	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1992	117	5					364	370		10.7326/0003-4819-117-5-364	http://dx.doi.org/10.7326/0003-4819-117-5-364			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK678	1380221				2022-12-28	WOS:A1992JK67800003
J	KUMARESAN, JA; MAGANU, ET				KUMARESAN, JA; MAGANU, ET			CASE HOLDING IN PATIENTS WITH TUBERCULOSIS IN BOTSWANA	BRITISH MEDICAL JOURNAL			English	Article								Objective-To evaluate the effectiveness of daily supervised short course chemotherapy in a national tuberculosis programme. Design-Observation of programme during 1984-90. In October 1986 short course chemotherapy was introduced with patients receiving treatment daily from staff in their nearest health facility. Setting-Botswana national tuberculosis programme. Subjects - All patients with tuberculosis. Main outcome measures-Proportions of patients complying with and defaulting from treatment (missing greater-than-or-equal-to 43 days' treatment). Results-2938 cases of tuberculosis were recorded in 1990, 1528 of which were of sputum positive pulmonary disease. 2711 (92.3%) patients complied with treatment and 227 (7.7%) defaulted. Before introduction of short course chemotherapy compliance was about 60% compared with over 90% in 1987-90. Conclusions-A programme using daily supervised short course chemotherapy integrated into the primary health care system is an effective method of treating tuberculosis. The costs of the programme need to be evaluated.	MINIST HLTH,GABORONE,BOTSWANA		KUMARESAN, JA (corresponding author), COMMUNITY HLTH SERV DIV,EPIDEMIOL UNIT,PRIVATE BAG 00269,GABORONE,BOTSWANA.							ARMSTRONG RH, 1984, CENT AFR J MED, V30, P144; Bailey W C, 1988, Am Rev Respir Dis, V138, P1075; BARNUM HN, 1986, SOC SCI MED, V23, P847, DOI 10.1016/0277-9536(86)90212-1; Iseman M D, 1986, Semin Respir Infect, V1, P213; Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6; REED JB, 1990, J EPIDEMIOL COMMUN H, V44, P20, DOI 10.1136/jech.44.1.20; RIEDER HL, 1985, TUBERCLE, V66, P179, DOI 10.1016/0041-3879(85)90034-0; TACHEZY P, 1985, NATIONAL TUBERCULOSI, P17; TEFUARANI N, 1989, PAPUA NEW GUINEA MED, V32, P177	9	10	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 8	1992	305	6849					340	341		10.1136/bmj.305.6849.340	http://dx.doi.org/10.1136/bmj.305.6849.340			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ032	1392885	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JJ03200021
J	CHUA, A; KEATING, J; HAMILTON, D; KEELING, PWN; DINAN, TG				CHUA, A; KEATING, J; HAMILTON, D; KEELING, PWN; DINAN, TG			CENTRAL SEROTONIN RECEPTORS AND DELAYED GASTRIC-EMPTYING IN NONULCER DYSPEPSIA	BRITISH MEDICAL JOURNAL			English	Article							NONULCER DYSPEPSIA; DIAGNOSIS; MOTILITY; GUT; EPIDEMIOLOGY; FENFLURAMINE; DISORDERS; RESPONSES; ANOREXIA; PATHWAYS	Objective-To determine whether central serotonin receptors are involved in the pathophysiology of non-ulcer dyspepsia. Design-Between subjects study of solid phase gastric emptying and prolactin response to buspirone challenge. Subjects-12 patients fulfilling criteria for non-ulcer dyspepsia and 12 age and sex matched controls. Main outcome measures-Solid phase gastric emptying measured by scintigraphic assessment of the movement of a standard meal labelled with technetium-99m and indium-111; responsiveness of central serotonin 1A receptors measured by the prolactin release following challenge with oral buspirone 60 mg. Results-Solid phase gastric emptying was significantly delayed in the patients with non-ulcer dyspepsia (t1/2=90.6 (SD 14.5) minutes in patients and 54.6 (10.7) minutes in controls; 95% confidence interval 24.7 to 46.7 minutes, p<0.001). Prolactin release was significantly greater in patients compared with controls (1272.7 (1039.9) mU/l v 292.9 (136.1) mU/l; 352.1 to 1607.5 mU/l, p<0.01). Gastric emptying and prolactin release were significantly correlated (r=0.59, p=0.04) in the patients but not in the controls (r=0.23). Conclusion-Central serotonin IA receptors may have a role in the pathophysiology of non-ulcer dyspepsia of the dysmotility subtype.	ST JAMES HOSP,TRINITY COLL,SCH MED,DEPT GASTROENTEROL,DUBLIN 8,IRELAND; ST JAMES HOSP,TRINITY COLL,SCH MED,DEPT NUCL MED,DUBLIN 8,IRELAND; ST JAMES HOSP,TRINITY COLL,SCH MED,DEPT PSYCHIAT,DUBLIN 8,IRELAND	Trinity College Dublin; Trinity College Dublin; Trinity College Dublin			Dinan, Timothy/ABA-8284-2020	Dinan, Timothy/0000-0002-2316-7220				ADAMI HO, 1984, SCAND J GASTROENTERO, V19, P216, DOI 10.1080/00365521.1984.12005712; BAKHEIT AMO, 1992, BRIT MED J, V304, P1010, DOI 10.1136/bmj.304.6833.1010; BLUNDELL JE, 1983, NUTR BRAIN, V6, P163; CAMILLERI M, 1986, DIGEST DIS SCI, V31, P1169, DOI 10.1007/BF01296514; CAMILLERI M, 1984, EUR J CLIN INVEST, V14, P420, DOI 10.1111/j.1365-2362.1984.tb01206.x; CAMILLERI M, 1985, GASTROENTEROLOGY, V88, P1852, DOI 10.1016/0016-5085(85)90010-1; CHECKLEY SA, 1980, PSYCHOL MED, V10, P35, DOI 10.1017/S0033291700039593; CHUA A, 1988, GUT, V29, pA1437; COCCARO EF, 1990, ARCH GEN PSYCHIAT, V47, P594; COLINJONES DG, 1988, LANCET, V1, P576; COLLINS PJ, 1983, GUT, V24, P1117, DOI 10.1136/gut.24.12.1117; COOTE JH, 1974, J PHYSIOL-LONDON, V241, P453, DOI 10.1113/jphysiol.1974.sp010666; DAVIES RF, 1983, PHYSIOL BEHAV, V30, P723, DOI 10.1016/0031-9384(83)90169-5; DINAN TG, 1990, INT CLIN PSYCHOPHARM, V5, P119, DOI 10.1097/00004850-199004000-00006; DINAN TG, 1990, SCAND J GASTROENTERO, V25, P541, DOI 10.3109/00365529009095527; DUHAULT J, 1980, PROG NEURO-PSYCHOPHA, V4, P341, DOI 10.1016/0364-7722(80)90004-1; ELIASSON S, 1953, ACTA PHYSL SCAND, V30, P199; GERSHON MD, 1981, GASTROENTEROLOGY, V80, P1571; Gilman AG, 1980, PHARM BASIS THERAPEU; HARRISON RJ, 1986, TXB INTERNAL MED; HARVEY RF, 1983, LANCET, V1, P632; HOPKINSON GB, 1989, SCAND J GASTROENTERO, V24, P923, DOI 10.3109/00365528909089236; KALIA M, 1980, J COMP NEUROL, V193, P467, DOI 10.1002/cne.901930211; KHURANA RK, 1980, NEUROLOGY, V30, P805, DOI 10.1212/WNL.30.8.805; LOEWY AD, 1981, J AUTONOM NERV SYST, V3, P265, DOI 10.1016/0165-1838(81)90068-0; MALAGELADA JR, 1985, GASTROENTEROLOGY, V88, P1223, DOI 10.1016/S0016-5085(85)80083-4; MANNING AP, 1978, BRIT MED J, V2, P653, DOI 10.1136/bmj.2.6138.653; PAGINI FD, 1984, AM J PHYSIOL, V246, pG253; ROWLAND N, 1984, LIFE SCI, V34, P2495, DOI 10.1016/0024-3205(84)90286-8; SILVERSTONE T, 1988, DRUG TREATMENT PSYCH; TALLEY NJ, 1985, SCAND J GASTROENTERO, V20, P896, DOI 10.3109/00365528509088842; THOMPSON WG, 1984, CAN MED ASSOC J, V130, P565; TIBBLIN G, 1985, SCAND J GASTROENTERO, V20, P29, DOI 10.3109/00365528509103932; VANPRAAG HM, 1980, COMPR PSYCHIAT, V21, P30, DOI 10.1016/0010-440X(80)90062-0; WOOD JR, 1985, GASTROENTEROLOGY, V89, P1411, DOI 10.1016/0016-5085(85)90663-8; YOU CH, 1981, ANN INTERN MED, V95, P449, DOI 10.7326/0003-4819-95-4-449; 1988, STAGRAPHICS 1988	37	40	43	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1992	305	6848					280	282		10.1136/bmj.305.6848.280	http://dx.doi.org/10.1136/bmj.305.6848.280			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG740	1392859	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JG74000016
J	GEISSLER, K; FORSTINGER, C; KALHS, P; KNOBL, P; KIER, P; KYRLE, P; LECHNER, K				GEISSLER, K; FORSTINGER, C; KALHS, P; KNOBL, P; KIER, P; KYRLE, P; LECHNER, K			EFFECT OF INTERLEUKIN-3 ON RESPONSIVENESS TO GRANULOCYTE-COLONY-STIMULATING FACTOR IN SEVERE APLASTIC-ANEMIA	ANNALS OF INTERNAL MEDICINE			English	Note						ANEMIA; GRANULOCYTE COLONY-STIMULATING FACTOR; INTERLEUKIN-3; HEMATOPOIETIC CELL GROWTH FACTORS; HEMATOPOIESIS	RECOMBINANT HUMAN INTERLEUKIN-3; PRIMATES	Patients with severe aplastic anemia rarcly respond to monotherapy with hematopoietic growth factors. This inadequate response is thought to be caused by a deficiency in hematopoietic progenitors. Interleukin-3 has recently been reported to expand the pool of hematopoictic progenitors in primates. This report describes a patient with severe, refractory aplastic anemia who initially failed to respond to treatment with granulocyte-colony-stimulating factor but who showed a dramatic response to the same agent after pretreatment with interleukin-3.			GEISSLER, K (corresponding author), UNIV VIENNA, INTERNAL MED CLIN 1, WAHRINGERGURTEL 18-20, A-1090 VIENNA, AUSTRIA.		Knoebl, Paul/G-2787-2010; geissler, klaus/L-8925-2013	Knoebl, Paul/0000-0002-7909-7225; geissler, klaus/0000-0003-1921-7034				ANTIN JH, 1988, BLOOD, V72, P705; CHAMPLIN RE, 1989, BLOOD, V73, P694; DONAHUE RE, 1988, SCIENCE, V241, P1820, DOI 10.1126/science.3051378; GANSER A, 1990, BLOOD, V76, P1287; GEISSLER K, 1990, BLOOD, V75, P2305; GEISSLER K, 1992, BLOOD, V79, P1155, DOI 10.1182/blood.V79.5.1155.bloodjournal7951155; NISSEN C, 1988, BLOOD, V72, P2045; UMEMURA T, 1989, BLOOD, V74, P1571; VAHANRAJ S, 1988, NEW ENGL J MED, V319, P1628; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	10	25	25	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1992	117	3					223	225		10.7326/0003-4819-117-3-223	http://dx.doi.org/10.7326/0003-4819-117-3-223			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF304	1377461				2022-12-28	WOS:A1992JF30400009
J	STOKES, M; JONES, DJ				STOKES, M; JONES, DJ			ABC OF COLORECTAL DISEASES - COLORECTAL TRAUMA	BRITISH MEDICAL JOURNAL			English	Article									HOPE HOSP,SALFORD M6 8HD,LANCS,ENGLAND		STOKES, M (corresponding author), ST VINCENTS HOSP,GEN SURG,DUBLIN 4,IRELAND.								0	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1992	305	6848					303	306		10.1136/bmj.305.6848.303	http://dx.doi.org/10.1136/bmj.305.6848.303			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG740	1392866	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992JG74000027
J	GODFREYFAUSSETT, P; MORTIMER, PR; JENKINS, PA; STOKER, NG				GODFREYFAUSSETT, P; MORTIMER, PR; JENKINS, PA; STOKER, NG			EVIDENCE OF TRANSMISSION OF TUBERCULOSIS BY DNA FINGERPRINTING	BRITISH MEDICAL JOURNAL			English	Article							IS6110	Objective-To determine whether a subject who had died of tuberculous meningitis had been infected by a neighbour. Design-Retrospective comparison of isolates of Mycobacterium tuberculosis from the two cases and from 10 controls by DNA fingerprinting. Setting-Public Health Service Reference Laboratory for Mycobacteria and bacterial molecular genetics unit of the London School of Hygiene and Tropical Medicine. Subjects-Deceased and neighbour; 10 controls from the same city, from whom isolates had been collected over three months before the subject's death. Main outcome measures-Identity and similarity values (S(AB)) between fingerprint patterns from different isolates obtained by hybridisation of restriction fragments produced by PvuII with a probe from the insertion element IS6110/986, present in multiple copies throughout the genome of M tuberculosis. Results-Isolates from the two cases under investigation had identical fingerprints whereas those from the controls were all distinct. Two clusters of isolates with a similarity coefficient >0.25 were identified: in one, four out of five patients were born in the midlands (the birth place of the fifth was not known) and in the other all three patients were born in the Indian subcontinent. Conclusions-The data are consistent with, but do not prove, transmission of tuberculosis from the neighbour to the deceased. Geographical separation of the pools of infection may have led to the evolution of distinct clusters of fingerprint patterns. DNA fingerprinting of M tuberculosis is a powerful new tool for study of the epidemiology and pathogenesis of tuberculosis.	UNIV LONDON LONDON SCH HYG & TROP MED,DEPT CLIN SCI,BACTERIAL MOLEC GENET UNIT,LONDON WC1E 7HT,ENGLAND; PUBL HLTH LABS,COVENTRY,ENGLAND; PUBL HLTH LABS,MYCOBACTERIUM REFERENCE UNIT,CARDIFF,WALES	University of London; London School of Hygiene & Tropical Medicine			Stoker, Neil G/L-8812-2016	Stoker, Neil G/0000-0001-7055-6184				BISHOP MJ, 1991, NUCLEIC ACID PROTEIN, P359; CAMPBELL A, 1981, ANNU REV MICROBIOL, V35, P55, DOI 10.1146/annurev.mi.35.100181.000415; GODFREYFAUSSETT P, 1991, LANCET, V337, P176, DOI 10.1016/0140-6736(91)90840-L; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P1204, DOI 10.1128/JCM.28.6.1204-1213.1990; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P2052; MAZUREK GH, 1991, J CLIN MICROBIOL, V29, P2030, DOI 10.1128/JCM.29.9.2030-2033.1991; OTAL I, 1991, J CLIN MICROBIOL, V29, P1252, DOI 10.1128/JCM.29.6.1252-1254.1991; SCHMID J, 1990, J CLIN MICROBIOL, V28, P1236, DOI 10.1128/JCM.28.6.1236-1243.1990; ZAINUDDIN ZF, 1989, J GEN MICROBIOL, V135, P2347	9	38	38	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1992	305	6847					221	223		10.1136/bmj.305.6847.221	http://dx.doi.org/10.1136/bmj.305.6847.221			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG112	1392824	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JG11200021
J	ROSEN, GD; SANES, JR; LACHANCE, R; CUNNINGHAM, JM; ROMAN, J; DEAN, DC				ROSEN, GD; SANES, JR; LACHANCE, R; CUNNINGHAM, JM; ROMAN, J; DEAN, DC			ROLES FOR THE INTEGRIN VLA-4 AND ITS COUNTER RECEPTOR VCAM-1 IN MYOGENESIS	CELL			English	Article							CELL-ADHESION MOLECULE; ADULT SKELETAL-MUSCLE; HEPARAN-SULFATE PROTEOGLYCAN; RAT LUMBRICAL MUSCLES; N-CAM; EXTRASYNAPTIC PORTIONS; FIBRONECTIN RECEPTOR; MYOBLAST INTERACTION; SECONDARY MYOTUBES; FIBER NUMBERS	Mammalian myogenesis is biphasic: primary myoblasts fuse to form primary myotubes, then secondary myoblasts align along the primary myotubes and form secondary myotubes, which comprise most of adult muscle. We provide evidence that an integrin (VLA-4) and its counter receptor (VCAM-1) have a role in secondary myogenesis. Both receptors are synthesized by cultured muscle cells: VLA-4 is induced as myotubes form, whereas VCAM-1 is present on myoblasts and myotubes. In vivo, both molecules are expressed at sites of secondary myogenesis, VLA-4 on primary and secondary myotubes, and VCAM-1 on secondary myoblasts and on regions of secondary myotubes apposed to primary myotubes. These patterns suggest that VLA-4-VCAM-1 interactions influence alignment of secondary myoblasts along primary myotubes and/or the fusion of secondary myoblasts. In support of the latter possibility, antibodies to VLA-4 or VCAM-1 inhibit myotube formation in culture.	WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)	ROSEN, GD (corresponding author), WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110, USA.				NHLBI NIH HHS [HL 43418, HL 29594] Funding Source: Medline; NINDS NIH HHS [NS 19195] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029594, R01HL043418] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019195, R37NS019195] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; ASHMORE CR, 1972, EXP NEUROL, V37, P241, DOI 10.1016/0014-4886(72)90071-4; BIRKENMEIER TM, 1991, J BIOL CHEM, V266, P20544; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; BOZYCZKO D, 1989, EXP CELL RES, V183, P72, DOI 10.1016/0014-4827(89)90419-9; CARLOS T, 1991, BLOOD, V77, P2266; CARLSON BM, 1983, MED SCI SPORT EXER, V15, P187; CASHMAN NR, 1987, ANN NEUROL, V21, P481, DOI 10.1002/ana.410210512; CHIU AY, 1984, DEV BIOL, V103, P456, DOI 10.1016/0012-1606(84)90333-6; COSSU G, 1987, CURR TOP DEV BIOL, V23, P185; COVAULT J, 1986, J CELL BIOL, V102, P716, DOI 10.1083/jcb.102.3.716; COVAULT J, 1985, P NATL ACAD SCI USA, V82, P4544, DOI 10.1073/pnas.82.13.4544; DICKSON G, 1990, NATURE, V344, P348, DOI 10.1038/344348a0; DUXSON MJ, 1989, DEVELOPMENT, V107, P743; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FREDETTE BJ, 1991, DEV BIOL, V143, P1, DOI 10.1016/0012-1606(91)90050-D; FREEDMAN AS, 1990, SCIENCE, V249, P1030, DOI 10.1126/science.1697696; FURST DO, 1989, J CELL BIOL, V109, P517, DOI 10.1083/jcb.109.2.517; GATCHALIAN CL, 1989, J CELL BIOL, V108, P1873, DOI 10.1083/jcb.108.5.1873; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HARRIS AJ, 1981, PHILOS T ROY SOC B, V293, P257, DOI 10.1098/rstb.1981.0076; HARRIS AJ, 1989, DEVELOPMENT, V107, P771; HARTLEY RS, 1991, DEV BIOL, V148, P249, DOI 10.1016/0012-1606(91)90334-Y; HEMLER ME, 1987, J BIOL CHEM, V262, P3300; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HOLZMANN B, 1989, IMMUNOL REV, V108, P45, DOI 10.1111/j.1600-065X.1989.tb00012.x; JAFFREDO T, 1988, DEVELOPMENT, V103, P431; KELLY AM, 1969, J CELL BIOL, V42, P135, DOI 10.1083/jcb.42.1.135; KNUDSEN KA, 1990, DEV BIOL, V138, P159, DOI 10.1016/0012-1606(90)90185-L; KNUDSEN KA, 1990, EXP CELL RES, V188, P175, DOI 10.1016/0014-4827(90)90157-6; KNUDSEN KA, 1977, DEV BIOL, V58, P328, DOI 10.1016/0012-1606(77)90095-1; KUHL U, 1986, DEV BIOL, V117, P628, DOI 10.1016/0012-1606(86)90331-3; MCLENNAN IS, 1983, DEV BIOL, V98, P287, DOI 10.1016/0012-1606(83)90359-7; MENKO AS, 1987, CELL, V51, P51, DOI 10.1016/0092-8674(87)90009-2; MILLER JB, 1990, J CELL BIOL, V111, P1149, DOI 10.1083/jcb.111.3.1149; MIYAKE K, 1991, J CELL BIOL, V114, P557, DOI 10.1083/jcb.114.3.557; MOULD AP, 1991, J BIOL CHEM, V266, P3579; NEUHAUS H, 1991, J CELL BIOL, V115, P1149, DOI 10.1083/jcb.115.4.1149; OLSON EN, 1991, MOL CELL BIOCHEM, V104, P7; ONTELL M, 1988, AM J ANAT, V181, P267, DOI 10.1002/aja.1001810305; ONTELL M, 1977, ANAT REC, V189, P669, DOI 10.1002/ar.1091890410; ONTELL M, 1984, AM J ANAT, V171, P133, DOI 10.1002/aja.1001710202; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PIERSCHBACHER MD, 1981, CELL, V26, P259, DOI 10.1016/0092-8674(81)90308-1; RICE GE, 1990, J EXP MED, V171, P1369, DOI 10.1084/jem.171.4.1369; RICE GE, 1991, AM J PATHOL, V138, P385; ROMAN J, 1989, J CELL BIOL, V108, P2529, DOI 10.1083/jcb.108.6.2529; ROSEN GD, 1991, P NATL ACAD SCI USA, V88, P4094, DOI 10.1073/pnas.88.10.4094; ROSS JJ, 1987, DEVELOPMENT, V100, P395; ROSS JJ, 1987, DEVELOPMENT, V100, P383; SANES JR, 1986, J CELL BIOL, V102, P420, DOI 10.1083/jcb.102.2.420; SCHEEREN RA, 1991, EUR J IMMUNOL, V21, P1101, DOI 10.1002/eji.1830210503; SHIMIZU Y, 1991, J CELL BIOL, V113, P1203, DOI 10.1083/jcb.113.5.1203; SOLER AP, 1991, DEV BIOL, V148, P389, DOI 10.1016/0012-1606(91)90346-5; STICKLAND NC, 1982, ANAT EMBRYOL, V164, P379, DOI 10.1007/BF00315759; STOCKDALE FE, 1987, DEV BIOL, V123, P1, DOI 10.1016/0012-1606(87)90420-9; TEIXIDO J, 1992, J BIOL CHEM, V267, P1786; TRASK RV, 1988, J BIOL CHEM, V263, P17142; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VONDERMARK H, 1991, J BIOL CHEM, V266, P23593; VONDERMARK K, 1989, DIFFERENTIATION, V40, P150, DOI 10.1111/j.1432-0436.1989.tb00823.x; WAKELAM MJO, 1985, BIOCHEM J, V228, P1; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WHEELOCK MJ, 1991, DIFFERENTIATION, V46, P35, DOI 10.1111/j.1432-0436.1991.tb00863.x; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477	66	329	336	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 26	1992	69	7					1107	1119		10.1016/0092-8674(92)90633-N	http://dx.doi.org/10.1016/0092-8674(92)90633-N			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JA431	1377605				2022-12-28	WOS:A1992JA43100006
J	GRATTAN, CEH; FRANCIS, DM; SLATER, NGP; BARLOW, RJ; GREAVES, MW				GRATTAN, CEH; FRANCIS, DM; SLATER, NGP; BARLOW, RJ; GREAVES, MW			PLASMAPHERESIS FOR SEVERE, UNREMITTING, CHRONIC URTICARIA	LANCET			English	Note								Histamine-releasing autoantibodies have been identified in chronic idiopathic urticaria. 8 patients with severe disease and histamine-releasing activity in their sera underwent plasmapheresis. Symptoms were abolished for 2 months in 1 patient and for 3 weeks in another, 2 showed almost complete resolution of symptoms, 2 had temporary relief, and the other 2 showed little change. Further investigation in 4 of the patients showed significantly reduced skin-test responses to fresh post-exchange autologous sera after plasmapheresis compared with stored pre-exchange sera, but the response to intradermal histamine remained unchanged. Blood cellular histamine increased as in-vitro serum histamine-releasing activity fell after plasmapheresis. These results favour a pathogenetic role for histamine-releasing autoantibodies in patients with chronic urticaria.	UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,ST JOHNS INST DERMATOL,LONDON,ENGLAND; ST THOMAS HOSP,DEPT HAEMATOL,LONDON SE1 7EH,ENGLAND	University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust								CHAMPION RH, 1990, CLIN EXP ALLERGY, V20, P221, DOI 10.1111/j.1365-2222.1990.tb02671.x; GRATTAN CEH, 1990, INT ARCH ALLER A IMM, V93, P198, DOI 10.1159/000235301; GRATTAN CEH, 1991, CLIN EXP ALLERGY, V21, P695, DOI 10.1111/j.1365-2222.1991.tb03198.x; RORSMAN H, 1962, ACTA ALLERGOL, V4, P265; SMITH CH, 1992, LANCET, V339, P91, DOI 10.1016/0140-6736(92)91000-X	5	175	181	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 2	1992	339	8801					1078	1080		10.1016/0140-6736(92)90666-Q	http://dx.doi.org/10.1016/0140-6736(92)90666-Q			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR446	1373787				2022-12-28	WOS:A1992HR44600005
J	WONG, G; MULLER, O; CLARK, R; CONROY, L; MORAN, MF; POLAKIS, P; MCCORMICK, F				WONG, G; MULLER, O; CLARK, R; CONROY, L; MORAN, MF; POLAKIS, P; MCCORMICK, F			MOLECULAR-CLONING AND NUCLEIC-ACID BINDING-PROPERTIES OF THE GAP-ASSOCIATED TYROSINE PHOSPHOPROTEIN P62	CELL			English	Article							RNA-BINDING; PROTEIN INTERACTIONS; SIGNAL TRANSDUCTION; RAS P21; GENE; EXPRESSION; DNA; PHOSPHORYLATION; PURIFICATION; CONSENSUS	p62 is a tyrosine phosphoprotein that associates with p21ras GTPase-activating protein (GAP). Purification and cDNA cloning of p62 reveal extensive sequence similarity to a putative hnRNP protein, GRP33. Recombinant human p62 purified from insect Sf9 cells binds to DNA and to mRNA and, like many proteins involved in mRNA processing, recombinant p62 is modified by dimethylation on multiple arginine residues. p62 also binds tightly to p21ras GAP in vitro: this binding depends on phosphorylation of p62 on tyrosine residues and occurs through SH2 regions of GAP. These data suggest that p120-GAP and p62 play a role in some aspect of mRNA processing or utilization and that this role may be regulated by tyrosine phosphorylation, and indirectly, by p21ras.	UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5G 1L6,ONTARIO,CANADA; UNIV TORONTO,BANTING & BEST DEPT MED RES,TORONTO M5G 1L6,ONTARIO,CANADA	University of Toronto; University of Toronto	WONG, G (corresponding author), CHIRON CORP,DEPT MOLEC BIOL,EMERYVILLE,CA 94608, USA.		Moran, Michael/GYD-3631-2022					BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOWEN B, 1980, NUCLEIC ACIDS RES, V8, P1, DOI 10.1093/nar/8.1.1; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; BUGLER B, 1987, J BIOL CHEM, V262, P10922; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COBIANCHI F, 1988, J BIOL CHEM, V263, P1063; CRUZALVAREZ M, 1987, J BIOL CHEM, V262, P13377; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; LISCHWE MA, 1985, J BIOL CHEM, V260, P14304; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MAIORELLA B, 1988, BIO-TECHNOL, V6, P1406, DOI 10.1038/nbt1288-1406; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATTAJ IW, 1989, CELL, V57, P1, DOI 10.1016/0092-8674(89)90164-5; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; PAWSON T, 1988, ONCOGENE, V3, P491; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SAPP M, 1986, NUCLEIC ACIDS RES, V14, P6803, DOI 10.1093/nar/14.17.6803; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SMITH GE, 1983, MOL CELL BIOL, V3, P2156, DOI 10.1128/MCB.3.12.2156; SUMMERS MD, 1987, TEX AGR EXP STN B, P1555; SUZUKI K, 1991, J BIOL CHEM, V266, P20007; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WILK HE, 1985, EUR J BIOCHEM, V146, P71, DOI 10.1111/j.1432-1033.1985.tb08621.x; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; ZAMORE PD, 1990, NATURE, V348, P485, DOI 10.1038/348485a0	38	269	282	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 1	1992	69	3					551	558		10.1016/0092-8674(92)90455-L	http://dx.doi.org/10.1016/0092-8674(92)90455-L			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HT078	1374686				2022-12-28	WOS:A1992HT07800016
J	NEHER, E				NEHER, E			ION CHANNELS FOR COMMUNICATION BETWEEN AND WITHIN CELLS	SCIENCE			English	Article							BOVINE CHROMAFFIN CELLS; MEASURING PATCH PIPETTE; PERITONEAL MAST-CELLS; MEMBRANE CAPACITANCE; CONDUCTANCE FLUCTUATIONS; BIOLOGICAL-MEMBRANES; DIFFUSIONAL EXCHANGE; GUANINE-NUCLEOTIDES; CALCIUM CHANNELS; BINDING-PROTEIN				NEHER, E (corresponding author), MAX PLANCK INST BIOPHYS CHEM,W-3400 GOTTINGEN,GERMANY.							ALMERS W, 1987, J PHYSIOL-LONDON, V386, P205, DOI 10.1113/jphysiol.1987.sp016530; ALMERS W, 1985, FEBS LETT, V192, P13, DOI 10.1016/0014-5793(85)80033-8; ANDERSON CR, 1973, J PHYSIOL-LONDON, V235, P655, DOI 10.1113/jphysiol.1973.sp010410; AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BEAN RC, 1969, J GEN PHYSIOL, V53, P741, DOI 10.1085/jgp.53.6.741; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; COCKCROFT S, 1985, NATURE, V314, P534, DOI 10.1038/314534a0; CONTI F, 1980, NATURE, V285, P140, DOI 10.1038/285140a0; DIVIRGILIO F, 1984, NATURE, V310, P691, DOI 10.1038/310691a0; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P577, DOI 10.1113/jphysiol.1982.sp014393; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P599, DOI 10.1113/jphysiol.1982.sp014394; FENWICK EM, 1981, J PHYSIOL-LONDON, V319, pP100; FERNANDEZ JM, 1984, NATURE, V312, P453, DOI 10.1038/312453a0; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; FISHMAN HM, 1973, P NATL ACAD SCI USA, V70, P876, DOI 10.1073/pnas.70.3.876; FRANK K, 1963, CELLULAR FUNCTION ME; GILLESPIE JI, 1979, PROC R SOC SER B-BIO, V206, P293, DOI 10.1098/rspb.1979.0106; GOMPERTS BD, 1986, FASEB J, V45, P2156; Hamill O.P., 1983, SINGLE CHANNEL RECOR, P451; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAMILL OP, 1981, J PHYSIOL-LONDON, V312, pP41; HASLAM RJ, 1984, FEBS LETT, V174, P90, DOI 10.1016/0014-5793(84)81084-4; HEIMAN AS, 1985, J IMMUNOL, V134, P548; HESCHELER J, 1986, PFLUG ARCH EUR J PHY, V407, P182, DOI 10.1007/BF00580674; Hille B., 1970, Progr. Biophys. molec. Biol., V21, P1, DOI 10.1016/0079-6107(70)90022-2; HILLE B, 1989, Q J EXP PHYSIOL CMS, V74, P785, DOI 10.1113/expphysiol.1989.sp003349; HLADKY SB, 1970, NATURE, V225, P451, DOI 10.1038/225451a0; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; HORN R, 1980, P NATL ACAD SCI-BIOL, V77, P6930, DOI 10.1073/pnas.77.11.6930; HORN R, 1988, J GEN PHYSIOL, V92, P154; JAFFE LA, 1978, DEV BIOL, V67, P243, DOI 10.1016/0012-1606(78)90314-7; KAMEYAMA M, 1986, PFLUG ARCH EUR J PHY, V407, P123, DOI 10.1007/BF00580662; KATZ B, 1972, J PHYSIOL-LONDON, V224, P665, DOI 10.1113/jphysiol.1972.sp009918; Katz B., 1966, NERVE MUSCLE SYNAPSE; KOSTYUK PG, 1980, NEUROSCIENCE, V5, P945, DOI 10.1016/0306-4522(80)90178-5; LIM NF, 1990, NATURE, V344, P449, DOI 10.1038/344449a0; LINDAU M, 1992, BIOPHYS J, V61, P19, DOI 10.1016/S0006-3495(92)81812-X; LINDAU M, 1986, NATURE, V319, P150, DOI 10.1038/319150a0; LLINAS R, 1991, J PHYSIOL-LONDON, V436, P257, DOI 10.1113/jphysiol.1991.sp018549; MARTY A, 1981, NATURE, V291, P497, DOI 10.1038/291497a0; Marty A., 1983, SINGLE CHANNEL RECOR, P107; MORAD M, 1988, SCIENCE, V241, P842, DOI 10.1126/science.2457253; MULLER P, 1963, J THEOR BIOL, V4, P243; NEHER E, 1969, PFLUG ARCH EUR J PHY, V311, P272, DOI 10.1007/BF00590532; NEHER E, 1978, J PHYSIOL-LONDON, V277, P153, DOI 10.1113/jphysiol.1978.sp012267; NEHER E, 1977, ANNU REV BIOPHYS BIO, V6, P345, DOI 10.1146/annurev.bb.06.060177.002021; NEHER E, 1988, J PHYSIOL-LONDON, V395, P193, DOI 10.1113/jphysiol.1988.sp016914; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; NEHER E, 1976, NATURE, V260, P799, DOI 10.1038/260799a0; NEHER E, 1988, MOL MECHANISMS SECRE, P262; PARNAS H, 1986, PFLUG ARCH EUR J PHY, V406, P121, DOI 10.1007/BF00586672; PENNER R, 1988, J EXP BIOL, V139, P329; PENNER R, 1989, TRENDS NEUROSCI, V12, P159, DOI 10.1016/0166-2236(89)90059-3; PENNER R, 1988, NATURE, V334, P499, DOI 10.1038/334499a0; PENNER R, 1988, P NATL ACAD SCI USA, V85, P9856, DOI 10.1073/pnas.85.24.9856; Pratt FH, 1919, AM J PHYSIOL, V49, P1; PUSCH M, 1988, PFLUG ARCH EUR J PHY, V411, P204, DOI 10.1007/BF00582316; SAKMANN B, 1992, SCIENCE, V256, P503, DOI 10.1126/science.1373907; SAKMANN B, 1980, NATURE, V286, P71, DOI 10.1038/286071a0; SAKMANN B, 1979, NATURE, V282, P336, DOI 10.1038/282336a0; SAKMANN B, 1978, FED PROC, V37, P2654; SHAAFI RI, 1983, BIOCHEM BIOPH RES CO, V114, P638, DOI 10.1016/0006-291X(83)90828-8; SIGWORTH FJ, 1980, NATURE, V287, P447, DOI 10.1038/287447a0; STRICKHOLM A, 1961, J GEN PHYSIOL, V44, P1073, DOI 10.1085/jgp.44.6.1073; THOMAS P, 1990, NEURON, V5, P723, DOI 10.1016/0896-6273(90)90226-6	66	62	65	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 24	1992	256	5056					498	502		10.1126/science.1373906	http://dx.doi.org/10.1126/science.1373906			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ187	1373906				2022-12-28	WOS:A1992HQ18700058
J	HONJO, T				HONJO, T			SEPPUKU AND AUTOIMMUNITY	SCIENCE			English	Editorial Material							PROGRAMMED CELL-DEATH; MICE				HONJO, T (corresponding author), KYOTO UNIV,FAC MED,DEPT MED CHEM,KYOTO 606,JAPAN.		Honjo, Tasuku/N-4470-2016					BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; DEFRANCO AL, 1982, IMMUNOL REV, V64, P161, DOI 10.1111/j.1600-065X.1982.tb00423.x; ERIKSON J, 1991, NATURE, V349, P331, DOI 10.1038/349331a0; GOLSTEIN P, 1991, IMMUNOL REV, V121, P29, DOI 10.1111/j.1600-065X.1991.tb00822.x; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; HEMAZEE DA, 1989, NATURE, V337, P562; ISHIDA Y, IN PRESS EMBO J; KRAMMER PH, COMMUNICATION; MURAKAMI M, 1992, NATURE, V357, P77, DOI 10.1038/357077a0; OKAMOTO M, 1992, J EXP MED, V175, P71, DOI 10.1084/jem.175.1.71; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; PARKER DC, 1980, IMMUNOL REV, V52, P115, DOI 10.1111/j.1600-065X.1980.tb00333.x; SCHWARTZ LM, 1990, P NATL ACAD SCI USA, V87, P6594, DOI 10.1073/pnas.87.17.6594; TSUBATA T, UNPUB; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531	15	9	13	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 23	1992	258	5082					591	592		10.1126/science.1384132	http://dx.doi.org/10.1126/science.1384132			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU745	1384132				2022-12-28	WOS:A1992JU74500044
J	MITCHELL, JM; SCOTT, E				MITCHELL, JM; SCOTT, E			PHYSICIAN OWNERSHIP OF PHYSICAL THERAPY SERVICES - EFFECTS ON CHARGES, UTILIZATION, PROFITS, AND SERVICE CHARACTERISTICS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONFLICTS	Objective.-To evaluate the effects of physician ownership of freestanding physical therapy and rehabilitation facilities on utilization, charges, profits, and three measures of service characteristics for physical therapy treatments. Design.-Statistical comparison by physician joint venture ownership status of freestanding physical therapy and comprehensive rehabilitation facilities providing physical therapy treatments in Florida. Participants.-A total of 118 outpatient physical therapy facilities and 63 outpatient comprehensive rehabilitation facilities providing services in Florida during 1989. The data from the facilities were collected under a legislative mandate. Main Outcome Measures.-Visits per patient, average revenue per patient, percent operating income, percent markup, profits per patient, licensed therapist time per visit, and licensed and nonlicensed medical worker time per visit. Results.-Visits per patient were 39% to 45% higher in joint venture facilities. Both gross and net revenue per patient were 30% to 40% higher in facilities owned by referring physicians. Percent operating income and percent markup were significantly higher in joint venture physical therapy and rehabilitation facilities. Licensed physical therapists and licensed therapist assistants employed in nonjoint venture facilities spend about 60% more time per visit treating physical therapy patients than licensed therapists and licensed therapist assistants working in joint venture facilities. Joint ventures also generate more of their revenues from patients with well-paying insurance. Conclusion.-Our results indicate that utilization, charges per patient, and profits are higher when physical therapy and rehabilitation facilities are owned by referring physicians. With respect to service characteristics, joint venture firms employ proportionately fewer licensed therapists and licensed therapist assistants to perform physical therapy, so that licensed professionals employed in joint venture businesses spend significantly less time per visit treating patients. These results should be of interest to the medical profession, third-party payers, and policymakers, all of whom are concerned about the consequences of physician self-referral arrangements.	FLORIDA STATE UNIV,DEPT ECON,TALLAHASSEE,FL 32306; FLORIDA STATE UNIV,DEPT FINANCE,TALLAHASSEE,FL 32306	State University System of Florida; Florida State University; State University System of Florida; Florida State University								BURDA D, 1992, MOD HEALTHCARE  0629, V23, P3; CRANE TS, 1992, JAMA-J AM MED ASSOC, V268, P85, DOI 10.1001/jama.268.1.85; DOBSON R, 1986, NEW ENGL J MED, V314, P250; IGLEHART JK, 1990, NEW ENGL J MED, V322, P1682, DOI 10.1056/NEJM199006073222327; MITCHELL JM, 1992, JAMA-J AM MED ASSOC, V268, P80, DOI 10.1001/jama.268.1.80; MITCHELL JM, 1991, JOINT VENTURES HLTH, V2; MORREIM EH, 1989, JAMA-J AM MED ASSOC, V262, P390, DOI 10.1001/jama.262.3.390; PEAR R, 1992, NY TIMES        0406, pA2; PEAR R, 1991, NY TIMES        1118, pA1; RELMAN AS, 1985, NEW ENGL J MED, V313, P749, DOI 10.1056/NEJM198509193131209; Rosenfeld R.H., 1984, MOD HEATHCARE, V14, P60; TODD JS, 1992, JAMA-J AM MED ASSOC, V268, P98, DOI 10.1001/jama.268.1.98; Waldholz Michael, 1989, WALL STREET J   0301, pA6; Waldholz Michael, 1989, WALL STREET J   0301, pA1; ZIMMERMAN M, 1989, COMMUNICATION    MAY; 1989, FINANCIAL ARRANGEMEN; 1991, FINAL OCCUPATIONAL S; 1991, 91390 US DEP LAB PUB; 1992, JAMA-J AM MED ASSOC, V267, P2366; 1986, FOR PROFIT ENTERPRIS, P153; 1992, SOURCES HLTH INSURAN	21	89	89	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 21	1992	268	15					2055	2059		10.1001/jama.268.15.2055	http://dx.doi.org/10.1001/jama.268.15.2055			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT520	1404742				2022-12-28	WOS:A1992JT52000029
J	STOTLAND, NL				STOTLAND, NL			THE MYTH OF THE ABORTION TRAUMA SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							THERAPEUTIC-ABORTION; TERMINATION; SEQUELAE				STOTLAND, NL (corresponding author), UNIV CHICAGO,MED CTR,DEPT PSYCHIAT,5841 S MARYLAND AVE,BOX 411,CHICAGO,IL 60637, USA.							ADLER NE, 1990, SCIENCE, V248, P41, DOI 10.1126/science.2181664; BLUMENTHAL SJ, 1991, PSYCHIATRIC ASPECTS; BREWER C, 1977, BRIT MED J, V1, P476, DOI 10.1136/bmj.1.6059.476; DAGG PKB, 1991, AM J PSYCHIAT, V148, P578; De Veber L L, 1991, Humane Med, V7, P203; DEMPSEY MA, 1987, STATE CHECKING PREGN; DEVEREUX G, 1958, ABORTION AM; FRIEDMAN CM, 1974, AM J PSYCHIAT, V131, P1332; GREER HS, 1976, BRIT J PSYCHIAT, V128, P74, DOI 10.1192/bjp.128.1.74; Koop C.E., 1991, KOOP MEMOIRS AM FAMI; KOOP CE, 1989, COMMUNICATION    JAN; KUMMER JM, 1963, AM J PSYCHIAT, V119, P980, DOI 10.1176/ajp.119.10.980; LASK B, 1975, BRIT J PSYCHIAT, V126, P173, DOI 10.1192/bjp.126.2.173; MARDER L, 1970, AM J PSYCHIAT, V126, P1230, DOI 10.1176/ajp.126.9.1230; MEIKLE S, 1977, CAN PSYCHIAT ASSOC J, V22, P67, DOI 10.1177/070674377702200203; OSOFSKY JD, 1972, AM J ORTHOPSYCHIAT, V42, P48, DOI 10.1111/j.1939-0025.1972.tb02470.x; PARTRIDGE J, 1971, N C MED J, V32, P132; RUSSO NF, 1992, PROF PSYCHOL-RES PR, V23, P269, DOI 10.1037/0735-7028.23.4.269; SCHUSTERMAN LR, 1976, PSYCHOL WOMEN Q, V1, P79; 1987, DIAGNOSTIC STATISTIC; WHAT THEY WONT TELL	21	55	56	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 21	1992	268	15					2078	2079		10.1001/jama.268.15.2078	http://dx.doi.org/10.1001/jama.268.15.2078			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JT520	1404747				2022-12-28	WOS:A1992JT52000034
J	PETERS, KG; MARIE, J; WILSON, E; IVES, HE; ESCOBEDO, J; DELROSARIO, M; MIRDA, D; WILLIAMS, LT				PETERS, KG; MARIE, J; WILSON, E; IVES, HE; ESCOBEDO, J; DELROSARIO, M; MIRDA, D; WILLIAMS, LT			POINT MUTATION OF AN FGF RECEPTOR ABOLISHES PHOSPHATIDYLINOSITOL TURNOVER AND CA2+ FLUX BUT NOT MITOGENESIS	NATURE			English	Article							PHOSPHOLIPASE-C-GAMMA; GROWTH-FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; EGF RECEPTOR; KINASE-ACTIVITY; BINDING-SITE; PDGF; HYDROLYSIS; SUBSTRATE; C-GAMMA-1	STIMULATION of certain receptor tyrosine kinases results in the tyrosine phosphorylation and activation of phospholipase C(gamma)(PLC-gamma), an enzyme that catalyses the hydrolysis of phosphatidylinositol ( PtdIns)1-8. This hydrolysis generates diacylglycerol and free inositol phosphate, which in turn activate protein kinase C and increase intracellular Ca2+, respectively. PLC-gamma physically associates with activated receptor tyrosine kinases, suggesting that it is a substrate for direct phosphorylation by these kinases7-10. Here we report that a fibroblast growth factor (FGF) receptor with a single point mutation at residue 766 replacing tyrosine with phenylalanine fails to associate with PLC-gamma in response to FGF. This mutant receptor also failed to mediate PtdIns hydrolysis and Ca2+ mobilization after FGF stimulation. However, the mutant receptor phosphorylated itself and several other cellular proteins, and it mediated mitogenesis in response to FGF. These findings show that a point mutation in the FGF receptor selectively eliminates activation of PLC-gamma and that neither Ca2+ mobilization nor PtdIns hydrolysis are required for FGF-induced mitogenesis.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,PROGRAM EXCELLENCE MOLEC BIOL,533 PARNASSUS AVE,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV NEPHROL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco								BROWN KD, 1989, FEBS LETT, V247, P227, DOI 10.1016/0014-5793(89)81340-7; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COCHET C, 1984, J BIOL CHEM, V259, P2553; CUADRADO A, 1990, MOL CELL BIOL, V10, P6069, DOI 10.1128/MCB.10.11.6069; DECKER SJ, 1992, J BIOL CHEM, V267, P1104; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FRIEDMAN B, 1989, P NATL ACAD SCI USA, V86, P812, DOI 10.1073/pnas.86.3.812; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; HUANG CL, 1991, J BIOL CHEM, V266, P4045; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KUMJIAN DA, 1991, J BIOL CHEM, V266, P3973; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MASLANSKI JA, 1992, SCIENCE, V256, P243, DOI 10.1126/science.1314424; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OLWIN BB, 1989, J CELL BIOCHEM, V39, P443, DOI 10.1002/jcb.240390410; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SULTZMAN L, 1991, MOL CELL BIOL, V11, P2018, DOI 10.1128/MCB.11.4.2018; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263	30	366	377	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 20	1992	358	6388					678	681		10.1038/358678a0	http://dx.doi.org/10.1038/358678a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ882	1379697				2022-12-28	WOS:A1992JJ88200057
J	GOLDING, J; GREENWOOD, R; BIRMINGHAM, K; MOTT, M				GOLDING, J; GREENWOOD, R; BIRMINGHAM, K; MOTT, M			CHILDHOOD-CANCER, INTRAMUSCULAR VITAMIN-K, AND PETHIDINE GIVEN DURING LABOR	BRITISH MEDICAL JOURNAL			English	Article							BENZO(A)PYRENE METABOLISM; DEFICIENCY; LEUKEMIA	Objective-To assess unexpected associations between childhood cancer and pethidine given in labour and the neonatal administration of vitamin K that had emerged in a study performed in the 1970 national birth cohort. Design and setting-195 children with cancer diagnosed in 1971-March 1991 and born in the two major Bristol maternity hospitals in 1965-87 were compared with 558 controls identified from the delivery books for the use of pethidine during labour and administration of vitamin K. Main outcome measures-Odds ratios for cancer in the presence of administration of pethidine or of intramuscular vitamin K. Both logistic regression and Mantel-Haenszel techniques were used for statistical analyses. Results-Children of mothers given pethidine in labour were not at increased risk of cancer (odds ratio 1.05, 95% confidence interval 0.7 to 1.5) after allowing for year and hospital of delivery, but there was a significant association (p=0.002) with intramuscular vitamin K (odds ratio 1.97, 95% confidence interval 1.3 to 3.0) when compared with oral vitamin K or no vitamin K. There was no significantly increased risk for children who had been given oral vitamin K when compared with no vitamin K (odds ratio 1.15, 95% confidence interval 0.5 to 2.7). These results could not be accounted for by other factors associated with administration of intramuscular vitamin K, such as type of delivery or admission to a special care baby unit. Conclusions-The only two studies so far to have examined the relation between childhood cancer and intramuscular vitamin K have shown similar results, and the relation is biologically plausible. The prophylactic benefits against haemorrhagic disease are unlikely to exceed the potential adverse effects from intramuscular vitamin K. Since oral vitamin K has major benefits but no obvious adverse effects this could be the prophylaxis of choice.			GOLDING, J (corresponding author), ROYAL HOSP SICK CHILDREN,INST CHILD HLTH,BRISTOL BS2 8BJ,ENGLAND.			Golding, Jean/0000-0003-2826-3307				BUTLER NR, 1982, J ROY SOC MED, V75, P781; Butler NR, 1986, BIRTH 5 STUDY HLTH B; Chamberlain R., 1975, BRIT BIRTHS, V1; CORNELISSEN M, 1991, PEDIATR RES, V30, P550, DOI 10.1203/00006450-199112000-00011; DOGRA SC, 1987, INT J BIOCHEM, V19, P471, DOI 10.1016/0020-711X(87)90070-X; Elwood M, 1988, CAUSAL RELATIONSHIPS; Gilman E A, 1989, Paediatr Perinat Epidemiol, V3, P66, DOI 10.1111/j.1365-3016.1989.tb00371.x; GILMAN EA, 1988, J SOC RADIOLOGICAL P, V3, P3; Golding J, 1990, West Engl Med J, V105, P80; GOLDING J, 1990, BRIT J CANCER, V62, P304, DOI 10.1038/bjc.1990.283; HILGARD P, 1977, BRIT J CANCER, V35, P891, DOI 10.1038/bjc.1977.135; ISRAELS LG, 1987, PEDIATR RES, V22, P405, DOI 10.1203/00006450-198710000-00008; ISRAELS LG, 1983, J CLIN INVEST, V71, P1130, DOI 10.1172/JCI110863; KNEALE GW, 1976, J NATL CANCER I, V56, P879, DOI 10.1093/jnci/56.5.879; MCKINNEY PA, 1987, ARCH DIS CHILD, V62, P279, DOI 10.1136/adc.62.3.279; MCNINCH AW, 1985, ARCH DIS CHILD, V60, P814, DOI 10.1136/adc.60.9.814; MCNINCH AW, 1991, BRIT MED J, V303, P1105, DOI 10.1136/bmj.303.6810.1105; ROBINS J, 1986, AM J EPIDEMIOL, V124, P719, DOI 10.1093/oxfordjournals.aje.a114447; STILLER CA, 1982, BRIT J CANCER, V45, P543, DOI 10.1038/bjc.1982.90; STJERNFELDT M, 1986, LANCET, V2, P687; von Kries R, 1992, Paediatr Perinat Epidemiol, V6, P7	21	224	229	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 8	1992	305	6849					341	346		10.1136/bmj.305.6849.341	http://dx.doi.org/10.1136/bmj.305.6849.341			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ032	1392886	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JJ03200022
J	MENKES, DB; TAGHAVI, E; MASON, PA; SPEARS, GFS; HOWARD, RC				MENKES, DB; TAGHAVI, E; MASON, PA; SPEARS, GFS; HOWARD, RC			FLUOXETINE TREATMENT OF SEVERE PREMENSTRUAL-SYNDROME	BRITISH MEDICAL JOURNAL			English	Article									UNIV OTAGO,PREVENT & SOCIAL MED,DUNEDIN,NEW ZEALAND; UNIV OTAGO,BEHAV SCI,DUNEDIN,NEW ZEALAND	University of Otago; University of Otago	MENKES, DB (corresponding author), UNIV OTAGO,PSYCHOL MED,POB 913,DUNEDIN,NEW ZEALAND.			menkes, david/0000-0003-3760-7896				BANCROFT J, 1991, PSYCHOL MED, V21, P305, DOI 10.1017/S0033291700020407; HALBREICH U, 1985, CAN J PSYCHIAT, V30, P489, DOI 10.1177/070674378503000706; REID RL, 1991, NEW ENGL J MED, V324, P1208, DOI 10.1056/NEJM199104253241710; ROYBYRNE PP, 1987, CLIN OBSTET GYNECOL, V30, P386, DOI 10.1097/00003081-198706000-00019; STEINBERG S, 1991, LIFE SCI, V49, P767, DOI 10.1016/0024-3205(91)90244-6	5	90	91	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 8	1992	305	6849					346	347		10.1136/bmj.305.6849.346	http://dx.doi.org/10.1136/bmj.305.6849.346			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ032	1392887	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992JJ03200023
J	LAFON, M; LAFAGE, M; MARTINEZARENDS, A; RAMIREZ, R; VUILLIER, F; CHARRON, D; LOTTEAU, V; SCOTTALGARA, D				LAFON, M; LAFAGE, M; MARTINEZARENDS, A; RAMIREZ, R; VUILLIER, F; CHARRON, D; LOTTEAU, V; SCOTTALGARA, D			EVIDENCE FOR A VIRAL SUPERANTIGEN IN HUMANS	NATURE			English	Article							T-CELL; MONOCLONAL-ANTIBODIES; STAPHYLOCOCCAL ENTEROTOXINS; N-PROTEIN; HLA-DR; STIMULATION; MOLECULES; ANTIGEN; NUCLEOPROTEIN; EXPRESSION	SUPERANTIGENS1-4 bind class II major histocompatibility proteins5,6 and stimulate powerful proliferative responses of T lymphocytes bearing particular V-beta sequences as part of their alpha-beta antigen receptor7. Exogenous bacterial superantigens are responsible for food poisoning and toxic shock syndrome. Murine virus-encoded self-superantigens induce clonal deletion of T lymphocytes. Although superantigen-like properties have been suggested for human immunodeficiency virus-1, no viral superantigen has been identified in humans8. Here we report that the nucleocapsid of the rabies virus is an exogenous superantigen specific for V-beta-8 human T lymphocytes which binds to HLA class II alpha-chains.	INST BIOMED CORDELIERS,IMMUNOGENET LAB,F-75006 PARIS,FRANCE; INST PASTEUR,UNITE IMMUNOHEMATOL & IMMUNOPATHOL,F-75724 PARIS 15,FRANCE	UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	LAFON, M (corresponding author), INST PASTEUR,UNITE RAGE,25-28 RUE DOCTEUR ROUX,F-75724 PARIS 15,FRANCE.		Scott, Daniel/AFK-5428-2022; lotteau, vincent/M-8143-2014; Vuillier, Françoise/T-4699-2019	Vuillier, Francoise/0000-0002-5551-9876; Lafon, Monique/0000-0002-4423-7996; Scott-Algara, Daniel/0000-0003-1851-503X; Rafael, Ramirez/0000-0003-4598-339X; Lotteau, Vincent/0000-0003-0997-3282				BANKAMP B, 1991, J VIROL, V65, P1695, DOI 10.1128/JVI.65.4.1695-1700.1991; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; CARREL S, 1981, MOL IMMUNOL, V18, P403, DOI 10.1016/0161-5890(81)90102-4; CHARRON DJ, 1979, P NATL ACAD SCI USA, V76, P6567, DOI 10.1073/pnas.76.12.6567; COLE BC, 1991, IMMUNOL TODAY, V12, P271, DOI 10.1016/0167-5699(91)90125-D; DEMARS R, 1984, DIS MARKERS, V2, P175; DIETZSCHOLD B, 1987, P NATL ACAD SCI USA, V84, P9165, DOI 10.1073/pnas.84.24.9165; DIETZSCHOLD B, 1987, VIRUS RES, V8, P103, DOI 10.1016/0168-1702(87)90023-2; FLEISCHER B, 1988, J EXP MED, V167, P1697, DOI 10.1084/jem.167.5.1697; FLEISCHER B, 1991, IMMUNOL RES, V10, P349, DOI 10.1007/BF02919720; HERZOG M, 1992, VIRUS RES, V24, P77, DOI 10.1016/0168-1702(92)90032-5; HERZOG M, 1991, CLIN EXP IMMUNOL, V85, P224, DOI 10.1111/j.1365-2249.1991.tb05709.x; JANEWAY C, 1991, NATURE, V349, P459, DOI 10.1038/349459a0; JANEWAY CA, 1989, IMMUNOL REV, V107, P61, DOI 10.1111/j.1600-065X.1989.tb00003.x; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KARP DR, 1990, NATURE, V346, P474, DOI 10.1038/346474a0; LAFON M, 1985, J GEN VIROL, V66, P2125, DOI 10.1099/0022-1317-66-10-2125; LAFON M, 1990, J GEN VIROL, V71, P1689, DOI 10.1099/0022-1317-71-8-1689; LIBEAU G, 1983, BIOL STANDARD, V57, P213; LIU H, 1991, P NATL ACAD SCI USA, V88, P8705, DOI 10.1073/pnas.88.19.8705; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; ONO SJ, 1991, J EXP MED, V173, P629, DOI 10.1084/jem.173.3.629; PREHAUD C, 1990, VIROLOGY, V178, P486, DOI 10.1016/0042-6822(90)90346-S; RUSSELL SM, 1979, NATURE, V280, P147, DOI 10.1038/280147a0; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; SHERLE PA, 1986, J EXP MED, V169, P1114; WATSON AJ, 1983, NATURE, V304, P358, DOI 10.1038/304358a0; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X	29	146	154	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 6	1992	358	6386					507	510		10.1038/358507a0	http://dx.doi.org/10.1038/358507a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG739	1386410				2022-12-28	WOS:A1992JG73900051
J	LEHMANN, PV; FORSTHUBER, T; MILLER, A; SERCARZ, EE				LEHMANN, PV; FORSTHUBER, T; MILLER, A; SERCARZ, EE			SPREADING OF T-CELL AUTOIMMUNITY TO CRYPTIC DETERMINANTS OF AN AUTOANTIGEN	NATURE			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MYELIN BASIC-PROTEIN; ENCEPHALITOGENIC EPITOPES; VACCINATION; SPECIFICITY; RECEPTORS; PEPTIDES	IMMUNIZATION with myelin basic protein (MBP) induces experimental allergic encephalomyelitis (EAE), a prototype of CD4+ T-cell mediated autoimmune disease. In rodents, MBP-reactive T-cell clones are specific for a single, dominant determinant on MBP and use a highly restricted number of T-cell receptor genes 1-3. Accordingly, EAE has been prevented by various receptor-specific treatments 1-8, suggesting similar strategies may be useful for therapy of human autoimmune disease. Here we report that in (SJL x B10.PL)F1 mice, immune dominance of a single determinant, MBP: Ac1-11, is confined to the inductive phase of EAE. In mice with chronic EAE, several additional determinants of MBP in peptides 35-47, 81-100 and 121-140 recall proliferative responses. Most importantly, reactivity to the latter determinants was also detected after induction of EAE with MBP peptide Ac1-11 alone; this demonstrates priming by endogenous MBP determinants. Thus, determinants of MBP that are cryptic 9-11 after primary immunization can become immunogenic in the course of EAE. Diversification of the autoreactive T-cell repertoire due to 'determinant spreading' has major implications for the pathogenesis of, and the therapeutic approach to, T-cell driven autoimmune disease.	UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, 405 HILGARD AVE, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles			Forsthuber, Thomas/AID-8080-2022	/0000-0003-0692-7125				ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; BENICHOU G, 1990, J EXP MED, V172, P1341, DOI 10.1084/jem.172.5.1341; BENNUN A, 1981, NATURE, V292, P60, DOI 10.1038/292060a0; DEIBLER GE, 1972, PREP BIOCHEM, V2, P139, DOI 10.1080/00327487208061467; FRITZ RB, 1989, CHEM IMMUNOL, V46, P101; GAMMON G, 1989, NATURE, V342, P183, DOI 10.1038/342183a0; GAMMON G, 1991, IMMUNOL TODAY, V12, P193, DOI 10.1016/0167-5699(91)90052-U; HEBERKATZ E, 1989, IMMUNOL TODAY, V10, P164, DOI 10.1016/0167-5699(89)90174-6; HOOD L, 1989, COLD SPRING HARB SYM, V54, P859; HOWELL MD, 1989, SCIENCE, V246, P668, DOI 10.1126/science.2814489; KENT SBH, 1985, SYNTHETIC PEPTIDES B, P29; LINTHICUM DS, 1982, J EXP MED, V156, P31, DOI 10.1084/jem.156.1.31; MCCARRON RM, 1990, J NEUROIMMUNOL, V29, P73, DOI 10.1016/0165-5728(90)90149-H; OFFNER H, 1991, SCIENCE, V251, P430, DOI 10.1126/science.1989076; OWHASHI M, 1988, J EXP MED, V168, P2153, DOI 10.1084/jem.168.6.2153; PERRY LL, 1987, J IMMUNOL, V138, P1434; PERRY LL, 1991, J NEUROIMMUNOL, V33, P7, DOI 10.1016/0165-5728(91)90029-7; SAKAI K, 1988, J NEUROIMMUNOL, V19, P21, DOI 10.1016/0165-5728(88)90032-X; SARVETNICK N, 1990, NATURE, V346, P844, DOI 10.1038/346844a0; URBAN JL, 1988, CELL, V54, P577, DOI 10.1016/0092-8674(88)90079-7; VANDENBARK AA, 1989, NATURE, V341, P541, DOI 10.1038/341541a0; ZALLER DM, 1990, J EXP MED, V171, P1943, DOI 10.1084/jem.171.6.1943; ZAMVIL SS, 1988, J EXP MED, V168, P1181, DOI 10.1084/jem.168.3.1181	23	1056	1088	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 9	1992	358	6382					155	157		10.1038/358155a0	http://dx.doi.org/10.1038/358155a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC583	1377368				2022-12-28	WOS:A1992JC58300053
J	TYLER, A; BALL, D; CRAUFURD, D				TYLER, A; BALL, D; CRAUFURD, D			PRESYMPTOMATIC TESTING FOR HUNTINGTONS-DISEASE IN THE UNITED-KINGDOM	BRITISH MEDICAL JOURNAL			English	Article							LINKED DNA MARKERS; ATTITUDES; DIAGNOSIS; CHOREA	Objective-To evaluate the United Kingdom Huntington's disease presymptomatic testing programme. Design-Postal questionnaire survey to collect data on all tests performed by clinical genetics centres between 1987 and 1990. Setting-Genetic centres providing presymptomatic testing in the United Kingdom. Subjects-248 subjects at risk of Huntington's disease who had presymptomatic testing at their request. Main outcome measures-Sex, age, prior risk, and risk after testing. Results-The risk of carrying the Huntington disease gene was reduced for 151 (61%) of the applicants and raised for 97 (39%). 158 (64%) of the subjects were female and 90 (36%) male. The median age at which the results were given was 32.5 years. Conclusions-The demand for testing was lower than expected and may have reached its peak in 1990. The excess of low risk results was not fully explained by the age effect. All the genetics centres concerned have agreed a common service protocol which requires extensive pre-test counselling and post-test follow up. The worth of the procedure remains to be decided. The availability of a large body of pooled data from all the United Kingdom testing centres, which individually are likely to have only a few results, will form a valuable resource for monitoring the long term psychosocial impact of testing.	ST MARYS HOSP,MANCHESTER M13 0JH,LANCS,ENGLAND	University of Manchester	TYLER, A (corresponding author), UNIV WALES COLL MED,DEPT MED GENET,CARDIFF CF4 4XW,S GLAM,WALES.		Craufurd, David/G-5277-2013					BLOCH M, 1989, AM J MED GENET, V32, P217, DOI 10.1002/ajmg.1320320215; BRANDT J, 1989, JAMA-J AM MED ASSOC, V261, P3108, DOI 10.1001/jama.261.21.3108; CRAUFURD D, 1989, LANCET, V2, P603; CRAUFURD DIO, 1986, BRIT MED J, V293, P249, DOI 10.1136/bmj.293.6541.249; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; HARPER PS, 1992, J MED GENET, V29, P239, DOI 10.1136/jmg.29.4.239; HARPER PS, 1991, MAJOR PROBLEMS NEURO, V22, P373; HARPER PS, 1991, MAJOR PROBLEMS NEURO, V22, P251; HAYDEN MR, 1988, AM J HUM GENET, V43, P689; LAM RW, 1988, J CLIN PSYCHIAT, V49, P444; MASTROMAURO C, 1987, AM J MED GENET, V26, P271, DOI 10.1002/ajmg.1320260205; MEISSEN GJ, 1988, NEW ENGL J MED, V318, P535, DOI 10.1056/NEJM198803033180903; MORRIS M, 1988, LANCET, V2, P1069, DOI 10.1016/S0140-6736(88)90078-5; SANDKUYL L, 1989, HUM GENET, V82, P159, DOI 10.1007/BF00284050; TYLER A, 1983, J MED GENET, V20, P179, DOI 10.1136/jmg.20.3.179; TYLER A, 1990, IN PRESS BR J PSYCHI; World Federation of Neurology, 1989, J NEUROL SCI, V94, P327	17	64	64	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 20	1992	304	6842					1593	1596		10.1136/bmj.304.6842.1593	http://dx.doi.org/10.1136/bmj.304.6842.1593			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA436	1385747	Bronze, Green Published			2022-12-28	WOS:A1992JA43600018
J	TRAVERS, AF; BURNS, E; PENN, ND; MITCHELL, SC; MULLEY, GP				TRAVERS, AF; BURNS, E; PENN, ND; MITCHELL, SC; MULLEY, GP			A SURVEY OF HOSPITAL TOILET FACILITIES	BRITISH MEDICAL JOURNAL			English	Article								Objective-To assess the quality of toilet facilities available for disabled people in a large provincial teaching hospital. Design-Survey of toilet facilities for patients on the wards and in the outpatient department. Setting-Teaching hospital in Leeds. Results-Although the quality of toilet facilities varied, none met the standards recommended by the British Standards Institution. The worst facilities were found on a ward accommodating elderly patients, where the toilets were unsuitable for use by disabled people and bedside commodes had to be used instead. Conclusion-Toilet provision within a major hospital failed to meet standards required for disabled people. Admission to hospital may therefore result in loss of independence and dignity. If hospitals are to be centres of excellence, greater consideration must be given to the requirements of disabled people in the design of new wards, and current inadequate facilities should be upgraded.	ST JAMES UNIV HOSP,MED ELDERLY,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND; GEN INFIRM,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND	Saint James's University Hospital; Leeds General Infirmary	TRAVERS, AF (corresponding author), UNIV LEEDS,SCH MED,RHEUMATOL & REHABIL RES UNIT,LEEDS LS2 9NZ,ENGLAND.							CHAMBERLAIN MA, 1982, BRIT MED J, V284, P1693, DOI 10.1136/bmj.284.6330.1693; CHAMBERLAIN MA, 1978, RHEUMATOL REHABIL, V17, P187, DOI 10.1093/rheumatology/17.3.187; Clarke M, 1984, Health Trends, V16, P3; GEORGE J, 1988, BRIT MED J, V296, P1365, DOI 10.1136/bmj.296.6633.1365; MARTIN J, 1988, OPCS GP1 REP; PENN ND, 1988, BRIT MED J, V296, P918, DOI 10.1136/bmj.296.6626.918; SKLAROFF SA, 1987, CLIN REHABIL, V1, P127; 1979, BSI BS5810 BRIT STAN; 1981, 37 DEP HLTH SOC SEC	9	9	9	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1992	304	6831					878	879		10.1136/bmj.304.6831.878	http://dx.doi.org/10.1136/bmj.304.6831.878			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM835	1392747	Bronze, Green Published			2022-12-28	WOS:A1992HM83500024
J	KHATTAK, MN; MATTHEWS, RC; BURNIE, JP				KHATTAK, MN; MATTHEWS, RC; BURNIE, JP			IS BORDETELLA-PERTUSSIS CLONAL	BRITISH MEDICAL JOURNAL			English	Article							LARGE DNA-MOLECULES	Objective - To establish whether Bordetella pertussis is essentially clonal. Design - Analysis of restriction fragments of XbaI digests of DNA from clinical and control isolates of B pertussis by pulse field gel electrophoresis. Materials - 105 isolates of B pertussis: 67 clinical isolates from throughout the United Kingdom and 23 from Germany (collected during the previous 18 months); vaccine strains 2991 and 3700; and 13 control isolates from Manchester University's culture collection. Main outcome measures - Frequency of DNA types according to country of origin and classical serotyping. Results - 17 DNA types were identified on the basis of the variation in 11 fragments, banding at 200-412 kilobases; 15 types were found in the clinical and control isolates from the United Kingdom and seven in those from Germany. There was no correlation with serotype. DNA type 1 was the commonest overall (22/105 strains, 22%), predominating in serotypes 1,2 and 1,2,3 and including the vaccine strains but not the isolates from Germany. Conclusions - Current infections due to B pertussis are not caused by a clonal pathogen as multiple strains are circulating in a given population at one time. There is also considerable epidemiological variation in the pathogen population between countries. These findings may have implications for the design of acellular vaccines.	UNIV MANCHESTER,SCH MED,DEPT MED MICROBIOL,PERTUSSIS REFERENCE LAB,MANCHESTER M13 9PT,LANCS,ENGLAND	University of Manchester					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], 1988, LANCET, Vi, P955; CANTOR CR, 1988, ANNU REV BIOPHYS BIO, V17, P287; CHERRY J D, 1988, Pediatrics, V81, P939; KIMURA M, 1990, LANCET, V336, P30, DOI 10.1016/0140-6736(90)91530-N; MCCLELLAND M, 1987, NUCLEIC ACIDS RES, V15, P5985, DOI 10.1093/nar/15.15.5985; MORTIMER E A JR, 1988, Tokai Journal of Experimental and Clinical Medicine, V13, P89; MUSSER JM, 1986, J BACTERIOL, V166, P230, DOI 10.1128/jb.166.1.230-237.1986; Preston N W, 1970, Lab Pract, V19, P482; PRESTON NW, 1986, BRIT MED J, V292, P901, DOI 10.1136/bmj.292.6524.901-c; ROBINSON A, 1988, PATHOGENESIS IMMUNIT, P399; SCHWARTZ MO, 1984, ERZMETALL, V37, P65; Smith C.L., 1988, P41; SMITH CL, 1987, METHOD ENZYMOL, V155, P449; WARDLAW AC, 1988, PATHOGENESIS IMMUNIT, P327; 1979, WHO TECH REP SER, V638; 1982, MMWR, V31; 1990, PHLS9041 COMM DIS SU	17	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1992	304	6830					813	815		10.1136/bmj.304.6830.813	http://dx.doi.org/10.1136/bmj.304.6830.813			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL827	1392709	Bronze, Green Published			2022-12-28	WOS:A1992HL82700021
J	MCGINNIS, JM; RICHMOND, JB; BRANDT, EN; WINDOM, RE; MASON, JO				MCGINNIS, JM; RICHMOND, JB; BRANDT, EN; WINDOM, RE; MASON, JO			HEALTH PROGRESS IN THE UNITED-STATES - RESULTS OF THE 1990 OBJECTIVES FOR THE NATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									UNIV OKLAHOMA,HLTH SCI CTR,OKLAHOMA CITY,OK 73190; HARVARD UNIV,DEPT SOCIAL MED,BOSTON,MA 02115	University of Oklahoma System; University of Oklahoma Health Sciences Center; Harvard University	MCGINNIS, JM (corresponding author), US PHS,330 C ST SW,ROOM 2132,WASHINGTON,DC 20201, USA.							ALBERMAN E, 1992, PHS921252 US DEP HLT; HARRIS S S, 1989, Journal of the American Medical Association, V261, P3590; KLEINMAN JC, 1992, PHS921252 US DEP HLT; 1968, VITAL STATISTICS RAT; 1990, PHS901232 US DEP HLT; 1988, STATE PROGR 1990 HLT; 1990, PHS9150212 US DEP HL; 1988, CDC898411 US DEP HLT; 1986, PHS871232 US DEP HLT; 1984, P PROSPECTS HLTH AM; 1991, HIV AIDS SURVEILLANC; 1983, PHS8350193A PUBL; 1988, PHS8850210 US DEP HL; 1990, VITAL STATISTICS US, V2; 1903, PHS841232 US DEP HLT; 1980, PROMOTING HLTH PREVE; 1992, PHS921232 US DEP HLT; 1990, 2ND 50 YEARS PROMOTI; 1991, SEXUALLY TRANSMITTED; 1990, DRUG EXPOSED INFANTS; 1979, US DHEW7955071 PUBL; 1980, PHS811232 US DEP HLT; 1986, 1990 HLTH OBJECTIVES	23	24	24	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1992	268	18					2545	2552		10.1001/jama.268.18.2545	http://dx.doi.org/10.1001/jama.268.18.2545			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW616	1404822				2022-12-28	WOS:A1992JW61600027
J	BRODY, H				BRODY, H			ASSISTED DEATH - A COMPASSIONATE RESPONSE TO A MEDICAL FAILURE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							EUTHANASIA; SUICIDE; ETHICS				BRODY, H (corresponding author), MICHIGAN STATE UNIV, DEPT FAMILY PRACTICE, CTR CLIN B100, E LANSING, MI 48824 USA.		Brody, Howard/GQA-6310-2022					ADMIRAAL PV, 1984, JUSTIFIED EUTHANASIA; [Anonymous], 1992, HARVARD LAW REV, V105, P2021; ARRAS JD, 1991, J MED PHILOS, V16, P29, DOI 10.1093/jmp/16.1.29; Battin M, 1992, Law Med Health Care, V20, P133; Benjamin Martin, 1990, SPLITTING DIFFERENCE; BENRUBI GI, 1992, NEW ENGL J MED, V326, P197, DOI 10.1056/NEJM199201163260311; Brody H., 1987, STORIES SICKNESS; BRODY H, 1992, HEALERS POWER; CALLAHAN D, 1977, HASTINGS CENT REP, V7, P32, DOI 10.2307/3560692; Callahan D., 1987, MED GOALS AGEING SOC; CALLAHAN D, 1991, COMMONWEAL S    0809, P12; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; CONWELL Y, 1991, NEW ENGL J MED, V325, P1100, DOI 10.1056/NEJM199110103251511; CRANFORD RE, 1984, I ETHICS COMMITTEES; DEWACHTER MAM, 1989, JAMA-J AM MED ASSOC, V262, P3316, DOI 10.1001/jama.262.23.3316; Drane JF, 1988, BECOMING GOOD DOCTOR; DUFFY TP, 1992, NEW ENGL J MED, V326, P933, DOI 10.1056/NEJM199204023261406; FENIGSEN R, 1991, ISSUES LAW MED, V7, P339; FOLEY KM, 1991, J PAIN SYMPTOM MANAG, V6, P289, DOI 10.1016/0885-3924(91)90052-6; GAYLIN W, 1988, JAMA-J AM MED ASSOC, V259, P2139; Gomez Carlos F., 1991, REGULATING DEATH EUT; GOMEZ CF, 1991, COMMONWEAL S, P5; Hampshire Stuart., 1983, MORALITY CONFLICT; Humphry Derek, 1991, FINAL EXIT PRACTICAL; Jonsen A. R., 1988, ABUSE CASUISTRY HIST; JONSEN AR, 1991, THEOR MED, V12, P295, DOI 10.1007/BF00489890; JONSEN AR, 1991, COMMONWEAL S, P2; KANOTI GA, 1987, HLTH CARE ETHICS GUI, P293; KASS LR, 1989, PUBLIC INTEREST, P25; KASS LR, 1991, COMMONWEAL S, P8; KEVORKIAN J, 1991, PRESCRIPTION MEDICID; LADD J, 1980, LANCET, V2, P1127; LO B, 1987, NEW ENGL J MED, V317, P46, DOI 10.1056/NEJM198707023170110; May W E, 1987, Issues Law Med, V3, P203; Miller R J, 1992, Law Med Health Care, V20, P127, DOI 10.1111/j.1748-720X.1992.tb01179.x; MISBIN RI, 1991, NEW ENGL J MED, V325, P1307, DOI 10.1056/NEJM199110313251811; ORENTLICHER D, 1990, JAMA-J AM MED ASSOC, V263, P2365, DOI 10.1001/jama.263.17.2365; Pellegrino E., 1981, PHILOS BASIS MED PRA; Pellegrino E., 1988, PATIENTS GOOD RESTOR; Pellegrino E D, 1992, J Clin Ethics, V3, P95; PENCE GE, 1988, AM J MED, V84, P139, DOI 10.1016/0002-9343(88)90022-8; PUTNAM H, 1983, NOT SOLVE ETHICAL PR; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; RACHELS J., 1986, END LIFE EUTHANASIA; SHAFFER CD, 1986, COLUMBIA LAW REV, V86, P348, DOI 10.2307/1122707; Shelp E. E., 1985, VIRTUE MED EXPLORATI; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; VANCE R, 1985, PERSPECT BIOL MED, V28, P282; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; Weir R F, 1992, Law Med Health Care, V20, P116, DOI 10.1111/j.1748-720X.1992.tb01178.x; WILSON WC, 1992, JAMA-J AM MED ASSOC, V267, P949; WOLF SM, 1989, HASTINGS CENT REP, V19, pS13; 1988, EUTHANASIA REPORT RE	54	108	108	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 5	1992	327	19					1384	1388		10.1056/NEJM199211053271912	http://dx.doi.org/10.1056/NEJM199211053271912			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW077	1383820				2022-12-28	WOS:A1992JW07700012
J	PUIGDOMINGO, M; WEBB, SM; SERRANO, J; PEINADO, MA; CORCOY, R; RUSCALLEDA, J; REITER, RJ; DELEIVA, A				PUIGDOMINGO, M; WEBB, SM; SERRANO, J; PEINADO, MA; CORCOY, R; RUSCALLEDA, J; REITER, RJ; DELEIVA, A			MELATONIN-RELATED HYPOGONADOTROPIC HYPOGONADISM - BRIEF REPORT	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							CIRCADIAN-RHYTHM; SERUM MELATONIN; PINEAL-GLAND; SECRETION; PUBERTY; HUMANS; CYCLE; WOMEN		UNIV TEXAS,HLTH SCI CTR,DEPT CELLULAR & STRUCT BIOL,SAN ANTONIO,TX 78284; UNIV AUTONOMA BARCELONA,HOSP SANTA CRUZ & SAN PABLO,NEURORADIOL SECT,BARCELONA,SPAIN	University of Texas System; University of Texas Health San Antonio; Autonomous University of Barcelona	PUIGDOMINGO, M (corresponding author), UNIV AUTONOMA BARCELONA,HOSP SANTA CREU & SANT PAU,SERV ENDOCRINOL & NUTR,E-08025 BARCELONA,SPAIN.		Puig-Domingo, Manel/S-2169-2019; Corcoy, Rosa/A-2140-2009; Webb, Susan SM/C-7294-2008; Peinado, Miguel A./A-5591-2008	Puig-Domingo, Manel/0000-0002-6744-7195; Corcoy, Rosa/0000-0001-5055-6814; Webb, Susan SM/0000-0001-7052-6436; Peinado, Miguel A./0000-0002-4090-793X; de Leiva, Alberto/0000-0002-0419-6771				BERGA SL, 1988, J CLIN ENDOCR METAB, V66, P242, DOI 10.1210/jcem-66-1-242; BRZEZINSKI A, 1988, J CLIN ENDOCR METAB, V66, P891, DOI 10.1210/jcem-66-5-891; CARDINALI DP, 1978, J NEURAL TRANSM    S, V13, P175; CHAMPNEY TH, 1985, ANAT REC, V211, P465, DOI 10.1002/ar.1092110414; COHEN HN, 1982, CLIN ENDOCRINOL, V17, P517; DELEIVA A, 1990, ACTA ENDOCRINOL-COP, V122, P76, DOI 10.1530/acta.0.1220076; Ebadi M., 1984, P1; FERRARI E, 1989, J PINEAL RES, V7, P115, DOI 10.1111/j.1600-079X.1989.tb00660.x; Greulich WW., 1959, CALIF MED, V91, P53; LEWY AJ, 1980, SCIENCE, V210, P1267, DOI 10.1126/science.7434030; LOW LCK, 1989, ADV PINEAL RES, V3, P287; LUKASZYK A, 1975, AM J ANAT, V143, P451, DOI 10.1002/aja.1001430404; OZAKI Y, 1978, P NATL ACAD SCI USA, V75, P531, DOI 10.1073/pnas.75.1.531; Reiter R.J., 1986, P100; Reiter R J, 1980, Endocr Rev, V1, P109; REITER RJ, 1976, AM J ANAT, V146, P427, DOI 10.1002/aja.1001460405; REITER RJ, 1990, NEUROENDOCRINE REGUL, P105; TORTOSA F, 1989, ACTA ENDOCRINOL-COP, V120, P574, DOI 10.1530/acta.0.1200574; TORTOSA F, 1988, 4TH M EUR SOC HUM RE; WALDHAUSER F, 1991, J CLIN ENDOCR METAB, V73, P793, DOI 10.1210/jcem-73-4-793; WALDHAUSER F, 1984, LANCET, V1, P362; WURTMAN RJ, 1991, ADV PINEAL, V5, P319	22	66	71	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 5	1992	327	19					1356	1359		10.1056/NEJM199211053271905	http://dx.doi.org/10.1056/NEJM199211053271905			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW077	1406837	Bronze			2022-12-28	WOS:A1992JW07700005
J	DOUGHERTY, D				DOUGHERTY, D			DOES HEALTH-INSURANCE MAKE A DIFFERENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											DOUGHERTY, D (corresponding author), US OFF TECHNOL ASSESSMENT,HLTH PROGRAM,WASHINGTON,DC 20510, USA.							1992, OTA BPH99 OFF TECHN	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 21	1992	268	15					1993	1993						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JT520	1404726				2022-12-28	WOS:A1992JT52000004
J	LINDSTEDT, S; HOLME, E; LOCK, EA; HJALMARSON, O; STRANDVIK, B				LINDSTEDT, S; HOLME, E; LOCK, EA; HJALMARSON, O; STRANDVIK, B			TREATMENT OF HEREDITARY TYROSINEMIA TYPE-I BY INHIBITION OF 4-HYDROXYPHENYLPYRUVATE DIOXYGENASE	LANCET			English	Article							TYROSINEMIA; SUCCINYLACETONE; DEFICIENCY; LIVER; FORM; ACID	Liver transplantation is the only effective treatment for hereditary tyrosinaemia type I (McKusick 276700). We have treated one acute and four subacute-chronic cases with 2-(2-nitro-4-trifluoro-methylbenzoyl)-1,3-cyclohexanedione (NTBC), a potent inhibitor of 4-hydroxyphenylpyruvate dioxygenase (EC 1.13.11.27), to prevent the formation of maleylacetoacetate and fumarylaceto-acetate and their saturated derivatives. The oral daily dose was 0.1-0.6 mg/kg. The excretion of succinylacetoacetate and succinylacetone decreased from 15-103 mmol/mol creatinine to the detection limit or slightly above (ie, to 20-150 mumol/mol creatinine). The concentration of succinylacetone in plasma decreased from 5.8-43-mumol/l to the detection limit (0.1 mumol/l) over 2-5 months of treatment. The almost complete inhibition of porphobilinogen synthase in erythrocytes was abolished and the excretion of 5-aminolevulinate decreased to within or slightly above the reference range. The concentration of alpha-fetoprotein decreased in four patients to 1.3-7.5% of initially high values over 6-8 months. Improved liver function was reflected by normal concentrations of prothrombin complex and in decreased activities of alkaline phosphatase and gamma-glutamyltransferase in serum. Computed tomography revealed regression of hepatic abnormalities in three patients. One patient developed rickets 6 months before treatment and had excreted high concentrations of markers of tubular dysfunction-after 3 weeks of treatment, this excretion had disappeared. No side-effects were encountered. Inhibition of 4-hydroxyphenylpyruvate dioxygenase may prevent the development of liver cirrhosis and abolish or diminish the risk of liver cancer. Normalisation of porphyrin synthesis will eliminate the risk of porphyric crises. This type of treatment may thus offer an alternative to liver transplantation in hereditary tryosinaemia.	ICI PLC, CENT TOXICOL LAB, MACCLESFIELD SK10 4TG, CHESHIRE, ENGLAND; GOTHENBURG UNIV, DEPT PAEDIAT, S-41124 GOTHENBURG, SWEDEN	University of Gothenburg	LINDSTEDT, S (corresponding author), GOTHENBURG UNIV, SAHLGRENS HOSP, DEPT CLIN CHEM, S-41345 GOTHENBURG, SWEDEN.		Lock, Edward/AAJ-1334-2020					COLLIER HB, 1971, CLIN BIOCHEM, V4, P222, DOI 10.1016/S0009-9120(71)91692-4; Danks DM, 1989, METABOLIC BASIS INHE, P1411; DEBRAEKELEER M, 1990, AM J HUM GENET, V47, P302; ENDO F, 1983, PEDIATR RES, V17, P92, DOI 10.1203/00006450-198302000-00002; GENTZ J, 1969, CLIN CHIM ACTA, V23, P257, DOI 10.1016/0009-8981(69)90040-0; GENTZ J, 1965, J PEDIATR-US, V66, P670, DOI 10.1016/S0022-3476(65)80002-6; GIARDINI O, 1983, PEDIATR RES, V17, P25, DOI 10.1203/00006450-198301000-00005; GRENIER A, 1982, CLIN CHIM ACTA, V123, P93, DOI 10.1016/0009-8981(82)90117-6; GRETER J, 1987, CLIN CHEM, V33, P473; HOLME E, 1992, LANCET, V340, P850, DOI 10.1016/0140-6736(92)92724-T; KUHLER TC, 1985, THESIS GOTHENBURG U; KVITTINGEN EA, 1986, SCAND J CLIN LAB INV, V46, P27; LAHDENNE P, 1991, J PEDIATR-US, V118, P272, DOI 10.1016/S0022-3476(05)80501-3; LINDBLAD B, 1977, P NATL ACAD SCI USA, V74, P4641, DOI 10.1073/pnas.74.10.4641; LINDSTEDT S, 1987, METHOD ENZYMOL, V142, P139; MANOWSKI Z, 1990, MODERN PATHOL, V3, P694; MITCHELL G, 1990, NEW ENGL J MED, V322, P432, DOI 10.1056/NEJM199002153220704; TSCHUDY DP, 1981, J BIOL CHEM, V256, P9915; TUCHMAN M, 1984, J CHROMATOGR SCI, V22, P211, DOI 10.1093/chromsci/22.5.211; VANSPRONSEN FJ, 1991, 29TH P SSIEM ANN S L; WEINBERG AG, 1976, J PEDIATR-US, V88, P434, DOI 10.1016/S0022-3476(76)80259-4	21	475	493	2	27	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 3	1992	340	8823					813	817		10.1016/0140-6736(92)92685-9	http://dx.doi.org/10.1016/0140-6736(92)92685-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR168	1383656				2022-12-28	WOS:A1992JR16800004
J	SHEKELLE, PG; ADAMS, AH; CHASSIN, MR; HURWITZ, EL; BROOK, RH				SHEKELLE, PG; ADAMS, AH; CHASSIN, MR; HURWITZ, EL; BROOK, RH			SPINAL MANIPULATION FOR LOW-BACK-PAIN	ANNALS OF INTERNAL MEDICINE			English	Review						BACKACHE; MANIPULATION, CHIROPRACTIC; MANIPULATION, ORTHOPEDIC; SPINE; LUMBOSACRAL REGION	THERAPY; TRIAL; MANAGEMENT; INJECTIONS; SCIATICA	Purpose: To review the use, complications, and efficacy of spinal manipulation as a treatment for low-back pain. Data Identification: Articles were identified through a MEDLINE search, review of articles' bibliographies, and advice from expert orthopedists and chiropractors. Study Selection: All studies reporting use and complications of spinal manipulation and all controlled trials of the efficacy of spinal manipulation were analyzed. Fifty-eight articles, including 25 controlled trials, were retrieved. Data Analysis: Data on the use and complications of spinal manipulation were summarized. Controlled trials of efficacy were critically appraised for study quality. Data from nine studies were combined using the confidence profile method of meta-analysis to estimate the effect of spinal manipulation on patients' pain and functional outcomes. Results of Data Synthesis: Chiropractors provide most of the manipulative therapy used in the United States for patients with low-back pain. Serious complications of lumbar manipulation, including paraplegia and death, have been reported. Although the occurrence rate of these complications is unknown, it is probably low. For patients with uncomplicated, acute low-back pain, the difference in probability of recovery at 3 weeks favoring treatment with spinal manipulation is 0.17 (for example, increase in recovery from 500/o to 67%; 95% probability limits of estimate, 0.07 to 0.28). For patients with low-back pain and sciatic nerve irritation, the difference in probabilities of recovery at 4 weeks is 0.098 (probability limits, -0.016 to 0.209). Conclusions: Spinal manipulation is of short-term benefit in some patients, particularly those with uncomplicated, acute low-back pain. Data are insufficient concerning the efficacy of spinal manipulation for chronic low-back pain.	UNIV CALIF LOS ANGELES, SCH MED, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH PUBL HLTH, LOS ANGELES, CA 90024 USA; VET AFFAIRS MED CTR, LOS ANGELES, CA USA; CONSORTIUM CHIROPRACT RES & VALUE HLTH SCI, LOS ANGELES, CA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA)								ARKUSZEWSKI Z, 1986, MANUAL MED, V2, P68; BALLANTINE HT, 1972, NEW ENGL J MED, V286, P237, DOI 10.1056/NEJM197202032860504; BERGQUISTULLMAN M, 1977, ACTA ORTHOP SCAND S, V170, P1; Bronfort G., 1989, AM J CHIROPRACTIC ME, V2, P145; BUERGER AA, 1984, MANUAL MED, V1, P54; BUERGER AA, 1980, MANUAL MED, V2, P17; CARETTE S, 1991, NEW ENGL J MED, V325, P1002, DOI 10.1056/NEJM199110033251405; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; CHRISMAN OD, 1964, J BONE JOINT SURG AM, V46, P517, DOI 10.2106/00004623-196446030-00005; COX JM, 1990, LOW BACK PAIN MECHAN; COXHEAD CE, 1981, LANCET, V1, P1065; COYER AB, 1955, BRIT MED J, V1, P705, DOI 10.1136/bmj.1.4915.705; DEYO RA, 1988, ARCH PHYS MED REHAB, V69, P1044; DEYO RA, 1983, JAMA-J AM MED ASSOC, V250, P1057; DORAN DML, 1975, BRIT MED J, V2, P161, DOI 10.1136/bmj.2.5964.161; Eddy D M, 1990, Int J Technol Assess Health Care, V6, P31; EDDY DM, 1990, MED DECIS MAKING, V10, P15, DOI 10.1177/0272989X9001000104; EDDY DM, 1992, FAST PRO SOFTWARE ME; Edwards B C, 1969, Aust J Physiother, V15, P104, DOI 10.1016/S0004-9514(14)61079-5; EVANS DP, 1978, RHEUMATOL REHABIL, V17, P46, DOI 10.1093/rheumatology/17.1.46; FARRELL JP, 1982, MED J AUSTRALIA, V1, P160, DOI 10.5694/j.1326-5377.1982.tb132242.x; FRYMOYER JW, 1988, NEW ENGL J MED, V318, P291, DOI 10.1056/NEJM198802043180506; GALLINARO P, 1983, LANCET, V1, P411; GIBSON T, 1985, LANCET, V1, P1258; GLOVER JR, 1974, BRIT J IND MED, V31, P59; GODFREY CM, 1984, SPINE, V9, P301, DOI 10.1097/00007632-198404000-00015; GRAYSON MF, 1987, BRIT MED J, V295, P1381, DOI 10.1136/bmj.295.6610.1381; HADLER NM, 1987, SPINE, V12, P703, DOI 10.1097/00007632-198709000-00012; HOEHLER FK, 1981, JAMA-J AM MED ASSOC, V245, P1835, DOI 10.1001/jama.245.18.1835; HOOPER J, 1973, MED J AUSTRALIA, V1, P549, DOI 10.5694/j.1326-5377.1973.tb110550.x; Kinalski R, 1989, J MANUAL MED, V4, P44; KIRKALDYWILLIS WH, 1985, CAN FAM PHYSICIAN, V31, P535; KOES BW, 1991, BRIT MED J, V303, P1298, DOI 10.1136/bmj.303.6813.1298; KORNBERG E, 1988, SURGERY, V103, P122; LADERMANN JP, 1981, ANN SWISS CHIROPRACT, V7, P161; MACDONALD RS, 1990, SPINE, V15, P364, DOI 10.1097/00007632-199005000-00005; MALMIVAARA A, 1982, LANCET, V2, P986; MATHEWS JA, 1987, BRIT J RHEUMATOL, V26, P416; MEADE TW, 1990, BRIT MED J, V300, P1431, DOI 10.1136/bmj.300.6737.1431; MIERAU D, 1987, J MANIP PHYSIOL THER, V10, P49; NWUGA VCB, 1982, AM J PHYS MED REHAB, V61, P273; NYIENDO J, 1987, MED CARE, V25, P516, DOI 10.1097/00005650-198706000-00006; ONGLEY MJ, 1987, LANCET, V2, P143; PHILLIPS RB, 1982, J MANIP PHYSIOL THER, V5, P83; POTTER GE, 1977, J CAN CHIROPRACTIC A, V4, P154; POVLSEN UJ, 1987, ACTA NEUROL SCAND, V76, P486, DOI 10.1111/j.1600-0404.1987.tb03607.x; Rasmussen G. G., 1979, MANUAL MED, V17, P8; RICHARD J, 1967, NEW YORK STATE J MED, V67, P2496; RUPERT RL, 1985, ICA INT REV CHIR WIN, P58; SHEKELLE PG, 1991, AM J PUBLIC HEALTH, V81, P439, DOI 10.2105/AJPH.81.4.439; Shekelle PG, 1991, APPROPRIATENESS SPIN; SHVARTZMAN P, 1988, POSTGRAD MED, V83, P57; Siehl D, 1971, J Am Osteopath Assoc, V70, P433; SIMSWILLIAMS H, 1978, BMJ-BRIT MED J, V2, P1338, DOI 10.1136/bmj.2.6148.1338; SIMSWILLIAMS H, 1979, BMJ-BRIT MED J, V2, P1318, DOI 10.1136/bmj.2.6201.1318; SPITZER WO, 1987, SPINE, V12, pS1; VERONESI U, 1981, NEW ENGL J MED, V305, P6, DOI 10.1056/NEJM198107023050102; Von Kuster T, 1980, CHIROPRACTIC HLTH CA; Waagen GN, 1986, MANUAL MED, V2, P63; WATERWORTH RF, 1985, NEW ZEAL MED J, V98, P372; WILSON JN, 1952, AM J SURG, V83, P173, DOI 10.1016/0002-9610(52)90204-3; ZYLBERGOLD RS, 1981, ARCH PHYS MED REHAB, V62, P176; 1989, FACTS B, V3, P32; 1976, 1975 AMBULATORY CARE; 1976, HSM11072377 DHEW HLT	65	309	312	1	19	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1992	117	7					590	598		10.7326/0003-4819-117-7-590	http://dx.doi.org/10.7326/0003-4819-117-7-590			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ226	1388006				2022-12-28	WOS:A1992JQ22600009
J	JONES, RVH				JONES, RVH			PARTNERS IN PRACTICE - GETTING BETTER - EDUCATION AND THE PRIMARY HEALTH-CARE TEAM .6.	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE				JONES, RVH (corresponding author), POSTGRAD MED SCH,DEPT GEN PRACTICE,EXETER EX2 5DW,ENGLAND.							BROOKFIELD S, 1987, UNDERSTANDING FACILI; Drucker PF, 1955, PRACTICE MANAGEMENT; ESSEX B, 1991, BRIT MED J, V302, P573, DOI 10.1136/bmj.302.6776.573; FOWLER G, 1988, J ROY COLL GEN PRACT, V38, P391; FULLARD E, 1987, BRIT MED J, V294, P1080, DOI 10.1136/bmj.294.6579.1080; HORDER J, 1986, J ROY COLL GEN PRACT, V36, P517; Jones R., 1992, J INTERPROF CARE, V6, P25, DOI [10.3109/13561829209049592, DOI 10.3109/13561829209049592]; Jones R.V.H., 1986, 33 ROYAL COLL GEN PR; JONES RVH, 1985, RUNNING PRACTICE; JONES RVH, 1990, POSTGRADUATE ED GENE, V3, P154; Knowles M., 1980, MODERN PRACTICE ADUL; LAMBERT DMD, 1988, TEAM WORKSHOPS HLTH; Pringle M, 1991, Health Trends, V23, P15; PRITCHARD PMM, 1984, GENERAL PRACTICE SER, V8; ROGERS J, 1977, ADULTS LEARNING; SPRATLEY J, 1989, TEAEM WORKSHOPS PREV; Woodley Alan, 1987, CHOOSING LEARN ADULT; 1972, FUTURE GENERAL PRACT; 1985, WHAT DOCTOR ASSESSIN	19	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 29	1992	305	6852					506	508		10.1136/bmj.305.6852.506	http://dx.doi.org/10.1136/bmj.305.6852.506			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JL609	1392997	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992JL60900020
J	ROTHNAGEL, JA; DOMINEY, AM; DEMPSEY, LD; LONGLEY, MA; GREENHALGH, DA; GAGNE, TA; HUBER, M; FRENK, E; HOHL, D; ROOP, DR				ROTHNAGEL, JA; DOMINEY, AM; DEMPSEY, LD; LONGLEY, MA; GREENHALGH, DA; GAGNE, TA; HUBER, M; FRENK, E; HOHL, D; ROOP, DR			MUTATIONS IN THE ROD DOMAINS OF KERATIN-1 AND KERATIN-10 IN EPIDERMOLYTIC HYPERKERATOSIS	SCIENCE			English	Article							INTERMEDIATE FILAMENTS; HUMAN CHROMOSOME-12; GENE-EXPRESSION; MOUSE EPIDERMIS; CELLS; SEQUENCE; ACID; CYTOKERATIN-18; ULTRASTRUCTURE; KERATINIZATION	Epidermolytic hyperkeratosis is a hereditary skin disorder characterized by blistering and a marked thickening of the stratum corneum. In one family, affected individuals exhibited a mutation in the highly conserved carboxyl terminal of the rod domain of keratin 1. In two other families, affected individuals had mutations in the highly conserved amino terminal of the rod domain of keratin 10. Structural analysis of these mutations predicts that heterodimer formation would be unaffected, although filament assembly and elongation would be severely compromised. These data imply that an intact keratin intermediate filament network is required for the maintenance of both cellular and tissue integrity.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT DERMATOL,HOUSTON,TX 77030; CHU VAUDOIS,HOP BEAUMONT,DEPT DERMATOL,CH-1011 LAUSANNE,SWITZERLAND	Baylor College of Medicine; Baylor College of Medicine; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)			Huber, Marcel/M-8822-2016; Hohl, Daniel M/N-7554-2016; Rothnagel, Joe/A-4874-2010	Huber, Marcel/0000-0003-3821-2378; Rothnagel, Joe/0000-0002-6710-3165	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025479] Funding Source: NIH RePORTER; NICHD NIH HHS [HD25479] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ACKERMAN AB, 1970, ARCH DERMATOL, V102, P253, DOI 10.1001/archderm.102.3.253; ANTONLAMPRECHT I, 1974, ARCH DERMATOL FORSCH, V250, P207, DOI 10.1007/BF00561188; BADER BL, 1988, EUR J CELL BIOL, V47, P300; BONIFAS JM, 1991, SCIENCE, V254, P1202, DOI 10.1126/science.1720261; BONIFAS JM, 1992, J INVEST DERMATOL, V98, P573; Brocq L, 1902, ANN DERMATOL SYPHIL, V4, P1; COLOUMBE PA, 1991, CELL, V66, P1301; COMPTON JG, 1992, NAT GENET, V1, P301, DOI 10.1038/ng0792-301; CONWAY JF, 1988, INT J BIOL MACROMOL, V10, P79, DOI 10.1016/0141-8130(88)90015-3; COULOMBE PA, 1990, J CELL BIOL, V111, P153, DOI 10.1083/jcb.111.1.153; EPSTEIN EH, 1992, SCIENCE, V256, P799, DOI 10.1126/science.1375393; FRASER RDB, 1986, P NATL ACAD SCI USA, V83, P1179, DOI 10.1073/pnas.83.5.1179; FRITSCH EFJ, 1989, MOL CLONING LABORATO; FROST P, 1966, ARCH DERMATOL, V94, P113, DOI 10.1001/archderm.94.2.113; FROST P, 1966, J INVEST DERMATOL, V47, P561, DOI 10.1038/jid.1966.185; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; GEISLER N, 1982, NATURE, V296, P448, DOI 10.1038/296448a0; GIBBS RA, 1990, GENOMICS, V7, P235, DOI 10.1016/0888-7543(90)90545-6; HATZFELD M, 1991, J CELL SCI, V99, P351; HATZFELD M, 1990, J CELL BIOL, V110, P119; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HEATH P, 1990, HUM GENET, V85, P669; HIRONE T, 1969, Journal of Electron Microscopy, V18, P63; HOHL D, 1991, J INVEST DERMATOL, V96, P414, DOI 10.1111/1523-1747.ep12469779; HOLBROOK KA, 1983, J INVEST DERMATOL, V80, P222, DOI 10.1111/1523-1747.ep12534504; ISHIDAYAMAMOTO A, 1992, J INVEST DERMATOL, V99, P19, DOI 10.1111/1523-1747.ep12611391; JACKSON DP, 1990, J CLIN PATHOL, V43, P499, DOI 10.1136/jcp.43.6.499; JOHNSON LD, 1985, P NATL ACAD SCI USA, V82, P1896, DOI 10.1073/pnas.82.7.1896; KANITAKIS J, 1987, BRIT J DERMATOL, V117, P479, DOI 10.1111/j.1365-2133.1987.tb04928.x; KORGE BP, 1992, P NATL ACAD SCI USA, V89, P910, DOI 10.1073/pnas.89.3.910; LANE EB, 1992, NATURE, V356, P244, DOI 10.1038/356244a0; LAPIERE S, 1932, ANN DERMATOL SYPHIL, V3, P401; LESSIN SR, 1988, J INVEST DERMATOL, V91, P572, DOI 10.1111/1523-1747.ep12477087; LETAI A, 1992, J CELL BIOL, V116, P1181, DOI 10.1083/jcb.116.5.1181; MAGIN TM, 1987, EMBO J, V6, P2607, DOI 10.1002/j.1460-2075.1987.tb02551.x; MALI JWH, 1976, BRIT J DERMATOL, V95, P627, DOI 10.1111/j.1365-2133.1976.tb07035.x; OGAWA H, 1979, ARCH DERMATOL RES, V266, P109, DOI 10.1007/BF00694618; PARRY D A D, 1992, Current Opinion in Cell Biology, V4, P94, DOI 10.1016/0955-0674(92)90064-J; PARRY DAD, 1987, INT J BIOL MACROMOL, V9, P137, DOI 10.1016/0141-8130(87)90041-9; POPESCU NC, 1989, HUM GENET, V82, P109, DOI 10.1007/BF00284039; RIEGER M, 1988, J MOL BIOL, V204, P841, DOI 10.1016/0022-2836(88)90045-9; ROMANO V, 1988, CYTOGENET CELL GENET, V48, P148, DOI 10.1159/000132612; ROOP DR, 1983, P NATL ACAD SCI-BIOL, V80, P716, DOI 10.1073/pnas.80.3.716; ROSENBERG M, 1991, CYTOGENET CELL GENET, V57, P33, DOI 10.1159/000133109; ROTHNAGEL JA, UNPUB; SCHWEIZER J, 1984, CELL, V37, P159, DOI 10.1016/0092-8674(84)90311-8; STEINERT PM, 1990, J BIOL CHEM, V265, P8766; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; WILGRAM GF, 1966, ARCH DERMATOL, V94, P127, DOI 10.1001/archderm.94.2.127; WILLIAMS ML, 1988, PEDIAT DERMATOLOGY, V1, P400; WOODCOCKMITCHELL J, 1982, J CELL BIOL, V95, P580, DOI 10.1083/jcb.95.2.580	51	323	328	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 21	1992	257	5073					1128	1130		10.1126/science.257.5073.1128	http://dx.doi.org/10.1126/science.257.5073.1128			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ884	1380725				2022-12-28	WOS:A1992JJ88400036
J	MOHAMMADI, M; DIONNE, CA; LI, W; LI, N; SPIVAK, T; HONEGGER, AM; JAYE, M; SCHLESSINGER, J				MOHAMMADI, M; DIONNE, CA; LI, W; LI, N; SPIVAK, T; HONEGGER, AM; JAYE, M; SCHLESSINGER, J			POINT MUTATION IN FGF RECEPTOR ELIMINATES PHOSPHATIDYLINOSITOL HYDROLYSIS WITHOUT AFFECTING MITOGENESIS	NATURE			English	Article							PHOSPHOLIPASE-C-GAMMA; FIBROBLAST GROWTH-FACTOR; STIMULATES TYROSINE PHOSPHORYLATION; PDGF RECEPTOR; EGF RECEPTOR; SIGNAL TRANSDUCTION; BINDING-SITE; KINASE; EXPRESSION; ASSOCIATION	STIMULATION of growth factor receptors with tyrosine kinase activity is followed by rapid receptor dimerization, tyrosine autophosphorylation and phosphorylation of signalling molecules such as phospholipase C(gamma)(PLC-gamma) and the ras GTPase-activating protein1,2. PLC-gamma and GTPase-activating protein bind to specific tyrosine-phosphorylated regions in growth factor receptors3-9 through their src-homologous SH2 domains7,8,10,11. Growth factor-induced tyrosine phosphorylation of PLC-gamma is essential for stimulation of phosphatidylinositol hydrolysis in vitro12 and in vivo13. We have shown that a short phosphorylated peptide containing tyrosine at position 766 from a conserved region14-18 of the fibroblast growth factor (FGF) receptor is a binding site for the SH2 domain of PLC-gamma (ref. 8). Here we show that an FGF receptor point mutant in which Tyr 766 is replaced by a phenylalanine residue (Y766F) is unable to associate with and tyrosine-phosphorylate PLC-gamma or to stimulate hydrolysis of phosphatidylinositol. Nevertheless, the Y766F FGF receptor mutant can be autophosphorylated, and can phosphorylate several cellular proteins and stimulate DNA synthesis. Our data show that phosphorylation of the conserved Tyr 766 of the FGF receptor is essential for phosphorylation of PLC-gamma and for hydrolysis of phosphatidylinositol, but that elimination of this hydrolysis does not affect FGF-induced mitogenesis.	RHONE POULENC RORER CENT RES,COLLEGEVILLE,PA 19426		MOHAMMADI, M (corresponding author), NYU MED CTR,DEPT PHARMACOL,550 1ST AVE,NEW YORK,NY 10016, USA.		kasaei, fahime/T-7197-2018; Mohammadi, Moosa/ABA-6745-2020	Mohammadi, Moosa/0000-0003-2434-9437; Honegger, Annemarie/0000-0002-3378-3967				AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CUADRADO A, 1990, MOL CELL BIOL, V10, P6069, DOI 10.1128/MCB.10.11.6069; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KUMJIAN DA, 1991, J BIOL CHEM, V266, P3973; LEE PL, 1989, SCIENCE, V245, P5760; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PATERNO GD, 1989, DEVELOPMENT, V106, P79; RUTA M, 1988, ONCOGENE, V3, P9; SMITH MR, 1990, SCIENCE, V247, P1074, DOI 10.1126/science.2408147; SMITH MR, 1989, P NATL ACAD SCI USA, V86, P3659, DOI 10.1073/pnas.86.10.3659; SUTZLMAN L, 1991, MOL CELL BIOL, V11, P2018; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568	34	393	408	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 20	1992	358	6388					681	684		10.1038/358681a0	http://dx.doi.org/10.1038/358681a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ882	1379698				2022-12-28	WOS:A1992JJ88200058
J	HESTRIN, S				HESTRIN, S			DEVELOPMENTAL REGULATION OF NMDA RECEPTOR-MEDIATED SYNAPTIC CURRENTS AT A CENTRAL SYNAPSE	NATURE			English	Article							SUPERIOR COLLICULUS; HIPPOCAMPAL SLICES; VISUAL-CORTEX; TIME COURSE; NEURONS; RAT	THE central nervous system has extraordinary plasticity in early life. This is thought to involve N-methyl-D-aspartate (NMDA) receptors 1 which, along with the non-NMDA receptors, mediate fast excitatory synaptic transmission 2. Although NMDA receptors may be transiently enhanced early in life 3-6, it has not been possible to demonstrate directly a functional change in the NMDA receptor-mediated synaptic response because of the voltage-dependence of the NMDA conductance and the overlapping inhibitory synaptic conductances. Here I report that the duration of evoked NMDA-receptor-mediated excitatory postsynaptic currents (e.p.s.cs) in the superior colliculus is several times longer at early developmental stages compared to that measured in older animals. In contrast, the amplitude of NMDA-receptor-mediated miniature e.p.s.cs does not change during development. The kinetic response of excised membrane patches to a brief activation of NMDA receptors is similar to that of the NMDA e.p.s.c, which suggests that the time course of the NMDA e.p.s.c. in the superior colliculus reflects slow NMDA channel properties as in the hippocampus 7-9. Therefore, these data indicate that the molecular properties of NMDA receptors are developmentally regulated and thus may be controlling the ability of synapses to change in early life.			HESTRIN, S (corresponding author), UNIV CALIF SAN FRANCISCO, SCH MED, DEPT PHYSIOL, BOX 0444, SAN FRANCISCO, CA 94143 USA.		Hestrin, Shaul/F-4410-2010					BENARI Y, 1988, NEUROSCI LETT, V94, P88, DOI 10.1016/0304-3940(88)90275-3; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BODEGREUEL KM, 1989, DEV BRAIN RES, V46, P197, DOI 10.1016/0165-3806(89)90283-6; COLEMAN PA, 1989, J NEUROPHYSIOL, V61, P218, DOI 10.1152/jn.1989.61.1.218; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; FISCHBACH GD, 1980, J PHYSIOL-LONDON, V303, P125, DOI 10.1113/jphysiol.1980.sp013275; FOX K, 1991, NATURE, V350, P342, DOI 10.1038/350342a0; GIBB AJ, 1991, P ROY SOC B-BIOL SCI, V243, P39, DOI 10.1098/rspb.1991.0007; HESTRIN S, 1990, NEURON, V5, P247, DOI 10.1016/0896-6273(90)90162-9; HESTRIN S, 1990, J PHYSIOL-LONDON, V422, P203, DOI 10.1113/jphysiol.1990.sp017980; KATO N, 1991, DEV BRAIN RES, V60, P43, DOI 10.1016/0165-3806(91)90153-A; KLECKNER NW, 1991, MOL BRAIN RES, V11, P151; KONNERTH A, 1990, EXP BRAIN RES, V81, P209; LESTER RAJ, 1990, NATURE, V346, P565, DOI 10.1038/346565a0; LOTURCO JJ, 1991, J NEUROSCI, V11, P792; LUND RD, 1972, BRAIN RES, V42, P1, DOI 10.1016/0006-8993(72)90038-8; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; MIYAMOTO T, 1990, BRAIN RES, V518, P166, DOI 10.1016/0006-8993(90)90968-H; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; SAKMANN B, 1978, NATURE, V276, P401, DOI 10.1038/276401a0; TRUSSELL LO, 1989, NEURON, V3, P209, DOI 10.1016/0896-6273(89)90034-2; TSUMOTO T, 1987, NATURE, V327, P513, DOI 10.1038/327513a0	26	458	463	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 25	1992	357	6380					686	689		10.1038/357686a0	http://dx.doi.org/10.1038/357686a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA430	1377360				2022-12-28	WOS:A1992JA43000070
J	EPSTEIN, EH				EPSTEIN, EH			MOLECULAR-GENETICS OF EPIDERMOLYSIS-BULLOSA	SCIENCE			English	Article							KERATIN INTERMEDIATE FILAMENTS; ANCHORING FIBRILS; EPITHELIAL-CELLS; MICRO-INJECTION; COILED-COIL; EXPRESSION; FIBROBLASTS; ANTIBODY; VIMENTIN; SIMPLEX	Blisters following minor trauma characterize epidermolysis bullosa, a group of hereditary diseases of the skin. In the simplex type, epidermal basal cells are fragile, and mutations of genes encoding keratin intermediate filament proteins underlie that fragility. In the dystrophic types, the causative mutation appears to be in the gene encoding type VII collagen, which is the major component of anchoring fibrils. These recent findings afford solid evidence that at least one function of the cytoskeletal intermediate filament network is the provision of mechanical stability and that anchoring fibrils indeed do anchor the epidermis to the underlying dermis.			EPSTEIN, EH (corresponding author), UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,BLDG 100,ROOM 269,1001 POTRERO AVE,SAN FRANCISCO,CA 94110, USA.							ALBERS K, 1987, J CELL BIOL, V105, P791, DOI 10.1083/jcb.105.2.791; ALBERS K, 1989, J CELL BIOL, V108, P1477, DOI 10.1083/jcb.108.4.1477; ANTONLAMPRECHT I, 1978, DERMATOLOGICA, V157, P65, DOI 10.1159/000250810; ANTONLAMPRECHT I, 1982, DERMATOLOGICA, V164, P221, DOI 10.1159/000250096; BARIBAULT H, 1991, J CELL BIOL, V115, P1675, DOI 10.1083/jcb.115.6.1675; BAUER EA, 1977, J INVEST DERMATOL, V68, P119, DOI 10.1111/1523-1747.ep12492226; BONIFAS JM, 1991, SCIENCE, V254, P1202, DOI 10.1126/science.1720261; BRIGGAMAN RA, 1975, J INVEST DERMATOL, V65, P203, DOI 10.1111/1523-1747.ep12598208; CHRISTIAN J L, 1990, New Biologist, V2, P700; COULOMBE PA, 1991, J CELL BIOL, V115, P1661, DOI 10.1083/jcb.115.6.1661; COULOMBE PA, 1990, J CELL BIOL, V111, P3049, DOI 10.1083/jcb.111.6.3049; COULOMBE PA, 1990, J CELL BIOL, V111, P153, DOI 10.1083/jcb.111.1.153; COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; Elliott GT, 1895, J CUTAN GENITOURIN D, V13, P10, DOI 10.1038/jid.2011.231; ERGUN GA, IN PRESS MEDICINE; FARRAR GJ, 1991, NATURE, V354, P478, DOI 10.1038/354478a0; FINE JD, 1991, J AM ACAD DERMATOL, V24, P199; GAWLITTA W, 1981, EUR J CELL BIOL, V26, P83; Gedde-Dahl Jr T., 1971, EPIDERMOLYSIS BULLOS; GILL SR, 1990, J CELL BIOL, V111, P2005, DOI 10.1083/jcb.111.5.2005; GOLDSMITH LA, 1983, J INVEST DERMATOL, V81, P464, DOI 10.1111/1523-1747.ep12522669; GRANEK H, 1980, ARCH OPHTHALMOL-CHIC, V98, P469; GREEN KJ, 1990, J BIOL CHEM, V265, P2603; HATZFELD M, 1990, J CELL BIOL, V110, P1199, DOI 10.1083/jcb.110.4.1199; HATZFELD M, 1991, J CELL SCI, V99, P351; HEDBERG KK, 1986, EXP CELL RES, V163, P509, DOI 10.1016/0014-4827(86)90081-9; HOVNANIAN A, 1991, J CLIN INVEST, V88, P1716, DOI 10.1172/JCI115489; HOVNANIAN A, 1992, J INVEST DERMATOL, V98, P477; HOYHEIM B, 1992, J INVEST DERMATOL, V98, P397; HUMPHRIES P, 1992, SCIENCE, V256, P804, DOI 10.1126/science.1589761; HUNTER JAA, 1974, BRIT J DERMATOL, V90, P491, DOI 10.1111/j.1365-2133.1974.tb06443.x; ISHIDAYAMAMOTO A, 1991, J INVEST DERMATOL, V97, P959, DOI 10.1111/1523-1747.ep12491885; ISHIDAYAMAMOTO A, IN PRESS J INVEST DE; KAJIWARA K, 1991, NATURE, V354, P480, DOI 10.1038/354480a0; KEENE DR, 1987, J CELL BIOL, V104, P611, DOI 10.1083/jcb.104.3.611; KITAJIMA Y, 1986, J INVEST DERMATOL, V87, P565, DOI 10.1111/1523-1747.ep12455792; KITAJIMA Y, 1989, ARCH DERMATOL RES, V281, P5, DOI 10.1007/BF00424265; KLYMKOWSKY MW, 1989, CELL MOTIL CYTOSKEL, V14, P309, DOI 10.1002/cm.970140302; KLYMKOWSKY MW, 1981, NATURE, V291, P249, DOI 10.1038/291249a0; KNAPP LW, 1983, SCIENCE, V219, P501, DOI 10.1126/science.6186022; KNAPP LW, 1983, J CELL BIOL, V97, P1788, DOI 10.1083/jcb.97.6.1788; LANE EB, 1992, NATURE, V356, P244, DOI 10.1038/356244a0; LETAI A, 1992, J CELL BIOL, V116, P1181, DOI 10.1083/jcb.116.5.1181; Lin AN, 1992, EPIDERMOLYSIS BULLOS; LIN JJC, 1981, CELL, V24, P185, DOI 10.1016/0092-8674(81)90514-6; LU X, 1990, CELL, V62, P681, DOI 10.1016/0092-8674(90)90114-T; MILLER RK, 1991, J CELL BIOL, V113, P843, DOI 10.1083/jcb.113.4.843; OLAISEN B, 1973, HUM HERED, V23, P189, DOI 10.1159/000152573; PARENTE MG, 1991, P NATL ACAD SCI USA, V88, P6931, DOI 10.1073/pnas.88.16.6931; PEARSON RW, 1962, J INVEST DERMATOL, V39, P551, DOI 10.1038/jid.1962.156; POWELL BC, 1990, EMBO J, V9, P1485, DOI 10.1002/j.1460-2075.1990.tb08266.x; RAATS JMH, 1990, J CELL BIOL, V111, P1971, DOI 10.1083/jcb.111.5.1971; RYYNANEN M, 1991, AM J HUM GENET, V49, P978; RYYNANEN M, 1992, J CLIN INVEST, V89, P974, DOI 10.1172/JCI115680; SCHULTHEISS T, 1991, J CELL BIOL, V114, P953, DOI 10.1083/jcb.114.5.953; STAPPENBECK TS, 1992, J CELL BIOL, V116, P1197, DOI 10.1083/jcb.116.5.1197; STEINERT PM, 1990, J BIOL CHEM, V265, P8766; STEINERT PM, 1985, CELL, V42, P411, DOI 10.1016/0092-8674(85)90098-4; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; SUN T, UNPUB; SUTHERLAND GR, 1981, HUM GENET, V57, P217; TIDMAN MJ, 1985, J INVEST DERMATOL, V84, P374, DOI 10.1111/1523-1747.ep12265460; TREVOR K T, 1990, New Biologist, V2, P1004; VANDENHEUVEL RMM, 1987, J CELL SCI, V88, P475; VASSAR R, 1991, CELL, V64, P365, DOI 10.1016/0092-8674(91)90645-F; WEINSTEIN DE, 1991, J CELL BIOL, V112, P1205, DOI 10.1083/jcb.112.6.1205; WILLIAMS ML, 1991, ADV LIPID RES, V24, P211; WINBERG JO, 1989, J INVEST DERMATOL, V92, P82, DOI 10.1111/1523-1747.ep13071274; WONG PC, 1990, J CELL BIOL, V111, P1987, DOI 10.1083/jcb.111.5.1987	69	103	106	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 8	1992	256	5058					799	804		10.1126/science.1375393	http://dx.doi.org/10.1126/science.1375393			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT235	1375393				2022-12-28	WOS:A1992HT23500033
J	PEARSON, ML; KAHN, KL; HARRISON, ER; RUBENSTEIN, LV; ROGERS, WH; BROOK, RH; KEELER, EB				PEARSON, ML; KAHN, KL; HARRISON, ER; RUBENSTEIN, LV; ROGERS, WH; BROOK, RH; KEELER, EB			DIFFERENCES IN QUALITY OF CARE FOR HOSPITALIZED ELDERLY MEN AND WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROSPECTIVE PAYMENT SYSTEM; BYPASS-SURGERY; SEX; TRANSPLANTATION; IMPLEMENTATION; MORTALITY; DISEASE; HEALTH; BIAS	Objective.-To analyze whether important gender differences exist in the quality of hospital care provided to patients with four major medical conditions. Design.-Bivariate and multivariate comparisons of clinically detailed sickness at admission, quality, utilization, and outcome measures. Setting.-Acute care hospitals located in five states. Patients or Other Participants.-A total of 11 242 patients 65 years or older who were hospitalized with one of four diseases: congestive heart failure, acute myocardial infarction, pneumonia, and cerebrovascular accident. We derived our data from the nationally representative sample used to study the quality of hospital care for Medicare patients before and after the implementation of the prospective payment system. A hierarchical (nested) cluster sampling design was used to draw disease-specific samples of patients hospitalized in 1981, 1982, 1985, or 1986 in one of 297 hospitals located in 30 areas within five states. Interventions.-This was an observational study. Main Outcome Measures.-Sickness at admission, process, use rates, length of stay, discharge status, discharge destination, and mortality. Results.-Sex differences in sickness at admission varied by disease. There was some evidence that women received worse process of care, but the difference was very small. We found many similarities in the process and outcomes of care for male and female patients. Conclusions.-After controlling for sickness at admission, age, and other important covariates, the in-hospital experiences of elderly men and women showed greater similarities than differences. The concern that sex bias enters into clinical decision making during hospitalization is eased, although not entirely eliminated.	VET ADM MED CTR,SEPULVEDA,CA 91343; UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT HLTH SERV,LOS ANGELES,CA 90024	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	PEARSON, ML (corresponding author), RAND CORP,HLTH PROGRAM,1700 MAIN ST,POB 2138,SANTA MONICA,CA 90407, USA.		Kahn, Katherine/AAE-2857-2020	Kahn, Katherine/0000-0002-6605-1455	AHRQ HHS [HS06546-02, T32 HS 00007] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BROOK RH, 1990, NEW ENGL J MED, V323, P1173, DOI 10.1056/NEJM199010253231705; DRAPER D, 1990, JAMA-J AM MED ASSOC, V264, P1956, DOI 10.1001/jama.264.15.1956; HANNAN EL, 1992, AM HEART J, V123, P866, DOI 10.1016/0002-8703(92)90689-S; HELD PJ, 1988, ARCH INTERN MED, V148, P2594, DOI 10.1001/archinte.148.12.2594; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1953, DOI 10.1001/jama.264.15.1953; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1969, DOI 10.1001/jama.264.15.1969; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1984, DOI 10.1001/jama.264.15.1984; KAHN KL, 1992, RAND R3931HCFA PUBL; KEELER EB, 1990, JAMA-J AM MED ASSOC, V264, P1962, DOI 10.1001/jama.264.15.1962; KEMPER P, 1991, NEW ENGL J MED, V324, P595, DOI 10.1056/NEJM199102283240905; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; KJELLSTRAND CM, 1988, ARCH INTERN MED, V148, P1305; KOSECOFF J, 1990, JAMA-J AM MED ASSOC, V264, P1980, DOI 10.1001/jama.264.15.1980; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; MAYNARD C, 1992, ARCH INTERN MED, V152, P972, DOI 10.1001/archinte.152.5.972; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; STRICKLAND BR, 1988, PSYCHOL WOMEN QUART, V12, P381, DOI 10.1111/j.1471-6402.1988.tb00972.x; TOBIN JN, 1987, ANN INTERN MED, V107, P19, DOI 10.7326/0003-4819-107-1-19; VERBRUGGE LM, 1987, WOMEN HEALTH, V12, P103, DOI 10.1300/J013v12n02_07; WELLS CK, 1988, AM J EPIDEMIOL, V125, P1016; 1991, JAMA-J AM MED ASSOC, V266, P559	23	36	36	1	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1992	268	14					1883	1889		10.1001/jama.268.14.1883	http://dx.doi.org/10.1001/jama.268.14.1883			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR439	1404712				2022-12-28	WOS:A1992JR43900037
J	LEE, JJ; VONKESSLER, DP; PARKS, S; BEACHY, PA				LEE, JJ; VONKESSLER, DP; PARKS, S; BEACHY, PA			SECRETION AND LOCALIZED TRANSCRIPTION SUGGEST A ROLE IN POSITIONAL SIGNALING FOR PRODUCTS OF THE SEGMENTATION GENE HEDGEHOG	CELL			English	Article							DROSOPHILA HEAD DEVELOPMENT; ANTENNA IMAGINAL DISK; POLARITY GENE; PATTERN-FORMATION; ENGRAILED GENE; MESSENGER-RNA; FUSHI-TARAZU; MOLECULAR-GENETICS; EMBRYONIC PATTERN; LARVAL CUTICLE	The segment polarity genes engrailed and wingless are expressed in neighboring stripes of cells on opposite sides of the Drosophila parasegment boundary. Each gene is mutually required for maintenance of the other's expression; continued expression of both also requires several other segment polarity genes. We show here that one such gene, hedgehog, encodes a protein targeted to the secretory pathway and is expressed coincidently with engrailed in embryos and in imaginal discs; maintenance of the hedgehog expression pattern is itself dependent upon other segment polarity genes including engrailed and wingless. Expression of hedgehog thus functions in, and is sensitive to, positional signaling. These properties are consistent with the non-cell autonomous requirement for hedgehog in cuticular patterning and in maintenance of wingless expression.			LEE, JJ (corresponding author), JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205, USA.							AKAM M, 1987, DEVELOPMENT, V101, P1; ARIAS AM, 1988, DEVELOPMENT, V103, P157; ARIAS AM, 1985, NATURE, V313, P639; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BAKER NE, 1988, DEVELOPMENT, V102, P489; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BIGGIN MD, 1989, TRENDS GENET, V5, P377, DOI 10.1016/0168-9525(89)90173-X; BISHOP JG, 1988, GENE DEV, V2, P567, DOI 10.1101/gad.2.5.567; BROWER DL, 1986, EMBO J, V5, P2649, DOI 10.1002/j.1460-2075.1986.tb04547.x; BROWER DL, 1981, DEV BIOL, V86, P448, DOI 10.1016/0012-1606(81)90203-7; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BRYANT PJ, 1975, J EXP ZOOL, V193, P49, DOI 10.1002/jez.1401930106; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; COHEN S, 1991, TRENDS GENET, V7, P267; COHEN SM, 1990, NATURE, V346, P482, DOI 10.1038/346482a0; DINARDO S, 1987, GENE DEV, V1, P1212, DOI 10.1101/gad.1.10.1212; DINARDO S, 1985, CELL, V43, P59, DOI 10.1016/0092-8674(85)90012-1; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; EKKER SC, 1991, EMBO J, V10, P1179, DOI 10.1002/j.1460-2075.1991.tb08058.x; EKKER SC, 1992, IN PRESS EMBO J; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINKELSTEIN R, 1991, DEVELOPMENT, V112, P899; FINKELSTEIN R, 1990, NATURE, V346, P485, DOI 10.1038/346485a0; FJOSE A, 1985, NATURE, V313, P284, DOI 10.1038/313284a0; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FLORENCE B, 1991, MOL CELL BIOL, V11, P3613, DOI 10.1128/MCB.11.7.3613; FROHMAN MA, 1990, AMPLIFICATIONS, V5, P11; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HAMA C, 1990, GENE DEV, V4, P1079, DOI 10.1101/gad.4.7.1079; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HAYNIE JL, 1986, J EXP ZOOL, V237, P293, DOI 10.1002/jez.1402370302; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; HIDALGO A, 1990, DEVELOPMENT, V110, P291; HOLLAND EC, 1984, P NATL ACAD SCI-BIOL, V81, P7338, DOI 10.1073/pnas.81.23.7338; HOLMGREN R, 1981, P NATL ACAD SCI-BIOL, V78, P3775, DOI 10.1073/pnas.78.6.3775; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; HOWARD K, 1986, CELL, V44, P949, DOI 10.1016/0092-8674(86)90018-8; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; IVES B, 1950, DROS INF SERV, V24, P58; JOYNER AL, 1985, CELL, V43, P29, DOI 10.1016/0092-8674(85)90009-1; JURGENS G, 1986, ROUX ARCH DEV BIOL, V195, P359, DOI 10.1007/BF00402870; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KARPEN G, 1992, IN PRESS GENETICS; KASSIS JA, 1990, GENE DEV, V4, P433, DOI 10.1101/gad.4.3.433; KEITH TP, 1987, GENETICS, V116, P67; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; KORNBERG T, 1981, P NATL ACAD SCI-BIOL, V78, P1095, DOI 10.1073/pnas.78.2.1095; KORNFELD K, 1989, GENE DEV, V3, P243, DOI 10.1101/gad.3.2.243; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; KYTE J, 1982, J MOL BIOL, V157, P133; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY SJ, 1991, TRENDS BIOCHEM SCI, V16, P159, DOI 10.1016/0968-0004(91)90060-9; LANGERSAFER PR, 1982, P NATL ACAD SCI-BIOL, V79, P4381, DOI 10.1073/pnas.79.14.4381; LIMBOURGBOUCHON B, 1991, DEVELOPMENT, V112, P417; LIS JT, 1983, CELL, V35, P403, DOI 10.1016/0092-8674(83)90173-3; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MLODZIK M, 1992, METHODS NEUROSCIENCE, V9, P397; MOHLER J, 1988, GENETICS, V120, P1061; MORATA G, 1979, DEV BIOL, V70, P355, DOI 10.1016/0012-1606(79)90033-2; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; OHARE K, 1983, CELL, V34, P25, DOI 10.1016/0092-8674(83)90133-2; PANKRATZ MJ, 1990, TRENDS GENET, V6, P287, DOI 10.1016/0168-9525(90)90234-W; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PEIFER M, 1991, DEVELOPMENT, V111, P1029; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; PHILLIPS RG, 1990, DEVELOPMENT, V110, P105; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; PREAT T, 1990, NATURE, V347, P87, DOI 10.1038/347087a0; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; ROOP DR, 1978, CELL, V15, P671, DOI 10.1016/0092-8674(78)90035-1; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER C, 1984, NATURE, V311, P675, DOI 10.1038/311675b0; SCHROTH GP, 1992, J BIOL CHEM, V267, P11846; SCHUBIGER G, 1971, DEV BIOL, V26, P277, DOI 10.1016/0012-1606(71)90127-8; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SPIESS M, 1986, CELL, V44, P177, DOI 10.1016/0092-8674(86)90496-4; STEIN J, 1990, BLOOD, V76, P1308, DOI 10.1182/blood.V76.7.1308.bloodjournal7671308; STEINER E, 1976, ROUX ARCH DEV BIOL, V180, P9, DOI 10.1007/BF00848882; STRUBIN M, 1984, EMBO J, V3, P869, DOI 10.1002/j.1460-2075.1984.tb01898.x; TARTOF KD, 1991, CELL, V65, P201, DOI 10.1016/0092-8674(91)90153-P; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TURNER FR, 1979, DEV BIOL, V68, P96, DOI 10.1016/0012-1606(79)90246-X; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VINCENT JP, 1992, CELL, V68, P923, DOI 10.1016/0092-8674(92)90035-B; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALLACE JC, 1992, COMPUT APPL BIOSCI, V8, P249; WEIR MP, 1985, NATURE, V318, P433, DOI 10.1038/318433a0; Wieschaus E., 1986, P199; WILKINS AS, 1991, DEV BIOL, V145, P1, DOI 10.1016/0012-1606(91)90208-K	101	502	527	2	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 2	1992	71	1					33	50		10.1016/0092-8674(92)90264-D	http://dx.doi.org/10.1016/0092-8674(92)90264-D			18	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1394430				2022-12-28	WOS:A1992JQ62300005
J	DAVIDSON, JAH; BOOM, SJ				DAVIDSON, JAH; BOOM, SJ			WARMING LIGNOCAINE TO REDUCE PAIN ASSOCIATED WITH INJECTION	BRITISH MEDICAL JOURNAL			English	Article							LOCAL-ANESTHETIC SOLUTIONS; TEMPERATURE	Objective-To investigate the effect of warming lignocaine on the pain associated with subcutaneous injection. Design-Double blind, randomised, crossover study. Setting-Hospital clinic. Subjects-40 healthy volunteers. Interventions-Subcutaneous injection with 1 ml of 1% lignocaine at 20-degrees-C and 1 ml of 1% lignocaine at 37-degrees-C. Main outcome measures-Pain assessed by linear analogue pain scores and subjects' comparison of pain on injection. Results-25 subjects (89%; 95% confidence interval 72% to 98%) thought that lignocaine at 20-degrees-C was more painful and 3 (11%; 2% to 28%) thought that lignocaine at 37-degrees-C was more painful (p<0.0001); 12 subjects did not express a difference. Median pain score for injection at 20-degrees-C was 11.00 and at 37-degrees-C was 3.25 (p<0.001). Median difference was 8.25 (4.00 to 13.50). Conclusions-The simple procedure of warming to 37-degrees-C reduced the pain associated with subcutaneous injection of lignocaine.			DAVIDSON, JAH (corresponding author), WESTERN INFIRM & ASSOCIATED HOSP,DEPT ANAESTHESIA,CLIN SHOCK STUDY GRP,GLASGOW G11 6NT,SCOTLAND.							BAINBRIDGE LC, 1991, BRIT J PLAST SURG, V44, P147, DOI 10.1016/0007-1226(91)90050-T; Boggia R, 1967, BR DENT J, V122, P287; BONHOMME L, 1987, Anesthesiology (Hagerstown), V67, pA279, DOI 10.1097/00000542-198709001-00279; CHRISTOPH RA, 1988, ANN EMERG MED, V17, P117, DOI 10.1016/S0196-0644(88)80293-2; CRAGG AH, 1988, AM J ROENTGENOL, V150, P1183, DOI 10.2214/ajr.150.5.1183; DALTON AM, 1989, ARCH EMERG MED, V6, P247; GARDNER MJ, 1989, CONFIDENCE INTERVAL; KAMAYA H, 1983, ANESTH ANALG, V62, P1025; KAPLAN PA, 1987, AM J ROENTGENOL, V148, P1291; MARTIN AJ, 1990, ANAESTHESIA, V45, P975, DOI 10.1111/j.1365-2044.1990.tb14636.x; MORRIS R, 1987, ANESTH ANALG, V66, P1180; MORRIS RW, 1984, ANAESTH INTENSIVE CA, V2, P113	12	56	56	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 12	1992	305	6854					617	618		10.1136/bmj.305.6854.617	http://dx.doi.org/10.1136/bmj.305.6854.617			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN698	1393074	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992JN69800017
J	WALD, NJ; KENNARD, A; DENSEM, JW; CUCKLE, HS; CHARD, T; BUTLER, L				WALD, NJ; KENNARD, A; DENSEM, JW; CUCKLE, HS; CHARD, T; BUTLER, L			ANTENATAL MATERNAL SERUM SCREENING FOR DOWNS-SYNDROME - RESULTS OF A DEMONSTRATION PROJECT	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PREGNANCY; AGE	Objectives-To assess the implementation of antenatal screening for Down's syndrome in practice, using individual risk estimates based on maternal age and the three serum markers: alpha-fetoprotein, unconjugated oestriol, and human chorionic gonadotrophin. Design-Demonstration project of Down's syndrome screening; women with a risk estimate at term of 1 in 250 or greater were classified as "screen positive" and offered diagnostic amniocentesis. Setting-Hospital and community antenatal clinics in four health districts in London. Subjects-12 603 women of all ages with singleton pregnancies seen between February 1989 and the end of May 1991, with follow up of the outcome of pregnancy completed to the end of 1991. Main outcome measures-Uptake of screening, detection rate for Down's syndrome, false positive rate, odds of being affected given a positive result, and uptake of amniocentesis in women with positive screening results, together with the costs of the screening programme. Results-The uptake of screening was 74%. The detection rate was 48% (12/25), and the false positive rate was 4.1%, consistent with results expected from previous work based on observational studies. There was a loss of detection due to thc selective use of ultrasound scans among women with positive screening results. One affected pregnancy occurred among 205 reclassified as negative; this illustrated the danger of false negatives occurring in this group and lends weight to the view that if an ultrasound estimate of gestational age is used it should be carried out routinely on all women rather than selectively among those with positive results. The estimated cost of avoiding the birth of a baby with Down's syndrome was about 38000 pounds, substantially less than the lifetime costs of care. Conclusion-Antenatal maternal serum screening for Down's syndrome is effective in practice and can be readily integrated into routine antenatal care. It is cost effective and performs better than selection for amniocentesis on the basis of maternal age alone.	ST BARTHOLOMEWS HOSP, DEPT REPROD PHYSIOL, LONDON EC1M 6EQ, ENGLAND; QUEEN ELIZABETH HOSP, REG CYTOGENET LAB, LONDON E2 8PS, ENGLAND	University of London; Queen Mary University London	WALD, NJ (corresponding author), ST BARTHOLOMEWS HOSP, COLL MED, WOLFSON INST PREVENT MED, DEPT ENVIRONM & PREVENT MED, LONDON EC1M 6BQ, ENGLAND.		Wald, Nicholas/AAY-2814-2021; Wald, Nicholas/AAY-8924-2021					[Anonymous], 1977, LANCET, V1, P1323; CUCKLE H, 1991, PRENATAL DIAG, V11, P29, DOI 10.1002/pd.1970110106; CUCKLE HS, 1987, BRIT J OBSTET GYNAEC, V94, P387, DOI 10.1111/j.1471-0528.1987.tb03115.x; GILL M, 1987, SOC SCI MED, V24, P725, DOI 10.1016/0277-9536(87)90109-2; HADDOW JE, IN PRESS N ENGL J ME; SHELDON TA, 1991, BRIT MED J, V302, P1133, DOI 10.1136/bmj.302.6785.1133; WALD NJ, 1992, BRIT J OBSTET GYNAEC, V99, P144, DOI 10.1111/j.1471-0528.1992.tb14474.x; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883; WALD NJ, IN PRESS PRENATAL DI	9	240	254	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 15	1992	305	6850					391	394		10.1136/bmj.305.6850.391	http://dx.doi.org/10.1136/bmj.305.6850.391			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK314	1382768	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992JK31400013
J	PRICE, DJ; GROVE, JR; CALVO, V; AVRUCH, J; BIERER, BE				PRICE, DJ; GROVE, JR; CALVO, V; AVRUCH, J; BIERER, BE			RAPAMYCIN-INDUCED INHIBITION OF THE 70-KILODALTON S6 PROTEIN-KINASE	SCIENCE			English	Article							PEPTIDYL-PROLYL ISOMERASE; IMMUNOSUPPRESSANT FK506; RIBOSOMAL PROTEIN-S6; DISTINCT; PHOSPHORYLATION; ACTIVATION; CELLS; PURIFICATION; CYCLOSPORINE; CYCLOPHILIN	The immunosuppressant rapamycin inhibited proliferation of the H4IIEC hepatoma cell line. Rapamycin, but not its structural analog FK506, also inhibited the basal and insulin-stimulated activity of the p70 ribosomal protein S6 kinase. By contrast, insulin stimulation of the p85 Rsk S6 kinase and mitogen-activated protein (MAP) kinase activity were unaffected by drug. Rapamycin treatment of COS cells transfected with recombinant p70 S6 kinase completely inhibited the appearance of the hyperphosphorylated form of p70 S6 kinase concomitant with the inhibition of enzyme activity toward 40S subunits. Thus, rapamycin inhibits a signal transduction element that is necessary for the activation of p70 S6 kinase and mitogenesis but unnecessary for activation of p85 Rsk S6 kinase or MAP kinase.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DIABET UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,MED SERV,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital			Calvo, Victor/L-5024-2014; Izquierdo, Manuel/D-2971-2017	Calvo, Victor/0000-0002-5913-7058; Bierer, Barbara/0000-0001-6448-8170; Izquierdo, Manuel/0000-0002-7701-1002	NCI NIH HHS [P01 CA39542] Funding Source: Medline; NIDDK NIH HHS [R01 DK17776] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA039542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017776] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN NG, 1990, J BIOL CHEM, V265, P11495; ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BANERJEE P, UNPUB; BARRETT CB, 1992, J BIOL CHEM, V267, P4408; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; CALVO V, IN PRESS P NATL ACAD; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; DUMONT FJ, 1990, J IMMUNOL, V144, P251; ERIKSON E, 1986, J BIOL CHEM, V261, P350; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GORDON J, 1982, CURR TOP CELL REGUL, V21, P89; GROVE JF, UNPUB; GROVE JR, 1991, MOL CELL BIOL, V11, P2159; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; JIN YJ, 1992, J BIOL CHEM, V26, P10942; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; KAY JE, 1991, IMMUNOLOGY, V72, P544; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; METCALFE SM, 1990, TRANSPLANTATION, V49, P798, DOI 10.1097/00007890-199004000-00028; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; NEMENOFF RA, 1986, ARCH BIOCHEM BIOPHYS, V245, P196, DOI 10.1016/0003-9861(86)90205-5; PRICE DJ, 1989, J BIOL CHEM, V264, P13825; PRICE DJ, 1990, P NATL ACAD SCI USA, V87, P7944, DOI 10.1073/pnas.87.20.7944; PRICE DJ, 1991, J BIOL CHEM, V266, P16821; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0	35	619	632	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 14	1992	257	5072					973	977		10.1126/science.1380182	http://dx.doi.org/10.1126/science.1380182			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH827	1380182				2022-12-28	WOS:A1992JH82700038
J	HULKS, G; THOMSON, NC				HULKS, G; THOMSON, NC			INHALED ATRIAL-NATRIURETIC-PEPTIDE AND ASTHMATIC AIRWAYS	BRITISH MEDICAL JOURNAL			English	Article							SMOOTH-MUSCLE; BRONCHODILATOR		WESTERN INFIRM & ASSOCIATED HOSP,DEPT RESP MED,GLASGOW G11 6NT,SCOTLAND					Thomson, Neil/0000-0003-1632-6630	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CHANEZ P, 1990, J ALLERGY CLIN IMMUN, V86, P321, DOI 10.1016/S0091-6749(05)80094-6; HULKS G, 1991, AM REV RESPIR DIS, V143, P778, DOI 10.1164/ajrccm/143.4_Pt_1.778; HULKS G, 1989, BRIT MED J, V299, P1081, DOI 10.1136/bmj.299.6707.1081; ISHII K, 1989, AM J PHYSIOL, V256, pC495, DOI 10.1152/ajpcell.1989.256.3.C495; ODONNELL M, 1985, PEPTIDES, V6, P597, DOI 10.1016/0196-9781(85)90159-7	5	20	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 2	1992	304	6835					1156	1156		10.1136/bmj.304.6835.1156	http://dx.doi.org/10.1136/bmj.304.6835.1156			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT232	1392795	Green Published, Bronze			2022-12-28	WOS:A1992HT23200024
J	KEMP, A; SIBERT, JR				KEMP, A; SIBERT, JR			DROWNING AND NEAR DROWNING IN CHILDREN IN THE UNITED-KINGDOM - LESSONS FOR PREVENTION	BRITISH MEDICAL JOURNAL			English	Article							5-YEAR TOTAL POPULATION; ACCIDENTS INVOLVING CHILDREN; SWIMMING POOLS; COUNTY; QUEENSLAND; 10-YEAR	Objectives - To determine the pattern of drowning and near drowning of children in Britain and identify means of prevention. Design - Study of drowned and nearly drowned children under 15 years old. Setting - United Kingdom, 1988 and 1989. Subjects - Children under 15 years either drowning or admitted to hospital after a submersion incident. Main outcome measures - Number of nearly drowned children, obtained from consultant paediatricians returning monthly notification cards through the British Paediatric Surveillance Unit. Number of drowned children notified by the Office of Population Censuses and Surveys and other national epidemiological offices; information from coroners. Results - 306 children had confirmed submersion incidents: 149 died and 157 survived after near drowning. The annual incidence in England and Wales was 1.5/100 000, and mortality 0.7/100 000. Mortality was lowest in public pools 6% (2/32) and highest in rivers, canals, and lakes (78%, 56/73). Most of the children (263, 83%) were unsupervised at the time of the accident. 208 (68%) children were under 5 years old. Conclusions - Drowning and near drowning of children are problems in the British Isles. Appropriate supervision and safety barriers seem important for preventing such accidents. Improving information on dangers of drowning given to parents through the child surveillance programmes, encouraging fencing or draining of garden ponds and domestic swimming pools, and increasing supervision of swimming in lakes, rivers, and beaches should reduce the number of accidents.	UNIV WALES COLL CARDIFF,LANSDOWNE HOSP,COLL MED,DEPT CHILD HLTH,COMMUNITY UNIT,CARDIFF CF1 8UL,WALES	Cardiff University								[Anonymous], 1974, HLTH SAFETY WORK ACT; BARRY W, 1982, BRIT MED J, V285, P542, DOI 10.1136/bmj.285.6341.542; COLVER AF, 1982, BMJ, V285, P1117; CONN AW, 1984, CAN ANAESTH SOC J, V31, P538; HEYWARD K, 1991, HLTH SAFETY STANDARD; KEMP AM, 1991, BRIT MED J, V302, P931, DOI 10.1136/bmj.302.6782.931; LANGLEY J, 1983, COMMUNITY HEALTH ST, V7, P285; MILLINER N, 1980, MED J AUSTRALIA, V2, P510; NIXON J, 1986, ACCIDENT ANAL PREV, V18, P199, DOI 10.1016/0001-4575(86)90003-5; OCARROLL PW, 1988, JAMA-J AM MED ASSOC, V260, P380, DOI 10.1001/jama.260.3.380; ORLOWSKI JP, 1989, PEDIATRICS, V83, P1065; PATRICK M, 1979, MED J AUSTRALIA, V1, P61, DOI 10.5694/j.1326-5377.1979.tb111997.x; PEARN J, 1977, MED J AUSTRALIA, V2, P702, DOI 10.5694/j.1326-5377.1977.tb99227.x; PEARN J, 1976, MED J AUSTRALIA, V2, P942, DOI 10.5694/j.1326-5377.1976.tb115532.x; PEARN JH, 1979, AM J PUBLIC HEALTH, V69, P450, DOI 10.2105/AJPH.69.5.450; QUAN L, 1989, PEDIATRICS, V83, P1035; SIBERT JR, 1991, ARCH DIS CHILD, V66, P890, DOI 10.1136/adc.66.7.890; SIBERT JR, 1987, PRACTITIONER, V232, P439; 1988, MORTALITY STATISTICS; 1985, MMWR, V34, P218; 1983, DROWNING UK; 1990, BEACH SAFETY PRESS P; 1991, HOLIDAY WHICH   0108, P30; 1988, SAFETY SWIMMING POOL	24	51	51	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 2	1992	304	6835					1143	1146		10.1136/bmj.304.6835.1143	http://dx.doi.org/10.1136/bmj.304.6835.1143			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT232	1392791	Bronze, Green Published			2022-12-28	WOS:A1992HT23200019
J	FALL, CHD; BARKER, DJP; OSMOND, C; WINTER, PD; CLARK, PMS; HALES, CN				FALL, CHD; BARKER, DJP; OSMOND, C; WINTER, PD; CLARK, PMS; HALES, CN			RELATION OF INFANT-FEEDING TO ADULT SERUM-CHOLESTEROL CONCENTRATION AND DEATH FROM ISCHEMIC-HEART-DISEASE	BRITISH MEDICAL JOURNAL			English	Article							PLASMA; LIFE; DIET; METABOLISM; MORTALITY; CHILDREN; WEIGHT; MILK; AGE	Objective - To examine whether method of infant feeding is associated with adult serum lipid concentrations and mortality from ischaemic heart disease. Design - Follow up study of men born during 1911-30. Setting - Hertfordshire, England. Subjects - 5718 men, for 5471 of whom information on infant feeding had been recorded by health visitors and 1314 of whom had died. 485 of the men born during 1920-30 and still living in Hertfordshire who had blood lipid measurements. Main outcome measures - Death from ischaemic heart disease; serum cholesterol and apolipoprotein concentrations. Results - 474 men had died from ischaemic heart disease. Standardised mortality ratios were 97 (95% confidence interval 81 to 115) in men who had been breast fed and had not been weaned at 1 year, 79 (69 to 90) in breast fed men who had been weaned at 1 year, and 73 (59 to 89) in men who had been breast and bottle fed. Compared with men weaned before one year men not weaned had higher mean serum concentrations of total cholesterol (6-9 (not weaned) v 6.6 (weaned) mmol/l), low density lipoprotein cholesterol (5.0 v 4.6 mmol/l) and apolipoprotein B (1.14 v 1.08 g/l). Men who had been bottle fed also had a high standardised mortality ratio for ischaemic heart disease (95; 68 to 130) and high mean serum concentrations of total cholesterol (7.0 mmol/l), low density lipoprotein cholesterol (5.1 mmol/l), and apolipoprotein B (1.14 g/l). In all feeding groups serum apolipoprotein B concentrations were lower in men with higher birth weight and weight at 1 year. Conclusions - Age of weaning and method of infant feeding may influence adult serum low density lipoprotein cholesterol concentrations and mortality from ischaemic heart disease. Adult serum apolipoprotein B concentrations are related to growth in fetal life and infancy.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT CLIN BIOCHEM,CAMBRIDGE CB2 2QR,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	FALL, CHD (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON S09 4XY,ENGLAND.			Osmond, Clive/0000-0002-9054-4655				ALLAIN CC, 1974, CLIN CHEM, V20, P470; ANDERSEN GE, 1979, ACTA PAEDIATR SCAND, V68, P165, DOI 10.1111/j.1651-2227.1979.tb04983.x; [Anonymous], 1980, CLASSIFICATION OCCUP; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1992, BMJ-BRIT MED J, V304, P148, DOI 10.1136/bmj.304.6820.148; BARKER DJP, 1991, BRIT MED J, V303, P671, DOI 10.1136/bmj.303.6804.671; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BELTON NR, 1986, ACTA PAEDIATR SC   S, V323, P68; BERENSON GS, 1980, CARDIOVASCULAR RISK, P289; BERRY G, 1983, BIOMETRICS, V39, P173, DOI 10.2307/2530817; BHATNAGAR D, 1991, ANN CLIN BIOCHEM, V28, P427, DOI 10.1177/000456329102800501; BURNSIDE EM, 1915, BOUNTY MED OFFICER H, P41; CHAPIN HD, 1909, POSTGRADUATE NY, V24, P272; CHEDALD WB, 1906, ARTIFICIAL FEEDING F; DAGEN MM, 1991, ANN CLIN BIOCHEM, V28, P359, DOI 10.1177/000456329102800408; DARMADY JM, 1972, BMJ-BRIT MED J, V2, P685, DOI 10.1136/bmj.2.5815.685; FOMON SJ, 1984, PEDIATR RES, V18, P1233, DOI 10.1203/00006450-198412000-00001; FOMON SJ, 1960, AM MED ASS J DIS CHI, V99, P43; FOSSATI P, 1982, CLIN CHEM, V28, P2077; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FRIEDMAN G, 1975, AM J CLIN NUTR, V28, P42, DOI 10.1093/ajcn/28.1.42; HAHN P, 1976, NUTR REP INT, V13, P87; HAHN P, 1989, ATHEROSCLEROSIS PEDI; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HAMMONS JL, 1988, J PEDIATR GASTR NUTR, V7, P30, DOI 10.1097/00005176-198801000-00008; HASSAN AS, 1989, ATHEROSCLEROSIS PEDI, P221; HODGSON PA, 1976, METABOLISM, V25, P739, DOI 10.1016/0026-0495(76)90145-1; HUTTUNEN JK, 1983, ATHEROSCLEROSIS, V46, P87, DOI 10.1016/0021-9150(83)90167-3; KANNEL WB, 1978, FRAMINGHAM STUDY EPI; KOLDOVSKY O, 1987, J PEDIATR GASTR NUTR, V6, P172, DOI 10.1097/00005176-198703000-00004; LABARTHE DR, 1991, ANNU REV PUBL HEALTH, V12, P519, DOI 10.1146/annurev.pu.12.050191.002511; LIE RF, 1976, CLIN CHEM, V22, P1627; LOPESVIRELLA MF, 1977, CLIN CHEM, V23, P882; MARMOT MG, 1980, J EPIDEMIOL COMMUN H, V34, P164, DOI 10.1136/jech.34.3.164; MILLER GJ, 1986, ATHEROSCLEROSIS, V60, P269, DOI 10.1016/0021-9150(86)90174-7; MOTT GE, 1990, J NUTR, V120, P243, DOI 10.1093/jn/120.3.243; PATERSON D, 1930, CHANCE EVERY CHILD R, P22; SAARINEN UM, 1978, J PEDIATR-US, V93, P177, DOI 10.1016/S0022-3476(78)80490-9; SALTER AM, 1988, ATHEROSCLEROSIS, V71, P77, DOI 10.1016/0021-9150(88)90304-8; SPORIK R, 1991, ARCH DIS CHILD, V66, P134, DOI 10.1136/adc.66.1.134; SUBBIAH MTR, 1985, AM J PHYSIOL, V249, pE251, DOI 10.1152/ajpendo.1985.249.3.E251; VANBIERVLIET JP, 1986, EUR J PEDIATR, V144, P489, DOI 10.1007/BF00441745; WANG XL, 1991, PEDIATR RES, V30, P544, DOI 10.1203/00006450-199112000-00010; WHITEHEAD R, 1987, INFANT FEEDING CARDI, P1; WHITEHEAD RG, 1986, ACTA PAEDIATR SC   S, V323, P14; 1942, SERIES WOMEN PUBLIC, V2, P1	46	257	262	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1992	304	6830					801	805		10.1136/bmj.304.6830.801	http://dx.doi.org/10.1136/bmj.304.6830.801			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL827	1392706	Green Published, Bronze			2022-12-28	WOS:A1992HL82700018
J	GOLDMAN, E; MILLER, R; LEE, CA				GOLDMAN, E; MILLER, R; LEE, CA			COUNSELING HIV POSITIVE HEMOPHILIC MEN WHO WISH TO HAVE CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							INFECTION		ROYAL FREE HOSP,SCH MED,DEPT HAEMATOL,HAEMOSTASIS UNIT,LONDON NW3 2QG,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	GOLDMAN, E (corresponding author), ROYAL FREE HOSP,SCH MED,CTR HAEMOPHILIA,LONDON NW3 2QG,ENGLAND.							LEE CA, 1989, BRIT J HAEMATOL, V73, P228, DOI 10.1111/j.1365-2141.1989.tb00257.x; LEE CA, 1990, LANCET, V335, P425, DOI 10.1016/0140-6736(90)90273-8; 1991, BMJ, V303, P541; [No title captured]	4	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1992	304	6830					829	830		10.1136/bmj.304.6830.829	http://dx.doi.org/10.1136/bmj.304.6830.829			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HL827	1392714	Green Published, Bronze			2022-12-28	WOS:A1992HL82700028
J	SMALLEY, RV; ANDERSEN, JW; HAWKINS, MJ; BHIDE, V; OCONNELL, MJ; OKEN, MM; BORDEN, EC				SMALLEY, RV; ANDERSEN, JW; HAWKINS, MJ; BHIDE, V; OCONNELL, MJ; OKEN, MM; BORDEN, EC			INTERFERON ALFA COMBINED WITH CYTOTOXIC CHEMOTHERAPY FOR PATIENTS WITH NON-HODGKINS-LYMPHOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; HUMAN-LEUKOCYTE INTERFERON; COOPERATIVE-ONCOLOGY-GROUP; SINGLE-AGENT CHEMOTHERAPY; METASTATIC BREAST-CANCER; HAIRY-CELL LEUKEMIA; MALIGNANT-LYMPHOMA; MULTIPLE-MYELOMA; COMBINATION CHEMOTHERAPY; RECOMBINANT LEUKOCYTE	Background. Interferon alfa has been found to be effective as an antitumor agent (with a response rate of 30 percent) in patients with low-grade non-Hodgkin's lymphoma, but its effectiveness in those with intermediate-grade non-Hodgkin's lymphoma has been less adequately tested. In a prospective randomized study we evaluated the effectiveness of adding interferon alfa to cytotoxic chemotherapy in patients with clinically aggressive, low-grade non-Hodgkin's lymphoma and certain histologic variants of intermediate-grade non-Hodgkin's lymphoma, not including diffuse histiocytic lymphoma. Methods. The patients were randomly assigned to a regimen of cyclophosphamide, vincristine, prednisone, and doxorubicin or to this regimen combined with recombinant interferon alfa. Treatment was administered every four weeks, for 8 to 10 cycles. Results. The two regimens produced comparable objective responses, but the regimen including interferon had a greater effect in prolonging the time to treatment failure (P<0.001) and the duration of complete response (P = 0.03). Interferon alfa also had a greater effect on overall survival (P = 0.014) when the results were adjusted for important covariates. Conclusions. Interferon alfa, when added to a four-drug doxorubicin-based chemotherapy regimen, is an effective antitumor agent in patients with clinically aggressive low-grade or intermediate-grade non-Hodgkin's lymphoma.	UNIV WISCONSIN,CTR CLIN CANC,MADISON,WI 53706; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,CTR BIOSTAT,BOSTON,MA 02115; VIRGINIA PIPER CANC INST,MINNEAPOLIS,MN; GEORGETOWN UNIV,WASHINGTON,DC 20057; MAYO CLIN & MAYO FDN,ROCHESTER,MN 55905; MED COLL WISCONSIN,MILWAUKEE,WI 53226	University of Wisconsin System; University of Wisconsin Madison; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Georgetown University; Mayo Clinic; Medical College of Wisconsin	SMALLEY, RV (corresponding author), SYNERTRON INC,575 SCI DR,MADISON,WI 53711, USA.				NCI NIH HHS [CA-06594, CA-14548, CA-14958] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA014548, U10CA006594, U10CA014958] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON T, 1982, CANCER, V50, P2699, DOI 10.1002/1097-0142(19821215)50:12<2699::AID-CNCR2820501202>3.0.CO;2-A; BALKWILL FR, 1984, CANCER RES, V44, P904; Bishop YM., 2007, DISCRETE MULTIVARIAT; CABANILLAS F, 1979, CANCER, V44, P1983, DOI 10.1002/1097-0142(197912)44:6<1983::AID-CNCR2820440604>3.0.CO;2-4; CHIRIGOS MA, 1973, J NATL CANCER I, V51, P1367, DOI 10.1093/jnci/51.4.1367; CHISESI T, 1987, INVEST NEW DRUG, V5, pS35; CLARK RH, 1989, AM J CLIN ONCOL-CANC, V12, P75, DOI 10.1097/00000421-198902000-00017; Cox D. R., 1984, ANAL SURVIVAL DATA; EZDINLI EZ, 1985, J CLIN ONCOL, V3, P769, DOI 10.1200/JCO.1985.3.6.769; FOON KA, 1986, SEMIN ONCOL, V13, P35; FOON KA, 1984, NEW ENGL J MED, V311, P1148, DOI 10.1056/NEJM198411013111803; GALLAGHER CJ, 1986, J CLIN ONCOL, V4, P1470, DOI 10.1200/JCO.1986.4.10.1470; GAMS R, 1984, P AN M AM SOC CLIN, V3, P65; GRESSER I, 1976, INT J CANCER, V17, P647, DOI 10.1002/ijc.2910170514; GRESSER I, 1978, EUR J CANCER, V14, P97, DOI 10.1016/0014-2964(78)90143-3; GUTTERMAN JU, 1980, ANN INTERN MED, V93, P399, DOI 10.7326/0003-4819-93-3-399; HOPPE RT, 1981, BLOOD, V58, P592; HORNING SJ, 1985, CANCER-AM CANCER SOC, V56, P1305, DOI 10.1002/1097-0142(19850915)56:6<1305::AID-CNCR2820560614>3.0.CO;2-N; LEAVITT RD, 1985, DEV ONCOLOGY, V27, P57; LISTER TA, 1978, BRIT MED J, V1, P533, DOI 10.1136/bmj.1.6112.533; LOUIE AC, 1981, BLOOD, V58, P712; MANDELLI F, 1990, NEW ENGL J MED, V322, P1430, DOI 10.1056/NEJM199005173222005; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; MERIGAN TC, 1978, NEW ENGL J MED, V299, P1449, DOI 10.1056/NEJM197812282992608; MOWSHOWITZ SL, 1982, J INTERFERON RES, V2, P587, DOI 10.1089/jir.1982.2.587; OCONNELL MJ, 1986, J CLIN ONCOL, V4, P128, DOI 10.1200/JCO.1986.4.2.128; OCONNELL MJ, 1987, J CLIN ONCOL, V5, P1329, DOI 10.1200/JCO.1987.5.9.1329; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; OZER H, 1987, INVEST NEW DRUG, V5, pS27; QAZI R, 1976, CANCER, V37, P1923, DOI 10.1002/1097-0142(197604)37:4<1923::AID-CNCR2820370443>3.0.CO;2-D; QUESADA JR, 1984, NEW ENGL J MED, V310, P15, DOI 10.1056/NEJM198401053100104; QUESADA JR, 1984, AM J MED, V77, P427, DOI 10.1016/0002-9343(84)90097-4; ROHATINER AZS, 1987, BRIT J CANCER, V55, P225, DOI 10.1038/bjc.1987.42; SCHILLER JH, 1989, J BIOL RESP MODIF, V8, P252; SLATER LM, 1981, CANCER, V48, P5, DOI 10.1002/1097-0142(19810701)48:1<5::AID-CNCR2820480103>3.0.CO;2-C; SMALLEY RV, 1991, BLOOD, V78, P3133; SOLALCELIGNY P, 1991, P AN M AM SOC CLIN, V10, P275; STEWARD WP, 1988, CANCER-AM CANCER SOC, V61, P441, DOI 10.1002/1097-0142(19880201)61:3<441::AID-CNCR2820610306>3.0.CO;2-N; STRAUS DJ, 1987, AM J MED, V82, P247, DOI 10.1016/0002-9343(87)90064-7; SULLIVAN KM, 1983, BLOOD, V62, P51; VANDERMOLEN LA, 1990, JNCI-J NATL CANCER I, V82, P235, DOI 10.1093/jnci/82.3.235; WAGSTAFF J, 1986, CANCER CHEMOTH PHARM, V18, P54, DOI 10.1007/BF00253065; WAGSTAFF K, 1985, DEV ONCOLOGY, V27, P51	43	179	182	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 5	1992	327	19					1336	1341		10.1056/NEJM199211053271902	http://dx.doi.org/10.1056/NEJM199211053271902			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW077	1406835	Bronze			2022-12-28	WOS:A1992JW07700002
J	LANGE, PH				LANGE, PH			IS THE PROSTATE PILL FINALLY HERE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											LANGE, PH (corresponding author), UNIV WASHINGTON,SCH MED,SEATTLE,WA 98195, USA.							BRAWER MK, 1992, J UROLOGY, V147, P841, DOI 10.1016/S0022-5347(17)37401-3; FAIR W R, 1991, Journal of Urology, V145, p317A; GORMLEY GJ, 1992, NEW ENGL J MED, V327, P1185, DOI 10.1056/NEJM199210223271701; KAFKA F, 1919, LANDARZT; LEPOR H, 1992, J UROL S, V147, pA365; MCCONNELL JD, 1992, CAMPBELLS UROLOGY, P1; TENOVER JS, 1991, ENDOCRIN METAB CLIN, V20, P893, DOI 10.1016/S0889-8529(18)30249-4; THIGPEN AE, 1992, NEW ENGL J MED, V327, P1216, DOI 10.1056/NEJM199210223271706	8	11	12	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 22	1992	327	17					1234	1236		10.1056/NEJM199210223271709	http://dx.doi.org/10.1056/NEJM199210223271709			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JU393	1383817				2022-12-28	WOS:A1992JU39300009
J	EYSMANN, SB; DOUGLAS, PS				EYSMANN, SB; DOUGLAS, PS			REPERFUSION AND REVASCULARIZATION STRATEGIES FOR CORONARY-ARTERY DISEASE IN WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; BYPASS-SURGERY; LONG-TERM; CONSECUTIVE PATIENTS; OPERATIVE MORTALITY; RANDOMIZED TRIAL; REDUCED EFFICACY; SEX-DIFFERENCES; HEART-DISEASE; FOLLOW-UP	Objective.-One third of all deaths in women in the United States each year are attributable to coronary heart disease. Gender differences exist in the course and management of patients with coronary heart disease. Few randomized trials have been conducted in women to evaluate effective therapeutic strategies. With the aim of developing rational approaches to women with coronary heart disease, we review gender-related outcomes with coronary revascularization and reperfusion therapies. Data Source.-English-language journal articles and reviews on the subject of women with coronary heart disease or gender-specific responses to coronary heart disease management, from 1970 through 1992, identified through MEDLINE searching. Study Selection.-Selected studies included only randomized controlled trials for topics related to thrombolysis, and articles considered to contribute significantly to the topic of women with coronary artery disease in the case of angioplasty and coronary artery bypass grafting. Data Extraction.-Two reviewers participated in extracting the data with the aim of presenting a balanced and comprehensive review of the subject. Data Synthesis.-Thrombolysis in acute myocardial infarction reduces mortality in men and women, although women may have a reduced mortality benefit compared with men. Angioplasty and the newer interventional devices result in greater procedural morbidity but similar if not better long-term outcomes in women. Women may have a greater mortality rate than men with coronary artery bypass surgery, although studies suggest that outcome after bypass surgery may depend more on coronary size and preoperative risk factors than on gender itself. Conclusions.-The existence of gender differences in the course of coronary heart disease and response to revascularization and reperfusion strategies suggests the need for unique clinical approaches to the female patient with coronary heart disease and stresses the importance of developing randomized trials that enroll adequate numbers of women and that are designed to answer gender-specific questions.	BETH ISRAEL HOSP, DIV CARDIOL, 330 BROOKLINE AVE, BOSTON, MA 02215 USA; HARVARD UNIV, BETH ISRAEL HOSP, THORNDIKE LAB, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center				Douglas, Pamela/0000-0001-9876-4049				[Anonymous], 1987, Lancet, V2, P871; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1971, Br Med J, V3, P325; ARORA RR, 1990, CATHETER CARDIO DIAG, V19, P17, DOI 10.1002/ccd.1810190106; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BECKER RC, 1990, CARDIOLOGY, V77, P110, DOI 10.1159/000174659; BICKELL NA, 1992, ANN INTERN MED, V116, P791, DOI 10.7326/0003-4819-116-10-791; Bobbio M, 1991, J Invasive Cardiol, V3, P214; BOLOOKI H, 1975, J THORAC CARDIOV SUR, V69, P271; BOVILL EG, 1991, ANN INTERN MED, V115, P256, DOI 10.7326/0003-4819-115-4-256; CALIFF RM, 1991, J AM COLL CARDIOL, V17, pB2; CARROZZA JP, 1992, J AM COLL CARDIOL, V20, P328, DOI 10.1016/0735-1097(92)90098-8; CASALE P N, 1992, Journal of the American College of Cardiology, V19, p94A; CHESEBRO JH, 1982, NEW ENGL J MED, V307, P73, DOI 10.1056/NEJM198207083070201; COWLEY MJ, 1985, CIRCULATION, V71, P90, DOI 10.1161/01.CIR.71.1.90; COWLEY MJ, 1987, CORONARY HEART DISEA, P251; DAVIS KB, 1987, CORONARY HEART DISEA, P247; DITTRICH H, 1988, AM J CARDIOL, V62, P1, DOI 10.1016/0002-9149(88)91356-2; DOUGLAS JS, 1981, CIRCULATION, V64, P11; EAKER ED, 1989, AM HEART J, V117, P71, DOI 10.1016/0002-8703(89)90658-3; ELLIS S, 1990, TXB INTERVENTIONAL C, P199; FIEBACH NH, 1990, JAMA-J AM MED ASSOC, V263, P1092, DOI 10.1001/jama.263.8.1092; FISHER LD, 1982, J THORAC CARDIOV SUR, V84, P334; FISHMAN RF, IN PRESS J AM COLL C; FISHMAN RF, IN PRESS CIRCULATION; FRESCO C, 1990, CLIN CARDIOL, V13, P32; Frid DJ, 1990, TXB INTERVENTIONAL C, P363; GARDNER TJ, 1985, ANN SURG, V201, P780, DOI 10.1097/00000658-198506000-00016; GOLDING L R, 1976, Cleveland Clinic Quarterly, V43, P113; GREENLAND P, 1991, CIRCULATION, V83, P484, DOI 10.1161/01.CIR.83.2.484; HALL RJ, 1983, CIRCULATION, V68, P20; Henning R., 1975, ACTA MED SCAND, V586, P27; HOLLMAN J, 1989, CLEV CLIN J MED, V56, P517, DOI 10.3949/ccjm.56.5.517; HOLMES DR, 1988, J AM COLL CARDIOL, V12, P1149, DOI 10.1016/0735-1097(88)92593-4; JOHNSON WD, 1984, AM HEART J, V108, P1190, DOI 10.1016/0002-8703(84)90741-5; KANNEL WB, 1979, AM J CARDIOL, V44, P53, DOI 10.1016/0002-9149(79)90250-9; KENNEDY JW, 1985, NEW ENGL J MED, V312, P1073, DOI 10.1056/NEJM198504253121701; KENNEDY JW, 1980, J THORAC CARDIOV SUR, V80, P876; KENNEDY JW, 1988, CIRCULATION, V77, P345, DOI 10.1161/01.CIR.77.2.345; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; KHAN SS, 1991, CARDIOL BOARD REV, V8, P54; KILLEN DA, 1982, ANN THORAC SURG, V34, P559, DOI 10.1016/S0003-4975(10)63003-2; KRUMHOLZ HM, 1992, ANN INTERN MED, V116, P785, DOI 10.7326/0003-4819-116-10-785; LAIRDMEETER K, 1984, EUR HEART J, V5, P35, DOI 10.1093/oxfordjournals.eurheartj.a061549; LOOP FD, 1986, NEW ENGL J MED, V314, P1, DOI 10.1056/NEJM198601023140101; LOOP FD, 1983, J AM COLL CARDIOL, V1, P383, DOI 10.1016/S0735-1097(83)80064-3; LOOP FD, 1977, AM J CARDIOL, V39, P516, DOI 10.1016/S0002-9149(77)80160-4; MAGGIONI AP, 1992, NEW ENGL J MED, V327, P1, DOI 10.1056/NEJM199207023270101; MAYNARD C, 1991, AM J CARDIOL, V68, P529, DOI 10.1016/0002-9149(91)90791-I; MAYNARD C, 1992, ARCH INTERN MED, V152, P972, DOI 10.1001/archinte.152.5.972; MCENIERY PT, 1987, CATHETER CARDIO DIAG, V13, P364, DOI 10.1002/ccd.1810130602; MYERS WO, 1985, ANN THORAC SURG, V40, P245, DOI 10.1016/S0003-4975(10)60037-9; PETER T, 1978, MED J AUSTRALIA, V1, P189, DOI 10.5694/j.1326-5377.1978.tb107829.x; PULETTI M, 1984, AM HEART J, V108, P63, DOI 10.1016/0002-8703(84)90545-3; RICHARDSON JV, 1986, ANN THORAC SURG, V42, pS16, DOI 10.1016/S0003-4975(10)64635-8; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; TOBIN JN, 1987, ANN INTERN MED, V107, P19, DOI 10.7326/0003-4819-107-1-19; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; TOPOL EJ, 1988, J AM COLL CARDIOL, V12, pA24, DOI 10.1016/0735-1097(88)92638-1; TYRAS DH, 1978, ANN THORAC SURG, V25, P449, DOI 10.1016/S0003-4975(10)63583-7; WILCOX RG, 1988, LANCET, V2, P525; 1988, LANCET, V1, P349	62	36	36	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1992	268	14					1903	1907		10.1001/jama.268.14.1903	http://dx.doi.org/10.1001/jama.268.14.1903			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR439	1404716				2022-12-28	WOS:A1992JR43900041
J	KENDLER, KS; HEATH, AC; NEALE, MC; KESSLER, RC; EAVES, LJ				KENDLER, KS; HEATH, AC; NEALE, MC; KESSLER, RC; EAVES, LJ			A POPULATION-BASED TWIN STUDY OF ALCOHOLISM IN WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ENVIRONMENTAL-FACTORS; DEPRESSION; GENETICS; SCHIZOPHRENIA; TRANSMISSION; INHERITANCE; SIMILARITY; CONTACT; MODELS; LISREL	Objective.-To clarify the role of genetic factors in the etiology of alcoholism in women. Design and Setting.-Personal structured psychiatric interviews conducted by researchers "blinded" to the status of the co-twin in an epidemiologic sample of 1030 female-female twin pairs of known zygosity from the population-based Virginia Twin Registry. Measures.-Three definitions of lifetime prevalence of alcoholism based on Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised criteria: (1) alcoholism with tolerance or dependence; (2) alcoholism with or without tolerance-dependence; and (3) alcoholism with or without tolerance-dependence or problem drinking. Results.-Using narrow, intermediate, or broad definitions, the probandwise concordance for alcoholism was consistently higher in monozygotic than in dizygotic twin pairs. Multifactorial threshold models suggested that the heritability of liability to alcoholism in women is in the range of 50% to 60%. Conclusions.-The results support the hypothesis that genetic factors play a major role in the etiology of alcoholism in women. Women should be well represented in the efforts currently under way to elucidate the molecular basis of the genetic susceptibility to alcoholism.	WASHINGTON UNIV,SCH MED,DEPT PSYCHIAT,ST LOUIS,MO 63110; UNIV MICHIGAN,INST SOCIAL RES,ANN ARBOR,MI 48109; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT HUMAN GENET,RICHMOND,VA 23298	Washington University (WUSTL); University of Michigan System; University of Michigan; Virginia Commonwealth University	KENDLER, KS (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PSYCHIAT,BOX 710,RICHMOND,VA 23298, USA.		Kendler, Kenneth/AAF-2876-2019; Neale, Michael C/B-1418-2008; Neale, Michael/AAD-5056-2020		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH040828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009095] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA-09095] Funding Source: Medline; NICHD NIH HHS [HD-26746] Funding Source: Medline; NIMH NIH HHS [MH-40828] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AKAIKE H, 1987, PSYCHOMETRIKA, V52, P317, DOI 10.1007/BF02294359; BEARDSLEE WR, 1986, BRIT J PSYCHIAT, V149, P584, DOI 10.1192/bjp.149.5.584; BOHMAN M, 1981, ARCH GEN PSYCHIAT, V38, P965; BROMET EJ, 1986, ARCH GEN PSYCHIAT, V43, P435; CADORET RJ, 1985, ARCH GEN PSYCHIAT, V42, P161, DOI 10.1001/archpsyc.1985.01790250055007; CLONINGER CR, 1991, JAMA-J AM MED ASSOC, V266, P1833; CLONINGER CR, 1981, ARCH GEN PSYCHIAT, V38, P861; CLONINGER CR, 1988, ALCOHOLISM ORIGINS O; DEVOR EJ, 1989, ANNU REV GENET, V23, P19, DOI 10.1146/annurev.ge.23.120189.000315; Eaves L, 1989, GENES CULTURE PERSON; FALCONER DS, 1965, ANN HUM GENET, V29, P51, DOI 10.1111/j.1469-1809.1965.tb00500.x; GOODWIN DW, 1977, ARCH GEN PSYCHIAT, V34, P751; GOODWIN DW, 1973, ARCH GEN PSYCHIAT, V28, P238; GURLING HMD, 1984, ACTA GENET MED GEMEL, V33, P333, DOI 10.1017/S0001566000007376; HEATH AC, 1989, BEHAV GENET, V19, P9, DOI 10.1007/BF01065881; HELLER RF, 1988, GENET EPIDEMIOL, V5, P311, DOI 10.1002/gepi.1370050503; HELZER JE, 1991, PSYCHIATRIC DISORDER; HOLDEN C, 1991, SCIENCE, V251, P163, DOI 10.1126/science.1824800; HOLMES SJ, 1988, PSYCHIATRY, V51, P24, DOI 10.1080/00332747.1988.11024377; HRUBEC Z, 1981, ALCOHOL CLIN EXP RES, V5, P207, DOI 10.1111/j.1530-0277.1981.tb04890.x; Joreskog K. G., 1989, LISREL 7 GUIDE PROGR; Joreskog KG, 1986, PRELIS PREPROCESSOR; KAIJ L, 1960, ALCOHOLISM TWINS; KENDLER KS, 1992, ARCH GEN PSYCHIAT, V49, P257; KENDLER KS, 1986, ARCH GEN PSYCHIAT, V43, P213; KENDLER KS, 1983, AM J PSYCHIAT, V140, P1551; KENDLER KS, 1983, AM J PSYCHIAT, V140, P1413; KENDLER KS, 1986, ANN HUM GENET, V50, P83, DOI 10.1111/j.1469-1809.1986.tb01941.x; LELAND J, 1982, GENDER PSYCHOPATHOLO; Loehlin J., 1976, HEREDITY ENV PERSONA, DOI DOI 10.7560/730038; LYKKEN DT, 1990, BEHAV GENET, V20, P547, DOI 10.1007/BF01065871; MARTIN NG, 1978, HEREDITY, V40, P97, DOI 10.1038/hdy.1978.10; MCGUE M, 1992, J ABNORM PSYCHOL, V101, P3, DOI 10.1037/0021-843X.101.1.3; MCGUFFIN P, 1989, BRIT J PSYCHIAT, V155, P294, DOI 10.1192/bjp.155.3.294; MERIKANGAS KR, 1990, PSYCHOL MED, V20, P11, DOI 10.1017/S0033291700013192; MORRISYATES A, 1990, ACTA PSYCHIAT SCAND, V81, P322, DOI 10.1111/j.1600-0447.1990.tb05457.x; NEALE MC, 1989, BEHAV GENET, V19, P37, DOI 10.1007/BF01065882; NEALE MC, 1991, STATISTICAL MODELLIN; PARSIAN A, 1991, ARCH GEN PSYCHIAT, V48, P655; PEARSON K, 1901, P R SOC, V66, P241; PICKENS RW, 1991, ARCH GEN PSYCHIAT, V48, P19; REICH T, 1988, ALCOHOL CLIN EXP RES, V12, P458, DOI 10.1111/j.1530-0277.1988.tb00227.x; REICH T, 1972, ANN HUM GENET, V36, P163, DOI 10.1111/j.1469-1809.1972.tb00767.x; ROSE RJ, 1990, BEHAV GENET, V20, P763, DOI 10.1007/BF01065919; SPENCE J E, 1988, American Journal of Human Genetics, V43, pA159; Spitzer R. L., 1987, STRUCTURED CLIN INTE; WANBERG KW, 1970, Q J STUD ALCOHOL, V31, P40; ZUCKER RA, 1986, AM PSYCHOL, V41, P783, DOI 10.1037/0003-066X.41.7.783; 1987, DIAGNOSTIC STATISTIC; 1985, SAS USERS GUIDE STAT	50	344	347	1	20	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1992	268	14					1877	1882		10.1001/jama.268.14.1877	http://dx.doi.org/10.1001/jama.268.14.1877			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JR439	1404711				2022-12-28	WOS:A1992JR43900036
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FDA PROPOSES TO PROHIBIT 415 INGREDIENTS FROM OTC DRUG PRODUCTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1992	268	14					1828	1828		10.1001/jama.268.14.1828	http://dx.doi.org/10.1001/jama.268.14.1828			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR439	1404696				2022-12-28	WOS:A1992JR43900009
J	SPECTOR, SL				SPECTOR, SL			ORAL STEROID-THERAPY FOR ASTHMA AND CONTACT-DERMATITIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											SPECTOR, SL (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA 90024, USA.							EPSTEIN E, 1973, CUTIS, V12, P47; FISHER AA, 1973, CONTACT DERMATITIS, P10; SPECTOR SL, 1985, CHEST, V87, pS73; SPECTOR SL, 1989, ANN ALLERGY, V63, P591	4	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1992	268	14					1926	1926						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR439	1404722				2022-12-28	WOS:A1992JR43900046
J	SABIN, JE				SABIN, JE			MIND THE GAP - REFLECTIONS OF AN AMERICAN HEALTH MAINTENANCE ORGANIZATION DOCTOR ON THE NEW NHS	BRITISH MEDICAL JOURNAL			English	Article											SABIN, JE (corresponding author), HARVARD COMMUNITY HLTH PLAN,CTR TEACHING,BOSTON,MA 02215, USA.							DOYAL L, 1991, B MED ETH, P19; KLEIN R, 1991, BRIT MED J, V303, P259, DOI 10.1136/bmj.303.6797.259; KLEIN R, 1989, POLITICS NATIONAL HL, P197; KLEIN R, 1990, HLTH CARE PROVISION, P127; MARIKER M, 1990, HLTH CARE PROVISION, P141; OSULLIVAN J, 1992, INDEPENDENT     0308, P9; OSULLIVAN J, 1992, INDEPENDENT     0417, P7; SCHWARTZ R, 1985, HASTINGS CENT REP, V15, P19, DOI 10.2307/3561380; SMITH R, 1991, BRIT MED J, V303, P1561, DOI 10.1136/bmj.303.6817.1561; 1991, PATIENTS CHARTER; 1991, AIMING BEST HLTH, P4; 1988, PHILOS PRACTICE MED, P72	12	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 29	1992	305	6852					514	516		10.1136/bmj.305.6852.514	http://dx.doi.org/10.1136/bmj.305.6852.514			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL609	1393000	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992JL60900024
J	VANDERWINDEN, JM; MAILLEUX, P; SCHIFFMANN, SN; VANDERHAEGHEN, JJ; DELAET, MH				VANDERWINDEN, JM; MAILLEUX, P; SCHIFFMANN, SN; VANDERHAEGHEN, JJ; DELAET, MH			NITRIC-OXIDE SYNTHASE ACTIVITY IN INFANTILE HYPERTROPHIC PYLORIC-STENOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEURONAL NADPH-DIAPHORASE; INHIBITORY TRANSMISSION; NERVOUS-SYSTEM; 2ND MESSENGER; GUINEA-PIG; MUSCLE; INVOLVEMENT; PEPTIDE; BRAIN; NO	Background. Hypertrophic pyloric stenosis is a common infantile disorder characterized by enlarged pyloric musculature and gastric-outlet obstruction. Its physiopathologic mechanism is not known, but a defect in pyloric relaxation (pylorospasm) has been postulated. Nitric oxide is a mediator of relaxation in the mammalian digestive tract, raising the possibility that pylorospasm could be caused by a defect in nitric oxide production. Since neuronal nitric oxide synthase and NADPH diaphorase are identical, we used the NADPH diaphorase histochemical reaction to study the distribution of nitric oxide synthase in pyloric tissue from patients with infantile hypertrophic pyloric stenosis. Methods. We studied pyloric tissue from nine infants with infantile hypertrophic pyloric stenosis and seven control infants and children. Cryostat sections were processed for NADPH diaphorase histochemical analysis. A polyclonal tau antiserum was used to identify the enteric nervous system by immunohistochemical methods. Results. NADPH diaphorase activity was restricted to the enteric nervous system and blood vessels. In the pyloric tissues from the control patients, intense diaphorase activity was present in the nerve fibers of the circular musculature, in the neurons and nerve bundles of the myenteric plexus, and in some nerve fibers of the longitudinal musculature. In the pyloric tissues from patients with infantile hypertrophic pyloric stenosis, the enteric nerve fibers in the hypertrophied circular musculature were enlarged and distorted and did not contain diaphorase activity, whereas the activity in the myenteric plexus and the longitudinal musculature was preserved. Conclusions. We suggest that a lack of nitric oxide synthase in pyloric tissue is responsible for pylorospasm in infantile hypertrophic pyloric stenosis.	ERASME ACAD HOSP,DEPT SURG,BRUSSELS,BELGIUM; ERASME ACAD HOSP,NEUROPATHOL & NEUROPEPTIDE RES LAB,BRUSSELS,BELGIUM; FREE UNIV BRUSSELS,CHILDRENS HOSP,DEPT PEDIAT SURG,B-1050 BRUSSELS,BELGIUM; UNIV LIBRE BRUXELLES,FAC MED,B-1050 BRUSSELS,BELGIUM	Universite Libre de Bruxelles; Universite Libre de Bruxelles; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles				Schiffmann, Serge/0000-0002-0118-9816				BRANCHEK TA, 1989, J COMP NEUROL, V285, P262, DOI 10.1002/cne.902850208; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BRION JP, 1991, BIOCHEM J, V273, P127, DOI 10.1042/bj2730127; BULT H, 1990, NATURE, V345, P346, DOI 10.1038/345346a0; COLLIER J, 1989, TRENDS PHARMACOL SCI, V10, P427, DOI 10.1016/S0165-6147(89)80001-X; CROSSIN KL, 1991, TRENDS BIOCHEM SCI, V16, P81, DOI 10.1016/0968-0004(91)90036-U; DALZIEL HH, 1991, AM J PHYSIOL, V260, pG789, DOI 10.1152/ajpgi.1991.260.5.G789; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; DESAI KM, 1991, NATURE, V351, P477, DOI 10.1038/351477a0; DIELER R, 1990, ACTA NEUROPATHOL, V80, P295, DOI 10.1007/BF00294648; DIELER R, 1989, ACTA NEUROPATHOL, V78, P649, DOI 10.1007/BF00691292; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GUSTAFSSON LE, 1990, BIOCHEM BIOPH RES CO, V173, P106, DOI 10.1016/S0006-291X(05)81028-9; HAYES MA, 1957, INT ABSTR SURG, V104, P105; HOPE BT, 1991, P NATL ACAD SCI USA, V88, P2811, DOI 10.1073/pnas.88.7.2811; HOPE BT, 1989, J HISTOCHEM CYTOCHEM, V37, P653, DOI 10.1177/37.5.2703701; LEHMANN W, 1931, Z KINDERHEILKD, V50, P691; LI CG, 1990, EUR J PHARMACOL, V191, P303; LYNN HB, 1960, ARCH SURG-CHICAGO, V81, P453; MONCADA S, 1991, EUR J CLIN INVEST, V21, P361, DOI 10.1111/j.1365-2362.1991.tb01383.x; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; SHUTTLEWORTH CWR, 1991, NEUROSCI LETT, V130, P77, DOI 10.1016/0304-3940(91)90231-H; SNYDER SH, 1991, TRENDS PHARMACOL SCI, V12, P125, DOI 10.1016/0165-6147(91)90526-X; Tam P K, 1985, Ann Acad Med Singap, V14, P523; TAM PKH, 1990, GASTROENTEROLOGY, V99, P1841, DOI 10.1016/0016-5085(90)90499-Q; TOTTRUP A, 1991, AM J PHYSIOL, V260, pG385, DOI 10.1152/ajpgi.1991.260.3.G385; UKABIALA O, 1987, J PEDIATR SURG, V22, P200, DOI 10.1016/S0022-3468(87)80326-3; WATTCHOW DA, 1987, GASTROENTEROLOGY, V92, P443, DOI 10.1016/0016-5085(87)90140-5; YAMASHIRO Y, 1981, EUR J PEDIATR, V136, P187, DOI 10.1007/BF00441922	30	284	290	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 20	1992	327	8					511	515		10.1056/NEJM199208203270802	http://dx.doi.org/10.1056/NEJM199208203270802			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ457	1378938	Bronze			2022-12-28	WOS:A1992JJ45700002
J	ADSHEAD, F; CODY, DD; PITT, B				ADSHEAD, F; CODY, DD; PITT, B			BASDEC - A NOVEL SCREENING INSTRUMENT FOR DEPRESSION IN ELDERLY MEDICAL INPATIENTS	BRITISH MEDICAL JOURNAL			English	Article							PSYCHIATRIC-ILLNESS; LONDON		HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED ELDERLY,LONDON W12 0HS,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT PSYCHOL MED,LONDON W12 0HS,ENGLAND	Imperial College London; Imperial College London								COOPER B, 1987, J ROY SOC MED, V80, P13, DOI 10.1177/014107688708000107; GOLDBERG D, 1985, BRIT MED J, V291, P161, DOI 10.1136/bmj.291.6489.161; MACDONALD AJD, 1982, PSYCHOL MED, V12, P193, DOI 10.1017/S0033291700043452; MANN AH, 1984, AGE AGEING, V13, P257, DOI 10.1093/ageing/13.5.257; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4	5	97	97	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 15	1992	305	6850					397	397		10.1136/bmj.305.6850.397	http://dx.doi.org/10.1136/bmj.305.6850.397			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JK314	1392921	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992JK31400016
J	CHAN, HC; NELSON, DJ				CHAN, HC; NELSON, DJ			CHLORIDE-DEPENDENT CATION CONDUCTANCE ACTIVATED DURING CELLULAR SHRINKAGE	SCIENCE			English	Article							EPITHELIAL-CELLS; CHANNEL	A chloride (Cl-)-dependent, nonselective cation conductance was activated during cellular shrinkage and inhibited during cellular swelling or by extracellular gadolinium. The shrinking-induced, nonselective cation conductance and the swelling-induced anion conductance appear to function in the regulation of cell volume in airway epithelia. The shrinking-induced cation conductance had an unusual dependence on Cl-: partial replacement of extracellular Cl- with aspartate reduced the magnitude of the shrinking-enhanced current without accompanying changes in the reversal potential. The Cl- dependence of the nonselective cation conductance could provide a mechanism that tightly regulates Cl- secretion and sodium reabsorption in cells under osmotic stress.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,DEPT NEUROL,CHICAGO,IL 60637	University of Chicago; University of Chicago			Chan, Hsiao Chang/E-1507-2016					BUTT AG, 1990, AM J PHYSIOL, V258, P630; Chamberlin ME, 1989, AM J PHYSIOL, Vl257, P159; CHAN HC, 1992, AM J PHYSIOL, V262, pC1273, DOI 10.1152/ajpcell.1992.262.5.C1273; GOGELEIN H, 1989, PFLUG ARCH EUR J PHY, V413, P287, DOI 10.1007/BF00583543; GRAY MA, 1990, BIOCHIM BIOPHYS ACTA, V1029, P33, DOI 10.1016/0005-2736(90)90433-O; JORISSEN M, 1990, PFLUG ARCH EUR J PHY, V415, P617, DOI 10.1007/BF02583515; KROUSE ME, 1989, AM J PHYSIOL, V257, P129; OKADA Y, 1989, NEWS PHYSIOL SCI, V4, P238; ROTHSTEIN A, 1990, AM J PHYSIOL, V258, P827; SOEJIMA M, 1984, PFLUG ARCH EUR J PHY, V400, P424, DOI 10.1007/BF00587544; SOLC CK, 1991, AM J PHYSIOL, V261, P658; WONG MMY, 1991, SCIENCE, V254, P1014, DOI 10.1126/science.1948071; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111	13	64	64	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 31	1992	257	5070					669	671		10.1126/science.1379742	http://dx.doi.org/10.1126/science.1379742			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF852	1379742				2022-12-28	WOS:A1992JF85200036
J	POCOCK, SJ				POCOCK, SJ			WHEN TO STOP A CLINICAL-TRIAL	BMJ-BRITISH MEDICAL JOURNAL			English	Article							THERAPY; DESIGNS; CANCER				POCOCK, SJ (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED, MED STAT UNIT, LONDON WC1E 7HT, ENGLAND.							[Anonymous], 1987, Lancet, V2, P871; [Anonymous], 1989, NEW ENGL J MED, V321, P406; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1988, NEW ENGL J MED; Armitage P., 1975, SEQUENTIAL MED TRIAL; DILLMAN RO, 1990, NEW ENGL J MED, V323, P940, DOI 10.1056/NEJM199010043231403; DOLL R, 1991, J BIOSOC SCI, V23, P365, DOI 10.1017/S002193200001943X; ERRINGTON RD, 1991, BRIT MED J, V302, P1045, DOI 10.1136/bmj.302.6784.1045; FLEMING TR, 1989, J NATL CANCER I, V81, P188, DOI 10.1093/jnci/81.3.188; FLEMING TR, 1984, CONTROL CLIN TRIALS, V5, P348, DOI 10.1016/S0197-2456(84)80014-8; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; FREEDMAN LS, 1989, CONTROL CLIN TRIALS, V10, P357, DOI 10.1016/0197-2456(89)90001-9; GELLER NL, 1987, BIOMETRICS, V43, P213, DOI 10.2307/2531962; HAMPTON JR, 1987, LANCET, V2, P1258; HENDERSON WG, 1991, CONTROL CLIN TRIALS, V12, P304, DOI 10.1016/0197-2456(91)90027-J; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; LAN KKG, 1984, COMMUN STAT-THEOR M, V13, P2339, DOI 10.1080/03610928408828830; MCPHERSON K, 1974, NEW ENGL J MED, V290, P501, DOI 10.1056/NEJM197402282900907; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; OROURKE PP, 1989, PEDIATRICS, V84, P957; PAWITAN Y, 1990, STAT MED, V9, P1081, DOI 10.1002/sim.4780090915; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; POCOCK SJ, 1990, J EPIDEMIOL COMMUN H, V44, P3, DOI 10.1136/jech.44.1.3; POCOCK SJ, 1990, STAT MED, V9, P657, DOI 10.1002/sim.4780090612; POCOCK SJ, 1989, CONTROL CLIN TRIALS, V10, pS209; Pocock SJ., 2013, CLIN TRIALS PRACTICA; PROPERT KJ, 1991, NEW ENGL J MED, V324, P1136; SOUTHAM RL, 1991, NEW ENGL J MED, V324, P1136; TANNOCK IF, 1990, NEW ENGL J MED, V323, P989, DOI 10.1056/NEJM199010043231410; VERSTRAETE M, 1989, BRIT MED J, V298, P424; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WARE JH, 1985, AM J MED, V78, P635, DOI 10.1016/0002-9343(85)90407-3; Ware JH, 1989, STAT SCI, V4, P298, DOI DOI 10.1214/ss/1177012384; Whitehead J., 1983, DESIGN ANAL SEQUENTI; YUSUF S, 1985, EUR HEART J, V6, P556, DOI 10.1093/oxfordjournals.eurheartj.a061905; 1987, LANCET, V1, P502; IN PRESS J CLIN EPID	38	179	181	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 25	1992	305	6847					235	240		10.1136/bmj.305.6847.235	http://dx.doi.org/10.1136/bmj.305.6847.235			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG112	1392832	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JG11200030
J	BURNETT, AL; LOWENSTEIN, CJ; BREDT, DS; CHANG, TSK; SNYDER, SH				BURNETT, AL; LOWENSTEIN, CJ; BREDT, DS; CHANG, TSK; SNYDER, SH			NITRIC-OXIDE - A PHYSIOLOGICAL MEDIATOR OF PENILE ERECTION	SCIENCE			English	Article							VASOACTIVE INTESTINAL POLYPEPTIDE; MONOMETHYL-L-ARGININE; RAT ANOCOCCYGEUS MUSCLE; CORPUS CAVERNOSUM; SMOOTH-MUSCLE; RELAXING FACTOR; RELAXATION; NEUROTRANSMITTER; STIMULATION; LOCALIZATION	Nitric oxide (NO) is a cytotoxic agent of macrophages, a messenger molecule of neurons, and a vasodilator produced by endothelial cells. NO synthase, the synthetic enzyme for NO, was localized to rat penile neurons innervating the corpora cavernosa and to neuronal plexuses in the adventitial layer of penile arteries. Small doses of NO synthase inhibitors abolished electrophysiologically induced penile erections. These results establish NO as a physiologic mediator of erectile function.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,725 N WOLFE ST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT UROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT CARDIOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Bredt, David/J-4872-2012	Lowenstein, Charles/0000-0003-0485-7514	NIDA NIH HHS [DA-00266] Funding Source: Medline; NIDDK NIH HHS [DK-19300] Funding Source: Medline; NIMH NIH HHS [MH-18501] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK019300] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH018501, R37MH018501] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BENSON GS, 1983, WORLD J UROL, V1, P209, DOI 10.1007/BF00326804; BLANCO R, 1988, AM J PHYSIOL, V254, P468; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BULT H, 1990, NATURE, V345, P346, DOI 10.1038/345346a0; COCKS TM, 1990, N-S ARCH PHARMACOL, V341, P364; DAIL WG, 1989, ANAT RECORD, V224, P94, DOI 10.1002/ar.1092240112; DESAI KM, 1991, NATURE, V351, P477, DOI 10.1038/351477a0; EMOND AM, 1980, ARCH INTERN MED, V140, P1434, DOI 10.1001/archinte.140.11.1434; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GIBSON A, 1990, BRIT J PHARMACOL, V99, P602, DOI 10.1111/j.1476-5381.1990.tb12976.x; GILLESPIE J S, 1989, British Journal of Pharmacology, V97, p453P; GILLESPIE JS, 1989, BRIT J PHARMACOL, V98, P1080, DOI 10.1111/j.1476-5381.1989.tb12650.x; HIBBS JB, 1987, J IMMUNOL, V138, P550; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HOLMQUIST F, 1991, ACTA PHYSIOL SCAND, V143, P299, DOI 10.1111/j.1748-1716.1991.tb09236.x; HOLMQUIST F, 1991, ACTA PHYSIOL SCAND, V141, P441, DOI 10.1111/j.1748-1716.1991.tb09103.x; IGNARRO LJ, 1990, BIOCHEM BIOPH RES CO, V170, P843, DOI 10.1016/0006-291X(90)92168-Y; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; JUENEMANN KP, 1987, J UROLOGY, V138, P871, DOI 10.1016/S0022-5347(17)43406-9; KIELY EA, 1989, BRIT J UROL, V64, P191, DOI 10.1111/j.1464-410X.1989.tb05986.x; KIM N, 1991, J CLIN INVEST, V88, P112, DOI 10.1172/JCI115266; LI CG, 1990, EUR J PHARMACOL, V191, P303; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; NOZAKI K, IN PRESS J CEREB BLO; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PALOMAR JM, 1980, J UROLOGY, V123, P680, DOI 10.1016/S0022-5347(17)56090-5; PICKARD RS, 1991, BRIT J PHARMACOL, V104, P755, DOI 10.1111/j.1476-5381.1991.tb12500.x; POLAK JM, 1981, LANCET, V2, P217; QUINLAN DM, 1989, J UROLOGY, V141, P656, DOI 10.1016/S0022-5347(17)40926-8; RAJFER J, 1992, NEW ENGL J MED, V326, P90, DOI 10.1056/NEJM199201093260203; RAMAGOPAL MV, 1989, EUR J PHARMACOL, V174, P297, DOI 10.1016/0014-2999(89)90325-7; ROY JB, 1990, J UROLOGY, V143, P302, DOI 10.1016/S0022-5347(17)39939-1; SJOSTRAND NO, 1990, ACTA PHYSIOL SCAND, V140, P297, DOI 10.1111/j.1748-1716.1990.tb09002.x; STEERS WD, 1984, J UROLOGY, V132, P1048, DOI 10.1016/S0022-5347(17)49997-6; TOTTRUP A, 1991, AM J PHYSIOL, V260, pG385, DOI 10.1152/ajpgi.1991.260.3.G385; WALSH PC, 1982, J UROLOGY, V128, P492, DOI 10.1016/S0022-5347(17)53012-8; WILLIS EA, 1983, LIFE SCI, V33, P383, DOI 10.1016/S0024-3205(83)80013-7	42	1011	1043	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 17	1992	257	5068					401	403		10.1126/science.1378650	http://dx.doi.org/10.1126/science.1378650			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD674	1378650				2022-12-28	WOS:A1992JD67400038
J	WLODAWER, A				WLODAWER, A			ANOTHER PIECE OF THE HIV PUZZLE FALLS INTO PLACE	SCIENCE			English	Editorial Material							PROTEASE				WLODAWER, A (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,MACROMOLEC STRUCT LAB,ABL BASIC RES PROGRAM,FREDERICK,MD 21702, USA.							APPELT K, 1991, J MED CHEM, V34, P1925, DOI 10.1021/jm00111a001; ARNOLD E, 1992, NATURE, V357, P85, DOI 10.1038/357085a0; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KROHN A, 1991, J MED CHEM, V34, P3340, DOI 10.1021/jm00115a028; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0	7	5	6	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 26	1992	256	5065					1766	1766		10.1126/science.1377402	http://dx.doi.org/10.1126/science.1377402			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA434	1377402				2022-12-28	WOS:A1992JA43400024
J	AGNELLO, V; CHUNG, RT; KAPLAN, LM				AGNELLO, V; CHUNG, RT; KAPLAN, LM			A ROLE FOR HEPATITIS-C VIRUS-INFECTION IN TYPE-II CRYOGLOBULINEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MIXED CRYOGLOBULINEMIA; RHEUMATOID-FACTOR; CROSS-IDIOTYPE; ANTIBODIES; ASSOCIATION; INTERFERON; DISEASES; CHAINS; HEAVY; ALPHA	Background. Type II cryoglobulinemia is a vasculitis characterized by cryoglobulins consisting of complexes of polyclonal IgG and monoclonal IgM rheumatoid factors. The cause of these immune complexes is unknown, though both the hepatitis B (HBV) and C (HCV) viruses have been suspected. Methods. We studied 19 patients with Type II cryoglobulinemia for markers of HCV and HBV infection. Quantitative HCV antibody and RNA studies were performed on whole serum, cryoprecipitates, and supernatants. Results. Eight patients (42 percent) had HCV antibodies, and 16 (84 percent) had HCV RNA. Of the 19 patients, 5 (26 percent) had HBV markers, but only 1 had evidence of active HBV infection. Control serum samples from nine patients with Type I cryoglobulinemia were negative for HCV antibody and HCV RNA. There was a close, although not exclusive, association of one type of rheumatoid factor (WA) with HCV RNA. HCV antibody and HCV RNA were concentrated approximately 10-fold and 1000-fold, respectively, in the Type II cryoglobulins examined. Conclusions. Type II cryogiobulinemia is strongly associated with concomitant HCV infection and a high rate of false negative serologic tests. HCV virions and HCV antigen-antibody complexes are concentrated in the cryoprecipitates, most commonly in association with the WA type of rheumatoid factor, suggesting a role for HCV in the pathogenesis of mixed cryoglobulinemia.	MASSACHUSETTS GEN HOSP,DEPT MED,GASTROINTESTINAL UNIT,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02115; EDITH NOURSE ROGERS MEM VET AFFAIRS HOSP,BEDFORD,MA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	AGNELLO, V (corresponding author), LAHEY CLIN MED CTR,DEPT LAB MED,CLIN IMMUNOL LAB,41 MALL RD,BURLINGTON,MA 01805, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035487] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007191, R29DK042189] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR35487] Funding Source: Medline; NIDDK NIH HHS [5T32DK07191, DK42189] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGNELLO V, 1986, J EXP MED, V164, P1809, DOI 10.1084/jem.164.5.1809; AGNELLO V, 1973, KIDNEY INT, V3, P90, DOI 10.1038/ki.1973.15; AGNELLO V, 1980, J EXP MED, V151, P1514, DOI 10.1084/jem.151.6.1514; AGNELLO V, 1981, ANN INTERN MED, V94, P266, DOI 10.7326/0003-4819-94-2-266; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; BARNES JL, 1990, ARTHRITIS RHEUM-US, V33, P1710, DOI 10.1002/art.1780331115; BONOMO L, 1987, AM J MED, V83, P726, DOI 10.1016/0002-9343(87)90904-1; BROUET JC, 1974, AM J MED, V57, P775, DOI 10.1016/0002-9343(74)90852-3; CASATO M, 1991, LANCET, V337, P1047, DOI 10.1016/0140-6736(91)92715-E; CHUNG RT, 1991, HEPATOLOGY, V14, pA65; COLTORTI M, 1991, 3RD INT S HCV STRASB; Dienstag J L, 1981, Semin Liver Dis, V1, P45, DOI 10.1055/s-2008-1063929; DIGHIERO G, 1986, ANN NY ACAD SCI, V475, P135, DOI 10.1111/j.1749-6632.1986.tb20863.x; ERLICH HA, 1991, SCIENCE, V252, P1643, DOI 10.1126/science.2047872; FERRI C, 1991, CLIN EXP RHEUMATOL, V9, P621; FERRI C, 1991, INFECTION, V19, P417, DOI 10.1007/BF01726453; FERRI C, 1991, ARTHRITIS RHEUM, V34, P1606; FERRI C, 1991, EUR J CANCER, V27, pS81, DOI 10.1016/0277-5379(91)90583-Y; GIUSTI G, 1980, B I SIEROTER MILAN, V59, P571; GOREVIC PD, 1991, SEMIN HEMATOL, V28, P79; GOREVIC PD, 1980, AM J MED, V69, P287, DOI 10.1016/0002-9343(80)90390-3; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; IKEDA Y, 1990, LANCET, V335, P1345, DOI 10.1016/0140-6736(90)91228-3; KNOX TA, 1991, AM J MED, V91, P554, DOI 10.1016/0002-9343(91)90196-5; KUNKEL HG, 1973, J EXP MED, V137, P331, DOI 10.1084/jem.137.2.331; LEVO Y, 1977, NEW ENGL J MED, V296, P1501, DOI 10.1056/NEJM197706302962605; MAGGIORE Q, 1981, KIDNEY INT, V19, P579, DOI 10.1038/ki.1981.55; MCFARLANE IG, 1990, LANCET, V335, P754, DOI 10.1016/0140-6736(90)90870-B; MELTZER M, 1966, AM J MED, V40, P837, DOI 10.1016/0002-9343(66)90200-2; MONTEVERDE A, 1988, ACTA HAEMATOL-BASEL, V79, P20, DOI 10.1159/000205684; PASCUAL M, 1990, J INFECT DIS, V162, P569, DOI 10.1093/infdis/162.2.569; PASCUAL V, 1992, ARTHRITIS RHEUM-US, V35, P11, DOI 10.1002/art.1780350103; PLAGEMANN PGW, 1991, ARCH VIROL, V120, P165, DOI 10.1007/BF01310473; REALDI G, 1974, Z IMMUNITATSFORSCH, V147, P114; SANZ I, 1989, J IMMUNOL, V142, P4054; TANAKA M, 1991, CLIN EXP RHEUMATOL, V9, P308	36	1211	1236	1	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 19	1992	327	21					1490	1495		10.1056/NEJM199211193272104	http://dx.doi.org/10.1056/NEJM199211193272104			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY165	1383822				2022-12-28	WOS:A1992JY16500004
J	WYLER, DJ				WYLER, DJ			BARK, WEEDS, AND IRON CHELATORS - DRUGS FOR MALARIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PLASMODIUM-FALCIPARUM; CEREBRAL MALARIA; DESFERRIOXAMINE; RESURGENCE; RESISTANCE; INVITRO; GROWTH				WYLER, DJ (corresponding author), TUFTS UNIV,SCH MED,BOSTON,MA 02111, USA.							GORDEUK V, 1992, NEW ENGL J MED, V327, P1473, DOI 10.1056/NEJM199211193272101; GORDEUK VR, 1992, BLOOD, V79, P308; LYTTON SD, 1991, MOL PHARMACOL, V40, P584; PETO TEA, 1986, BRIT J HAEMATOL, V63, P273, DOI 10.1111/j.1365-2141.1986.tb05550.x; PHILLIPS RE, 1990, LANCET, V336, P1355, DOI 10.1016/0140-6736(90)92903-U; POLLACK S, 1987, P SOC EXP BIOL MED, V184, P162, DOI 10.3181/00379727-184-42461; RAVENTOSSUAREZ C, 1982, AM J TROP MED HYG, V31, P919, DOI 10.4269/ajtmh.1982.31.919; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; WARRELL DA, 1982, NEW ENGL J MED, V306, P313, DOI 10.1056/NEJM198202113060601; WYLER DJ, 1983, NEW ENGL J MED, V308, P934, DOI 10.1056/NEJM198304213081605; WYLER DJ, 1983, NEW ENGL J MED, V308, P875, DOI 10.1056/NEJM198304143081505	11	18	17	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 19	1992	327	21					1519	1521		10.1056/NEJM199211193272110	http://dx.doi.org/10.1056/NEJM199211193272110			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY165	1406884				2022-12-28	WOS:A1992JY16500010
J	SINGER, DE				SINGER, DE			RANDOMIZED TRIALS OF WARFARIN FOR ATRIAL-FIBRILLATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											SINGER, DE (corresponding author), MASSACHUSETTS GEN HOSP, BOSTON, MA 02114 USA.							ASCHENBERG W, 1986, J AM COLL CARDIOL, V7, P163, DOI 10.1016/S0735-1097(86)80275-3; CHESEBRO JH, 1990, NEW ENGL J MED, V323, P1557, DOI 10.1056/NEJM199011293232209; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; FLETCHER RH, 1988, CLIN EPIDEMIOLOGY ES, P132; FRIEDMAN LM, 1985, FUNDAMENTALS CLIN TR, P213; KASSIRER JP, 1992, NEW ENGL J MED, V327, P273, DOI 10.1056/NEJM199207233270411; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; MCBRIDE R, 1990, NEW ENGL J MED, V322, P863; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; PETERSEN P, 1989, LANCET, V1, P175; SINGER DE, IN PRESS AM HEART J; WALKER MD, 1989, LANCET, V1, P325; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561	14	45	45	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 12	1992	327	20					1451	1453		10.1056/NEJM199211123272009	http://dx.doi.org/10.1056/NEJM199211123272009			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX479	1406862				2022-12-28	WOS:A1992JX47900009
J	KAPOOR, WN				KAPOOR, WN			EVALUATION AND MANAGEMENT OF THE PATIENT WITH SYNCOPE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEAD-UP TILT; UNEXPLAINED SYNCOPE; UNKNOWN ORIGIN; RECURRENT SYNCOPE; UPRIGHT TILT; FOLLOW-UP; DIAGNOSTIC EVALUATION; UNDETERMINED ORIGIN; TRANSIENT LOSS; YOUNG-PATIENTS	Objective.-To review the studies on diagnostic evaluation of syncope and to provide an approach to the diagnostic testing and management of this condition. Data Source.-Published studies on the evaluation of syncope in the English language. Study Selection.-Cohort studies and case series of patients presenting with syncope and focused studies of various diagnostic tests such as prolonged electrocardiographic monitoring, electrophysiologic studies, and upright tilt testing. Specific selection criteria were used in the case of prolonged electrocardiographic monitoring, in which all studies had to have performed at least 12 hours of monitoring. Data Extraction.-Studies reviewed by the author. Data Synthesis.-Studies in the 1980s have shown that a cause of syncope is not diagnosed in as many as 47% of the patients presenting with this symptom. When a cause of syncope is established, a history and physical examination lead to the identification of 56% to 85% of the causes. In the remaining patients, arrhythmia detection is a central issue. A major problem with the use of ambulatory electrocardiographic (Holter) monitoring in the diagnosis of arrhythmias is that symptomatic correlation with arrhythmias is rarely found (only 4% of patients). Increasing the duration of monitoring from 24 to 72 hours does not lead to increased yield of symptomatic arrhythmias. Patient-activated intermittent loop recorders that can be worn for several weeks may occasionally show a symptomatic correlation, but they are most useful in patients with multiple recurrences of syncope. Electrophysiologic studies are more likely to be abnormal in patients with underlying heart disease or those who have abnormalities on surface electrocardiogram. The most common abnormality found on electrophysiologic studies is inducible ventricular tachycardia. Upright tilt testing has been used to induce vasovagal syncope in patients with syncope of unknown cause. A positive response has been found in 26% to 87% of patients undergoing this type of testing. The specificity of this test needs to be further investigated. In patients with recurrent syncope of unknown cause, psychiatric evaluation should also be pursued for illnesses such as generalized anxiety disorder, panic disorder, somatization, and major depression. Conclusions.-A directed approach to the evaluation is possible using the studies on diagnostic testing of syncope.			KAPOOR, WN (corresponding author), UNIV PITTSBURGH,DEPT MED,ROOM 100,LOTHROP HALL,190 LOTHROP ST,PITTSBURGH,PA 15261, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036735] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL36735] Funding Source: Medline; PHS HHS [K04L 01899] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABBOUD FM, 1989, NEW ENGL J MED, V320, P390, DOI 10.1056/NEJM198902093200609; ABISAMRA F, 1987, PACE, V10, P406; AKHTAR M, 1983, PACE, V6, P192, DOI 10.1111/j.1540-8159.1983.tb04346.x; ALMQUIST A, 1989, NEW ENGL J MED, V320, P346, DOI 10.1056/NEJM198902093200603; ATKINS D, 1991, AM J MED, V91, P179, DOI 10.1016/0002-9343(91)90012-M; BACHINSKY WB, 1992, AM J CARDIOL, V69, P1044, DOI 10.1016/0002-9149(92)90861-R; BASS EB, 1990, ARCH INTERN MED, V150, P1073, DOI 10.1001/archinte.150.5.1073; BASS EB, 1988, AM J CARDIOL, V62, P1186, DOI 10.1016/0002-9149(88)90257-3; BENDITT DG, 1983, AM J CARDIOL, V52, P1223, DOI 10.1016/0002-9149(83)90578-7; BOUDOULAS H, 1979, J ELECTROCARDIOL, V12, P1036; BRIGNOLE M, 1991, AM HEART J, V122, P1651; CLARK PI, 1980, CHEST, V77, P722, DOI 10.1378/chest.77.6.722; DAVIS TL, 1990, ARCH INTERN MED, V150, P2027, DOI 10.1001/archinte.150.10.2027; DAY SC, 1982, AM J MED, V73, P15, DOI 10.1016/0002-9343(82)90913-5; DENES P, 1988, ARCH INTERN MED, V148, P1922, DOI 10.1001/archinte.148.9.1922; DIMARCO JP, 1990, ANN INTERN MED, V113, P53, DOI 10.7326/0003-4819-113-1-53; DIMARCO JP, 1982, ANN INTERN MED, V97, P490, DOI 10.7326/0003-4819-97-4-490; DIMARCO JP, 1981, ANN INTERN MED, V95, P542, DOI 10.7326/0003-4819-95-5-542; DIMARCO JP, 1987, CIRCULATION, V75, P140; DOHERTY JU, 1985, AM J CARDIOL, V55, P703, DOI 10.1016/0002-9149(85)90140-7; EAGLE KA, 1983, YALE J BIOL MED, V56, P1; FIELDS WS, 1972, J AMER MED ASSOC, V222, P1139, DOI 10.1001/jama.222.9.1139; FITZPATRICK A, 1991, PACE, V14, P13, DOI 10.1111/j.1540-8159.1991.tb04042.x; FITZPATRICK AP, 1991, J AM COLL CARDIOL, V17, P125, DOI 10.1016/0735-1097(91)90714-K; FUJIMURA O, 1989, NEW ENGL J MED, V321, P1703, DOI 10.1056/NEJM198912213212503; GANG ES, 1986, AM J CARDIOL, V58, P1014, DOI 10.1016/S0002-9149(86)80030-3; GIBSON TC, 1984, AM J CARDIOL, V53, P1013, DOI 10.1016/0002-9149(84)90628-3; GLICK RL, 1987, AM JC ARDIOL, V59, P817; GRUBB BP, 1991, AM J MED, V90, P6, DOI 10.1016/0002-9343(91)90499-N; GULAMHUSEIN S, 1982, AM J MED, V73, P700, DOI 10.1016/0002-9343(82)90413-2; HAMMILL SC, 1984, J AM COLL CARDIOL, V4, P65, DOI 10.1016/S0735-1097(84)80320-4; HESS DS, 1982, AM J CARDIOL, V50, P1309, DOI 10.1016/0002-9149(82)90468-4; HOEFNAGELS WAJ, 1991, J NEUROL, V238, P39, DOI 10.1007/BF00319709; JONAS S, 1977, ANN NEUROL, V1, P470, DOI 10.1002/ana.410010511; KALA R, 1982, ACTA MED SCAND S, V668, P13; KAPOOR W, 1989, CLIN RES, V37, pA316; KAPOOR WN, 1989, AM J CARDIOL, V63, P730, DOI 10.1016/0002-9149(89)90260-9; KAPOOR WN, 1982, JAMA-J AM MED ASSOC, V247, P2687, DOI 10.1001/jama.247.19.2687; KAPOOR WN, 1985, JAMA-J AM MED ASSOC, V253, P796, DOI 10.1001/jama.253.6.796; KAPOOR WN, 1991, AM J MED, V90, P91; KAPOOR WN, 1990, MEDICINE, V69, P160, DOI 10.1097/00005792-199005000-00004; KAPOOR WN, 1992, ANN INTERN MED, V116, P358, DOI 10.7326/0003-4819-116-5-358; KAPOOR WN, 1987, AM J MED, V83, P700, DOI 10.1016/0002-9343(87)90901-6; KAPOOR WN, 1983, NEW ENGL J MED, V309, P197, DOI 10.1056/NEJM198307283090401; KAPOOR WN, 1986, ARCH INTERN MED, V146, P2377; KAPOOR WN, 1991, HEART DISEASE TXB CA, P875; KENNY RA, 1986, LANCET, V1, P1352; KROL RB, 1987, J AM COLL CARDIOL, V10, P358, DOI 10.1016/S0735-1097(87)80019-0; LINZER M, 1990, PSYCHOSOMATICS, V31, P181, DOI 10.1016/S0033-3182(90)72192-5; LINZER M, 1990, AM J CARDIOL, V66, P214, DOI 10.1016/0002-9149(90)90591-N; LINZER M, 1991, J GEN INTERN MED, V6, P113, DOI 10.1007/BF02598305; LIPSITZ LA, 1985, Q J MED, V55, P45; MARK AL, 1983, J AM COLL CARDIOL, V1, P90, DOI 10.1016/S0735-1097(83)80014-X; MARTIN GJ, 1984, ANN EMERG MED, V13, P499, DOI 10.1016/S0196-0644(84)80511-9; MCANULTY JH, 1987, CIRCULATION, V75, P144; MCLARAN CJ, 1986, BRIT HEART J, V55, P53; MILSTEIN S, 1990, AM J CARDIOL, V65, P1339, DOI 10.1016/0002-9149(90)91324-Y; MORADY F, 1983, INT J CARDIOL, V4, P229, DOI 10.1016/0167-5273(83)90142-0; NELSON SD, 1991, ARCH INTERN MED, V151, P2425, DOI 10.1001/archinte.151.12.2425; NELSON SD, 1987, AM J CARDIOL, V60, P1073, DOI 10.1016/0002-9149(87)90355-9; OLSHANSKY B, 1985, J AM COLL CARDIOL, V5, P216, DOI 10.1016/S0735-1097(85)80040-1; PONGIGLIONE G, 1990, J AM COLL CARDIOL, V16, P165, DOI 10.1016/0735-1097(90)90474-4; RAVIELE A, 1990, AM J CARDIOL, V65, P1322, DOI 10.1016/0002-9149(90)91321-V; ROSS RT, 1988, MSYNCOPE; SILVERSTEIN MD, 1982, JAMA-J AM MED ASSOC, V248, P1185, DOI 10.1001/jama.248.10.1185; SRA JS, 1991, ANN INTERN MED, V114, P1013, DOI 10.7326/0003-4819-114-12-1013; STRASBERG B, 1989, AM HEART J, V118, P923, DOI 10.1016/0002-8703(89)90225-1; STRASBERG B, 1989, PROG CARDIOVASC DIS, V5, P379; SWANSON JW, 1978, NEUROLOGY, V28, P782, DOI 10.1212/WNL.28.8.782; TEICHMAN SL, 1985, AM HEART J, V110, P469, DOI 10.1016/0002-8703(85)90171-1; WAXMAN MB, 1989, AM J CARDIOL, V63, P58, DOI 10.1016/0002-9149(89)91076-X; WINTERS SL, 1987, J AM COLL CARDIOL, V10, P775, DOI 10.1016/S0735-1097(87)80269-3; ZELDIS SM, 1980, CHEST, V78, P456, DOI 10.1378/chest.78.3.456; 1984, ANN INTERN MED, V100, P452	74	180	189	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1992	268	18					2553	2560		10.1001/jama.268.18.2553	http://dx.doi.org/10.1001/jama.268.18.2553			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW616	1404823				2022-12-28	WOS:A1992JW61600028
J	QUILL, TE; CASSEL, CK; MEIER, DE				QUILL, TE; CASSEL, CK; MEIER, DE			CARE OF THE HOPELESSLY ILL - PROPOSED CLINICAL-CRITERIA FOR PHYSICIAN-ASSISTED SUICIDE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							EUTHANASIA; DEATH; RESPONSIBILITY; NETHERLANDS		UNIV ROCHESTER, SCH MED, ROCHESTER, NY 14607 USA; UNIV CHICAGO, CHICAGO, IL 60637 USA; CUNY MT SINAI SCH MED, NEW YORK, NY 10029 USA	University of Rochester; University of Chicago; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai								ANGELL M, 1988, NEW ENGL J MED, V319, P1348, DOI 10.1056/NEJM198811173192010; ARIES P, 1982, HOUR OF OUR DEATH; BENRUBI GI, 1992, NEW ENGL J MED, V326, P197, DOI 10.1056/NEJM199201163260311; BRAHAMS D, 1990, LANCET, V335, P591; Broadfield L, 1988, J Palliat Care, V4, P21; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; CHARLSON ME, 1987, J GEN INTERN MED, V2, P359, DOI 10.1007/BF02596176; CONWELL Y, 1991, NEW ENGL J MED, V325, P1100, DOI 10.1056/NEJM199110103251511; GAYLIN W, 1988, JAMA-J AM MED ASSOC, V259, P2139; GEST T, 1990, US NEWS WORLD R 0709, P22; Glantz L H, 1987, Law Med Health Care, V15, P231; GLOVER J, 1977, CAUSING DEATH SAVING, P182; Gomez Carlos F., 1991, REGULATING DEATH EUT; HEILIG S, 1988, SAN FRANCISCO MED, V24, P34; JECKER NS, 1991, J AM GERIATR SOC, V39, P831, DOI 10.1111/j.1532-5415.1991.tb02708.x; LACHS J, 1976, NEW ENGL J MED, V294, P838, DOI 10.1056/NEJM197604082941513; LEENEN HJJ, 1990, BRIT MED J, V300, P69; MALCOLM A, 1990, NY TIMES        0614, pA6; MEIER DE, 1983, J AM GERIATR SOC, V31, P294, DOI 10.1111/j.1532-5415.1983.tb04874.x; MISBIN RI, 1991, NEW ENGL J MED, V325, P1307, DOI 10.1056/NEJM199110313251811; NEWMAN SA, 1991, U PITT LAW REV, V53, P153; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2229; ORENTLICHER D, 1989, JAMA-J AM MED ASSOC, V262, P1844, DOI 10.1001/jama.262.13.1844; OVERMYER M, 1991, PHYSICIANS MANAGE, V31, P40; POSES RM, 1989, CRIT CARE MED, V17, P827, DOI 10.1097/00003246-198908000-00021; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; RACHELS J, 1975, NEW ENGL J MED, V292, P78, DOI 10.1056/NEJM197501092920206; REICHEL W, 1989, LANCET, V2, P1321; RHYMES J, 1990, JAMA-J AM MED ASSOC, V264, P369, DOI 10.1001/jama.264.3.369; Schonwetter R S, 1990, Hosp J, V6, P65; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; VAUX KL, 1988, JAMA-J AM MED ASSOC, V259, P2140, DOI 10.1001/jama.259.14.2140; WALLSTON KA, 1988, MED CARE, V26, P177, DOI 10.1097/00005650-198802000-00008; WANZER SH, 1984, NEW ENGL J MED, V310, P955, DOI 10.1056/NEJM198404123101505; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; Weir R F, 1992, Law Med Health Care, V20, P116, DOI 10.1111/j.1748-720X.1992.tb01178.x; WOLF SM, 1989, HASTINGS CENT REP, V19, pS13; 1988, WITHHOLDING WITHDRAW; 1990, 1990 ROPER POLL PHYS; 1988, 1987 SURVEY CALIFORN; 1991, 1991 ROPER POLL W CO	42	221	220	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 5	1992	327	19					1380	1384		10.1056/NEJM199211053271911	http://dx.doi.org/10.1056/NEJM199211053271911			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW077	1406842				2022-12-28	WOS:A1992JW07700011
J	MILLER, C				MILLER, C			ION CHANNEL STRUCTURE AND FUNCTION	SCIENCE			English	Editorial Material							ACETYLCHOLINE-RECEPTOR; K+ CHANNELS; INACTIVATION				MILLER, C (corresponding author), BRANDEIS UNIV,HOWARD HUGHES MED INST,WALTHAM,MA 02254, USA.							DEMO SD, 1991, NEURON, V7, P743, DOI 10.1016/0896-6273(91)90277-7; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; KAVANAUGH MP, 1992, NEURON, V8, P493, DOI 10.1016/0896-6273(92)90277-K; LI M, 1992, NEURON, V8, P1151, DOI 10.1016/0896-6273(92)90135-Z; LISTERUD M, 1991, SCIENCE, V254, P1518, DOI 10.1126/science.1720573; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MURRELL-LAGNADO R D, 1992, Biophysical Journal, V61, pA290; SINE SM, 1991, J BIOL CHEM, V266, P19369; TOMASELLI GF, 1991, BIOPHYS J, V60, P721, DOI 10.1016/S0006-3495(91)82102-6; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; WEST JW, 1991, SCIENCE, V254, P866, DOI 10.1126/science.1658937; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	15	21	22	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 9	1992	258	5080					240	241		10.1126/science.1384128	http://dx.doi.org/10.1126/science.1384128			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR860	1384128				2022-12-28	WOS:A1992JR86000018
J	BORGSTAHL, GEO; PARGE, HE; HICKEY, MJ; BEYER, WF; HALLEWELL, RA; TAINER, JA				BORGSTAHL, GEO; PARGE, HE; HICKEY, MJ; BEYER, WF; HALLEWELL, RA; TAINER, JA			THE STRUCTURE OF HUMAN MITOCHONDRIAL MANGANESE SUPEROXIDE-DISMUTASE REVEALS A NOVEL TETRAMERIC INTERFACE OF 2 4-HELIX BUNDLES	CELL			English	Article							TUMOR NECROSIS FACTOR; OXIDATIVE DAMAGE; ESCHERICHIA-COLI; THERMUS-THERMOPHILUS; PSEUDOMONAS-OVALIS; OXYGEN RADICALS; CDNA SEQUENCE; CYTO-TOXICITY; RESOLUTION; EXPRESSION	The 2.2 angstrom resolution crystal structure of recombinant human manganese superoxide dismutase, a homotetrameric enzyme that protects mitochondria against oxygen-mediated free radical damage, has been determined. Within each subunit, both the N-terminal helical hairpin and C-terminal alpha/beta domains contribute ligands to the catalytic manganese site. Two identical 4-helix bundles, symmetrically assembled from the N-terminal helical hairpins, form novel tetrameric interfaces that stabilize the active sites. Structurally altered polymorphic variants with reduced activity, such as tetrameric interface mutant Ile-58 to Thr, may produce not only an early selective advantage, through enhanced cytotoxicity of tumor necrosis factor for virus-infected cells, but also detrimental effects from increased mitochondrial oxidative damage, contributing to degenerative conditions, including diabetes, aging, and Parkinson's and Alzheimer's diseases.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University	BORGSTAHL, GEO (corresponding author), SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA.		Borgstahl, Gloria/AAZ-4114-2020; Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429	NIGMS NIH HHS [GM39345] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039345] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADELMAN R, 1988, P NATL ACAD SCI USA, V85, P2706, DOI 10.1073/pnas.85.8.2706; ALLISON AC, 1956, SCI AM, V195, P87, DOI 10.1038/scientificamerican0856-87; AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11; BANNER DW, 1987, J MOL BIOL, V196, P657, DOI 10.1016/0022-2836(87)90039-8; BECK Y, 1987, NUCLEIC ACIDS RES, V15, P9076, DOI 10.1093/nar/15.21.9076; BECK Y, 1988, BIO-TECHNOL, V6, P930, DOI 10.1038/nbt0888-930; BEEM KM, 1976, J MOL BIOL, V105, P327, DOI 10.1016/0022-2836(76)90115-7; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P5561; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BEYER W, 1991, PROG NUCLEIC ACID RE, V40, P221; BEYER WF, 1987, BIOCHEMISTRY-US, V26, P1251, DOI 10.1021/bi00379a008; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CAMPBELL IL, 1988, J IMMUNOL, V141, P2325; CARLIOZ A, 1988, J BIOL CHEM, V263, P1555; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHURCH SL, 1990, BIOCHIM BIOPHYS ACTA, V1087, P250, DOI 10.1016/0167-4781(90)90213-L; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; CROUCH RK, 1981, DIABETES, V30, P235, DOI 10.2337/diab.30.3.235; DEUTSCH HF, 1991, J MOL BIOL, V219, P103, DOI 10.1016/0022-2836(91)90860-9; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FLOYD RA, 1991, SCIENCE, V254, P1597, DOI 10.1126/science.1684251; FRAGA CG, 1990, P NATL ACAD SCI USA, V87, P4533, DOI 10.1073/pnas.87.12.4533; FRIDOVICH I, 1986, ADV ENZYMOL RAMB, V58, P61; GETZOFF ED, 1992, NATURE, V358, P347, DOI 10.1038/358347a0; GORECKI M, 1991, FREE RADICAL RES COM, V12-3, P401, DOI 10.3109/10715769109145810; HALLEWELL RA, 1989, J BIOL CHEM, V264, P5260; HALLEWELL RA, 1985, NUCLEIC ACIDS RES, V13, P2017, DOI 10.1093/nar/13.6.2017; HALLEWELL RA, 1986, NUCLEIC ACIDS RES, V14, P9539, DOI 10.1093/nar/14.23.9539; HALLIWELL B, 1985, PHILOS T ROY SOC B, V311, P659, DOI 10.1098/rstb.1985.0171; Halliwell B, 1989, FREE RADICAL BIO MED, P22; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; HASSAN HM, 1988, FREE RADICAL BIO MED, V5, P377, DOI 10.1016/0891-5849(88)90111-6; HECKL K, 1988, NUCLEIC ACIDS RES, V16, P6224, DOI 10.1093/nar/16.13.6224; HO YS, 1988, FEBS LETT, V229, P256, DOI 10.1016/0014-5793(88)81136-0; HO YS, 1991, AM J RESP CELL MOL, V4, P278, DOI 10.1165/ajrcmb/4.3.278; HOUSSET B, 1981, CLIN RES PROC, V17, P107; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; INGRAM VM, 1957, NATURE, V180, P326, DOI 10.1038/180326a0; KIRBY TW, 1981, ARCH BIOCHEM BIOPHYS, V210, P140, DOI 10.1016/0003-9861(81)90174-0; KRALL J, 1988, J BIOL CHEM, V263, P1910; LUDWIG ML, 1991, J MOL BIOL, V219, P335, DOI 10.1016/0022-2836(91)90569-R; MALAISSE WJ, 1982, P NATL ACAD SCI-BIOL, V79, P927, DOI 10.1073/pnas.79.3.927; MASUDA A, 1988, FASEB J, V2, P3087, DOI 10.1096/fasebj.2.15.3263930; MATSUDA Y, 1990, EUR J BIOCHEM, V194, P713, DOI 10.1111/j.1432-1033.1990.tb19461.x; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCREE DE, 1990, J BIOL CHEM, V265, P14234; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MUROHARA Y, 1991, AM J CARDIOL, V67, P765, DOI 10.1016/0002-9149(91)90538-V; NAIN M, 1990, J IMMUNOL, V145, P1921; NAKAZONO K, 1991, P NATL ACAD SCI USA, V88, P10045, DOI 10.1073/pnas.88.22.10045; NAMBA K, 1989, J MOL BIOL, V208, P307, DOI 10.1016/0022-2836(89)90391-4; NATH N, 1984, DIABETES, V33, P586, DOI 10.2337/diabetes.33.6.586; NATVIG DO, 1987, J BIOL CHEM, V262, P14697; NIWA Y, 1990, BLOOD, V76, P835; NOMIKOS IN, 1989, IMMUNOL CELL BIOL, V67, P85, DOI 10.1038/icb.1989.12; OBERLEY LW, 1987, ARCH BIOCHEM BIOPHYS, V254, P69, DOI 10.1016/0003-9861(87)90082-8; ODA T, 1989, SCIENCE, V244, P974, DOI 10.1126/science.2543070; PARGE HE, 1992, P NATL ACAD SCI USA, V89, P6109, DOI 10.1073/pnas.89.13.6109; PARKER MW, 1988, J MOL BIOL, V199, P649, DOI 10.1016/0022-2836(88)90308-7; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; REVEILLAUD I, 1991, MOL CELL BIOL, V11, P632, DOI 10.1128/MCB.11.2.632; Richardson J.S., 1990, PREDICTION PROTEIN S, P1; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; SATO S, 1978, J BIOCHEM-TOKYO, V83, P1165, DOI 10.1093/oxfordjournals.jbchem.a132007; SATO S, 1977, EUR J BIOCHEM, V73, P373, DOI 10.1111/j.1432-1033.1977.tb11328.x; SMITH MW, 1992, J MOL EVOL, V34, P175; STALLINGS WC, 1984, J BIOL CHEM, V259, P695; STCLAIR DK, 1991, CANCER RES, V51, P939; STINE OC, 1992, J MOL EVOL, V34, P336; STODDARD BL, 1990, PROTEIN ENG, V4, P113, DOI 10.1093/protein/4.2.113; STODDARD BL, 1990, BIOCHEMISTRY-US, V29, P8885, DOI 10.1021/bi00490a002; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; TAINER JA, 1991, STUDY ENZYMES, V2, P499; TAYLOR R, 1992, J NIH RES, V4, P62; TOUATI D, 1988, FREE RADICAL BIO MED, V5, P393, DOI 10.1016/0891-5849(88)90113-X; WAGNER UG, 1989, J MOL BIOL, V206, P787, DOI 10.1016/0022-2836(89)90586-X; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WHITE CW, 1991, J CLIN INVEST, V87, P2162, DOI 10.1172/JCI115249; WISPE JR, 1989, BIOCHIM BIOPHYS ACTA, V994, P30, DOI 10.1016/0167-4838(89)90058-7; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Yoon JW, 1990, CURR TOP MICROBIOL I, V164, P95; ZWEIER JL, 1987, P NATL ACAD SCI USA, V84, P1404, DOI 10.1073/pnas.84.5.1404	86	410	421	2	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 2	1992	71	1					107	118		10.1016/0092-8674(92)90270-M	http://dx.doi.org/10.1016/0092-8674(92)90270-M			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1394426				2022-12-28	WOS:A1992JQ62300011
J	OOI, CE; WEISS, J				OOI, CE; WEISS, J			BIDIRECTIONAL MOVEMENT OF A NASCENT POLYPEPTIDE ACROSS MICROSOMAL-MEMBRANES REVEALS REQUIREMENTS FOR VECTORIAL TRANSLOCATION OF PROTEINS	CELL			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; SIGNAL RECOGNITION PARTICLE; PERMEABILITY-INCREASING PROTEIN; POLYMORPHONUCLEAR LEUKOCYTES; ROUGH MICROSOMES; ER MEMBRANE; RECEPTOR; SEQUENCE; TRANSLATION; IDENTIFICATION	The translocation of polypeptides across the endoplasmic reticulum is a vectorial process that occurs probably through a protein channel by a mechanism as yet undetermined. Here, we demonstrate bidirectional movement of a 221 residue nascent polypeptide across microsomal membranes and provide evidence suggesting that the retrograde movement is through the translocation channel. Retrograde movement is observed only when the polypeptide is generated from a truncated transcript; addition of a stop codon after codon 221 confers vectorial movement. Retrograde movement can also be prevented by glycosylation of the nascent polypeptide, as well as by inclusion of 32 additional amino acids that may promote folding of the translocated chain. We propose that the protein translocation channel is a passive pore that does not create a directional bias in polypeptide movement and that vectorial translocation is driven by nascent chain elongation and sustained by posttranslocation events that prevent retrograde movement.			OOI, CE (corresponding author), NYU, SCH MED, DEPT MICROBIOL, NEW YORK, NY 10016 USA.			Weiss, Jerrold/0000-0003-1476-4485	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK005472] Funding Source: NIH RePORTER; NIDDK NIH HHS [R37 DK 05472] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BLOBEL G, 1970, J CELL BIOL, V45, P130, DOI 10.1083/jcb.45.1.130; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; Blobel G., 1971, BIOMEMBRANE, P193; CASKEY CT, 1980, TRENDS BIOCHEM SCI, V5, P234, DOI 10.1016/S0968-0004(80)80809-7; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; CONNOLLY T, 1991, SCIENCE, V252, P1171, DOI 10.1126/science.252.5009.1171; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; DOOHAN JP, 1992, VIROLOGY, V186, P409, DOI 10.1016/0042-6822(92)90006-B; ELSBACH P, 1990, TRENDS BIOTECHNOL, V8, P26, DOI 10.1016/0167-7799(90)90127-J; Elsbach P., 1988, INFLAMMATION BASIC P, P445; GILMORE R, 1983, CELL, V35, P677, DOI 10.1016/0092-8674(83)90100-9; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GRAY PW, 1989, J BIOL CHEM, V264, P9505; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; HOFFMAN KE, 1988, J BIOL CHEM, V263, P4381; KELLARIS KV, 1991, J CELL BIOL, V114, P21, DOI 10.1083/jcb.114.1.21; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINGAPPA VR, 1991, CELL, V65, P527, DOI 10.1016/0092-8674(91)90081-9; MALKIN LI, 1967, J MOL BIOL, V26, P329, DOI 10.1016/0022-2836(67)90301-4; MANNION BA, 1990, J CLIN INVEST, V86, P631, DOI 10.1172/JCI114755; MARRA MN, 1990, J IMMUNOL, V144, P662; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; NICCHITTA CV, 1990, CELL, V60, P259, DOI 10.1016/0092-8674(90)90741-V; OOI CE, 1987, J BIOL CHEM, V262, P14891; OOI CE, 1991, J EXP MED, V174, P649, DOI 10.1084/jem.174.3.649; PERARA E, 1986, SCIENCE, V232, P348, DOI 10.1126/science.3961485; RABINOVICH YM, 1991, BIOCHIM BIOPHYS ACTA, V1089, P193, DOI 10.1016/0167-4781(91)90007-9; RAPOPORT TA, 1990, TRENDS BIOCHEM SCI, V15, P355, DOI 10.1016/0968-0004(90)90076-N; REDMAN CM, 1966, P NATL ACAD SCI USA, V56, P608, DOI 10.1073/pnas.56.2.608; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; TRAUT RR, 1964, J MOL BIOL, V10, P63, DOI 10.1016/S0022-2836(64)80028-0; WALTER P, 1980, P NATL ACAD SCI-BIOL, V77, P7112, DOI 10.1073/pnas.77.12.7112; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WEISS J, 1978, J BIOL CHEM, V253, P2664; WELPLY JK, 1983, J BIOL CHEM, V258, P1856; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; WOLIN SL, 1988, EMBO J, V7, P3559, DOI 10.1002/j.1460-2075.1988.tb03233.x; YU YH, 1989, P NATL ACAD SCI USA, V86, P9931, DOI 10.1073/pnas.86.24.9931	50	77	77	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 2	1992	71	1					87	96		10.1016/0092-8674(92)90268-H	http://dx.doi.org/10.1016/0092-8674(92)90268-H			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1394433				2022-12-28	WOS:A1992JQ62300009
J	BHARANI, A				BHARANI, A			SEXUAL DYSFUNCTION AFTER GEMFIBROZIL	BRITISH MEDICAL JOURNAL			English	Letter							INDUCED IMPOTENCE				BHARANI, A (corresponding author), MGM MED COLL,DEPT MED,INDORE 452001,INDIA.							BAIN SC, 1990, LANCET, V336, P1389, DOI 10.1016/0140-6736(90)92954-G; FRICK MH, 1987, NEW ENGL J MED, V317, P237; PIZARRO S, 1990, LANCET, V336, P1135, DOI 10.1016/0140-6736(90)92618-R	3	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 19	1992	305	6855					693	693		10.1136/bmj.305.6855.693	http://dx.doi.org/10.1136/bmj.305.6855.693			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP511	1393117	Green Submitted, Bronze, Green Published			2022-12-28	WOS:A1992JP51100024
J	ESMAIL, A; ANDERSON, HR; RAMSEY, JD; TAYLOR, J; POTTIER, A				ESMAIL, A; ANDERSON, HR; RAMSEY, JD; TAYLOR, J; POTTIER, A			CONTROLLING DEATHS FROM VOLATILE SUBSTANCE-ABUSE IN UNDER 18S - THE EFFECTS OF LEGISLATION	BRITISH MEDICAL JOURNAL			English	Article									ST GEORGE HOSP,TOXICOL UNIT,LONDON SW17 0RE,ENGLAND	St Georges University London	ESMAIL, A (corresponding author), ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.		Esmail, Aneez/I-6903-2013					ANDERSON HR, 1985, BRIT MED J, V290, P304, DOI 10.1136/bmj.290.6464.304; FLANAGAN RJ, 1990, DRUG SAFETY, V5, P359, DOI 10.2165/00002018-199005050-00005; LISS BI, 1989, HUM TOXICOL, V8, P327, DOI 10.1177/096032718900800413; WRIGHT SP, 1991, TRENDS DEATHS ASS AB; 1986, GENERALISED LINEAR I	5	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 19	1992	305	6855					692	692		10.1136/bmj.305.6855.692	http://dx.doi.org/10.1136/bmj.305.6855.692			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JP511	1393114	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JP51100023
J	CARLSEN, E; GIWERCMAN, A; KEIDING, N; SKAKKEBAEK, NE				CARLSEN, E; GIWERCMAN, A; KEIDING, N; SKAKKEBAEK, NE			EVIDENCE FOR DECREASING QUALITY OF SEMEN DURING PAST 50 YEARS	BRITISH MEDICAL JOURNAL			English	Article							SPERM COUNT; TESTICULAR CANCER; HUMAN-SPERMATOZOA; MALE-FERTILITY; CHANGING PARAMETERS; MEN; PERIOD; VOLUME; PENETRATION; VASECTOMY	Objective-To investigate whether semen quality has changed during the past 50 years. Design - Review of publications on semen quality in men without a history of infertility selected by means of Cumulated Index Medicus and Current List (1930-1965) and MEDLINE Silver Platter database (1966-August 1991). Subjects-14947 men included in a total of 61 papers published between 1938 and 1991. Main outcome measures-Mean sperm density and mean seminal volume. Results-Linear regression of data weighted by number of men in each study showed a significant decrease in mean sperm count from 113x10(6)/ml in 1940 to 66x10(6)/ml in 1990 (p<0.0001) and in seminal volume from 3.40 ml to 2.75 ml (p=0.027), indicating an even more pronounced decrease in sperm production than expressed by the decline in sperm density. Conclusions-There has been a genuine decline in semen quality over the past 50 years. As male fertility is to some extent correlated with sperm count the results may reflect an overall reduction in male fertility. The biological significance of these changes is emphasised by a concomitant increase in the incidence of genitourinary abnormalities such as testicular cancer and possibly also cryptorchidism and hypospadias, suggesting a growing impact of factors with serious effects on male gonadal function.	UNIV COPENHAGEN,RIGSHOSP 5064,DEPT GROWTH & REPROD,DK-2100 COPENHAGEN,DENMARK; UNIV COPENHAGEN,STAT RES UNIT,DK-1168 COPENHAGEN,DENMARK	Rigshospitalet; University of Copenhagen; University of Copenhagen								AABYHOLM T, 1981, INT J ANDROL, V4, P646; ARIBARG A, 1986, INT J ANDROL, V9, P170, DOI 10.1111/j.1365-2605.1986.tb00880.x; BADENOCH DF, 1989, BRIT J UROL, V64, P521, DOI 10.1111/j.1464-410X.1989.tb05291.x; BAHAMONDES L, 1979, INT J ANDROL, V2, P526, DOI 10.1111/j.1365-2605.1979.tb00083.x; BARRATT CLR, 1988, ANDROLOGIA, V20, P264; BENDVOLD E, 1989, INT J FERTIL, V34, P401; BERTHELSEN JG, 1983, FERTIL STERIL, V39, P68; BHUSHAN S, 1978, Indian Journal of Physiology and Pharmacology, V22, P393; BONDE JP, 1990, BRIT J IND MED, V47, P508; BORGHI MR, 1983, J ANDROL, V4, P316; BOSTOFTE E, 1982, INT J ANDROL, V5, P267, DOI 10.1111/j.1365-2605.1982.tb00255.x; BOSTOFTE E, 1983, INT J FERTIL, V28, P91; BOYLE P, 1987, EUR J CANCER CLIN ON, V23, P827, DOI 10.1016/0277-5379(87)90286-0; BROER KH, 1978, J REPROD MED, V20, P67; BROWN LM, 1986, INT J EPIDEMIOL, V15, P164, DOI 10.1093/ije/15.2.164; CHAN SYW, 1987, FERTIL STERIL, V47, P717; CHAN SYW, 1989, INT J ANDROL, V12, P339, DOI 10.1111/j.1365-2605.1989.tb01322.x; COUTINHO EM, 1988, CONTRACEPTION, V37, P137, DOI 10.1016/0010-7824(88)90124-2; Eliasson R, 1971, ANDROLOGIE, V3, P49, DOI [10.1111/j.1439-0272.1971.tb01125.x, DOI 10.1111/J.1439-0272.1971.TB01125.X]; FALK HC, 1950, FERTIL STERIL, V1, P489; FARRIS EJ, 1949, J UROLOGY, V61, P1099, DOI 10.1016/S0022-5347(17)69189-4; FREUND M, 1969, FERTIL STERIL, V20, P163; GIBLIN PT, 1988, FERTIL STERIL, V49, P127; GLAUB JC, 1976, FERTIL STERIL, V27, P1283; HAKULINEN T, 1986, APMIS S, V288; HAMILL PVV, 1982, J OCCUP ENVIRON MED, V24, P985; Hammen R., 1944, STUDIES IMPAIRED FER; HANDELSMAN DJ, 1984, INT J ANDROL, V7, P369, DOI 10.1111/j.1365-2605.1984.tb00794.x; HENDERSON BE, 1979, INT J CANCER, V23, P598, DOI 10.1002/ijc.2910230503; HENDERSON BE, 1982, CANCER RES, V42, P3232; HEUSSNER JC, 1985, MUTAT RES, V155, P143, DOI 10.1016/0165-1218(85)90133-8; Hotchkiss RS, 1941, J UROLOGY, V45, P875, DOI 10.1016/S0022-5347(17)71125-1; Hotchkiss RS, 1938, AM J MED SCI, V196, P362, DOI 10.1097/00000441-193809000-00009; IBRAHIM ME, 1988, ARCH ANDROLOGY, V21, P129, DOI 10.3109/01485018808986723; JACKSON MB, 1988, HORM RES, V30, P153, DOI 10.1159/000181052; JAMES WH, 1980, ANDROLOGIA, V12, P381; KIREI BR, 1987, E AFR MED J, V64, P453; LAMPE EH, 1956, FERTIL STERIL, V7, P123; LAPIDO OA, 1980, J NATL MED ASSOC, V72, P785; LAUFER N, 1985, ARCH ANDROLOGY, V14, P217, DOI 10.3109/01485018508988302; LETO S, 1981, FERTIL STERIL, V36, P766; LEVIN RM, 1986, FERTIL STERIL, V45, P732; LEWIS EL, 1984, FERTIL STERIL, V42, P895; MACLEOD J, 1951, J UROLOGY, V66, P436, DOI 10.1016/S0022-5347(17)74358-3; MACLEOD J, 1945, J UROLOGY, V54, P474, DOI 10.1016/S0022-5347(17)70101-2; MENKVELD R, 1986, ARCH ANDROLOGY, V17, P143, DOI 10.3109/01485018608990186; MEYER CR, 1981, J OCCUP ENVIRON MED, V23, P435, DOI 10.1097/00043764-198106000-00018; MURATURE DA, 1987, BIOMED ENVIRON MASS, V14, P4731; NELSON CMK, 1974, FERTIL STERIL, V25, P503; NEUWINGER J, 1990, FERTIL STERIL, V54, P308; NIESCHLAG E, 1982, J CLIN ENDOCR METAB, V55, P676, DOI 10.1210/jcem-55-4-676; NIKKANEN V, 1979, ANDROLOGIA, V11, P123; OSEGBE DN, 1986, EUR UROL, V12, P164; OSSER S, 1983, ARCH ANDROLOGY, V10, P127, DOI 10.3109/01485018308987553; OSSER S, 1984, ARCH ANDROLOGY, V12, P113, DOI 10.3109/01485018409161159; OSTERLIND A, 1986, BRIT J CANCER, V53, P501, DOI 10.1038/bjc.1986.79; PANIDIS DK, 1984, EUR J OBSTET GYN R B, V16, P411, DOI 10.1016/0028-2243(84)90022-4; Pol P. S., 1989, FERTIL STERIL, V51, P1030; POLAKOSKI KL, 1977, FERTIL STERIL, V28, P668; RASMUSSEN K, 1988, INT ARCH OCC ENV HEA, V60, P419, DOI 10.1007/BF00381389; Rehan N, 1975, Fertil Steril, V26, P492; REHEWY MSE, 1978, EUR J OBSTET GYN R B, V8, P247, DOI 10.1016/0028-2243(78)90073-4; ROBLES GG, 1947, ARCH PERUANOS PATOL, V1, P615; ROY S, 1979, J STEROID BIOCHEM, V11, P675, DOI 10.1016/0022-4731(79)90099-2; RUTHERFORD RN, 1963, FERTIL STERIL, V14, P521; SANTOMAURO AG, 1972, FERTIL STERIL, V23, P245; SANTTI R, 1990, INT J ANDROL, V13, P77, DOI 10.1111/j.1365-2605.1990.tb00963.x; SCHWARTZ D, 1983, FERTIL STERIL, V39, P530; SHERIFF DS, 1983, ANDROLOGIA, V15, P687; SHRIVASTAV P, 1989, DIABETES CARE, V12, P742, DOI 10.2337/diacare.12.10.742; SMITH ML, 1979, FERTIL STERIL, V32, P312; SOBOWALE OB, 1989, INT J GYNECOL OBSTET, V28, P155, DOI 10.1016/0020-7292(89)90476-1; STANWELLSMITH R, 1983, FERTIL STERIL, V40, P670; STURDE HC, 1971, ARCH DERMATOL FORSCH, V241, P426, DOI 10.1007/BF00595274; Swanson R J, 1984, Arch Androl, V12 Suppl, P69; TJOA WS, 1982, FERTIL STERIL, V38, P454; VARNEK J, 1944, SPERMAUNDERSOGESER V, P42; WANG C, 1985, INT J ANDROL, V8, P257, DOI 10.1111/j.1365-2605.1985.tb00840.x; WEISMAN AI, 1943, UROL CUTAN REV, V47, P166; WELCH LS, 1988, AM J IND MED, V14, P509, DOI 10.1002/ajim.4700140503; ZIMMERMAN SJ, 1964, FERTIL STERIL, V15, P505; 1987, WHO LABORATORY MANUA; 1989, LANCET, V1, P360; 1985, LANCET, V1, P1311	84	1934	2093	10	220	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 12	1992	305	6854					609	613		10.1136/bmj.305.6854.609	http://dx.doi.org/10.1136/bmj.305.6854.609			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN698	1393072	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JN69800015
J	OVERGAARD, K; HANSEN, MA; JENSEN, SB; CHRISTIANSEN, C				OVERGAARD, K; HANSEN, MA; JENSEN, SB; CHRISTIANSEN, C			EFFECT OF SALCATONIN GIVEN INTRANASALLY ON BONE MASS AND FRACTURE RATES IN ESTABLISHED OSTEOPOROSIS - A DOSE-RESPONSE STUDY	BRITISH MEDICAL JOURNAL			English	Article							POSTMENOPAUSAL OSTEOPOROSIS; CALCITONIN; WOMEN; ABSORPTIOMETRY; THERAPY; SINGLE; PHOTON	Objective-To study the dose related response of salmon calcitonin (salcatonin) given intranasally on bone mass and bone turnover and the effect of salcatonin on rates of fracture in elderly women with moderate oteoporosis. Design-Double blind, placebo controlled, randomised group comparison. Setting-Outpatient clinic for research into osteoporosis. Subjects-208 healthy women aged 68-72 years who had a bone mineral content of the distal forearm on average 30% below the mean value for healthy premenopausal women. Interventions-The 208 women were allocated randomly in blocks of four to two years of treatment with either salcatonin 50 IU, 100 IU, or 200 IU given intranasally or placebo. All groups received a calcium supplement of 500 mg. 32 of the women left the study before its end and 164 women complied with the study criteria throughout. Main outcome measures-Bone mineral content of the distal forearm and lumbar spine and rates of vertebral and peripheral fractures after two years of treatment. Results-The average changes in bone mineral content of the spine showed positive outcomes of 1% (95% confidence interval -0.1% to 1.5%) in the group treated with calcium (placebo) and 3% (1.8% to 4.2%) in the group treated with salcatonin 200 IU. There was a significant dose related response to salcatonin, manifested by an increase of 1.0%/100 IU (0.2% to 1.7%, p=0.008). The rate of patients with new fractures was reduced significantly in the women treated with salcatonin to about one third of that in the non-salcatonin treated women (relative risk 0.23 (0.07 to 0.77)). Conclusion-The results suggest that, compared with calcium alone, salcatonin given intranasally reduces the rates of fracture by two thirds in elderly women with moderate osteoporosis. Furthermore, it increases spinal bone mass in a dose dependent manner.			OVERGAARD, K (corresponding author), UNIV COPENHAGEN,GLOSTRUP HOSP,DEPT CLIN CHEM,DK-2600 GLOSTRUP,DENMARK.							ALTMAN DG, 1991, BRIT MED J, V302, P1481, DOI 10.1136/bmj.302.6791.1481; CHESNUT CH, 1983, METABOLISM, V32, P571, DOI 10.1016/0026-0495(83)90027-6; CHRISTIANSEN C, 1990, J CLIN ENDOCR METAB, V71, P836, DOI 10.1210/jcem-71-4-836; GRUBER HE, 1984, METABOLISM, V33, P295, DOI 10.1016/0026-0495(84)90187-2; HANSEN MA, 1990, J NUCL MED, V31, P1156; HANSEN MA, IN PRESS OSTEOPOROSI; Heaney R P, 1991, Osteoporos Int, V1, P215; HEDLUND T, 1983, ACTA ORTHOP SCAND, V54, P802, DOI 10.3109/17453678308992912; KLEEREKOPER M, 1984, OSTEOPOROSIS, V1, P103; LUFKIN EG, 1990, OSTEOPOROSIS 1990, V3, P1995; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; MELTON LJ, 1989, AM J EPIDEMIOL, V129, P1000, DOI 10.1093/oxfordjournals.aje.a115204; MeltonIII L. J., 1988, OSTEOPOROSIS ETIOLOG, P133; NILAS L, 1985, J NUCL MED, V26, P1257; NILAS L, 1988, BONE MINER, V4, P95; OVERGAARD K, 1989, CLIN ENDOCRINOL, V30, P435, DOI 10.1111/j.1365-2265.1989.tb00443.x; OVERGAARD K, 1989, BRIT MED J, V299, P477, DOI 10.1136/bmj.299.6697.477; OVERGAARD K, 1992, CALCIFIED TISSUE INT, V50, P30, DOI 10.1007/BF00297294; OVERGAARD K, 1990, AM J MED, V89, P1, DOI 10.1016/0002-9343(90)90089-V; OVERGAARD K, 1991, CALCIFIED TISSUE INT, V49, pS60, DOI 10.1007/BF02555091; OVERGAARD K, IN PRESS CALCIF TISS; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; SINGER FR, 1976, CLIN ENDOCRINOL, V5, P333; STORM T, 1990, NEW ENGL J MED, V322, P1265, DOI 10.1056/NEJM199005033221803; WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201	25	355	358	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 5	1992	305	6853					556	561		10.1136/bmj.305.6853.556	http://dx.doi.org/10.1136/bmj.305.6853.556			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM495	1393035	Bronze, Green Submitted, Green Published			2022-12-28	WOS:A1992JM49500017
J	WIDGERY, D				WIDGERY, D			AIDS FAREWELLS	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 5	1992	305	6853					590	590						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM495	1393064				2022-12-28	WOS:A1992JM49500072
J	LATRON, F; PAZMANY, L; MORRISON, J; MOOTS, R; SAPER, MA; MCMICHAEL, A; STROMINGER, JL				LATRON, F; PAZMANY, L; MORRISON, J; MOOTS, R; SAPER, MA; MCMICHAEL, A; STROMINGER, JL			A CRITICAL ROLE FOR CONSERVED RESIDUES IN THE CLEFT OF HLA-A2 IN PRESENTATION OF A NONAPEPTIDE TO T-CELLS	SCIENCE			English	Article							ANTIGEN-BINDING SITE; TOXIC LYMPHOCYTES-T; HISTOCOMPATIBILITY ANTIGEN; PEPTIDE; RECOGNITION; MOLECULES	The peptide binding cleft of the class I human histocompatibility antigen, HLA-A2, contains conserved amino acid residues clustered in the two ends of the cleft in pockets A and F as well as polymorphic residues. The function of two conserved tyrosines in the A pocket was investigated by mutating them to phenylalanines and of a conserved tyrosine and threonine in the F pocket by mutating them to phenylalanine and valine, respectively. Presentation of influenza virus peptides and of intact virus to cytolytic T lymphocytes (CTLs) was then examined. The magnitude of the reduction seen by the mutation of the two tyrosines in the A pocket suggests that hydrogen bonds involving them have a critical function in the binding of the NH2-terminal NH3+ of the peptide nonamer and possibly of all bound peptide nonamers. In contrast, the mutations in the F pocket had no effect on CTL recognition.	UNIV OXFORD,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND; HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138	University of Oxford; Harvard University	LATRON, F (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115, USA.		Moots, Robert/AAM-8091-2020; Morrison, Jo/AAK-2858-2020	Morrison, Jo/0000-0003-0000-520X	NATIONAL CANCER INSTITUTE [R35CA047554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020182] Funding Source: NIH RePORTER; NCI NIH HHS [CA 47554] Funding Source: Medline; NIAID NIH HHS [AI 20182] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEDNAREK MA, 1991, J IMMUNOL, V147, P4047; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BODMER HC, 1989, NATURE, V337, P653, DOI 10.1038/337653a0; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; CERUNDOLO V, 1991, EUR J IMMUNOL, V21, P2069, DOI 10.1002/eji.1830210915; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GOTCH F, 1987, NATURE, V326, P653; LATRON F, 1991, P NATL ACAD SCI USA, V88, P11325, DOI 10.1073/pnas.88.24.11325; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, IN PRESS CELL; MCMICHAEL AJ, 1988, P NATL ACAD SCI USA, V85, P9194, DOI 10.1073/pnas.85.23.9194; MORRISON J, 1992, EUR J IMMUNOL, V22, P903, DOI 10.1002/eji.1830220404; ROBBINS PA, 1989, J IMMUNOL, V143, P4098; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SANTOSAGUADO J, 1989, P NATL ACAD SCI USA, V86, P8936, DOI 10.1073/pnas.86.22.8936; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; VANBLEEK GM, 1990, NATURE, V348, P213	21	77	79	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 14	1992	257	5072					964	967		10.1126/science.1380181	http://dx.doi.org/10.1126/science.1380181			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH827	1380181				2022-12-28	WOS:A1992JH82700035
J	BEEKEN, S; WATERSTON, T				BEEKEN, S; WATERSTON, T			HEALTH-SERVICE SUPPORT OF BREAST-FEEDING - ARE WE PRACTICING WHAT WE PREACH	BRITISH MEDICAL JOURNAL			English	Article								Objective-To ascertain the attitudes of health professionals and breast feeding mothers to breast feeding and their views on current practice. Design-Questionnaire to all midwives and health visitors and to breast feeding mothers in Newcastle upon Tyne. Setting-Maternity units and community in Newcastle upon Tyne. Subjects-127 hospital midwives, 23 community midwives, 63 health visitors, and 50 first time breast feeding mothers. Results-Optimum practice guidelines were not followed. 30 (60%) mothers said they were separated from their babies on the first night after birth. 82 (42%) professionals said that breast fed babies were frequently given water to drink. 28 (56%) babies in the mothers survey had received food or water other than breast milk; 19 of these had been given water. Professionals expressed mainly positive attitudes towards breast feeding in general but less positive attitudes to specific issues such as the beneficial effects on child health and the value of voluntary organisations in breast feeding promotion and management. Conclusions-Although many health workers are in favour of breast feeding there is conflict among the professions working most closely with breast feeding mothers. Good breast feeding support requires closer attention to monitoring hospital practices and continued training on good lactation management.	NEWCASTLE GEN HOSP,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND	Newcastle General Hospital								BLOOM K, 1982, ACTA PAEDIATR SC   S, V300, P9; CRUSE P, 1978, ARCH DIS CHILD, V53, P76, DOI 10.1136/adc.53.1.76; EMERY JL, 1990, ARCH DIS CHILD-FETAL, V65, P369, DOI 10.1136/adc.65.4_Spec_No.369; FRANK DA, 1987, PEDIATRICS, V80, P845; Grant J. Shaw, 1992, SHILLING YOUR SCOWL, P44; HOWIE PW, 1990, BRIT MED J, V300, P11, DOI 10.1136/bmj.300.6716.11; JELLIFE DB, 1988, PROGRAMMES PROMOTE B; LUCAS A, 1990, LANCET, V336, P1519, DOI 10.1016/0140-6736(90)93304-8; MARTIN J, 1988, INFANT FEEDING 1985; SALARIYA EM, 1978, LANCET, V2, P1141; WELLS N, 1987, PROGR CHILD HLTH, V3; 1988, C LAUNCH JOINT BREAS; 1988, SUCCESSFUL BREASTFEE	13	33	33	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1992	305	6848					285	287		10.1136/bmj.305.6848.285	http://dx.doi.org/10.1136/bmj.305.6848.285			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG740	1392861	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JG74000019
J	SHOU, C; FARNSWORTH, CL; NEEL, BG; FEIG, LA				SHOU, C; FARNSWORTH, CL; NEEL, BG; FEIG, LA			MOLECULAR-CLONING OF CDNAS ENCODING A GUANINE-NUCLEOTIDE-RELEASING FACTOR FOR RAS P21	NATURE			English	Article							PROTO-ONCOGENE; CELLS; GENE; MUTATION; EXCHANGE; PROTEINS; GROWTH; YEAST; GDP	THE stimulation of a variety of cell surface receptors promotes the accumulation of the active, GTP-bound form of Ras proteins in cells1-4. This is a critical step in signal transduction because inhibition of Ras activation by anti-Ras antibodies or dominant inhibitory Ras mutants blocks many of the effects of these receptors on cellular function5-8. To reach the active GTP-bound state, Ras proteins must first release bound GDP. This rate-limiting step in GTP binding is thought to be catalysed by a guanine-nucleotide-releasing factor (GRF)9-11. Here we report the cloning of complementary DNAs from a rat brain library that encode a approximately 140K GRF for Ras p21 (p140Ras-GRF). Its carboxy-terminal region is similar to that of CDC25, a GRF for Saccharomyces cerevisiae RAS11. This portion of Ras-GRF accelerated the release of GDP from RasH and RasN p21 in vitro, but not from the related RalA, or CDC42Hs GTP-binding proteins. A region in the aminoterminal end of Ras-GRF is similar to both the human breakpoint cluster protein, Bcr12, and the dbl oncogene product13, a guanine-nucleotide-releasing factor for CDC42Hs14. An understanding of Ras-GRF function will enhance our knowledge of the many signal transduction pathways mediated by Ras proteins.	TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111; BETH ISRAEL HOSP,MOLEC MED UNIT,BOSTON,MA 02215	Tufts University; Harvard University; Beth Israel Deaconess Medical Center								BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; DANAK F, 1991, MOL CELL BIOL, V11, P202; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HUGHES DA, 1990, NATURE, V344, P355, DOI 10.1038/344355a0; JOHN J, 1988, J BIOL CHEM, V263, P11792; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KAIBUCHI K, 1991, MOL CELL BIOL, V11, P2873, DOI 10.1128/MCB.11.5.2873; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; RON D, 1991, NEW BIOL, V3, P372; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; WOLFMAN A, 1990, SCIENCE, V248, P247	32	356	366	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 23	1992	358	6384					351	354		10.1038/358351a0	http://dx.doi.org/10.1038/358351a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE684	1379346				2022-12-28	WOS:A1992JE68400070
J	SILVA, AJ; STEVENS, CF; TONEGAWA, S; WANG, YY				SILVA, AJ; STEVENS, CF; TONEGAWA, S; WANG, YY			DEFICIENT HIPPOCAMPAL LONG-TERM POTENTIATION IN ALPHA-CALCIUM-CALMODULIN KINASE-II MUTANT MICE	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; RAT-BRAIN; EXPRESSION; AUTOPHOSPHORYLATION; TRANSMISSION; GENE	As a first step in a program to use genetically altered mice in the study of memory mechanisms, mutant mice were produced that do not express the alpha-calcium-calmodulin-dependent kinase II (alpha-CaMKII). The alpha-CaMKII is highly enriched in postsynaptic densities of hippocampus and neocortex and may be involved in the regulation of long-term potentiation (LTP). Such mutant mice exhibited mostly normal behaviors and presented no obvious neuroanatomical defects. Whole cell recordings reveal that postsynaptic mechanisms, including N-methyl-D-aspartate (NMDA) receptor function, are intact. Despite normal postsynaptic mechanisms, these mice are deficient in their ability to produce LTP and are therefore a suitable model for studying the relation between LTP and learning processes.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,LA JOLLA,CA 92037	Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Salk Institute	SILVA, AJ (corresponding author), MIT,HOWARD HUGHES MED INST,CTR CANC RES,CAMBRIDGE,MA 02139, USA.		Silva, Alcino/ABD-7684-2021	Silva, Alcino/0000-0002-1587-4558; Silva, Alcino/0000-0001-5525-0494	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS012961] Funding Source: NIH RePORTER; NINDS NIH HHS [5 R01 NS 12961-17] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BURGIN KE, 1990, J NEUROSCI, V10, P1788; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; DAVIS M, 1992, TRENDS PHARMACOL SCI, V13, P35, DOI 10.1016/0165-6147(92)90014-W; DOUGLAS RJ, 1967, PSYCHOL BULL, V67, P416, DOI 10.1037/h0024599; ERONDU NE, 1985, J NEUROSCI, V5, P3270; FALLS WA, 1992, J NEUROSCI, V12, P854; GUTHRIE PB, 1991, NATURE, V354, P76, DOI 10.1038/354076a0; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; JAHR CE, 1990, J NEUROSCI, V10, P1830; JAHR CE, 1990, J NEUROSCI, V10, P3178; LIN JW, 1990, P NATL ACAD SCI USA, V87, P8257, DOI 10.1073/pnas.87.21.8257; LISMAN JE, 1988, P NATL ACAD SCI USA, V85, P5320, DOI 10.1073/pnas.85.14.5320; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MCGUINESS T, 1985, J BIOL CHEM, V260, P1969; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MORRIS RGM, 1991, LONG TERM POTENTIATI; MULLER W, 1991, NATURE, V354, P74; SCHULMAN H, 1989, TRENDS BIOCHEM SCI, V14, P62, DOI 10.1016/0968-0004(89)90045-5; SILVA AJ, 1992, SCIENCE, V257, P209; SILVA AMS, UNPUB; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7	29	1176	1205	3	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 10	1992	257	5067					201	206		10.1126/science.1378648	http://dx.doi.org/10.1126/science.1378648			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC585	1378648				2022-12-28	WOS:A1992JC58500026
J	ARAKAWA, H; UMEMURA, K; IKAI, A				ARAKAWA, H; UMEMURA, K; IKAI, A			PROTEIN IMAGES OBTAINED BY STM, AFM AND TEM	NATURE			English	Article							SCANNING TUNNELING MICROSCOPY; ATOMIC FORCE MICROSCOPY; TUNNELLING MICROSCOPY; PHOSPHORYLASE-KINASE; DNA; BIOMOLECULES; WATER	Scanning tunnelling microscopy and atomic force microscopy, one scanning the tunnelling current and the other the repulsive atomic force between sample and probe, can give high-quality surface topographies of proteins, which have been difficult to obtain by more conventional methods such as transmission electron microscopy.			ARAKAWA, H (corresponding author), TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,MIDORI KU,YOKOHAMA,KANAGAWA 227,JAPAN.							ARSCOTT PG, 1989, NATURE, V339, P484, DOI 10.1038/339484a0; CLEMMER CR, 1991, SCIENCE, V251, P640, DOI 10.1126/science.1992517; DRAKE B, 1989, SCIENCE, V243, P1586, DOI 10.1126/science.2928794; DRISCOLL RJ, 1990, NATURE, V346, P294, DOI 10.1038/346294a0; DUNLAP DD, 1989, NATURE, V342, P204, DOI 10.1038/342204a0; EDSTROM RD, 1990, BIOPHYS J, V58, P1437, DOI 10.1016/S0006-3495(90)82489-9; EDSTROM RD, 1989, BIOCHEMISTRY-US, V28, P4939, DOI 10.1021/bi00438a004; HOH JH, 1991, SCIENCE, V253, P1405, DOI 10.1126/science.1910206; HORBER JKH, 1988, CHEM PHYS LETT, V145, P151, DOI 10.1016/0009-2614(88)80169-6; IKAI A, 1987, J PROTEIN CHEM, V6, P81; LEATHERBARROW RJ, 1991, J MOL BIOL, V221, P361, DOI 10.1016/0022-2836(91)80056-Z; LINDSAY SM, 1989, SCIENCE, V244, P1063, DOI 10.1126/science.2727694; OSADA T, 1988, J ULTRA MOL STRUCT R, V101, P62, DOI 10.1016/0889-1605(88)90082-1; SALMERON M, 1990, J VAC SCI TECHNOL A, V8, P635, DOI 10.1116/1.576361; VERNETTI LA, 1991, J VAC SCI TECHNOL B, V9, P1223, DOI 10.1116/1.585209; WEISENHORN AL, 1990, BIOPHYS J, V58, P1251, DOI 10.1016/S0006-3495(90)82465-6; WIGREN R, 1991, FEBS LETT, V280, P225, DOI 10.1016/0014-5793(91)80298-H	17	58	58	4	64	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 9	1992	358	6382					171	&		10.1038/358171a0	http://dx.doi.org/10.1038/358171a0			0	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC583	1377369				2022-12-28	WOS:A1992JC58300060
J	KELEN, GD; GREEN, GB; PURCELL, RH; CHAN, DW; QAQISH, BF; SIVERTSON, KT; QUINN, TC				KELEN, GD; GREEN, GB; PURCELL, RH; CHAN, DW; QAQISH, BF; SIVERTSON, KT; QUINN, TC			HEPATITIS-B AND HEPATITIS-C IN EMERGENCY DEPARTMENT PATIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; NON-A; HEPATOCELLULAR-CARCINOMA; SEXUAL TRANSMISSION; UNITED-STATES; CIRCULATING ANTIBODIES; RISK; INFECTION; EPIDEMIOLOGY; PREVALENCE	Background. Infections with hepatitis B virus (HBV), hepatitis C virus (HCV), and the human immunodeficiency virus type 1 (HIV-1) are common in inner-city populations, but their frequency and interrelations are not well established. Methods. During a six-week period, excess serum samples were collected, along with information on risk factors, from all adult patients presenting to an inner-city emergency department. The samples were assayed for hepatitis B surface antigen (HBsAg) and antibodies to HCV and HIV-1. Results. Of the 2523 patients tested, 612 (24 percent) were infected with at least one of the three viruses. Five percent were seropositive for HBV, 18 percent for HCV, and 6 percent for HIV-1. HCV was found in 145 of the 175 intravenous drug users (83 percent), 36 of the 171 transfusion recipients (21 percent), and 5 of the 24 homosexual men (21 percent). Among black men 35 to 44 years of age, the seroprevalence of HCV was 51 percent. HBsAg was present in 9 percent of those whose only identifiable risk was possible heterosexual exposure. At least one viral marker was found in about 30 percent of the patients who were actively bleeding or in whom procedures were performed. Testing for HIV-1 alone would have failed to identify 87 percent of the patients infected with HBV and 80 percent of those infected with HCV. Conclusions. In a population of patients in an inner-city emergency room, HBV, HCV, and HIV-1 are all highly prevalent. However, routine screening for HIV-1 alone would identify only a small fraction of the patients who pose risks of severe viral infections, including HBV and HCV, to providers.	JOHNS HOPKINS UNIV,SCH MED,DIV EMERGENCY MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DIV INFECT DIS,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV HOSP,DEPT LAB MED,BALTIMORE,MD 21205; UNIV N CAROLINA,DEPT BIOSTAT,CHAPEL HILL,NC 27514; NIAID,INFECT DIS LAB,BETHESDA,MD 20892; NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Quinn, Thomas/A-2494-2010	Kelen, Gabor/0000-0002-3236-8286				AHTONE J, 1980, LANCET, V1, P1142; ALEXANDER PG, 1990, PUBLIC HEALTH REP, V105, P610; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER MJ, 1982, J INFECT DIS, V145, P886, DOI 10.1093/infdis/145.6.886; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; ALTER MJ, 1989, JAMA-J AM MED ASSOC, V262, P1201, DOI 10.1001/jama.262.9.1201; ANGELL M, 1991, NEW ENGL J MED, V324, P1498, DOI 10.1056/NEJM199105233242110; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; COLOMBO M, 1989, LANCET, V2, P1006; DIENSTAG JL, 1983, GASTROENTEROLOGY, V85, P439; DIENSTAG JL, 1982, AM J EPIDEMIOL, V115, P26, DOI 10.1093/oxfordjournals.aje.a113277; DONAHUE JG, 1991, AM J EPIDEMIOL, V134, P1206, DOI 10.1093/oxfordjournals.aje.a116023; ESTEBAN JI, 1990, NEW ENGL J MED, V323, P1107, DOI 10.1056/NEJM199010183231605; ESTEBAN JI, 1989, LANCET, V2, P294; EVATT BL, 1985, NEW ENGL J MED, V312, P483, DOI 10.1056/NEJM198502213120805; EVERHART JE, 1990, ANN INTERN MED, V112, P544, DOI 10.7326/0003-4819-112-7-544; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; GORDIN FM, 1990, J INFECT DIS, V161, P14, DOI 10.1093/infdis/161.1.14; HANDSFIELD HH, 1987, JAMA-J AM MED ASSOC, V258, P3395, DOI 10.1001/jama.258.23.3395; HESS G, 1989, LANCET, V2, P987; HOPF U, 1990, J HEPATOL, V10, P69, DOI 10.1016/0168-8278(90)90075-3; JOHNSON RE, 1985, AM J EPIDEMIOL, V121, P797, DOI 10.1093/oxfordjournals.aje.a114051; JOVANOVICH JF, 1983, JAMA-J AM MED ASSOC, V250, P1893; KELEN GD, 1989, JAMA-J AM MED ASSOC, V262, P516, DOI 10.1001/jama.262.4.516; KELEN GD, 1988, NEW ENGL J MED, V318, P1645, DOI 10.1056/NEJM198806233182503; KEW MC, 1990, LANCET, V335, P873, DOI 10.1016/0140-6736(90)90474-J; KIYOSAWA K, 1991, ANN INTERN MED, V115, P367, DOI 10.7326/0003-4819-115-5-367; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LIANG KY, IN PRESS J R STAT B; LIDDLE C, 1990, MED J AUSTRALIA, V153, P265, DOI 10.5694/j.1326-5377.1990.tb136898.x; MARCUS R, 1990, MAY ANN M SOC AC EM; MAYOSMITH MF, 1987, AM J INFECT CONTROL, V15, P266, DOI 10.1016/0196-6553(87)90120-9; MELBYE M, 1990, BRIT MED J, V301, P210, DOI 10.1136/bmj.301.6745.210; MOSLEY JW, 1990, JAMA-J AM MED ASSOC, V263, P77, DOI 10.1001/jama.263.1.77; NALPAS B, 1991, J HEPATOL, V12, P70, DOI 10.1016/0168-8278(91)90912-U; PARES A, 1990, HEPATOLOGY, V12, P1295, DOI 10.1002/hep.1840120608; RHAME FS, 1989, NEW ENGL J MED, V320, P1248, DOI 10.1056/NEJM198905113201905; SAKAMOTO M, 1988, CANCER RES, V48, P7294; SCHLIPKOTER U, 1990, SCAND J INFECT DIS, V22, P757, DOI 10.3109/00365549009027136; SEEFF LB, 1991, ANN INTERN MED, V115, P411, DOI 10.7326/0003-4819-115-5-411_1; STEVENS CE, 1990, JAMA-J AM MED ASSOC, V263, P49, DOI 10.1001/jama.263.1.49; TOR J, 1990, BRIT MED J, V301, P1130, DOI 10.1136/bmj.301.6761.1130; VALLARI DS, 1992, J CLIN MICROBIOL, V30, P552, DOI 10.1128/JCM.30.3.552-556.1992; Watson GS., 1964, SANKHYA A, V26, P359, DOI DOI 10.2307/25049340; WEARS RL, 1991, ANN EMERG MED, V20, P749, DOI 10.1016/S0196-0644(05)80836-4; WEINER AJ, 1990, LANCET, V336, P695, DOI 10.1016/0140-6736(90)92194-M; WERNER AJ, 1990, LANCET, V335, P1; WILLIAMS AE, 1990, ANN CLIN LAB SCI, V20, P192; 1989, MMWR SS6, V38; 1991, MMWR SRR13, V40, P1; 1990, MMWR SRR2, V39, P5; 1991, MMWR SRR8, V40, P1; 1989, 1ST P INT S HEP C VI, pCH2; 1987, MMWR, V36, P353	54	247	249	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 21	1992	326	21					1399	1404		10.1056/NEJM199205213262105	http://dx.doi.org/10.1056/NEJM199205213262105			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU890	1373867				2022-12-28	WOS:A1992HU89000005
J	BUELER, H; FISCHER, M; LANG, Y; BLUETHMANN, H; LIPP, HP; DEARMOND, SJ; PRUSINER, SB; AGUET, M; WEISSMANN, C				BUELER, H; FISCHER, M; LANG, Y; BLUETHMANN, H; LIPP, HP; DEARMOND, SJ; PRUSINER, SB; AGUET, M; WEISSMANN, C			NORMAL DEVELOPMENT AND BEHAVIOR OF MICE LACKING THE NEURONAL CELL-SURFACE PRP PROTEIN	NATURE			English	Article							SCRAPIE PRION PROTEINS; EMBRYONIC STEM-CELLS; INCUBATION PERIOD; MOLECULAR-CLONING; TRANSGENIC MICE; CULTURED-CELLS; MOUSE-BRAIN; T-CELLS; GENE; DEFICIENT	PrP(c) is a host protein anchored to the outer surface of neurons and to a lesser extent of lymphocytes and other cells. The transmissible agent (prion) responsible for scrapie is believed to be a modified form of PrP(c). Mice homozygous for disrupted PrP genes have been generated. Surprisingly, they develop and behave normally for at least seven months, and no immunological defects are apparent. It is now feasible to determine whether mice devoid of PrP(c) can propagate prions and are susceptible to scrapie pathogenesis.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV ZURICH, INST ANAT, CH-8057 ZURICH, SWITZERLAND; F HOFFMANN LA ROCHE & CO LTD, PRTB, CH-4002 BASEL, SWITZERLAND; UNIV CALIF SAN FRANCISCO, DEPT PATHOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT NEUROL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of Zurich; Roche Holding; University of California System; University of California San Francisco; University of California System; University of California San Francisco	BUELER, H (corresponding author), UNIV ZURICH, INST MOLEK BIOL 1, CH-8093 ZURICH, SWITZERLAND.		Büeler, Hansruedi/J-6965-2017	Büeler, Hansruedi/0000-0002-4892-7177				ANISMAN H, 1978, PSYCHOPHARMACOLOGY A, P1; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BUTLER DA, 1988, J VIROL, V62, P1558, DOI 10.1128/JVI.62.5.1558-1564.1988; CAPECCHI MR, 1989, TRENDS GENET, V5, P70, DOI 10.1016/0168-9525(89)90029-2; CARLSON GA, 1989, P NATL ACAD SCI USA, V86, P7475, DOI 10.1073/pnas.86.19.7475; CARLSON GA, 1986, CELL, V46, P503, DOI 10.1016/0092-8674(86)90875-5; CASHMAN NR, 1990, CELL, V61, P185, DOI 10.1016/0092-8674(90)90225-4; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DEARMOND SJ, 1987, NEUROLOGY, V37, P1271, DOI 10.1212/WNL.37.8.1271; DICKINSON AG, 1971, MOL GEN GENET, V112, P73, DOI 10.1007/BF00266934; DICKINSON AG, 1968, J COMP PATHOL, V78, P293, DOI 10.1016/0021-9975(68)90005-4; DIRINGER H, 1983, NATURE, V306, P476, DOI 10.1038/306476a0; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FERGUSON EL, 1989, GENETICS, V123, P109; GABIZON R, 1988, P NATL ACAD SCI USA, V85, P6617, DOI 10.1073/pnas.85.18.6617; GOEBL MG, 1986, CELL, V46, P983, DOI 10.1016/0092-8674(86)90697-5; GOLDMANN W, 1991, J GEN VIROL, V72, P201, DOI 10.1099/0022-1317-72-1-201; HARRIS DA, 1991, P NATL ACAD SCI USA, V88, P7664, DOI 10.1073/pnas.88.17.7664; HOGAN B, 1986, MANIPULATING MOUSE E; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; HSIAO K, 1990, NEUROLOGY, V40, P1820, DOI 10.1212/WNL.40.12.1820; HSIAO KK, 1990, SCIENCE, V250, P1587, DOI 10.1126/science.1980379; HUNTER N, 1987, J GEN VIROL, V68, P2711, DOI 10.1099/0022-1317-68-10-2711; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KRETZSCHMAR HA, 1986, AM J PATHOL, V122, P1; KRETZSCHMAR HA, 1986, DNA-J MOLEC CELL BIO, V5, P315, DOI 10.1089/dna.1986.5.315; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPP HP, 1988, J NEUROSCI, V8, P1905; LIPP HP, 1991, BEHAV BRAIN RES, V45, P135, DOI 10.1016/S0166-4328(05)80079-8; LOCHT C, 1986, P NATL ACAD SCI USA, V83, P6372, DOI 10.1073/pnas.83.17.6372; MANSON J, IN PRESS DEVELOPMENT; MCKINLEY M P, 1990, Journal of Cell Biology, V111, p316A; MCKINLEY MP, 1983, CELL, V35, P57, DOI 10.1016/0092-8674(83)90207-6; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; NAGASE S, 1979, SCIENCE, V205, P590, DOI 10.1126/science.451621; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; PUCKETT C, 1991, AM J HUM GENET, V49, P320; RACE RE, 1990, J GEN VIROL, V71, P493, DOI 10.1099/0022-1317-71-2-493; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; Schopke R, 1991, Hippocampus, V1, P315, DOI 10.1002/hipo.450010322; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; Siegel S., 1956, NONPARAMETRIC STAT B; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; TARABOULOS A, 1990, J CELL BIOL, V110, P2117, DOI 10.1083/jcb.110.6.2117; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THOMAS LJ, 1991, J BIOL CHEM, V266, P23175; WEHNER JM, 1990, BRAIN RES, V523, P181, DOI 10.1016/0006-8993(90)91485-Y; WESTAWAY D, 1991, NEURON, V7, P59, DOI 10.1016/0896-6273(91)90074-A; WESTAWAY D, 1987, CELL, V51, P651, DOI 10.1016/0092-8674(87)90134-6; WESTAWAY D, 1986, NUCLEIC ACIDS RES, V14, P2035, DOI 10.1093/nar/14.5.2035; WOLFER DP, 1992, J NEUROSCI METH, V41, P65, DOI 10.1016/0165-0270(92)90124-V; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	68	1424	1477	0	66	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 16	1992	356	6370					577	582		10.1038/356577a0	http://dx.doi.org/10.1038/356577a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HP031	1373228				2022-12-28	WOS:A1992HP03100039
J	CANELLOS, GP; ANDERSON, JR; PROPERT, KJ; NISSEN, N; COOPER, MR; HENDERSON, ES; GREEN, MR; GOTTLIEB, A; PETERSON, BA				CANELLOS, GP; ANDERSON, JR; PROPERT, KJ; NISSEN, N; COOPER, MR; HENDERSON, ES; GREEN, MR; GOTTLIEB, A; PETERSON, BA			CHEMOTHERAPY OF ADVANCED HODGKINS-DISEASE WITH MOPP, ABVD, OR MOPP ALTERNATING WITH ABVD	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TERM FOLLOW-UP; COMBINATION CHEMOTHERAPY; PROGNOSTIC FACTORS; DACARBAZINE ABVD; BLEOMYCIN; VINBLASTINE; SURVIVAL; ADRIAMYCIN; TOXICITY; THERAPY	Background and Methods. MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) has been the standard treatment for Hodgkin's disease for almost 20 years. In a randomized, multicenter trial, we compared three regimens of primary systemic therapy for newly diagnosed advanced Hodgkin's disease in Stages IIIA2, IIIB, and IVA or IVB: (1) MOPP alone given for 6 to 8 cycles, (2) MOPP alternating with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) for 12 cycles, and (3) ABVD alone for 6 to 8 cycles. Patients in a first relapse after radiation therapy were eligible. No additional radiation therapy was given. Patients who did not have a complete response or who had a relapse with either MOPP alone or ABVD alone were switched to the opposite regimen. Results. Of 361 eligible patients, 123 received MOPP, 123 received MOPP alternating with ABVD, and 115 received ABVD alone. The patients were stratified according to age, stage, previous radiation, histologic features, and performance status. The overall response rate was 93 percent, with complete responses in 77 percent: 67 percent in the MOPP group, 82 percent in the ABVD group, and 83 percent in the MOPP-ABVD group (P = 0.006 for the comparison of MOPP with the other two regimens, both of which contained doxorubicin). The rates of failure-free survival at five years were 50 percent for MOPP, 61 percent for ABVD, and 65 percent for MOPP-ABVD. Age, stage (III vs. IV), and regimen influenced failure-free survival significantly. Overall survival at five years was 66 percent for MOPP, 73 percent for ABVD, and 75 percent for MOPP-ABVD (P = 0.28 for the comparison of MOPP with the doxorubicin regimens). MOPP had more severe toxic effects on bone marrow than ABVD and was associated with greater reductions in the prescribed dose. Conclusions. In this trial, ABVD therapy for 6 to 8 months was as effective as 12 months of MOPP alternating with ABVD, and both were superior to MOPP alone in the treatment of advanced Hodgkin's disease. ABVD was less myelotoxic than MOPP or ABVD alternating with MOPP.	SUNY HLTH SCI CTR,DEPT MED,SYRACUSE,NY; UNIV MINNESOTA,DEPT MED,MINNEAPOLIS,MN 55455; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; UNIV NEBRASKA,MED CTR,OMAHA,NE 68105; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; RIGSHOSP,DEPT HEMATOL,DK-2100 COPENHAGEN,DENMARK; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT MED,WINSTON SALEM,NC 27103; US FDA,ROCKVILLE,MD 20857; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; University of Minnesota System; University of Minnesota Twin Cities; Harvard University; Harvard Medical School; University of Nebraska System; University of Nebraska Medical Center; Harvard University; Harvard T.H. Chan School of Public Health; Rigshospitalet; University of Copenhagen; Wake Forest University; Wake Forest Baptist Medical Center; US Food & Drug Administration (FDA); University of California System; University of California San Diego	CANELLOS, GP (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV MED ONCOL,44 BINNEY ST,BOSTON,MA 02115, USA.				NATIONAL CANCER INSTITUTE [U10CA031946] Funding Source: NIH RePORTER; NCI NIH HHS [CA 31946] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKEMEIER RF, 1984, ANN INTERN MED, V101, P447, DOI 10.7326/0003-4819-101-4-447; BONADONNA G, 1986, ANN INTERN MED, V104, P739, DOI 10.7326/0003-4819-104-6-739; BONADONNA G, 1975, CANCER, V36, P252, DOI 10.1002/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7; BURGERS JMV, 1991, ANN ONCOL, V2, P63, DOI 10.1093/annonc/2.suppl_2.63; CARDE P, 1983, J CLIN ONCOL, V1, P146, DOI 10.1200/JCO.1983.1.2.146; DEVITA VT, 1970, ANN INTERN MED, V73, P881, DOI 10.7326/0003-4819-73-6-881; FLEISS JL, 1973, STATISTICAL METHODS; GLICK J, 1991, P AN M AM SOC CLIN, V10, P271; HARKER WG, 1984, ANN INTERN MED, V101, P440, DOI 10.7326/0003-4819-101-4-440; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KLIMO P, 1985, J CLIN ONCOL, V3, P1174, DOI 10.1200/JCO.1985.3.9.1174; LISTER TA, 1989, J CLIN ONCOL, V7, P1630, DOI 10.1200/JCO.1989.7.11.1630; Lister TA, 1990, J CLIN ONCOL, V8, P1602; LONGO DL, 1986, J CLIN ONCOL, V4, P1295, DOI 10.1200/JCO.1986.4.9.1295; PAPA G, 1982, EUR J CANCER CLIN ON, V18, P803, DOI 10.1016/0277-5379(82)90188-2; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PIGA A, 1984, CANCER TREAT REP, V68, P947; PILLAI GN, 1985, CANCER, V55, P691, DOI 10.1002/1097-0142(19850215)55:4<691::AID-CNCR2820550403>3.0.CO;2-Q; SANTORO A, 1987, J CLIN ONCOL, V5, P27, DOI 10.1200/JCO.1987.5.1.27; SCHILSKY RL, 1981, AM J MED, V71, P552, DOI 10.1016/0002-9343(81)90205-9; SELBY P, 1990, BRIT J CANCER, V62, P279, DOI 10.1038/bjc.1990.278; STRAUS DJ, 1990, J CLIN ONCOL, V8, P1173, DOI 10.1200/JCO.1990.8.7.1173; SUTCLIFFE SB, 1979, CANCER CHEMOTH PHARM, V2, P209; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; VALAGUSSA P, 1986, J CLIN ONCOL, V4, P830, DOI 10.1200/JCO.1986.4.6.830; VANRIJSWIJK REN, 1989, J CLIN ONCOL, V7, P1776, DOI 10.1200/JCO.1989.7.12.1776; VIVIANI S, 1985, EUR J CANCER CLIN ON, V21, P601, DOI 10.1016/0277-5379(85)90088-4; WAGSTAFF J, 1988, BRIT J CANCER, V58, P487, DOI 10.1038/bjc.1988.246; WAXMAN JHX, 1982, BRIT MED J, V285, P1612, DOI 10.1136/bmj.285.6355.1612	29	810	832	1	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 19	1992	327	21					1478	1484		10.1056/NEJM199211193272102	http://dx.doi.org/10.1056/NEJM199211193272102			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY165	1383821				2022-12-28	WOS:A1992JY16500002
J	DOUGHERTY, CJ				DOUGHERTY, CJ			ETHICAL VALUES AT STAKE IN HEALTH-CARE REFORM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COSTS				DOUGHERTY, CJ (corresponding author), CREIGHTON UNIV,CTR HLTH POLICY & ETH,CALIF & 24TH ST,OMAHA,NE 68178, USA.							ATTFIELD R, 1987, THEORY VALUE OBLIGAT, P25; BAUCHAMP TL, 1979, J MED PHILOS, V4, P119; BEAUCHAMP TL, 1989, PRINCIPLES BIOMEDICA, P275; Bellah R. N., 1985, HABITS OF THE HEART; Callahan D., 1987, MED GOALS AGEING SOC; DEWEY J, 1977, J DEWEY ESSENTIAL WR, P171; Dougherty C J, 1992, Law Med Health Care, V20, P82; DOUGHERTY CJ, 1991, HASTINGS CENT REP S, V21, P1; DOUGHERTY CJ, 1988, AM HLTH CARE, P50; DOUGHERTY CJ, 1989, THEOR MED, V11, P275; EDDY DM, 1990, JAMA-J AM MED ASSOC, V264, P1161, DOI 10.1001/jama.264.9.1161; FRIED C, 1978, RIGHT WRONG, P108; FRIEDMAN E, 1989, JAMA-J AM MED ASSOC, V261, P1481; HUGHES JS, 1991, JAMA-J AM MED ASSOC, V265, P2347, DOI 10.1001/jama.265.18.2347; IGLEHART JK, 1989, NEW ENGL J MED, V321, P198, DOI 10.1056/NEJM198907203210327; JENNINGS B, 1990, HASTINGS CENT REP, V20, P16; KAMMER F, 1991, DOING FAITHJUSTICE, P80; KANT I, 1964, GROUNDWORK METAPHYSI, P96; Leininger M. M., 1981, CARING ESSENTIAL NEE; MARMOR TR, 1990, AM PROSPECT, V3, P18; Norman Richard, 1983, MORAL PHILOS INTRO E; Pellegrino ED, 1979, HUMANISM PHYS, P222; Rawls J., 1971, THEORY JUSTICE; Walzer Michael, 1983, SPHERES JUSTICE DEFE, P31; WILSFORD D, 1991, DOCTORS STATE POLITI, P56; 1991, JUSTICE ALL ETHICS H; 1992, GPO SN003009005973 U; 1991, NATIONAL HLTH CARE S	28	36	36	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 4	1992	268	17					2409	2412		10.1001/jama.268.17.2409	http://dx.doi.org/10.1001/jama.268.17.2409			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JV694	1404798				2022-12-28	WOS:A1992JV69400027
J	KWAK, LW; CAMPBELL, MJ; CZERWINSKI, DK; HART, S; MILLER, RA; LEVY, R				KWAK, LW; CAMPBELL, MJ; CZERWINSKI, DK; HART, S; MILLER, RA; LEVY, R			INDUCTION OF IMMUNE-RESPONSES IN PATIENTS WITH B-CELL LYMPHOMA AGAINST THE SURFACE-IMMUNOGLOBULIN IDIOTYPE EXPRESSED BY THEIR TUMORS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACTIVE-SPECIFIC IMMUNOTHERAPY; TRANSPLANTATION RESISTANCE; RANDOMIZED TRIAL; IMMUNIZATION; VACCINATION; ANTIBODIES; MELANOMA; CYCLOPHOSPHAMIDE; COMBINATION	Background. The idiotypic determinants of the surface immunoglobulin of a B-cell lymphoma can serve as a clonal tumor-specific marker, which may have implications for immunotherapy. We sought to determine whether idiotype-specific immune responses against this autologous antigen could be induced in patients with B-cell lymphoma. Methods. Nine patients were selected who had minimal residual disease or a complete remission after chemotherapy. Each received a series of subcutaneous injections of the immunoglobulin derived from his or her tumor cells (immunoglobulin-idiotype protein), which had been conjugated to a protein carrier and mixed with an immunologic adjuvant. Results. In seven of the nine patients the injections induced sustained idiotype-specific immunologic responses of the humoral type (two patients), the cell-mediated type (four patients), or both (one patient). The use of an adjuvant was essential for these immune responses. The induced antibodies bound specifically to autologous immunoglobulin idiotype, inhibited the binding of murine monoclonal antiidiotype antibodies, and bound autologous tumor cells. Cell-mediated responses were demonstrated by the specific proliferation of immune peripheral-blood mononuclear cells to the soluble immunoglobulin-idiotype protein in vitro. The tumors of both of the patients with measurable disease regressed completely. Toxicity associated with the vaccine was minimal and consisted only of mild reactions at the site of intramuscular injection. Conclusions. These results demonstrate that autologous immunoglobulin idiotype can be formulated into an immunogenic, tumor-specific antigen in humans with B-cell lymphoma, and they provide the background for large-scale trials of active specific immunotherapy of this disease.	STANFORD UNIV,MED CTR,SCH MED,DEPT MED,DIV ONCOL,STANFORD,CA 94305	Stanford University				Levy, Ronald/0000-0003-2061-0650; Kwak, Larry/0000-0002-1884-5349	NATIONAL CANCER INSTITUTE [R37CA033399, R01CA033399] Funding Source: NIH RePORTER; NCI NIH HHS [CA-33399] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLISON AC, 1986, J IMMUNOL METHODS, V95, P157, DOI 10.1016/0022-1759(86)90402-3; BERD D, 1990, J CLIN ONCOL, V8, P1858, DOI 10.1200/JCO.1990.8.11.1858; BRIDGES SH, 1978, J IMMUNOL, V121, P479; BROWN SL, 1989, BLOOD, V73, P651; BYSTRYN JC, 1988, CANCER, V61, P1065, DOI 10.1002/1097-0142(19880315)61:6<1065::AID-CNCR2820610602>3.0.CO;2-L; Campbell M J, 1989, Int Rev Immunol, V4, P251, DOI 10.3109/08830188909044782; CAMPBELL MJ, 1988, J IMMUNOL, V141, P3227; CAMPBELL MJ, 1990, J IMMUNOL, V145, P1029; CAMPBELL MJ, 1987, J IMMUNOL, V139, P2825; CARROLL WL, 1986, J IMMUNOL METHODS, V89, P61, DOI 10.1016/0022-1759(86)90032-3; CHAIN B, 1987, J IMMUNOL METHODS, V99, P221, DOI 10.1016/0022-1759(87)90131-1; DALEY MJ, 1978, J IMMUNOL, V120, P1620; FREEDMAN PM, 1976, J NATL CANCER I, V56, P735, DOI 10.1093/jnci/56.4.735; GEORGE AJT, 1988, J IMMUNOL, V141, P2168; GEORGE AJT, 1987, J IMMUNOL, V138, P628; HOON DSB, 1990, CANCER RES, V50, P5358; HOOVER HC, 1985, CANCER, V55, P1236, DOI 10.1002/1097-0142(19850315)55:6<1236::AID-CNCR2820550616>3.0.CO;2-#; JORGENSEN T, 1980, SCAND J IMMUNOL, V11, P29, DOI 10.1111/j.1365-3083.1980.tb00205.x; KAMINSKI MS, 1987, J IMMUNOL, V138, P1289; MEEKER T, 1985, NEW ENGL J MED, V312, P1658, DOI 10.1056/NEJM198506273122602; MEEKER TC, 1985, BLOOD, V65, P1349, DOI 10.1182/blood.V65.6.1349.bloodjournal6561349; MILLER RA, 1982, NEW ENGL J MED, V306, P517, DOI 10.1056/NEJM198203043060906; MITCHELL MS, 1990, J CLIN ONCOL, V8, P856, DOI 10.1200/JCO.1990.8.5.856; SIRISINHA S, 1971, P NATL ACAD SCI USA, V68, P3130, DOI 10.1073/pnas.68.12.3130; STEVENSON FK, 1983, J IMMUNOL, V130, P970; STEVENSON GT, 1975, NATURE, V254, P714, DOI 10.1038/254714a0; STEVENSON GT, 1977, FED PROC, V36, P2268; SUGAI S, 1974, Journal of Experimental Medicine, V140, P1547, DOI 10.1084/jem.140.6.1547	28	489	550	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 22	1992	327	17					1209	1215		10.1056/NEJM199210223271705	http://dx.doi.org/10.1056/NEJM199210223271705			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JU393	1406793	Bronze			2022-12-28	WOS:A1992JU39300005
J	THIGPEN, AE; DAVIS, DL; GAUTIER, T; IMPERATOMCGINLEY, J; RUSSELL, DW				THIGPEN, AE; DAVIS, DL; GAUTIER, T; IMPERATOMCGINLEY, J; RUSSELL, DW			THE MOLECULAR-BASIS OF STEROID 5-ALPHA-REDUCTASE DEFICIENCY IN A LARGE DOMINICAN KINDRED	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							MALE PSEUDOHERMAPHRODITISM; 5ALPHA-REDUCTASE DEFICIENCY; DNA; POLYMERASE; POLYMORPHISMS; FORM		UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,5323 HARRY HINES BLVD,DALLAS,TX 75235; NATL UNIV PEDRO HENRIQUEZ URENA,DEPT PEDIAT,SANTO DOMINGO,DOMINICAN REP; CORNELL UNIV,SCH MED,DEPT MED,NEW YORK,NY 10021	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Universidad Nacional Pedro Henriquez Urena; Cornell University				Russell, David/0000-0002-0277-403X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD009421] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043753] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-07504, HD-09421] Funding Source: Medline; NIGMS NIH HHS [GM-43753] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON S, 1990, P NATL ACAD SCI USA, V87, P3640, DOI 10.1073/pnas.87.10.3640; ANDERSSON S, 1991, NATURE, V354, P159, DOI 10.1038/354159a0; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; DIAMOND JM, 1987, NATURE, V329, P105, DOI 10.1038/329105a0; GAJDUSEK DC, 1977, CIBA F S, V49, P69; GRIFFIN JE, 1981, J BIOL CHEM, V256, P3662; GRIFFIN JE, 1989, METABOLIC BASIS INHE, V2, P1919; IMPERATO.J, 1974, SCIENCE, V186, P1213, DOI 10.1126/science.186.4170.1213; IMPERATOMCGINLE.J, 1992, CECIL TXB MED, P1320; IMPERATOMCGINLEY J, 1979, NEW ENGL J MED, V300, P1233, DOI 10.1056/NEJM197905313002201; IMPERATOMCGINLEY J, 1985, J CLIN ENDOCR METAB, V60, P553, DOI 10.1210/jcem-60-3-553; IMPERATOMCGINLEY J, 1979, J STEROID BIOCHEM, V11, P637, DOI 10.1016/0022-4731(79)90093-1; IMPERATOMCGINLEY J, 1986, TRENDS GENET, V2, P130, DOI 10.1016/0168-9525(86)90202-7; JENKINS EP, 1992, J CLIN INVEST, V89, P293, DOI 10.1172/JCI115574; JENKINS EP, 1991, GENOMICS, V11, P1102, DOI 10.1016/0888-7543(91)90038-G; LEE JS, 1991, DNA CELL BIOL, V10, P67, DOI 10.1089/dna.1991.10.67; LESHIN M, 1978, J CLIN INVEST, V62, P685, DOI 10.1172/JCI109176; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PETERSON RE, 1977, AM J MED, V62, P170, DOI 10.1016/0002-9343(77)90313-8; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; THIGPEN AE, 1992, J CLIN INVEST, V90, P799, DOI 10.1172/JCI115954; THIGPEN AE, 1992, J BIOL CHEM, V267, P8577; WALSH PC, 1974, NEW ENGL J MED, V291, P944, DOI 10.1056/NEJM197410312911806	24	104	110	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 22	1992	327	17					1216	1219		10.1056/NEJM199210223271706	http://dx.doi.org/10.1056/NEJM199210223271706			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JU393	1406794				2022-12-28	WOS:A1992JU39300006
J	HILLMAN, BJ; OLSON, GT; GRIFFITH, PE; SUNSHINE, JH; JOSEPH, CA; KENNEDY, SD; NELSON, WR; BERNHARDT, LB				HILLMAN, BJ; OLSON, GT; GRIFFITH, PE; SUNSHINE, JH; JOSEPH, CA; KENNEDY, SD; NELSON, WR; BERNHARDT, LB			PHYSICIANS UTILIZATION AND CHARGES FOR OUTPATIENT DIAGNOSTIC-IMAGING IN A MEDICARE POPULATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FINANCIAL INCENTIVES; OFFICE PRACTICE	Objectives and Rationale.-For 10 common clinical presentations, we assessed differences in physicians' utilization of and charges for diagnostic imaging, depending on whether they performed imaging examinations in their offices (self-referral) or referred their patients to radiologists (radiologist-referral). Methods.-Using previously developed methodologies, we generated episodes of medical care from an insurance claims database. Within each episode, we determined whether diagnostic imaging had been performed, and if so, whether by a self-referring physician or a radiologist. For each of the 10 clinical presentations, we compared the mean imaging frequency, mean imaging charges per episode of care, and mean imaging charges for diagnostic imaging attributable to self- and radiologist-referral. Results.-Depending on the clinical presentation, self-referral resulted in 1.7 to 7.7 times more frequent performance of imaging examinations than radiologist-referral (P<.01, all presentations). Within all physician specialties, self-referral uniformly led to significantly greater utilization of diagnostic imaging than radiologist-referral. Mean imaging charges per episode of medical care (calculated as the product of the frequency of utilization and mean imaging charges) were 1.6 to 6.2 times greater for self-referral than for radiologist-referral (P<.01, all presentations). When imaging examinations were performed-including those performed in both physicians' offices and hospital outpatient departments-mean imaging charges were significantly greater for radiologists than for self-referring physicians in seven of the clinical presentations (P<.01). This result is related to the high technical charges of hospital outpatient departments; in office practice, radiologists' mean charges for imaging examinations were significantly less than those of self-referring physicians for seven clinical presentations (P<.01). Conclusions.-Nonradiologist physicians who operate diagnostic imaging equipment in their offices perform imaging examinations more frequently, resulting in higher imaging charges per episode of medical care. These results extend our previous research on this subject by their focus on a broader range of clinical presentations; a mostly elderly, retired population; and the inclusion of higher-technology imaging examinations.	ALTA HLTH STRATEGIES INC,LOS ANGELES,CA; AMER COLL RADIOL,RES DEPT,RESTON,VA; ABT ASSOCIATES INC,HLTH RES AREA,CAMBRIDGE,MA 02138; UNITED MINE WORKERS AMER,HLTH & RETIREMENT FUNDS,WASHINGTON,DC	American College of Radiology; ABT Associates	HILLMAN, BJ (corresponding author), UNIV VIRGINIA,HLTH SCI CTR,DEPT RADIOL,CHARLOTTESVILLE,VA 22908, USA.							Childs A W, 1972, Med Care, V10, P323, DOI 10.1097/00005650-197207000-00005; HEMENWAY D, 1990, NEW ENGL J MED, V322, P1059, DOI 10.1056/NEJM199004123221507; HILLMAN BJ, 1990, NEW ENGL J MED, V323, P1604, DOI 10.1056/NEJM199012063232306; HOLAHAN J, 1990, JAMA-J AM MED ASSOC, V263, P1658, DOI 10.1001/jama.263.12.1658; KUSSEROW RP, 1989, OAI128801410 HLTH CA; MILLER M, 1990, 37250103 URB I WORK; MITCHELL JM, 1991, JOINT VENTURES HLTH, P1; RADECKI SE, 1990, INVEST RADIOL, V25, P190, DOI 10.1097/00004424-199002000-00017; SCHROEDER SA, 1978, MED CARE, V16, P289, DOI 10.1097/00005650-197804000-00002; WENNEKER MB, 1990, JAMA-J AM MED ASSOC, V264, P1255, DOI 10.1001/jama.264.10.1255; 1988, 1988 PHYS PAYM REV C; 1991, HLTH CARE FINANCING, V13, P29; 1989, FED REG         0302, V54, P8894; 1989, INT CLASSIFICATION D, V1; 1990, CPT PHYSICIANS CURRE	15	169	168	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 21	1992	268	15					2050	2054		10.1001/jama.268.15.2050	http://dx.doi.org/10.1001/jama.268.15.2050			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT520	1404741				2022-12-28	WOS:A1992JT52000028
J	LAND, MF				LAND, MF			PREDICTABLE EYE HEAD COORDINATION DURING DRIVING	NATURE			English	Article							MOVEMENTS	LARGE changes in the direction of gaze are made with a combination of fast saccadic eye movements and rather slower head movements. Since the first study on freely moving subjects1, most authors have agreed that the head movement component of gaze is very variable, with a high 'volitional' component2. But in some circumstances head and eye movements can be quite predictable, for example when a subject is asked to shift gaze as quickly as possible3. Under these conditions, laboratory studies have shown that the eye and head motor-systems both receive gaze-change commands, although they execute them in rather different ways3-6. Here I reconsider the way gaze direction is changed during free movement, but in the performance of a task where the subject is too busy to exert conscious control over head or eye movements. Using a new portable and inexpensive method for recording head and eye movements, I examine the oculomotor behaviour of car drivers, particularly during the large gaze changes made at road junctions. The results show that the pattern of eye and head movements is highly preditable, given only the sequence of gaze targets.			LAND, MF (corresponding author), UNIV SUSSEX,SCH BIOL SCI,CTR NEUROSCI,BRIGHTON BN1 9QG,E SUSSEX,ENGLAND.							BECKER W, 1991, VISION VISUAL DYSFUN, P95; BIZZI E, 1971, SCIENCE, V173, P452, DOI 10.1126/science.173.3995.452; Carpenter RHS, 1988, MOVEMENTS EYES; Collewijn H., 1977, CONTROL GAZE BRAIN S, P13; Delreux V., 1991, BRAIN SPACE, P38; GUITTON D, 1992, TRENDS NEUROSCI, V15, P174, DOI 10.1016/0166-2236(92)90169-9; LAND MF, 1990, J COMP PHYSIOL A, V167, P155; LAURUTIS VP, 1986, J PHYSIOL-LONDON, V373, P209, DOI 10.1113/jphysiol.1986.sp016043; MORASSO P, 1973, EXP BRAIN RES, V16, P492, DOI 10.1007/BF00234475; TOMLINSON RD, 1990, J NEUROPHYSIOL, V64, P1873, DOI 10.1152/jn.1990.64.6.1873; Yarbus A.L., 1967, EYE MOVEMENTS VISION, DOI 10.1007/978-1-4899-5379-7; ZANGEMEISTER WH, 1982, EXP NEUROL, V77, P563, DOI 10.1016/0014-4886(82)90228-X; ZANGEMEISTER WH, 1981, EXP NEUROL, V71, P76, DOI 10.1016/0014-4886(81)90072-8	13	117	117	1	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 24	1992	359	6393					318	320		10.1038/359318a0	http://dx.doi.org/10.1038/359318a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP503	1406934				2022-12-28	WOS:A1992JP50300055
J	FERRO, D; VIOLI, F; QUINTARELLI, C; SEBASTIANELLI, A; DAMELIO, R; ZICHELLA, L; BALSANO, F				FERRO, D; VIOLI, F; QUINTARELLI, C; SEBASTIANELLI, A; DAMELIO, R; ZICHELLA, L; BALSANO, F			FIBRINOLYTIC BALANCE AND LUPUS ANTICOAGULANT IN PATIENTS WITH REPEATED SPONTANEOUS FETAL LOSS	BRITISH MEDICAL JOURNAL			English	Article							PREGNANCY		UNIV ROME,IST CLIN MED GEN & TERAPIA MED 1,VIALE POLICLIN,I-00185 ROME,ITALY; UNIV ROME LA SAPIENZA,IST CLIN MED 1,I-00185 ROME,ITALY	Sapienza University Rome; Sapienza University Rome			Violi, Francesco/K-1509-2016; ferro, domenico/AAT-5861-2020	Violi, Francesco/0000-0002-6610-7068; 				GRIS JC, 1990, BRIT MED J, V300, P1500, DOI 10.1136/bmj.300.6738.1500; JOHNSON PM, 1989, BRIT J OBSTET GYNAEC, V96, P1231, DOI 10.1111/j.1471-0528.1989.tb03203.x; LUBBE WF, 1984, BRIT J OBSTET GYNAEC, V91, P357, DOI 10.1111/j.1471-0528.1984.tb05923.x; TRIPLETT DA, 1989, AM J REPROD IMMUNOL, V20, P52, DOI 10.1111/j.1600-0897.1989.tb00639.x; VIOLI F, 1990, BRIT MED J, V300, P1099, DOI 10.1136/bmj.300.6732.1099	5	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 29	1992	305	6852					504	505		10.1136/bmj.305.6852.504	http://dx.doi.org/10.1136/bmj.305.6852.504			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL609	1392996	Green Submitted, Bronze, Green Published			2022-12-28	WOS:A1992JL60900018
J	RUTTER, DR; CALNAN, M; VAILE, MSB; FIELD, S; WADE, KA				RUTTER, DR; CALNAN, M; VAILE, MSB; FIELD, S; WADE, KA			DISCOMFORT AND PAIN DURING MAMMOGRAPHY - DESCRIPTION, PREDICTION, AND PREVENTION	BRITISH MEDICAL JOURNAL			English	Article							PATIENT	Objective-To identify the nature of pain and discomfort experienced during mammography and how it can be ameliorated. Design-Questionnaire survey before invitation for mammography and immediately after mammography. Responses before screening were related to experience of discomfort. Setting-Health district in South East Thames region. Subjects-1160 women aged 50-64 invited routinely for screening; 774 completed first questionnaire, of whom 617 had mammography. 597 completed the second questionnaire. Main outcome measures-Reported discomfort and pain, comparisons of discomfort with that experienced during other medical procedures, qualitative description of pain with adjective checklist. Results-35% (206/597) of the women reported discomfort and 6% (37/595) pain. 10 minutes after mammography these figures were 4% (24/595) and 0.7% (4/595) respectively. More than two thirds of women ranked having a tooth drilled, having a smear test, and giving blood as more uncomfortable than mammography. The most important predictor of discomfort was previous expectation of pain (discomfort was reported by 21/32 (66%) women who expected pain and 186/531 (35%) who did not). Discomfort had little effect on satisfaction or intention to reattend. Conclusions-The low levels of reported pain and discomfort shortly after mammography and the favourable comparisons with other investigations suggest that current procedures are acceptable. Since two thirds of the women experienced less pain than expected health education and promotion must ensure that accurate information is made available and publicised.	UNIV KENT,CTR HLTH SERV STUDIES,CANTERBURY CT2 7LZ,ENGLAND; KENT & CANTERBURY HOSP,KENT BREAST SCREENING SERV,CANTERBURY,ENGLAND	University of Kent; University of Kent	RUTTER, DR (corresponding author), UNIV KENT,INST SOCIAL & APPL PSYCHOL,CTR RES HLTH BEHAV,CANTERBURY CT2 7LZ,ENGLAND.							EARDLEY A, 1990, SOC SCI MED, V30, P693, DOI 10.1016/0277-9536(88)90254-7; JACKSON VP, 1988, RADIOLOGY, V168, P421, DOI 10.1148/radiology.168.2.3393659; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; ORTON M, 1991, BRIT J GEN PRACT, V41, P320; SPIELBERGER CD, 1970, MANUAL STATE TRAIT A; STOMPER PC, 1988, ARCH INTERN MED, V148, P521, DOI 10.1001/archinte.148.3.521; VAILE MSB, IN PRESS J PUBLIC HL	7	53	54	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 22	1992	305	6851					443	445		10.1136/bmj.305.6851.443	http://dx.doi.org/10.1136/bmj.305.6851.443			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK680	1392955	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JK68000019
J	DEWAR, JA; HOROBIN, JM; PREECE, PE; TAVENDALE, R; TUNSTALLPEDOE, H; WOOD, RAB				DEWAR, JA; HOROBIN, JM; PREECE, PE; TAVENDALE, R; TUNSTALLPEDOE, H; WOOD, RAB			LONG-TERM EFFECTS OF TAMOXIFEN ON BLOOD LIPID VALUES IN BREAST-CANCER	BRITISH MEDICAL JOURNAL			English	Article									UNIV DUNDEE,DEPT SURG,DUNDEE DD1 4HN,SCOTLAND; UNIV DUNDEE,DEPT CARDIOVASC EPIDEMIOL,DUNDEE DD1 4HN,SCOTLAND; UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT RADIOTHERAPY & ONCOL,DUNDEE DD1 9SY,SCOTLAND	University of Dundee; University of Dundee; University of Dundee								Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; LOVE RR, 1990, JNCI-J NATL CANCER I, V82, P1327, DOI 10.1093/jnci/82.16.1327; MCDONALD CC, 1991, BRIT MED J, V303, P435, DOI 10.1136/bmj.303.6800.435; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; 1987, LANCET, V2, P171; 1992, LANCET, V339, P71	6	84	84	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1992	305	6847					225	226		10.1136/bmj.305.6847.225	http://dx.doi.org/10.1136/bmj.305.6847.225			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG112	1392827	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JG11200024
J	AMIGORENA, S; SALAMERO, J; DAVOUST, J; FRIDMAN, WH; BONNEROT, C				AMIGORENA, S; SALAMERO, J; DAVOUST, J; FRIDMAN, WH; BONNEROT, C			TYROSINE-CONTAINING MOTIF THAT TRANSDUCES CELL ACTIVATION SIGNALS ALSO DETERMINES INTERNALIZATION AND ANTIGEN PRESENTATION VIA TYPE-III RECEPTORS FOR IGG	NATURE			English	Article							LAMBDA-REPRESSOR; ENDOCYTOSIS; MACROPHAGE; ANTIBODIES; MOLECULES	TYPE III receptors for IgG (Fc-gamma-RII; ref. 1), high-affinity IgE receptors (Fc-epsilon-RI; ref. 2), as well as the T- and B-cell antigen receptors3,4, consist of multiple components with specialized ligand-binding and signal transduction functions5-10. Fc-gamma-RII-alpha (ligand-binding) and gamma (signal-transducing) subunits are expressed in macrophages1, a cell type involved in the uptake of antigen, its processing and the presentation of the resulting peptides to major histocompatibility complex class II-restricted T lymphocytes11,12. Here we show that murine Fc-gamma-RIII, transfected into Fc-gamma-R-negative antigen-presenting B-lymphoma cells, mediate rapid ligand internalization and strongly increase the efficiency of antigen presentation when antigen is complexed to IgG. Efficient internalization and antigen presentation via Fc-gamma-RIII did not require the cytoplasmic domain of the ligand-binding alpha-chain, but did require the gamma-subunit. Using chimaeric molecules, we show that gamma-chain contains a signal for receptor internalization and that the mutation of either of the two tyrosine residues present in its cytoplasmic domain prevents efficient internalization and antigen presentation of immune complexes. Thus, associated chains and their tyrosine-containing motif are not exclusively involved in cell activation, but also determine multimeric receptor internalization.	INST CURIE, INSERM, U255, IMMUNOL CELLULAIRE & CLIN LAB, F-75005 PARIS, FRANCE; CTR IMMUNOL MARSEILLE LUMINY, CNRS, INSERM, F-13288 MARSEILLE 9, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite				Amigorena, Sebastian/0000-0001-8583-8416; salamero, jean/0000-0002-2610-5826; fridman, wolf herman/0000-0002-1332-0973; Davoust, Jean/0000-0002-3098-7665				AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; BONNEROT C, 1992, EMBO J, V11, P2747, DOI 10.1002/j.1460-2075.1992.tb05340.x; BREYER RM, 1989, J BIOL CHEM, V264, P13348; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; DRAKE JR, 1989, J IMMUNOL, V143, P1768; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; ISERSKY C, 1983, J IMMUNOL, V131, P388; JONES B, 1986, J IMMUNOL, V136, P348; JUSTEMENT LB, 1989, J IMMUNOL, V143, P881; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KSITAKIS NT, 1990, J CELL BIOL, V111, P1393; LAI MZ, 1987, J IMMUNOL, V139, P3973; LANZAVECCHIA A, 1990, ANNU REV IMMUNOL, V8, P773, DOI 10.1146/annurev.immunol.8.1.773; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; NOMURA J, 1991, INT IMMUNOL, V3, P117, DOI 10.1093/intimm/3.2.117; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; SALAMERO J, 1990, EMBO J, V9, P3489, DOI 10.1002/j.1460-2075.1990.tb07557.x; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; UNANUE ER, 1984, ANNU REV IMMUNOL, V2, P395, DOI 10.1146/annurev.iy.02.040184.002143; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T	26	164	168	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 23	1992	358	6384					337	341		10.1038/358337a0	http://dx.doi.org/10.1038/358337a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE684	1386408				2022-12-28	WOS:A1992JE68400066
J	PINTO, LH; HOLSINGER, LJ; LAMB, RA				PINTO, LH; HOLSINGER, LJ; LAMB, RA			INFLUENZA-VIRUS M2 PROTEIN HAS ION CHANNEL ACTIVITY	CELL			English	Article							INTEGRAL MEMBRANE-PROTEIN; PHOTOSYNTHETIC REACTION CENTER; INFECTED-CELL SURFACE; ENDOPLASMIC-RETICULUM; MOLECULAR-BASIS; A VIRUSES; AMANTADINE; HEMAGGLUTININ; RIMANTADINE; RESTRICTION	The influenza virus M2 Protein was expressed in Xenopus laevis oocytes and shown to have an associated ion channel activity selective for monovalent ions. The anti-influenza virus drug amantadine hydrochloride significantly attenuated the inward current induced by hyperpolarization of oocyte membranes. Mutations in the M2 membrane-spanning domain that confer viral resistance to amantadine produced currents that were resistant to the drug. Analysis of the currents of these altered M2 proteins suggests that the channel pore is formed by the transmembrane domain of the M2 protein. The wild-type M2 Channel was found to be regulated by pH. The wild-type M2 ion channel activity is proposed to have a pivotal role in the biology of influenza virus infection.	NORTHWESTERN UNIV, DEPT BIOCHEM MOLEC BIOL & CELL BIOL, EVANSTON, IL 60208 USA; NORTHWESTERN UNIV, HOWARD HUGHES MED INST, EVANSTON, IL 60208 USA	Northwestern University; Howard Hughes Medical Institute; Northwestern University	PINTO, LH (corresponding author), NORTHWESTERN UNIV, DEPT NEUROBIOL & PHYSIOL, EVANSTON, IL 60208 USA.				NATIONAL EYE INSTITUTE [R01EY001221] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020201, R37AI020201] Funding Source: NIH RePORTER; NEI NIH HHS [EY-01221] Funding Source: Medline; NIAID NIH HHS [AI-20201] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS GA, 1985, CELL, V41, P1007, DOI 10.1016/S0092-8674(85)80081-7; ALLEN JP, 1987, P NATL ACAD SCI USA, V84, P6162, DOI 10.1073/pnas.84.17.6162; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; APPLEYARD G, 1977, J GEN VIROL, V36, P249, DOI 10.1099/0022-1317-36-2-249; BUKRINSKAYA AG, 1982, J GEN VIROL, V60, P49, DOI 10.1099/0022-1317-60-1-49; BUKRINSKAYA AG, 1982, J GEN VIROL, V60, P61, DOI 10.1099/0022-1317-60-1-61; CIAMPOR F, 1992, IN PRESS VIRUS RES; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; DAVIES WL, 1964, SCIENCE, V144, P862, DOI 10.1126/science.144.3620.862; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; EISENMAN G, 1983, J MEMBRANE BIOL, V76, P197, DOI 10.1007/BF01870364; FOLANDER K, 1990, P NATL ACAD SCI USA, V87, P2975, DOI 10.1073/pnas.87.8.2975; GOLDSTEIN SAN, 1991, NEURON, V7, P403, DOI 10.1016/0896-6273(91)90292-8; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HAY AJ, 1979, J GEN VIROL, V42, P189, DOI 10.1099/0022-1317-42-1-189; HAY AJ, 1985, EMBO J, V4, P3021, DOI 10.1002/j.1460-2075.1985.tb04038.x; HAY AJ, 1986, J ANTIMICROB CHEMOTH, V18, P19, DOI 10.1093/jac/18.Supplement_B.19; HAY AJ, 1989, CONCEPTS VIRAL PATHO, V3, P361; HAY AJ, 1984, ANTIVIRAL DRUGS INTE, P301; Hille B., 1991, IONIC CHANNELS EXCIT; HOSLINGER LJ, 1991, VIROLOGY, V183, P32; HULL JD, 1988, J CELL BIOL, V106, P1489, DOI 10.1083/jcb.106.5.1489; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; Lamb R.A., 1989, INFLUENZA VIRUSES, P1; LAMB RA, 1978, VIROLOGY, V91, P60, DOI 10.1016/0042-6822(78)90355-0; LAMB RA, 1976, VIROLOGY, V74, P504, DOI 10.1016/0042-6822(76)90356-1; LAMB RA, 1985, CELL, V40, P627, DOI 10.1016/0092-8674(85)90211-9; LEONARD RJ, 1988, SCIENCE, V242, P1578, DOI 10.1126/science.2462281; LUBECK MD, 1978, J VIROL, V28, P710, DOI 10.1128/JVI.28.3.710-716.1978; MARSH M, 1989, ADV VIRUS RES, V36, P107, DOI 10.1016/S0065-3527(08)60583-7; MARTIN K, 1991, CELL, V67, P117, DOI 10.1016/0092-8674(91)90576-K; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; PRAGNELL M, 1990, NEURON, V4, P807, DOI 10.1016/0896-6273(90)90207-V; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROTH M, 1989, NATURE, V340, P659, DOI 10.1038/340659a0; RUIGROK RWH, 1991, J GEN VIROL, V72, P191, DOI 10.1099/0022-1317-72-1-191; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOLTISSEK C, 1979, J GEN VIROL, V44, P807, DOI 10.1099/0022-1317-44-3-807; SKEHEL JJ, 1978, J GEN VIROL, V38, P97, DOI 10.1099/0022-1317-38-1-97; SKEHEL JJ, 1982, P NATL ACAD SCI-BIOL, V79, P968, DOI 10.1073/pnas.79.4.968; STEINHAUER DA, 1991, P NATL ACAD SCI USA, V88, P11525, DOI 10.1073/pnas.88.24.11525; SUGIMOTO T, 1990, J MEMBRANE BIOL, V113, P39, DOI 10.1007/BF01869604; SUGRUE RJ, 1990, EMBO J, V9, P3469, DOI 10.1002/j.1460-2075.1990.tb07555.x; SUGRUE RJ, 1991, VIROLOGY, V180, P617, DOI 10.1016/0042-6822(91)90075-M; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V189, P239; WHARTON SA, 1990, USE XRAY CRYSTALLOGR, P112; WILLIAMS MA, 1986, MOL CELL BIOL, V6, P4317, DOI 10.1128/MCB.6.12.4317; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; ZEBEDEE SL, 1985, J VIROL, V56, P502, DOI 10.1128/JVI.56.2.502-511.1985; ZEBEDEE SL, 1989, P NATL ACAD SCI USA, V86, P1061, DOI 10.1073/pnas.86.3.1061; ZEBEDEE SL, 1988, J VIROL, V62, P2762, DOI 10.1128/JVI.62.8.2762-2772.1988; ZHIRNOV OP, 1990, VIROLOGY, V176, P274, DOI 10.1016/0042-6822(90)90253-N	55	960	1026	3	71	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 1	1992	69	3					517	528		10.1016/0092-8674(92)90452-I	http://dx.doi.org/10.1016/0092-8674(92)90452-I			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HT078	1374685				2022-12-28	WOS:A1992HT07800013
J	FU, XD; MANIATIS, T				FU, XD; MANIATIS, T			ISOLATION OF A COMPLEMENTARY-DNA THAT ENCODES THE MAMMALIAN SPLICING FACTOR SC35	SCIENCE			English	Article							RNA; PROTEIN; PURIFICATION; SEQUENCE; INVITRO	The mammalian splicing factor SC35 is required for the first step in the splicing reaction and for spliceosome assembly. The cloning and characterization of a complementary DNA encoding this protein revealed that it is a member of a family of splicing factors that includes mammalian SF2/ASF. This family of proteins is characterized by the presence of a ribonucleoprotein (RNP)-type RNA binding motif and a carboxyl-terminal serine-arginine-rich (SR) domain. A search of the DNA sequence database revealed that the thymus-specific exon (E(T)) of the c-myb proto-oncogene is encoded on the antisense strand of the SC35 gene.			FU, XD (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, 7 DIVIN AVE, CAMBRIDGE, MA 02138 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042231] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42231] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; Fu X, UNPUB; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; FU XD, 1992, P NATL ACAD SCI USA, V89, P1725, DOI 10.1073/pnas.89.5.1725; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; MAYEDA A, 1992, P NATL ACAD SCI USA, V89, P1301, DOI 10.1073/pnas.89.4.1301; PERBAL B, 1990, CR ACAD SCI III-VIE, V311, P467; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; REED R, 1990, P NATL ACAD SCI USA, V87, P8031, DOI 10.1073/pnas.87.20.8031; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; ROTH MB, 1990, J CELL BIOL, V111, P2217, DOI 10.1083/jcb.111.6.2217; RUBY SW, 1991, TRENDS GENET, V7, P79; Sambrook J, 1989, MOL CLONING LABORATO; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; Summers MD, 1987, TEXAS AGR EXPT STATI; SUREAU A, 1991, CR ACAD SCI III-VIE, V312, P323; VELLARD M, 1991, CR ACAD SCI III-VIE, V313, P591; VELLARD M, 1991, ONCOGENE, V6, P505; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; ZAHLER A, IN PRESS GENES DEV; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243	33	223	235	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 24	1992	256	5056					535	538		10.1126/science.1373910	http://dx.doi.org/10.1126/science.1373910			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ187	1373910				2022-12-28	WOS:A1992HQ18700068
J	WANG, GH; SEEGER, C				WANG, GH; SEEGER, C			THE REVERSE-TRANSCRIPTASE OF HEPATITIS-B VIRUS ACTS AS A PROTEIN PRIMER FOR VIRAL-DNA SYNTHESIS	CELL			English	Article							P-GENE-PRODUCT; RNA ENCAPSIDATION; TERMINAL PROTEIN; POLYMERASE; GENOME; INITIATION; SEQUENCE; IDENTIFICATION; REPLICATION; WOODCHUCK	Hepatitis B viruses (hepadnaviruses) replicate their DNA genomes by reverse transcription of an RNA intermediate. Efforts to examine the biochemical mechanism for viral DNA synthesis have been hampered by the failure to solubilize the reverse transcriptase from virions and to express the polymerase in heterologous systems in an enzymatically active form. Here, we demonstrate that the polymerase of a hepadnavirus synthesized in an in vitro translation reaction exhibits reverse transcriptase activity. Furthermore, our results show that the polymerase acts as a primer for DNA synthesis and remains covalently linked to nascent DNA, a feature that is not known to exist in any other RNA-directed DNA polymerases. Priming of DNA synthesis requires viral RNA but occurs independently of other viral components. The ability to express the hepadnavirus reverse transcriptase in an enzymatically active form will allow detailed biochemical and functional analyses of this complex enzyme, and may facilitate the identification of inhibitors required for antiviral therapy.			WANG, GH (corresponding author), FOX CHASE CANC CTR,INST CANC RES,PHILADELPHIA,PA 19111, USA.				NCI NIH HHS [CA-06927] Funding Source: Medline; NIAID NIH HHS [AI-30544, AI-24972] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024972, R01AI030544, R29AI024972] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARTENSCHLAGER R, 1990, J VIROL, V64, P5324, DOI 10.1128/JVI.64.11.5324-5332.1990; BARTENSCHLAGER R, 1988, EMBO J, V7, P4185, DOI 10.1002/j.1460-2075.1988.tb03315.x; CHANG LJ, 1990, J VIROL, V64, P5553, DOI 10.1128/JVI.64.11.5553-5558.1990; CHANG LJ, 1989, NATURE, V337, P364, DOI 10.1038/337364a0; CONDREAY LD, 1992, VIROLOGY, V188, P208, DOI 10.1016/0042-6822(92)90751-A; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GERLICH WH, 1980, CELL, V21, P801, DOI 10.1016/0092-8674(80)90443-2; HELGSTRAND E, 1978, SCIENCE, V201, P819, DOI 10.1126/science.210500; HIRSCH RC, 1990, NATURE, V344, P552, DOI 10.1038/344552a0; HOSTOMSKY Z, 1992, J VIROL, V66, P3179, DOI 10.1128/JVI.66.5.3179-3182.1992; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P550; JUNKERNIEPMANN M, 1990, EMBO J, V9, P3389, DOI 10.1002/j.1460-2075.1990.tb07540.x; KAPLAN PM, 1973, J VIROL, V12, P995, DOI 10.1128/JVI.12.5.995-1005.1973; KHUDYAKOV YE, 1989, FEBS LETT, V243, P115, DOI 10.1016/0014-5793(89)80110-3; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; LIEN JM, 1987, J VIROL, V61, P3832, DOI 10.1128/JVI.61.12.3832-3840.1987; MANDART E, 1984, J VIROL, V49, P782, DOI 10.1128/JVI.49.3.782-792.1984; Mason W. S., 1987, Hepadna viruses. Proceedings of a Director's Sponsors-UCLA Symposium. Held at Keystone, Colorado, March 29-April 3, 1987, P3; MOLNARKIMBER KL, 1983, J VIROL, V45, P165, DOI 10.1128/JVI.45.1.165-172.1983; PUGH JC, 1988, J VIROL, V62, P3513, DOI 10.1128/JVI.62.9.3513-3516.1988; RADZIWILL G, 1990, J VIROL, V64, P613, DOI 10.1128/JVI.64.2.613-620.1990; ROYCHOUDHURY S, 1991, J VIROL, V65, P3617, DOI 10.1128/JVI.65.7.3617-3624.1991; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; Sambrook J, 1989, MOL CLONING LABORATO; SCHLICHT HJ, 1989, CELL, V56, P85, DOI 10.1016/0092-8674(89)90986-0; SEEGER C, 1991, J VIROL, V65, P5190, DOI 10.1128/JVI.65.10.5190-5195.1991; SEEGER C, 1990, J VIROL, V64, P16, DOI 10.1128/JVI.64.1.16-23.1990; SUMMERS J, 1982, CELL, V29, P403, DOI 10.1016/0092-8674(82)90157-X; TOH H, 1983, NATURE, V305, P827, DOI 10.1038/305827a0; WIMMER E, 1982, CELL, V28, P199, DOI 10.1016/0092-8674(82)90335-X; WU TT, 1991, J VIROL, V65, P2155, DOI 10.1128/JVI.65.5.2155-2163.1991	32	313	329	1	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 13	1992	71	4					663	670		10.1016/0092-8674(92)90599-8	http://dx.doi.org/10.1016/0092-8674(92)90599-8			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JY676	1384989				2022-12-28	WOS:A1992JY67600013
J	CLARK, IA; ROCKETT, KA; COWDEN, WB				CLARK, IA; ROCKETT, KA; COWDEN, WB			POSSIBLE CENTRAL ROLE OF NITRIC-OXIDE IN CONDITIONS CLINICALLY SIMILAR TO CEREBRAL MALARIA	LANCET			English	Article							TUMOR-NECROSIS-FACTOR; ETHANOL; MORPHINE; CALCIUM; INHIBITION; WITHDRAWAL; RECEPTORS; TOLERANCE; SEIZURES; RELEASE	The changes in mental status during cerebral malaria, heat stroke, and recovery from major surgery are clinically similar, and are associated with high circulating concentrations of cytokines that can induce nitric oxide generation in vascular walls. This vascular nitric oxide could diffuse across the blood-brain barrier, causing functional changes that include inhibition of glutamate-induced calcium entry, reduced activity of the calcium-dependent nitric oxide synthase, and thus reduced nitric oxide formation, in post-synaptic neurons. Certain general anaesthetics and ethanol reduce glutamate-induced calcium entry into post-synaptic cells, and so would also reduce the rate of formation of neuronal nitric oxide. In view of the apparent importance of glutamate-induced nitric oxide in excitatory neurotransmission, a reduction in neuronal nitric oxide could help explain why these otherwise unrelated influences alter central nervous system function in a similar manner. In particular, this reduction could rationalise why heat stroke, ethanol excess, morphine poisoning, and conditions with high blood ammonia concentrations are easily confused clinically with cerebral malaria.	AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV CELL BIOL,CANBERRA,ACT 2601,AUSTRALIA	Australian National University; John Curtin School of Medical Research	CLARK, IA (corresponding author), AUSTRALIAN NATL UNIV,SCH LIFE SCI,DIV BIOCHEM & MOLEC BIOL,GPO BOX 4,CANBERRA,ACT 2601,AUSTRALIA.		Clark, Ian A./K-2069-2012					ARN PH, 1990, NEW ENGL J MED, V322, P1652, DOI 10.1056/NEJM199006073222307; BAIGRIE RJ, 1991, LYMPHOKINE CYTOK RES, V10, P253; BIANCHI M, 1991, NEUROCHEM RES, V16, P443, DOI 10.1007/BF00965564; BOUCHAMA A, 1991, J APPL PHYSIOL, V70, P2640, DOI 10.1152/jappl.1991.70.6.2640; CLARK IA, 1991, PARASITOL TODAY, V7, P205, DOI 10.1016/0169-4758(91)90142-B; COTMAN CW, 1987, TRENDS NEUROSCI, V10, P263, DOI 10.1016/0166-2236(87)90170-6; DENICOFF KD, 1987, ANN INTERN MED, V107, P293, DOI 10.7326/0003-4819-107-2-293; DESARRO GB, 1991, FUNDAM CLIN PHARM, V5, P503; DILDYMAYFIELD JE, 1991, J NEUROCHEM, V56, P1536, DOI 10.1111/j.1471-4159.1991.tb02048.x; ECCLES JC, 1946, J NEUROPHYSIOL, V9, P87, DOI 10.1152/jn.1946.9.2.87; FIDECKA S, 1986, POL J PHARMACOL PHAR, V38, P277; FIDECKA S, 1989, POL J PHARMACOL PHAR, V41, P23; FRASER CL, 1985, NEW ENGL J MED, V313, P865, DOI 10.1056/NEJM198510033131406; GRANT KA, 1990, EUR J PHARMACOL, V176, P289, DOI 10.1016/0014-2999(90)90022-X; HARRIS RA, 1977, LIFE SCI, V20, P501; HEGESCHEUING G, 1989, ANAESTHESIST, V38, P443; HIBBS JB, 1992, J CLIN INVEST, V89, P867, DOI 10.1172/JCI115666; HOFFMAN PL, 1989, J NEUROCHEM, V52, P1937, DOI 10.1111/j.1471-4159.1989.tb07280.x; JOHNS RA, 1991, ANESTHESIOLOGY, V75, P927; KWIATKOWSKI D, 1990, LANCET, V336, P1201, DOI 10.1016/0140-6736(90)92827-5; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; MANZONI O, 1992, NEURON, V8, P653, DOI 10.1016/0896-6273(92)90087-T; PUIL E, 1990, J PHARMACOL EXP THER, V255, P955; ROCKETT KA, 1992, INFECT IMMUN, V60, P3725, DOI 10.1128/IAI.60.9.3725-3730.1992; SIMSON PE, 1991, J PHARMACOL EXP THER, V257, P225; SPRIGGS DR, 1988, J NATL CANCER I, V80, P1039, DOI 10.1093/jnci/80.13.1039; SZERB JC, 1992, PROG NEUROBIOL, V39, P135, DOI 10.1016/0301-0082(92)90008-3; TANG TT, 1975, JAMA-J AM MED ASSOC, V232, P1339, DOI 10.1001/jama.232.13.1339; TANGANELLI S, 1991, NEUROSCI LETT, V122, P270, DOI 10.1016/0304-3940(91)90875-T; 1942, MEMORANDUM 24 MED DI, P154	30	120	122	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 10	1992	340	8824					894	896		10.1016/0140-6736(92)93295-X	http://dx.doi.org/10.1016/0140-6736(92)93295-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT327	1383658				2022-12-28	WOS:A1992JT32700014
J	MONTELL, DJ; RORTH, P; SPRADLING, AC				MONTELL, DJ; RORTH, P; SPRADLING, AC			SLOW BORDER CELLS, A LOCUS REQUIRED FOR A DEVELOPMENTALLY REGULATED CELL-MIGRATION DURING OOGENESIS, ENCODES DROSOPHILA C/EBP	CELL			English	Article							ENHANCER-BINDING-PROTEIN; GENE; EXPRESSION; ELEMENTS	During Drosophila oogenesis six to ten follicle cells, the border cells, undergo a dramatic and stereotypic migration through the developing egg chamber. We identified four independent P element insertion mutations that specifically blocked border cell migration. They defined a single, novel locus that was named slow border cells (slbo), because hypomorphic alleles caused delayed onset of the migration. Laser ablation of the border cells, or failure of their migration, caused improper morphogenesis of the micropyle, the eggshell structure through which the sperm enters at fertilization. The slbo locus was found to encode a product homologous to the CCAAT/enhancer-binding protein (C/EBP), a basic region-leucine zipper transcription factor. Drosophila C/EBP may be required for the expression of gene products mediating border cell migration.	CARNEGIE INST WASHINGTON, HOWARD HUGHES MED INST, DEPT EMBRYOL, BALTIMORE, MD 21210 USA	Carnegie Institution for Science; Howard Hughes Medical Institute			Rørth, Pernille/H-3020-2011		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046425] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NIGMS NIH HHS [R29GM46425] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BERG CA, 1991, GENETICS, V127, P515; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; FALB D, 1992, GENE DEV, V6, P454, DOI 10.1101/gad.6.3.454; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GUTZEIT HO, 1982, J EMBRYOL EXP MORPH, V67, P101; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KALT MR, 1971, J ULTRA MOL STRUCT R, V36, P633, DOI 10.1016/S0022-5320(71)90020-7; KIMBLE M, 1990, GENETICS, V126, P991; King R. C., 1970, OVARIAN DEV DROSOPHI; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MILLER DM, 1992, NATURE, V355, P841, DOI 10.1038/355841a0; MLODZIK M, 1992, GENE EXPRESSION NEUR, V9, P397; MONTELL DJ, 1991, SCIENCE, V254, P290, DOI 10.1126/science.1925585; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; SALSER SJ, 1992, NATURE, V355, P255, DOI 10.1038/355255a0; Sambrook J, 1989, MOL CLONING LABORATO; SPRADLING AC, 1992, IN PRESS DROSOPHILA; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THIERY JP, 1988, CIBA F SYMP, V141, P48; Tressler R J, 1989, Cancer Commun, V1, P55; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; ZARANI FE, 1986, CAN J ZOOL, V64, P2509, DOI 10.1139/z86-372	31	269	273	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 2	1992	71	1					51	62		10.1016/0092-8674(92)90265-E	http://dx.doi.org/10.1016/0092-8674(92)90265-E			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1394432				2022-12-28	WOS:A1992JQ62300006
J	ATTARD, AR; CORLETT, MJ; KIDNER, NJ; LESLIE, AP; FRASER, IA				ATTARD, AR; CORLETT, MJ; KIDNER, NJ; LESLIE, AP; FRASER, IA			SAFETY OF EARLY PAIN RELIEF FOR ACUTE ABDOMINAL-PAIN	BRITISH MEDICAL JOURNAL			English	Article								Objectives-(a) to determine the efficacy of papaveretum in treating pain when administered early to patients presenting with acute abdominal pain and (b) to assess its effect on subsequent diagnosis and management. Design-Prospective, randomised, placebo controlled study. Setting-Walsgrave Hospital, Coventry. Subjects-100 consecutive patients with clinically significant abdominal pain who were admitted as emergencies to a surgical firm. Interventions-Intramuscular injection of up to 20 mg papaveretum or an equivalent volume of saline. Outcome measures-Pain and tenderness scores, assessment of patient comfort, accuracy of diagnosis, and management decisions. Results-Median pain and tenderness scores were lower after papaveretum (pain score 8.3 in control group and 3.1 in treatment group, p<0.0001; tenderness score 8.1 in control group and 5.1 in treatment group, p<0.0001). Forty eight patients were deemed to be comfortable after papaveretum compared with nine after saline. Incorrect diagnoses and management decisions applied to two patients after papaveretum compared with nine patients after saline. Conclusion-Early administration of opiate analgesia to patients with acute abdominal pain can greatly reduce their pain. This does not interfere with diagnosis, which may even be facilitated despite a reduction in the severity of physical signs. These patients should not be denied effective treatment.	WALSGRAVE GEN HOSP,DEPT GEN SURG WALSGRAVE,COVENTRY CV2 2DX,ENGLAND									BOEY JH, 1991, CURRENT SURG DIAGNOS, P440; COPE Z, 1979, EARLY DIAGNOSIS ACUT; CUSCHIERI A, 1986, ESSENTIALS SURG PRAC, P1238; DUDLEY H, 1979, BRIT MED J, V2, P1289, DOI 10.1136/bmj.2.6200.1289-b; FRASER ID, 1979, BRIT MED J, V2, P1363, DOI 10.1136/bmj.2.6201.1363-b; HAMILTON WAP, 1979, BRIT MED J, V2, P1363, DOI 10.1136/bmj.2.6201.1363-a; LAVELLE M, 1979, BRIT MED J, V2, P1289, DOI 10.1136/bmj.2.6200.1289; PIPER JV, 1979, BRIT MED J, V2, P1443, DOI 10.1136/bmj.2.6202.1443-a; QUAYLE J, 1979, BRIT MED J, V2, P1290, DOI 10.1136/bmj.2.6200.1290; SHEPHERD J, 1979, BRIT MED J, V2, P1289, DOI 10.1136/bmj.2.6200.1289-a; ZOLTIE N, 1986, ANN ROY COLL SURG, V68, P209; 1991, CURRENT PROBLEMS; 1979, BMJ, V2, P1093	13	121	126	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 5	1992	305	6853					554	556		10.1136/bmj.305.6853.554	http://dx.doi.org/10.1136/bmj.305.6853.554			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM495	1393034	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992JM49500016
J	PELECH, SL; SANGHERA, JS				PELECH, SL; SANGHERA, JS			MAP KINASES - CHARTING THE REGULATORY PATHWAYS	SCIENCE			English	Editorial Material							THREONINE PROTEIN-KINASE; SIGNAL TRANSDUCTION; SCHIZOSACCHAROMYCES-POMBE; ACTIVATION; TYROSINE; RAF-1; CASCADE; YEAST		UNIV BRITISH COLUMBIA,DEPT MED,VANCOUVER V6T 1Z3,BC,CANADA; UNIV BRITISH COLUMBIA,BIOMED RES CTR,VANCOUVER V6T 1Z3,BC,CANADA	University of British Columbia; University of British Columbia	PELECH, SL (corresponding author), KINETEK BIOTECHNOL CORP,7600 NO 1 RD,RICHMOND V7C 1T6,BC,CANADA.			Pelech, Steven/0000-0003-1112-903X				AHN NG, 1991, J BIOL CHEM, V266, P4220; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COSTIGAN C, 1992, MOL CELL BIOL, V12, P1162, DOI 10.1128/MCB.12.3.1162; CREW C, IN PRESS P NATL ACAD; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HATTORI S, IN PRESS J BIOL CHEM; KOSAKO H, 1992, EMBO J, V11, P2309; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEE RM, 1992, J BIOL CHEM, V267, P1088; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; NADINDAVIS SA, 1988, EMBO J, V7, P985, DOI 10.1002/j.1460-2075.1988.tb02905.x; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1990, BIOCHEM CELL BIOL, V68, P1297, DOI 10.1139/o90-194; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; RAPP UR, 1991, ONCOGENE, V6, P495; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SEGER R, 1992, J BIOL CHEM, V267, P14373; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TEAGUE MA, 1986, P NATL ACAD SCI USA, V83, P7371, DOI 10.1073/pnas.83.19.7371; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANG Y, 1991, MOL CELL BIOL, V11, P3554, DOI 10.1128/MCB.11.7.3554; WARBRICK E, 1991, EMBO J, V10, P4291, DOI 10.1002/j.1460-2075.1991.tb05007.x; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU J, 1992, BIOCHEM J, V285, P701, DOI 10.1042/bj2850701	44	381	388	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 4	1992	257	5075					1355	1356		10.1126/science.1382311	http://dx.doi.org/10.1126/science.1382311			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL612	1382311				2022-12-28	WOS:A1992JL61200021
J	EGGER, M; SMITH, GD; TEUSCHER, A				EGGER, M; SMITH, GD; TEUSCHER, A			FOR DEBATE - HUMAN INSULIN AND UNAWARENESS OF HYPOGLYCEMIA - NEED FOR A LARGE RANDOMIZED TRIAL	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DEPENDENT DIABETES-MELLITUS; SEMISYNTHETIC HUMAN INSULIN; BLIND CROSSOVER TRIAL; PURIFIED PORK INSULIN; PORCINE INSULIN; INDUCED HYPOGLYCEMIA; RECOMBINANT DNA; COUNTERREGULATORY RESPONSES; GLUCOSE COUNTERREGULATION; SYMPTOMATIC AWARENESS		UNIV GLASGOW, DEPT PUBL HLTH, GLASGOW G12 8RZ, SCOTLAND; UNIV LONDON UNIV COLL, DEPT EPIDEMIOL & PUBL HLTH, LONDON WC1E 6BT, ENGLAND; UNIV BERN, DEPT ENDOCRINOL & DIABET, CH-3000 BERN, SWITZERLAND	University of Glasgow; University of London; University College London; University of Bern			Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314; Egger, Matthias/0000-0001-7462-5132				AMIEL SA, 1987, NEW ENGL J MED, V316, P1376, DOI 10.1056/NEJM198705283162205; [Anonymous], 1991, LANCET, V338, P853; BENDTSON I, 1991, J INTERN MED, V229, P293, DOI 10.1111/j.1365-2796.1991.tb00348.x; BERGER M, 1987, DIABETOLOGIA, V30, P829; BERGER W, 1989, LANCET, V1, P1041, DOI 10.1016/S0140-6736(89)92444-6; BERGER WG, 1987, DIABETES CARE, V10, P260, DOI 10.2337/diacare.10.2.260; BOLLI G, 1983, DIABETES, V32, P134, DOI 10.2337/diabetes.32.2.134; CLARK AJL, 1982, LANCET, V2, P354; DCCT Res Grp, 1986, DIABETES, V35, P530; DCCT Res Grp, 1991, AM J MED, V90, P450, DOI 10.1016/0002-9343(91)80085-Z; DUNCAN C, 1990, PRACTICAL DIABETES, V7, P18; EGGER M, 1988, DIABETOLOGIA, V31, P453, DOI 10.1007/BF00271592; EGGER M, 1990, DIABETIC MED, V7, P269, DOI 10.1111/j.1464-5491.1990.tb01385.x; EGGER M, 1991, BMJ-BRIT MED J, V303, P617, DOI 10.1136/bmj.303.6803.617; EGGER M, 1991, BMJ-BRIT MED J, V303, P622, DOI 10.1136/bmj.303.6803.622; EGGER M, 1991, BMJ-BRIT MED J, V303, P1267, DOI 10.1136/bmj.303.6812.1267-a; EGGER M, 1991, LANCET, V338, P950, DOI 10.1016/0140-6736(91)91820-K; FISHER BM, 1988, DIABETES RES CLIN EX, V8, P1; FRIER BM, 1991, BMJ-BRIT MED J, V303, P1266, DOI 10.1136/bmj.303.6812.1266-b; GERICH JE, 1973, SCIENCE, V182, P171, DOI 10.1126/science.182.4108.171; GORDEN P, 1990, NEW ENGL J MED, V322, P1007; HAUPT E, 1991, HYPOGLYCAEMIA HUMAN, P119; HEINE RJ, 1990, LANCET, V335, P62, DOI 10.1016/0140-6736(90)90203-H; HEINE RJ, 1989, LANCET, V2, P946; HELLER SR, 1987, LANCET, V2, P359; HEPBURN DA, 1989, LANCET, V1, P1394; HEPBURN DA, 1989, DIABETIC MED, V6, P586, DOI 10.1111/j.1464-5491.1989.tb01233.x; Home P D, 1984, Diabet Med, V1, P93; HOME PD, 1982, DRUGS, V24, P401, DOI 10.2165/00003495-198224050-00003; KAREM JH, 1991, CLIN DIABETES    NOV, P94; KEEN H, 1980, LANCET, V2, P398; KEEN H, 1981, MED INT, V1, P330; KERN W, 1989, LANCET, V2, P485; LANDGRAFLEURS MMC, 1984, KLIN WOCHENSCHR, V62, P659, DOI 10.1007/BF01716462; MANN NP, 1983, BMJ-BRIT MED J, V387, P1580; MARAN A, 1991, DIABETES, V40, pA544; ORCHARD TJ, 1991, DIABETIC MED, V8, P469, DOI 10.1111/j.1464-5491.1991.tb01634.x; OWENS DR, 1988, DIABETES RES CLIN EX, V8, P17; PARR JH, 1982, LANCET, V2, P831; PATRICK AW, 1991, LANCET, V338, P528, DOI 10.1016/0140-6736(91)91098-F; PATRICK AW, 1991, BRIT MED J, V303, P1266, DOI 10.1136/bmj.303.6812.1266-a; PICKUP J, 1986, BRIT MED J, V292, P155, DOI 10.1136/bmj.292.6514.155; REDMOND S, 1988, BALANCE          AUG, P66; ROSAK C, 1982, DIABETES CARE, V5, P82, DOI 10.2337/diacare.5.2.S82; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; SCHLUTER KJ, 1982, DIABETES CARE, V5, P78, DOI 10.2337/diacare.5.2.S78; SIEBER P, 1974, HELV CHIM ACTA, V57, P2617, DOI 10.1002/hlca.19740570839; SJOBOM NC, 1990, DIABETIC MED, V7, P775; SONNENBERG GE, 1983, DIABETOLOGIA, V25, P457; SPRAUL M, 1990, AKTUELLE ENDOKRINOLO, V11, P169; STEPHENSON J, 1990, LANCET, V335, P661, DOI 10.1016/0140-6736(90)90448-E; SWTOCKS AE, 1991, MED J AUSTRALIA, V154, P295; TATTERSALL RB, 1991, DIABETIC MED, V8, P49, DOI 10.1111/j.1464-5491.1991.tb01516.x; TATTERSALL RB, 1989, BRIT MED J, V299, P1339, DOI 10.1136/bmj.299.6711.1339-b; TEUSCHER A, 1987, LANCET, V2, P382; TEUSCHER A, 1979, SCHWEIZ MED WSCHR, V109, P743; TEUSCHER A, 1980, LANCET, V2, P1186; 1992, SCRIP           0207, P22	58	9	9	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 8	1992	305	6849					351	355		10.1136/bmj.305.6849.351	http://dx.doi.org/10.1136/bmj.305.6849.351			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ032	1392889	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992JJ03200025
J	HANKINSON, SE; STAMPFER, MJ; SEDDON, JM; COLDITZ, GA; ROSNER, B; SPEIZER, FE; WILLETT, WC				HANKINSON, SE; STAMPFER, MJ; SEDDON, JM; COLDITZ, GA; ROSNER, B; SPEIZER, FE; WILLETT, WC			NUTRIENT INTAKE AND CATARACT-EXTRACTION IN WOMEN - A PROSPECTIVE-STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FOOD FREQUENCY QUESTIONNAIRE; PLASMA BETA-CAROTENE; VITAMIN-C STATUS; CIGARETTE-SMOKING; ASCORBIC-ACID; NUTRITIONAL-STATUS; ALPHA-TOCOPHEROL; SENILE CATARACT; LENS; RISK	Objective-To examine prospectively the association between dietary intake of vitamins C and E, carotene, and riboflavin and cataract extraction in women. Design-Prospective cohort study beginning in 1980 with eight years of follow up. Setting- 11 states of the United States. Participants - Female registered nurses who were 45 to 67 years of age. 50 828 women were included in 1980 and others were added as they became 45 years of age. Main outcome measure-Incidence of extraction of senile cataracts. Results-493 cataracts were extracted during 470 302 person years of follow up. Intake of carotene and vitamin A was inversely associated with cataract: in multivariate analyses, women in the highest fifth of total vitamin A intake (excluding supplements) had a 39% lower risk of cataract relative to women in the lowest fifth (relative risk 0.61; 95% confidence interval 0.45 to 0.81). Neither riboflavin nor dietary vitamins E or C were associated with cataract in a multivariate analysis. Among specific food items spinach (rather than carrots, the greatest source of beta-carotene) was most consistently associated with a lower relative risk. The risk of cataract was 45% lower among women who used vitamin C supplements for 10 or more years (relative risk 0.55 (0.32 to 0.96)), but no association was noted for multivitamin intake. Conclusion-Dietary carotenoids, although not necessarily beta-carotene, and long term vitamin C supplementation may decrease the risk of cataracts severe enough to require extraction.	BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA; MASSACHUSETTS EYE & EAR INFIRM, BOSTON, MA 02114 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts Eye & Ear Infirmary	HANKINSON, SE (corresponding author), HARVARD UNIV, SCH MED, CHANNING LAB, DEPT MED, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA40356] Funding Source: Medline; PHS HHS [5T32 E507069] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS CF, 1975, NUTRITIVE VALUES AM; BHAT KS, 1987, NUTR REP INT, V36, P685; BHUYAN KC, 1984, CURR EYE RES, V3, P67, DOI 10.3109/02713688408997188; BLACKMAN BC, 1984, ANN NY ACAD SCI, V435, P385, DOI 10.1111/j.1749-6632.1984.tb13828.x; BLONDIN J, 1986, Journal of Free Radicals in Biology and Medicine, V2, P275; BUNCE GE, 1990, ANNU REV NUTR, V10, P233, DOI 10.1146/annurev.nu.10.070190.001313; BUNCE GE, 1988, NUTR TODAY, V4, P6; COX DR, 1972, J R STAT SOC B, V34, P187; CREIGHTON MO, 1985, EXP EYE RES, V40, P213, DOI 10.1016/0014-4835(85)90006-5; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; DI MASCIO P, 1989, ARCH BIOCHEM BIOPHYS, V274, P532, DOI 10.1016/0003-9861(89)90467-0; FLAYE DE, 1989, EYE, V3, P379, DOI 10.1038/eye.1989.56; GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P904; JACOB RA, 1987, AM J CLIN NUTR, V46, P818, DOI 10.1093/ajcn/46.5.818; JACQUES PF, 1988, ARCH OPHTHALMOL-CHIC, V106, P337, DOI 10.1001/archopht.1988.01060130363022; JACQUES PF, 1991, AM J CLIN NUTR, V53, pS352, DOI 10.1093/ajcn/53.1.352S; JACQUES PF, 1988, AM J CLIN NUTR, V48, P152, DOI 10.1093/ajcn/48.1.152; KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428; KRINSKY NI, 1989, FREE RADICAL BIO MED, V7, P617, DOI 10.1016/0891-5849(89)90143-3; LESKE MC, 1991, ARCH OPHTHALMOL-CHIC, V109, P244, DOI 10.1001/archopht.1991.01080020090051; MARAINI G, 1991, AM J EPIDEMIOL, V133, P541; MCLAUGHLIN PJ, 1979, J AM DIET ASSOC, V75, P647; MILLER ER, 1954, J NUTR, V52, P405; MOHAN M, 1989, ARCH OPHTHALMOL-CHIC, V107, P670, DOI 10.1001/archopht.1989.01070010688028; NISHIGORI H, 1985, EXP EYE RES, V40, P445, DOI 10.1016/0014-4835(85)90157-5; OGINO S, 1957, AM J OPHTHALMOL, V43, P936, DOI 10.1016/0002-9394(57)91798-1; ROBERTSON JM, 1989, ANN NY ACAD SCI, V570, P372; ROMIEU I, 1990, AM J EPIDEMIOL, V131, P864, DOI 10.1093/oxfordjournals.aje.a115577; Rothman K, 1986, MODERN EPIDEMIOLOGY; SCHECTMAN G, 1989, AM J PUBLIC HEALTH, V79, P158, DOI 10.2105/AJPH.79.2.158; SRIVASTAVA SK, 1972, BIOCHEM MED METAB B, V6, P372, DOI 10.1016/0006-2944(72)90023-3; STARK WJ, 1989, ARCH OPHTHALMOL-CHIC, V107, P1441, DOI 10.1001/archopht.1989.01070020515030; STEPHENS RJ, 1988, EXP EYE RES, V47, P237, DOI 10.1016/0014-4835(88)90007-3; STRYKER WS, 1988, AM J EPIDEMIOL, V127, P283, DOI 10.1093/oxfordjournals.aje.a114804; TAYLOR A, 1991, CURR EYE RES, V10, P751, DOI 10.3109/02713689109013869; TREVITHICK JR, 1989, ANN NY ACAD SCI, V570, P358; VARMA SD, 1987, ANN NY ACAD SCI, V498, P280, DOI 10.1111/j.1749-6632.1987.tb23768.x; VARMA SD, 1991, AM J CLIN NUTR, V53, pS335, DOI 10.1093/ajcn/53.1.335S; WEST S, 1989, ARCH OPHTHALMOL-CHIC, V107, P1166, DOI 10.1001/archopht.1989.01070020232031; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WILLETT WC, 1987, NEW ENGL J MED, V316, P22, DOI 10.1056/NEJM198701013160105; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; WU SY, 1991, 3RD NEI S EYE DIS EP; NIH832473 US DEP H 3; 1982, USDA HDB SERIES, V1	45	215	221	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 8	1992	305	6849					335	339		10.1136/bmj.305.6849.335	http://dx.doi.org/10.1136/bmj.305.6849.335			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ032	1392884	Green Submitted, Green Published			2022-12-28	WOS:A1992JJ03200020
J	MARTIN, C				MARTIN, C			PARTNERS IN PRACTICE - ATTACHED, DETACHED, OR NEW RECRUITS .3.	BRITISH MEDICAL JOURNAL			English	Article											MARTIN, C (corresponding author), E SUSSEX FAMILY HLTH SERV,LEWES BN7 2PB,E SUSSEX,ENGLAND.							GRIFFITHS J, 1991, FHSAS JUNIOR PARTNER; Ottewill R., 1990, GROWTH DEV COMMUNITY; 1987, CMND249; 1986, PRIMARY HLTH CARE AG; 1990, NURSING COMMUNITY; 1981, CARE COMMUNITY CONSU; 1991, REPORT PROPOSALS FUT; 1986, NEIGHBOURHOOD NURSIN; 1992, REPORT PROPOSALS FUT; 1989, CMND555	10	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 8	1992	305	6849					348	350		10.1136/bmj.305.6849.348	http://dx.doi.org/10.1136/bmj.305.6849.348			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ032	1392888	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992JJ03200024
J	MASON, JC; DOLLERY, CT; SO, A; COHEN, J; BLOOM, SR; BULPITT, C; RUSSELLJONES, R; OAKLEY, CM				MASON, JC; DOLLERY, CT; SO, A; COHEN, J; BLOOM, SR; BULPITT, C; RUSSELLJONES, R; OAKLEY, CM			HAMMERSMITH STAFF ROUNDS - AN INFECTED PROSTHETIC HIP	BRITISH MEDICAL JOURNAL			English	Discussion							ANTIBIOTIC COVERAGE; JOINT REPLACEMENTS; DENTAL TREATMENT; ARTHROPLASTY; PROPHYLAXIS		HAMMERSMITH HOSP,RHEUMATOL UNIT,LONDON W12 0NN,ENGLAND	Imperial College London	MASON, JC (corresponding author), HAMMERSMITH HOSP,DEPT MED,LONDON W12 0NN,ENGLAND.			Mason, Justin/0000-0001-7783-1660				AHLBERG A, 1978, CLIN ORTHOP RELAT R, V137, P69; AINSCOW DAP, 1984, J BONE JOINT SURG BR, V66, P580, DOI 10.1302/0301-620X.66B4.6430907; BLACKBURN WD, 1991, ARTHRITIS RHEUM, V34, P110, DOI 10.1002/art.1780340118; BLOMGREN G, 1981, CLIN ORTHOP RELAT R, V155, P244; BRAUSE BD, 1986, CLIN RHEUM DIS, V12, P523; FITZGERALD RH, 1986, CLIN RHEUM DIS, V12, P537; GRISTINA AG, 1983, J BONE JOINT SURG AM, V65, P128, DOI 10.2106/00004623-198365010-00021; INMAN RD, 1984, AM J MED, V77, P47, DOI 10.1016/0002-9343(84)90434-0; Jacobson J J, 1988, J Dent Educ, V52, P599; JASPERS MT, 1985, J AM DENT ASSOC, V111, P943, DOI 10.14219/jada.archive.1985.0224; LITTLE JW, 1983, ORAL SURG ORAL MED O, V55, P20, DOI 10.1016/0030-4220(83)90300-6; Maderazo EG, 1988, CLIN ORTHOP RELAT R, P131; NELSON JP, 1990, J BONE JOINT SURG AM, V72A, P1; THYNE GM, 1991, J BONE JOINT SURG BR, V73, P191, DOI 10.1302/0301-620X.73B2.2005136	14	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1992	305	6848					300	302		10.1136/bmj.305.6848.300	http://dx.doi.org/10.1136/bmj.305.6848.300			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG740	1392865	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JG74000026
J	GRAY, S; BOLGER, G; ONG, G				GRAY, S; BOLGER, G; ONG, G			TOBACCO ADVERTISING ON POST OFFICES	BRITISH MEDICAL JOURNAL			English	Article									W BERKSHIRE HLTH AUTHOR,PUBL HLTH MED,READING,ENGLAND		GRAY, S (corresponding author), BRISTOL & DIST HLTH AUTHOR,PUBL HLTH MED,BRISTOL BS1 3NP,ENGLAND.							JARMAN B, 1983, BMJ, V286, P17058; MATTHEWS P, 1986, BMJ, V293, P442; 1991, TOBACCO ADVERTISING; 1991, HLTH NATION; 1992, VOLUNTARY AGREEMENT	5	4	4	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1992	305	6847					223	224		10.1136/bmj.305.6847.223	http://dx.doi.org/10.1136/bmj.305.6847.223			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG112	1392825	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JG11200022
J	BUSTELO, XR; BARBACID, M				BUSTELO, XR; BARBACID, M			TYROSINE PHOSPHORYLATION OF THE VAV PROTOONCOGENE PRODUCT IN ACTIVATED B-CELLS	SCIENCE			English	Article							ANTI-IGM; STIMULATION	Activation of B lymphocytes by engagement of their immunoglobulin M antigen receptors results in phosphorylation of a number of proteins on tyrosine residues. One such protein is p95vav, the product of the vav proto-oncogene. Tyrosine phosphorylation of p95-vav occurred within seconds of immunoglobulin M cross-linking and was independent of other events induced during stimulation of B cells, such as protein kinase C activation, guanosine triphosphate-binding protein signaling, and calcium mobilization. Moreover, engagement of antigen receptors induced the rapid (approximately 5 seconds) and transient (approximately 60 seconds) association of p95vav with a 70-kilodalton tyrosine-phosphorylated protein, Vap-1, an interaction mediated by the Src homology 2 domain of p95vav. These results suggest that the vav proto-oncogene participates in the signaling processes that mediate the antigen-induced activation of B lymphocytes.			BUSTELO, XR (corresponding author), BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543, USA.		Bustelo, Xose R./A-9526-2010; Bustelo, Xose R./AAD-2081-2022	Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072				ADAMS JM, IN PRESS ONCOGENE; BRUNSWICK M, 1991, P NATL ACAD SCI USA, V88, P1311, DOI 10.1073/pnas.88.4.1311; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; COLIGAN JE, 1991, CURRENT PROTOCOLS IM, pCH3; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; GALLAND F, 1992, ONCOGENE, V7, P585; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MIZUGUCHI J, 1986, J IMMUNOL, V137, P2162; MIZUGUCHI J, 1988, J IMMUNOL, V140, P2495; MIZUGUCHI J, 1986, P NATL ACAD SCI USA, V83, P4474, DOI 10.1073/pnas.83.12.4474; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903	18	211	220	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 22	1992	256	5060					1196	1199		10.1126/science.256.5060.1196	http://dx.doi.org/10.1126/science.256.5060.1196			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV192	1375396				2022-12-28	WOS:A1992HV19200034
J	COLLINS, FS				COLLINS, FS			CYSTIC-FIBROSIS - MOLECULAR-BIOLOGY AND THERAPEUTIC IMPLICATIONS	SCIENCE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; RESPIRATORY EPITHELIA; TRANSPORT; GENE; IDENTIFICATION; EXPRESSION; INVITRO; DISEASE; CELLS; DNA	Cystic fibrosis is the most common potentially lethal autosomal recessive disease of Caucasians, affecting 1 in 2500 newborns. Since the recent identification of the gene that is defective in patients with cystic fibrosis, a wealth of information about gene structure, the mutational basis of disease, and the function of the protein product ha's been derived. The product of the gene is a chloride channel that is regulated by adenosine 3',5'-monophosphate (cyclic AMP)-dependent protein kinase phosphorylation and that requires binding of adenosine triphosphate (ATP) for channel opening. Several new approaches to drug therapy for cystic fibrosis are now emerging, and the possibility of successful gene therapy by transfer of the normal gene to airway epithelial cells is being vigorously pursued.	UNIV MICHIGAN, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT HUMAN GENET, ANN ARBOR, MI 48109 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	COLLINS, FS (corresponding author), UNIV MICHIGAN, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA.				NIDDK NIH HHS [DK42718, DK39690] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK042718, R01DK039690] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; Andersen DH, 1938, AM J DIS CHILD, V56, P344, DOI 10.1001/archpedi.1938.01980140114013; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; ANGUIANO A, 1992, JAMA-J AM MED ASSOC, V267, P1794, DOI 10.1001/jama.267.13.1794; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BEAR CE, 1991, J BIOL CHEM, V266, P19142; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; BIESECKER L, 1992, AM J HUM GENET, V50, P438; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; CARTER B, 1991, PEDIATR PULM, V6, P187; CASKEY CT, 1990, AM J HUM GENET, V46, P393; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; COHN JA, 1991, BIOCHEM BIOPH RES CO, V181, P36, DOI 10.1016/S0006-291X(05)81378-6; COHN JA, 1992, P NATL ACAD SCI USA, V89, P2340, DOI 10.1073/pnas.89.6.2340; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; COTTEN M, 1990, P NATL ACAD SCI USA, V87, P4033, DOI 10.1073/pnas.87.11.4033; CRAWFORD I, 1991, P NATL ACAD SCI USA, V88, P9262, DOI 10.1073/pnas.88.20.9262; CURIEL DT, 1991, P NATL ACAD SCI USA, V88, P8850, DOI 10.1073/pnas.88.19.8850; CUTTING GR, IN PRESS AM J HUM GE; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DISANTAGNESE PA, 1953, PEDIATRICS, V12, P549; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; Engelhardt J., UNPUB; FERKOL T, IN PRESS CLIN RES; FUJIMURA FK, 1990, NEW ENGL J MED, V322, P61; GIBSON LE, 1959, PEDIATRICS, V23, P545; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; HAZINSKI TA, 1991, AM J RESP CELL MOL, V4, P206, DOI 10.1165/ajrcmb/4.3.206; HUANG L, 1991, PEDIATR PULM S, V6, P189; HUBBARD RC, 1992, NEW ENGL J MED, V326, P812, DOI 10.1056/NEJM199203193261207; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JOHNSON LK, UNPUB; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KARTNER N, 1992, J CELL BIOCH F S, V16, P12; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KEREM E, 1990, NEW ENGL J MED, V323, P1517, DOI 10.1056/NEJM199011293232203; KNOWLES M, 1981, NEW ENGL J MED, V305, P1489, DOI 10.1056/NEJM198112173052502; KNOWLES MR, 1983, SCIENCE, V221, P1067, DOI 10.1126/science.6308769; KNOWLES MR, 1990, NEW ENGL J MED, V322, P1189, DOI 10.1056/NEJM199004263221704; KNOWLES MR, 1991, NEW ENGL J MED, V325, P533, DOI 10.1056/NEJM199108223250802; KOLLER BH, 1991, P NATL ACAD SCI USA, V88, P10730, DOI 10.1073/pnas.88.23.10730; KRISTIDIS P, IN PRESS AM J HUM GE; MARINO CR, 1991, J CLIN INVEST, V88, P712, DOI 10.1172/JCI115358; OLSEN JC, IN PRESS HUM GENE TH; QUINTON PM, 1990, NATURE, V347, P226, DOI 10.1038/347226a0; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; QUINTON PM, 1983, NATURE, V301, P421, DOI 10.1038/301421a0; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1991, ADV EXP MED BIOL, V290, P19; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1991, P NATL ACAD SCI USA, V88, P7500, DOI 10.1073/pnas.88.17.7500; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; SAMULSKI RJ, 1991, EMBO J, V10, P3941, DOI 10.1002/j.1460-2075.1991.tb04964.x; SARKADI B, 1992, J BIOL CHEM, V267, P2087; SATO K, 1984, J CLIN INVEST, V73, P1763, DOI 10.1172/JCI111385; SHAK S, 1990, P NATL ACAD SCI USA, V87, P9188, DOI 10.1073/pnas.87.23.9188; STRONG TV, 1991, NEW ENGL J MED, V325, P1630, DOI 10.1056/NEJM199112053252307; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TILLY BC, IN PRESS J BIOL CHEM; TREZISE AEO, 1991, NATURE, V353, P434, DOI 10.1038/353434a0; Tsui L C, 1991, Adv Hum Genet, V20, P153; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; WHITTSETT JA, 1991, PED PULM S, V6, P185; ZEITLIN PL, 1992, P NATL ACAD SCI USA, V89, P344, DOI 10.1073/pnas.89.1.344; [No title captured]	75	719	752	2	88	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 8	1992	256	5058					774	779		10.1126/science.1375392	http://dx.doi.org/10.1126/science.1375392			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT235	1375392				2022-12-28	WOS:A1992HT23500028
J	ARONSON, NE				ARONSON, NE			DISSEMINATED SPOROTRICHOSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SPOROTHRIX-SCHENCKII; FUNGEMIA		WILLIAM BEAUMONT ARMY MED CTR,INFECT DIS SERV,EL PASO,TX 79920	William Beaumont Army Medical Center								BAKER JH, 1989, ARCH PATHOL LAB MED, V113, P1279; FETTER BF, 1964, ARCH PATHOL, V78, P613; MORGAN MA, 1984, DIAGN MICR INFEC DIS, V2, P151, DOI 10.1016/0732-8893(84)90011-7; PLOUFFE JF, 1979, J INFECT DIS, V139, P152, DOI 10.1093/infdis/139.2.152; SMITH AG, 1970, AM J CLIN PATHOL, V154, P401	5	10	11	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 21	1992	268	15					2021	2021		10.1001/jama.268.15.2021	http://dx.doi.org/10.1001/jama.268.15.2021			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT520	1404730				2022-12-28	WOS:A1992JT52000008
J	COCHRANE, RA; MANDAL, AR; LEDGERSCOTT, M; WALKER, R				COCHRANE, RA; MANDAL, AR; LEDGERSCOTT, M; WALKER, R			CHANGES IN DRUG-TREATMENT AFTER DISCHARGE FROM HOSPITAL IN GERIATRIC-PATIENTS	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To ascertain changes in drug treatment of elderly patients after discharge from hospital and to identify areas of communication which may require improvement. Design-Follow up of patients six to 14 days after discharge, when the drugs supplied by the hospital should have run out and a further supply obtained from the general practitioner. Patients were also asked about information supplied to them by health care professionals during their hospital stay. Subjects - 50 elderly patients discharged from five geriatric wards (mean age 76.9 years). Setting- Sunderland District Health Authority. Main outcome measure-Drugs taken after discharge from hospital. Results-After returning home the drug regimen of 45 patients differed from that prescribed on discharge from hospital, with 11 patients taking a different dose, 10 having stopped drugs, and 20 taking new drugs. Possible influencing factors included an incomplete drug history, the continuation of drugs taken before hospital admission, and changes in the prescription not attributable to a conscious clinical decision. Lack of information also contributed; 46 patients could not recall being told when to take drugs before discharge. Conclusion-Closer communication is needed between hospital and community health care professionals to ensure that patients are informed about their discharge prescription and continuation of treatment.	SUNDERLAND DIST GEN HOSP,SUNDERLAND SR4 7TP,ENGLAND; ROYAL INFIRM,SUNDERLAND SR2 7JE,ENGLAND; SUNDERLAND POLYTECH,SCH PHARMACEUT & CHEM SCI,SUNDERLAND SR2 7EE,DURHAM,ENGLAND	Sunderland Royal Hospital; University of Sunderland								Davidson J R, 1974, Nurs Times, V70, P391; Hatch A M, 1982, Nurs Times, V78, P1773; MACDONALD ET, 1977, BMJ-BRIT MED J, V2, P618, DOI 10.1136/bmj.2.6087.618; MOTTRAM DR, 1989, PHARM J, V243, P458; PARKIN DM, 1976, BMJ-BRIT MED J, V2, P686, DOI 10.1136/bmj.2.6037.686; Sweeney SJ, 1989, PHARM J, V242; WALKER CA, 1987, BRIT J PHARM PRACTIC, V9, P47; WINFIELD AJ, 1990, BR J PHARM PRACT, V12, P206	8	86	89	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 19	1992	305	6855					694	696		10.1136/bmj.305.6855.694	http://dx.doi.org/10.1136/bmj.305.6855.694			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP511	1393119	Bronze, Green Submitted, Green Published			2022-12-28	WOS:A1992JP51100028
J	PSATY, BM; FURBERG, CD; KULLER, LH; BORHANI, NO; RAUTAHARJU, PM; OLEARY, DH; BILD, DE; ROBBINS, J; FRIED, LP; REID, C				PSATY, BM; FURBERG, CD; KULLER, LH; BORHANI, NO; RAUTAHARJU, PM; OLEARY, DH; BILD, DE; ROBBINS, J; FRIED, LP; REID, C			ISOLATED SYSTOLIC HYPERTENSION AND SUBCLINICAL CARDIOVASCULAR-DISEASE IN THE ELDERLY - INITIAL FINDINGS FROM THE CARDIOVASCULAR HEALTH STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNRECOGNIZED MYOCARDIAL-INFARCTION; CAROTID ATHEROSCLEROSIS; RISK-FACTORS; POPULATION; DETERMINANTS; HYPERTROPHY; PREVALENCE; MORTALITY; TRIAL	Objective.-To assess the association between isolated systolic hypertension (ISH) and subclinical disease in adults aged 65 years and above. Design.-Medicare eligibility lists were used to obtain a representative sample of 5201 community-dwelling elderly persons for the Cardiovascular Health Study, a National Heart, Lung, and Blood Institute-sponsored cohort study of risk factors for coronary heart disease and stroke. In this cross-sectional analysis of baseline data, we excluded 3012 participants who were receiving antihypertensive medications, had clinical cardiovascular disease, or had a diastolic blood pressure of at least 90 mm Hg. Main Outcome Measures.-For electrocardiogram: myocardial infarction, left ventricular hypertrophy, and left ventricular mass as measures of myocardial damage and strain; for echocardiography: left ventricular mass, fractional shortening, and Doppler flow velocities as measures of cardiac systolic and diastolic function; and for carotid sonography: carotid arterial intima-media thickness as a measure of atherosclerosis. Results.-Among the 2189 men and women in this analysis, 195 (9%) had ISH (systolic blood pressure, greater-than-or-equal-to 160 mm Hg) and 596 (23%) had borderline ISH (systolic blood pressure, 140 to 159 mm Hg). Systolic blood pressure was associated with myocardial infarction by electrocardiogram (P=.02). Borderline and definite ISH were strongly associated with left ventricular mass (P<.001). While there was little association with cardiac systolic function, borderline and definite ISH were associated with cardiac diastolic function (P<.001). Isolated systolic hypertension was also strongly associated with increased intima-media thickness of the carotid artery (P<.001). Conclusions.-While cohort analyses of future repeated measures will provide a better assessment of risk, both borderline and definite ISH were strongly related to a variety of measures of subclinical disease in elderly men and women.	UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98105; UNIV WASHINGTON,DEPT HLTH SERV,SEATTLE,WA 98105; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT PUBL HLTH SCI,WINSTON SALEM,NC 27103; UNIV PITTSBURGH,DEPT EPIDEMIOL,PITTSBURGH,PA 15260; CARDIOVASC HLTH STUDY COORDINATING CTR,SEATTLE,WA; UNIV ALBERTA,DEPT MED,EDMONTON T6G 2E1,ALBERTA,CANADA; GEISINGER MED CTR,DANVILLE,PA 17822; NHLBI,DIV EPIDEMIOL & CLIN APPLICAT,EPIDEMIOL & BIOMETRY PROGRAM,BETHESDA,MD 20892; UNIV CALIF DAVIS,DEPT MED,DAVIS,CA 95616; JOHNS HOPKINS UNIV,DEPT MED,BALTIMORE,MD 21218; UNIV CALIF IRVINE,DEPT MED,IRVINE,CA 92717	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Wake Forest University; Wake Forest Baptist Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Alberta; Geisinger Medical Center; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of California System; University of California Davis; Johns Hopkins University; University of California System; University of California Irvine	PSATY, BM (corresponding author), UNIV WASHINGTON,COORDINATING CTR,DEPT MED,JD-30,1107 NE 45TH ST,SUITE 530,SEATTLE,WA 98105, USA.				NHLBI NIH HHS [N01-HC-85081, N01-HC-85080, N01-HC-85079] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC085079, N01HC085080, N01HC085081] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Cochran W.G, 1957, STAT METHODS, V6th ed; COLANDREA MA, 1970, CIRCULATION, V41, P239, DOI 10.1161/01.CIR.41.2.239; DAHLOF B, 1986, J HYPERTENS, V4, P511, DOI 10.1097/00004872-198608000-00019; DEVEREUX RB, 1989, AM J HYPERTENS, V2, pS186, DOI 10.1093/ajh/2.6.186S; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; Gardin J M, 1992, J Am Soc Echocardiogr, V5, P63; GARLAND C, 1983, AM J EPIDEMIOL, V118, P365, DOI 10.1093/oxfordjournals.aje.a113644; KANNEL WB, 1980, CIRCULATION, V61, P1179, DOI 10.1161/01.CIR.61.6.1179; KANNEL WB, 1985, AM HEART J, V109, P581, DOI 10.1016/0002-8703(85)90566-6; KITABATAKE A, 1989, Heart and Vessels, V5, P33, DOI 10.1007/BF02058356; LEVY D, 1988, ANN INTERN MED, V108, P7, DOI 10.7326/0003-4819-108-1-7; McCullagh P., 1983, GEN LINEAR MODELS, DOI [10.1007/978-1-4899-3244-0, DOI 10.1007/978-1-4899-3244-0]; NORUSIS MJ, 1990, SPSS PC PLUS 4 0 BAS; OLEARY DH, 1988, STROKE, V19, P143; OLEARY DH, 1991, STROKE, V22, P1155, DOI 10.1161/01.STR.22.9.1155; PSATY BM, 1992, J CLIN EPIDEMIOL, V45, P683, DOI 10.1016/0895-4356(92)90143-B; RAUTAHARJU PM, 1990, METHOD INFORM MED, V29, P362; Rose GA, 1982, WHO MONOGRAPH SERIES, V56; RUTAN GH, 1988, CIRCULATION, V77, P504, DOI 10.1161/01.CIR.77.3.504; SALONEN R, 1991, ANN MED, V23, P23, DOI 10.3109/07853899109147926; SALONEN R, 1990, ATHEROSCLEROSIS, V81, P33, DOI 10.1016/0021-9150(90)90056-O; Schlesselman JJ, 1982, CASE CONTROL STUDIES; STAESSEN J, 1990, J HYPERTENS, V8, P393, DOI 10.1097/00004872-199005000-00001; Stamler J, 1989, Hypertension, V13, pI2; Stokes 3rd J, 1989, HYPERTENSION S1, V13, pI13; TELL GS, 1989, J CLIN EPIDEMIOL, V42, P551, DOI 10.1016/0895-4356(89)90151-0; VERDECCHIA P, 1990, EUR HEART J, V11, P679, DOI 10.1093/oxfordjournals.eurheartj.a059783; 1985, BMJ, V291, P97; 1967, JAMA-J AM MED ASSOC, V202, P116; 1979, JAMA-J AM MED ASSOC, V242, P2562; 1991, JAMA-J AM MED ASSOC, V265, P3255; 1988, ARCH INTERN MED, V148, P1023	32	149	152	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 9	1992	268	10					1287	1291		10.1001/jama.268.10.1287	http://dx.doi.org/10.1001/jama.268.10.1287			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL608	1387172				2022-12-28	WOS:A1992JL60800029
J	GATENBY, R; LYONS, K; STEWART, T; TAYLOR, J; SCOTT, J; PAYNE, G; REID, J; GLASS, D; CARROLL, D; MCLEAN, A; MENNIE, G; MAIR, F; BARCLAY, D; MCCRONE, M; MORTON, K; KENNEDY, N; ANDERSON, J; INNES, D; SCOTT, D; GUTHRIE, C; DAWSON, H; KINNON, J; MURRAY, B; FRASER, K; MORRISON, W; BURGESS, C; DONALDSON, A; PUCCI, M; SIMPSON, I; MCKERCHER, D; MACKAY, I; BELL, R; BICHAN, R; GORDON, G; HAYWORTH, A; MASSIE, R; WISLEY, A; TOSH, V; STEELE, W; WILSON, E; LOGAN, R; NICOL, H; MCLEAN, I; TAYLOR, A; ROBERTSON, S; WALLACE, R; CONNELL, D; RAE, J; FERGUSON, G; SANDEMAN, J; COSGROVE, E; SHIRREFFS, G; EASTON, D; SINCLAIR, A; CARTER, G; KAY, M; MACKIE, H; MORRICE, G; JOHNSTON, V; FISKEN, A; BEATTIE, J; BLACK, J; MACDONALD, J; GILL, G; CRUICKSHANK, I; HOOD, D; HARKNESS, S; SMYLIE, D; MORRISON, M; HARRINGTON, J; HERD, G; HUTCHISON, R; THOMASON, J; HAWSON, D; YOUNG, G; GREEN, P; MACK, N; BROOKER, I; BARBOUR, A; MILLER, J; GAULD, A; GOODBRAND, T; MCINNES, R; NICOL, D; ROBERTSON, A; MCLEMAN, D; CROCKETT, S; TAYLOR, I; MORGAN, A; MCINTOSH, G; STEWART, A; HERD, J; SMITH, J; MACCUISH, A; DELAAT, A; SNEDDON, A; CROWLEY, D; DUTHIE, A; FRASER, R; SMITH, A; LIDDELL, R; BEVAN, J; BEWSHER, P; BRUNT, P; BENJAMIN, N; CATTO, G; EDWARD, N; HIMSWORTH, R; JEFFERS, A; JENNINGS, K; JOHNSTON, A; KENMURE, A; MCLEOD, A; MOWAT, A; MURCHISON, L; PEARSON, D; PETRIE, J; POWER, D; RAWLES, J; SINCLAIR, T; SMITH, C; WALTON, S; WEBSTER, J; WILLIAMS, M; LIGHT, J; WATT, M; MCKNIGHT, J; SIMPSON, M; CREE, F; WELLWOOD, M				GATENBY, R; LYONS, K; STEWART, T; TAYLOR, J; SCOTT, J; PAYNE, G; REID, J; GLASS, D; CARROLL, D; MCLEAN, A; MENNIE, G; MAIR, F; BARCLAY, D; MCCRONE, M; MORTON, K; KENNEDY, N; ANDERSON, J; INNES, D; SCOTT, D; GUTHRIE, C; DAWSON, H; KINNON, J; MURRAY, B; FRASER, K; MORRISON, W; BURGESS, C; DONALDSON, A; PUCCI, M; SIMPSON, I; MCKERCHER, D; MACKAY, I; BELL, R; BICHAN, R; GORDON, G; HAYWORTH, A; MASSIE, R; WISLEY, A; TOSH, V; STEELE, W; WILSON, E; LOGAN, R; NICOL, H; MCLEAN, I; TAYLOR, A; ROBERTSON, S; WALLACE, R; CONNELL, D; RAE, J; FERGUSON, G; SANDEMAN, J; COSGROVE, E; SHIRREFFS, G; EASTON, D; SINCLAIR, A; CARTER, G; KAY, M; MACKIE, H; MORRICE, G; JOHNSTON, V; FISKEN, A; BEATTIE, J; BLACK, J; MACDONALD, J; GILL, G; CRUICKSHANK, I; HOOD, D; HARKNESS, S; SMYLIE, D; MORRISON, M; HARRINGTON, J; HERD, G; HUTCHISON, R; THOMASON, J; HAWSON, D; YOUNG, G; GREEN, P; MACK, N; BROOKER, I; BARBOUR, A; MILLER, J; GAULD, A; GOODBRAND, T; MCINNES, R; NICOL, D; ROBERTSON, A; MCLEMAN, D; CROCKETT, S; TAYLOR, I; MORGAN, A; MCINTOSH, G; STEWART, A; HERD, J; SMITH, J; MACCUISH, A; DELAAT, A; SNEDDON, A; CROWLEY, D; DUTHIE, A; FRASER, R; SMITH, A; LIDDELL, R; BEVAN, J; BEWSHER, P; BRUNT, P; BENJAMIN, N; CATTO, G; EDWARD, N; HIMSWORTH, R; JEFFERS, A; JENNINGS, K; JOHNSTON, A; KENMURE, A; MCLEOD, A; MOWAT, A; MURCHISON, L; PEARSON, D; PETRIE, J; POWER, D; RAWLES, J; SINCLAIR, T; SMITH, C; WALTON, S; WEBSTER, J; WILLIAMS, M; LIGHT, J; WATT, M; MCKNIGHT, J; SIMPSON, M; CREE, F; WELLWOOD, M			FEASIBILITY, SAFETY, AND EFFICACY OF DOMICILIARY THROMBOLYSIS BY GENERAL-PRACTITIONERS - GRAMPIAN REGION EARLY ANISTREPLASE TRIAL	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE MYOCARDIAL-INFARCTION; MOBILE CORONARY-CARE; CARDIAC-ARREST; MORTALITY; REDUCTION; UNIT	Objective-To assess the feasibility, safety, and efficacy of domiciliary thrombolysis by general practitioners. Design-Randomised double blind parallel group trial of anistreplase 30 units intravenously and placebo given either at home or in hospital. Setting-29 rural practices in Grampian admitting patients to teaching hospitals in Aberdeen (average distance 36 (range 16-62) miles). Patients-311 patients with suspected acute myocardial infarction and no contraindications to thrombolytic therapy seen at home within four hours of onset of symptoms. Main outcome measures-Time saving, adverse events, Q wave infarction, left ventricular function. Results-Anistreplase was administered at home 101 minutes after onset of symptoms, while anistreplase was given in hospital 240 minutes after onset of symptoms (median times). Adverse events after thrombolysis were infrequent and, apart from cardiac arrest, not a serious problem when they occurred in the community: seven of 13 patients were resuscitated after cardiac arrest out of hospital. By three months after trial entry the relative reduction of deaths from all causes in patients given thrombolytic therapy at home was 49% (13/163 (8.0%) v 23/148 (15.5%); difference -7.6% (95% confidence interval -14.7% to -0.4%), p=0.04). Full thickness Q wave infarction was less common in patients with confirmed infarction receiving treatment at home (65/122 (53.3%) v 76/112 (67.9%); difference -14.6% (95% confidence interval -27.0% to -2.2%), p=0.02). Conclusions-General practitioners provided rapid pre-hospital coronary care of a high standard. Compared with later administration in hospital, giving anistreplase at home resulted in reduction in mortality, fewer cardiac arrests, fewer Q wave infarcts, and better left ventricular function. Benefits were most marked where thrombolytic therapy was administered within two hours of the onset of symptoms.	UNIV ABERDEEN, MED ASSESSMENT RES UNIT, FORESTERHILL, ABERDEEN AB9 2ZD, SCOTLAND	University of Aberdeen								[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; BAUGHMAN KL, 1981, CIRCULATION, V63, P317, DOI 10.1161/01.CIR.63.2.317; BERGMANN SR, 1982, AM J MED, V73, P573, DOI 10.1016/0002-9343(82)90338-2; CHAMBERLAIN DA, 1988, LANCET, V1, P545; COBBE SM, 1991, BRIT MED J, V302, P1517, DOI 10.1136/bmj.302.6791.1517; COLQUHOUN MC, 1992, LANCET, V339, P1167, DOI 10.1016/0140-6736(92)90765-U; CRAMPTON RS, 1975, AM J MED, V58, P151, DOI 10.1016/0002-9343(75)90564-1; DICKINSON RJ, 1991, BRIT MED J, V302, P111; HAITES NE, 1985, BRIT HEART J, V53, P123; LEIZOROVICZ A, 1988, EUR HEART J, V9, P118; MACLENNAN AC, 1989, BMJ-BRIT MED J, V301, P321; MATHEWSON ZM, 1985, LANCET, V1, P441; METCALFE MJ, 1990, BRIT HEART J, V63, P267; METCALFE MJ, 1989, LANCET, V1, P1371; PAI GR, 1987, BRIT MED J, V294, P352, DOI 10.1136/bmj.294.6568.352; PANTRIDG.JF, 1967, LANCET, V2, P271; PANTRIDGE J F, 1970, QJM, V39, P621; PETCH MC, 1991, BMJ-BRIT MED J, V302, P1287, DOI 10.1136/bmj.302.6788.1287; RAWLES JM, 1988, BRIT MED J, V296, P882, DOI 10.1136/bmj.296.6626.882; RAWLES JM, 1987, BRIT MED J, V295, P639, DOI 10.1136/bmj.295.6599.639; ROWLEY JM, 1992, BRIT HEART J, V67, P255; SHAH M, 1990, BRIT MED J, V301, P1219, DOI 10.1136/bmj.301.6762.1219-a; WENNERBLOM B, 1982, EUR HEART J, V3, P504, DOI 10.1093/oxfordjournals.eurheartj.a061345; WILCOX RG, 1988, LANCET, V2, P525	25	235	237	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 5	1992	305	6853					548	553						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM495	1393033				2022-12-28	WOS:A1992JM49500015
J	SMITH, LJ; MARRAFFA, C				SMITH, LJ; MARRAFFA, C			HOW TO PREPARE FOR A FOREIGN FELLOW	BRITISH MEDICAL JOURNAL			English	Article									CENT MIDDLESEX HOSP,LONDON NW10,ENGLAND		SMITH, LJ (corresponding author), HOSP SICK CHILDREN,DEPT PAEDIAT NEUROL,LONDON WC1N 3JH,ENGLAND.		Marraffa, Catherine/H-7771-2019						0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 22	1992	305	6851					460	461		10.1136/bmj.305.6851.460	http://dx.doi.org/10.1136/bmj.305.6851.460			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK680	1392962	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992JK68000027
J	JONES, DJ				JONES, DJ			ABC OF COLORECTAL DISEASES - PILONIDAL-SINUS	BRITISH MEDICAL JOURNAL			English	Article											JONES, DJ (corresponding author), HOPE HOSP,GEN SURG,SALFORD M6 8HD,LANCS,ENGLAND.								0	23	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 15	1992	305	6850					410	412		10.1136/bmj.305.6850.410	http://dx.doi.org/10.1136/bmj.305.6850.410			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK314	1392926	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JK31400022
J	SHEAN, CS; GOTTESMAN, ME				SHEAN, CS; GOTTESMAN, ME			TRANSLATION OF THE PROPHAGE-LAMBDA CL TRANSCRIPT	CELL			English	Article								Mutations in rpsB that reduce the levels of the ribosomal protein S2 enhance the translation of cl in lambda lysogens. Two features of the cl transcript are required for enhanced translation: the absence of a leader and the presence of a downstream box, a sequence within the cl coding region that is complementary to the 16S rRNA. 30S ribosomal subunits deficient in S2 form ternary complexes with the cl transcript more efficiently than wild-type subunits. The absence of S2 may change the structure of the 16S rRNA, improving contacts with the cl downstream box.			SHEAN, CS (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, INST CANC RES, 701 W 168TH ST, NEW YORK, NY 10032 USA.				NIGMS NIH HHS [5 R01 GM 37219] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037219] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AN G, 1981, NUCLEIC ACIDS RES, V9, P4163, DOI 10.1093/nar/9.16.4163; BAYLIS HA, 1987, NUCLEIC ACIDS RES, V15, P7176, DOI 10.1093/nar/15.17.7176; BOLLEN A, 1979, J MOL BIOL, V132, P219, DOI 10.1016/0022-2836(79)90392-9; BRIMACOMBE R, 1988, J MOL BIOL, V199, P115, DOI 10.1016/0022-2836(88)90383-X; CAM K, 1991, J BACTERIOL, V173, P734, DOI 10.1128/jb.173.2.734-740.1991; DANIELS DL, 1983, LAMBDA, V2, P519; DEBOER HA, 1983, P NATL ACAD SCI-BIOL, V80, P21; DREYFUS M, 1988, J MOL BIOL, V204, P79, DOI 10.1016/0022-2836(88)90601-8; FAXEN M, 1991, NUCLEIC ACIDS RES, V19, P5247, DOI 10.1093/nar/19.19.5247; GOLD L, 1988, ANNU REV BIOCHEM, V57, P199, DOI 10.1146/annurev.bi.57.070188.001215; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTZ D, 1991, J MOL BIOL, V218, P83, DOI 10.1016/0022-2836(91)90875-7; HORINOUCHI S, 1987, J BACTERIOL, V169, P1929, DOI 10.1128/jb.169.5.1929-1937.1987; HOWARD BH, 1982, EUKARYOTIC VIRAL VEC, P211; JACOB WF, 1987, P NATL ACAD SCI USA, V84, P4757, DOI 10.1073/pnas.84.14.4757; JANSSEN GR, 1989, GENE DEV, V3, P415, DOI 10.1101/gad.3.3.415; JONES MO, 1979, P NATL ACAD SCI USA, V76, P150, DOI 10.1073/pnas.76.1.150; KING TC, 1987, ESCHERICHIA COLI SAL, V1, P703; KLOCK G, 1986, J MOL BIOL, V189, P633, DOI 10.1016/0022-2836(86)90493-6; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAUGHREA M, 1978, J MOL BIOL, V121, P411, DOI 10.1016/0022-2836(78)90391-1; LOPEZCABRERA M, 1989, J BACTERIOL, V171, P321, DOI 10.1128/jb.171.1.321-328.1989; MEYER BJ, 1980, J MOL BIOL, V139, P163, DOI 10.1016/0022-2836(80)90303-4; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MIZUSAWA S, 1982, GENE, V20, P317, DOI 10.1016/0378-1119(82)90200-1; MURRAY IA, 1989, GENE, V85, P283, DOI 10.1016/0378-1119(89)90420-4; NAGAI H, 1991, P NATL ACAD SCI USA, V88, P10515, DOI 10.1073/pnas.88.23.10515; Noller H. F, 1987, ESCHERICHIA COLI SAL, P104; OBERTO J, 1989, J MOL BIOL, V207, P675, DOI 10.1016/0022-2836(89)90237-4; OCONNOR M, 1989, EMBO J, V8, P4315, DOI 10.1002/j.1460-2075.1989.tb08618.x; OHTSUBO H, 1978, P NATL ACAD SCI USA, V75, P615, DOI 10.1073/pnas.75.2.615; POWERS T, 1988, J MOL BIOL, V201, P697, DOI 10.1016/0022-2836(88)90468-8; PTASHNE M, 1976, SCIENCE, V194, P156, DOI 10.1126/science.959843; REICHARDT L, 1971, P NATL ACAD SCI USA, V68, P2185, DOI 10.1073/pnas.68.9.2185; REICHARDT LF, 1975, J MOL BIOL, V93, P289, DOI 10.1016/0022-2836(75)90133-3; SCHERER GFE, 1980, NUCLEIC ACIDS RES, V8, P3895, DOI 10.1093/nar/8.17.3895; SCHNEIDER TD, 1986, J MOL BIOL, V188, P415, DOI 10.1016/0022-2836(86)90165-8; SHIMATAKE H, 1981, NATURE, V292, P128, DOI 10.1038/292128a0; SHINEDLING S, 1987, MOL GEN GENET, V207, P224, DOI 10.1007/BF00331582; Silhavy T. J., 1984, EXPT GENE FUSIONS; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; SPRENGART ML, 1990, NUCLEIC ACIDS RES, V18, P1719, DOI 10.1093/nar/18.7.1719; STEITZ JA, 1969, NATURE, V224, P957, DOI 10.1038/224957a0; STERN S, 1989, SCIENCE, V244, P783, DOI 10.1126/science.2658053; STORMO GD, 1982, NUCLEIC ACIDS RES, V10, P2971, DOI 10.1093/nar/10.9.2971; WAY JC, 1984, GENE, V32, P369, DOI 10.1016/0378-1119(84)90012-X; Zimmermann R A, 1979, Methods Enzymol, V59, P551	48	90	93	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 7	1992	70	3					513	522		10.1016/0092-8674(92)90175-C	http://dx.doi.org/10.1016/0092-8674(92)90175-C			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1386558				2022-12-28	WOS:A1992JH12400016
J	SHEPPARD, J				SHEPPARD, J			PARTNERS IN PRACTICE .2. THE CLINICAL TASK	BRITISH MEDICAL JOURNAL			English	Article																		BEATON S, 1991, BR J GEN PRACT, V41, P19; CROWN JM, 1991, PRIMARY HLTH CARE, V1, P30; MARSH GN, 1991, BRIT MED J, V303, P1312, DOI 10.1136/bmj.303.6813.1312; 1990, STATISTICS GENERAL M	4	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1992	305	6848					288	290		10.1136/bmj.305.6848.288	http://dx.doi.org/10.1136/bmj.305.6848.288			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG740	1392862	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992JG74000020
J	PERREN, T; SELBY, P				PERREN, T; SELBY, P			CURRENT ISSUES IN CANCER .1. BIOLOGICAL THERAPY	BRITISH MEDICAL JOURNAL			English	Article							IMMUNOTHERAPY; REMISSION; INDUCTION; MELANOMA		ST JAMES UNIV HOSP,DEPT CLIN MED,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND	Saint James's University Hospital			Perren, Timothy J/D-5387-2013	Perren, Timothy J/0000-0001-8472-8856				BALKWILL FR, 1989, IMMUNOL TODAY, V10, P299, DOI 10.1016/0167-5699(89)90085-6; CRAWFORD J, 1991, NEW ENGL J MED, V325, P164, DOI 10.1056/NEJM199107183250305; DEVITA VT, 1991, BIOL THERAPY CANCER; HALE G, 1988, LANCET, V2, P1394; HONSIK CJ, 1986, P NATL ACAD SCI USA, V83, P7893, DOI 10.1073/pnas.83.20.7893; JONES A, 1991, RADIOTHER ONCOL, V20, P211, DOI 10.1016/0167-8140(91)90119-2; JONES AL, 1989, CANCER SURV, V8, P817; KURZROCK R, 1991, BIOL THERAPY CANCER, P247; MANDELLI F, 1990, NEW ENGL J MED, V322, P1430, DOI 10.1056/NEJM199005173222005; MITCHELL MS, 1988, CANCER RES, V48, P5883; OHNO R, 1990, NEW ENGL J MED, V323, P1871; PALMER PA, IN PRESS EUR J CANCE; QUESEDA JR, 1988, J INTERFERON RES, V6, P678; ROSENBERG SA, 1990, NEW ENGL J MED, V323, P570, DOI 10.1056/NEJM199008303230904; SCARFFE JH, 1991, EUR J CANCER, V27, P1493; TALPAZ M, 1986, NEW ENGL J MED, V314, P1065, DOI 10.1056/NEJM198604243141701; WADLER S, 1991, J CLIN ONCOL, V9, P1806, DOI 10.1200/JCO.1991.9.10.1806	17	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 20	1992	304	6842					1621	1623		10.1136/bmj.304.6842.1621	http://dx.doi.org/10.1136/bmj.304.6842.1621			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA436	1378335	Green Published, Bronze			2022-12-28	WOS:A1992JA43600031
J	SMITH, R				SMITH, R			MEDICINE IN EUROPE .15. EUROPEAN RESEARCH - BACK TO PREEMINENCE	BRITISH MEDICAL JOURNAL			English	Article																		Martin B. R., 1990, SCI PUBL POLICY, V17, P14; MARTIN BR, 1992, NATURE, V355, P760, DOI 10.1038/355760a0; MAYNARD A, 1990, EVALUATION 4TH MED H; RICHARDS T, 1990, BRIT MED J, V301, P950; VANHEERINGEN A, 1989, SCI TECHNOLOGY INDIC; 1990, EC RES FUNDING; 1991, MAIN SCI TECHNOLOGY; 1991, BASIC SCI TECHNOLOGY; 1986, EVALUATION NATIONAL; 1989, EUROPEAN MOL BIOL OR	10	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1992	304	6831					899	903		10.1136/bmj.304.6831.899	http://dx.doi.org/10.1136/bmj.304.6831.899			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM835	1392760	Bronze, Green Published			2022-12-28	WOS:A1992HM83500039
J	MITCHELL, JM; SUNSHINE, JH				MITCHELL, JM; SUNSHINE, JH			CONSEQUENCES OF PHYSICIANS OWNERSHIP OF HEALTH-CARE FACILITIES - JOINT VENTURES IN RADIATION-THERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FINANCIAL INCENTIVES; OFFICE PRACTICE; PREPAID; DEMAND	Background. Physicians are increasingly the owners of health care facilities to which they refer patients for services but at which they do not practice. We studied such ownership arrangements, known as "joint ventures," in the field of radiation therapy, examining their effects on access, use of services, costs, and quality. Methods. Because 44 percent of free-standing facilities providing radiation therapy in Florida in 1989 were joint ventures, as compared with 7 percent elsewhere (95 percent confidence interval, 3 to 10 percent), we compared data for Florida with comparable data for the remainder of the United States. We also compared radiation-therapy facilities in Florida that were established as joint ventures with those that were not. Since most data were derived from entire populations rather than from samples, any differences found were of necessity statistically significant. Results. No joint-venture facilities providing radiation therapy were located in inner-city neighborhoods or rural areas, but 11 percent of other free-standing facilities and hospital-based facilities were located in such areas. Among free-standing facilities, joint ventures received 39 percent of their revenues from patients with well-paying insurance coverage, as compared with 31 percent for facilities that were not joint ventures (P<0.01). The frequency and costs of radiation-therapy treatments at free-standing centers were 40 to 60 percent higher in Florida than in the rest of the United States; there was no below-average use of radiation therapy at hospitals or higher cancer rates that explained the higher rates of use or higher costs in Florida. Radiation physicists at joint-venture facilities (the principal personnel involved in quality control other than physicians) spent 18 percent less time with each patient over the course of treatment than did their counterparts at free-standing facilities that were not joint ventures (P<0.05). Mortality among patients with cancer in Florida was not lower than the U.S. average, even though joint ventures are much more common in that state. Conclusions. Joint ventures in radiation therapy appear to have adverse effects on patients' access to care. They also appear to increase the use of services and costs substantially. Some indicators show that joint ventures cause either no improvement in quality or a decline. Our results add to the evidence indicating that physicians' self-referral generally has negative consequences. We recommend legislation to ban ownership of joint ventures by referring physicians. Such legislation needs to be carefully designed in order to achieve its objectives and forestall new, financially abusive arrangements.	AMER COLL RADIOL,RES DEPT,RESTON,VA; FLORIDA STATE UNIV,DEPT ECON,TALLAHASSEE,FL 32306	American College of Radiology; State University System of Florida; Florida State University	MITCHELL, JM (corresponding author), GEORGETOWN UNIV,GRAD PUBL POLICY PROGRAM,3600 N ST NW,SUITE 200,WASHINGTON,DC 20007, USA.							EPSTEIN AM, 1986, NEW ENGL J MED, V314, P1089, DOI 10.1056/NEJM198604243141706; FUCHS VR, 1978, J HUM RESOUR, V13, P35, DOI 10.2307/145247; GRAY BH, 1986, FOR PROFIT ENTERPRIS, P151; HANKS G E, 1984, International Journal of Radiation Oncology, Biology, Physics, V10, P87; HEMENWAY D, 1990, NEW ENGL J MED, V322, P1059, DOI 10.1056/NEJM199004123221507; HILLMAN BJ, 1990, NEW ENGL J MED, V323, P1604, DOI 10.1056/NEJM199012063232306; IGLEHART JK, 1990, NEW ENGL J MED, V322, P1682, DOI 10.1056/NEJM199006073222327; IGLEHART JK, 1989, NEW ENGL J MED, V321, P198, DOI 10.1056/NEJM198907203210327; KRAMER S, 1984, STAT MED, V3, P353, DOI 10.1002/sim.4780030411; KRAMER S, 1984, International Journal of Radiation Oncology, Biology, Physics, V10, P49; MANNING WG, 1984, NEW ENGL J MED, V310, P1505, DOI 10.1056/NEJM198406073102305; MITCHELL JM, 1992, JAMA-J AM MED ASSOC, V268, P80, DOI 10.1001/jama.268.1.80; MITCHELL JM, 1991, 1991 FLOR HLTH CAR C; Morrison D.E., 1970, SIGNIFICANCE TEST CO; PEAR R, 1991, NY TIMES        1105, pA17; PEAR R, 1991, NY TIMES        1118, pA1; RELMAN AS, 1985, NEW ENGL J MED, V313, P749, DOI 10.1056/NEJM198509193131209; RIES LAG, 1991, NCI NIH912789 PUBL; Rosenfeld R.H., 1984, MOD HEATHCARE, V14, P60; SCHROEDER SA, 1978, MED CARE, V16, P289, DOI 10.1097/00005650-197804000-00002; SUNSHINE JH, 1992, RADIOLOGY, V183, P535, DOI 10.1148/radiology.183.2.1561364; Waldholz Michael, 1989, WALL STREET J   0301, pA1; WILENSKY GR, 1983, MILBANK FUND Q, V61, P252, DOI 10.2307/3349907; 1990, PHYSICIANS CURRENT P; 1989, FINANCIAL ARRANGEMEN; 1989, FED REGISTER, V54, P8894; 1992, JAMA-J AM MED ASSOC, V267, P2366; 1992, PRESIDENTS COMPREHEN, P68	28	99	99	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 19	1992	327	21					1497	1501		10.1056/NEJM199211193272106	http://dx.doi.org/10.1056/NEJM199211193272106			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY165	1406881				2022-12-28	WOS:A1992JY16500006
J	COHEN, DJ; KUNTZ, RE; GORDON, SPF; PIANA, RN; SAFIAN, RD; MCKAY, RG; BAIM, DS; GROSSMAN, W; DIVER, DJ				COHEN, DJ; KUNTZ, RE; GORDON, SPF; PIANA, RN; SAFIAN, RD; MCKAY, RG; BAIM, DS; GROSSMAN, W; DIVER, DJ			PREDICTORS OF LONG-TERM OUTCOME AFTER PERCUTANEOUS BALLOON MITRAL VALVULOPLASTY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SURGICAL CLOSED COMMISSUROTOMY; FOLLOW-UP; VALVE REPLACEMENT; ACTUARIAL ANALYSIS; STENOSIS; VALVOTOMY; CATHETER; RISK; REOPERATIONS; IMPROVEMENT	Background. Percutaneous balloon mitral valvuloplasty is known to produce short-term hemodynamic and symptomatic improvement in many patients with mitral stenosis. Comprehensive assessment of the clinical usefulness of balloon valvuloplasty requires evaluation of patients' long-term outcomes. Methods. We performed balloon mitral valvuloplasty in 146 patients between October 1, 1985, and October 1, 1991. Base-line demographic, clinical, echocardiographic, and hemodynamic variables were evaluated in order to identify predictors of long-term event-free survival. Results. Balloon mitral valvuloplasty was completed successfully in 136 (93 percent) of the patients in whom the procedure was attempted; it resulted in an increase in the mean (+/-SD) mitral-valve area from 1.0+/-0.4 to 2.1+/-0.9 cm2 and a decrease in the mean transmitral pressure gradient from 14+/-5 to 6+/-3 mm Hg (P<0.001 for both comparisons). The estimated overall five-year survival rate was 76+/-5 percent, and the estimated five-year event-free survival rate (the percentage of patients without mitral-valve replacement, repeat valvuloplasty, or death from cardiac causes) was 51+/-6 percent. According to multivariate Cox proportional-hazards analysis, the independent predictors ot longer event-tree survival were a lower mitral-valve echocardiographic score (a measure ot mitral-valve deformity; range, 0 tor a normal valve to 16 tor a seriously deformed valve; P<0.001), lower left ventricular end-diastolic pressure (P = 0.001), and a lower New York Heart Association (NYHA) functional class (P = 0.04). Patients with no risk tactors tor early restenosis or only one risk factor (echocardiographic score >8, left ventricular end-diastolic pressure >10 mm Hg, or NYHA functional class IV) had a predicted five-year event-free survival rate of 60 to 84 percent, whereas patients with two or three risk factors had a predicted five-year event-free survival rate of only 13 to 41 percent. Conclusions. Balloon mitral valvuloplasty as a treatment for selected patients with mitral stenosis has good long-term results. The long-term outcome after this procedure can be predicted on the basis of patients' base-line characteristics.	BETH ISRAEL HOSP,DIV CARDIOVASC,330 BROOKLINE AVE,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT MED,HARVARD THORNDIKE LAB,DIV CARDIOVASC,BOSTON,MA 02115; CHARLES A DANA RES INST,BOSTON,MA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University								ABASCAL VM, 1990, CIRCULATION, V82, P448, DOI 10.1161/01.CIR.82.2.448; ALZAIBAG M, 1986, LANCET, V1, P757; BASSAND JP, 1991, J AM COLL CARDIOL, V18, P982, DOI 10.1016/0735-1097(91)90757-Z; BLOCK PC, 1992, AM J CARDIOL, V69, P537, DOI 10.1016/0002-9149(92)91000-T; CHAFFIN JS, 1979, ANN THORAC SURG, V27, P312, DOI 10.1016/S0003-4975(10)63305-X; CHEN CR, 1990, AM HEART J, V119, P102, DOI 10.1016/S0002-8703(05)80089-4; COHN LH, 1985, J THORAC CARDIOV SUR, V90, P872; COHN LH, 1985, AM J CARDIOL, V55, P731, DOI 10.1016/0002-9149(85)90146-8; COME PC, 1988, AM J CARDIOL, V61, P817, DOI 10.1016/0002-9149(88)91073-9; COMMERFORD PJ, 1982, ANN THORAC SURG, V33, P473, DOI 10.1016/S0003-4975(10)60788-6; COX DR, 1972, J R STAT SOC B, V34, P187; ELLIS LB, 1968, AM HEART J, V75, P743, DOI 10.1016/0002-8703(68)90034-3; ELLIS LB, 1973, CIRCULATION, V48, P357, DOI 10.1161/01.CIR.48.2.357; FERNANDEZORTIZ A, 1992, AM J CARDIOL, V69, P1100, DOI 10.1016/0002-9149(92)90875-Y; GAMRA H, 1991, CIRCULATION S2, V84, P204; GORDON SPF, 1992, J AM COLL CARDIOL, V19, P968, DOI 10.1016/0735-1097(92)90280-Z; GRANTHAM RN, 1974, CIRCULATION, V50, P200; GROSS RI, 1981, AM J CARDIOL, V47, P821, DOI 10.1016/0002-9149(81)90180-6; Grossman W, 1991, CARDIAC CATHETERIZAT, P166; HERRMANN HC, 1988, J THORAC CARDIOV SUR, V96, P33; HICKEY MSJ, 1991, J AM COLL CARDIOL, V17, P29, DOI 10.1016/0735-1097(91)90701-A; HUNG JS, 1991, AM J CARDIOL, V67, P854, DOI 10.1016/0002-9149(91)90619-V; INOUE K, 1984, J THORAC CARDIOV SUR, V87, P394; JOHN S, 1983, CIRCULATION, V68, P891, DOI 10.1161/01.CIR.68.5.891; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KARP RB, 1981, J THORAC CARDIOV SUR, V81, P602; Kay R, 1977, APPL STATIST, V26, P227, DOI 10.2307/2346962; KIRKLIN JW, 1991, CIRCULATION, V83, P1450, DOI 10.1161/01.CIR.83.4.1450; LEVINE MJ, 1989, CIRCULATION, V79, P1061, DOI 10.1161/01.CIR.79.5.1061; LOCK JE, 1985, NEW ENGL J MED, V313, P1515, DOI 10.1056/NEJM198512123132405; LYTLE BW, 1986, ANN THORAC SURG, V42, P632, DOI 10.1016/S0003-4975(10)64597-3; MCKAY CR, 1988, CIRCULATION, V77, P1013, DOI 10.1161/01.CIR.77.5.1013; MCKAY RG, 1987, J AM COLL CARDIOL, V9, P723, DOI 10.1016/S0735-1097(87)80224-3; MCKAY RG, 1986, J AM COLL CARDIOL, V7, P1410, DOI 10.1016/S0735-1097(86)80164-4; MOLAJO AO, 1988, ANN THORAC SURG, V45, P364, DOI 10.1016/S0003-4975(98)90006-6; NOBUYOSHI M, 1989, CIRCULATION, V80, P782, DOI 10.1161/01.CIR.80.4.782; PALACIOS I, 1987, CIRCULATION, V75, P778, DOI 10.1161/01.CIR.75.4.778; PALACIOS IF, 1989, CIRCULATION, V79, P573, DOI 10.1161/01.CIR.79.3.573; PANSINI S, 1990, ANN THORAC SURG, V50, P590, DOI 10.1016/0003-4975(90)90195-C; REID CL, 1989, CIRCULATION, V80, P515, DOI 10.1161/01.CIR.80.3.515; RIHAL C S, 1992, Journal of the American College of Cardiology, V19, p363A; SALOMON NW, 1977, ANN THORAC SURG, V24, P519, DOI 10.1016/S0003-4975(10)63450-9; SMITH WM, 1981, J THORAC CARDIOV SUR, V82, P738; TURI ZG, 1991, CIRCULATION, V83, P1179, DOI 10.1161/01.CIR.83.4.1179; TUZCU EM, 1991, J AM COLL CARDIOL, V17, P1121, DOI 10.1016/0735-1097(91)90841-V; TUZCU EM, 1992, CIRCULATION, V85, P963, DOI 10.1161/01.CIR.85.3.963; VAHANIAN A, 1989, AM J CARDIOL, V63, P847, DOI 10.1016/0002-9149(89)90055-6; VAHANIAN A, 1991, EUR HEART J, V12, P84, DOI 10.1093/eurheartj/12.suppl_B.84; WILKINS GT, 1988, BRIT HEART J, V60, P299; 1992, CIRCULATION, V85, P2014; 1992, CIRCULATION, V85, P448	51	153	161	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 5	1992	327	19					1329	1335		10.1056/NEJM199211053271901	http://dx.doi.org/10.1056/NEJM199211053271901			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW077	1406834	Bronze			2022-12-28	WOS:A1992JW07700001
J	LAFFEL, GL; BARNETT, AI; FINKELSTEIN, S; KAYE, MP				LAFFEL, GL; BARNETT, AI; FINKELSTEIN, S; KAYE, MP			THE RELATION BETWEEN EXPERIENCE AND OUTCOME IN HEART-TRANSPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTERNATIONAL SOCIETY; MORTALITY; VOLUME	Background. Current policies related to organ transplantation in the United States are designed to ensure that centers and physicians with experience in transplantation perform these procedures. It is essential to confirm the validity of such policies, since they may limit access to transplantation services. Methods. To determine the relation between experience with heart transplantation and mortality after the procedure, we merged data from the registry of the International Society for Heart and Lung Transplantation with data from a survey that provided additional information about patients and transplantation centers. Our study included 1123 patients who received a heart transplant at one of 56 hospitals in the United States from 1984 through 1986. We used univariate and bivariate techniques, as well as logistic regression, to analyze our data. Results. We observed an institutional learning curve for heart transplantation. Patients who received one of a center's first five transplants had higher mortality rates than patients who received a subsequent transplant (20 percent vs. 12 percent; P = 0.002; relative risk, 2.2; 95 percent confidence interval, 1.6 to 3.4). In addition, we found a correlation between the training of key personnel on the transplantation team and mortality at new transplantation centers. For example, new centers staffed by cardiologists with previous training in heart transplantation had lower mortality rates among heart-transplant recipients than centers without experienced cardiologists (7 percent vs. 16 percent; P = 0.001; relative risk, 2.7; 95 percent confidence interval, 1.3 to 5.9). By contrast, the previous training of the surgeons who performed transplantations was not related to the mortality rate associated with the procedure. Conclusions. Experience with heart transplantation is associated with a better outcome for patients after that procedure. Opportunities exist to refine transplantation policies on the basis of the experience of a center and its transplantation team and to develop similar policies for other forms of organ transplantation.	MIT,ALFRED P SLOAN SCH MANAGEMENT,CAMBRIDGE,MA 02139; UNIV CALIF SAN DIEGO,DEPT CARDIOTHORAC SURG,SAN DIEGO,CA 92103	Massachusetts Institute of Technology (MIT); University of California System; University of California San Diego	LAFFEL, GL (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,NEVILLE HOUSE,75 FRANCIS ST,BOSTON,MA 02115, USA.							[Anonymous], 1986, ORGAN TRANSPLANTATIO; BANLAHRACHE C, 1987, CLIN TRANSPLANT, P75; Billingham M E, 1990, J Heart Transplant, V9, P587; CICCIARELLI J, 1985, CLIN KIDNEY TRANSPLA, P82; COLTON T, 1981, STATISTICS MED; EVANS RW, 1984, NATIONAL HEART TRANS; FLOOD AB, 1984, MED CARE, V22, P98, DOI 10.1097/00005650-198402000-00002; KELLY JV, 1986, MED CARE, V24, P785, DOI 10.1097/00005650-198609000-00001; KRAKAUER H, 1983, TRANSPLANTATION, V36, P372, DOI 10.1097/00007890-198310000-00005; KRIETT JM, 1990, J HEART TRANSPLANT, V9, P323; LAFFEL GL, 1987, J AM COLL CARDIOL, V10, pB79, DOI 10.1016/S0735-1097(87)80432-1; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; LUFT HS, 1987, HLTH SERV RES, V22, P158; SLOAN FA, 1989, ORGAN TRANSPLANTATIO, P115; 1987, FED REGISTER, V52, P10935; 1968, PERSPECTIVE EXPERIEN; 1989, GAOHRD8961 GEN ACC O; 1988, RATIONAL IRRATIONAL	18	89	89	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 22	1992	327	17					1220	1225		10.1056/NEJM199210223271707	http://dx.doi.org/10.1056/NEJM199210223271707			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JU393	1406795				2022-12-28	WOS:A1992JU39300007
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FDAS ELECTRONIC BULLETIN BOARD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1992	268	14					1828	1828		10.1001/jama.268.14.1828	http://dx.doi.org/10.1001/jama.268.14.1828			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR439	1404696				2022-12-28	WOS:A1992JR43900010
J	THOMPSON, AM				THOMPSON, AM			HOW SAFE IS SCOTTISH HOT AIR	BRITISH MEDICAL JOURNAL			English	Article									RAIGMORE HOSP,DEPT SURG,INVERNESS IV2 3UJ,SCOTLAND									HARDING RM, 1983, BRIT MED J, V287, P277, DOI 10.1136/bmj.287.6387.277; THOMPSON AM, 1983, BRIT MED J, V287, P614, DOI 10.1136/bmj.287.6392.614; 1991, FLIGHT SAFETY B, V27, P44; 1992, OBSERVER        0112, P1	4	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 19	1992	305	6855					691	691		10.1136/bmj.305.6855.691	http://dx.doi.org/10.1136/bmj.305.6855.691			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP511	1393113	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JP51100022
J	HOSKING, SW; LING, TKW; YUNG, MY; CHENG, A; CHUNG, SCS; LEUNG, JWC; LI, AKC				HOSKING, SW; LING, TKW; YUNG, MY; CHENG, A; CHUNG, SCS; LEUNG, JWC; LI, AKC			RANDOMIZED CONTROLLED TRIAL OF SHORT-TERM TREATMENT TO ERADICATE HELICOBACTER-PYLORI IN PATIENTS WITH DUODENAL-ULCER	BRITISH MEDICAL JOURNAL			English	Article							CAMPYLOBACTER PYLORI; PEPTIC-ULCER	Objective-To determine whether one week's drug treatment is sufficient to eradicate Helicobacter pylori in patients with duodenal ulcer. Design-Single blind, randomised controlled trial. Setting-Specialised ulcer clinic in a teaching hospital. Patients-155 patients with H pylori and a duodenal ulcer verified endoscopically which had either bled within the previous 24 hours or was causing dyspepsia. Interventions-Patients were allocated randomly to receive either omeprazole for four weeks plus bismuth 120 mg, tetracycline 500 mg, and metronidazole 400 mg (all four times a day) for the first week (n=78), or omeprazole alone for four weeks (n=77). Further endoscopy was performed four weeks after cessation of all drugs. Main outcome measures-Presence or absence of H pylori (by urease testing, microscopy, and culture of antral biopsy specimens), duodenal ulcer, and side effects. Results-Eradication of H pylori occurred in 70 (95%) patients taking the four drugs (95% confidence interval 86% to 97%) compared with three (4%) patients taking omeprazole alone (1% to 11%). Duodenal ulcers were found in four (5%) patients taking the four drugs (2% to 12%) and in 16 (22%) patients taking omeprazole alone (14% to 32%). Mild dizziness was the only reported side effect (six patients in each group) and did not affect compliance. Conclusions-A one week regimen of bismuth, tetracycline, and metronidazole is safe and effective in eradicating H pylori and reduces the number of duodenal ulcers four weeks after completing treatment.	CHINESE UNIV HONG KONG,PRINCE WALES HOSP,DEPT SURG,SHA TIN,HONG KONG; CHINESE UNIV HONG KONG,PRINCE WALES HOSP,DEPT MED,SHA TIN,HONG KONG; CHINESE UNIV HONG KONG,PRINCE WALES HOSP,DEPT MICROBIOL,SHA TIN,HONG KONG	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital								AXON ATR, 1991, J GASTROEN HEPATOL, V6, P131, DOI 10.1111/j.1440-1746.1991.tb01452.x; BORODY T, 1990, Gastroenterology, V98, pA24; COGHLAN JG, 1987, LANCET, V2, P1109; FIOCCA R, 1987, DIGESTION, V38, P234, DOI 10.1159/000199597; LOGAN RPH, 1991, LANCET, V338, P1249, DOI 10.1016/0140-6736(91)92111-E; MARSHALL BJ, 1988, LANCET, V2, P1437; RAUWS EAJ, 1990, LANCET, V335, P1233, DOI 10.1016/0140-6736(90)91301-P; SOLVELL L, 1990, DIGESTION, V47, P59, DOI 10.1159/000200519	8	142	143	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 29	1992	305	6852					502	504		10.1136/bmj.305.6852.502	http://dx.doi.org/10.1136/bmj.305.6852.502			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL609	1392995	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JL60900017
J	MARKUS, H; POLKEY, M; HARRISON, M				MARKUS, H; POLKEY, M; HARRISON, M			VISUAL-LOSS AND OPTIC ATROPHY ASSOCIATED WITH CYPROTERONE-ACETATE	BRITISH MEDICAL JOURNAL			English	Letter											MARKUS, H (corresponding author), MIDDLESEX HOSP,DEPT NEUROL,LONDON W1N 8AA,ENGLAND.								0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1992	305	6846					159	159		10.1136/bmj.305.6846.159-a	http://dx.doi.org/10.1136/bmj.305.6846.159-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF063	1387573	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JF06300026
J	KISS, T; FILIPOWICZ, W				KISS, T; FILIPOWICZ, W			EVIDENCE AGAINST A MITOCHONDRIAL LOCATION OF THE 7-2/MRP RNA IN MAMMALIAN-CELLS	CELL			English	Editorial Material							RIBONUCLEASE-P; NUCLEAR GENE; MRP; SEQUENCES; DNA; TRANSCRIPTION; CONTAINS; ENZYME; SITE				KISS, T (corresponding author), FRIEDRICH MIESCHER INST, POB 2543, CH-4002 BASEL, SWITZERLAND.			Kiss, Tamas/0000-0003-0293-3093				ALTMAN S, 1990, J BIOL CHEM, V265, P20053; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; ATTARDI G, 1982, MITOCHONDRIAL GENES, P51; Baserga R, 1969, Int Rev Exp Pathol, V7, P1; BENNE R, 1990, TRENDS GENET, V6, P177, DOI 10.1016/0168-9525(90)90173-4; BENNETT JL, 1990, MOL CELL BIOL, V10, P2191, DOI 10.1128/MCB.10.5.2191; BROWN JW, 1990, CELL, V62, P407, DOI 10.1016/0092-8674(90)90003-W; CHANG DD, 1989, CELL, V56, P131, DOI 10.1016/0092-8674(89)90991-4; CHANG DD, 1985, EMBO J, V4, P1559, DOI 10.1002/j.1460-2075.1985.tb03817.x; CHANG DD, 1987, EMBO J, V6, P409, DOI 10.1002/j.1460-2075.1987.tb04770.x; CHANG DD, 1987, SCIENCE, V235, P1178, DOI 10.1126/science.2434997; CLAYTON DA, 1991, TRENDS BIOCHEM SCI, V16, P107, DOI 10.1016/0968-0004(91)90043-U; CREWS S, 1980, CELL, V19, P775, DOI 10.1016/S0092-8674(80)80053-5; FILIPOWICZ W, 1990, METHOD ENZYMOL, V181, P499; GELFAND R, 1981, MOL CELL BIOL, V1, P497, DOI 10.1128/MCB.1.6.497; GOLD HA, 1989, SCIENCE, V245, P1377, DOI 10.1126/science.2476849; GOODALL GJ, 1990, METHOD ENZYMOL, V181, P148; GOODALL GJ, 1989, CELL, V58, P473, DOI 10.1016/0092-8674(89)90428-5; Greenawalt J W, 1974, Methods Enzymol, V31, P310; JAMES BD, 1988, CELL, V52, P19, DOI 10.1016/0092-8674(88)90527-2; KARWAN R, 1991, GENE DEV, V5, P1264, DOI 10.1101/gad.5.7.1264; KISS T, 1991, CELL, V65, P517, DOI 10.1016/0092-8674(91)90469-F; NAGLEY P, 1989, TRENDS GENET, V5, P67, DOI 10.1016/0168-9525(89)90028-0; NELSONREES WA, 1976, SCIENCE, V191, P96, DOI 10.1126/science.1246601; PACE NR, 1990, J BIOL CHEM, V265, P3587; PARRY HD, 1989, TRENDS BIOCHEM SCI, V14, P15, DOI 10.1016/0968-0004(89)90083-2; POSAKONY JW, 1977, J CELL BIOL, V74, P468, DOI 10.1083/jcb.74.2.468; REDDY R, 1981, J BIOL CHEM, V256, P8452; Reddy R., 1988, STRUCTURE FUNCTION M, P1, DOI 10.1007/978-3-642-73020-7_1; REIMER G, 1988, EXP CELL RES, V176, P117, DOI 10.1016/0014-4827(88)90126-7; STEELE WJ, 1965, J BIOL CHEM, V240, P1742; TAPPER DP, 1983, METHOD ENZYMOL, V97, P426; TOPPER JN, 1990, NUCLEIC ACIDS RES, V18, P793, DOI 10.1093/nar/18.4.793; YUAN Y, 1989, J BIOL CHEM, V264, P14835; YUAN Y, 1991, MOL CELL BIOL, V11, P5266, DOI 10.1128/MCB.11.10.5266	35	100	102	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 10	1992	70	1					11	16		10.1016/0092-8674(92)90528-K	http://dx.doi.org/10.1016/0092-8674(92)90528-K			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JC957	1377982				2022-12-28	WOS:A1992JC95700003
J	KINGMAN, S				KINGMAN, S			THE NEW NHS - 1ST YEARS EXPERIENCE - FREEMAN HOSPITAL - WORKING TO IMPROVE SERVICES	BRITISH MEDICAL JOURNAL			English	Article																			0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1992	304	6831					907	909		10.1136/bmj.304.6831.907	http://dx.doi.org/10.1136/bmj.304.6831.907			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM835	1392762	Green Published, Bronze			2022-12-28	WOS:A1992HM83500041
J	IGLEHART, JK				IGLEHART, JK			THE AMERICAN HEALTH-CARE SYSTEM - MEDICARE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PROSPECTIVE PAYMENT SYSTEM; PHYSICIANS											BERENSON R, 1992, JAMA-J AM MED ASSOC, V267, P687, DOI 10.1001/jama.267.5.687; Cohen WJ., 1985, HLTH CARE FINANCIN S, P3; Coulam R F, 1991, Health Care Financ Rev Annu Suppl, P45; GORNICK M, 1991, HEALTH POLICY, V17, P209, DOI 10.1016/0168-8510(91)90125-H; GORNICK M, 1985, HLTH CARE FINANC R S, V13, P59; HSIAO WC, 1988, NEW ENGL J MED, V319, P835, DOI 10.1056/NEJM198809293191305; IGLEHART JK, 1992, NEW ENGL J MED, V326, P962, DOI 10.1056/NEJM199204023261426; IGLEHART JK, 1990, NEW ENGL J MED, V322, P1247, DOI 10.1056/NEJM199004263221728; IGLEHART JK, 1983, NEW ENGL J MED, V308, P1428, DOI 10.1056/NEJM198306093082331; IGLEHART JK, 1991, NEW ENGL J MED, V324, P503, DOI 10.1056/NEJM199102143240725; IGLEHART JK, 1992, NEW ENGL J MED, V327, P742, DOI 10.1056/NEJM199209033271029; JENCKS SF, 1992, JAMA-J AM MED ASSOC, V268, P900, DOI 10.1001/jama.268.7.900; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1953, DOI 10.1001/jama.264.15.1953; KASSIRER JP, 1992, NEW ENGL J MED, V326, P945, DOI 10.1056/NEJM199204023261408; KNOX RA, 1992, BOSTON GOBLE    0525; KOSECOFF J, 1990, JAMA-J AM MED ASSOC, V264, P1980, DOI 10.1001/jama.264.15.1980; MCLLRATH S, 1992, AM MED NEWS     0907, pP1; RELMAN AS, 1988, NEW ENGL J MED, V319, P1220, DOI 10.1056/NEJM198811033191810; ROPER WL, 1988, NEW ENGL J MED, V319, P1197, DOI 10.1056/NEJM198811033191805; SMITH DG, 1992, PAYING MEDICARE POLI; THORPE KE, 1992, HEALTH AFFAIR, V11, P41, DOI 10.1377/hlthaff.11.2.41; Waldo D R, 1989, Health Care Financ Rev, V10, P111; Waldo D R, 1984, Health Care Financ Rev, V6, P1; 1991, DHHS FCOA9128001 PUB; 1992, MEDICARE AM HLTH CAR; 1992, GREEN BOOK WAYS 102; 1987, LIFE SUSTAINING TECH	27	29	29	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 12	1992	327	20					1467	1472		10.1056/NEJM199211123272027	http://dx.doi.org/10.1056/NEJM199211123272027			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX479	1406878				2022-12-28	WOS:A1992JX47900033
J	DAJANI, AS; AYOUB, E; BIERMAN, FZ; BISNO, AL; DENNY, FW; DURACK, DT; FERRIERI, P; FREED, M; GERBER, M; KAPLAN, EL; KARCHMER, AW; MARKOWITZ, M; RAHIMTOOLA, SH; SHULMAN, ST; STOLLERMAN, G; TAKAHASHI, M; TARANTA, A; TAUBERT, KA; WILSON, W				DAJANI, AS; AYOUB, E; BIERMAN, FZ; BISNO, AL; DENNY, FW; DURACK, DT; FERRIERI, P; FREED, M; GERBER, M; KAPLAN, EL; KARCHMER, AW; MARKOWITZ, M; RAHIMTOOLA, SH; SHULMAN, ST; STOLLERMAN, G; TAKAHASHI, M; TARANTA, A; TAUBERT, KA; WILSON, W			GUIDELINES FOR THE DIAGNOSIS OF RHEUMATIC-FEVER - JONES CRITERIA, 1992 UPDATE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								The Jones Criteria for guidance in the diagnosis of acute rheumatic fever were first published by T. Duckett Jones, MD, in 1944 and have been revised over the years by the American Heart Association. The current guidelines are an update of these criteria. For the first time, the guidelines are designed to establish the initial attack of acute rheumatic fever. Major manifestations, minor manifestations, and supporting evidence of antecedent group A streptococcal infection are discussed. These updated guidelines expand on the available tools to diagnose streptococcal pharyngitis and clarify the available antibody tests for detecting antecedent group A streptococcal infection. At the present time echocardiography without accompanying auscultatory findings is insufficient to be the sole criterion for valvulitis in acute rheumatic fever. Finally, this article addresses overdiagnosis of rheumatic fever and lists exceptions to the Jones Criteria, including recurrent attacks in individuals with a history of rheumatic fever.	AMER HEART ASSOC,7272 GREENVILLE AVE,DALLAS,TX 75231									Ayoub EM, 1989, MOSS HEART DISEASE I, P692; Jones TD, 1944, J AMER MED ASSOC, V126, P481, DOI 10.1001/jama.1944.02850430015005; Markowitz M., 1972, RHEUMATIC FEVER, P62; RUTSTEIN DD, 1955, MOD CONCEPTS CARDIOV, V24, P291; SHULMAN ST, 1984, CIRCULATION, V69, pA203; STOLLERMAN G, 1975, STREPTOCOCCAL INFECT; STOLLERMAN GH, 1965, EM145 AM HEART ASS P; Taranta A, 1989, RHEUMATIC FEVER; 1988, WHO TECHNICAL REP SE, V764	9	544	564	1	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 21	1992	268	15					2069	2073		10.1001/jama.1992.03490150121036	http://dx.doi.org/10.1001/jama.1992.03490150121036			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT520	1404745				2022-12-28	WOS:A1992JT52000032
J	LEUNGHAGESTEIJN, CY; SPENCE, AM; STERN, BD; ZHOU, YW; SU, MW; HEDGECOCK, EM; CULOTTI, JG				LEUNGHAGESTEIJN, CY; SPENCE, AM; STERN, BD; ZHOU, YW; SU, MW; HEDGECOCK, EM; CULOTTI, JG			UNC-5, A TRANSMEMBRANE PROTEIN WITH IMMUNOGLOBULIN AND THROMBOSPONDIN TYPE-1 DOMAINS, GUIDES CELL AND PIONEER AXON MIGRATIONS IN C-ELEGANS	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; GROWTH CONES; CIRCUMSPOROZOITE PROTEIN; NEURITE OUTGROWTH; MEMBRANE-PROTEINS; ATTACHMENT SITE; PHOSPHOLIPASE-C; M2 PROTEIN; GENE; SEQUENCE	The unc-5 gene is required for guiding pioneering axons and migrating cells along the body wall in C. elegans. In mutants, dorsal migrations are disrupted, but ventral and longitudinal movements are largely unaffected. The gene was tagged for molecular cloning by transposon insertions. Based on genomic and cDNA sequencing, the gene encodes UNC-5, a transmembrane protein of 919 aa. The predicted extracellular N-terminus comprises two immunoglobulin and two thrombospondin type 1 domains. Except for an SH3-like motif, the large intracellular C-terminus is novel. Mosaic analysis shows that unc-5 acts in migrating cells and pioneering neurons. We propose that UNC-5 is a transmembrane receptor expressed on the surface of motile cells and growth cones to guide dorsal movements.	MRC, MOLEC BIOL LAB, CAMBRIDGE CB2 2QH, ENGLAND; ROCHE INST MOLEC BIOL, DEPT CELL & DEV BIOL, NUTLEY, NJ 07110 USA; JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5S 1A8, ONTARIO, CANADA	MRC Laboratory Molecular Biology; Johns Hopkins University; University of Toronto	LEUNGHAGESTEIJN, CY (corresponding author), MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC IMMUNOL & NEUROBIOL, TORONTO M5G 1X5, ONTARIO, CANADA.		Culotti, Joseph/G-6467-2013	Culotti, Joseph/0000-0001-6325-4612	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026295, R37NS026295] Funding Source: NIH RePORTER; NINDS NIH HHS [NS26295] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BORNSTEIN P, 1990, J BIOL CHEM, V265, P16691; BORNSTEIN P, 1991, J BIOL CHEM, V266, P12821; Bray D., 1992, CELL MOVEMENTS; CHENEVERT J, 1992, NATURE, V356, P77, DOI 10.1038/356077a0; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COLLINS J, 1987, NATURE, V328, P726, DOI 10.1038/328726a0; CONRAD R, 1991, MOL CELL BIOL, V11, P1921, DOI 10.1128/MCB.11.4.1921; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; EIDE D, 1985, P NATL ACAD SCI USA, V82, P1756, DOI 10.1073/pnas.82.6.1756; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GILBERT W, 1987, COLD SPRING HARB SYM, V52, P901, DOI 10.1101/SQB.1987.052.01.098; GOLDBERG DJ, 1989, TRENDS NEUROSCI, V12, P503, DOI 10.1016/0166-2236(89)90110-0; GOUNDIS D, 1988, NATURE, V335, P82, DOI 10.1038/335082a0; HAEFLIGER JA, 1989, J BIOL CHEM, V264, P18041; HEDGECOCK EM, 1985, DEV BIOL, V111, P158, DOI 10.1016/0012-1606(85)90443-9; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HERMAN RK, 1989, NEUROGENETICS, V5, P1; HOLT GD, 1990, J BIOL CHEM, V265, P2852; IRUELAARISPE ML, 1991, P NATL ACAD SCI USA, V88, P5026, DOI 10.1073/pnas.88.11.5026; ISHII N, UNPUB LAMININ RELATE; JING S, 1987, EMBO J, V6, P327, DOI 10.1002/j.1460-2075.1987.tb04758.x; KAUFMAN JF, 1984, J BIOL CHEM, V259, P7230; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LABEIT S, 1990, NATURE, V345, P273, DOI 10.1038/345273a0; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; Maniatis T., 1982, MOL CLONING; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MITCHISON T, 1988, NEURON, V1, P761, DOI 10.1016/0896-6273(88)90124-9; MOERMAN DG, 1986, P NATL ACAD SCI USA, V83, P2579, DOI 10.1073/pnas.83.8.2579; MORI I, 1988, GENETICS, V120, P397; NAEVE CW, 1990, EMBO J, V9, P3857, DOI 10.1002/j.1460-2075.1990.tb07604.x; NEUGEBAUER KM, 1991, NEURON, V6, P345, DOI 10.1016/0896-6273(91)90244-T; OSHEA KS, 1990, J CELL BIOL, V110, P1275, DOI 10.1083/jcb.110.4.1275; OSHEA KS, 1991, NEURON, V7, P231, DOI 10.1016/0896-6273(91)90261-W; OSHEA KS, 1988, J CELL BIOL, V107, P2737, DOI 10.1083/jcb.107.6.2737; OWENS GC, 1987, P NATL ACAD SCI USA, V84, P294, DOI 10.1073/pnas.84.1.294; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; Rathjen FG, 1991, CURR OPIN CELL BIOL, V3, P992, DOI 10.1016/0955-0674(91)90119-J; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.neuro.14.1.531; RICH KA, 1990, SCIENCE, V249, P1574, DOI 10.1126/science.2120774; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; RUAN KS, 1984, P NATL ACAD SCI-BIOL, V81, P4018, DOI 10.1073/pnas.81.13.4018; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SABRY JH, 1991, J CELL BIOL, V115, P381, DOI 10.1083/jcb.115.2.381; SANES JR, 1989, ANNU REV NEUROSCI, V12, P491, DOI 10.1146/annurev.ne.12.030189.002423; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH SJ, 1988, SCIENCE, V242, P708, DOI 10.1126/science.3055292; SPENCE AM, 1990, CELL, V60, P981, DOI 10.1016/0092-8674(90)90346-G; STADEN R, 1987, NUCLEIC ACID PROTEIN, P173; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUGRUE RJ, 1990, VIROLOGY, V179, P51, DOI 10.1016/0042-6822(90)90272-S; SUGRUE RJ, 1991, VIROLOGY, V180, P617, DOI 10.1016/0042-6822(91)90075-M; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; Sulston J., 1988, NEMATODE CAENORHABDI, P587; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SUN XJ, 1989, J BIOL CHEM, V264, P11288; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; Wadsworth William G., 1992, Current Opinion in Neurobiology, V2, P36, DOI 10.1016/0959-4388(92)90159-I; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WHITE JM, 1990, ANNU REV PHYSIOL, V52, P675, DOI 10.1146/annurev.ph.52.030190.003331; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; [No title captured]	78	348	367	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 16	1992	71	2					289	299		10.1016/0092-8674(92)90357-I	http://dx.doi.org/10.1016/0092-8674(92)90357-I			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JU395	1384987				2022-12-28	WOS:A1992JU39500014
J	PARKER, LL; PIWNICAWORMS, H				PARKER, LL; PIWNICAWORMS, H			INACTIVATION OF THE P34(CDC2)-CYCLIN-B COMPLEX BY THE HUMAN WEE1 TYROSINE KINASE	SCIENCE			English	Article							FISSION YEAST; CELL-CYCLE; P34CDC2 KINASE; SCHIZOSACCHAROMYCES-POMBE; PHOSPHORYLATION SITES; ACTIVATES P34CDC2; MITOTIC INDUCER; CDC25 PROTEIN; GENE; DEPHOSPHORYLATION	Entry into mitosis in Schizosaccharomyces pombe is negatively regulated by the wee1+ gene, which encodes a protein kinase with serine-, theonine-, and tyrosine-phosphorylating activities. The wee1+ kinase negatively regulates mitosis by phosphorylating p34cdc2 on tyrosine 15, thereby inactivating the p34cdc2-cyclin B complex. The human homolog of the wee1+ gene (WEE1Hu) was overproduced in bacteria and assayed in an in vitro system. Unlike its fission yeast homolog, the product of the WEE1Hu gene encoded a tyrosine-specific protein kinase. The human WEE1 kinase phosphorylated the p34cdc2-cyclin B complex on tyrosine 15 but not on threonine 14 in vitro and inactivated the p34cdc2-cyclin B kinase. This inhibition was reversed by the human Cdc25C protein, which catalyzed the dephosphorylation of p34cdc2. These results indicate that the product of the WEE1Hu gene directly regulates the p34cdc2-cyclin B complex in human cells and that a kinase other than that encoded by WEE1Hu phosphorylates p34cdc2 on threonine 14.	TUFTS UNIV, DEPT PHYSIOL, BOSTON, MA 02111 USA	Tufts University			Piwnica-Worms, Helen/C-5214-2012					BOOHER R, 1986, MOL CELL BIOL, V6, P3523, DOI 10.1128/MCB.6.10.3523; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MURRAY AW, 1989, NATURE, V342, P14, DOI 10.1038/342014a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARKER L, UNPUB; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PINES J, 1990, New Biologist, V2, P389; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	26	546	569	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 25	1992	257	5078					1955	1957		10.1126/science.1384126	http://dx.doi.org/10.1126/science.1384126			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP594	1384126				2022-12-28	WOS:A1992JP59400034
J	KIFF, ES				KIFF, ES			ABC OF COLORECTAL DISEASES - FECAL INCONTINENCE	BRITISH MEDICAL JOURNAL			English	Article											KIFF, ES (corresponding author), UNIV HOSP S MANCHESTER,GEN SURG,MANCHESTER M20 8LR,LANCS,ENGLAND.								0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 19	1992	305	6855					702	704		10.1136/bmj.305.6855.702	http://dx.doi.org/10.1136/bmj.305.6855.702			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP511	1393121	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JP51100032
J	PATEL, V; RASSAM, S; NEWSOM, R; WIEK, J; KOHNER, E				PATEL, V; RASSAM, S; NEWSOM, R; WIEK, J; KOHNER, E			RETINAL BLOOD-FLOW IN DIABETIC-RETINOPATHY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LASER DOPPLER VELOCIMETRY; AUTO-REGULATION; FUNDUS CAMERA; MELLITUS; PRESSURE; CIRCULATION	Objectives - (a) To report on the basic parameters of retinal blood flow in a population of diabetic patients with and without retinopathy and nondiabetic controls; (b) to formulate a haemodynamic model for the pathogenesis of diabetic retinopathy from this and other studies. Design-Laser-Doppler velocimetry and computerised image analysis to determine retinal blood flow in a large cross sectional study. Setting-Diabetic retinopathy outpatient clinic. Subjects-24 non-diabetic controls and 76 diabetic subjects were studied (63 patients with insulin dependent diabetes, 13 with non-insulin dependent diabetes). Of the diabetic subjects, 12 had no diabetic retinopathy, 27 had background retinopathy, 13 had pre-proliferative retinopathy, 12 had proliferative retinopathy, and 12 had had pan-retinal photocoagulation for proliferative retinopathy. Main outcome measures-Retinal blood flow (mu-l/min) and conductance (rate of flow per unit of perfusion pressure). Results-In comparison with non-diabetic controls (9.52-mu-l/min) and diabetic patients with no diabetic retinopathy (9.12-mu-l/min) retinal blood flow was significantly increased in all grades of untreated diabetic retinopathy (background 12.13-mu-l/min, preproliferative 15.27-mu-l/min, proliferative 13.88-mu-l/min). There was a significant decrease in flow after pan-retinal photocoagulation in comparison with all the other groups studied (4-48-mu-l/min). Conductance of the retinal circulation was higher in the untreated diabetic retinopathy groups. These results were independent of age, sex, type of diabetes, duration of diabetes, glycated haemoglobin concentration, blood glucose concentration, blood pressure, and intraocular pressure. Conclusions-Retinal blood flow is significantly increased in diabetic retinopathy in comparison with non-diabetic controls and diabetic subjects with no retinopathy. This has implications for controlling hypertension and hyperglycaemia as a strategy in reducing morbidity from diabetic retinopathy.	HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, DEPT MED, DIABET RETINOPATHY UNIT, LONDON W12 0NN, ENGLAND	Imperial College London				newsom, Richard/0000-0002-2221-0653				BAUDOIN C, 1989, DIABETES, V38, P491; Behrendt T, 1970, Trans Am Acad Ophthalmol Otolaryngol, V74, P28; BENGTSSON B, 1977, ACTA OPHTHALMOL, V55, P123; BERKMAN J, 1973, METABOLISM, V21, P715, DOI 10.1016/0026-0495(73)90243-6; BRENNER BM, 1982, NEW ENGL J MED, V307, P652, DOI 10.1056/NEJM198209093071104; BRINCHMANN HO, 1986, ACTA OPHTHALMOL, V95, P861; BURTON AC, 1954, PHYSIOL REV, V34, P619, DOI 10.1152/physrev.1954.34.4.619; CALDWELL G, 1990, DIABETOLOGIA, V33, P262, DOI 10.1007/BF00403318; CHEN HC, 1992, INVEST OPHTH VIS SCI, V33, P811; CUNHAVAZ JG, 1978, ARCH OPHTHALMOL-CHIC, V96, P809, DOI 10.1001/archopht.1978.03910050415001; DAMON DN, 1979, MICROVASC RES, V17, P330, DOI 10.1016/S0026-2862(79)80008-4; DELORI FC, 1988, GRAEF ARCH CLIN EXP, V226, P393, DOI 10.1007/BF02172974; FEKE GT, 1989, INVEST OPHTH VIS SCI, V30, P58; FRY DL, 1969, CIRC RES, V24, P93, DOI 10.1161/01.RES.24.1.93; GAY AJ, 1966, ARCH OPHTHALMOL-CHIC, V75, P78; GRUNWALD JE, 1992, INVEST OPHTH VIS SCI, V33, P356; GRUNWALD JE, 1984, OPHTHALMOLOGY, V91, P1447; GRUNWALD JE, 1987, OPHTHALMOLOGY, V94, P1614; GRUNWALD JE, 1986, ARCH OPHTHALMOL-CHIC, V104, P991; JUHAN I, 1982, LANCET, V1, P535; KLEIN BEK, 1990, DIABETES CARE, V13, P34, DOI 10.2337/diacare.13.1.34; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010; KNOWLER WC, 1980, NEW ENGL J MED, V302, P645, DOI 10.1056/NEJM198003203021201; KOHNER EM, 1975, DIABETOLOGIA, V11, P27, DOI 10.1007/BF00422814; KUWABARA T, 1963, ARCH OPHTHALMOL-CHIC, V69, P492, DOI 10.1001/archopht.1963.00960040498013; LANIGAN LP, 1989, EYE, V3, P39, DOI 10.1038/eye.1989.6; MCMILLAN DE, 1983, DIABETES, V32, P56, DOI 10.2337/diab.32.2.S56; Milnor W, 1989, HEMODYNAMICS, P140; MORGENSEN CE, 1982, BRIT MED J, V285, P685; MOSS SE, 1988, OPHTHALMOLOGY, V95, P1340; Oakley N, 1967, Diabetologia, V3, P402, DOI 10.1007/BF02342633; OGASAWARA H, 1991, INVEST OPHTH VIS SCI, V32, P864; PARVING HH, 1983, METABOLISM, V32, P943, DOI 10.1016/0026-0495(83)90210-X; PATZ A, 1984, BRIT J OPHTHALMOL, V68, P42, DOI 10.1136/bjo.68.1.42; RIVA CE, 1981, APPL OPTICS, V20, P117, DOI 10.1364/AO.20.000117; ROBINSON F, 1986, INVEST OPHTH VIS SCI, V27, P722; ROSS J, 1990, BEST TAYLORS PHYSL B, P138; SINCLAIR SH, 1982, OPHTHALMOLOGY, V89, P748, DOI 10.1016/s0161-6420(82)34720-x; STRAUSS AL, 1987, MED INSTRUM, V21, P255; SULLIVAN P, 1990, Folia Ophthalmologica (Leipzig), V15, P99; TAKAHASHI K, 1989, DIABETES, V38, P1200, DOI 10.2337/diabetes.38.9.1200; TOOKE JE, 1986, CLIN SCI, V70, P119, DOI 10.1042/cs0700119; 1987, ARCH INTERN MED, V147, P830; 1990, ARCH OPHTHALMOL-CHIC, V108, P1577	45	259	264	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 19	1992	305	6855					678	683		10.1136/bmj.305.6855.678	http://dx.doi.org/10.1136/bmj.305.6855.678			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP511	1393111	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JP51100019
J	KOROMILAS, AE; ROY, S; BARBER, GN; KATZE, MG; SONENBERG, N				KOROMILAS, AE; ROY, S; BARBER, GN; KATZE, MG; SONENBERG, N			MALIGNANT TRANSFORMATION BY A MUTANT OF THE IFN-INDUCIBLE DSRNA-DEPENDENT PROTEIN-KINASE	SCIENCE			English	Article							DOUBLE-STRANDED-RNA; NF-KAPPA-B; EIF-2-ALPHA KINASE; 3T3-F442A CELLS; INTERFERON; RECEPTOR; BINDING; AUTOPHOSPHORYLATION; INITIATION; EXPRESSION	The double-stranded RNA-dependent protein kinase (dsRNA-PK) is thought to be a key mediator of the antiviral and antiproliferative effects of interferons (IFNs). Studies examining the physiological function of the kinase suggest that it participates in cell growth and differentiation by regulating protein synthesis. Autophosphorylation and consequent activation of dsRNA-PK in vitro and in vivo result in phosphorylation of the alpha-subunit of eukaryotic initiation factor-2 (eIF-2) and inhibition of protein synthesis. Expression of a functionally defective mutant of human dsRNA-PK in NIH 3T3 cells resulted in malignant transformation, suggesting that dsRNA-PK may function as a suppressor of cell proliferation and tumorigenesis.	MCGILL UNIV, FAC MED, DEPT BIOCHEM, MONTREAL H3G 1Y6, QUEBEC, CANADA; MCGILL UNIV, FAC MED, MCGILL CANC CTR, MONTREAL H3G 1Y6, QUEBEC, CANADA; UNIV WASHINGTON, SCH MED, DEPT MICROBIOL, SEATTLE, WA 98195 USA	McGill University; McGill University; University of Washington; University of Washington Seattle					NCRR NIH HHS [RR00166] Funding Source: Medline; NIAID NIH HHS [AI22646] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022646] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BELL JS, COMMUNICATION; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENG GS, 1992, P NATL ACAD SCI USA, V89, P5447, DOI 10.1073/pnas.89.12.5447; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FLEURY S, 1991, CELL, V66, P1037, DOI 10.1016/0092-8674(91)90447-7; GALABRU J, 1989, EUR J BIOCHEM, V178, P581, DOI 10.1111/j.1432-1033.1989.tb14485.x; GALABRU J, 1987, J BIOL CHEM, V262, P15538; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HONEGGER A, 1988, EMBO J, V7, P3053, DOI 10.1002/j.1460-2075.1988.tb03170.x; HONEGGER A, 1990, J CELL BIOL, V10, P1541; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; HOVANESSIAN AG, 1987, EUR J BIOCHEM, V167, P467, DOI 10.1111/j.1432-1033.1987.tb13360.x; HOVANESSIAN AG, 1989, J INTERFERON RES, V9, P641, DOI 10.1089/jir.1989.9.641; Jagus R, 1981, Prog Nucleic Acid Res Mol Biol, V25, P127, DOI 10.1016/S0079-6603(08)60484-5; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KOROMILAS AE, UNPUB; KOSTURA M, 1989, MOL CELL BIOL, V9, P1576, DOI 10.1128/MCB.9.4.1576; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LANGLAND JO, 1992, J BIOL CHEM, V267, P10729; LAURENT AG, 1984, BIOCHEM BIOPH RES CO, V125, P1, DOI 10.1016/S0006-291X(84)80324-1; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LI JH, 1991, EUR J BIOCHEM, V195, P41, DOI 10.1111/j.1432-1033.1991.tb15673.x; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; NIELSCH U, 1991, EMBO J, V10, P4169, DOI 10.1002/j.1460-2075.1991.tb04995.x; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PETRYSHYN R, 1984, J BIOL CHEM, V259, P4736; PETRYSHYN R, 1988, P NATL ACAD SCI USA, V85, P1427, DOI 10.1073/pnas.85.5.1427; RAMIREZ M, 1991, MOL CELL BIOL, V11, P3027, DOI 10.1128/MCB.11.6.3027; RAMIREZ M, 1992, CELL, V68, P585; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEN GC, 1992, J BIOL CHEM, V267, P5017; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; WEINBERG RA, 1989, CANCER RES, V49, P3713; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741	45	531	544	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 18	1992	257	5077					1685	1689		10.1126/science.1382315	http://dx.doi.org/10.1126/science.1382315			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN501	1382315				2022-12-28	WOS:A1992JN50100032
J	MANDAL, BK; SCHOFIELD, PF				MANDAL, BK; SCHOFIELD, PF			ABC OF COLORECTAL DISEASES - TROPICAL COLONIC DISEASES	BRITISH MEDICAL JOURNAL			English	Article									WITHINGTON HOSP,MANCHESTER M20 8LR,LANCS,ENGLAND		MANDAL, BK (corresponding author), MONSALL HOSP,DEPT INFECT DIS & TROP MED,MANCHESTER,ENGLAND.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 12	1992	305	6854					638	641		10.1136/bmj.305.6854.638	http://dx.doi.org/10.1136/bmj.305.6854.638			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN698	1393080	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992JN69800026
J	TILLER, J; TREASURE, J				TILLER, J; TREASURE, J			PURGING WITH PARACETAMOL - REPORT OF 4 CASES	BRITISH MEDICAL JOURNAL			English	Article											TILLER, J (corresponding author), INST PSYCHIAT,DE CRESPIGNY PK,LONDON SE5 8AZ,ENGLAND.							BLACKLEDGE HM, 1991, HUM EXP TOXICOL, V10, P159, DOI 10.1177/096032719101000302; OGRADY JG, 1991, BRIT MED J, V303, P221, DOI 10.1136/bmj.303.6796.221; PROUDFOOT AT, 1970, BMJ-BRIT MED J, V3, P557, DOI 10.1136/bmj.3.5722.557; SCHMIDT U, 1992, INT J EAT DISORDER, V12, P93, DOI 10.1002/1098-108X(199207)12:1&lt;93::AID-EAT2260120112&gt;3.0.CO;2-G; TREASURE J, 1991, International Review of Psychiatry, V3, P43, DOI 10.3109/09540269109067520	5	6	6	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 12	1992	305	6854					618	618		10.1136/bmj.305.6854.618	http://dx.doi.org/10.1136/bmj.305.6854.618			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN698	1393075	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JN69800018
J	CHENG, J; SYDER, AJ; YU, QC; LETAI, A; PALLER, AS; FUCHS, E				CHENG, J; SYDER, AJ; YU, QC; LETAI, A; PALLER, AS; FUCHS, E			THE GENETIC-BASIS OF EPIDERMOLYTIC HYPERKERATOSIS - A DISORDER OF DIFFERENTIATION-SPECIFIC EPIDERMAL KERATIN GENES	CELL			English	Article							BULLOSA SIMPLEX; DOWLING-MEARA; LAMIN-A; EXPRESSION; SEQUENCE; DISEASE; CELLS; CPG; ABNORMALITIES; DINUCLEOTIDE	Epidermolytic hyperkeratosis (EH) is a skin disease characterized by keratin filament clumping and degeneration in terminally differentiating epidermal cells. We have discovered that the genetic basis for EH resides in mutations in differentiation-specific keratins. Two of six distinct incidences of EH had a keratin 10 (K10) point mutation in a highly conserved arginine. Remarkably, this same residue is mutated in the basal epidermal K14 in three incidences of another skin disease, epidermolysis bullosa simplex (EBS). By genetic engineering, gene transfection, and 10 nm filament assembly, we show that this mutation is functionally responsible for the keratin filament clumping that occurs in basal (EBS) or suprabasal (EH) cells. These studies strengthen the link between filament perturbations, cell fragility, and degeneration first established with EBS. They also suggest a correlation between filament disorganization and either cytokinesis or nuclear shape, giving rise to the seemingly binuceate cells typical of EH.	NORTHWESTERN UNIV,CHILDRENS MEM HOSP,SCH MED,DEPT DERMATOL,CHICAGO,IL 60614	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University	CHENG, J (corresponding author), UNIV CHICAGO,HOWARD HUGHES MED INST,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637, USA.		Fuchs, Elaine/G-1565-2016	Paller, Amy/0000-0001-6187-6549	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR027883, R01AR027883] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR27883] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBERS K, 1987, J CELL BIOL, V105, P791, DOI 10.1083/jcb.105.2.791; ANTONLAMPRECHT I, 1974, ARCH DERMATOL FORSCH, V250, P207, DOI 10.1007/BF00561188; ANTONLAMPRECHT I, 1982, DERMATOLOGICA, V164, P221, DOI 10.1159/000250096; ANTONLAMPRECHT I, 1983, J INVEST DERMATOL, V81, pS149, DOI 10.1111/1523-1747.ep12540961; BIRD AP, 1980, NUCLEIC ACIDS RES, V8, P1499, DOI 10.1093/nar/8.7.1499; BONIFAS JM, 1991, SCIENCE, V254, P1202, DOI 10.1126/science.1720261; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COMPTON JG, 1992, NAT GENET, V1, P301, DOI 10.1038/ng0792-301; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; COULOMBE PA, 1991, J CELL BIOL, V115, P1661, DOI 10.1083/jcb.115.6.1661; COULOMBE PA, 1989, J CELL BIOL, V109, P2295, DOI 10.1083/jcb.109.5.2295; COULOMBE PA, 1990, J CELL BIOL, V111, P3049, DOI 10.1083/jcb.111.6.3049; COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; DODEMONT H, 1990, EMBO J, V9, P4083, DOI 10.1002/j.1460-2075.1990.tb07630.x; FISHER DZ, 1986, P NATL ACAD SCI USA, V83, P6450, DOI 10.1073/pnas.83.17.6450; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; FUCHS E, 1992, P NATL ACAD SCI USA, V89, P6906, DOI 10.1073/pnas.89.15.6906; GRIPPO P, 1968, J MOL BIOL, V36, P195, DOI 10.1016/0022-2836(68)90375-6; HATZFELD M, 1991, J CELL SCI, V99, P351; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; ISHIDAYAMAMOTO A, 1992, J INVEST DERMATOL, V99, P19, DOI 10.1111/1523-1747.ep12611391; ISHIDAYAMAMOTO A, 1991, J INVEST DERMATOL, V97, P959, DOI 10.1111/1523-1747.ep12491885; JOHNSON LD, 1985, P NATL ACAD SCI USA, V82, P1896, DOI 10.1073/pnas.82.7.1896; KITAJIMA Y, 1989, ARCH DERMATOL RES, V281, P5, DOI 10.1007/BF00424265; KORGE BP, 1992, P NATL ACAD SCI USA, V89, P910, DOI 10.1073/pnas.89.3.910; LANE EB, 1992, NATURE, V356, P244, DOI 10.1038/356244a0; LETAI A, 1992, J CELL BIOL, V116, P1181, DOI 10.1083/jcb.116.5.1181; MISCHKE D, 1987, J INVEST DERMATOL, V88, P191, DOI 10.1111/1523-1747.ep12525329; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; NUSSINOV R, 1981, J MOL BIOL, V149, P125, DOI 10.1016/0022-2836(81)90264-3; PERUTZ MF, 1990, J MOL BIOL, V213, P203, DOI 10.1016/S0022-2836(05)80178-0; QUAXJEUKEN YEFM, 1983, P NATL ACAD SCI-BIOL, V80, P3548, DOI 10.1073/pnas.80.12.3548; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RIEGER M, 1988, J MOL BIOL, V204, P841, DOI 10.1016/0022-2836(88)90045-9; ROOP DR, 1987, DIFFERENTIATION, V35, P143, DOI 10.1111/j.1432-0436.1987.tb00162.x; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; VASSAR R, 1991, CELL, V64, P365, DOI 10.1016/0092-8674(91)90645-F; WAHLBERG J, 1990, P NATL ACAD SCI USA, V87, P6569, DOI 10.1073/pnas.87.17.6569; WILGRAM GF, 1966, ARCH DERMATOL, V94, P127, DOI 10.1001/archderm.94.2.127; WILSON AK, 1992, IN PRESS J CELL BIOL	40	296	298	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 4	1992	70	5					811	819		10.1016/0092-8674(92)90314-3	http://dx.doi.org/10.1016/0092-8674(92)90314-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JL663	1381287				2022-12-28	WOS:A1992JL66300012
J	OKEEFE, SJ; TAMURA, J; KINCAID, RL; TOCCI, MJ; ONEILL, EA				OKEEFE, SJ; TAMURA, J; KINCAID, RL; TOCCI, MJ; ONEILL, EA			FK-506-SENSITIVE AND CSA-SENSITIVE ACTIVATION OF THE INTERLEUKIN-2 PROMOTER BY CALCINEURIN	NATURE			English	Article							EXPRESSION; CALMODULIN; DOMAIN; CELLS	ANTIGEN recognition by the T-cell receptor (TCR) initiates events including lymphokine gene transcription 1, particularly interleukin-2, that lead to T-cell activation. The immunosuppressive drugs, cyclosporin A (CsA) and FK-506, prevent T-cell proliferation by inhibiting a Ca2+-dependent event required for induction of interleukin-2 transcription 2. Complexes of FK-506 or CsA and their respective intracellular binding proteins inhibit the calmodulin-dependent protein phosphatase, calcineurin, in vitro 3. The pharmacological relevance of this observation to immunosuppression or drug toxicity is undetermined. Calcineurin, although present in lymphocytes 4, has not been implicated in TCR-mediated activation of lymphokine genes or in transcriptional regulation in general. Here we report that transfection of a calcineurin catalytic subunit increases the 50% inhibitory concentration (IC50) of the immunosuppressants FK-506 and CsA, and that a mutant subunit acts in synergy with phorbol ester alone to activate the interleukin-2 promoter in a drug-sensitive manner. These results implicate calcineurin as a component of the TCR signal transduction pathway by demonstrating its role in the drug-sensitive activation of the interleukin-2 promoter.	NIAAA,MOLEC & CELLULAR NEUROBIOL LAB,IMMUNOL SECT,ROCKVILLE,MD 20852	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	OKEEFE, SJ (corresponding author), MERCK SHARP & DOHME LTD,DEPT MOLEC IMMUNOL,RAHWAY,NJ 07065, USA.							ALTMEYER A, 1991, INT J IMMUNOPHARMACO, V13, P1187, DOI 10.1016/0192-0561(91)90170-C; BANERJI SS, 1991, MOL CELL BIOL, V11, P4074, DOI 10.1128/MCB.11.8.4074; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; FORREST MJ, 1991, BIOCHEM PHARMACOL, V42, P1221, DOI 10.1016/0006-2952(91)90257-6; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HOLLON T, 1989, ANAL BIOCHEM, V182, P411, DOI 10.1016/0003-2697(89)90616-7; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; KINCAID RL, 1990, J BIOL CHEM, V265, P11312; KINCAID RL, 1987, NATURE, V330, P176, DOI 10.1038/330176a0; KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8983, DOI 10.1073/pnas.85.23.8983; KINCAID RL, 1986, BIOCHEM BIOPH RES CO, V140, P320, DOI 10.1016/0006-291X(86)91093-4; KINCAID RL, 1991, ADV PROT PHOSPHATASE, V6, P73; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; SWANSON SKH, 1992, P NATL ACAD SCI USA, V89, P3741, DOI 10.1073/pnas.89.9.3741; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAMURA J, 1990, FASEB J, V4, pA2236	19	855	877	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 25	1992	357	6380					692	694		10.1038/357692a0	http://dx.doi.org/10.1038/357692a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA430	1377361				2022-12-28	WOS:A1992JA43000072
J	FUCHS, E; COULOMBE, PA				FUCHS, E; COULOMBE, PA			OF MICE AND MEN - GENETIC SKIN DISEASES OF KERATIN	CELL			English	Review							INTERMEDIATE FILAMENTS; EPIDERMAL KERATINS; EXPRESSION; ULTRASTRUCTURE; SEQUENCE				FUCHS, E (corresponding author), UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,HOWARD HUGHES MED INST,CHICAGO,IL 60637, USA.		Fuchs, Elaine/G-1565-2016					ANTONLAMPRECHT I, 1974, ARCH DERMATOL FORSCH, V250, P207, DOI 10.1007/BF00561188; ANTONLAMPRECHT I, 1983, J INVEST DERMATOL, V81, pS149, DOI 10.1111/1523-1747.ep12540961; BADER BL, 1991, J CELL BIOL, V115, P1293, DOI 10.1083/jcb.115.5.1293; BARIBAULT H, 1991, J CELL BIOL, V115, P1675, DOI 10.1083/jcb.115.6.1675; BONIFAS JM, 1991, SCIENCE, V254, P1202, DOI 10.1126/science.1720261; CHRISTIAN J L, 1990, New Biologist, V2, P700; CONWAY JF, 1988, INT J BIOL MACROMOL, V10, P79, DOI 10.1016/0141-8130(88)90015-3; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; COULOMBE PA, 1991, J CELL BIOL, V115, P1661, DOI 10.1083/jcb.115.6.1661; COULOMBE PA, 1990, J CELL BIOL, V111, P3049, DOI 10.1083/jcb.111.6.3049; COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; DALE BA, 1985, J CELL BIOL, V101, P1257, DOI 10.1083/jcb.101.4.1257; EICHNER R, 1984, J CELL BIOL, V98, P1388, DOI 10.1083/jcb.98.4.1388; FINE JD, 1991, J AM ACAD DERMATOL, V24, P119, DOI 10.1016/0190-9622(91)70021-S; FUCHS E, 1992, IN PRESS P NATL ACAD, V89; GEORGATOS SD, 1987, P NATL ACAD SCI USA, V84, P6780, DOI 10.1073/pnas.84.19.6780; HANEKE E, 1982, J INVEST DERMATOL, V78, P219, DOI 10.1111/1523-1747.ep12506502; HATZFELD M, 1990, J CELL SCI, V97, P317; HATZFELD M, 1991, J CELL SCI, V99, P351; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; JANMEY PA, 1991, J CELL BIOL, V113, P155, DOI 10.1083/jcb.113.1.155; KLYMKOWSKY MW, 1989, CELL MOTIL CYTOSKEL, V14, P309, DOI 10.1002/cm.970140302; KOUKLIS PD, 1991, J CELL BIOL, V114, P773, DOI 10.1083/jcb.114.4.773; LANE EB, 1992, NATURE, V356, P244, DOI 10.1038/356244a0; LETAI A, 1992, J CELL BIOL, V116, P1181, DOI 10.1083/jcb.116.5.1181; LU X, 1990, CELL, V62, P681, DOI 10.1016/0092-8674(90)90114-T; NEWPORT JW, 1990, J CELL BIOL, V111, P2247, DOI 10.1083/jcb.111.6.2247; POWELL BC, 1990, EMBO J, V9, P1485, DOI 10.1002/j.1460-2075.1990.tb08266.x; RYYNANEN M, 1991, AM J HUM GENET, V49, P978; SCHULTHEISS T, 1991, J CELL BIOL, V114, P953, DOI 10.1083/jcb.114.5.953; STEINERT PM, 1983, NATURE, V302, P794, DOI 10.1038/302794a0; VASSAR R, 1991, CELL, V64, P365, DOI 10.1016/0092-8674(91)90645-F; WILGRAM GF, 1966, ARCH DERMATOL, V94, P127, DOI 10.1001/archderm.94.2.127	33	139	142	1	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 12	1992	69	6					899	902		10.1016/0092-8674(92)90607-E	http://dx.doi.org/10.1016/0092-8674(92)90607-E			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HY792	1376637				2022-12-28	WOS:A1992HY79200002
J	NICOLAIDES, KH; RODECK, CH				NICOLAIDES, KH; RODECK, CH			MATERNAL SERUM ANTI-D ANTIBODY CONCENTRATION AND ASSESSMENT OF RHESUS ISOIMMUNIZATION	BRITISH MEDICAL JOURNAL			English	Article							ISOIMMUNIZATION		UNIV COLL & MIDDLESEX SCH MED,DEPT OBSTET & GYNAECOL,LONDON,ENGLAND	University of London; University College London	NICOLAIDES, KH (corresponding author), UNIV LONDON KINGS COLL HOSP,SCH MED & DENT,HARRIS BIRTHRIGHT RES CTR FETAL MED,LONDON SE5 8RX,ENGLAND.			Nicolaides, Kypros/0000-0003-1266-0711				MARSH W L, 1968, Journal of Medical Laboratory Technology, V25, P335; NICOLAIDES K H, 1986, Fetal Therapy, V1, P185; NICOLAIDES KH, 1988, LANCET, V1, P1073; NICOLINI U, 1988, BRIT MED J, V297, P1379, DOI 10.1136/bmj.297.6660.1379; RODECK CH, 1984, AM J OBSTET GYNECOL, V150, P769, DOI 10.1016/0002-9378(84)90683-5	5	59	60	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 2	1992	304	6835					1155	1156		10.1136/bmj.304.6835.1155	http://dx.doi.org/10.1136/bmj.304.6835.1155			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT232	1382765	Green Published, Bronze			2022-12-28	WOS:A1992HT23200023
J	SWERDLOW, AJ; DOUGLAS, AJ; HUDSON, GV; HUDSON, BV; BENNETT, MH; MACLENNAN, KA				SWERDLOW, AJ; DOUGLAS, AJ; HUDSON, GV; HUDSON, BV; BENNETT, MH; MACLENNAN, KA			RISK OF 2ND PRIMARY CANCERS AFTER HODGKINS-DISEASE BY TYPE OF TREATMENT - ANALYSIS OF 2846 PATIENTS IN THE BRITISH NATIONAL LYMPHOMA INVESTIGATION	BRITISH MEDICAL JOURNAL			English	Article							LEUKEMIA; CHEMOTHERAPY; RADIOTHERAPY; EXPERIENCE; MORTALITY	Objective - To analyse the risk of second primary cancers during long term follow up of patients with Hodgkin's disease. Design - Cohort study. Setting - The British National Lymphoma Investigation (a collaborative group of over 60 participating centres in Britain treating lymphomas). Patients - 2846 patients first treated for Hodgkin's disease during 1970-87, for whom follow up was complete in 99.8%. Main outcome measures - Second primary cancers; uniform pathology reviews confirmed the diagnosis of Hodgkin's disease and of second primary non-Hodgkin's lymphomas. Results - 113 second primary cancers occurred. Relative risk of cancer other than Hodgkin's disease was 2.7 (95% confidence interval 2.3 to 3.3) compared with the general population, with significant risks of leukaemia (16.0 (9.1 to 26.0)); non-Hodgkin's lymphoma (16.8 (9.8 to 26.9)); and cancers of the colon (3.2 (1.4 to 6.2)), lung (3.8 (2.6 to 5.4)), bone (15.1 (1.8 to 54.7)), and thyroid (9.4 (1.1 to 33.9)). Absolute excess risk associated with treatment was greater for solid tumours than for leukaemia and lymphomas. Relative risk of leukaemia increased soon after treatment, reaching a peak after five to nine years. It was increased substantially after chemotherapy (27.9 (12.7 to 52.9)), combined treatment with radiotherapy and chemotherapy (21.5 (7.9 to 46.8)), and relative to number of courses of chemotherapy but was not significantly increased after radiotherapy (2.5 (0.1 to 14.1)). Relative risk of non-Hodgkin's lymphoma increased in the first five years after treatment and remained high but showed no clear relation with type or extent of treatment. Relative risk of solid tumours was less raised initially but increased throughout follow up and for lung cancer 10 years or more after entry was 8.3 (4.0 to 15.3). The risk of solid tumours increased after treatments including radiotherapy and after chemotherapy alone. The risk after chemotherapy increased significantly with time since first treatment. Conclusions - The risk of solid cancer, not of leukaemia, is the major long term hazard of treatment for Hodgkin's disease, and this seemed to apply after chemotherapy as well as after radiotherapy. These risks of second cancers are important in choice of treatment and in follow up of patients, but they are small compared with the great improvements in survival which have been brought about by modern therapeutic methods for Hodgkin's disease.	UNIV COLL & MIDDLESEX SCH MED,DEPT ONCOL,LONDON,ENGLAND; MT VERNON HOSP,DEPT HISTOPATHOL,NORTHWOOD HA6 2RN,MIDDX,ENGLAND; ROYAL MARSDEN HOSP,DEPT HISTOPATHOL,LONDON,ENGLAND	University of London; University College London; Royal Marsden NHS Foundation Trust	SWERDLOW, AJ (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,EPIDEMIOL MONITORING UNIT,LONDON WC1E 7HT,ENGLAND.			Swerdlow, Anthony/0000-0001-5550-4159				[Anonymous], 1974, IARC MONOGRAPHS EVAL, V4; [Anonymous], 1990, HLTH EFFECTS EXPOSUR; BENNETT MH, 1991, ANN ONCOL, V2, P83, DOI 10.1093/annonc/2.suppl_2.83; BLAYNEY DW, 1987, NEW ENGL J MED, V316, P710, DOI 10.1056/NEJM198703193161203; BOICE JD, 1984, PROGR CANCER RES THE, V26; BOIVIN JF, 1984, JNCI-J NATL CANCER I, V72, P233; BOIVIN JF, 1988, CANCER, V61, P2541, DOI 10.1002/1097-0142(19880615)61:12<2541::AID-CNCR2820611225>3.0.CO;2-G; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; COLEMAN CN, 1977, NEW ENGL J MED, V297, P1249, DOI 10.1056/NEJM197712082972303; COLEMAN M, 1986, INT J EPIDEMIOL, V15, P134, DOI 10.1093/ije/15.1.134; COLMAN M, 1988, RADIOTHER ONCOL, V11, P229, DOI 10.1016/0167-8140(88)90005-9; DAY NE, 1983, IARC SCI PUBL, V52, P137; DEVEREUX S, 1990, BRIT MED J, V301, P1077, DOI 10.1136/bmj.301.6760.1077; HANCOCK BW, 1991, BRIT J CANCER, V63, P579, DOI 10.1038/bjc.1991.134; HENRYAMAR M, 1988, NATL CANCER I MONOGR, V6, P65; KALDOR JM, 1987, INT J CANCER, V39, P571, DOI 10.1002/ijc.2910390506; KALDOR JM, 1990, NEW ENGL J MED, V322, P7, DOI 10.1056/NEJM199001043220102; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KINLEN LJ, 1982, CANCER EPIDEMIOL, P494; PEDERSENBJERGAARD J, 1987, LANCET, V2, P83, DOI 10.1016/S0140-6736(87)92744-9; POLEDNAK AP, 1978, AM J EPIDEMIOL, V107, P179, DOI 10.1093/oxfordjournals.aje.a112524; SELBY P, 1990, BRIT J CANCER, V62, P279, DOI 10.1038/bjc.1990.278; SMITH PG, 1977, CANCER, V39, P1901, DOI 10.1002/1097-0142(197704)39:4+<1901::AID-CNCR2820390826>3.0.CO;2-T; SMITH PG, 1981, BRIT J RADIOL, V54, P187, DOI 10.1259/0007-1285-54-639-187; TESTER WJ, 1984, J CLIN ONCOL, V2, P762, DOI 10.1200/JCO.1984.2.7.762; TOMATIS L, 1990, IARC SCI PUBLICATION, V100; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; VALAGUSSA P, 1986, J CLIN ONCOL, V4, P830, DOI 10.1200/JCO.1986.4.6.830; VANLEEUWEN FE, 1989, J CLIN ONCOL, V7, P1046, DOI 10.1200/JCO.1989.7.8.1046; VANRIJSWIJK REN, 1984, CANCER, V53, P62, DOI 10.1002/1097-0142(19840101)53:1<62::AID-CNCR2820530112>3.0.CO;2-3; YOUNG RC, 1990, J NCI MONOGR, V10, P55; 1981, IARC MONOGRAPHS EVAL, V26; 1967, MANUAL INT STATISTIC; 1989, EGRET; [No title captured]	35	193	197	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 2	1992	304	6835					1137	1143		10.1136/bmj.304.6835.1137	http://dx.doi.org/10.1136/bmj.304.6835.1137			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT232	1392790	Green Published, Bronze			2022-12-28	WOS:A1992HT23200018
J	ORENTLICHER, D; MCMURRAY, RJ; CLARKE, OW; BARRASSO, JA; CLOHAN, DB; EPPS, CH; GLASSON, J; MCQUILLAN, R; PLOWS, CW; PUZAK, MA; HALKOLA, KA; SCHWEICKART, AK				ORENTLICHER, D; MCMURRAY, RJ; CLARKE, OW; BARRASSO, JA; CLOHAN, DB; EPPS, CH; GLASSON, J; MCQUILLAN, R; PLOWS, CW; PUZAK, MA; HALKOLA, KA; SCHWEICKART, AK			DECISIONS NEAR THE END OF LIFE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NETHERLANDS; EUTHANASIA; ILL				ORENTLICHER, D (corresponding author), AMER MED ASSOC,COUNCIL ETH & JUDICIAL AFFAIRS,515 N STATE ST,CHICAGO,IL 60610, USA.							BATTIN MP, 1991, FEB U FLOR COLL MED; BEAUCHAMP DW, 1989, MED ETHICS; Beauchamp T, 1989, PRINCIPLES BIOMEDICA; BILLINGS JA, 1985, J AM GERIATR SOC, V33, P808, DOI 10.1111/j.1532-5415.1985.tb04196.x; BROCK DW, 1989, MED ETHICS; Buchanan Allen E., 1989, DECIDING OTHERS ETHI; Capron A M, 1986, Law Med Health Care, V14, P141; DEWACHTER MAM, 1989, JAMA-J AM MED ASSOC, V262, P3316, DOI 10.1001/jama.262.23.3316; GELMAN D, 1990, NEWSWEEK        0723, P46; KAMISAR Y, 1958, MINN LAW REV, V42, P969; KASS LR, 1989, PUBLIC INTEREST, V94, P25; Lifton R. J., 1986, NAZI DOCTORS MED KIL; LIPTON HL, 1986, JAMA-J AM MED ASSOC, V256, P1164, DOI 10.1001/jama.256.9.1164; LYNN J, 1983, HASTING CANC RE 1013, P17; MERZ B, 1991, AM MED NEWS     1118, P29; ORENTLICHER D, 1989, JAMA-J AM MED ASSOC, V262, P1844, DOI 10.1001/jama.262.13.1844; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; RAMSEY P, 1970, PATIENT PERSON, P113; RHYMES J, 1990, JAMA-J AM MED ASSOC, V264, P369, DOI 10.1001/jama.264.3.369; RIGTER H, 1989, HASTINGS CENT REP, V19, P31, DOI 10.2307/3561968; SCHMITZ P, 1986, BY NO EXTRAORDINARY; SPRUNG CL, 1990, JAMA-J AM MED ASSOC, V263, P2211, DOI 10.1001/jama.263.16.2211; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; 1988, LIFE SUSTAINING TECH; 1990, VITAL STATISTICS U A, V2; 1991, JUN P HOUS DEL AMA C, P261; 1987, GUIDELINES TERMINATI; 1989, CURRENT OPINIONS, P13; 1987, DEC P HOUS DEL AMA C, P170; 1990, DEC P HOUS DEL AMA C, P180; 1987, DECIDING FOREGO LIFE; 1989, JUN P HOUS DEL AMA C, P314; 1988, JUN P HOUS DEL AMA C, P258	34	174	175	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 22	1992	267	16					2229	2233						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN841	1372944				2022-12-28	WOS:A1992HN84100035
J	NINAN, TK; RUSSELL, G				NINAN, TK; RUSSELL, G			RESPIRATORY SYMPTOMS AND ATOPY IN ABERDEEN SCHOOLCHILDREN - EVIDENCE FROM 2 SURVEYS 25 YEARS APART	BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD ASTHMA; PREVALENCE; ADMISSIONS; MANAGEMENT; MORTALITY; INCREASE; ENGLAND; TRENDS; HEALTH; WALES	Objective-To estimate changes in the prevalence of respiratory symptoms and the reported diagnoses of asthma, eczema, and hay fever in primary school children in Aberdeen between 1964 and 1989. Design-Determination of incidence prevalence and prevalence from survey data. Setting-Aberdeen, Scotland. Participants-2743 primary school children (aged 8-13) from 1964 and 3942 from 1989. Main outcome measures-Survey data on whether, according to the parent or guardian, the child wheezed or was troubled with shortness of breath; the number of episodes of breathlessness in the past year; and whether asthma, eczema, or hay fever had ever been diagnosed. Results-Questionnaires were completed by the parents of 2510 children in 1964 and 3403 children in 1989. The prevalence of wheeze rose from 10.4% in 1964 to 19.8% in 1989, and the prevalence of episodes of shortness of breath increased from 5.4% to 10.0%. In both surveys wheeze and shortness of breath were more prevalent in boys than in girls. The reported diagnosis of asthma rose from 4.1% to 10.2%, hay fever from 3.2% to 11.9%, and eczema from 5.3% to 12%. The proportion of boys suffering from eczema rose from 47.7% to 60.0%. Hay fever showed a similar increase, from 49.4% to 60.1%, in boys over the 25 year period. Though the parents of a higher proportion of children with wheeze were aware of the diagnosis of asthma in 1989, because of the increased prevalence of wheeze the absolute number of parents of wheezy children who were not aware of a diagnosis of asthma increased from 7.4% to 9.6% of the population studied. Conclusion-The higher diagnosis rate for asthma is due not simply to changes in diagnostic fashion but reflects an increase over the past 25 years in the prevalence of respiratory symptoms, which in turn may reflect a more general change in the prevalence of atopy, the increase in which was particularly noticeable in boys. This increase explains some of the increase in hospital admission rates for children with asthma.	ROYAL ABERDEEN CHILDRENS HOSP,DEPT MED PAEDIAT,ABERDEEN AB9 2ZG,SCOTLAND	University of Aberdeen	NINAN, TK (corresponding author), UNIV ABERDEEN,DEPT CHILD HLTH,ABERDEEN AB9 2ZD,SCOTLAND.							ANDERSON HR, 1989, THORAX, V44, P614, DOI 10.1136/thx.44.8.614; ANDERSON HR, 1989, ARCH DIS CHILD, V64, P172, DOI 10.1136/adc.64.1.172; BAUMAN A, 1990, AUSTR MED RES J, V20, P105; BURNEY PGJ, 1986, LANCET, V2, P323; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; CHARLTON JRH, 1986, BRIT MED J, V292, P295, DOI 10.1136/bmj.292.6516.295; DAWSON B, 1969, LANCET, V1, P827; FLEMING DM, 1987, BRIT MED J, V294, P279, DOI 10.1136/bmj.294.6567.279; Gardner MJ, 1989, BRIT MED J LONDON; GERRARD JW, 1983, ANN ALLERGY, V51, P300; HALFON N, 1986, AM J PUBLIC HEALTH, V76, P1308, DOI 10.2105/AJPH.76.11.1308; HAY IFC, 1987, LANCET, V2, P609; HILL R, 1989, BRIT MED J, V299, P898, DOI 10.1136/bmj.299.6704.898; HILL RA, 1989, ARCH DIS CHILD, V64, P246, DOI 10.1136/adc.64.2.246; KORSGAARD J, 1982, AM REV RESPIR DIS, V125, P80; LEE DA, 1983, BRIT MED J, V286, P1256, DOI 10.1136/bmj.286.6373.1256; MAXKJELLMAN NJ, 1977, ACTA PEDIATR SCAND, V665, P465; MITCHELL EA, 1984, NEW ZEAL MED J, V97, P67; MITCHELL EA, 1983, NEW ZEAL MED J, V96, P463; PECKHAM C, 1978, J EPIDEMIOL COMMUN H, V32, P79, DOI 10.1136/jech.32.2.79; REINHARDT MC, 1983, ANN ALLERGY, V51, P311; TAYLOR B, 1984, LANCET, V1, P465; WILLIAMS H, 1969, BRIT MED J, V4, P321, DOI 10.1136/bmj.4.5679.321	23	548	562	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1992	304	6831					873	875		10.1136/bmj.304.6831.873	http://dx.doi.org/10.1136/bmj.304.6831.873			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM835	1392746	Green Published, Bronze			2022-12-28	WOS:A1992HM83500022
J	CARTER, RH; FEARON, DT				CARTER, RH; FEARON, DT			CD19 - LOWERING THE THRESHOLD FOR ANTIGEN RECEPTOR STIMULATION OF LYMPHOCYTES-B	SCIENCE			English	Article							MONOCLONAL-ANTIBODY; CELL-SURFACE; IMMUNOGLOBULIN; CD4; PROLIFERATION; DOMAINS; SIGNAL	Lymphocytes must proliferate and differentiate in response to low concentrations of a vast array of antigens. The requirements of broad specificity and sensitivity conflict because the former is met by low-affinity antigen receptors, which precludes achieving the latter with high-affinity receptors. Coligation of the membrane protein CD19 with the antigen receptor of B lymphocytes decreased the threshold for antigen receptor-dependent stimulation by two orders of magnitude. B lymphocytes proliferated when approximately 100 antigen receptors per cell, 0.03 percent of the total, were coligated with CD19. The B cell resolves its dilemma by having an accessory protein that enables activation when few antigen receptors are occupied.	JOHNS HOPKINS UNIV, SCH MED, GRAD PROGRAM IMMUNOL, BALTIMORE, MD 21205 USA	Johns Hopkins University	CARTER, RH (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV MOLEC & CLIN RHEUMATOL, BALTIMORE, MD 21205 USA.				NIAID NIH HHS [AI-28191, AI-22833] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028191, R01AI022833] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON P, 1987, J IMMUNOL, V139, P678; BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; BANK I, 1985, J EXP MED, V162, P1294, DOI 10.1084/jem.162.4.1294; BRADBURY L, 1991, FASEB J, V5, pA611; CARTER R, UNPUB; CARTER RH, 1988, J IMMUNOL, V141, P457; CARTER RH, 1991, J IMMUNOL, V147, P3663; CHANGELIAN PS, 1985, J IMMUNOL, V134, P1851; DORKEN B, 1989, LEUCOCYTE TYPING, V4, P34; HEBELL T, 1991, SCIENCE, V254, P102, DOI 10.1126/science.1718035; HEYMAN B, 1990, J EXP MED, V172, P665, DOI 10.1084/jem.172.2.665; LEDBETTER JA, 1988, EUR J IMMUNOL, V18, P525, DOI 10.1002/eji.1830180406; MATSUMOTO AK, 1991, J EXP MED, V173, P55, DOI 10.1084/jem.173.1.55; NADLER LM, 1983, J IMMUNOL, V131, P244; PESANDO JM, 1989, J EXP MED, V170, P2159, DOI 10.1084/jem.170.6.2159; PEZZUTTO A, 1987, J IMMUNOL, V138, P2793; RAVETCH JV, 1986, SCIENCE, V234, P718, DOI 10.1126/science.2946078; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; STAMENKOVIC I, 1988, J EXP MED, V168, P1205, DOI 10.1084/jem.168.3.1205; TAKAHASHI S, 1990, J IMMUNOL, V145, P2207; THYPHRONITIS G, 1991, J IMMUNOL, V147, P224; TUVESON DA, 1991, J EXP MED, V173, P1083, DOI 10.1084/jem.173.5.1083; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; YAMADA H, 1990, FASEB J, V4, pA1882; ZHOU LJ, 1991, J IMMUNOL, V147, P1424	25	563	579	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 3	1992	256	5053					105	107		10.1126/science.1373518	http://dx.doi.org/10.1126/science.1373518			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HL822	1373518				2022-12-28	WOS:A1992HL82200038
J	GOODING, LR				GOODING, LR			VIRUS PROTEINS THAT COUNTERACT HOST IMMUNE DEFENSES	CELL			English	Review							EPSTEIN-BARR-VIRUS; OPEN READING FRAME; ADENOVIRUS; COMPLEMENT; NEUTRALIZATION; EXPRESSION; RECEPTOR; HOMOLOGY; TYPE-1; KINASE				GOODING, LR (corresponding author), EMORY UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,ATLANTA,GA 30322, USA.							ALBRECHT JC, 1992, J VIROL, V66, P3937, DOI 10.1128/JVI.66.6.3937-3940.1992; ALCAMI A, 1992, CELL, V71; BELL S, 1990, J VIROL, V64, P2181, DOI 10.1128/JVI.64.5.2181-2186.1990; BHAT RA, 1983, P NATL ACAD SCI-BIOL, V80, P4789, DOI 10.1073/pnas.80.15.4789; BROWNE H, 1990, NATURE, V347, P770, DOI 10.1038/347770a0; GINSBERG HS, 1989, P NATL ACAD SCI USA, V86, P3823, DOI 10.1073/pnas.86.10.3823; GUNNERY S, 1990, P NATL ACAD SCI USA, V87, P8687, DOI 10.1073/pnas.87.22.8687; HARRIS SL, 1990, J INFECT DIS, V162, P331, DOI 10.1093/infdis/162.2.331; HSU DH, 1990, SCIENCE, V250, P830, DOI 10.1126/science.2173142; ISAACS SN, 1992, P NATL ACAD SCI USA, V89, P628, DOI 10.1073/pnas.89.2.628; KADOTA J, 1991, MICROBIOL IMMUNOL, V35, P443, DOI 10.1111/j.1348-0421.1991.tb01575.x; KOTWAL GJ, 1990, SCIENCE, V250, P827, DOI 10.1126/science.2237434; MATHEWS MB, 1991, J VIROL, V65, P5657, DOI 10.1128/JVI.65.11.5657-5662.1991; MCNEARNEY TA, 1987, J EXP MED, V166, P1525, DOI 10.1084/jem.166.5.1525; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SMITH CA, 1991, BIOCHEM BIOPH RES CO, V176, P335, DOI 10.1016/0006-291X(91)90929-2; SNYDERMAN R, 1984, IMMUNOL TODAY, V5, P240, DOI 10.1016/0167-5699(84)90097-5; SPRIGGS MK, 1992, CELL, V71, P145, DOI 10.1016/0092-8674(92)90273-F; UPTON C, 1991, VIROLOGY, V184, P370, DOI 10.1016/0042-6822(91)90853-4; VIEIRA P, 1991, P NATL ACAD SCI USA, V88, P1172, DOI 10.1073/pnas.88.4.1172; WOLD WSM, 1991, VIROLOGY, V184, P1, DOI 10.1016/0042-6822(91)90815-S	22	305	324	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 2	1992	71	1					5	7						3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JQ623	1394431				2022-12-28	WOS:A1992JQ62300002
J	LEON, DA; VAGERO, D; OLAUSSON, PO				LEON, DA; VAGERO, D; OLAUSSON, PO			SOCIAL-CLASS DIFFERENCES IN INFANT-MORTALITY IN SWEDEN - COMPARISON WITH ENGLAND AND WALES	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BRITAIN; HEALTH; REGISTRY	Objectives-To investigate social class differences in infant mortality in Sweden in the mid-1980s and to compare their magnitude with that of those found in England and Wales. Design-Analysis of risk of infant death by social class in aggregated routine data for the mid-1980s, which included the linkage of Swedish births to the 1985 census. Setting-Sweden and England and Wales. Subjects-All live births in Sweden (1985-6) and England and Wales (1983-5) and corresponding infant deaths were analysed. The Swedish data were coded to the British registrar general's social class schema. Main outcome measures-Risk of death in the neonatal and postneonatal period. Results-Taking the non-manual classes as the reference group, in the neonatal period in Sweden the manual social classes had a relative risk for mortality of 1.20 (95% confidence interval 1.02 to 1.43) and those not classified into a social class a relative risk of 1.08 (0.88 to 1.33). In the postneonatal period the equivalent relative risks were 1.38 (1.08 to 1.77) for manual classes and 2.14 (1.65 to 2.79) for the residual; these are similar to those for England and Wales (1.43 (1.36 to 1.51) for manual classes, 2.62 (2.45 to 2.81) for the residual). Conclusions-The existence of an equitable health care system and a strong social welfare policy in Sweden has not eliminated inequalities in postneonatal mortality. Furthermore, the very low risk of infant death in the Swedish non-manual group (4.8/1000 live births) represents a target towards which public health interventions should aim. If this rate prevailed in England and Wales, 63% of postneonatal deaths would be avoided.	SWEDISH INST SOCIAL RES, S-10609 STOCKHOLM, SWEDEN; NATL BOARD HLTH & SOCIAL WELF, MED BIRTH REGISTRY, S-10630 STOCKHOLM, SWEDEN	National Board of Health & Welfare	LEON, DA (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & POPULAT SCI, LONDON WC1E 7HT, ENGLAND.		Leon, David A/G-2195-2010	Leon, David A/0000-0001-9747-1762				ADELSTEIN AM, 1980, STUDIES MED POPULATI, V41; [Anonymous], 1980, CLASSIFICATION OCCUP; BRESLO NE, 1987, IARC SCI PUBLICATION, V82; CNATTINGIUS S, 1990, SCAND J SOC MED, V18, P143, DOI 10.1177/140349489001800209; DIDERICHSEN F, 1990, SOC SCI MED, V31, P359, DOI 10.1016/0277-9536(90)90283-X; ERICSON A, 1989, ACTA PAEDIATR SCAND, P48; ERICSON A, 1984, ACTA PAEDIATR SCAND, V73, P69, DOI 10.1111/j.1651-2227.1984.tb09900.x; ERICSON A, 1984, ACTA PAEDIATR SCAND, V73, P664, DOI 10.1111/j.1651-2227.1984.tb09992.x; ERICSON A, 1987, ACTA PAEDIATR SCAND, V76, P512, DOI 10.1111/j.1651-2227.1987.tb10508.x; ERICSON A, 1990, ACTA PAEDIATR SCAND, V79, P1009, DOI 10.1111/j.1651-2227.1990.tb11376.x; GEIJERST.G, 1969, PUBLIC HEALTH REP, V84, P939, DOI 10.2307/4593720; GREENLAND S, 1987, STAT MED, V6, P701, DOI 10.1002/sim.4780060607; GUYER B, 1981, NEW ENGL J MED, V37, P259; HOLSTEIN BE, 1985, INEQUALITIES HLTH HL, P45; ILLSLEY R, 1990, SOC SCI MED, V31, P229, DOI 10.1016/0277-9536(90)90269-X; LUNDBERG O, 1986, SOC SCI MED, V23, P511, DOI 10.1016/0277-9536(86)90011-0; MACFARLANE A, 1984, BIRTH COUNTS STATIST; MITCHELL EA, 1990, ARCH DIS CHILD, V65, P607, DOI 10.1136/adc.65.6.607; NAKAMURA Y, 1991, PUBLIC HEALTH, V105, P145, DOI 10.1016/S0033-3506(05)80289-6; Olausson PO, 1991, J OFF STAT, V7, P93; Pharoah P O, 1979, Epidemiol Rev, V1, P170; POWELLGRINER E, 1990, INT J EPIDEMIOL, V19, P391, DOI 10.1093/ije/19.2.391; QUINE S, 1990, SOC SCI MED, V30, P1283, DOI 10.1016/0277-9536(90)90308-F; RIETZ E, 1930, ACTA PAEDIATR SCA S3, V9; SJOLIN S, 1975, HLTH CARE MOTHERS CH, P29; SZRETER SRS, 1984, BRIT J SOCIOL, V35, P522, DOI 10.2307/590433; Townsend P, 1990, INEQUALITIES HLTH BL; VAGERO D, 1989, LANCET, V2, P35, DOI 10.1016/S0140-6736(89)90266-3; VALKONEN T, 1987, EUROPEAN POPULATION, P201; Wallace H M, 1990, J Perinatol, V10, P3; WALLACE HM, 1975, HLTH CARE MOTHERS CH; WENNEMO I, 1992, INFANT MORTALITY INE; WHITEHEAD M, 1990, INEQUALITIES HLTH HL; WILKINSON RG, 1992, BRIT MED J, V304, P165, DOI 10.1136/bmj.304.6820.165	34	71	72	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 19	1992	305	6855					687	691		10.1136/bmj.305.6855.687	http://dx.doi.org/10.1136/bmj.305.6855.687			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP511	1393112	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JP51100021
J	PFEFFER, MA; BRAUNWALD, E; MOYE, LA; BASTA, L; BROWN, EJ; CUDDY, TE; DAVIS, BR; GELTMAN, EM; GOLDMAN, S; FLAKER, GC; KLEIN, M; LAMAS, GA; PACKER, M; ROULEAU, J; ROULEAU, JL; RUTHERFORD, J; WERTHEIMER, JH; HAWKINS, CM				PFEFFER, MA; BRAUNWALD, E; MOYE, LA; BASTA, L; BROWN, EJ; CUDDY, TE; DAVIS, BR; GELTMAN, EM; GOLDMAN, S; FLAKER, GC; KLEIN, M; LAMAS, GA; PACKER, M; ROULEAU, J; ROULEAU, JL; RUTHERFORD, J; WERTHEIMER, JH; HAWKINS, CM			EFFECT OF CAPTOPRIL ON MORTALITY AND MORBIDITY IN PATIENTS WITH LEFT-VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL-INFARCTION - RESULTS OF THE SURVIVAL AND VENTRICULAR ENLARGEMENT TRIAL	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONGESTIVE-HEART-FAILURE; THERAPY; RISK; DILATATION; MANAGEMENT; PROGNOSIS; DISEASE; VOLUME; RAT	Background. Left ventricular dilatation and dysfunction after myocardial infarction are major predictors of death. In experimental and clinical studies, long-term therapy with the angiotensin-converting-enzyme inhibitor captopril attenuated ventricular dilatation and remodeling. We investigated whether captopril could reduce morbidity and mortality in patients with left ventricular dysfunction after a myocardial infarction. Methods. Within 3 to 16 days after myocardial infarction, 2231 patients with ejection fractions of 40 percent or less but without overt heart failure or symptoms of myocardial ischemia were randomly assigned to receive double-blind treatment with either placebo (1116 patients) or captopril (1115 patients) and were followed for an average of 42 months. Results. Mortality from all causes was significantly reduced in the captopril group (228 deaths, or 20 percent) as compared with the placebo group (275 deaths, or 25 percent); the reduction in risk was 19 percent (95 percent confidence interval, 3 to 32 percent; P = 0.019). In addition, the incidence of both fatal and nonfatal major cardiovascular events was consistently reduced in the captopril group. The reduction in risk was 21 percent (95 percent confidence interval, 5 to 35 percent; P = 0.014) for death from cardiovascular causes, 37 percent (95 percent confidence interval, 20 to 50 percent; P<0.001) for the development of severe heart failure, 22 percent (95 percent confidence interval, 4 to 37 percent; P = 0.019) for congestive heart failure requiring hospitalization, and 25 percent (95 percent confidence interval, 5 to 40 percent; P = 0.015) for recurrent myocardial infarction. Conclusions. In patients with asymptomatic left ventricular dysfunction after myocardial infarction, long-term administration of captopril was associated with an improvement in survival and reduced morbidity and mortality due to major cardiovascular events. These benefits were observed in patients who received thrombolytic therapy, aspirin, or beta-blockers, as well as those who did not, suggesting that treatment with captopril leads to additional improvement in outcome among selected survivors of myocardial infarction.	UNIV TEXAS, HLTH SCI CTR, HOUSTON, TX 77225 USA; UNIV TEXAS, SCH PUBL HLTH, HOUSTON, TX 77025 USA; TULSA HEART CTR, TULSA, OK USA; SUNY STONY BROOK, HLTH SCI CTR, STONY BROOK, NY 11794 USA; UNIV MANITOBA, WINNIPEG R3T 2N2, MANITOBA, CANADA; WASHINGTON UNIV, SCH MED, ST LOUIS, MO 63110 USA; UNIV ARIZONA, TUCSON, AZ 85721 USA; UNIV MISSOURI, HLTH SCI CTR, COLUMBIA, MO 65201 USA; HOP SACRE COEUR, MONTREAL H4J 1C5, QUEBEC, CANADA; CUNY MT SINAI SCH MED, NEW YORK, NY 10029 USA; QUEBEC HEART INST, Ste Foy, QUEBEC, CANADA; ALBERT EINSTEIN MED CTR, NO DIV, N DIV, PHILADELPHIA, PA 19141 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Manitoba; Washington University (WUSTL); University of Arizona; University of Missouri System; University of Missouri Columbia; Universite de Montreal; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Yeshiva University	PFEFFER, MA (corresponding author), HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DIV CARDIOVASC, 75 FRANCIS ST, BOSTON, MA 02115 USA.							AHNVE, 1987, AM J CARDIOL, V59, pA12; AHNVE S, 1986, AM J CARDIOL, V58, P872, DOI 10.1016/S0002-9149(86)80002-9; ALDERMAN MH, 1991, NEW ENGL J MED, V324, P1098, DOI 10.1056/NEJM199104183241605; COHN JN, 1986, NEW ENGL J MED, V314, P1547, DOI 10.1056/NEJM198606123142404; EATON LW, 1979, NEW ENGL J MED, V300, P57, DOI 10.1056/NEJM197901113000202; FLETCHER PJ, 1981, CIRC RES, V49, P618, DOI 10.1161/01.RES.49.3.618; GAUDRON P, 1990, EUR HEART J, V11, P139, DOI 10.1093/eurheartj/11.suppl_B.139; GREENE HL, 1989, AM J CARDIOL, V63, P393, DOI 10.1016/0002-9149(89)90306-8; GUNNAR RM, 1990, J AM COLL CARDIOL, V16, P249, DOI 10.1016/0735-1097(90)90575-A; HAMMERMEISTER KE, 1979, CIRCULATION, V59, P421, DOI 10.1161/01.CIR.59.3.421; JEREMY RW, 1989, J AM COLL CARDIOL, V13, P304, DOI 10.1016/0735-1097(89)90503-2; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KANNEL WB, 1987, EUR HEART J, V8, P23, DOI 10.1093/eurheartj/8.suppl_F.23; KANNEL WB, 1979, AM J CARDIOL, V44, P53, DOI 10.1016/0002-9149(79)90250-9; LICHSTEIN E, 1990, J AM COLL CARDIOL, V16, P1327, DOI 10.1016/0735-1097(90)90372-V; MCKAY RG, 1986, CIRCULATION, V74, P693, DOI 10.1161/01.CIR.74.4.693; MOSS AJ, 1990, NEW ENGL J MED, V322, P743, DOI 10.1056/NEJM199003153221107; MOSS AJ, 1983, NEW ENGL J MED, V309, P331, DOI 10.1056/nejm198308113090602; MOYE LA, 1991, AM J CARDIOL, V68, pD70; PACKER M, 1987, CIRCULATION, V75, P80; PFEFFER JM, 1991, AM J PHYSIOL, V260, pH1406, DOI 10.1152/ajpheart.1991.260.5.H1406; PFEFFER JM, 1985, CIRC RES, V57, P84, DOI 10.1161/01.RES.57.1.84; PFEFFER MA, 1990, CIRCULATION, V81, P1161, DOI 10.1161/01.CIR.81.4.1161; PFEFFER MA, 1988, NEW ENGL J MED, V319, P80, DOI 10.1056/NEJM198807143190204; PFEFFER MA, 1985, CIRCULATION, V72, P406, DOI 10.1161/01.CIR.72.2.406; ROSS J, 1989, CIRCULATION, V79, P292, DOI 10.1161/01.CIR.79.2.292; ROULEAU JL, 1991, AM J CARDIOL, V68, pD80; SHARPE N, 1988, LANCET, V1, P255; SMITH P, 1990, NEW ENGL J MED, V323, P147, DOI 10.1056/NEJM199007193230302; STADIUS ML, 1986, CIRCULATION, V74, P703, DOI 10.1161/01.CIR.74.4.703; SUSSEX B A, 1992, Journal of the American College of Cardiology, V19, p205A; SUTTON M S, 1992, Journal of the American College of Cardiology, V19, p205A; SUTTON MS, 1991, CIRCULATION S2, V84, P66; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; TAN LB, 1991, CIRC RES, V69, P1185, DOI 10.1161/01.RES.69.5.1185; WHITE HD, 1987, CIRCULATION, V76, P44, DOI 10.1161/01.CIR.76.1.44; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2088, DOI 10.1001/jama.260.14.2088; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	38	4912	5030	0	174	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 3	1992	327	10					669	677		10.1056/NEJM199209033271001	http://dx.doi.org/10.1056/NEJM199209033271001			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL235	1386652				2022-12-28	WOS:A1992JL23500001
J	CHICZ, RM; URBAN, RG; LANE, WS; GORGA, JC; STERN, LJ; VIGNALI, DAA; STROMINGER, JL				CHICZ, RM; URBAN, RG; LANE, WS; GORGA, JC; STERN, LJ; VIGNALI, DAA; STROMINGER, JL			PREDOMINANT NATURALLY PROCESSED PEPTIDES BOUND TO HLA-DR1 ARE DERIVED FROM MHC-RELATED MOLECULES AND ARE HETEROGENEOUS IN SIZE	NATURE			English	Article							HLA-DR MOLECULES; T-CELL RECOGNITION; CLASS-II; IMMUNOGENIC PEPTIDE; BINDING-SITE; SEQUENCE; ANTIGENS; SELF; PURIFICATION; ASSOCIATION	PEPTIDES bound to class I molecules are 8-10 amino acids long, and possess a binding motif representative of peptides that bind to a given class I allele1-4. In the only published study of naturally processed peptides bound to class II molecules (mouse I-A(b) and I-E(b)), these peptides were longer (13-17 amino acids) and had heterogenous carboxy terminals but precise amino-terminal truncations5. Here we report the characterization of acid-eluted peptides bound to HLA-DR1 by high-performance liquid chromatography, mass spectrometry and microsequencing analyses. The relative molecular masses of the peptides varied between 1,602 and 2,996 (13-25 residues), the most abundant individual M(r) values being between 1,700 and 1,800, corresponding to an average peptide length of 15 residues. Complete sequence data were obtained for twenty peptides derived from five epitopes, of which all but one were from self proteins. These peptides represented sets nested at both the N- and C-terminal ends. Binding experiments confirmed that all of the isolated peptides had high affinity for the groove of DR1. Alignment of the peptides bound to HLA-DR1 and the sequences of 35 known HLA-DR1-binding peptides revealed a putative motif. Although peptides bound to class II molecules may have some related features (due to the nonpolymorphic HLA-DR alpha-chain), accounting for degenerate binding to different alleles6, particular amino acids in the HLA-DR beta-chains presumably define allelic specificity of peptide binding.	HARVARD UNIV,MICROCHEM FACIL,CAMBRIDGE,MA 02138	Harvard University	CHICZ, RM (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.							BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; CHEN BP, 1990, J EXP MED, V172, P779, DOI 10.1084/jem.172.3.779; CRESSWELL P, 1985, P NATL ACAD SCI USA, V82, P8188, DOI 10.1073/pnas.82.23.8188; DEMAGISTRIS MT, 1992, P NATL ACAD SCI USA, V89, P2990, DOI 10.1073/pnas.89.7.2990; DONERMEYER DL, 1989, J IMMUNOL, V142, P1063; DORNMAIR K, 1989, COLD SPRING HARB SYM, V54, P409; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GORGA JC, 1991, RES IMMUNOL, V142, P401, DOI 10.1016/0923-2494(91)90038-K; GORGA JC, 1987, J BIOL CHEM, V262, P16087; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; GUTTINGER M, 1988, EMBO J, V7, P2555, DOI 10.1002/j.1460-2075.1988.tb03104.x; GUTTINGER M, 1991, INT IMMUNOL, V3, P899, DOI 10.1093/intimm/3.9.899; HAIL M, 1990, BIOLOGICAL MASS SPECTROMETRY /, P101; HARRIS PE, 1992, J IMMUNOL, V148, P2169; HILL CM, 1991, J IMMUNOL, V147, P189; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; JARDETZKY TS, 1990, EMBO J, V9, P1797, DOI 10.1002/j.1460-2075.1990.tb08304.x; JONES PP, 1978, IMMUNOCHEMISTRY, V16, P51; KROPSHOFER H, 1991, BIOCHEMISTRY-US, V30, P9177, DOI 10.1021/bi00102a008; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LATRON F, 1991, P NATL ACAD SCI USA, V88, P11325, DOI 10.1073/pnas.88.24.11325; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; OSULLIVAN D, 1990, J IMMUNOL, V145, P1799; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROCHE PA, 1990, J IMMUNOL, V144, P1849; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROCHE PA, 1991, P NATL ACAD SCI USA, V88, P3150, DOI 10.1073/pnas.88.8.3150; ROTHBARD JB, 1988, EMBO J, V7, P93, DOI 10.1002/j.1460-2075.1988.tb02787.x; ROTHBARD JB, 1988, CELL, V52, P515, DOI 10.1016/0092-8674(88)90464-3; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SPRINGER TA, 1977, J BIOL CHEM, V252, P6201; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; THOMAS LJ, 1988, J IMMUNOL, V140, P2670; VANBLEEK GM, 1990, NATURE, V348, P213	38	681	719	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 27	1992	358	6389					764	768		10.1038/358764a0	http://dx.doi.org/10.1038/358764a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JK699	1380674				2022-12-28	WOS:A1992JK69900056
J	GORE, SM; ARMITAGE, WJ; BRIGGS, JD; CROMBIE, A; EASTY, DL; HINDS, CJ; JAMIESON, NV; JOHNSTON, P; LARGE, S; MAJOR, E; SMITHERS, F; TAYLOR, RMR; WALLWORK, J				GORE, SM; ARMITAGE, WJ; BRIGGS, JD; CROMBIE, A; EASTY, DL; HINDS, CJ; JAMIESON, NV; JOHNSTON, P; LARGE, S; MAJOR, E; SMITHERS, F; TAYLOR, RMR; WALLWORK, J			CONSENSUS ON GENERAL MEDICAL CONTRAINDICATIONS TO ORGAN DONATION	BRITISH MEDICAL JOURNAL			English	Article									ST MARYS HOSP,LONDON W2 1NY,ENGLAND; WESTERN INFIRM & ASSOCIATED HOSP,RENAL UNIT,GLASGOW G11 6NT,SCOTLAND; UNITED KINGDOM TRANSPLANT SUPPORT SERV,BRISTOL BS10 5ND,ENGLAND; BRISTOL EYE HOSP,BRISTOL BS1 2LX,ENGLAND; ST BARTHOLOMEWS HOSP,LONDON EC1A 7BE,ENGLAND; ADDENBROOKES HOSP,CAMBRIDGE CB2 2QQ,ENGLAND; PAPWORTH HOSP,CAMBRIDGE CB3 8RE,ENGLAND; MORRISTON HOSP,SWANSEA,W GLAM,WALES; WESTERN GEN HOSP,NUFFIELD TRANSPLANT UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; ROYAL VICTORIA INFIRM,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND	Imperial College London; Bristol Eye Hospital; University of London; Queen Mary University London; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Papworth Hospital; Morriston Hospital; University of Edinburgh; Newcastle University - UK	GORE, SM (corresponding author), MRC,BIOSTAT UNIT,CAMBRIDGE CB2 2SR,ENGLAND.							GORE SM, 1992, BRIT MED J, V304, P349, DOI 10.1136/bmj.304.6823.349	1	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 15	1992	305	6850					406	409		10.1136/bmj.305.6850.406	http://dx.doi.org/10.1136/bmj.305.6850.406			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK314	1392925	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JK31400021
J	WALD, N; STONE, R; CUCKLE, HS; GRUDZINSKAS, JG; BARKAI, G; BRAMBATI, B; TEISNER, B; FUHRMANN, W				WALD, N; STONE, R; CUCKLE, HS; GRUDZINSKAS, JG; BARKAI, G; BRAMBATI, B; TEISNER, B; FUHRMANN, W			1ST TRIMESTER CONCENTRATIONS OF PREGNANCY ASSOCIATED PLASMA PROTEIN-A AND PLACENTAL PROTEIN-14 IN DOWNS-SYNDROME	BRITISH MEDICAL JOURNAL			English	Article									UNIV LEEDS,DEPT CLIN MED,INST EPIDEMIOL & HLTH SERV,LEEDS LS2 9LN,W YORKSHIRE,ENGLAND; ROYAL LONDON HOSP,DEPT OBSTET & GYNAECOL,LONDON,ENGLAND; CHAIM SHEBA MED CTR,INST HUMAN GENET,DEPT OBSTET & GYNECOL,IL-52621 TEL HASHOMER,ISRAEL; UNIV MILAN,IST OSTETR GINECOLOG L MANGIAGALLI,CLIN 2,PRENATAL DIAG UNIT,I-20122 MILAN,ITALY; STATENS SERUM INST,DIV IMMUNOL,DK-2300 COPENHAGEN,DENMARK; UNIV GIESSEN,INST HUMAN GENET,W-6300 GIESSEN,GERMANY	University of Leeds; Barts Health NHS Trust; Royal London Hospital; Chaim Sheba Medical Center; University of Milan; Statens Serum Institut; Justus Liebig University Giessen	WALD, N (corresponding author), ST BARTHOLOMEWS HOSP,COLL MED,WOLFSON INST PREVENT MED,DEPT ENVIRONM & PREVENT MED,LONDON EC1A 7BE,ENGLAND.		Wald, Nicholas/AAY-2814-2021; Wald, Nicholas/AAY-8924-2021					Brambati B., 1990, EMBRYO NORMAL ABNORM, P181; CUCKLE HS, 1988, LANCET, V2, P851	2	101	109	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1992	305	6844					28	28		10.1136/bmj.305.6844.28	http://dx.doi.org/10.1136/bmj.305.6844.28			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC799	1379094	Bronze, Green Submitted, Green Published			2022-12-28	WOS:A1992JC79900027
J	SHIBUYA, H; IRIE, K; NINOMIYATSUJI, J; GOEBL, M; TANIGUCHI, T; MATSUMOTO, K				SHIBUYA, H; IRIE, K; NINOMIYATSUJI, J; GOEBL, M; TANIGUCHI, T; MATSUMOTO, K			NEW HUMAN GENE ENCODING A POSITIVE MODULATOR OF HIV TAT-MEDIATED TRANSACTIVATION	NATURE			English	Article							LONG TERMINAL REPEAT; CELL LEUKEMIA-VIRUS; EXPRESSION SYSTEM; TRANS-ACTIVATION; PROMOTER; PROTEIN; REGION; CDNA; SEQUENCES; VERSATILE	THE human immunodeficiency virus-1 (HIV-1) protein Tat is a potent activator of virus gene expression 1,2. Tat functions through a sequence known as TAR, located immediately downstream of the transcription start site in the long terminal repeat 3-5. Several observations suggest that cellular factors cooperate with Tat in the overall transactivating process. We have isolated a human complementary DNA from the new gene MSS1, which may encode such a cellular factor, by transcomplementation of a yeast sgv1- mutant. The MSS1 protein shares 42% sequence identity with the human TBP-1 protein, which binds Tat in vitro and suppresses Tat-mediated transactivation in vivo (ref. 6). We report here that the levels of HIV activation by Tat correlate with endogenous levels of MSS1 messenger RNA. Furthermore, we provide evidence that expression of MSS1 enhances the Tat-mediated transactivation. Our results suggest that MSS1 has a key role in activation of HIV genes regulated by Tat.	NAGOYA UNIV,FAC SCI,DEPT MOLEC BIOL,CHIKUSA KU,NAGOYA 46401,JAPAN; INDIANA UNIV,SCH MED,WALTHER ONCOL CTR,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202; OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN	Nagoya University; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Osaka University				Ninomiya-Tsuji, Jun/0000-0002-5584-0176				ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ARYA SK, 1985, SCIENCE, V229, P69, DOI 10.1126/science.2990040; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; GARCIA JA, 1989, EMBO J, V8, P765, DOI 10.1002/j.1460-2075.1989.tb03437.x; GENDELMAN HE, 1986, P NATL ACAD SCI USA, V83, P9759, DOI 10.1073/pnas.83.24.9759; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HAUBER J, 1988, J VIROL, V62, P673, DOI 10.1128/JVI.62.3.673-679.1988; IRIE K, 1991, CELL, V65, P785, DOI 10.1016/0092-8674(91)90386-D; KIM DW, 1990, GENE, V91, P217, DOI 10.1016/0378-1119(90)90091-5; KOBAYASHI N, 1986, Cancer Reviews, V1, P64; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHIBUYA H, 1990, NUCLEIC ACIDS RES, V18, P3697, DOI 10.1093/nar/18.13.3697; Shibuya H, 1989, INT IMMUNOL, V1, P43, DOI 10.1093/intimm/1.1.43; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466	20	168	173	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 25	1992	357	6380					700	702		10.1038/357700a0	http://dx.doi.org/10.1038/357700a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA430	1377363				2022-12-28	WOS:A1992JA43000075
J	LANZAVECCHIA, A; REID, PA; WATTS, C				LANZAVECCHIA, A; REID, PA; WATTS, C			IRREVERSIBLE ASSOCIATION OF PEPTIDES WITH CLASS-II MHC MOLECULES IN LIVING CELLS	NATURE			English	Article							INVARIANT CHAIN; T-CELLS; B-CELLS; HLA-DR; ANTIGEN PRESENTATION; PROTEIN ANTIGENS; LYMPHOCYTE-B; BREFELDIN-A; BINDING; IA	FUNCTIONAL, morphological and biochemical evidence indicates that class II major histocompatibility complex (MHC) molecules associate with processed peptides during biosynthesis 1-9. Peptide/MHC complexes in living cells have been reported to be less stable than similar complexes generated in vitro, which has led to the suggestion that there may be a peptide exchange mechanism operating in vivo 10-12. Although this could increase the capacity for binding incoming antigens, it would reduce the efficacy of processed antigenic peptides by exchanging these for self peptides. Here we measure the half-life of peptide/class II complexes in human antigen-presenting cells and find that it is very similar to the half-life of class II molecules themselves, indicating that peptides are bound irreversibly under physiological conditions. Thus class II MHC retains long-term 'memory' of past encounters with antigen to maximize the opportunity for T cell/antigen-presenting cell interaction.	UNIV DUNDEE,INST MED SCI,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND	University of Dundee	LANZAVECCHIA, A (corresponding author), BASEL INST IMMUNOL,GRENZACHERSTR 487,CH-4005 BASEL,SWITZERLAND.			Watts, Colin/0000-0001-6183-2087	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADORINI L, 1990, NATURE, V346, P63, DOI 10.1038/346063a0; ADORINI L, 1989, NATURE, V342, P800, DOI 10.1038/342800a0; BRETSCHER MS, 1988, EMBO J, V7, P4087, DOI 10.1002/j.1460-2075.1988.tb03302.x; BUSCH R, 1990, INT IMMUNOL, V2, P443, DOI 10.1093/intimm/2.5.443; DAVIDSON HW, 1989, J CELL BIOL, V109, P85, DOI 10.1083/jcb.109.1.85; DAVIDSON HW, 1991, CELL, V67, P105, DOI 10.1016/0092-8674(91)90575-J; DAVIS JE, 1990, J IMMUNOL, V144, P990; FLAJNIK MF, 1991, P NATL ACAD SCI USA, V88, P537, DOI 10.1073/pnas.88.2.537; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; GUY K, 1982, EUR J IMMUNOL, V12, P942, DOI 10.1002/eji.1830121109; HARDING CV, 1989, P NATL ACAD SCI USA, V86, P4230, DOI 10.1073/pnas.86.11.4230; HARDING CV, 1989, J IMMUNOL, V142, P12; JENSEN PE, 1990, J EXP MED, V171, P1779, DOI 10.1084/jem.171.5.1779; JENSEN PE, 1989, J IMMUNOL, V143, P420; KAMPGEN E, 1991, P NATL ACAD SCI USA, V88, P3014, DOI 10.1073/pnas.88.8.3014; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; LANZAVECCHIA A, 1987, IMMUNOL REV, V99, P39, DOI 10.1111/j.1600-065X.1987.tb01171.x; LEE JM, 1990, J IMMUNOL, V144, P1829; MATHIS L, 1983, P NATL ACAD SCI USA, V80, P6019; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; NYGARD NR, 1991, J EXP MED, V174, P243, DOI 10.1084/jem.174.1.243; PANINABORDIGNON P, 1991, SCIENCE, V252, P1548, DOI 10.1126/science.1710827; PANINABORDIGNON P, 1989, EUR J IMMUNOL, V19, P2237, DOI 10.1002/eji.1830191209; PEDRAZZINI T, 1991, J IMMUNOL, V146, P3496; PERNIS B, 1985, IMMUNOL TODAY, V6, P45, DOI 10.1016/0167-5699(85)90046-5; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PURE E, 1990, J EXP MED, V172, P1459, DOI 10.1084/jem.172.5.1459; REID PA, 1990, NATURE, V346, P655, DOI 10.1038/346655a0; RIPPMANN F, 1991, EMBO J, V10, P1053, DOI 10.1002/j.1460-2075.1991.tb08044.x; ROCHE PA, 1990, J IMMUNOL, V144, P1849; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROTHBARD JB, 1991, ANNU REV IMMUNOL, V9, P527, DOI 10.1146/annurev.iy.09.040191.002523; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; STPIERRE Y, 1990, J IMMUNOL, V145, P812; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; THOMPSON JA, 1987, BIOCHEMISTRY-US, V26, P743, DOI 10.1021/bi00377a014	40	175	181	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1992	357	6375					249	252		10.1038/357249a0	http://dx.doi.org/10.1038/357249a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV195	1375347				2022-12-28	WOS:A1992HV19500057
J	MEGURO, H; MORI, H; ARAKI, K; KUSHIYA, E; KUTSUWADA, T; YAMAZAKI, M; KUMANISHI, T; ARAKAWA, M; SAKIMURA, K; MISHINA, M				MEGURO, H; MORI, H; ARAKI, K; KUSHIYA, E; KUTSUWADA, T; YAMAZAKI, M; KUMANISHI, T; ARAKAWA, M; SAKIMURA, K; MISHINA, M			FUNCTIONAL-CHARACTERIZATION OF A HETEROMERIC NMDA RECEPTOR CHANNEL EXPRESSED FROM CLONED CDNAS	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; METHYL-D-ASPARTATE; EXCITATORY AMINO-ACIDS; SELECTIVE ANTAGONIST; NEURONS; GLYCINE; FAMILY; RESPONSES; CLONING; COMPLEX	THE glutamate receptor (GluR) channel plays a kev part in brain function 1,2. Among GluR channel subtypes, the NMDA (N-methyl-D-aspartate) receptor channel which is highly permeable to Ca2+ is essential for the synaptic plasticity underlying memory, learning and development 3,4. Furthermore, abnormal activation of the NMDA receptor channel may trigger the neuronal cell death observed in various brain disorders 5,6. A complementary DNA encoding a subunit of the rodent NMDA receptor channel (NMDAR1 or zeta-1) has been cloned and its functional properties investigated 7,8. Here we report the identification and primary structure of a novel mouse NMDA receptor channel subunit, designated as epsilon-1, after cloning and sequencing the cDNA. The epsilon-1 subunit shows 11-18% amino-acid sequence identity with rodent GluR channel subunits that have been characterized so far and has structural features common to neurotransmitter-gated ion channels. Expression from cloned cDNAs of the epsilon-1 subunit together with the zeta-1 subunit in Xenopus oocytes yields functional GluR channels with high activity and characteristics of the NMDA receptor channel. Furthermore, the heteromeric NMDA receptor channel can be activated by glycine alone.	NIIGATA UNIV,BRAIN RES INST,DEPT NEUROPHARMACOL,ASAHIMACHI 1,NIIGATA 951,JAPAN; NIIGATA UNIV,BRAIN RES INST,DEPT NEUROPATHOL,NIIGATA 951,JAPAN; NIIGATA UNIV,SCH MED,DEPT MED 2,NIIGATA 951,JAPAN	Niigata University; Niigata University; Niigata University								BETTLER B, 1990, NEURON, V5, P583, DOI 10.1016/0896-6273(90)90213-Y; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; DAVIES J, 1981, NEUROSCI LETT, V21, P77, DOI 10.1016/0304-3940(81)90061-6; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HONORE T, 1989, EUR J PHARM-MOLEC PH, V172, P239, DOI 10.1016/0922-4106(89)90054-0; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KEMP JA, 1988, P NATL ACAD SCI USA, V85, P6547, DOI 10.1073/pnas.85.17.6547; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; MISHINA M, 1991, BIOCHEM BIOPH RES CO, V180, P813, DOI 10.1016/S0006-291X(05)81137-4; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MORITA T, IN PRESS MOL BRAIN R; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; OLNEY JW, 1990, ANNU REV PHARMACOL, V30, P47; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; PETERS S, 1987, SCIENCE, V236, P589, DOI 10.1126/science.2883728; SAKIMURA K, 1992, NEURON, V8, P267, DOI 10.1016/0896-6273(92)90293-M; SAKIMURA K, 1990, FEBS LETT, V272, P73, DOI 10.1016/0014-5793(90)80452-O; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; WERNER P, 1991, NATURE, V351, P742, DOI 10.1038/351742a0; WESTBROOK GL, 1987, NATURE, V328, P640, DOI 10.1038/328640a0; WISDEN W, 1991, MOL NEUROBIOLOGY PRA, P205; WONG EHF, 1986, P NATL ACAD SCI USA, V83, P7104, DOI 10.1073/pnas.83.18.7104; YAMAZAKI M, IN PRESS FEBS LETT; YAMAZAKI M, IN PRESS BIOCH BIOPH; YOKOYAMA S, 1989, FEBS LETT, V259, P37, DOI 10.1016/0014-5793(89)81488-7	35	772	797	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 7	1992	357	6373					70	74		10.1038/357070a0	http://dx.doi.org/10.1038/357070a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT229	1374164				2022-12-28	WOS:A1992HT22900060
J	LATCHMAN, DS				LATCHMAN, DS			BASIC MOLECULAR AND CELL BIOLOGY .1. GENE-REGULATION	BRITISH MEDICAL JOURNAL			English	Article							PROMOTER				LATCHMAN, DS (corresponding author), UNIV COLL & MIDDLESEX SCH MED,DIV MOLEC PATHOL,LONDON W1P 6DB,ENGLAND.							BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; CROSSLEY M, 1990, NATURE, V345, P444, DOI 10.1038/345444a0; CURAN T, 1988, CELL, V55, P315; GRANDCHAMP B, 1989, P NATL ACAD SCI USA, V86, P661, DOI 10.1073/pnas.86.2.661; LATCHMAN D S, 1990, New Biologist, V2, P297; LATCHMAN DS, 1990, BIOCHEM J, V270, P281, DOI 10.1042/bj2700281; LATCHMAN DS, 1990, GENE REGULATION EUKA; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; NEVINS JR, 1983, ANNU REV BIOCHEM, V52, P441, DOI 10.1146/annurev.bi.52.070183.002301; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; REITH W, 1988, CELL, V53, P897, DOI 10.1016/S0092-8674(88)90389-3; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217	12	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 25	1992	304	6834					1103	1105		10.1136/bmj.304.6834.1103	http://dx.doi.org/10.1136/bmj.304.6834.1103			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR136	1375124	Green Published, Bronze			2022-12-28	WOS:A1992HR13600024
J	USHERWOOD, T				USHERWOOD, T			SEX BIAS IN THE BMJ - AN AUDIT	BRITISH MEDICAL JOURNAL			English	Article											USHERWOOD, T (corresponding author), UNIV SHEFFIELD,DEPT GEN PRACTICE,SHEFFIELD S10 2RX,S YORKSHIRE,ENGLAND.							BURKHART S, 1987, BRIT MED J, V295, P1585, DOI 10.1136/bmj.295.6613.1585; Cameron Deborah., 1985, FEMINISM LINGUISTIC; HOFSTADTER D, 1986, METAMAGICAL THEMAS; HORNE EM, 1988, BRIT MED J, V296, P431, DOI 10.1136/bmj.296.6619.431; VETTERLINGBRAGG.M, 1981, SEXIST LANGUAGE MODE	5	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1992	304	6831					880	881		10.1136/bmj.304.6831.880	http://dx.doi.org/10.1136/bmj.304.6831.880			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM835	1392749	Green Published, Bronze			2022-12-28	WOS:A1992HM83500026
J	COTE, TR; BIGGAR, RJ; DANNENBERG, AL				COTE, TR; BIGGAR, RJ; DANNENBERG, AL			RISK OF SUICIDE AMONG PERSONS WITH AIDS - A NATIONAL ASSESSMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							ACQUIRED IMMUNODEFICIENCY SYNDROME; IOWA RECORD-LINKAGE; MORTALITY; DISORDERS	Objective.-We sought to describe the rate, risk, trends, methods, and distribution of suicide among persons with the acquired immunodeficiency syndrome (AIDS) in the United States. Design.-We used National Center for Health Statistics multiple-cause mortality data from 1987 through 1989 to identify suicides among persons with AIDS (PWAs) and public-access AIDS surveillance data to determine person-years of observation of PWAs. Patients.-Residents of the United States with death certificates indicating suicide. Main Outcome Measure.-Death certificates indicating both AIDS and suicide. Results.-In 1987 through 1989, a total of 165 suicides among PWAs occurred in 45 states and the District of Columbia. All but one case were male. Among males the rate was 165 per 100 000 person-years of observation, 7.4-fold higher than among demographically similar men in the general population. Self-poisoning with drugs was both the most common method (35%) and the method with the highest standardized mortality ratio (35). Suicide risk for PWAs decreased significantly (P<.05) from 1987 to 1989. Conclusion.-Persons with AIDS have an increased risk of suicide, and assessment of such risk should be a standard practice in their care. These assessments should be carefully considered when potentially lethal medications are prescribed. The declining trend in suicide rates between 1987 and 1989 is encouraging; possible causes include emerging therapies for human immunodeficiency virus/AIDS, better psychiatric care for these patients, and lessened social stigma against PWAs.	JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, CTR INJURY PREVENT, BALTIMORE, MD 21218 USA	Johns Hopkins University	COTE, TR (corresponding author), NCI, VIRAL EPIDEMIOL SECT, 6130 EXECUT PLAZA, EPN-434, ROCKVILLE, MD 20852 USA.							ABRAM HS, 1971, AM J PSYCHIAT, V127, P1199, DOI 10.1176/ajp.127.9.1199; BERKELMAN RL, 1989, AM J MED, V86, P761, DOI 10.1016/0002-9343(89)90470-1; BLACK D, 1985, ARCHIT DIGEST, V42, P82; BLACK DW, 1985, ARCH GEN PSYCHIAT, V42, P71; BLACK DW, 1985, ARCH GEN PSYCHIAT, V42, P78; BUEHLER JW, 1990, AM J PUBLIC HEALTH, V80, P1080, DOI 10.2105/AJPH.80.9.1080; BUEHLER JW, 1992, J ACQ IMMUN DEF SYND, V5, P257; GERTIG DM, 1991, AIDS, V5, P1157, DOI 10.1097/00002030-199110000-00001; GOODMAN RA, 1987, SOUTH MED J, V82, P1128; GROW M, 1989, VERSICHERUNGSMEDIZIN, V41, P188; HOLLAND JC, 1985, ANN INTERN MED, V103, P760, DOI 10.7326/0003-4819-103-5-760; ISRAEL RA, 1986, AM J EPIDEMIOL, V124, P161, DOI 10.1093/oxfordjournals.aje.a114375; KIZER KW, 1988, JAMA-J AM MED ASSOC, V260, P1881, DOI 10.1001/jama.1988.03410130075021; MARSHALL JR, 1983, SUICIDE LIFE-THREAT, V13, P15; MARZUK PM, 1988, JAMA-J AM MED ASSOC, V259, P1333, DOI 10.1001/jama.259.9.1333; MOYER LA, 1989, AM J EPIDEMIOL, V130, P1024, DOI 10.1093/oxfordjournals.aje.a115403; SCHOENFELD M, 1986, AM J MED GENET, V24, P305; 1991, DHHS PHS911260 US DE	18	77	77	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 21	1992	268	15					2066	2068		10.1001/jama.268.15.2066	http://dx.doi.org/10.1001/jama.268.15.2066			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT520	1404744				2022-12-28	WOS:A1992JT52000031
J	TAKAHASHI, JS				TAKAHASHI, JS			CIRCADIAN CLOCK GENES ARE TICKING	SCIENCE			English	Editorial Material							VISUAL-SYSTEM; DNA-BINDING; DROSOPHILA; PERIOD; RHYTHMS; PROTEIN; TRANSCRIPTION; OSCILLATOR; PRODUCT; MYOD		NORTHWESTERN UNIV, DEPT NEUROBIOL & PHYSIOL, EVANSTON, IL 60208 USA	Northwestern University	TAKAHASHI, JS (corresponding author), NORTHWESTERN UNIV, NATL SCI FDN, CTR BIOL TIMING, EVANSTON, IL 60208 USA.		Takahashi, Joseph S/E-8482-2012; Takahashi, Joseph S./Y-2781-2019	Takahashi, Joseph S/0000-0003-0384-8878; Takahashi, Joseph S./0000-0003-0384-8878				BARGIELLO TA, IN PRESS BIOL B; BAYLIES MK, IN PRESS MOL GENETIC; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; DUNLAP JC, 1989, IN PRESS ANN REV PHY, V45; EWER J, 1992, J NEUROSCI, V12, P3321; HALL JC, 1990, ANNU REV GENET, V24, P659; HARDIN DE, 1991, IN PRESS P NATL ACAD, V88; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; KORNHAUSER JM, 1992, SCIENCE, V255, P1581, DOI 10.1126/science.1549784; KORNHAUSER JM, IN PRESS MOL GENETIC; LIU X, 1992, J NEUROSCI, V12, P2735; MILLAR AJ, 1991, PLANT CELL, V3, P541, DOI 10.1105/tpc.3.5.541; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; RAJU U, 1991, SCIENCE, V253, P673, DOI 10.1126/science.1871602; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; ROSBASH M, 1989, NEURON, V3, P387, DOI 10.1016/0896-6273(89)90199-2; ROSBASH M, COMMUNICATION; SIWICKI KK, 1988, NEURON, V1, P141, DOI 10.1016/0896-6273(88)90198-5; Takahashi J S, 1991, Curr Opin Neurobiol, V1, P556, DOI 10.1016/S0959-4388(05)80028-5; TAKAHASHI JS, 1989, RECENT PROG HORM RES, V45, P279; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WUARIN J, 1990, CELL, V63, P1257, DOI 10.1016/0092-8674(90)90421-A; YOUNG MW, COMMUNICATION; YU Q, 1987, NATURE, V326, P765, DOI 10.1038/326765a0; ZERR DM, 1990, J NEUROSCI, V10, P2749; ZWIEBEL LJ, 1991, P NATL ACAD SCI USA, V88, P3882, DOI 10.1073/pnas.88.9.3882	30	64	66	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 9	1992	258	5080					238	240		10.1126/science.1384127	http://dx.doi.org/10.1126/science.1384127			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR860	1384127				2022-12-28	WOS:A1992JR86000017
J	ZHENG, XM; WANG, Y; PALLEN, CJ				ZHENG, XM; WANG, Y; PALLEN, CJ			CELL-TRANSFORMATION AND ACTIVATION OF PP60(C-SRC) BY OVEREXPRESSION OF A PROTEIN TYROSINE PHOSPHATASE	NATURE			English	Article							MITOTIC ACTIVATION; PP60C-SRC; KINASE; PHOSPHORYLATION; MITOSIS; GENE; DEPHOSPHORYLATION; EXPRESSION; P60C-SRC; CLONING	THE kinase activity of pp60c-src is specifically and transiently increased during mitosis and repressed during interphase1. Loss of cell-cycle control of pp60c-src occurs on mutation of Tyr 527 to Phe or when pp60c-src is associated with polyoma middle-T-antigen, and these conditions result in cell transformation or tumorigenesis2,3. In both cases, pp60c-src has elevated kinase activity which is maintained throughout the cell cycle and accompanied by dephosphorylation of the carboxy-terminal negative regulatory4-7 Tyr 527 site, or mimicry of Tyr 527 dephosphorylation in the case of the mutant. Here we report that overexpression of the receptor-like protein tyrosine phosphatase PTP-alpha-8-10 results in persistent activation of pp60c-src kinase, with concomitant cell transformation and tumorigenesis. In PTP-alpha-overexpressing cells the pp60c-src kinase activation is accompanied by dephosphorylation at Tyr 527, and direct dephosphorylation of this site by purified PTP-alpha occurs in vitro. Our results suggest that PTP-alpha is involved in the regulation of cell proliferation, exerting at least some of its effects through pp60c-src kinase, and has oncogenic capability when overexpressed.	NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,CELL REGULAT LAB,10 KENT RIDGE CRESCENT,SINGAPORE 0511,SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore			Wang, Yue/H-2107-2011; Wang, Yue/AGN-6053-2022	Wang, Yue/0000-0002-1211-2822; Pallen, Catherine/0000-0002-3576-5295				AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BOLEN JB, 1987, ONCOGENE RES, V1, P149; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; COURTNEIDGE SA, 1980, P NATL ACAD SCI-BIOL, V77, P3783, DOI 10.1073/pnas.77.7.3783; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRUEGER NX, 1990, EMBO J, V9, P3241; KAECH S, 1991, NATURE, V350, P431, DOI 10.1038/350431a0; KAWAKAMI T, 1988, P NATL ACAD SCI USA, V85, P3870, DOI 10.1073/pnas.85.11.3870; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1989, J BIOL CHEM, V264, P20886; PARKER RC, 1984, CELL, V37, P131, DOI 10.1016/0092-8674(84)90308-8; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G	30	437	462	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 24	1992	359	6393					336	339		10.1038/359336a0	http://dx.doi.org/10.1038/359336a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP503	1383828				2022-12-28	WOS:A1992JP50300062
J	DOIG, CM				DOIG, CM			ABC OF COLORECTAL DISEASES - PEDIATRIC PROBLEMS .1.	BRITISH MEDICAL JOURNAL			English	Article											DOIG, CM (corresponding author), UNIV MANCHESTER,BOOTH HALL CHILDRENS HOSP,MANCHESTER M13 9PL,LANCS,ENGLAND.								0	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 22	1992	305	6851					462	464		10.1136/bmj.305.6851.462	http://dx.doi.org/10.1136/bmj.305.6851.462			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK680	1392963	Bronze, Green Submitted, Green Published			2022-12-28	WOS:A1992JK68000028
J	STEITZ, JA				STEITZ, JA			SPLICING TAKES A HOLIDAY	SCIENCE			English	Editorial Material							PRE-MESSENGER-RNA; MITOCHONDRIAL TRANSFER-RNAS; JUNCTION SEQUENCES; MAMMALIAN INTRONS; GROUP-II; SITE; YEAST; CLEAVAGE; RIBONUCLEOPROTEIN; SPLICEOSOME				STEITZ, JA (corresponding author), YALE UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC BIOPHYS & BIOCHEM,295 CONGRESS AVE,NEW HAVEN,CT 06536, USA.							AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; BARRELL BG, 1980, P NATL ACAD SCI-BIOL, V77, P3164, DOI 10.1073/pnas.77.6.3164; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HECKMAN JE, 1980, P NATL ACAD SCI-BIOL, V77, P3159, DOI 10.1073/pnas.77.6.3159; HOLBROOK SR, 1991, NATURE, V353, P579, DOI 10.1038/353579a0; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; JACQUIER A, 1991, J MOL BIOL, V219, P415, DOI 10.1016/0022-2836(91)90183-7; JACQUIER A, 1990, TRENDS BIOCHEM SCI, V15, P351, DOI 10.1016/0968-0004(90)90075-M; LECUYER K, UNPUB; LERNER MR, 1980, NATURE, V283, P220, DOI 10.1038/283220a0; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MURCHIE AIH, 1990, NUCLEIC ACIDS RES, V18, P2599, DOI 10.1093/nar/18.9.2599; NEWMAN A, 1991, CELL, V65, P115, DOI 10.1016/0092-8674(91)90413-S; NEWMAN AJ, 1992, CELL, V68, P1; NILSEN TW, 1989, EXP PARASITOL, V69, P413, DOI 10.1016/0014-4894(89)90191-4; OHSHIMA Y, 1987, J MOL BIOL, V195, P247, DOI 10.1016/0022-2836(87)90647-4; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; REICH CI, 1992, CELL, V69, P1159, DOI 10.1016/0092-8674(92)90637-R; ROGERS J, 1980, P NATL ACAD SCI-BIOL, V77, P1877, DOI 10.1073/pnas.77.4.1877; RYMOND BC, 1988, GENE DEV, V2, P428, DOI 10.1101/gad.2.4.428; RYMOND BC, 1985, NATURE, V317, P735, DOI 10.1038/317735a0; SAWA H, 1991, NUCLEIC ACIDS RES, V19, P3953, DOI 10.1093/nar/19.14.3953; SMITH CWJ, 1989, NATURE, V342, P243, DOI 10.1038/342243a0	24	107	111	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 14	1992	257	5072					888	889		10.1126/science.1386941	http://dx.doi.org/10.1126/science.1386941			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH827	1386941				2022-12-28	WOS:A1992JH82700019
J	GROH, J; WELTE, M; AZAD, SC; FORST, H; PRATSCHKE, E; KRATZER, MAA				GROH, J; WELTE, M; AZAD, SC; FORST, H; PRATSCHKE, E; KRATZER, MAA			DOES APROTININ AFFECT BLOOD-LOSS IN LIVER-TRANSPLANTATION	LANCET			English	Letter									UNIV MUNICH,INST CLIN CHEM,W-8000 MUNICH 70,GERMANY; UNIV MUNICH,DEPT SURG,W-8000 MUNICH 70,GERMANY	University of Munich; University of Munich	GROH, J (corresponding author), UNIV MUNICH,INST ANAESTHESIOL,W-8000 MUNICH 70,GERMANY.							ARNOUX D, 1989, THROMB RES, V55, P319, DOI 10.1016/0049-3848(89)90064-9; GROSSE H, 1991, THROMB RES, V63, P287, DOI 10.1016/0049-3848(91)90132-G; KRATZER MAA, 1991, TRANSPL P, V23, P1906; MALLETT SV, 1990, LANCET, V336, P886, DOI 10.1016/0140-6736(90)92404-6; NEUHAUS P, 1989, LANCET, V2, P924	5	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 18	1992	340	8812					173	173		10.1016/0140-6736(92)93246-J	http://dx.doi.org/10.1016/0140-6736(92)93246-J			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE382	1378166				2022-12-28	WOS:A1992JE38200019
J	KUTSUWADA, T; KASHIWABUCHI, N; MORI, H; SAKIMURA, K; KUSHIYA, E; ARAKI, K; MEGURO, H; MASAKI, H; KUMANISHI, T; ARAKAWA, M; MISHINA, M				KUTSUWADA, T; KASHIWABUCHI, N; MORI, H; SAKIMURA, K; KUSHIYA, E; ARAKI, K; MEGURO, H; MASAKI, H; KUMANISHI, T; ARAKAWA, M; MISHINA, M			MOLECULAR DIVERSITY OF THE NMDA RECEPTOR CHANNEL	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; METHYL-D-ASPARTATE; EXCITATORY AMINO-ACIDS; FUNCTIONAL EXPRESSION; SELECTIVE ANTAGONIST; PROTEIN-KINASE; GLUTAMATE; CLONING; FAMILY; SUBUNIT	Two novel subunits of the mouse NMDA receptor channel, the epsilon-2 and epsilon-3 subunits, have been identified by cloning and expression of complementary DNAs. The heteromeric epsilon-1/zeta-1, epsilon-2/zeta-1 and epsilon-3/zeta-1 NMDA receptor channels exhibit distinct functional properties in affinities for agonists and sensitivities to competitive antagonists and Mg2+ block. In contrast to the wide distribution of the epsilon-1 and zeta-1 subunit messenger RNAs in the brain, the epsilon-2 subunit mRNA is expressed only in the forebrain and the epsilon-3 subunit mRNA is found predominantly in the cerebellum. The epsilon-1/zeta-1 and epsilon-2/zeta-1 channels expressed in Xenopus oocytes, but not the epsilon-3/zeta-1 channel, are activated by treatment with 12-O-tetradecanoylphorbol 13-acetate. These findings suggest that the molecular diversity of the epsilon-subunit family underlies the functional heterogeneity of the NMDA receptor channel.	NIIGATA UNIV,DEPT NEUROPHARMACOL,NIIGATA 951,JAPAN; NIIGATA UNIV,BRAIN RES INST,DEPT NEUROPATHOL,NIIGATA 951,JAPAN; NIIGATA UNIV,SCH MED,DEPT MED 2,NIIGATA 951,JAPAN	Niigata University; Niigata University; Niigata University								BETTLER B, 1990, NEURON, V5, P583, DOI 10.1016/0896-6273(90)90213-Y; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; DAVIES J, 1981, NEUROSCI LETT, V21, P77, DOI 10.1016/0304-3940(81)90061-6; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; GARTHWAITE J, 1989, NEUROSCIENCE, V29, P401, DOI 10.1016/0306-4522(89)90067-5; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HOWE JR, 1991, J PHYSIOL-LONDON, V432, P143, DOI 10.1113/jphysiol.1991.sp018381; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KEMP JA, 1988, P NATL ACAD SCI USA, V85, P6547, DOI 10.1073/pnas.85.17.6547; LEONARD JP, 1990, NEURON, V4, P53, DOI 10.1016/0896-6273(90)90443-J; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MISHINA M, 1991, BIOCHEM BIOPH RES CO, V180, P813, DOI 10.1016/S0006-291X(05)81137-4; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MONAGHAN DT, 1988, P NATL ACAD SCI USA, V85, P9836, DOI 10.1073/pnas.85.24.9836; MONAGHAN DT, 1991, EXCITATORY AMINO ACI, P33; MORITA T, 1992, MOL BRAIN RES, V14, P143, DOI 10.1016/0169-328X(92)90023-5; MORYOSHI K, 1991, NATURE, V354, P31; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; OLNEY JW, 1991, REV PHARM TOX, V30, P47; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; PUCKETT C, 1991, P NATL ACAD SCI USA, V88, P7557, DOI 10.1073/pnas.88.17.7557; SAKIMURA K, 1992, NEURON, V8, P267, DOI 10.1016/0896-6273(92)90293-M; SAKIMURA K, 1990, FEBS LETT, V272, P73, DOI 10.1016/0014-5793(90)80452-O; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILVER RA, 1992, NATURE, V355, P163, DOI 10.1038/355163a0; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TRAYNELIS SF, 1991, J PHYSIOL-LONDON, V433, P727, DOI 10.1113/jphysiol.1991.sp018453; USUI H, 1991, MOL CHEM NEUROPATHOL, V15, P207, DOI 10.1007/BF03161060; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WERNER P, 1991, NATURE, V351, P742, DOI 10.1038/351742a0; YAMAZAKI M, 1992, FEBS LETT, V300, P39, DOI 10.1016/0014-5793(92)80160-I; YAMAZAKI M, 1992, BIOCHEM BIOPH RES CO, V183, P886, DOI 10.1016/0006-291X(92)90566-4	39	1262	1301	0	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1992	358	6381					36	41		10.1038/358036a0	http://dx.doi.org/10.1038/358036a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JB341	1377365				2022-12-28	WOS:A1992JB34100044
J	BRYNDORF, T; CHRISTENSEN, B; PHILIP, J; HANSEN, W; YOKOBATA, K; BUI, N; GAISER, C				BRYNDORF, T; CHRISTENSEN, B; PHILIP, J; HANSEN, W; YOKOBATA, K; BUI, N; GAISER, C			NEW RAPID TEST FOR PRENATAL DETECTION OF TRISOMY-21 (DOWNS-SYNDROME) - PRELIMINARY-REPORT	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INSITU HYBRIDIZATION; CHROMOSOME; INTERPHASE; GENE	Objective - To devise and evaluate a rapid screening method for detecting trisomy 21 (Down's syndrome) in samples of uncultured amniotic fluid cells. Design - Non-radioactive in situ hybridisation with HY128, a 500 000 base pair yeast artificial chromosome probe specific for chromosome 21. Blinded study of 12 karyotypically normal amniotic fluid samples and eight samples trisomic for chromosome 21. Setting - Cytogenetic and obstetric services at a tertiary referral centre, Copenhagen. Main outcome measures - Time necessary to complete the test. Proportion of cell nuclei containing two and three hybridisation signals in karyotypically normal and abnormal amniotic fluid samples. Results - The test could be completed within three to four days after amniocentesis. In the normal samples a mean of 73% (range 61-82%) of the amniotic cell nuclei showed two hybridisation signals and 6% (0-18%) showed three signals. By contrast, among the trisomic samples 29% (19-38%) of the nuclei exhibited two signals and 48% (31-60%) showed three signals. Conclusion - The technique clearly distinguished between normal and trisomic samples. Prenatal diagnosis with in situ hybridisation with chromosome specific probes was fast and may make it possible to screen for selected, aneuploidies. However, the technique is still at a preliminary stage and needs further evaluation and refinement.	BECTON DICKINSON IMMUNOCYTOMETRY SYST, SAN JOSE, CA 95131 USA	Becton Dickinson	BRYNDORF, T (corresponding author), UNIV COPENHAGEN HOSP, RIGSHOSP, DEPT OBSTET & GYNAECOL, CLIN GENET SECT, CHROMOSOME LAB, DK-2100 COPENHAGEN, DENMARK.							BURKE DT, 1991, METHOD ENZYMOL, V194, P251; CHRISTENSEN B, 1992, PRENAT DIAGN, V12, P251; CREMER T, 1986, HUM GENET, V74, P346, DOI 10.1007/BF00280484; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GOSDEN CM, 1983, BRIT MED BULL, V39, P348, DOI 10.1093/oxfordjournals.bmb.a071847; GUYOT B, 1988, PRENATAL DIAG, V8, P485, DOI 10.1002/pd.1970080703; HOPMAN AHN, 1990, IN SITU HYBRIDIZATIO, P165; KLINGER KW, 1991, AM J HUM GENET, V49, P23; KUO W, 1991, AM J HUM GENET, V49, P382; KUO WL, 1991, AM J HUM GENET, V49, P112; LAWRENCE JB, 1990, SCIENCE, V249, P928, DOI 10.1126/science.2203143; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; PINKEL D, 1988, P NATL ACAD SCI USA, V85, P9138, DOI 10.1073/pnas.85.23.9138; WHITEMAN DAH, 1991, AM J HUM GENET, V49, P234; WILLARD HF, 1983, NUCLEIC ACIDS RES, V11, P2017, DOI 10.1093/nar/11.7.2017; YU LC, 1991, AM J HUM GENET, V49, P235	17	14	15	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 13	1992	304	6841					1536	1539		10.1136/bmj.304.6841.1536	http://dx.doi.org/10.1136/bmj.304.6841.1536			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ178	1385745	Green Published, Bronze			2022-12-28	WOS:A1992HZ17800022
J	SANTALUCIA, J; KIERZEK, R; TURNER, DH				SANTALUCIA, J; KIERZEK, R; TURNER, DH			CONTEXT DEPENDENCE OF HYDROGEN-BOND FREE-ENERGY REVEALED BY SUBSTITUTIONS IN AN RNA HAIRPIN	SCIENCE			English	Article							RIBOSOMAL-RNA; SECONDARY STRUCTURES; PHAGE-T4 LYSOZYME; DUPLEX STABILITY; SEQUENCE; ARCHITECTURE; PREDICTIONS	Prediction and modeling of RNA structure requires knowledge of the free energy contributions of various interactions. Many unusual hydrogen bonds were recently proposed in the structure of a GCAA hairpin determined from nuclear magnetic resonance. The contributions of these hydrogen bonds to the folding stability of the hairpin formed by rGGCGCAAGCC have now been investigated through the use of functional group substitutions. These and previous results suggest a strong context dependence for the free energy of hydrogen bond formation. The results also suggest that the phylogenetic preference for GNRA (where N = A, C, G, or U and R = A or G) tetraloops may have afunctional rather than thermodynamic basis.	UNIV ROCHESTER,DEPT CHEM,ROCHESTER,NY 14627; POLISH ACAD SCI,INST BIOORGAN CHEM,PL-60704 POZNAN,POLAND	University of Rochester; Polish Academy of Sciences; Institute of Bioorganic Chemistry of the Polish Academy of Sciences			Schroeder, Susan/D-3946-2011	Kierzek, Ryszard/0000-0002-7644-0016	NIGMS NIH HHS [GM22939] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022939] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBER T, 1988, SCIENCE, V239, P631, DOI 10.1126/science.3277275; ALBER T, 1987, NATURE, V330, P41, DOI 10.1038/330041a0; ANTAO VP, 1991, NUCLEIC ACIDS RES, V19, P5901, DOI 10.1093/nar/19.21.5901; BEVILACQUA PC, 1991, BIOCHEMISTRY-US, V30, P10632, DOI 10.1021/bi00108a005; CHOU SH, 1989, BIOCHEMISTRY-US, V28, P2422, DOI 10.1021/bi00432a013; CROTHERS DM, 1974, J MOL BIOL, V87, P63, DOI 10.1016/0022-2836(74)90560-9; FERSHT AR, 1987, TRENDS BIOCHEM SCI, V12, P301, DOI 10.1016/0968-0004(87)90146-0; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; GROEBE DR, 1988, NUCLEIC ACIDS RES, V16, P11725, DOI 10.1093/nar/16.24.11725; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; KIERZEK R, 1986, BIOCHEMISTRY-US, V25, P7840, DOI 10.1021/bi00372a009; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MOAZED D, 1986, J MOL BIOL, V187, P399, DOI 10.1016/0022-2836(86)90441-9; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; RIESNER D, 1973, PHYSICO CHEMICAL PRO, V2, P237; SANTALUCIA J, 1991, BIOCHEMISTRY-US, V30, P8242, DOI 10.1021/bi00247a021; SANTALUCIA J, 1991, J AM CHEM SOC, V113, P4313, DOI 10.1021/ja00011a039; SANTALUCIA J, UNPUB; SHIRLEY BA, 1992, BIOCHEMISTRY-US, V31, P725, DOI 10.1021/bi00118a013; TUERK C, 1988, P NATL ACAD SCI USA, V85, P1364, DOI 10.1073/pnas.85.5.1364; TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167; TURNER DH, 1987, J AM CHEM SOC, V109, P3783, DOI 10.1021/ja00246a047; VARANI G, 1991, BIOCHEMISTRY-US, V30, P3280, DOI 10.1021/bi00227a016; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P8467, DOI 10.1073/pnas.87.21.8467	27	204	204	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 10	1992	256	5054					217	219		10.1126/science.1373521	http://dx.doi.org/10.1126/science.1373521			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM896	1373521				2022-12-28	WOS:A1992HM89600027
J	HANCOCK, BD				HANCOCK, BD			ABC OF COLORECTAL DISEASES - ANAL FISSURES AND FISTULAS	BRITISH MEDICAL JOURNAL			English	Article											HANCOCK, BD (corresponding author), WYTHENSHAWE HOSP,MANCHESTER M23 9LT,LANCS,ENGLAND.								0	6	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1992	304	6831					904	907		10.1136/bmj.304.6831.904	http://dx.doi.org/10.1136/bmj.304.6831.904			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM835	1392761	Bronze, Green Published			2022-12-28	WOS:A1992HM83500040
J	RITCHIE, LD; BISSET, AF; RUSSELL, D; LESLIE, V; THOMSON, I				RITCHIE, LD; BISSET, AF; RUSSELL, D; LESLIE, V; THOMSON, I			PRIMARY AND PRESCHOOL IMMUNIZATION IN GRAMPIAN - PROGRESS AND THE 1990 CONTRACT	BRITISH MEDICAL JOURNAL			English	Article							IMMUNIZATION	Objective - To examine changes in immunisation performance in Grampian region after the introduction of the 1990 contract for general practitioners. Design - Retrospective descriptive study using data held on the Grampian immunisation record system's computer. Setting - All 95 general practices in Grampian region (313 general practitioners). Patients - All children in the primary immunisation and preschool booster age groups. This formed two groups of children for each of the four calendar quarters of 1990 and first three quarters of 1991 analysed as (a) those aged 2 years on the first day of the relevant quarter and (b) those aged 5 years on the first day of the relevant quarter, with an average population of 6600 and 6400 respectively. Main outcome measure - Percentage immunised by practice. Results - For primary immunisation the number of practices achieving immunisation rates of at least 95% increased from 29 (31%) to 76 (81%), and practices achieving 90% rates rose from 69 (73%) to 87 (93%). For preschool boosters, the number of practices achieving at least 95% immunisation rates increased from 22 (23%) to 61 (64%). By the end of September 1991, 76 (80%) practices were achieving at least 90% levels compared with 36 (39%) at the beginning of 1990. Since the beginning of 1989 the proportion of immunisations not given by general practitioners declined from 14% to 2%. Conclusions - Primary and preschool immunisation rates for preschool children in Grampian showed a sustained improvement during 1990 and consolidation in 1991. Although overall trends were unchanged, 18 months after the introduction of the 1990 contract only one practice failed to meet lower target levels of 70% for both primary and preschool immunisation. By September 1991 more than three out of four practices had reached levels of at least 95% for primary immunisation.	UNIV ABERDEEN,DEPT PUBL HLTH,ABERDEEN AB9 1FX,SCOTLAND; GRAMPIAN AREA HLTH BOARD,CTR COMP,ABERDEEN AB9 8QP,SCOTLAND; GRAMPIAN AREA HLTH BOARD,DEPT PRIMARY CARE,ABERDEEN AB9 8QP,SCOTLAND	University of Aberdeen	RITCHIE, LD (corresponding author), GRAMPIAN AREA HLTH BOARD,PUBL HLTH MED,ABERDEEN AB9 8QP,SCOTLAND.		Angus, Valerie/A-5324-2008					Adams B, 1990, Health Serv J, V100, P1176; BEECHAM L, 1991, BRIT MED J, V302, P367; BISSET A F, 1990, Health Bulletin (Edinburgh), V48, P294; JEFFERIES S, 1991, J PUBLIC HEALTH MED, V13, P312; JONES K, 1991, BRIT MED J, V303, P28, DOI 10.1136/bmj.303.6793.28; LI J, 1991, BRIT MED J, V303, P1035, DOI 10.1136/bmj.303.6809.1035; NARAYAN KMV, 1989, LANCET, V1, P271; NICOLL A, 1989, BRIT MED J, V299, P808, DOI 10.1136/bmj.299.6703.808; NICOLL A, 1989, BRIT PAEDIATRIC ASS; QUAM L, 1989, BRIT MED J, V299, P448, DOI 10.1136/bmj.299.6696.448; REID GS, 1991, BRIT MED J, V303, P447, DOI 10.1136/bmj.303.6800.447; RUDD PT, 1991, BRIT MED J, V302, P481, DOI 10.1136/bmj.302.6775.481; WALKER D, 1989, BRIT MED J, V299, P458, DOI 10.1136/bmj.299.6696.458; WALKER D, 1991, BRIT MED J, V302, P787; WRENCH J, 1991, BRIT MED J, V302, P787, DOI 10.1136/bmj.302.6779.787-d; 1989, GENERAL PRACTICE NAT; 1990, IMMUNIATION INFECTIO; 1991, HLTH NATION; 1989, UPTAKE PRESCHOOL IMM; 1990, SPSS PC PLUS VERSION	20	24	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1992	304	6830					816	819		10.1136/bmj.304.6830.816	http://dx.doi.org/10.1136/bmj.304.6830.816			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL827	1392710	Green Published, Bronze			2022-12-28	WOS:A1992HL82700022
J	HENNEKENS, CH; BURING, JE; PETO, R				HENNEKENS, CH; BURING, JE; PETO, R			ASPIRIN IN ISCHEMIC-HEART-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									UNIV OXFORD, OXFORD, ENGLAND	University of Oxford	HENNEKENS, CH (corresponding author), HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA.							Buring JE, 1992, J MYOCARDIAL ISCHEMI, V4, P27; HENNEKENS CH, 1989, CIRCULATION, V80, P749, DOI 10.1161/01.CIR.80.4.749; 1988, BMJ, V296, P320	3	2	2	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 12	1992	327	20					1455	1456						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX479	1406866				2022-12-28	WOS:A1992JX47900013
J	AGUAYO, SM; MILLER, YE; WALDRON, JA; BOGIN, RM; SUNDAY, ME; STATON, GW; BEAM, WR; KING, TE				AGUAYO, SM; MILLER, YE; WALDRON, JA; BOGIN, RM; SUNDAY, ME; STATON, GW; BEAM, WR; KING, TE			BRIEF REPORT - IDIOPATHIC DIFFUSE HYPERPLASIA OF PULMONARY NEUROENDOCRINE CELLS AND AIRWAYS DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							BOMBESIN-LIKE IMMUNOREACTIVITY; GASTRIN-RELEASING PEPTIDE; ENDOCRINE-CELLS; FETAL LUNG; TUMORLETS; GROWTH; TRACT		UNIV COLORADO,HLTH SCI CTR,DEPT VET AFFAIRS MED CTR,DEPT MED,DENVER,CO 80262; UNIV ARKANSAS MED SCI HOSP,DEPT PATHOL,LITTLE ROCK,AR 72205; UNIV COLORADO,HLTH SCI CTR,NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,DENVER,CO 80262; BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; EMORY UNIV,CRAWFORD LONG HOSP,SCH MED,DEPT MED,ATLANTA,GA 30322	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Arkansas System; University of Arkansas Medical Sciences; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Emory University	AGUAYO, SM (corresponding author), EMORY UNIV,SCH MED,DEPT VET AFFAIRS MED CTR,DEPT MED 111A,1670 CLAIRMONT RD,ATLANTA,GA 30322, USA.			Sunday, Mary E./0000-0002-6788-1469	NHLBI NIH HHS [HL-27353, R01HL44984, R01HL45745] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045745, P50HL027353, R01HL044984] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGUAYO SM, 1989, J CLIN INVEST, V84, P1105, DOI 10.1172/JCI114273; AGUAYO SM, 1990, J CLIN INVEST, V86, P838, DOI 10.1172/JCI114782; AGUAYO SM, 1992, CLIN RES, V40, pA297; AGUAYO SM, 1989, MEDIATORS INFLAMMATO, V6, P219; BECKER KL, 1984, ENDOCRINE LUNG HLTH, P155; BONIKOS DS, 1976, HUM PATHOL, V7, P461, DOI 10.1016/S0046-8177(76)80060-3; CHURG A, 1976, CANCER, V37, P1469; DAGATI VD, 1985, CANCER, V55, P2472, DOI 10.1002/1097-0142(19850515)55:10<2472::AID-CNCR2820551027>3.0.CO;2-Y; Feyrter F, 1938, DIFFUSE ENDOKRINE EP; FROLICH F, 1949, FRANKFURT Z PATHOL, V60, P517; GOSNEY JR, 1989, J PATHOL, V157, P127, DOI 10.1002/path.1711570207; GOSNEY JR, 1988, THORAX, V43, P878, DOI 10.1136/thx.43.11.878; GOULD VE, 1983, LAB INVEST, V49, P519; Gray SH, 1929, ARCH SURG-CHICAGO, V19, P1618, DOI 10.1001/archsurg.1929.01150060680038; HORRELL JB, 1952, CANCER, V5, P911, DOI 10.1002/1097-0142(195209)5:5<911::AID-CNCR2820050507>3.0.CO;2-4; IMPICCIATORE M, 1973, J PHARM PHARMACOL, V25, P872, DOI 10.1111/j.2042-7158.1973.tb09965.x; JOHNSON DE, 1982, PEDIATR RES, V16, P446, DOI 10.1203/00006450-198206000-00009; JOHNSON DE, 1989, AM REV RESPIR DIS, V140, P1807, DOI 10.1164/ajrccm/140.6.1807; JOHNSON DE, 1988, AM REV RESPIR DIS, V137, P123, DOI 10.1164/ajrccm/137.1.123; KARSNER HT, 1930, AM J PATHOL, V6, P533; LUNDGREN JD, 1990, AM J PHYSIOL, V258, pL68, DOI 10.1152/ajplung.1990.258.2.L68; PETERSEN AB, 1949, CANCER, V2, P991, DOI 10.1002/1097-0142(194911)2:6<991::AID-CNCR2820020607>3.0.CO;2-B; PRIOR JT, 1953, AM J PATHOL, V29, P703; RANCHOD M, 1977, CANCER, V39, P1135, DOI 10.1002/1097-0142(197703)39:3<1135::AID-CNCR2820390319>3.0.CO;2-B; SKINNER C, 1976, THORAX, V31, P212, DOI 10.1136/thx.31.2.212; Sorokin SP, 1989, LUNG CELL BIOL, P191; SPINDEL ER, 1987, J CLIN INVEST, V80, P1172, DOI 10.1172/JCI113176; STANISLAWSKI EC, 1981, ARCH INVEST MED, V12, P559; Stewart MJ, 1943, J PATHOL BACTERIOL, V55, P105, DOI 10.1002/path.1700550118; SUNDAY ME, 1990, AM J RESP CELL MOL, V3, P199, DOI 10.1165/ajrcmb/3.3.199; WATANABE H, 1985, ACTA PATHOL JAPON, V35, P1221; WHARTON J, 1978, NATURE, V273, P769, DOI 10.1038/273769a0; WHITWELL F, 1955, J PATHOL BACTERIOL, V70, P529, DOI 10.1002/path.1700700231	33	230	233	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 29	1992	327	18					1285	1288		10.1056/NEJM199210293271806	http://dx.doi.org/10.1056/NEJM199210293271806			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV259	1406819				2022-12-28	WOS:A1992JV25900006
J	NIGHTINGALE, SL				NIGHTINGALE, SL			UPDATE ON EMS AND L-TRYPTOPHAN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1992	268	14					1828	1828		10.1001/jama.268.14.1828	http://dx.doi.org/10.1001/jama.268.14.1828			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR439	1404696				2022-12-28	WOS:A1992JR43900008
J	TATSUKA, M; MITSUI, H; WADA, M; NAGATA, A; NOJIMA, H; OKAYAMA, H				TATSUKA, M; MITSUI, H; WADA, M; NAGATA, A; NOJIMA, H; OKAYAMA, H			ELONGATION FACTOR-1-ALPHA GENE DETERMINES SUSCEPTIBILITY TO TRANSFORMATION	NATURE			English	Article							NEOPLASTIC TRANSFORMATION; GROWTH-FACTOR; CELLS; PROTEIN; LINE	ELONGATION factor-1-alpha (EF-1-alpha), an essential component of the eukaryotic translational apparatus, is a GTP-binding protein that catalyses the binding of aminoacyl-transfer RNAs to the ribosome1-3. Expression of the EF-1-alpha gene decreases towards the end of the lifespans of mouse and human fibroblasts4,5, but forced expression of EF-1-alpha prolongs the lifespan of Drosophila melanogaster6. Eukaryotic initiation factor-4E, another component of the translational machinery, is mitogenic or oncogenic when constitutively expressed in some mammalian cells7-9. Thus, components of the protein synthesis apparatus seem to be involved in the control of cell proliferation. Using expression cloning, we have isolated a complementary DNA clone from a BALB/c 3T3 mouse fibroblast variant, A31-I-13 (ref. 10), which specifies a factor determining the susceptibility of BALB/c 3T3 to chemically and physically induced transformation. Here we report that the factor is EF-1-alpha and that its constitutive expression causes BALB/c 3T3 A31-I-1 (ref. 10), C3H10T1/2 (ref. 11) and Syrian hamster SHOK12 fibroblasts to become highly susceptible to transformation induced by 3-methylcholanthrene and ultraviolet light. EF-1-alpha messenger RNA is also constitutively expressed in a quiescent culture of the highly susceptible variant A31-I-13. We conclude that the removal of regulation of the expression of these components of the translational machinery may predispose cells to become more susceptible to malignant transformation.	OSAKA UNIV,MICROBIAL DIS RES INST,DEPT MOLEC GENET,SUITA,OSAKA 565,JAPAN; KYOTO PHARMACEUT UNIV,INST MOLEC & CELLULAR BIOL PHARMACEUT SCI,DEPT MOLEC BIOREGULAT,KYOTO 607,JAPAN	Osaka University; Kyoto Pharmaceutical University								AUSABEL FM, 1987, CURRENT PROTOCOLS MO; BENEDETTI AD, 1990, P NATL ACAD SCI USA, V87, P8212; BOCKUS BJ, 1984, EXP CELL RES, V153, P186, DOI 10.1016/0014-4827(84)90460-9; BREITMAN ML, 1982, MOL CELL BIOL, V2, P966, DOI 10.1128/MCB.2.8.966; CAVALLIUS J, 1986, EXP GERONTOL, V21, P149, DOI 10.1016/0531-5565(86)90068-9; CHEM C, 1987, MOL CELL BIOL, V7, P2745; CURRAN T, 1982, J VIROL, V44, P672; HERMAN B, 1985, J CELL BIOL, V100, P1031, DOI 10.1083/jcb.100.4.1031; HERSHEY JWB, 1980, BIOL COMPREHENSIVE T, V4; HIGASHI T, 1990, P NATL ACAD SCI USA, V87, P2409, DOI 10.1073/pnas.87.7.2409; HIRAKAWA T, 1982, SCIENCE, V216, P527, DOI 10.1126/science.6280280; KAKUNAGA T, 1980, SCIENCE, V209, P505, DOI 10.1126/science.7394516; Kakunaga T., 1985, IARC SCI PUBLICATION, V67; KARIRO T, 1978, BIOCHIM BIOPHYS ACTA, V505, P95; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LO KY, 1982, CANCER RES, V42, P2644; LU X, 1989, Nucleic Acids Research, V17, P442, DOI 10.1093/nar/17.1.442; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; SHEPHERD JCW, 1989, P NATL ACAD SCI USA, V86, P7520, DOI 10.1073/pnas.86.19.7520; SMITH M R, 1990, New Biologist, V2, P648; TANIGUCHI S, 1991, NUCLEIC ACIDS RES, V19, P6949, DOI 10.1093/nar/19.24.6949; TATAUKA M, 1992, CANCER RES, V52, P4232; TATSUKA M, 1989, J CELL PHYSIOL, V139, P18, DOI 10.1002/jcp.1041390104; TATSUKA M, 1988, EXP CELL RES, V178, P154, DOI 10.1016/0014-4827(88)90386-2; WEBSTER GC, 1985, MOL BIOL AGING GENE, P263; YAGI T, 1989, MOL CARCINOGEN, V1, P222, DOI 10.1002/mc.2940010404; YAMASAKI H, 1985, CANCER RES, V45, P637; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0	30	155	163	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 24	1992	359	6393					333	336		10.1038/359333a0	http://dx.doi.org/10.1038/359333a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP503	1383827				2022-12-28	WOS:A1992JP50300061
J	DORIN, JR; DICKINSON, P; ALTON, EWFW; SMITH, SN; GEDDES, DM; STEVENSON, BJ; KIMBER, WL; FLEMING, S; CLARKE, AR; HOOPER, ML; ANDERSON, L; BEDDINGTON, RSP; PORTEOUS, DJ				DORIN, JR; DICKINSON, P; ALTON, EWFW; SMITH, SN; GEDDES, DM; STEVENSON, BJ; KIMBER, WL; FLEMING, S; CLARKE, AR; HOOPER, ML; ANDERSON, L; BEDDINGTON, RSP; PORTEOUS, DJ			CYSTIC-FIBROSIS IN THE MOUSE BY TARGETED INSERTIONAL MUTAGENESIS	NATURE			English	Article							EMBRYONIC STEM-CELLS; POTENTIAL DIFFERENCE; GENE; IDENTIFICATION; REGULATOR	Cystic fibrosis is a fatal genetic disorder which afflicts 50,000 people worldwide. A viable animal model would be invaluable for investigating and combating this disease. The mouse cystic fibrosis transmembrane conductance regulator gene was disrupted in embryonal stem cells using an insertional gene targeting vector. Germ-line chimaeras were derived and the off spring of heterozygous crosses studied. These homozygous mutant mice survive beyond weaning. In vivo electrophysiology demonstrates the predicted defect in chloride ion transport in these mice and can distinguish between each genotype. Histological analysis detects important hallmarks of human disease pathology, including abnormalities of the colon, lung and vas deferens. This insertional mouse mutation provides a valid model system for the development and testing of therapies for cystic fibrosis patients.	WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,CREWE RD,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; NATL HEART & LUNG INST,ION TRANSPORT LAB,LONDON SW3 6LR,ENGLAND; UNIV EDINBURGH,SCH MED,DEPT PATHOL,CANC RES CAMPAIGN LABS,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND; AFRC,CTR GENOME RES,EDINBURGH EH9 3JQ,MIDLOTHIAN,SCOTLAND	University of Edinburgh; Imperial College London; University of Edinburgh			Dickinson, Paul/B-7598-2014; Clarke, Alan R/A-6256-2008; Porteous, David J/C-7289-2013; clarke, alan r/P-2820-2014; Porteous, David/AAA-3446-2021	Porteous, David J/0000-0003-1249-6106; Porteous, David/0000-0003-1249-6106; Clarke, Alan/0000-0002-4281-426X; Alton, Eric WFW/0000-0003-3852-6764				ALTON EWF, IN PRESS THORAX; ALTON EWFW, 1991, EUR RESPIR J, V4, P5; ALTON EWFW, 1990, EUR RESPIR J, V3, P922; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; CLARKE LL, 1992, SCIENCE, V257, P1125, DOI 10.1126/science.257.5073.1125; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; CUTTING GR, 1990, NEW ENGL J MED, V323, P1685, DOI 10.1056/NEJM199012133232407; DENG CX, 1992, MOL CELL BIOL, V12, P3365, DOI 10.1128/MCB.12.8.3365; DIAMOND G, 1991, J BIOL CHEM, V266, P22761; Dorin Julia R., 1992, Transgenic Research, V1, P101, DOI 10.1007/BF02513027; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; GOLDSTEIN JL, 1988, AM J PHYSIOL, V254, P718; HASTY P, 1991, NATURE, V350, P243, DOI 10.1038/350243a0; HASTY P, 1992, MOL CELL BIOL, V12, P1464; IVANSCHENKO T, 1991, GENOMICS, V10, P298; JACKSON ADM, 1989, CYSTIC FIBROSIS, P1; JONES CT, 1992, HUM MOL GENET, V1, P11, DOI 10.1093/hmg/1.1.11; KAPLAN E, 1968, NEW ENGL J MED, V279, P65, DOI 10.1056/NEJM196807112790203; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KNOWLES M, 1981, NEW ENGL J MED, V305, P1489, DOI 10.1056/NEJM198112173052502; KOLLER BH, 1991, P NATL ACAD SCI USA, V88, P10730, DOI 10.1073/pnas.88.23.10730; KRISTIDIS P, 1992, AM J HUM GENET, V50, P1178; MOENS CB, 1992, GENE DEV, V6, P691, DOI 10.1101/gad.6.5.691; Oppenheimer E H, 1975, Perspect Pediatr Pathol, V2, P241; QUINTON PM, 1990, NATURE, V347, P226, DOI 10.1038/347226a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SCHWACHMAN H, 1965, PEDIATRICS, V36, P689; SHOSHANI T, 1992, AM J HUM GENET, V50, P222; SMITH SN, 1992, CLIN SCI, V82, P667, DOI 10.1042/cs0820667; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; WIDDICOMBE JH, 1985, P NATL ACAD SCI USA, V82, P6167, DOI 10.1073/pnas.82.18.6167; WILLUMSEN NJ, 1991, AM J PHYSIOL, V261, P319; WINE JJ, 1992, NAT GENET, V1, P10, DOI 10.1038/ng0492-10	35	253	263	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 17	1992	359	6392					211	215		10.1038/359211a0	http://dx.doi.org/10.1038/359211a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN944	1382232	Green Submitted			2022-12-28	WOS:A1992JN94400051
J	ALBERT, T				ALBERT, T			HOW TO SET UP A NEWSLETTER	BRITISH MEDICAL JOURNAL			English	Article																		ALBERT T, 1992, MED JOURNALISM WRITE; GOODMAN NW, 1991, MED WRITING PRESCRIP; Strunk W., 1959, ELEMENTS STYLE; 1990, MAKING PRINT LEGIBLE	4	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 12	1992	305	6854					631	635		10.1136/bmj.305.6854.631	http://dx.doi.org/10.1136/bmj.305.6854.631			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN698	1393079	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JN69800024
J	MORL, M; NIEMER, I; SCHMEIZER, C				MORL, M; NIEMER, I; SCHMEIZER, C			NEW REACTIONS CATALYZED BY A GROUP-II INTRON RIBOZYME WITH RNA AND DNA SUBSTRATES	CELL			English	Article							SELF-SPLICING RNA; TETRAHYMENA; INVITRO; ENDONUCLEASE; SELECTION; MATURASE; MOBILITY; ENZYME	Here we describe three novel reactions of the self-splicing group II intron bl1 (the first intron of the COB gene of yeast mitochondria) demonstrating its catalytic versatility: reversal of the first step of the self-splicing reaction catalyzed by a linear form of the intron utilizing the energy of a phosphoanhydride bond for transesterification, ligation of a single-stranded DNA to an RNA, and cleavage of a single-stranded DNA substrate. These results have the following evolutionary implications: use of the alpha-beta-bond of a terminal triphosphate for transesterification suggests that an RNA RNA replicase could use mononucleotide triphosphates as precursors, and cleavage of single-stranded DNA and DNA-RNA ligation suggests that excised group II introns might integrate directly into DNA without prior reverse transcription.			MORL, M (corresponding author), UNIV MUNICH,INST GENET & MIKROBIOL,MARIA WARD STR 1A,W-8000 MUNICH 19,GERMANY.			Morl, Mario/0000-0003-0972-9386				AUGUSTIN S, 1990, NATURE, V343, P383, DOI 10.1038/343383a0; BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; COLLEAUX L, 1986, CELL, V44, P521, DOI 10.1016/0092-8674(86)90262-X; DELAHODDE A, 1989, CELL, V56, P431, DOI 10.1016/0092-8674(89)90246-8; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; JACQUIER A, 1987, CELL, V50, P17, DOI 10.1016/0092-8674(87)90658-1; JACQUIER A, 1990, TRENDS BIOCHEM SCI, V15, P351, DOI 10.1016/0968-0004(90)90075-M; LAMBOWITZ AM, 1989, CELL, V56, P323, DOI 10.1016/0092-8674(89)90232-8; MORL M, 1990, NUCLEIC ACIDS RES, V18, P6545, DOI 10.1093/nar/18.22.6545; MORL M, 1990, CELL, V60, P629, DOI 10.1016/0092-8674(90)90666-3; MUSCARELLA DE, 1989, CELL, V56, P443, DOI 10.1016/0092-8674(89)90247-X; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; QUIRK SM, 1989, CELL, V56, P455, DOI 10.1016/0092-8674(89)90248-1; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; WARING RB, 1986, NATURE, V321, P133, DOI 10.1038/321133a0; WENZLAU JM, 1989, CELL, V56, P421, DOI 10.1016/0092-8674(89)90245-6; WOODSON SA, 1989, CELL, V57, P335, DOI 10.1016/0092-8674(89)90971-9	18	53	56	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 4	1992	70	5					803	810		10.1016/0092-8674(92)90313-2	http://dx.doi.org/10.1016/0092-8674(92)90313-2			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JL663	1381286				2022-12-28	WOS:A1992JL66300011
J	SNOUWAERT, JN; BRIGMAN, KK; LATOUR, AM; MALOUF, NN; BOUCHER, RC; SMITHIES, O; KOLLER, BH				SNOUWAERT, JN; BRIGMAN, KK; LATOUR, AM; MALOUF, NN; BOUCHER, RC; SMITHIES, O; KOLLER, BH			AN ANIMAL-MODEL FOR CYSTIC-FIBROSIS MADE BY GENE TARGETING	SCIENCE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; IDENTIFICATION; PANCREAS; CLONING; CELLS	Cystic fibrosis results from defects in the gene encoding a cyclic adenosine monophosphate-dependent chloride ion channel known as the cystic fibrosis transmembrane conductance regulator (CFTR). To create an animal model for cystic fibrosis, mice were generated from embryonic stem cells in which the CFTR gene was disrupted by gene targeting. Mice homozygous for the disrupted gene display many features common to young human cystic fibrosis patients, including failure to thrive, meconium ileus, alteration of mucous and serous glands, and obstruction of glandlike structures with inspissated eosinophilic material. Death resulting from intestinal obstruction usually occurs before 40 days of age.	UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NHLBI NIH HHS [HL 42384] Funding Source: Medline; NIGMS NIH HHS [GM20069] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042384] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020069, R01GM020069] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersen DH, 1938, AM J DIS CHILD, V56, P344, DOI 10.1001/archpedi.1938.01980140114013; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; DISANTAGNESE PA, 1984, CYSTIC FIBROSIS, P212; DONNISON AB, 1966, PEDIATRICS, V37, P833; Dorin Julia R., 1992, Transgenic Research, V1, P101, DOI 10.1007/BF02513027; Farber S, 1944, ARCH PATHOL, V37, P0238; FOX WW, 1976, PEDIATRICS, V54, P293; GILMAN M, 1989, CURRENT PROTOCOLS MO; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KNOWLES ME, COMMUNICATION; KOLLER BH, 1991, P NATL ACAD SCI USA, V88, P10730, DOI 10.1073/pnas.88.23.10730; MARINO CR, 1991, J CLIN INVEST, V88, P712, DOI 10.1172/JCI115358; MCCARTHY VP, 1984, GASTROENTEROLOGY, V86, P564; Oppenheimer E H, 1975, Perspect Pediatr Pathol, V2, P241; OPPENHEIMER EH, 1973, ARCH PATHOL, V96, P149; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; STURGESS J, 1982, AM J PATHOL, V106, P303; TATA F, 1991, GENOMICS, V10, P301, DOI 10.1016/0888-7543(91)90312-3; TAUSSIG LM, 1984, CYSTIC FIBROSIS, P115; TREZISE AEO, 1991, NATURE, V353, P434, DOI 10.1038/353434a0	25	781	827	2	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 21	1992	257	5073					1083	1088		10.1126/science.257.5073.1083	http://dx.doi.org/10.1126/science.257.5073.1083			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ884	1380723				2022-12-28	WOS:A1992JJ88400024
J	STEINER, JP; DAWSON, TM; FOTUHI, M; GLATT, CE; SNOWMAN, AM; COHEN, N; SNYDER, SH				STEINER, JP; DAWSON, TM; FOTUHI, M; GLATT, CE; SNOWMAN, AM; COHEN, N; SNYDER, SH			HIGH BRAIN DENSITIES OF THE IMMUNOPHILIN FKBP COLOCALIZED WITH CALCINEURIN	NATURE			English	Article							CIS-TRANS ISOMERASE; A-BINDING-PROTEIN; T-CELL ACTIVATION; CYCLOPHILIN-CYCLOSPORINE-A; PEPTIDYL-PROLYL ISOMERASE; IMMUNOSUPPRESSANT FK506; FK506-BINDING PROTEIN; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; B-50 GAP-43	THE immunophilins cyclophilin and FK506 binding protein (FKBP) are small, predominantly soluble proteins that bind the immunosuppressant drugs cyclosporin A and FK506, respectively, with high affinity, and which seem to mediate their pharmacological actions1,2. The Ca2+-dependent protein phosphatase, calcineurin, binds the cyclophilin-cyclosporin A and FKBP-FK506 complexes, indicating that calcineurin might mediate the actions of these drugs3. A physiological role for the immunophilins in the nervous system is implied by a close homology between the structure of NINA A, a protein in the neural retina of Drosophila, and cyclophilin4,5, as well as by the high density of FKBP messenger RNA in brain tissue6. Here we report that the levels of FKBP and mRNA in rat brain are extraordinarily high and that their regional localization is virtually identical to that of calcineurin, indicating that there may be a physiological link between calcineurin and the immunophilins. We also show that at low concentrations FK506 and cyclosporin A enhance the phosphorylation of endogenous protein substrates in brain tissue and in intact PC12 cells, indicating that these drugs may inhibit phosphatase activity by interacting with the immunophilin-calcineurin complexes.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,725 N WOLFE ST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT BLOOD BANK,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT & BEHAV SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University				Cohen, Noam/0000-0002-9462-3932; Fotuhi, Majid/0000-0002-0980-1176				ANDREASEN TJ, 1983, BIOCHEMISTRY-US, V22, P4618; BENOWITZ LI, 1987, TRENDS NEUROSCI, V10, P527, DOI 10.1016/0166-2236(87)90135-4; BIERER BE, 1991, EUR J IMMUNOL, V21, P439, DOI 10.1002/eji.1830210228; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COGGINS PJ, 1991, J NEUROCHEM, V56, P1095, DOI 10.1111/j.1471-4159.1991.tb11398.x; DEKKER LV, 1989, NATURE, V342, P74, DOI 10.1038/342074a0; DUMONT FJ, 1990, J IMMUNOL, V144, P251; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; GOLDSMITH MA, 1988, SCIENCE, V240, P1029, DOI 10.1126/science.3259335; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HULTSCH T, 1991, P NATL ACAD SCI USA, V88, P6229, DOI 10.1073/pnas.88.14.6229; ITO A, 1989, BIOCHEM BIOPH RES CO, V163, P1492, DOI 10.1016/0006-291X(89)91148-0; KIMBALL PM, 1988, CELL IMMUNOL, V113, P107, DOI 10.1016/0008-8749(88)90010-X; KUNO T, 1989, BIOCHEM BIOPH RES CO, V165, P1352, DOI 10.1016/0006-291X(89)92752-6; LAD RP, 1991, MOL BRAIN RES, V9, P239, DOI 10.1016/0169-328X(91)90007-K; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MAKI N, 1990, P NATL ACAD SCI USA, V87, P5440, DOI 10.1073/pnas.87.14.5440; ROSS CA, 1989, P NATL ACAD SCI USA, V86, P2923, DOI 10.1073/pnas.86.8.2923; SCHNEUWLY S, 1989, P NATL ACAD SCI USA, V86, P5390, DOI 10.1073/pnas.86.14.5390; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHWARCZ R, 1983, SCIENCE, V219, P316, DOI 10.1126/science.6849138; SHIEH BH, 1989, NATURE, V338, P67, DOI 10.1038/338067a0; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; THOMSON AW, 1989, IMMUNOL TODAY, V10, P6, DOI 10.1016/0167-5699(89)90057-1; TRENN G, 1989, J IMMUNOL, V142, P3796; TRIGGIANI M, 1989, INT ARCH ALLER A IMM, V88, P253, DOI 10.1159/000234801	31	324	376	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 13	1992	358	6387					584	587		10.1038/358584a0	http://dx.doi.org/10.1038/358584a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH829	1380130				2022-12-28	WOS:A1992JH82900060
J	JONES, DJ				JONES, DJ			ABC OF COLORECTAL DISEASES - LARGE-BOWEL VOLVULUS	BRITISH MEDICAL JOURNAL			English	Article											JONES, DJ (corresponding author), HOPE HOSP,SALFORD M6 8HD,LANCS,ENGLAND.			Jones, David/0000-0001-5743-8562					0	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 8	1992	305	6849					358	360		10.1136/bmj.305.6849.358	http://dx.doi.org/10.1136/bmj.305.6849.358			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ032	1392890	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992JJ03200028
J	ANDREWS, NJ; JONES, DJ				ANDREWS, NJ; JONES, DJ			ABC OF COLORECTAL DISEASES - RECTAL PROLAPSE AND ASSOCIATED CONDITIONS	BRITISH MEDICAL JOURNAL			English	Article									HOPE HOSP,SALFORD M6 8HD,LANCS,ENGLAND		ANDREWS, NJ (corresponding author), PILGRIM HOSP,DEPT GEN SURG,BOSTON,LINCS,ENGLAND.								0	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1992	305	6847					243	246		10.1136/bmj.305.6847.243	http://dx.doi.org/10.1136/bmj.305.6847.243			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG112	1392834	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992JG11200034
J	VELAZQUEZ, L; FELLOUS, M; STARK, GR; PELLEGRINI, S				VELAZQUEZ, L; FELLOUS, M; STARK, GR; PELLEGRINI, S			A PROTEIN TYROSINE KINASE IN THE INTERFERON-ALPHA/BETA SIGNALING PATHWAY	CELL			English	Article							INDUCED NUCLEAR FACTORS; DOUBLE-STRANDED-RNA; TRANSCRIPTIONAL ACTIVATION; STIMULATED TRANSCRIPTION; PROMOTER ELEMENT; RESPONSE ELEMENT; SYNTHETASE GENE; DNA; BINDING; GAMMA	The mutant human cell line 11,1 is unresponsive to interferon-alpha. Here we describe the genetic complementation of this mutant and the identification and cloning of the wild-type gene that corrects the defect. Using transfection with genomic DNA in conjunction with a powerful back-selection, we isolated a cosmid that reverts the mutant phenotype of 11,1 cells. The cosmid encodes a single message whose level is greatly reduced in mutant cells. Complementary DNAs were cloned and found to be virtually identical to tyk2, a human mRNA encoding a non-receptor protein tyrosine kinase of previously unknown function. This finding shows that tyk2 links the interferon alpha/beta-receptor to the cytoplasmic transcription factor that mediates activation of interferon-responsive genes.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	Cancer Research UK	VELAZQUEZ, L (corresponding author), INST PASTEUR, INSERM, U276, F-75724 PARIS 15, FRANCE.		Pellegrini, Sandra/Y-6351-2019; Pellegrini, Sandra -/G-5546-2015	Pellegrini, Sandra/0000-0001-5837-7589; Pellegrini, Sandra -/0000-0001-5837-7589				ALLEN G, 1982, J GEN VIROL, V63, P207, DOI 10.1099/0022-1317-63-1-207; ATWATER JA, 1990, ANNU REV GENET, V24, P519; BERNARDS A, 1991, ONCOGENE, V6, P1185; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COBB BS, 1991, MOL CELL BIOL, V11, P5832, DOI 10.1128/MCB.11.12.5832; COHEN B, 1988, EMBO J, V7, P1411, DOI 10.1002/j.1460-2075.1988.tb02958.x; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DALE TC, 1989, EMBO J, V8, P831, DOI 10.1002/j.1460-2075.1989.tb03444.x; DECKER T, 1991, MOL CELL BIOL, V11, P5147, DOI 10.1128/MCB.11.10.5147; DELUCA JG, 1977, MUTAT RES, V46, P11, DOI 10.1016/0165-1161(77)90106-6; Demaeyer E., 1988, INTERFERONS OTHER RE; FAN XD, 1988, P NATL ACAD SCI USA, V85, P5122, DOI 10.1073/pnas.85.14.5122; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; JOHN J, 1991, MOL CELL BIOL, V11, P4189, DOI 10.1128/MCB.11.8.4189; KESSLER DS, 1991, J BIOL CHEM, V266, P23471; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KROLEWSKI JJ, 1990, ONCOGENE, V5, P277; LANGER JA, 1988, IMMUNOL TODAY, V9, P393, DOI 10.1016/0167-5699(88)91241-8; LEVY D, 1990, New Biologist, V2, P923; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1990, EMBO J, V9, P1105, DOI 10.1002/j.1460-2075.1990.tb08216.x; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1989, MOL CELL BIOL, V9, P5404, DOI 10.1128/MCB.9.12.5404; LITT M, 1985, P NATL ACAD SCI USA, V82, P6206, DOI 10.1073/pnas.82.18.6206; Maniatis T., 1982, MOL CLONING; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; MERLIN G, 1985, J GEN VIROL, V66, P1149, DOI 10.1099/0022-1317-66-5-1149; MOGENSEN KE, 1989, EXPERIENTIA, V45, P500, DOI 10.1007/BF01990498; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; PERUCHO M, 1980, NATURE, V285, P207, DOI 10.1038/285207a0; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PFEFFER LM, 1990, P NATL ACAD SCI USA, V87, P6537, DOI 10.1073/pnas.87.17.6537; PORTER ACG, 1988, EMBO J, V7, P85, DOI 10.1002/j.1460-2075.1988.tb02786.x; REICH NC, 1990, P NATL ACAD SCI USA, V87, P8761, DOI 10.1073/pnas.87.22.8761; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; Ruddle F. H., 1984, GENETIC ENG, V6, P319; RUTHERFORD MN, 1988, EMBO J, V7, P751, DOI 10.1002/j.1460-2075.1988.tb02872.x; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; TIWARI RK, 1988, MOL CELL BIOL, V8, P4289, DOI 10.1128/MCB.8.10.4289; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; Wahl G. M., 1987, METHOD ENZYMOL, V152, P199; WATHELET MG, 1989, EUR J BIOCHEM, V184, P503, DOI 10.1111/j.1432-1033.1989.tb15043.x; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILLIAMS BRG, 1991, EUR J BIOCHEM, V200, P1, DOI 10.1111/j.1432-1033.1991.tb21041.x	59	774	814	0	5	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 24	1992	70	2					313	322		10.1016/0092-8674(92)90105-L	http://dx.doi.org/10.1016/0092-8674(92)90105-L			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JE757	1386289				2022-12-28	WOS:A1992JE75700014
J	PACE, NR				PACE, NR			NEW HORIZONS FOR RNA CATALYSIS	SCIENCE			English	Editorial Material							EVOLUTION				PACE, NR (corresponding author), INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405, USA.							ABELSON J, 1990, SCIENCE, V249, P488, DOI 10.1126/science.1696394; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; PICCIRILLI JA, 1992, SCIENCE, V256, P1420, DOI 10.1126/science.1604316; Woese C.R., 1967, MOL BASIS GENETIC EX, P186; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987	7	5	5	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 5	1992	256	5062					1402	1403		10.1126/science.1376496	http://dx.doi.org/10.1126/science.1376496			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX337	1376496				2022-12-28	WOS:A1992HX33700022
J	SATIN, J; KYLE, JW; CHEN, M; BELL, P; CRIBBS, LL; FOZZARD, HA; ROGART, RB				SATIN, J; KYLE, JW; CHEN, M; BELL, P; CRIBBS, LL; FOZZARD, HA; ROGART, RB			A MUTANT OF TTX-RESISTANT CARDIAC SODIUM-CHANNELS WITH TTX-SENSITIVE PROPERTIES	SCIENCE			English	Article							VOLTAGE-DEPENDENT BLOCK; NA+ CHANNEL; SKELETAL-MUSCLE; PURKINJE-FIBERS; TETRODOTOXIN; SAXITOXIN; BINDING; HEART; MEMBRANES; RECEPTOR	The cardiac sodium channel alpha-subunit (RHI) is less sensitive to tetrodotoxin (TTX) and saxitoxin (STX and more sensitive to cadmium than brain and skeletal muscle (mu-l) isoforms. An RHI mutant, with Tyr substituted for Cys at position 374 (as in mu-l) confers three properties of TTX-sensitive channels: (i) greater sensitivity to TTX (730-fold); (ii) lower sensitivity to cadmium (28-fold); and (iii) altered additional block by toxin upon repetitive stimulation. Thus, the primary determinant of high-affinity TTX-STX binding is a critical aromatic residue at position 374, and the interaction may take place possibly through an ionized hydrogen bond. This finding requires revision of the sodium channel pore structure that has been previously suggested by homology with the potassium channel.	UNIV CHICAGO, DEPT PHARMACOL & PHYSIOL SCI, CHICAGO, IL 60637 USA; UNIV CHICAGO, COMM CELL PHYSIOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MED, MOLEC NEUROCARIOL LAB, CHICAGO, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago	SATIN, J (corresponding author), UNIV CHICAGO, DEPT MED, CARDIAC ELECTROPHYSIOL LAB, MC-6094, 5841 S MARYLAND AVE, CHICAGO, IL 60637 USA.				NHLBI NIH HHS [HL-20592, HL-37217] Funding Source: Medline; NINDS NIH HHS [NS 23360] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020592, R01HL037217] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023360] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARCHI RL, 1979, J PHYSIOL-LONDON, V295, P383, DOI 10.1113/jphysiol.1979.sp012975; BARCHI RL, 1987, TRENDS NEUROSCI, V10, P221, DOI 10.1016/0166-2236(87)90159-7; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; CARMELIET E, 1987, BIOPHYS J, V51, P109, DOI 10.1016/S0006-3495(87)83315-5; COHEN CJ, 1981, J GEN PHYSIOL, V78, P383, DOI 10.1085/jgp.78.4.383; CRIBBS LL, 1990, FEBS LETT, V275, P195, DOI 10.1016/0014-5793(90)81470-9; DIFRANCESCO D, 1985, PROC R SOC SER B-BIO, V223, P475, DOI 10.1098/rspb.1985.0013; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; EICKHORN R, 1990, PFLUG ARCH EUR J PHY, V416, P398, DOI 10.1007/BF00370746; FRELIN C, 1986, EUR J PHARMACOL, V122, P245, DOI 10.1016/0014-2999(86)90109-3; GONOI T, 1985, J NEUROSCI, V5, P2559; GREEN WN, 1987, J GEN PHYSIOL, V89, P873, DOI 10.1085/jgp.89.6.873; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HANCK DA, IN PRESS J PHYSL LON; HILLE B, 1975, BIOPHYS J, V15, P615, DOI 10.1016/S0006-3495(75)85842-5; Hille B., 1992, IONIC CHANNELS EXCIT; HU SL, 1991, J GEN PHYSIOL, V97, P561, DOI 10.1085/jgp.97.3.561; LONNENDONKER U, 1990, PFLUG ARCH EUR J PHY, V416, P750, DOI 10.1007/BF00370625; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; NODA M, 1989, FEBS LETT, V259, P213, DOI 10.1016/0014-5793(89)81531-5; PAPPONE PA, 1980, J PHYSIOL-LONDON, V306, P377, DOI 10.1113/jphysiol.1980.sp013403; PATTON DE, 1991, NEURON, V7, P637, DOI 10.1016/0896-6273(91)90376-B; REED JK, 1976, BIOCHEMISTRY-US, V15, P944, DOI 10.1021/bi00650a002; RENAUD JF, 1983, J BIOL CHEM, V258, P8799; RITCHIE JM, 1977, REV PHYSIOL BIOCH P, V79, P1, DOI 10.1007/BFb0037088; ROGART R, 1981, ANNU REV PHYSIOL, V43, P711, DOI 10.1146/annurev.ph.43.030181.003431; ROGART RB, 1986, ANN NY ACAD SCI, V479, P402, DOI 10.1111/j.1749-6632.1986.tb15585.x; ROGART RB, 1989, P NATL ACAD SCI USA, V86, P8170, DOI 10.1073/pnas.86.20.8170; SALGADO VL, 1986, ANN NY ACAD SCI, V479, P84, DOI 10.1111/j.1749-6632.1986.tb15563.x; SATIN J, UNPUB; SCHILD L, 1991, BIOPHYS J, V59, P523, DOI 10.1016/S0006-3495(91)82269-X; SHRAGER P, 1973, BIOCHIM BIOPHYS ACTA, V318, P141; SPALDING BC, 1980, J PHYSIOL-LONDON, V305, P485, DOI 10.1113/jphysiol.1980.sp013377; STRICHARTZ G, 1986, ANN NY ACAD SCI, V479, P96, DOI 10.1111/j.1749-6632.1986.tb15564.x; STRICHARTZ G, 1987, ANNU REV NEUROSCI, V10, P237; TERLAU H, 1991, FEBS LETT, V293, P93, DOI 10.1016/0014-5793(91)81159-6; TRIMMER JS, 1989, ANNU REV PHYSIOL, V51, P401, DOI 10.1146/annurev.physiol.51.1.401; VASSILEV PM, 1986, AM J PHYSIOL, V251, pH475, DOI 10.1152/ajpheart.1986.251.2.H475; WHITE MM, 1991, MOL PHARMACOL, V39, P604	40	336	345	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 22	1992	256	5060					1202	1205		10.1126/science.256.5060.1202	http://dx.doi.org/10.1126/science.256.5060.1202			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV192	1375397				2022-12-28	WOS:A1992HV19200036
J	ONEILL, D; GREGSON, R; MCHUGH, D				ONEILL, D; GREGSON, R; MCHUGH, D			CURRENT USES OF OPHTHALMIC LASERS	BRITISH MEDICAL JOURNAL			English	Review							OPEN-ANGLE GLAUCOMA; POSTERIOR CAPSULOTOMY; PARTIAL SIGHT; NEOVASCULARIZATION; TRABECULOPLASTY; REGISTRATION; BLINDNESS				ONEILL, D (corresponding author), MOORFIELDS EYE HOSP,LONDON EC1V 2PD,ENGLAND.							[Anonymous], 1981, OPHTHALMOLOGY, V88, P583; BOLDREY EE, 1989, OPHTHALMOLOGY, V96, P1430; CHISHOLM IH, 1983, T OPHTHAL SOC UK, V103, P354; FICKER LA, 1987, EYE-T OPHTH SOC UK, V1, P86, DOI 10.1038/eye.1987.13; GARTRY G, 1991, BR J OPHTHALMOL, V75, P258; GHAFOUR IM, 1983, BRIT J OPHTHALMOL, V67, P209, DOI 10.1136/bjo.67.4.209; GREY RHB, 1989, BRIT J OPHTHALMOL, V73, P88, DOI 10.1136/bjo.73.2.88; GUNDUZ K, 1989, BRIT J OPHTHALMOL, V73, P241, DOI 10.1136/bjo.73.4.241; HANNA IT, 1989, EYE, V3, P468, DOI 10.1038/eye.1989.70; HOSKINS HD, 1990, OPHTHALMIC SURG LAS, V21, P589; KOHNER E M, 1991, Eye (London), V5, P222; LESPERANCE FA, 1989, OPHTHALMIC LASERS, P13; MARSHALL J, 1988, EYE S, V2, P308; MCHUGH D, 1990, BRIT J OPHTHALMOL, V74, P743, DOI 10.1136/bjo.74.12.743; SCHUMAN JS, 1990, OPHTHALMOLOGY, V97, P571; SCHWARTZ AL, 1985, ARCH OPHTHALMOL-CHIC, V103, P1482; SEILER T, 1988, AM J OPHTHALMOL, V105, P117, DOI 10.1016/0002-9394(88)90173-0; SHIMIZU K, 1981, OPHTHALMOLOGY, V88, P601; THOMPSON JR, 1989, BRIT J OPHTHALMOL, V73, P95, DOI 10.1136/bjo.73.2.95; WARING GO, 1985, OPHTHALMOLOGY, V92, P177; 1991, ARCH OPHTHALMOL-CHIC, V109, P1220; 1990, Q B COLLEGE OPHT SPR, P1; 1986, ARCH OPHTHALMOL-CHIC, V104, P503	23	7	7	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 2	1992	304	6835					1161	1165		10.1136/bmj.304.6835.1161	http://dx.doi.org/10.1136/bmj.304.6835.1161			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT232	1392797	Green Published, Bronze			2022-12-28	WOS:A1992HT23200029
J	KOSLOWSKY, DJ; GORINGER, HU; MORALES, TH; STUART, K				KOSLOWSKY, DJ; GORINGER, HU; MORALES, TH; STUART, K			INVITRO GUIDE RNA MESSENGER-RNA CHIMERA FORMATION IN TRYPANOSOMA-BRUCEI RNA EDITING	NATURE			English	Article							LIGASE; DNA	THE post-transcriptional processing of various mitochondrial transcripts in kinetoplastids, kRNA editing, adds and removes uridines, producing mature messenger RNAs 1,2. This editing seems to be directed by 'guide' RNAs (gRNAs) which are complementary to portions of the mature message 3. The editing mechanism has been proposed to entail transesterification 4,5. Detection of chimaeric gRNA-mRNA molecules, intermediates predicted by transesterification, support this model 4. We report here the in vitro formation of such chimaeras where endogenous gRNAs are covalently linked to added synthetic mRNA. Addition of gel-purified gRNAs to the standard reaction mix increases chimaera formation. This increase is not observed when the gRNA 3'-hydroxyl group is chemically modified, identifying this terminal hydroxyl as the reactive group. These results provide the first experimental evidence for an in vitro RNA editing event and support the involvement of transesterification as a chemical mechanism.			KOSLOWSKY, DJ (corresponding author), SEATTLE BIOMED RES INST,4 NICKERSON ST,SEATTLE,WA 98109, USA.							BAKALARA N, 1989, J BIOL CHEM, V264, P18679; BHAT GJ, 1990, CELL, V61, P885, DOI 10.1016/0092-8674(90)90199-O; BLUM B, 1991, CELL, V65, P543, DOI 10.1016/0092-8674(91)90087-F; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BRUCE AG, 1978, NUCLEIC ACIDS RES, V5, P3665, DOI 10.1093/nar/5.10.3665; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; GORINGER HU, 1984, J BIOL CHEM, V259, P491; KOSLOWSKY DJ, 1991, CELL, V67, P537, DOI 10.1016/0092-8674(91)90528-7; KOSLOWSKY DJ, 1990, CELL, V62, P901, DOI 10.1016/0092-8674(90)90265-G; READ LK, IN PRESS NUCLEIC ACI; STUART K, 1983, J CELL BIOCHEM, V23, P13, DOI 10.1002/jcb.240230103; STUART K, 1991, TRENDS BIOCHEM SCI, V16, P68, DOI 10.1016/0968-0004(91)90027-S; Stuart K, 1991, CURR OPIN GENET DEV, V1, P412, DOI 10.1016/S0959-437X(05)80308-9	13	55	55	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1992	356	6372					807	809		10.1038/356807a0	http://dx.doi.org/10.1038/356807a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR186	1374163				2022-12-28	WOS:A1992HR18600055
J	SAYERS, RD; THOMPSON, MM; LONDON, NJM; BELL, PRF				SAYERS, RD; THOMPSON, MM; LONDON, NJM; BELL, PRF			LESSON OF THE WEEK - CRITICAL ISCHEMIA OF THE LOWER-LIMB - FEMORODISTAL BYPASS IN PREFERENCE TO AMPUTATION	BRITISH MEDICAL JOURNAL			English	Article							PULSE-GENERATED RUNOFF				SAYERS, RD (corresponding author), LEICESTER ROYAL INFIRM,DEPT SURG,CLIN SCI BLDG,LEICESTER LE2 7LX,ENGLAND.							BEARD JD, 1988, BRIT J SURG, V75, P361, DOI 10.1002/bjs.1800750422; Bell P, 1982, BR J SURG S, V69, pS2; BELL PRF, 1985, BRIT J SURG, V72, P335, DOI 10.1002/bjs.1800720502; SCOTT DJA, 1990, BRIT J SURG, V77, P391, DOI 10.1002/bjs.1800770412	4	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1992	304	6831					898	898		10.1136/bmj.304.6831.898	http://dx.doi.org/10.1136/bmj.304.6831.898			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM835	1392759	Green Published, Bronze			2022-12-28	WOS:A1992HM83500038
J	ADINOFF, A				ADINOFF, A			CHRONIC COUGH IN CHILDREN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											ADINOFF, A (corresponding author), UNIV COLORADO,HLTH SCI CTR,DENVER,CO 80262, USA.							ADINOFF AD, 1988, ANN ALLERGY, V61, P282; MCALISTER WH, 1989, AM J ROENTGENOL, V153, P1259, DOI 10.2214/ajr.153.6.1259; ROJAS AR, 1991, AM J RESPIR DIS, V12, P891	3	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1992	268	18					2572	2572		10.1001/jama.268.18.2572	http://dx.doi.org/10.1001/jama.268.18.2572			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW616	1404826				2022-12-28	WOS:A1992JW61600032
J	BERTONI, JM; BROWN, P; GOLDFARB, LG; RUBENSTEIN, R; GAJDUSEK, DC				BERTONI, JM; BROWN, P; GOLDFARB, LG; RUBENSTEIN, R; GAJDUSEK, DC			FAMILIAL CREUTZFELDT-JAKOB DISEASE (CODON-200 MUTATION) WITH SUPRANUCLEAR PALSY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective.-To identify a possible gene defect in a large kindred with atypical Creutzfeldt-Jakob disease (CJD). Subjects.-Over 360 kindred members, with and without progressive dementia. Methods.-Family, hospital, and clinic records were reviewed. The DNA was extracted from paraffin-embedded brain tissue of two deceased patients, and from blood leukocytes of nine healthy persons at risk. DNA was subjected to polymerase chain reaction and then analyzed by restriction endonuclease and single nucleotide primer extension. Results.-Nine family members had progressive fatal neurological disease consistent with CJD without myoclonus or typical electroencephalographic findings. Supranuclear gaze palsy was present in all five patients who underwent eye examinations. Two neuropathologically confirmed cases and five of nine at-risk family members had an identical mutation (GAG to AAG, glutamic acid to lysine) in codon 200 of the amyloid gene (PRNP) on chromosome 20. Conclusions.-Clinically atypical CJD with early supranuclear gaze palsy but without myoclonus or characteristic electroencephalographic periodicity patterns is associated with the codon 200Lys mutation in the largest CJD kindred yet reported. The clinical concept of familial CJD should be enlarged to include this unusual phenotype.	NINCDS,CNS STUDIES LAB,BETHESDA,MD 20892; NEW YORK STATE INST BASIC RES DEV DISABILITIES,STATEN ISL,NY 10314	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Institute for Basic Research in Developmental Disabilities	BERTONI, JM (corresponding author), CREIGHTON UNIV,DEPT NEUROL,601 N 30TH ST,SUITE 2342,OMAHA,NE 68131, USA.							BERTONI JM, 1983, ARCH NEUROL-CHICAGO, V40, P618, DOI 10.1001/archneur.1983.04050090054008; BROWN P, 1991, LANCET, V337, P1019, DOI 10.1016/0140-6736(91)92670-W; BROWN P, 1991, EUR J EPIDEMIOL, V7, P469, DOI 10.1007/BF00143124; GOLDFARB LG, 1990, LANCET, V336, P174, DOI 10.1016/0140-6736(90)91693-5; GOLDFARB LG, 1991, EUR J EPIDEMIOL, V7, P477, DOI 10.1007/BF00143125; HSIAO K, 1990, NEUROLOGY, V40, P1820, DOI 10.1212/WNL.40.12.1820; KAHANA E, 1991, NEUROLOGY, V41, P1390, DOI 10.1212/WNL.41.9.1390; KUPPUSWAMY MN, 1991, P NATL ACAD SCI USA, V88, P1143, DOI 10.1073/pnas.88.4.1143; TIETJEN GE, 1990, ANN NEUROL, V28, P585, DOI 10.1002/ana.410280420	9	51	51	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 4	1992	268	17					2413	2415		10.1001/jama.268.17.2413	http://dx.doi.org/10.1001/jama.268.17.2413			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV694	1404799				2022-12-28	WOS:A1992JV69400028
J	FRANZOSO, G; BOURS, V; PARK, S; TOMITAYAMAGUCHI, M; KELLY, K; SIEBENLIST, U				FRANZOSO, G; BOURS, V; PARK, S; TOMITAYAMAGUCHI, M; KELLY, K; SIEBENLIST, U			THE CANDIDATE ONCOPROTEIN BCL-3 IS AN ANTAGONIST OF P50/NF-KAPPA-B-MEDIATED INHIBITION	NATURE			English	Article							NF-KAPPA-B; DNA-BINDING SUBUNIT; REL-ASSOCIATED PP40; CELL-CYCLE CONTROL; HUMAN T-CELLS; P65 SUBUNIT; TRANSCRIPTION; CLONING; HOMOLOGY; PROTEIN	THE candidate oncogene bcl-3 was discovered as a translocation into the immunoglobulin alpha-locus in some cases of B-cell chronic lymphocytic leukaemias1. The protein Bcl-3 contains seven so-called ankyrin repeats. Similar repeat motifs are found in a number of diverse regulatory proteins but the motifs of Bcl-3 are most closely related to those found in I-kappa-B proteins in which the ankyrin repeat domain is thought to be directly involved in inhibition of NF-kappa-B activity. No biological function has yet been described for Bcl-3, but it was noted recently2 that Bcl-3 interferes with DNA-binding of the p50 subunit of NF-kappa-B in vitro. Here we demonstrate that Bcl-3 can aid kappa-B site-dependent transcription in vivo by counteracting the inhibitory effects of p50/NF-kappa-B homodimers. Bcl-3 may therefore aid activation of select NF-kappa-B-regulated genes, including those of the human immunodeficiency virus.	NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892; NCI,PATHOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Franzoso, Guido/GRR-8628-2022	Franzoso, Guido/0000-0002-0778-988X				BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GENDELMAN HE, 1986, P NATL ACAD SCI USA, V83, P9759, DOI 10.1073/pnas.83.24.9759; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; ISRAEL DI, 1989, NUCLEIC ACIDS RES, V17, P4589, DOI 10.1093/nar/17.12.4589; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LU D, 1991, ONCOGENE, V6, P1235; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; RIVIERE Y, 1991, NATURE, V350, P625, DOI 10.1038/350625a0; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; ZIPFEL PF, 1989, MOL CELL BIOL, V9, P1041, DOI 10.1128/MCB.9.3.1041	35	291	296	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 24	1992	359	6393					339	342		10.1038/359339a0	http://dx.doi.org/10.1038/359339a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP503	1406939	Green Published			2022-12-28	WOS:A1992JP50300063
J	HAASS, C; SCHLOSSMACHER, MG; HUNG, AY; VIGOPELFREY, C; MELLON, A; OSTASZEWSKI, BL; LIEBERBURG, I; KOO, EH; SCHENK, D; TEPLOW, DB; SELKOE, DJ				HAASS, C; SCHLOSSMACHER, MG; HUNG, AY; VIGOPELFREY, C; MELLON, A; OSTASZEWSKI, BL; LIEBERBURG, I; KOO, EH; SCHENK, D; TEPLOW, DB; SELKOE, DJ			AMYLOID BETA-PEPTIDE IS PRODUCED BY CULTURED-CELLS DURING NORMAL METABOLISM	NATURE			English	Article							ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; IDENTIFICATION; LOCALIZATION; TISSUES; BRAIN	ALZHEIMER's disease is characterized by the extracellular deposition in the brain and its blood vessels of insoluble aggregates of the amyloid beta-peptide (A-beta), a fragment, of about 40 amino acids in length, of the integral membrane protein beta-amyloid precursor protein (beta-APP)1. The mechanism of extracellular accumulation of A-beta in brain is unknown and no simple in vitro or in vivo model systems that produce extracellular A-beta have been described. We report here the unexpected identification of the 4K (M(r) 4,000) A-beta and a truncated form of A-beta (approximately 3K) in media from cultures of primary cells and untransfected and beta-APP-transfected cell lines grown under normal conditions. These peptides were immunoprecipitated readily from culture medium by A-beta-specific antibodies and their identities confirmed by sequencing. The concept that pathological processes are responsible for the production of A-beta must now be reassessed in light of the observation that A-beta is produced in soluble form in vitro and in vivo2 during normal cellular metabolism. Further, these findings provide the basis for using simple cell culture systems to identify drugs that block the formation or release of A-beta, the primary protein constituent of the senile plaques of Alzheimer's disease.	HARVARD UNIV,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02155; BRIGHAM & WOMENS HOSP,CTR NEUROL DIS,DEPT MED NEUROL,BOSTON,MA 02155; ATHENA NEUROSCI INC,S SAN FRANCISCO,CA 94090	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	HAASS, C (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02155, USA.			Schlossmacher, Michael/0000-0002-0394-0300				ANDERSON JP, IN PRESS J NEUROCHEM; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; GABUZDA D H, 1992, Neurology, V42, P304; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GREENBERG SM, 1988, BLOOD, V72, P1968; HAASS C, 1991, J NEUROSCI, V11, P3783; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; JOACHIM CL, 1989, NATURE, V341, P226, DOI 10.1038/341226a0; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; MORI H, 1992, J BIOL CHEM, V267, P17082; NORDSTEDT C, 1991, P NATL ACAD SCI USA, V88, P8910, DOI 10.1073/pnas.88.20.8910; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; PODLISNY MB, 1991, AM J PATHOL, V138, P1423; SELKOE DJ, 1989, NEUROBIOL AGING, V10, P387, DOI 10.1016/0197-4580(89)90072-9; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; TAMAOKA A, 1992, P NATL ACAD SCI USA, V89, P1345, DOI 10.1073/pnas.89.4.1345; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3	20	1739	1830	0	130	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 24	1992	359	6393					322	325		10.1038/359322a0	http://dx.doi.org/10.1038/359322a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JP503	1383826				2022-12-28	WOS:A1992JP50300057
J	NIGHTINGALE, SL				NIGHTINGALE, SL			TREATMENT IND GROUP-C DISTRIBUTION FOR ADVANCED METASTATIC OVARIAN-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	8	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 16	1992	268	11					1390	1390						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM849	1380995				2022-12-28	WOS:A1992JM84900003
J	TREMELLEN, J				TREMELLEN, J			ASSESSMENT OF PATIENTS AGED OVER 75 IN GENERAL-PRACTICE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED TRIAL; ELDERLY PEOPLE; HEALTH; CARE	Objectives-To evaluate the assessment scheme for people aged 75, to establish doctors' and nurses' views on the value of the assessment scheme, and to seek patients' opinions on elderly assessments. Design-Data on the assessment process were collected from individual practices. Questionnaires were sent to doctors and practice nurses undertaking assessments and to a sample of elderly patients. Subjects-31 565 patients aged 75 and over and all doctors registered with Wiltshire Family Health Services Authority, as well as practice nurses assessing elderly patients. A 2% random sample of elderly patients was selected to answer questions on patient satisfaction. Main outcome measures-Numbers of patients accepting the invitation for assessment, who carried out the assessments and where, what unmet needs were identified, and by whom. Results-20192 patients (64%) accepted the assessment offer. Doctors carried out 8786 assessments and nurses 10 779. Although 12 317 (61%) were carried out in the home, nurses did most domiciliary assessments (7122/11 883). Nurses with extra qualifications identified the highest number of unmet needs (400/1000 visits). 155 of 228 (68%) doctors thought assessments unnecessary whereas 25 of 48 (52%) of nurses thought them important. 93% of patients found assessment useful. Conclusions-Doctors see no merit in the scheme; most undertake assessments opportunistically and pick up few new problems. Nurses who see it as important require further training to fit them to do home visits confidently. Patients who were assessed found it worth while. The case for developing a specialist community nurse for elderly people should be investigated.			TREMELLEN, J (corresponding author), WILTSHIRE FAMILY HLTH SERV AUTHOR, TROWBRIDGE BA14 7JF, WILTS, ENGLAND.							Barber J H, 1980, J R Coll Gen Pract, V30, P49; BATCHELOR I, 1984, 1 NUFF PROV HOSP TRU; EBRAHIM S, 1984, BRIT MED J, V289, P1273, DOI 10.1136/bmj.289.6454.1273; FREER CB, 1987, J ROY COLL GEN PRACT, V37, P455; GRUNDY E, 1992, TXB GERIATRIC MED GE, P1; HAUG M, 1986, SELF CARE HLTH OLD A, P230; HENDRIKSEN C, 1984, BMJ-BRIT MED J, V289, P1522, DOI 10.1136/bmj.289.6457.1522; ILIFFE S, 1991, BRIT J GEN PRACT, V41, P9; ILIFFE S, 1991, BRIT J GEN PRACT, V41, P13; LUKER KA, 1979, HLTH VISITOR COMMUNI, V15, P457; MCEWAN RT, 1990, BRIT J GEN PRACT, V40, P94; REDFERN SJ, 1986, NURSING ELDERLY PEOP; TAYLOR R, 1983, RES PROSPECTIVES AGE; TAYLOR RC, 1987, 35 ROYAL COLL GEN PR; TREMELLEN J, 1989, J ROY COLL GEN PRACT, V39, P142; Tulloch A J, 1979, J R Coll Gen Pract, V29, P733; VETTER NJ, 1984, BRIT MED J, V288, P369, DOI 10.1136/bmj.288.6414.369; WALLACE P, 1990, BRIT J GEN PRACT, V40, P267; Wells N.E., 1988, AGEING POPULATION BU; WILLIAMS ES, 1985, BRIT MED J, V291, P251, DOI 10.1136/bmj.291.6490.251; WILLIAMSON J, 1964, LANCET, V1, P1117; WILLIAMSON J, 1987, 35 ROYAL COLL GEN PR; 1987, GENERAL HOUSEHOLD SU	23	23	23	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 12	1992	305	6854					621	624		10.1136/bmj.305.6854.621	http://dx.doi.org/10.1136/bmj.305.6854.621			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN698	1393077	Green Submitted, Bronze, Green Published			2022-12-28	WOS:A1992JN69800020
J	PIETRONI, PC				PIETRONI, PC			PARTNERS IN PRACTICE .7. BEYOND THE BOUNDARIES - RELATIONSHIP BETWEEN GENERAL-PRACTICE AND COMPLEMENTARY MEDICINE	BRITISH MEDICAL JOURNAL			English	Article											PIETRONI, PC (corresponding author), ST MARYS HOSP,SCH MED,LONDON,ENGLAND.							BEIER LM, 1987, SUFFERERS HEALERS EX, P38; DESSER A, IN PRESS J R COLL GE; FULDER S, 1981, STATUS COMPLEMENTARY; MCLEAN J, 1990, SOC SCI MED, V30, P591, DOI 10.1016/0277-9536(90)90157-N; PETERS D, IN PRESS J R COLL GE; PIETRONI PC, 1988, J R SOC ARTS, P791; REASON P, 1992, J ROY SOC MED, V85, P161; REASON P, 1991, J RES COUNCIL COMPLE, V5, P144; REILLY DT, 1983, BRIT MED J, V287, P337, DOI 10.1136/bmj.287.6388.337; WHARTON R, 1986, BRIT MED J, V292, P1498, DOI 10.1136/bmj.292.6534.1498; 1989, TIMES           1113; 1981, WHICH            AUG; 1991, REPORT OSTEOPATHY	13	28	28	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 5	1992	305	6853					564	566		10.1136/bmj.305.6853.564	http://dx.doi.org/10.1136/bmj.305.6853.564			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM495	1393039	Green Published, Green Submitted, hybrid			2022-12-28	WOS:A1992JM49500021
J	SCHNEIDER, A; MONTAGUE, P; GRIFFITHS, I; FANARRAGA, M; KENNEDY, PGE; BROPHY, P; NAVE, KA				SCHNEIDER, A; MONTAGUE, P; GRIFFITHS, I; FANARRAGA, M; KENNEDY, PGE; BROPHY, P; NAVE, KA			UNCOUPLING OF HYPOMYELINATION AND GLIAL-CELL DEATH BY A MUTATION IN THE PROTEOLIPID PROTEIN GENE	NATURE			English	Article							JIMPY MUTANT MOUSE; MESSENGER-RNA; MYELIN; MICE; EXPRESSION; PLP; OLIGODENDROCYTES; BACKGROUNDS; MEMBRANES; DEFECT	PROTEOLIPID protein (PLP; M(r) 30,000) is a highly conserved major polytopic membrane protein in myelin but its cellular function remains obscure. Neurological mutant mice can often provide model systems for human genetic disorders. Mutations of the X-chromosome-linked PLP gene are lethal, identified first in the jimpy mouse1,2 and subsequently in patients with Pelizaeus-Merzbacher disease3,4. The unexplained phenotype of these mutations includes degeneration and premature cell death of oligodendrocytes with associated hypomyelination5. Here we show that a new mouse mutant rumpshaker6 is defined by the amino-acid substitution Ile-to-Thr at residue 186 in a membrane-embedded domain of PLP. Surprisingly, rumpshaker mice, although myelin-deficient, have normal longevity and a full complement of morphologically normal oligodendrocytes7. Hypomyelination can thus be genetically separated from the PLP-dependent oligodendrocyte degeneration. We suggest that PLP has a vital function in glial cell development, distinct from its later role in myelin assembly, and that this dichotomy of action may explain the clinical spectrum8 of Pelizaeus-Merzbacher disease.	UNIV HEIDELBERG, ZENTRUM MOLEK BIOL, W-6900 HEIDELBERG, GERMANY; UNIV GLASGOW, APPL NEUROBIOL GRP, GLASGOW G61 1QH, SCOTLAND; UNIV STIRLING, DEPT BIOL & MOLEC SCI, STIRLING FK9 4LA, SCOTLAND	Ruprecht Karls University Heidelberg; University of Glasgow; University of Stirling			Fanarraga, Monica/AAE-5804-2019; Fanarraga, Mónica L./M-6177-2014; Nave, Klaus-Armin/C-8883-2011	Fanarraga, Monica/0000-0003-4754-311X; Fanarraga, Mónica L./0000-0003-4754-311X; 				BARTLETT WP, 1988, GLIA, V1, P253, DOI 10.1002/glia.440010404; BILLINGSGAGLIARDI S, 1980, BRAIN RES, V194, P325, DOI 10.1016/0006-8993(80)91215-9; BOISON D, 1989, EMBO J, V8, P3295, DOI 10.1002/j.1460-2075.1989.tb08490.x; CHALFIE M, 1990, NATURE, V345, P410, DOI 10.1038/345410a0; DAUTIGNY A, 1986, NATURE, V321, P867, DOI 10.1038/321867a0; DIEHL HJ, 1986, P NATL ACAD SCI USA, V83, P9807, DOI 10.1073/pnas.83.24.9807; FANARRAGA ML, 1992, GLIA, V5, P161, DOI 10.1002/glia.440050302; GENCIC S, 1990, J NEUROSCI, V10, P117; GRIFFITHS IR, 1990, J NEUROCYTOL, V19, P273, DOI 10.1007/BF01217305; HELYNCK G, 1983, EUR J BIOCHEM, V133, P689, DOI 10.1111/j.1432-1033.1983.tb07518.x; HUDSON LD, 1987, P NATL ACAD SCI USA, V84, P1454, DOI 10.1073/pnas.84.5.1454; HUDSON LD, 1989, P NATL ACAD SCI USA, V86, P8128, DOI 10.1073/pnas.86.20.8128; HUDSON LD, 1990, ANN NY ACAD SCI, V605, P155, DOI 10.1111/j.1749-6632.1990.tb42390.x; IKENAKA K, 1992, J NEUROCHEM, V58, P2248, DOI 10.1111/j.1471-4159.1992.tb10970.x; KNAPP PE, 1986, J NEUROSCI, V6, P2813; KTIMMERMAN V, IN PRESS NATURE GENE; MANFIOLETTI G, 1990, MOL CELL BIOL, V10, P2924, DOI 10.1128/MCB.10.6.2924; MEYER C, 1974, J NEUROPATHOL EXP NE, V33, P343; MILNER RJ, 1985, CELL, V42, P931, DOI 10.1016/0092-8674(85)90289-2; MITCHELL LS, IN PRESS J NEUROSCI; NAVE KA, 1987, P NATL ACAD SCI USA, V84, P5665, DOI 10.1073/pnas.84.16.5665; NAVE KA, 1989, CRIT REV NEUROBIOL, V5, P65; NAVE KA, 1986, P NATL ACAD SCI USA, V83, P9264, DOI 10.1073/pnas.83.23.9264; POPOT JL, 1991, J MEMBRANE BIOL, V120, P233, DOI 10.1007/BF01868534; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Sambrook J., 1989, MOL CLONING; SIDMAN RL, 1964, SCIENCE, V144, P309, DOI 10.1126/science.144.3616.309; SIETELBERGER F, 1970, HDB CLIN NEUROLOGY, P150; SKOFF RP, 1976, NATURE, V264, P560, DOI 10.1038/264560a0; SUTER U, 1992, NATURE, V356, P241, DOI 10.1038/356241a0; VERMEESCH MK, 1990, DEV NEUROSCI-BASEL, V12, P303, DOI 10.1159/000111859; WOLF MK, 1983, BRAIN RES, V271, P121, DOI 10.1016/0006-8993(83)91371-9	32	182	185	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 27	1992	358	6389					758	761		10.1038/358758a0	http://dx.doi.org/10.1038/358758a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JK699	1380672				2022-12-28	WOS:A1992JK69900054
J	CLARKE, LL; GRUBB, BR; GABRIEL, SE; SMITHIES, O; KOLLER, BH; BOUCHER, RC				CLARKE, LL; GRUBB, BR; GABRIEL, SE; SMITHIES, O; KOLLER, BH; BOUCHER, RC			DEFECTIVE EPITHELIAL CHLORIDE TRANSPORT IN A GENE-TARGETED MOUSE MODEL OF CYSTIC-FIBROSIS	SCIENCE			English	Article							POTENTIAL DIFFERENCE; AIRWAY EPITHELIUM; INTESTINAL TRANSPORT; TRACHEAL EPITHELIUM; ADENYLATE-CYCLASE; RECTAL MUCOSA; ION-TRANSPORT; SECRETION; ACTIVATION; CHANNELS	The cystic fibrosis transmembrane conductance regulator (CFTR) gene encodes an adenosine 3',5'-monophosphate (cyclic AMP)-activated chloride channel. In cystic fibrosis (CF) patients, loss of CFTR function because of a genetic mutation results in defective cyclic AMP-mediated chloride secretion across epithelia. Because of their potential role as an animal model for CF, mice with targeted disruption of the murine CFTR gene [CFTR(-/-)] were tested for abnormalities in epithelial chloride transport. In both freshly excised tissue from the intestine and in cultured epithelia from the proximal airways, the cyclic AMP-activated chloride secretory response was absent in CFTR(-/-) mice as compared to littermate controls. Thus, disruption of the murine CFTR gene results in the chloride transport abnormalities predicted from studies of human CF epithelia.	UNIV N CAROLINA,DEPT MED,DIV PULM DIS,CHAPEL HILL,NC 27514	University of North Carolina; University of North Carolina Chapel Hill			Clarke, Lane L/AAK-2866-2020	Clarke, Lane L/0000-0002-4938-6261	NHLBI NIH HHS [HL 42384] Funding Source: Medline; NIGMS NIH HHS [GM20069] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042384] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020069, R01GM020069] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; BAXTER P, 1990, GUT, V31, P817, DOI 10.1136/gut.31.7.817; BAXTER PS, 1989, LANCET, V1, P464; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BERSCHNEIDER HM, 1988, FASEB J, V2, P2625, DOI 10.1096/fasebj.2.10.2838365; BERSCHNEIDER HM, 1987, GASTROENTEROLOGY, V92, P1315; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; CAREY HV, 1989, AM J PHYSIOL, V256, pR481, DOI 10.1152/ajpregu.1989.256.2.R481; CAREY HV, 1989, DIGEST DIS SCI, V34, P185, DOI 10.1007/BF01536049; CLARKE LL, IN PRESS AM J PHYSL; DEJONGE HR, 1989, BIOCHEM SOC T, V17, P816, DOI 10.1042/bst0170816; EGGERMONT E, 1991, EUR J PEDIATR, V150, P824, DOI 10.1007/BF01954999; FRIZZELL RA, 1986, SCIENCE, V233, P558, DOI 10.1126/science.2425436; GOLDSTEIN JL, 1991, GASTROENTEROLOGY, V101, P1012, DOI 10.1016/0016-5085(91)90728-4; HAAS M, 1989, ANNU REV PHYSIOL, V51, P443, DOI 10.1146/annurev.physiol.51.1.443; HARDCASTLE J, 1991, GUT, V32, P1035, DOI 10.1136/gut.32.9.1035; HARDCASTLE J, 1987, MED SCI RES-BIOCHEM, V15, P471; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; JORIS L, 1989, PFLUG ARCH EUR J PHY, V415, P118, DOI 10.1007/BF00373149; KNOWLES MR, 1983, SCIENCE, V221, P1067, DOI 10.1126/science.6308769; KNOWLES MR, 1991, NEW ENGL J MED, V325, P533, DOI 10.1056/NEJM199108223250802; MASON SJ, 1991, BRIT J PHARMACOL, V103, P1649, DOI 10.1111/j.1476-5381.1991.tb09842.x; OLOUGHLIN EV, 1991, AM J PHYSIOL, V260, pG758, DOI 10.1152/ajpgi.1991.260.5.G758; ORLANDO RC, 1989, GASTROENTEROLOGY, V96, P1041, DOI 10.1016/0016-5085(89)91621-1; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; SHELDON RJ, 1989, J PHARMACOL EXP THER, V249, P572; SNOUWAERT J, 1992, SCIENCE, V253, P257; STUTTS MJ, 1992, P NATL ACAD SCI USA, V89, P1621, DOI 10.1073/pnas.89.5.1621; TAYLOR CJ, 1988, GUT, V29, P957, DOI 10.1136/gut.29.7.957; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; WIDDICOMBE JH, 1985, P NATL ACAD SCI USA, V82, P6167, DOI 10.1073/pnas.82.18.6167; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC1045, DOI 10.1152/ajpcell.1989.256.5.C1045; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC1033, DOI 10.1152/ajpcell.1989.256.5.C1033; Willumsen NJ, 1989, AM J PHYSIOL, V256, pC1054, DOI 10.1152/ajpcell.1989.256.5.C1054; Yankaskas J R, 1987, Prog Clin Biol Res, V254, P139	36	276	294	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 21	1992	257	5073					1125	1128		10.1126/science.257.5073.1125	http://dx.doi.org/10.1126/science.257.5073.1125			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ884	1380724				2022-12-28	WOS:A1992JJ88400035
J	OKAMOTO, Y				OKAMOTO, Y			HEALTH-CARE FOR THE ELDERLY IN JAPAN - MEDICINE AND WELFARE IN AN AGING SOCIETY FACING A CRISIS IN LONG-TERM CARE	BRITISH MEDICAL JOURNAL			English	Article											OKAMOTO, Y (corresponding author), HANNAN CHUO HOSP,DEPT INTERNAL MED & HOME CARE,3-3-28 MINAMISHINMACHI,MATSUBARA,OSAKA 580,JAPAN.							ANDERSEN BR, 1990, KOSEIFUKUSHI J, P2; CHARLTON JRH, 1986, BRIT MED J, V292, P295, DOI 10.1136/bmj.292.6516.295; HASEGAWA T, 1990, J HLTH WELFARE STATI, V36, P23; HENDRICS J, 1986, AGING MASS SOC MYTHS; HIATT HH, 1987, AM HLTH BALANCE CHOI; IGLEHEART JK, 1989, NEW ENGL J MED, V319, P1166; IGLEHEART JK, 1989, NEW ENGL J MED, V319, P807; MARMOT MG, 1989, BMJ, V99, P23; MENDERSON MA, 1975, TENDER LOVING GREED; MUNDINGWER MO, 1983, HOME CARE CONTROVERS; OKAMOTO Y, 1984, AM NO IRYO TO KANGO; PEGLES CC, 1981, HLTH CARE ELDERLY; SHIEBER G, 1989, HLTH AFF         FAL, P169; SHIMAMOTO T, 1989, CIRCULATION, V79, P503, DOI 10.1161/01.CIR.79.3.503; SHIRAISHI M, 1986, J HLTH WELFARE STATI, V33, P200; SUGAYA Y, 1990, J HLTH WELFARE STATI, V137, P8; Vladeck B.C., 1980, UNLOVING CARE NURSIN; YAMAMOTO M, 1989, J HLTH WELFARE STATI, V36, P13; 1987, OECD SOCIAL POLICY S, P37; 1992, ANN REPORT 1990 91; 1989, NETAKIRI ZERO MEZASH; 1989, J HLTH WELFARE STATI, V36, P91; 1992, NIPPON CHARTED SURVE; 1991, SHAKAI HOKEN JUNPO J, P28	24	26	26	1	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 15	1992	305	6850					403	405		10.1136/bmj.305.6850.403	http://dx.doi.org/10.1136/bmj.305.6850.403			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JK314	1392924	Green Submitted, Bronze, Green Published			2022-12-28	WOS:A1992JK31400020
J	WANG, HY; WATKINS, DC; MALBON, CC				WANG, HY; WATKINS, DC; MALBON, CC			ANTISENSE OLIGODEOXYNUCLEOTIDES TO G(S) PROTEIN ALPHA-SUBUNIT SEQUENCE ACCELERATE DIFFERENTIATION OF FIBROBLASTS TO ADIPOCYTES	NATURE			English	Article							MESSENGER-RNA LEVELS; ADIPOSE CELL LINE; 3T3-L1 CELLS; ADENYLATE-CYCLASE; BETA-SUBUNITS; INHIBITION; STIMULATION; CONVERSION; EXPRESSION; RECEPTOR	FULLY-DIFFERENTIATED mouse 3T3-L1 fibroblasts accumulate large amounts of lipid at 7-10 days after induction by insulin or by dexamethasone and a methyl xanthine1-3. G proteins mediate transmembrane signalling from a diverse group of cell-surface receptors to effector units that include phospholipase C, adenylyl cyclase and ion channels4-6. They are also targets or regulation themselves7-10. 3T3-L1 fibroblasts display marked changes in levels of G protein when induced to differentiate to adipocytes11-15. Here we show that cholera toxin, which ADP-ribosylates and activates the G protein subunit G(s-alpha), blocks the induction of differentiation, whereas increasing intracellular cyclic AMP directly with the dibutyryl analogue or indirectly with pertussis toxin or forskolin does not affect differentiation. Oligodeoxynucleotides antisense to the sequence encoding G(s-alpha) accelerate differentiation markedly. The time course of adipogenesis declined from 7-10 days in controls to roughly 3 days in cultures treated with antisense-G(s-alpha) oligodeoxynucleotides, whereas oligodeoxynucleotides, antisense to G(i-alpha-1), G(i-alpha-3), and sense and missense to G(s-alpha), had no such effect. Antisense-G(s-alpha) alone induced differentiation by day 7, indicating that G(s-alpha) activity modulates differentiation in 3T3-L1 cells, acting in a new role which is independent of increased intracellular cAMP.	SUNY HLTH SCI CTR,DEPT PHARMACOL,DIABET & METAB DIS RES PROGRAM,STONY BROOK,NY 11794; NATL DEF MED CTR,DEPT BIOCHEM,TAIPEI 10764,TAIWAN	State University of New York (SUNY) System; National Defense Medical Center			malbon, craig/ABF-3604-2020					BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; GIERSCHIK P, 1986, FEBS LETT, V199, P103, DOI 10.1016/0014-5793(86)81233-9; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; HADCOCK JR, 1990, J BIOL CHEM, V265, P14784; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; LAI E, 1981, J BIOL CHEM, V256, P2866; MAGUIRE ME, 1980, J BIOL CHEM, V255, P1030; MALBON CC, 1988, TRENDS PHARMACOL SCI, V9, P33, DOI 10.1016/0165-6147(88)90240-4; MALBON CC, 1985, J BIOL CHEM, V260, P2558; ROS M, 1989, BIOCHEM J, V260, P271, DOI 10.1042/bj2600271; ROS M, 1988, J BIOL CHEM, V263, P4632; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; RUSSELL TR, 1976, P NATL ACAD SCI USA, V73, P4516, DOI 10.1073/pnas.73.12.4516; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; WATKINS DC, 1989, BIOCHEM BIOPH RES CO, V165, P929, DOI 10.1016/0006-291X(89)92692-2; WATKINS DC, 1987, J BIOL CHEM, V262, P10651; WATKINS DC, 1989, J BIOL CHEM, V264, P4186; YATANI A, 1988, J BIOL CHEM, V263, P9887	22	148	151	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 23	1992	358	6384					334	337		10.1038/358334a0	http://dx.doi.org/10.1038/358334a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE684	1379345				2022-12-28	WOS:A1992JE68400065
J	LIESCHKE, GJ; BURGESS, AW				LIESCHKE, GJ; BURGESS, AW			DRUG-THERAPY - GRANULOCYTE COLONY-STIMULATING FACTOR AND GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTOR .1.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HUMAN GM-CSF; HEMATOPOIETIC GROWTH-FACTORS; TRANSITIONAL-CELL-CARCINOMA; NECROSIS FACTOR-ALPHA; MOLECULAR-CLONING; PROGENITOR CELLS; PHASE-I; BIOLOGICAL-ACTIVITY; ADVANCED MALIGNANCY; ENZYME-IMMUNOASSAY				LIESCHKE, GJ (corresponding author), ROYAL MELBOURNE HOSP, LUDWIG INST CANC RES, MELBOURNE TUMOUR BIOL BRANCH, PARKVILLE, VIC 3050, AUSTRALIA.			Lieschke, Graham/0000-0003-0325-798X				ADDISON IE, 1989, CLIN EXP IMMUNOL, V76, P149; AGLIETTA M, 1989, J CLIN INVEST, V83, P551, DOI 10.1172/JCI113917; ANTMAN KS, 1988, NEW ENGL J MED, V319, P593, DOI 10.1056/NEJM198809083191001; ASANO S, 1988, Behring Institute Mitteilungen, P222; BODEY GP, 1966, ANN INTERN MED, V64, P328, DOI 10.7326/0003-4819-64-2-328; BRONCHUD MH, 1988, BRIT J CANCER, V58, P64, DOI 10.1038/bjc.1988.163; BRONCHUD MH, 1987, BRIT J CANCER, V56, P809, DOI 10.1038/bjc.1987.295; BROWN SL, 1991, NEW ENGL J MED, V325, P587; BURGESS AW, 1987, BLOOD, V69, P43; CANTRELL MA, 1985, P NATL ACAD SCI USA, V82, P6250, DOI 10.1073/pnas.82.18.6250; CEBON J, 1992, BRIT J HAEMATOL, V80, P144, DOI 10.1111/j.1365-2141.1992.tb08891.x; CEBON J, 1990, J BIOL CHEM, V265, P4483; CEBON J, 1988, BLOOD, V72, P1340; CEBON JS, 1990, EUR J CANCER, V26, P1064, DOI 10.1016/0277-5379(90)90053-V; CRAWFORD J, 1991, NEW ENGL J MED, V325, P164, DOI 10.1056/NEJM199107183250305; DAVEY RT, 1991, J INFECT DIS, V164, P43, DOI 10.1093/infdis/164.1.43; DEVEREUX S, 1989, BRIT J HAEMATOL, V71, P323; DEVEREUX S, 1987, LANCET, V2, P1523; DEVRIES EGE, 1991, LANCET, V338, P517, DOI 10.1016/0140-6736(91)90594-F; DONAHUE RE, 1986, COLD SPRING HARB SYM, V51, P685, DOI 10.1101/SQB.1986.051.01.081; DUHRSEN U, 1988, BLOOD, V72, P2074; ERSLEV AJ, 1991, NEW ENGL J MED, V324, P1339, DOI 10.1056/NEJM199105093241907; GABRILOVE JL, 1988, NEW ENGL J MED, V318, P1414, DOI 10.1056/NEJM198806023182202; GABRILOVE JL, 1988, J CLIN INVEST, V82, P1454, DOI 10.1172/JCI113751; GILLIS S, 1988, BEHRING I MITT, V83, P1; GLASPY JA, 1988, ANN INTERN MED, V109, P789, DOI 10.7326/0003-4819-109-10-789; GOUGH NM, 1984, NATURE, V309, P763, DOI 10.1038/309763a0; GRIBBEN JG, 1990, LANCET, V335, P434, DOI 10.1016/0140-6736(90)90665-R; GRIFFIN JD, 1984, BLOOD, V63, P904; GROOPMAN JE, 1989, NEW ENGL J MED, V321, P1449, DOI 10.1056/NEJM198911233212106; HAZENBERG BPC, 1989, BLOOD, V74, P2769, DOI 10.1182/blood.V74.8.2769.2769; HERRMANN F, 1989, J CLIN ONCOL, V7, P159, DOI 10.1200/JCO.1989.7.2.159; HOEKMAN K, 1991, LANCET, V338, P541, DOI 10.1016/0140-6736(91)91103-2; KAIYESIMI I, 1991, NEW ENGL J MED, V325, P587; KAPLAN SS, 1989, BLOOD, V73, P636; KAWAKAMI M, 1990, BLOOD, V76, P1962; KITAMURA T, 1989, BLOOD, V73, P375; LAYTON JE, 1989, BLOOD, V74, P1303; LAYTON JE, 1991, EXP HEMATOL, V19, P506; LIESCHKE GJ, 1989, ANN INTERN MED, V110, P357, DOI 10.7326/0003-4819-110-5-357; LIESCHKE GJ, 1990, CANCER RES, V50, P606; LIESCHKE GJ, 1989, BLOOD, V74, P2634; LIESCHKE GJ, 1990, HEMATOPOIETIC GROWTH, P191; LIESCHKE GJ, IN PRESS 2ND P INT S; LINDEMANN A, 1989, BLOOD, V74, P2644; LOGOTHETIS CJ, 1990, J NATL CANCER I, V82, P667, DOI 10.1093/jnci/82.8.667; LORD BI, 1989, P NATL ACAD SCI USA, V86, P9499, DOI 10.1073/pnas.86.23.9499; LORD BI, 1992, INT J CANCER, V50, P26, DOI 10.1002/ijc.2910500107; MAYER P, 1987, BLOOD, V70, P206; METCALF D, 1991, BIOL THERAPY CANC, P417; MILES SA, 1991, BLOOD, V77, P2109; MOONEN P, 1987, P NATL ACAD SCI USA, V84, P4428, DOI 10.1073/pnas.84.13.4428; MOORE MAS, 1991, BLOOD, V78, P1; MORSTYN G, 1988, CANCER RES, V48, P5624; MORSTYN G, 1988, LANCET, V1, P667, DOI 10.1016/S0140-6736(88)91475-4; MORSTYN G, 1989, J CLIN ONCOL, V7, P1554, DOI 10.1200/JCO.1989.7.10.1554; MOTOJIMA H, 1989, J IMMUNOL METHODS, V118, P187, DOI 10.1016/0022-1759(89)90005-7; NAGATA S, 1986, NATURE, V319, P415, DOI 10.1038/319415a0; NATHAN FE, 1992, NEW ENGL J MED, V326, P904; NATHAN FE, 1992, NEW ENGL J MED, V326, P417; NEMUNAITIS J, 1991, NEW ENGL J MED, V324, P1773, DOI 10.1056/NEJM199106203242504; NIMER SD, 1988, JAMA-J AM MED ASSOC, V260, P3297, DOI 10.1001/jama.260.22.3297; PETERS WP, 1988, LANCET, V1, P950; PHILLIPS N, 1989, BLOOD, V74, P26; SHADDUCK R K, 1990, Experimental Hematology (Charlottesville), V18, P601; SIMON RM, 1989, CANCER PRINCIPLES PR, V1, P396; SOCINSKI MA, 1988, BLOOD, V72, P691; SOCINSKI MA, 1988, LANCET, V1, P1194; SOUZA LM, 1986, SCIENCE, V232, P61, DOI 10.1126/science.2420009; STEHLE B, 1990, BLOOD, V75, P1895; STEWARD WP, 1989, BRIT J CANCER, V59, P142, DOI 10.1038/bjc.1989.28; SULLIVAN R, 1989, BRIT J HAEMATOL, V71, P475, DOI 10.1111/j.1365-2141.1989.tb06305.x; THOMPSON JA, 1989, J CLIN ONCOL, V7, P629, DOI 10.1200/JCO.1989.7.5.629; VILLEVAL JL, 1990, BRIT J HAEMATOL, V74, P36, DOI 10.1111/j.1365-2141.1990.tb02535.x; WATARI K, 1989, BLOOD, V73, P117; WELTE K, 1990, BLOOD, V75, P1056; WILLIAMS WJ, 1990, HEMATOLOGY, P24; WING EJ, 1989, BLOOD, V73, P643; WITTE, 1990, CELL, V63, P1113; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; WODZINSKI MA, 1991, BRIT J HAEMATOL, V77, P249, DOI 10.1111/j.1365-2141.1991.tb07987.x; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; ZSEBO KM, 1986, IMMUNOBIOLOGY, V172, P175, DOI 10.1016/S0171-2985(86)80097-3; 1991, IMMUNEX; 1991, NEUPOGEN PRODUCT MON, P41; 1991, AMGEN	86	648	662	3	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 2	1992	327	1					28	35						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA761	1375975				2022-12-28	WOS:A1992JA76100006
J	CHAO, NJ; LONG, GD; NEGRIN, RS; SCHRIBER, JR; RAIMONDI, CM; BROWN, SL; BLUME, KG				CHAO, NJ; LONG, GD; NEGRIN, RS; SCHRIBER, JR; RAIMONDI, CM; BROWN, SL; BLUME, KG			G-CSF AND PERIPHERAL-BLOOD PROGENITOR CELLS	LANCET			English	Letter									AMGEN INC,THOUSAND OAKS,CA	Amgen	CHAO, NJ (corresponding author), STANFORD UNIV,MED CTR,BONE MARROW TRANSPLANT PROGRAM,STANFORD,CA 94305, USA.			Leone, Giuseppe/0000-0002-7812-5300				ADVANI R, 1992, ANN INTERN MED, V116, P183, DOI 10.7326/0003-4819-116-3-183; DEMETRI GD, 1991, BLOOD, V78, P2791; NEMUNAITIS J, 1988, BLOOD, V72, P834; SHERIDAN, 1992, LANCET, V339, P640	4	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 6	1992	339	8806					1410	1410		10.1016/0140-6736(92)91227-Y	http://dx.doi.org/10.1016/0140-6736(92)91227-Y			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX636	1375969				2022-12-28	WOS:A1992HX63600025
J	FILSHIE, GM; MAYNARD, P; HUTTER, C; COOPER, JC; ROBINSON, G; RUBIN, P				FILSHIE, GM; MAYNARD, P; HUTTER, C; COOPER, JC; ROBINSON, G; RUBIN, P			URINARY 5-HYDROXYINDOLE ACETATE CONCENTRATION IN PREGNANCY INDUCED HYPERTENSION	BRITISH MEDICAL JOURNAL			English	Article							ECLAMPSIA				FILSHIE, GM (corresponding author), UNIV NOTTINGHAM HOSP,QUEENS MED CTR,DEPT PATHOL,NOTTINGHAM NG7 2UH,ENGLAND.							HORN EH, 1990, BRIT MED J, V301, P794, DOI 10.1136/bmj.301.6755.794; JAAMERI KEU, 1965, GYNAECOLOGIA, V160, P315; JELEN I, 1979, BRIT J OBSTET GYNAEC, V86, P468, DOI 10.1111/j.1471-0528.1979.tb10791.x; WEINER CP, 1987, AM J OBSTET GYNECOL, V156, P885, DOI 10.1016/0002-9378(87)90345-0; WHIGHAM KAE, 1978, BRIT J OBSTET GYNAEC, V85, P28, DOI 10.1111/j.1471-0528.1978.tb15820.x	5	13	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 9	1992	304	6836					1223	1223		10.1136/bmj.304.6836.1223	http://dx.doi.org/10.1136/bmj.304.6836.1223			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT964	1381251	Green Published, Bronze			2022-12-28	WOS:A1992HT96400023
J	BOSCH, X; SOBRINO, J; LOPEZSOTO, A; URBANOMARQUEZ, A				BOSCH, X; SOBRINO, J; LOPEZSOTO, A; URBANOMARQUEZ, A			PAROTITIS DUE TO NICARDIPINE	BRITISH MEDICAL JOURNAL			English	Letter							STABLE ANGINA; HYPERTENSION; EFFICACY; SAFETY				BOSCH, X (corresponding author), HOSP CLIN BARCELONA,E-08036 BARCELONA,SPAIN.							AGRE K, 1987, AM J CARDIOL, V59; BOSCH X, 1986, LANCET, V2, P467; CHEN JH, 1977, JAMA-J AM MED ASSOC, V238, P1399, DOI 10.1001/jama.238.13.1399; DUBOIS C, 1989, CLIN THER, V11, P452; GHEORGHIADE M, 1989, EUR HEART J, V10, P695, DOI 10.1093/oxfordjournals.eurheartj.a059553; MARDH PA, 1974, ACTA MED SCAND, V195, P333; MASSIMO C, 1988, AM J CARDIOL, V61, P874, DOI 10.1016/0002-9149(88)91093-4; PELLINEN TJ, 1982, BRIT MED J, V285, P344, DOI 10.1136/bmj.285.6338.344; SCHEIDT S, 1986, AM J CARDIOL, V58, P715, DOI 10.1016/0002-9149(86)90343-7; WALLIN JD, 1988, AM J MED, V85, P331, DOI 10.1016/0002-9343(88)90582-7	10	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1992	304	6831					882	882		10.1136/bmj.304.6831.882-a	http://dx.doi.org/10.1136/bmj.304.6831.882-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM835	1392752	Green Published, Bronze			2022-12-28	WOS:A1992HM83500029
J	FAHAL, IH; WILLIAMS, PS; CLARK, RE; BELL, GM				FAHAL, IH; WILLIAMS, PS; CLARK, RE; BELL, GM			THROMBOTIC THROMBOCYTOPENIC PURPURA DUE TO RIFAMPICIN	BRITISH MEDICAL JOURNAL			English	Letter											FAHAL, IH (corresponding author), ROYAL LIVERPOOL UNIV HOSP,LIVERPOOL L7 8XP,ENGLAND.		Fahal, Ibrahim/ABC-1366-2021	Fahal, Ibrahim/0000-0003-4897-6427				AHMED F, 1987, ARCH INTERN MED, V138, P1292; AMOROSI EL, 1966, MEDICINE, V45, P139, DOI 10.1097/00005792-196603000-00003; MCSHANE PM, 1983, AM J OBSTET GYNECOL, V145, P762, DOI 10.1016/0002-9378(83)90588-4; PARKER JC, 1971, ARCH INTERN MED, V127, P474, DOI 10.1001/archinte.127.3.474; POOLE G, 1971, BMJ-BRIT MED J, V3, P343, DOI 10.1136/bmj.3.5770.343	5	13	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1992	304	6831					882	882		10.1136/bmj.304.6831.882	http://dx.doi.org/10.1136/bmj.304.6831.882			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM835	1392753	Green Published, Bronze			2022-12-28	WOS:A1992HM83500028
J	SURENDRAKUMAR, D; DUNN, M; ROBERTS, CJC				SURENDRAKUMAR, D; DUNN, M; ROBERTS, CJC			HOSPITAL ADMISSION AND THE START OF BENZODIAZEPINE USE	BRITISH MEDICAL JOURNAL			English	Article									BRISTOL ROYAL INFIRM & GEN HOSP,BRISTOL BS2 8HW,AVON,ENGLAND	Bristol Royal Infirmary								Ashton H, 1986, ADVERSE DRUG REACT, V118, P440; CATALAN J, 1985, BMJ-BRIT MED J, V290, P1374, DOI 10.1136/bmj.290.6479.1374; EDWARDS C, 1991, BRIT J CLIN PHARMACO, V31, P190, DOI 10.1111/j.1365-2125.1991.tb05513.x; SHAN K, 1990, J ROY SOC MED, V83, P306, DOI 10.1177/014107689008300509; TREWIN VF, 1986, BR J PHARM PRACT, V8, P359	5	21	21	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1992	304	6831					881	881		10.1136/bmj.304.6831.881	http://dx.doi.org/10.1136/bmj.304.6831.881			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM835	1392750	Green Published, Bronze			2022-12-28	WOS:A1992HM83500027
J	GORDEUK, V; THUMA, P; BRITTENHAM, G; MCLAREN, C; PARRY, D; BACKENSTOSE, A; BIEMBA, G; MSISKA, R; HOLMES, L; MCKINLEY, E; VARGAS, L; GILKESON, R; POLTERA, AA				GORDEUK, V; THUMA, P; BRITTENHAM, G; MCLAREN, C; PARRY, D; BACKENSTOSE, A; BIEMBA, G; MSISKA, R; HOLMES, L; MCKINLEY, E; VARGAS, L; GILKESON, R; POLTERA, AA			EFFECT OF IRON CHELATION-THERAPY ON RECOVERY FROM DEEP COMA IN CHILDREN WITH CEREBRAL MALARIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TISSUE-INJURY; PLASMODIUM-FALCIPARUM; DESFERRIOXAMINE; HEMOGLOBIN; COMPLEMENT; INVITRO	Background. Cerebral malaria is a severe complication of Plasmodium falciparum infection in children, with a mortality rate of 15 to 50 percent despite antimalarial therapy. Methods. To determine whether combining iron chelation with quinine therapy speeds the recovery of consciousness, we conducted a randomized, double-blind, placebo-controlled trial of the iron chelator deferoxamine in 83 Zambian children with cerebral malaria. To be enrolled, patients had to be less than six years old, have P. falciparum parasitemia, have normal cerebrospinal fluid without evidence of bacterial infection, and be in a coma from which they could not be aroused. Deferoxamine (100 mg per kilogram of body weight per day, infused intravenously for 72 hours) or placebo was added to standard therapy with quinine and sulfadoxine-pyrimethamine. The time to the recovery of full consciousness, time to parasite clearance, and mortality were examined with Cox proportional-hazards regression analysis. Results. The rate of recovery of full consciousness among the 42 patients given deferoxamine was 1.3 times that among the 41 given placebo (95 percent confidence interval, 0.7 to 2.3); the median time to recovery was 20.2 hours in the deferoxamine group and 43.1 hours in the placebo group (P = 0.38). Among 50 patients with deep coma, the rate of recovery of full consciousness was increased 2.2-fold with deferoxamine (95 percent confidence interval, 1.1 to 4.7), decreasing the median recovery time from 68.2 to 24.1 hours (P = 0.03). Among 69 patients for whom data on parasite clearance were available, the rate of clearance with deferoxamine was 2.0 times that with placebo (95 percent confidence interval, 1.2 to 3.6). Among all 83 patients, mortality was 17 percent in the deferoxamine group and 22 percent in the placebo group (P = 0.52). Conclusions. Iron chelation therapy may hasten the clearance of parasitemia and enhance recovery from deep coma in cerebral malaria.	MOORHEAD STATE UNIV,MOORHEAD,MN; MACHA MISS HOSP,CHOMA,ZAMBIA; CASE WESTERN RESERVE UNIV,SCH MED,CLEVELAND,OH 44106; PENN STATE UNIV,MILTON S HERSHEY MED CTR,HERSHEY,PA 17033; CIBA GEIGY AG,CH-4002 BASEL,SWITZERLAND	Minnesota State Colleges & Universities; Minnesota State University Moorhead; Case Western Reserve University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Novartis			Gordeuk, Victor/AAG-6577-2019; Biemba, Godfrey/AAQ-4599-2020	Biemba, Godfrey/0000-0002-6064-6722	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042814] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL-42814-02] Funding Source: Medline; FDA HHS [FD-R-000657-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FDA HHS		AIKAWA M, 1988, AM J TROP MED HYG, V39, P3, DOI 10.4269/ajtmh.1988.39.3; AIKAWA M, 1990, AM J TROP MED HYG, V43, P30, DOI 10.4269/ajtmh.1990.43.30; AMBROSIO G, 1987, CIRCULATION, V76, P906, DOI 10.1161/01.CIR.76.4.906; ATKINSON CT, 1991, AM J TROP MED HYG, V45, P593, DOI 10.4269/ajtmh.1991.45.593; BREWSTER DR, 1990, LANCET, V336, P1039, DOI 10.1016/0140-6736(90)92498-7; COX DR, 1972, J R STAT SOC B, V34, P187; Folin O, 1914, J BIOL CHEM, V17, P475; GORDEUK VR, 1992, BLOOD, V79, P308; GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2; HENSON PM, 1987, J CLIN INVEST, V79, P669, DOI 10.1172/JCI112869; MACPHERSON GG, 1985, AM J PATHOL, V119, P385; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MODELL B, 1984, CLIN APPROACH THALAS, P217; MOLYNEUX ME, 1989, Q J MED, V71, P441; PHILLIPS RE, 1990, LANCET, V336, P1355, DOI 10.1016/0140-6736(90)92903-U; RAVENTOSSUAREZ C, 1982, AM J TROP MED HYG, V31, P919, DOI 10.4269/ajtmh.1982.31.919; SADRZADEH SMH, 1987, J CLIN INVEST, V79, P662, DOI 10.1172/JCI112865; SADRZADEH SMH, 1984, J BIOL CHEM, V259, P4354; SANFORD ARTHUR H., 1933, AMER JOUR CLIN PATH, V3, P405; SHUTE GT, 1988, MALARIA, V1, P781; WARD PA, 1983, J CLIN INVEST, V72, P789, DOI 10.1172/JCI111050; WARD PA, 1985, J CLIN INVEST, V76, P517, DOI 10.1172/JCI112001; WHITE NJ, 1985, LANCET, V1, P776; 1978, WHO CHRON, V32, P9	24	167	167	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 19	1992	327	21					1473	1477		10.1056/NEJM199211193272101	http://dx.doi.org/10.1056/NEJM199211193272101			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY165	1406879				2022-12-28	WOS:A1992JY16500001
J	ROSENBERG, SA				ROSENBERG, SA			GENE-THERAPY FOR CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Discussion							TUMOR-INFILTRATING LYMPHOCYTES; METASTATIC MELANOMA; CELLS; IMMUNOTHERAPY; INVIVO; INTERLEUKIN-2; EXPRESSION; HUMANS; POTENT				ROSENBERG, SA (corresponding author), NCI,SURG BRANCH,BLDG 10,ROOM 2B42,BETHESDA,MD 20892, USA.							ALEXANDER RB, 1991, BIOL THERAPY CANCER, P378; ASHER AL, 1991, J IMMUNOL, V146, P3227; BENDER MA, 1987, J VIROL, V61, P1639, DOI 10.1128/JVI.61.5.1639-1646.1987; COLOMBO MP, 1991, J EXP MED, V173, P889, DOI 10.1084/jem.173.4.889; CORNETTA K, 1991, HUM GENE THER, V2, P5, DOI 10.1089/hum.1991.2.1-5; FEARON ER, 1990, CELL, V60, P397, DOI 10.1016/0092-8674(90)90591-2; FISHER B, 1989, J CLIN ONCOL, V7, P250, DOI 10.1200/JCO.1989.7.2.250; FRIEDMANN T, 1989, SCIENCE, V244, P1275, DOI 10.1126/science.2660259; GANSBACHER B, 1990, CANCER RES, V50, P7820; GRIFFITH KD, 1989, J NATL CANCER I, V81, P1709, DOI 10.1093/jnci/81.22.1709; GROSS G, 1989, P NATL ACAD SCI USA, V86, P10024, DOI 10.1073/pnas.86.24.10024; HOM SS, 1991, J IMMUNOTHER, V10, P153; KASID A, 1990, P NATL ACAD SCI USA, V87, P473, DOI 10.1073/pnas.87.1.473; KAWAKAMI Y, 1992, J IMMUNOL, V148, P638; KRIEGLER M, 1990, GENE TRANSFER EXPRES, P1; MORECKI S, 1991, CANCER IMMUNOL IMMUN, V32, P342, DOI 10.1007/BF01741329; ROSENBERG SA, 1992, J CLIN ONCOL, V10, P180, DOI 10.1200/JCO.1992.10.2.180; ROSENBERG SA, 1990, NEW ENGL J MED, V323, P570, DOI 10.1056/NEJM199008303230904; ROSENBERG SA, 1988, NEW ENGL J MED, V319, P1676, DOI 10.1056/NEJM198812223192527; ROSENBERG SA, 1986, SCIENCE, V233, P1318, DOI 10.1126/science.3489291; ROSENBERG SA, 1991, BIOL THERAPY CANCER, P214; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2; Topalian S L, 1990, Important Adv Oncol, P19; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703	24	101	114	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 4	1992	268	17					2416	2419		10.1001/jama.268.17.2416	http://dx.doi.org/10.1001/jama.268.17.2416			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV694	1404800				2022-12-28	WOS:A1992JV69400029
J	PLOTZ, PH				PLOTZ, PH			NOT MYOSITIS - A SERIES OF CHANCE ENCOUNTERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEFICIENCY; MYOPATHY				PLOTZ, PH (corresponding author), NIAMSD,ARTHRIT RHEUMATISM BRANCH,CONNECT TISSUE DIS SECT,CTR CLIN 9N244,BETHESDA,MD 20892, USA.							BLAND JH, 1970, NEW ENGL J MED, V282, P1171, DOI 10.1056/NEJM197005212822103; DORWART BB, 1975, AM J MED, V59, P780, DOI 10.1016/0002-9343(75)90463-5; Estes M L, 1987, Am J Med, V82, P447, DOI 10.1016/0002-9343(87)90444-X; HOCHBERG MC, 1976, ARTHRITIS RHEUM, V19, P1363, DOI 10.1002/art.1780190621; NAKAJIMA H, 1990, J BIOL CHEM, V265, P9392; PALMER EP, 1985, NEW ENGL J MED, V313, P1457, DOI 10.1056/NEJM198512053132306; RATLIFF NB, 1987, NEW ENGL J MED, V316, P191, DOI 10.1056/NEJM198701223160405; REASOR MJ, 1989, TOXICOL APPL PHARM, V97, P47, DOI 10.1016/0041-008X(89)90054-9; SHAGAN BP, 1980, ARCH INTERN MED, V140, P832, DOI 10.1001/archinte.140.6.832; SIGURGEIRSSON B, 1992, NEW ENGL J MED, V326, P363, DOI 10.1056/NEJM199202063260602; SUGIE H, 1984, MUSCLE NERVE, V7, P54, DOI 10.1002/mus.880070109; ZUCKNER J, 1990, SEMIN ARTHRITIS RHEU, V19, P259, DOI 10.1016/0049-0172(90)90048-K	12	9	11	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 21	1992	268	15					2074	2077		10.1001/jama.268.15.2074	http://dx.doi.org/10.1001/jama.268.15.2074			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT520	1404746				2022-12-28	WOS:A1992JT52000033
J	AKABAS, MH; STAUFFER, DA; XU, M; KARLIN, A				AKABAS, MH; STAUFFER, DA; XU, M; KARLIN, A			ACETYLCHOLINE-RECEPTOR CHANNEL STRUCTURE PROBED IN CYSTEINE-SUBSTITUTION MUTANTS	SCIENCE			English	Article							SITE-DIRECTED MUTAGENESIS; AFFINITY BINDING-SITE; DELTA-SUBUNIT; H-3 CHLORPROMAZINE; ALPHA-SUBUNIT; TORPEDO-CALIFORNICA; NICOTINIC RECEPTOR; ION CHANNEL; NONCOMPETITIVE BLOCKERS; GAMMA-SUBUNIT	In order to understand the structural bases of ion conduction, ion selectivity, and gating in the nicotinic acetylcholine receptor, mutagenesis and covalent modification were combined to identify the amino acid residues that line the channel. The side chains of alternate residues-Ser248, Leu250, Ser252, and Thr254-in M2, a membrane-spanning segment of the alpha subunit, are exposed in the closed channel. Thus alpha248-254 probably forms a beta strand, and the gate is closer to the cytoplasmic end of the channel than any of these residues. On channel opening, Leu251 is also exposed. These results lead to a revised view of the closed and open channel structures.	COLUMBIA UNIV COLL PHYS & SURG,CTR MOLEC RECOGNIT,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT PHYSIOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT NEUROL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University				KARLIN, ARTHUR/0000-0002-4813-752X; Akabas, Myles/0000-0001-8781-7846	NINDS NIH HHS [NS07065, NS07258] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; ANDERSON DJ, 1981, P NATL ACAD SCI-BIOL, V78, P5598, DOI 10.1073/pnas.78.9.5598; ARNOLD E, 1990, J MOL BIOL, V211, P763, DOI 10.1016/0022-2836(90)90076-X; BERTRAND D, 1992, P NATL ACAD SCI USA, V89, P1261, DOI 10.1073/pnas.89.4.1261; CHARNET P, 1990, NEURON, V2, P87; CHAVEZ RA, 1991, J BIOL CHEM, V266, P15532; CLAUDIO T, 1983, P NATL ACAD SCI-BIOL, V80, P1111, DOI 10.1073/pnas.80.4.1111; COHEN BN, 1992, J GEN PHYSIOL, V99, P545, DOI 10.1085/jgp.99.4.545; COLQUHOUN D, 1981, NATURE, V294, P464, DOI 10.1038/294464a0; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DANI JA, 1989, J NEUROSCI, V9, P884; DIPAOLA M, 1989, J BIOL CHEM, V264, P15457; DIPAOLA M, 1990, J BIOL CHEM, V265, P11017; DWYER TM, 1980, J GEN PHYSIOL, V75, P469, DOI 10.1085/jgp.75.5.469; FALKE JJ, 1988, J BIOL CHEM, V263, P14850; FATT P, 1951, J PHYSIOL-LONDON, V115, P320, DOI 10.1113/jphysiol.1951.sp004675; GIRAUDAT J, 1986, P NATL ACAD SCI USA, V83, P2719, DOI 10.1073/pnas.83.8.2719; GIRAUDAT J, 1987, BIOCHEMISTRY-US, V26, P2410, DOI 10.1021/bi00383a003; GIRAUDAT J, 1989, FEBS LETT, V253, P190, DOI 10.1016/0014-5793(89)80957-3; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HUCHO F, 1986, FEBS LETT, V205, P137, DOI 10.1016/0014-5793(86)80881-X; IMOTO K, 1986, NATURE, V324, P670, DOI 10.1038/324670a0; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; JAKES KS, 1990, J BIOL CHEM, V265, P6984; JONES TA, 1988, EMBO J, V7, P1597, DOI 10.1002/j.1460-2075.1988.tb02985.x; KAO PN, 1984, J BIOL CHEM, V259, P1662; Kenyon G L, 1977, Methods Enzymol, V47, P407; KONNO T, 1991, P ROY SOC B-BIOL SCI, V244, P69, DOI 10.1098/rspb.1991.0053; KUIPERS OP, 1991, NUCLEIC ACIDS RES, V19, P4558, DOI 10.1093/nar/19.16.4558; LASTERS I, 1988, P NATL ACAD SCI USA, V85, P3338, DOI 10.1073/pnas.85.10.3338; LEATHY DJ, 1992, CELL, V68, P1145; LEONARD RJ, 1988, SCIENCE, V242, P1578, DOI 10.1126/science.2462281; LO DC, 1991, NEURON, V6, P31, DOI 10.1016/0896-6273(91)90119-K; MCCREA PD, 1987, EMBO J, V6, P3619, DOI 10.1002/j.1460-2075.1987.tb02693.x; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; NODA M, 1983, NATURE, V302, P528, DOI 10.1038/302528a0; OBERTHUR W, 1986, EMBO J, V5, P1815, DOI 10.1002/j.1460-2075.1986.tb04431.x; PAKULA AA, 1992, P NATL ACAD SCI USA, V89, P4144, DOI 10.1073/pnas.89.9.4144; PEDERSEN SE, 1992, J BIOL CHEM, V267, P10489; POPOT JL, 1984, PHYSIOL REV, V64, P1162, DOI 10.1152/physrev.1984.64.4.1162; REVAH F, 1990, P NATL ACAD SCI USA, V87, P4675, DOI 10.1073/pnas.87.12.4675; REVAH F, 1991, NATURE, V353, P846, DOI 10.1038/353846a0; REYNOLDS JA, 1978, BIOCHEMISTRY-US, V17, P2035, DOI 10.1021/bi00604a001; STAUFFER D, UNPUB; TODD AP, 1989, PROTEINS, V6, P294, DOI 10.1002/prot.340060312; UNWIN N, 1989, NEURON, V3, P65; VILLARROEL A, 1991, P ROY SOC B-BIOL SCI, V243, P69, DOI 10.1098/rspb.1991.0012; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	50	611	619	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 9	1992	258	5080					307	310		10.1126/science.1384130	http://dx.doi.org/10.1126/science.1384130			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR860	1384130				2022-12-28	WOS:A1992JR86000037
J	BALDUF, M; STEINKRAUS, V; RING, J				BALDUF, M; STEINKRAUS, V; RING, J			CAPTOPRIL ASSOCIATED LACRIMATION AND RHINORRHEA	BRITISH MEDICAL JOURNAL			English	Letter											BALDUF, M (corresponding author), UNIV HAMBURG,DEPT DERMATOL,W-2000 HAMBURG 20,GERMANY.		Ring, Johannes/GLN-4341-2022	Ring, Johannes/0000-0001-8236-3152				FULLER RW, 1987, BMJ-BRIT MED J, V295, P1025, DOI 10.1136/bmj.295.6605.1025-a; MORICE AH, 1987, LANCET, V2, P1116; STEINER JA, 1988, MEYLERS SIDE EFFECTS, P397	3	2	2	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 19	1992	305	6855					693	693		10.1136/bmj.305.6855.693-a	http://dx.doi.org/10.1136/bmj.305.6855.693-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP511	1393115	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992JP51100025
J	HADORN, DC				HADORN, DC			THE PROBLEM OF DISCRIMINATION IN HEALTH-CARE PRIORITY SETTING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREDICTING SURVIVAL; COST-EFFECTIVENESS; QUALITY; OREGON; POPULATION; WEIGHTS; SYSTEM; LIFE	Increasingly stringent fiscal restrictions on the scope of medical services available to patients have resulted in calls for explicit health care priority setting. Several commentators have called for the application of decision-analytic principles to such efforts, which would assign services priority based on the extent to which they produce preferred health outcomes. The Oregon Medicaid exercise is an example of such a process. An important challenge to these utilitarian efforts is the need to avoid discrimination against people with medical disabilities. Both of the key elements entailed by decision-analytic approaches to priority setting-estimation of outcomes and assignment of values to those outcomes-are vulnerable to charges of discrimination, primarily because both the medical outcomes expected in disabled individuals and the values they place on those outcomes may differ from the general public. Priority-setting efforts must proceed carefully to avoid the appearance (and reality) of discrimination.	UNIV COLORADO,CTR HLTH ETH & POLICY,DENVER,CO 80202	University of Colorado System; University of Colorado Denver	HADORN, DC (corresponding author), RAND CORP,DEPT SOCIAL POLICY,1700 MAIN ST,POB 2138,SANTA MONICA,CA 90407, USA.							BALABAN DJ, 1986, MED CARE, V24, P973, DOI 10.1097/00005650-198611000-00001; Blank R.H., 1988, RATIONING MED; BONSEL GJ, 1990, LANCET, V335, P493, DOI 10.1016/0140-6736(90)90734-M; Callahan D, 1987, SETTING LIMITS; DANIELS N, 1983, SECURING ACCESS HLTH, V2, P265; DRUMMOND MF, 1987, J CHRON DIS, V40, P605, DOI 10.1016/0021-9681(87)90021-X; EDDY DM, 1991, JAMA-J AM MED ASSOC, V266, P2135, DOI 10.1001/jama.266.15.2135; EDDY DM, 1991, JAMA-J AM MED ASSOC, V266, P2439, DOI 10.1001/jama.266.17.2439; EDDY DM, 1988, OCT PHYS PAYM REV CO; EISENBERG M, 1981, JAMA-J AM MED ASSOC, V246, P50, DOI 10.1001/jama.246.1.50; FELDBLUM CR, 1991, MILBANK Q, V69, P81, DOI 10.2307/3350159; FOX DM, 1991, HEALTH AFFAIR, V10, P7, DOI 10.1377/hlthaff.10.2.7; FRIEDMAN E, 1988, MED DECIS MAKING, V9, P65; FROBERG DG, 1989, J CLIN EPIDEMIOL, V42, P585, DOI 10.1016/0895-4356(89)90155-8; FUCHS VR, 1984, NEW ENGL J MED, V311, P1569; GAUTHIER D, 1982, SECURING ACCESS HLTH, V2, P179; GIBBARD A, 1982, SECURING ACCESS HLTH, V2, P153; GOSTIN LO, 1991, MILBANK Q, V69, P268, DOI 10.2307/3350166; Hadorn David C., 1992, BASIC BENEFITS CLIN; HADORN DC, 1991, SOC SCI MED, V32, P773, DOI 10.1016/0277-9536(91)90303-T; HADORN DC, 1991, JAMA-J AM MED ASSOC, V265, P2218, DOI 10.1001/jama.265.17.2218; HADORN DC, 1992, AM J LAW MED, V18, P73; HADORN DC, 1992, DESIGNING FAIR REASO; HADORN DC, 1991, HASTINGS CENT REP, V21, P11; HADORN DC, 1991, STAT MED, V11, P475; JOHNSON M, 1989, DISABILITY RAG, V10, P5; KAPLAN RM, 1978, P AM STAT ASSOC, P704; KEELER EB, 1990, JAMA-J AM MED ASSOC, V264, P1962, DOI 10.1001/jama.264.15.1962; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEMESHOW S, 1985, CRIT CARE MED, V13, P519, DOI 10.1097/00003246-198507000-00001; MARZEN TJ, 1991, UNPUB; MERRIKIN KJ, 1986, J HLTH POLIT POLICY, V10, P7; MERRILEES MA, 1984, BRIT MED J, V288, P356, DOI 10.1136/bmj.288.6414.356; MOSTELLER F, 1987, J CHRON DIS, V40, P645, DOI 10.1016/0021-9681(87)90029-4; PAUKER SG, 1987, NEW ENGL J MED, V316, P250, DOI 10.1056/NEJM198701293160505; Rokeach M., 1973, NATURE HUMAN VALUES; Torrance G W, 1972, Health Serv Res, V7, P118; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; 1983, NEW ENGL J MED, V303, P331; 1992, FED REG         0726, V56, P35717; 1992, ANAL AM DISABILITIES; 1992, FED REG         0726, V56, P35593	43	70	70	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 16	1992	268	11					1454	1459		10.1001/jama.268.11.1454	http://dx.doi.org/10.1001/jama.268.11.1454			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JM849	1387422				2022-12-28	WOS:A1992JM84900031
J	BOLGER, PG; DAVIES, R				BOLGER, PG; DAVIES, R			SIMULATION-MODEL FOR PLANNING RENAL SERVICES IN A DISTRICT HEALTH AUTHORITY	BRITISH MEDICAL JOURNAL			English	Article							FAILURE; RESOURCES	Objective-To investigate the use of a computer simulation model in planning and budgeting for renal replacement services. Setting-Regional renal unit. Results-The simulation provided projections that accurately reflected the actual numbers of people maintained on different forms of renal replacement therapy in previous years. Projections up to the end of the century showed that with no change in the demand for the service the total number of people on the renal replacement programme would increase by 40%. Increasing the uptake of new patients from 40 per million to 55 per million would mean an increase of 66% in patient numbers over the same period. Similarly, at present day prices the cost of providing the service would rise by 31% with no change in demand and by twice this with the greater uptake of new patients. Increasing the number of transplant operations was shown to offer little prospect of a reduction in these costs. Conclusion-The simulation program could be used by individual renal units to evaluate different treatment policies and to budget for resource use. Even at current demand levels resource requirements for renal replacement therapy win continue to grow until after the end of the century.	SOUTHMEAD HLTH AUTHOR,BRISTOL,ENGLAND; UNIV SOUTHAMPTON,DEPT ACCOUNTING & MANAGEMENT SCI,SOUTHAMPTON SO9 5NH,HANTS,ENGLAND	University of Southampton								[Anonymous], 1989, CM555; DAVIES H, 1987, J OPER RES SOC, V38, P693, DOI 10.1057/jors.1987.118; DAVIES R, 1986, J ROY SOC MED, V79, P154, DOI 10.1177/014107688607900308; DAVIES R, 1987, J OPERATIONAL RES SO, V36, P597; DOWIE R, 1984, BRIT MED J, V288, P988, DOI 10.1136/bmj.288.6422.988; FEEST TG, 1990, BRIT MED J, V301, P897, DOI 10.1136/bmj.301.6757.897; FORD C, 1976, DIALYSIS TRANSPLANT, V5, P15; LAING W, 1980, 11 BRIEF PAP; LUDBROOK A, 1981, APPL ECON, V13, P337, DOI 10.1080/00036848100000004; PATTEN J, 1984, HOUSE COMMONS OFFICI, V710, P309; PINCHERLE G, 1977, HLTH TRENDS, V9, P41; SHAH AR, 1981, LECTURE NOTES MED IN, V11, P143; TAUBE DH, 1983, BRIT MED J, V286, P2018, DOI 10.1136/bmj.286.6383.2018; WOOD IT, 1987, BRIT MED J, V294, P1467, DOI 10.1136/bmj.294.6585.1467; WOOD IT, 1980, BRIT MED J, V281, P575, DOI 10.1136/bmj.281.6240.575; 1988, STRATEGY SERVICES CH	16	18	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 12	1992	305	6854					605	608		10.1136/bmj.305.6854.605	http://dx.doi.org/10.1136/bmj.305.6854.605			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN698	1393071	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JN69800014
J	BROWN, K; WILLIAMS, EI; GROOM, L				BROWN, K; WILLIAMS, EI; GROOM, L			HEALTH CHECKS ON PATIENTS 75 YEARS AND OVER IN NOTTINGHAMSHIRE AFTER THE NEW GP CONTRACT	BRITISH MEDICAL JOURNAL			English	Article								Objective-To investigate annual health checks for patients of 75 years and over required by the 1990 contract for general practitioners. Design-Visits to practices to collect information on how assessments were organised and carried out; completion of questionnaires for every patient who had been assessed in a sample month, using information provided by the practice records. Setting-20 general practices in one family health services authority. Subjects-Patients of 75 years and over in 20 general practices. Results-Three practices (15%) had not performed checks. Thirteen practices sent a letter to invite patients to undergo a check. Of these practices, seven followed up non-responders. Two practices visited patients' homes unannounced, and two did checks on an opportunistic basis only. Sixteen practices used a checklist. Sixteen practices involved their practice nurses; at eight of these, doctors also performed checks; in six practices the nurses undertaking the checks had no training in assessing old people. Ten practices assessed more than 75% of their old people in the first year of the new contract. Practices that did not follow up patients who had not responded to the invitation for assessment completed significantly fewer checks. During the sample month, 331 patients were assessed in the 17 practices. 204 new problems were discovered in 143 patients. Significantly more problems per patient were found in inner city areas. Conclusions-The way health checks were performed varied greatly, both in their organisation and the practices' attitudes. Many old people did not respond to letters asking if they wanted an assessment but very few refused one if followed up. Forty three per cent of those assessed had some unmet need. The number of new problems found per patient may reduce over the next few years if the assessments are successful. The need for annual assessment should be kept under review and adequate resources made available for the needs uncovered. Improved training for practice nurses in assessment is needed. Effectiveness of the checks must be monitored. If most unmet need falls in particular high risk groups it would seem sensible to modify the annual check to target these groups.			BROWN, K (corresponding author), UNIV NOTTINGHAM,QUEENS MED CTR,DEPT GEN PRACTICE,NOTTINGHAM NG7 2UH,ENGLAND.							CLARK CM, 1991, BRIT MED J, V303, P584, DOI 10.1136/bmj.303.6802.584; HEPPLE J, 1989, AGE AGEING, V18, P61, DOI 10.1093/ageing/18.1.61; Tulloch A J, 1979, J R Coll Gen Pract, V29, P733; Varnam M A, 1991, BMJ, V303, P649; VETTER NJ, 1984, BRIT MED J, V288, P369, DOI 10.1136/bmj.288.6414.369; WORMALD RPL, 1992, BRIT MED J, V304, P1226, DOI 10.1136/bmj.304.6836.1226	6	25	25	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 12	1992	305	6854					619	621		10.1136/bmj.305.6854.619	http://dx.doi.org/10.1136/bmj.305.6854.619			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN698	1393076	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JN69800019
J	SMITH, EF; SALE, WS				SMITH, EF; SALE, WS			REGULATION OF DYNEIN-DRIVEN MICROTUBULE SLIDING BY THE RADIAL SPOKES IN FLAGELLA	SCIENCE			English	Article							SWIMMING SPERM FLAGELLA; CHLAMYDOMONAS-FLAGELLA; GENETIC-ANALYSIS; SEA-URCHIN; INNER-ARM; MUTANTS; OUTER; REINHARDTII; COMPONENTS; DIRECTION	The regulation of microtubule sliding in flagellar axonemes was studied with the use of Chlamydomonas mutants and in vitro assays. Microtubule sliding velocities were diminished in axonemes from mutant cells missing radial spoke structures but could be restored upon reconstitution with dynein from axonemes with wild-type radial spokes. These experiments demonstrate that the radial spokes activate dynein's microtubule sliding activity.			SMITH, EF (corresponding author), EMORY UNIV,SCH MED,DEPT ANAT & CELL BIOL,ATLANTA,GA 30322, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020497] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008367] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 20497] Funding Source: Medline; NIGMS NIH HHS [GM 08367] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLOOM G S, 1992, Current Opinion in Cell Biology, V4, P66, DOI 10.1016/0955-0674(92)90060-P; BROKAW CJ, 1991, J CELL BIOL, V114, P1201, DOI 10.1083/jcb.114.6.1201; BROKAW CJ, 1980, SCIENCE, V207, P1365, DOI 10.1126/science.6898364; BROKAW CJ, 1982, J CELL BIOL, V92, P722, DOI 10.1083/jcb.92.3.722; BROKAW CJ, 1987, CELL MOTIL CYTOSKEL, V8, P68, DOI 10.1002/cm.970080110; BROKAW CJ, 1989, SCIENCE, V243, P1593, DOI 10.1126/science.2928796; DIENER DR, 1990, P NATL ACAD SCI USA, V87, P5739, DOI 10.1073/pnas.87.15.5739; FOX LA, 1987, J CELL BIOL, V105, P1781, DOI 10.1083/jcb.105.4.1781; HUANG B, 1982, CELL, V28, P115, DOI 10.1016/0092-8674(82)90381-6; HUANG B, 1981, J CELL BIOL, V88, P80, DOI 10.1083/jcb.88.1.80; HUANG BPH, 1986, INT REV CYTOL, V99, P181; JOHNSON KA, 1985, ANNU REV BIOPHYS BIO, V14, P161, DOI 10.1146/annurev.bb.14.060185.001113; KAMIYA R, 1989, CELL MOVEMENT DYNEIN, V1, pCH15; KURIMOTO E, 1991, CELL MOTIL CYTOSKEL, V19, P275, DOI 10.1002/cm.970190406; LUCK D, 1977, P NATL ACAD SCI USA, V74, P3456, DOI 10.1073/pnas.74.8.3456; LUCK DJL, 1989, CELL MOVEMENT DYNEIN, V1, pCH4; MUTO E, 1991, J CELL SCI, V99, P57; OKAGAKI T, 1986, J CELL BIOL, V103, P1895, DOI 10.1083/jcb.103.5.1895; OMOTO CK, 1980, J CELL BIOL, V87, P33, DOI 10.1083/jcb.87.1.33; PIPERNO G, 1991, J CELL BIOL, V112, P701, DOI 10.1083/jcb.112.4.701; PIPERNO G, 1981, CELL, V27, P331, DOI 10.1016/0092-8674(81)90416-5; PIPERNO G, 1990, J CELL BIOL, V110, P379, DOI 10.1083/jcb.110.2.379; PIPERNO G, 1981, J CELL BIOL, V88, P73, DOI 10.1083/jcb.88.1.73; SALE WS, 1977, P NATL ACAD SCI USA, V74, P2045, DOI 10.1073/pnas.74.5.2045; SATIR P, 1968, J CELL BIOL, V39, P77, DOI 10.1083/jcb.39.1.77; SMITH EF, 1992, J CELL BIOL, V117, P573, DOI 10.1083/jcb.117.3.573; SUMMERS KE, 1971, P NATL ACAD SCI USA, V68, P3092, DOI 10.1073/pnas.68.12.3092; WARNER FD, 1974, J CELL BIOL, V63, P35, DOI 10.1083/jcb.63.1.35; WITMAN GB, 1978, J CELL BIOL, V76, P729, DOI 10.1083/jcb.76.3.729; WITMAN GB, 1992, CURR OPIN CELL BIOL, V4, P77	30	151	153	2	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 11	1992	257	5076					1557	1559		10.1126/science.1387971	http://dx.doi.org/10.1126/science.1387971			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM570	1387971				2022-12-28	WOS:A1992JM57000035
J	AMSTERCHODER, O; WRIGHT, A				AMSTERCHODER, O; WRIGHT, A			MODULATION OF THE DIMERIZATION OF A TRANSCRIPTIONAL ANTITERMINATOR PROTEIN BY PHOSPHORYLATION	SCIENCE			English	Article							DNA-BINDING PROTEINS; ESCHERICHIA-COLI; LEUCINE ZIPPER; BGL OPERON	The transcriptional antiterminator protein BgIG inhibits transcription termination of the bgl operon in Escherichia coli when it is in the nonphosphorylated state. The BgIG protein is now shown to exist in two configurations, an active, dimeric nonphosphorylated form and an inactive, monomeric phosphorylated form. The migration of BgIG on native polyacrylamide gels was consistent with it existing as a dimer when nonphosphorylated and as a monomer when phosphorylated. Only the nonphosphorylated dimer was found to bind to the target RNA. When the dimerization domain of the lambda-repressor was replaced with BgIG, the resulting chimera behaved like an intact lambda-repressor in its ability to repress lambda-gene expression, which suggests that BgIG dimerizes in vivo. Repression by the lambda-BgIG hybrid was significantly reduced by BgIF, the BgIG kinase, an effect that was relieved by conditions that stimulate dephosphorylation of BgIG by BgIF. These results suggest that the phosphorylation and the dephosphorylation of BgIG regulate its activity by controlling its dimeric state.			AMSTERCHODER, O (corresponding author), TUFTS UNIV,DEPT MOLEC BIOL & MICROBIOL,HLTH SCI CAMPUS,BOSTON,MA 02111, USA.							AMSTERCHODER O, 1990, SCIENCE, V249, P540, DOI 10.1126/science.2200123; AMSTERCHODER O, 1989, CELL, V58, P847, DOI 10.1016/0092-8674(89)90937-9; AMSTERCHODER O, UNPUB; BRYAN JK, 1977, ANAL BIOCHEM, V78, P523; DIAZTORRES MR, UNPUB; FRANKEL AD, 1991, CELL, V67, P1041, DOI 10.1016/0092-8674(91)90282-4; HOUMAN F, 1990, CELL, V62, P1153, DOI 10.1016/0092-8674(90)90392-R; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; Hu Jintao, COMMUNICATION; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MAHADEVAN S, 1987, CELL, V50, P485, DOI 10.1016/0092-8674(87)90502-2; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; REVEL HR, 1967, VIROLOGY, V31, P688, DOI 10.1016/0042-6822(67)90197-3; REYNOLDS AE, 1986, J MOL BIOL, V191, P85, DOI 10.1016/0022-2836(86)90424-9; RUDNER DZ, 1991, J BACTERIOL, V173, P1388, DOI 10.1128/jb.173.4.1388-1398.1991; STEINMETZ M, 1988, GENETICS BIOTECHNOLO, V2, P11; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ZAGURSKY RJ, 1984, GENE, V27, P183, DOI 10.1016/0378-1119(84)90139-2	21	122	122	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 4	1992	257	5075					1395	1398		10.1126/science.1382312	http://dx.doi.org/10.1126/science.1382312			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL612	1382312				2022-12-28	WOS:A1992JL61200032
J	COWAN, SW; SCHIRMER, T; RUMMEL, G; STEIERT, M; GHOSH, R; PAUPTIT, RA; JANSONIUS, JN; ROSENBUSCH, JP				COWAN, SW; SCHIRMER, T; RUMMEL, G; STEIERT, M; GHOSH, R; PAUPTIT, RA; JANSONIUS, JN; ROSENBUSCH, JP			CRYSTAL-STRUCTURES EXPLAIN FUNCTIONAL-PROPERTIES OF 2 ESCHERICHIA-COLI PORINS	NATURE			English	Article							PHOTOSYNTHETIC REACTION CENTER; INTEGRAL MEMBRANE-PROTEIN; ESCHERICHIA-COLI; OUTER-MEMBRANE; MACROMOLECULAR CRYSTALLOGRAPHY; RHODOPSEUDOMONAS-VIRIDIS; RHODOBACTER-CAPSULATUS; ELECTRON-MICROSCOPY; BACTERIAL PORIN; PHOE PORIN	Porins form aqueous channels that aid the diffusion of small hydrophilic molecules across the outer membrane of Gram-negative bacteria. The crystal structures of matrix porin and phosphoporin both reveal trimers of identical subunits, each subunit consisting of a 16-stranded anti-parallel beta-barrel containing a pore. A long loop inside the barrel contributes to a constriction of the channel where the charge distribution affects ion selectivity. The structures explain at the molecular level functional characteristics and their alterations by known mutations.	UNIV BASEL,BIOCTR,DEPT STRUCT BIOL,CH-4056 BASEL,SWITZERLAND; UNIV BASEL,BIOCTR,DEPT MICROBIOL,CH-4056 BASEL,SWITZERLAND	University of Basel; University of Basel								BAUER K, 1989, J BIOL CHEM, V264, P16393; BENSON SA, 1988, J MOL BIOL, V203, P961, DOI 10.1016/0022-2836(88)90121-0; BENZ R, 1985, J BACTERIOL, V162, P722, DOI 10.1128/JB.162.2.722-727.1985; BOSCH D, 1989, MOL GEN GENET, V216, P144, DOI 10.1007/BF00332243; BRUNGER AT, 1990, XPLOR MANUAL; BUHLER LK, 1991, J BIOL CHEM, V266, P24446; DARGENT B, 1986, EMBO J, V5, P773, DOI 10.1002/j.1460-2075.1986.tb04280.x; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DEISENHOFER J, 1989, SCIENCE, V245, P1463, DOI 10.1126/science.245.4925.1463; ENGEL A, 1985, NATURE, V317, P643, DOI 10.1038/317643a0; GARAVITO RM, 1980, J CELL BIOL, V86, P327, DOI 10.1083/jcb.86.1.327; GARAVITO RM, 1983, J MOL BIOL, V164, P313, DOI 10.1016/0022-2836(83)90079-7; HANCOCK REW, 1987, J BACTERIOL, V169, P929, DOI 10.1128/jb.169.3.929-933.1987; HENDERSON R, 1975, NATURE, V257, P28, DOI 10.1038/257028a0; HONGER A, 1990, J STRUCT BIOL, V103, P185; JAP BK, 1991, NATURE, V350, P167, DOI 10.1038/350167a0; JAP BK, 1990, Q REV BIOPHYS, V23, P367, DOI 10.1017/S003358350000559X; JAP BK, 1989, J MOL BIOL, V205, P407, DOI 10.1016/0022-2836(89)90351-3; JAP BK, 1990, J STRUCT BIOL, V103, P57, DOI 10.1016/1047-8477(90)90086-R; JEANTEUR D, 1991, MOL MICROBIOL, V5, P2153, DOI 10.1111/j.1365-2958.1991.tb02145.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1990, MANUAL O; KLEBBA PE, 1990, J BIOL CHEM, V265, P6800; KORTELAND J, 1985, EUR J BIOCHEM, V152, P691, DOI 10.1111/j.1432-1033.1985.tb09249.x; LAKEY JH, 1991, FEBS LETT, V278, P31, DOI 10.1016/0014-5793(91)80076-F; LESK AM, 1989, PROTEINS, V5, P139, DOI 10.1002/prot.340050208; LEWIS BA, 1983, J MOL BIOL, V166, P211, DOI 10.1016/S0022-2836(83)80007-2; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MICHEL H, 1983, TRENDS BIOCHEM SCI, V8, P56, DOI 10.1016/0968-0004(83)90390-0; MISRA R, 1988, J BACTERIOL, V170, P3611, DOI 10.1128/jb.170.8.3611-3617.1988; MIZUNO T, 1983, J BIOL CHEM, V258, P6932; NIKAIDO H, 1981, J GEN PHYSIOL, V77, P121, DOI 10.1085/jgp.77.2.121; NIKAIDO H, 1983, J BACTERIOL, V153, P241, DOI 10.1128/JB.153.1.241-252.1983; NIKAIDO H, 1992, MOL MICROBIOL, V6, P435, DOI 10.1111/j.1365-2958.1992.tb01487.x; PAUPTIT RA, 1991, J MOL BIOL, V218, P505, DOI 10.1016/0022-2836(91)90696-4; PAUPTIT RA, 1991, J STRUCT BIOL, V107, P136, DOI 10.1016/1047-8477(91)90017-Q; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROCQUE WJ, 1990, BIOCHEMISTRY-US, V29, P5344, DOI 10.1021/bi00474a020; ROSENBUSCH JP, 1974, J BIOL CHEM, V249, P8019; ROSENBUSCH JP, 1990, EXPERIENTIA, V46, P167; ROSENBUSCH JP, 1977, SOLUBILIZATION LIPOP, P59; Rossmann M. G., 1972, MOL REPLACEMENT METH; SASS HJ, 1989, J MOL BIOL, V209, P171, DOI 10.1016/0022-2836(89)90180-0; SCHINDLER H, 1978, P NATL ACAD SCI USA, V75, P3751, DOI 10.1073/pnas.75.8.3751; Schirmer T, 1991, CURR OPIN STRUC BIOL, V1, P539, DOI 10.1016/S0959-440X(05)80075-2; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; STEIERT M, 1992, Experientia (Basel), V48, pA22; STEVEN AC, 1977, J CELL BIOL, V72, P292, DOI 10.1083/jcb.72.2.292; STRUYVE M, 1991, J MOL BIOL, V218, P141, DOI 10.1016/0022-2836(91)90880-F; VANDERLEY P, 1986, J BIOL CHEM, V261, P2222; VOGEL H, 1986, J MOL BIOL, V190, P191, DOI 10.1016/0022-2836(86)90292-5; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEISS MS, 1990, FEBS LETT, V267, P268, DOI 10.1016/0014-5793(90)80942-C; WEISS MS, 1991, FEBS LETT, V280, P379, DOI 10.1016/0014-5793(91)80336-2; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242; 1979, SERC UK4 DAR LAB COL	58	1345	1370	0	72	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 27	1992	358	6389					727	733		10.1038/358727a0	http://dx.doi.org/10.1038/358727a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JK699	1380671				2022-12-28	WOS:A1992JK69900043
J	BERRY, M; GROSVELD, F; DILLON, N				BERRY, M; GROSVELD, F; DILLON, N			A SINGLE POINT MUTATION IS THE CAUSE OF THE GREEK FORM OF HEREDITARY PERSISTENCE OF FETAL HEMOGLOBIN	NATURE			English	Article							GAMMA-GLOBIN GENE; ERYTHROID-SPECIFIC PROTEIN; DISTAL CCAAT BOX; TRANSGENIC MICE; DEVELOPMENTAL EXPRESSION; BINDING; HEMOGLOBIN; REGION; DNA; BREAKPOINT	IN normal humans the fetal stage-specific gamma-globin genes are silenced after birth and not expressed in the adult. Exceptions are seen in cases of hereditary persistence of fetal haemoglobin (HPFH). These are clinically important because the elevated levels of gamma-globin can alleviate beta-thalassaemia and sickle cell anaemia. One class of mutations is associated with point mutations in the promoter of the gamma-globin genes (non-deletion HPFH), whereas others seem to be caused by large deletions 3' to the gamma-globin genes1. To test whether the point mutation found in the Greek non-deletion HPFH2,3 (guanine to adenine at nucleotide position -117) is the cause of the raised gamma-globin levels in the adult stage and is not just a linked polymorphism, we engineered this mutation into a gamma-globin gene. When this gene was introduced into mice, the presence of the -117 mutation results in persistence of gamma-globin expression at a high level and a concomitant decrease in beta-globin expression in fetal and adult mice. We show that these changes correlate with the loss of binding of the transcription factor GATA1 to the gamma-globin promoter, suggesting that it may act as a negative regulator of the gamma-globin gene in adults.			BERRY, M (corresponding author), NATL INST MED RES,GENE STRUCT & EXPRESS LAB,RIDGEWAY,LONDON NW7 1AA,ENGLAND.							ANAGNOU NP, 1990, CLIN RES, V38, pA301; BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; COLLINS FS, 1985, NATURE, V313, P325, DOI 10.1038/313325a0; DIGNAM J, 1983, NUCLEIC ACIDS RES, V113, P1475; DILLON N, 1991, NATURE, V350, P252, DOI 10.1038/350252a0; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; EVANS T, 1991, MOL CELL BIOL, V11, P843, DOI 10.1128/MCB.11.2.843; FEINGOLD EA, 1989, BLOOD, V74, P2178; GELINAS R, 1985, NATURE, V313, P323, DOI 10.1038/313323a0; GIGLIONI B, 1984, EMBO J, V3, P2641, DOI 10.1002/j.1460-2075.1984.tb02187.x; GILMAN J, 1988, NUCLEIC ACIDS RES, V18, P10635; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HANSCOMBE O, 1991, GENE DEV, V5, P1387, DOI 10.1101/gad.5.8.1387; MANTOVANI R, 1989, NUCLEIC ACIDS RES, V17, P6681, DOI 10.1093/nar/17.16.6681; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MORLEY BJ, 1992, MOL CELL BIOL, V12, P2057, DOI 10.1128/MCB.12.5.2057; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; PONCZ M, 1989, OXFORD SURVEYS EUKAR, P163; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; STAMATOYANNOPOU.G, 1991, REGULATION HEMOGLOBI, pCH6; SUPERTIFURGA G, 1988, EMBO J, V7, P3099, DOI 10.1002/j.1460-2075.1988.tb03176.x; WALL L, 1988, GENE DEV, V2, P1089, DOI 10.1101/gad.2.9.1089; Weatherall D.J., 1981, THALASSAEMIA SYNDROM, V3rd ed.; WHITELAW E, 1990, MOL CELL BIOL, V10, P6596, DOI 10.1128/MCB.10.12.6596	25	123	126	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 6	1992	358	6386					499	502		10.1038/358499a0	http://dx.doi.org/10.1038/358499a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG739	1379347	Green Submitted			2022-12-28	WOS:A1992JG73900048
J	FREUDENSTEIN, U; BORGWARDT, G				FREUDENSTEIN, U; BORGWARDT, G			PRIMARY MEDICAL-CARE IN FORMER EAST-GERMANY - THE FROSTY WINDS OF CHANGE	BRITISH MEDICAL JOURNAL			English	Article									E GERMAN ASSOC GEN PRACTITIONERS,O-1170 BERLIN,GERMANY									ARNOLD M, 1990, GESUNDHEIT DEUTSCHLA; HESS R, 1991, HUMANITAS, V7, P7; HOFEMANN K, 1991, SOZIALE SICHERHEIT, V2, P37; NOWAK M, 1990, BEWERTENDE BESCHREID; SCHRAEDER W, 1991, ENTWICKLUNG AMBULANT; VONSTACKELBERG JM, 1991, SOZIALE SICHERHEIT, V2, P43; 1990, GESUNDHEITSWESEN JAH; 1990, GUTACHTEN ANAL LEIST; 1991, GUTACHTEN ANAL LEIST	9	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1992	304	6830					827	829		10.1136/bmj.304.6830.827	http://dx.doi.org/10.1136/bmj.304.6830.827			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL827	1392713	Green Published, Bronze			2022-12-28	WOS:A1992HL82700027
J	MILES, SH				MILES, SH			WHAT ARE WE TEACHING ABOUT INDIGENT PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIANS; CARE; AIDS				MILES, SH (corresponding author), UNIV MINNESOTA,SCH MED,DEPT MED,CTR BIOMED ETH,DIV GERIATR MED,MINNEAPOLIS,MN 55455, USA.							ARNOW PM, 1989, PUBLIC HEALTH REP, V104, P121; BLENDON RJ, 1991, SYSTEM CRISIS CASE H, V166, P186; COLWILL JM, 1992, NEW ENGL J MED, V326, P387, DOI 10.1056/NEJM199202063260606; CONNELLY JE, 1987, ARCH INTERN MED, V147, P1829; DUBOVSKY SL, 1986, NEW ENGL J MED, V315, P1674; DUNHAM NC, 1991, JAMA-J AM MED ASSOC, V265, P2982, DOI 10.1001/jama.265.22.2982; ENFIELD LM, 1988, AM J LAW MED, V13, P561; GERBERT B, 1991, JAMA-J AM MED ASSOC, V266, P2837, DOI 10.1001/jama.266.20.2837; HARVEY L, 1991, SURVEY PUBLIC OPINIO; PELLEGRINO ED, 1988, LIT MED, V7, P22, DOI 10.1353/lm.2011.0164; PRICE JH, 1988, J FAM PRACTICE, V27, P615; SCHIEDERMAYER DL, 1989, ARCH INTERN MED, V149, P1303, DOI 10.1001/archinte.149.6.1303; SCHROEDER SA, 1989, JAMA-J AM MED ASSOC, V262, P803, DOI 10.1001/jama.262.6.803; Simon M S, 1991, AIDS Educ Prev, V3, P124; SINGER PA, 1992, ARCH INTERN MED, V152, P22, DOI 10.1001/archinte.152.1.22; STARR P, 1982, TRANSFORMATION AM ME; Stevens Rosemary, 1989, SICKNESS WEALTH AM H; STOBOS J, 1991, ANN INTERN MED, V20, P302; TAYLOR H, 1991, SYSTEM CRISIS CASE H, P168; WALKER RM, 1991, J GEN INTERN MED, V6, P424, DOI 10.1007/BF02598164; ZUGER A, 1987, JAMA-J AM MED ASSOC, V258, P1924, DOI 10.1001/jama.258.14.1924; 1988, JAMA-J AM MED ASSOC, V259, P1360; 1986, CURRENT OPINIONS	23	18	19	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1992	268	18					2561	2562		10.1001/jama.268.18.2561	http://dx.doi.org/10.1001/jama.268.18.2561			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW616	1404824				2022-12-28	WOS:A1992JW61600029
J	UDVARHELYI, IS; GATSONIS, C; EPSTEIN, AM; PASHOS, CL; NEWHOUSE, JP; MCNEIL, BJ				UDVARHELYI, IS; GATSONIS, C; EPSTEIN, AM; PASHOS, CL; NEWHOUSE, JP; MCNEIL, BJ			ACUTE MYOCARDIAL-INFARCTION IN THE MEDICARE POPULATION - PROCESS OF CARE AND CLINICAL OUTCOMES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEART-DISEASE; PROGNOSIS; WOMEN; MEN; MANAGEMENT; MORTALITY; MORBIDITY; SURVIVAL; TRIALS	Objective.-To describe the process of care and clinical outcomes associated with acute myocardial infarction (AMI) in the Medicare population, and to examine differences in process of care and outcome of care as a function of patient age, gender, and race. Design.-Retrospective cohort study using a longitudinal database created from Medicare utilization and administrative files. Patient Populations.-A cohort of AMI patients covered by Medicare in 1987 and a random sample of Medicare patients without AMI. Main Process and Outcome Measurements.-(1) The use of coronary angiography, coronary artery bypass graft surgery, and percutaneous transluminal coronary angioplasty during the first 90 days after a new AMI; (2) mortality at 30 days, 1 year, and 2 years; (3) reinfarction rates; and (4) reoperation rates for coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty. Main Results.-Mortality rates were high: 26% at 30 days, 40% at 1 year, and 47% at 2 years. They varied greatly by age, less so by gender and race, and were high even among patients who survived the first 30 days. Compared with mortality, reinfarction was uncommon, occurring in 7.3% of patients. During the first 90 days, 23% of all patients underwent angiography and 13% underwent coronary revascularization (coronary artery bypass graft surgery, 8%; percutaneous transluminal coronary angioplasty, 5%). The use of all three procedures decreased with age and was less common among women and blacks than among men and whites. Differential use by age and race was greater for angiography than for revascularization procedures. Conclusions.-The prognosis following AMI in patients aged 65 years and above is much worse than is commonly realized. Procedure use in these patients varies as a function of gender and race, even though mortality does not. Further research is needed to reduce the mortality of elderly patients with AMI and to understand the significance of differences in procedure use on the basis of sociodemographic characteristics.	HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,25 SHATTUCK ST,PARCEL B,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,DIV GEN MED,HLTH SERV & POLICY RES SECT,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT RADIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BOSTON,MA 02115; HARVARD UNIV,JOHN F KENNEDY SCH GOVT,CAMBRIDGE,MA 02138	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University			Newhouse, Joseph/AGJ-5632-2022		AHRQ HHS [HS06341] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ANDERSON GM, 1989, NEW ENGL J MED, V321, P1443, DOI 10.1056/NEJM198911233212105; ANTMANEM, 1992, JAMA-J AM MED ASSOC, V268, P240; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BRAUNWALD E, 1988, HEART DISEASE TXB CA; CASTANER A, 1988, ANN INTERN MED, V109, P33, DOI 10.7326/0003-4819-109-1-33; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; COOPER RS, 1986, AM J CARDIOL, V57, P208, DOI 10.1016/0002-9149(86)90892-1; FIEBACH NH, 1990, JAMA-J AM MED ASSOC, V263, P1092, DOI 10.1001/jama.263.8.1092; FISHER ES, 1990, AM J PUBLIC HEALTH, V80, P1487, DOI 10.2105/AJPH.80.12.1487; FISHER LD, 1985, CIRCULATION, V72, P110; GOLDBERG RJ, 1989, AM HEART J, V117, P543, DOI 10.1016/0002-8703(89)90727-8; GRAVES EJ, 1990, PUBLICATION NATIONAL, V185; GREENLAND P, 1991, CIRCULATION, V83, P484, DOI 10.1161/01.CIR.83.2.484; HURST JW, 1989, HEART ARTERIES VEINS; IEZZONI LI, 1988, ANN INTERN MED, V109, P745, DOI 10.7326/0003-4819-109-9-745; KANNEL WB, 1979, AM J CARDIOL, V44, P53, DOI 10.1016/0002-9149(79)90250-9; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; LEW EA, 1990, MED RISKS TRENDS MOR, pCH5; MERRILEES MA, 1984, BRIT MED J, V288, P356, DOI 10.1136/bmj.288.6414.356; PELL S, 1985, NEW ENGL J MED, V312, P1005, DOI 10.1056/NEJM198504183121601; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; YUSUF S, 1990, CIRCULATION, V82, P117; 1989, INT CLASSIFICATION D	26	210	213	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1992	268	18					2530	2536		10.1001/jama.268.18.2530	http://dx.doi.org/10.1001/jama.268.18.2530			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW616	1404820				2022-12-28	WOS:A1992JW61600024
J	NIPPER, HC				NIPPER, HC			A NONWORKLOADED TASK	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 4	1992	268	17					2362	2362						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV694	1404786				2022-12-28	WOS:A1992JV69400009
J	WEISSMAN, JS; GATSONIS, C; EPSTEIN, AM				WEISSMAN, JS; GATSONIS, C; EPSTEIN, AM			RATES OF AVOIDABLE HOSPITALIZATION BY INSURANCE STATUS IN MASSACHUSETTS AND MARYLAND	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL-CARE; CASE-MIX; HEALTH; MORTALITY; QUALITY; AREA; INTERVENTION; SERVICES; DISTRICT; PAYMENT	Objective.-To determine whether uninsured and Medicaid patients have higher rates of avoidable hospitalizations than do insured patients. Design.-We used 1987 computerized hospital discharge data to select a cross-sectional sample of hospitalized patients. Population estimates from the Current Population Survey were used to estimate rates of admission, standardized for age and sex. Setting.-Nonfederal acute care hospitals in Massachusetts and Maryland. Patients.-All patients under 65 years of age who were uninsured, privately insured, or insured by Medicaid. Hospitalizations for obstetric and psychiatric conditions were excluded. Main Outcome Measures.-Relative risk of admission for 12 avoidable hospital conditions (AHCs) identified by a physician panel. Results.-Uninsured and Medicaid patients were more likely than insured patients to be hospitalized for AHCs. Rates for uninsured patients were significantly greater than for privately insured patients in Massachusetts for 10 of 12 individual AHCs, and in Maryland for five of 12 AHCs. After adjustment for baseline utilization, the results were statistically significant for 10 of 12 AHCs in Massachusetts and seven of 12 AHCs in Maryland. For Medicaid patients, rates were significantly greater than for privately insured patients for all AHCs in each state before adjustment, and for nine of 12 and seven of 12 AHCs in each state, respectively, after adjustment for baseline utilization. Conclusion.-Our findings suggest that patients who are uninsured or who have Medicaid coverage have higher rates of hospitalization for conditions that can often be treated out of hospital or avoided altogether. Our approach is potentially useful for routine monitoring of access and quality of care for selected groups of patients.	HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,25 SHATTUCK ST,PARCEL B,1ST FLOOR,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,DIV GEN MED,HLTH SERV & POLICY RES SECT,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health					AHRQ HHS [R01 HS06235] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ADAY LA, 1984, AM J PUBLIC HEALTH, V74, P1331, DOI 10.2105/AJPH.74.12.1331; BILLINGS J, 1990, HEALTH AFFAIR, V9, P158, DOI 10.1377/hlthaff.9.4.158; BRAVEMAN P, 1989, NEW ENGL J MED, V321, P508, DOI 10.1056/NEJM198908243210805; BROOK RH, 1983, NEW ENGL J MED, V309, P1426, DOI 10.1056/NEJM198312083092305; Brown E R, 1989, Med Care Rev, V46, P349, DOI 10.1177/107755878904600402; BUCK C, 1986, INT J HEALTH SERV, V16, P553, DOI 10.2190/QWWN-518N-5VFC-6272; CARR W, 1988, SERIES UNITED HOSPIT, V8, P5; CHARLTON JRH, 1983, LANCET, V1, P691; CHRISTOFFERSSON J, 1986, DRG MONITOR, V6, P1; Craddick J W, 1979, QRB Qual Rev Bull, V5, P2; DIEHR P, 1990, HEALTH SERV RES, V24, P741; GARFINKEL S, 1986, 20213 DEP HLTH HUM B; GONNELLA JS, 1984, JAMA-J AM MED ASSOC, V251, P637; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; Howell E M, 1991, Health Care Financ Rev, V12, P1; HSIA DC, 1988, NEW ENGL J MED, V318, P352, DOI 10.1056/NEJM198802113180604; LURIE N, 1986, NEW ENGL J MED, V314, P1266, DOI 10.1056/NEJM198605083141934; MARTINI CJM, 1977, INT J HEALTH SERV, V7, P293, DOI 10.2190/XFYT-R576-0R6C-RJ4M; MOYER ME, 1989, HEALTH AFFAIR, V8, P102, DOI 10.1377/hlthaff.8.2.102; NEWHOUSE JP, 1991, HLTH SERVICES RES KE, P161; PERLOFF JD, 1987, J HEALTH POLIT POLIC, V12, P221, DOI 10.1215/03616878-12-2-221; Roos N P, 1988, Health Care Financ Rev, V9, P53; RUNDALL T, 1991, 119TH ANN M AM PUBL; RUTSTEIN DD, 1976, NEW ENGL J MED, V294, P582, DOI 10.1056/NEJM197603112941104; RUTSTEIN DD, 1977, NEW ENGL J MED, V297, P508; SCHWARTZ E, 1990, INT J EPIDEMIOL, V19, P591, DOI 10.1093/ije/19.3.591; SOLBERG LI, 1990, INQUIRY-J HEALTH CAR, V27, P359; WEISSMAN J, 1989, JAMA-J AM MED ASSOC, V261, P3572, DOI 10.1001/jama.261.24.3572; WEISSMAN JS, 1991, ANN INTERN MED, V114, P325, DOI 10.7326/0003-4819-114-4-325; WENNEKER MB, 1990, JAMA-J AM MED ASSOC, V264, P1255, DOI 10.1001/jama.264.10.1255; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; WOOLHANDLER S, 1985, INT J HEALTH SERV, V15, P1, DOI 10.2190/90P3-LEFF-WNU0-GLY6; YERGAN J, 1988, MED CARE, V26, P1111, DOI 10.1097/00005650-198811000-00009; YOUNG GJ, 1991, INQUIRY-J HEALTH CAR, V28, P255; 1989, INT CLASSIFICATION D; 1987, SPECIAL REPORT ACCES, P2; 1989, CURRENT POPULATION S	37	515	519	1	30	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 4	1992	268	17					2388	2394		10.1001/jama.268.17.2388	http://dx.doi.org/10.1001/jama.268.17.2388			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JV694	1404795				2022-12-28	WOS:A1992JV69400024
J	BAGHURST, PA; MCMICHAEL, AJ; WIGG, NR; VIMPANI, GV; ROBERTSON, EF; ROBERTS, RJ; TONG, SL				BAGHURST, PA; MCMICHAEL, AJ; WIGG, NR; VIMPANI, GV; ROBERTSON, EF; ROBERTS, RJ; TONG, SL			ENVIRONMENTAL EXPOSURE TO LEAD AND CHILDRENS INTELLIGENCE AT THE AGE OF 7 YEARS - THE PORT-PIRIE COHORT STUDY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-LEVEL EXPOSURE; BLOOD-LEAD; IRON-DEFICIENCY; EARLY-CHILDHOOD; SOCIAL-CLASS; PERFORMANCE; ATTAINMENT; BEHAVIOR; IQ	Background. Exposure to lead in early childhood is thought to result in delayed neuropsychological development. As yet there is little longitudinal evidence to establish whether these effects persist into later childhood. Methods. We measured IQ scores in 494 seven-year-old children from the lead-smelting community of Port Pirie, Australia, in whom developmental deficits associated with elevated blood lead concentrations had already been reported at the ages of two and four years. Exposure to lead was estimated from the lead concentrations in maternal blood samples drawn antenatally and at delivery and from blood samples drawn from the children at birth (umbilical-cord blood), at the ages of 6 and 15 months and 2 years, and annually thereafter. Data relating to known covariates of child development were collected systematically for each child throughout the first seven years of life. Results. We found inverse relations between IQ at the age of seven years and both antenatal and postnatal blood lead concentrations. After adjustment by multiple regression for sex, parents' level of education, maternal age at delivery, parents' smoking status, socioeconomic status, quality of the home environment, maternal IQ, birth weight, birth order, feeding method (breast, bottle, or both), duration of breast-feeding, and whether the child's natural parents were living together, the relation with lead exposure was still evident for postnatal blood samples, particularly within the age range of 15 months to 4 years. For an increase in blood lead concentration from 10 mug per deciliter (0.48 mumol per liter) to 30 mug per deciliter (1.45 mumol per liter), expressed as the average of the concentrations at 15 months and 2, 3, and 4 years, the estimated reduction in the IQ of the children was in the range of 4.4 points (95 percent confidence interval, 2.2 to 6.6) to 5.3 points (95 percent confidence interval, 2.8 to 7.8). This reduction represents an approximate deficit in IQ of 4 to 5 percent. Conclusions. Low-level exposure to lead during early childhood is inversely associated with neuropsychological development through the first seven years of life.	CHILD ADOLESCENT & FAMILY HLTH SERV,ADELAIDE,SA,AUSTRALIA; ADELAIDE CTR WOMENS & CHILDRENS HLTH,DEPT CHEM PATHOL,ADELAIDE,SA,AUSTRALIA; NATL HLTH EDUC INST,DEPT SPECIAL PROGRAMMES,BEIJING,PEOPLES R CHINA; UNIV ADELAIDE,DEPT COMMUNITY MED,ADELAIDE,SA 5001,AUSTRALIA; FLINDERS UNIV,SCH NURSING,ADELAIDE,SA,AUSTRALIA; UNIV NEWCASTLE,FAC MED,NEWCASTLE,NSW 2308,AUSTRALIA	University of Adelaide; Flinders University South Australia; University of Newcastle	BAGHURST, PA (corresponding author), CSIRO,DIV HUMAN NUTR,POB 10041,GOUGER ST,ADELAIDE,SA 5000,AUSTRALIA.							BAGHURST P, 1985, ENVIRON RES, V38, P24, DOI 10.1016/0013-9351(85)90069-6; BAGHURST PA, 1992, ARCH ENVIRON HEALTH, V47, P203, DOI 10.1080/00039896.1992.9938350; BELLINGER D, 1989, INT J EPIDEMIOL, V18, P180, DOI 10.1093/ije/18.1.180; BELLINGER D, 1991, PEDIATRICS, V87, P219; BELLINGER D, 1987, NEW ENGL J MED, V316, P1037, DOI 10.1056/NEJM198704233161701; BINDER S, 1991, STRATEGIC PLAN ELIMI; BRADLEY RH, 1979, AM J MENT DEF, V84, P235; COONEY GH, 1989, NEUROTOXICOL TERATOL, V11, P95, DOI 10.1016/0892-0362(89)90047-0; DANIEL A, 1984, COMMUNITY HEALTH ST, V8, P218; DIETRICH KN, 1987, PEDIATRICS, V80, P721; ERNHART CB, 1988, SCI TOTAL ENVIRON, V71, P453, DOI 10.1016/0048-9697(88)90218-5; ERNHART CB, 1989, NEUROTOXICOL TERATOL, V11, P161, DOI 10.1016/0892-0362(89)90055-X; FULTON M, 1987, LANCET, V1, P1221; GILBERT SG, 1987, TOXICOL APPL PHARM, V91, P484, DOI 10.1016/0041-008X(87)90070-6; HARVEY PG, 1984, SCI TOTAL ENVIRON, V40, P45, DOI 10.1016/0048-9697(84)90341-3; HATZAKIS A, 1989, LEAD EXPOSURE AND CHILD DEVELOPMENT, P211; Kaufman A.S., 1979, INTELLIGENT TESTING; LANSDOWN R, 1986, INT ARCH OCC ENV HEA, V57, P225, DOI 10.1007/BF00405790; LEE WR, 1990, BMJ-BRIT MED J, V301, P504, DOI 10.1136/bmj.301.6751.504; LOZOFF B, 1991, NEW ENGL J MED, V325, P687, DOI 10.1056/NEJM199109053251004; MCMICHAEL AJ, 1985, MED J AUSTRALIA, V143, P499, DOI 10.5694/j.1326-5377.1985.tb119911.x; MCMICHAEL AJ, 1988, NEW ENGL J MED, V319, P468, DOI 10.1056/NEJM198808253190803; NEEDLEMAN HL, 1990, NEW ENGL J MED, V322, P83, DOI 10.1056/NEJM199001113220203; NEEDLEMAN HL, 1989, LEAD EXPOSURE AND CHILD DEVELOPMENT, P293; NEEDLEMAN HL, 1990, JAMA-J AM MED ASSOC, V263, P673, DOI 10.1001/jama.263.5.673; NEEDLEMAN HL, 1979, NEW ENGL J MED, V300, P689, DOI 10.1056/NEJM197903293001301; NEEDLEMAN HL, 1991, ANNU REV PUBL HEALTH, V12, P111, DOI 10.1146/annurev.pu.12.050191.000551; POCOCK SJ, 1987, INT J EPIDEMIOL, V16, P57, DOI 10.1093/ije/16.1.57; Rothman K, 1986, MODERN EPIDEMIOLOGY; SMITH RE, 1983, SOIL SCI SOC AM J, V47, P1; WALTER T, 1989, PEDIATRICS, V84, P7; Wechsler D., 2008, WECHSLER ADULT INTEL, P257; Wechsler D, 1974, WECHSLER ADULT INTEL; WIGG NR, 1988, J EPIDEMIOL COMMUN H, V42, P213, DOI 10.1136/jech.42.3.213; WINNEKE G, 1983, INT ARCH OCC ENV HEA, V51, P231, DOI 10.1007/BF00377755; 1988, JAMA-J AM MED ASSOC, V260, P1523; 1986, EPA600883028AF ENV C; 1985, 27871985 STAND ASS A	38	407	413	0	34	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 29	1992	327	18					1279	1284		10.1056/NEJM199210293271805	http://dx.doi.org/10.1056/NEJM199210293271805			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV259	1383818				2022-12-28	WOS:A1992JV25900005
J	LEE, IM; PAFFENBARGER, RS				LEE, IM; PAFFENBARGER, RS			CHANGE IN BODY-WEIGHT AND LONGEVITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK FACTOR; CARDIOVASCULAR-DISEASE; PHYSICAL-ACTIVITY; CORONARY-DISEASE; RELATIVE WEIGHT; COLLEGE ALUMNI; MORTALITY; FRAMINGHAM; HEALTH; MEN	Objective.-To investigate the effect of body weight change on longevity. Design.-Cohort analytic study, following men from 1977 through 1988. Setting.-The study was conducted among Harvard University alumni with mean age of 58 years. Patients.-Alumni, free of cardiovascular disease and cancer, completed questionnaires on weight, height, cigarette habit, and physical activities in 1962 or 1966 and in 1977 (n=11 703). We assessed weight change between questionnaires, based on self-reported weights. Main Outcome Measure.-Mortality from all causes (n=1441), coronary heart disease (n=345), and cancer (n=459), determined from death certificates. Results.-Lowest all-cause mortality was among alumni maintaining stable weight (+/-1 kg). With this category as referent (relative risk=1.00), relative risks of death associated with losing more than 5 kg, losing between 1 and 5 kg, (more than 1 kg and up to 5 kg) gaining between 1 and 5 kg (more than 1 kg and up to 5 kg), and gaining more than 5 kg were 1.57 (95% confidence interval, 1.34 to 1.84), 1.26 (1.10 to 1.46), 1.06 (0.90 to 1.24), and 1.36 (1.11 to 1.66), respectively. For coronary heart disease mortality, relative risks were 1.75 (1.26 to 2.43), 1.43 (1.05 to 1.93), 1.28 (0.91 to 1.80), and 2.01 (1.36 to 2.97), respectively. Weight change did not predict cancer mortality. Findings were not explained by cigarette habit, physical activity, or body mass index. We observed similar trends for follow-up between 1977 and 1982 and between 1983 and 1988. Those losing or gaining more weight also reported greater total lifetime weight loss, which may indicate weight cycling. Conclusions.-Both body weight loss and weight gain are associated with significantly increased mortality from all causes and from coronary heart disease but not from cancer.	STANFORD UNIV, MED CTR, SCH MED, DIV EPIDEMIOL, STANFORD, CA 94305 USA	Stanford University	LEE, IM (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, 677 HUNTINGTON AVE, BOSTON, MA 02115 USA.		Lee, I-Min/ABD-5409-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034174] Funding Source: NIH RePORTER; NCI NIH HHS [CA 09001] Funding Source: Medline; NHLBI NIH HHS [HL 34174] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1985, ANN INTERN MED, V103, P1073, DOI 10.7326/0003-4819-103-6-1073; [Anonymous], 1990, NUTR EPIDEMIOLGY; ASHLEY FW, 1974, J CHRON DIS, V27, P103, DOI 10.1016/0021-9681(74)90079-4; AVONS P, 1983, LANCET, V1, P1104; BORKAN GA, 1986, AM J EPIDEMIOL, V124, P410, DOI 10.1093/oxfordjournals.aje.a114411; BOUCHARD C, 1991, NEW ENGL J MED, V324, P1887, DOI 10.1056/NEJM199106273242609; COX DR, 1972, J R STAT SOC B, V34, P187; HAMM P, 1989, AM J EPIDEMIOL, V129, P312, DOI 10.1093/oxfordjournals.aje.a115135; HARRIS T, 1988, JAMA-J AM MED ASSOC, V259, P1520; HEYDEN S, 1971, ARCH INTERN MED, V128, P956, DOI 10.1001/archinte.128.6.956; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; KEYS A, 1972, J CHRON DIS, V25, P329, DOI 10.1016/0021-9681(72)90027-6; LARSSON B, 1984, BRIT MED J, V288, P1401, DOI 10.1136/bmj.288.6428.1401; LEE IM, 1992, AM J EPIDEMIOL, V135, P169, DOI 10.1093/oxfordjournals.aje.a116269; LEE IM, 1991, J NATL CANCER I, V83, P1324, DOI 10.1093/jnci/83.18.1324; LISSNER L, 1991, NEW ENGL J MED, V324, P1839, DOI 10.1056/NEJM199106273242602; Lissner L., 1989, Obesity in Europe 88. Proceedings of the 1st European Congress on Obesity, 5-6 June, 1988, Stockholm, Sweden., P55; LISSNER L, 1990, INT J OBESITY, V14, P373; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MANSON JE, 1987, JAMA-J AM MED ASSOC, V257, P353, DOI 10.1001/jama.257.3.353; NOPPA H, 1980, AM J EPIDEMIOL, V111, P693, DOI 10.1093/oxfordjournals.aje.a112947; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; PALTA M, 1982, AM J EPIDEMIOL, V115, P223, DOI 10.1093/oxfordjournals.aje.a113294; PHINNEY SD, 1991, AM J CLIN NUTR, V53, P1404, DOI 10.1093/ajcn/53.6.1404; RHOADS GG, 1983, LANCET, V1, P492; RODIN J, 1990, INT J OBESITY, V14, P303; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P41; SIDNEY S, 1987, AM J PUBLIC HEALTH, V77, P317, DOI 10.2105/AJPH.77.3.317; SIMOPOULOS AP, 1984, ANN INTERN MED, V100, P285, DOI 10.7326/0003-4819-100-2-285; SNEDECOR GW, 1980, STATISTICAL METHODS, P215; SONNICHSEN AC, 1990, INT J OBESITY, V14, P487; STEVENS J, 1990, INT J OBESITY, V14, P385; STEWART AW, 1987, AM J EPIDEMIOL, V125, P122, DOI 10.1093/oxfordjournals.aje.a114494; STUNKARD AJ, 1981, AM J CLIN NUTR, V34, P1593, DOI 10.1093/ajcn/34.8.1593; WANNAMETHEE G, 1990, POSTGRAD MED J, V66, P910, DOI 10.1136/pgmj.66.781.910; [No title captured]; 1983, VITAL HLTH STAT 11, V230; 1960, STAT B METROP INSUR, V41, P1; 1987, VITAL HLTH STAT 11, V238	39	215	219	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 21	1992	268	15					2045	2049		10.1001/jama.268.15.2045	http://dx.doi.org/10.1001/jama.268.15.2045			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT520	1404740				2022-12-28	WOS:A1992JT52000027
J	SMITH, HE; FREW, AJ				SMITH, HE; FREW, AJ			LETTER FROM BRITISH-COLUMBIA - CONTAINING THE COSTS OF MEDICARE	BRITISH MEDICAL JOURNAL			English	Article									UNIV BRITISH COLUMBIA,VANCOUVER V6T 1W5,BC,CANADA	University of British Columbia			Smith, Helen E/M-2449-2016; Kelly, Frank J/C-6125-2009	Smith, Helen E/0000-0003-1883-6124; Kelly, Frank J/0000-0003-2558-8392				1991, CLOSER HOME	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 19	1992	305	6855					705	706		10.1136/bmj.305.6855.705	http://dx.doi.org/10.1136/bmj.305.6855.705			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP511	1393122	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JP51100033
J	HINDS, PW; MITTNACHT, S; DULIC, V; ARNOLD, A; REED, SI; WEINBERG, RA				HINDS, PW; MITTNACHT, S; DULIC, V; ARNOLD, A; REED, SI; WEINBERG, RA			REGULATION OF RETINOBLASTOMA PROTEIN FUNCTIONS BY ECTOPIC EXPRESSION OF HUMAN CYCLINS	CELL			English	Article							LARGE-T-ANTIGEN; ADENOVIRUS E1A PROTEINS; CELL-CYCLE; GENE-PRODUCT; SUSCEPTIBILITY GENE; SACCHAROMYCES-CEREVISIAE; G1-SPECIFIC CYCLINS; CANDIDATE ONCOGENE; KINASE COMPLEX; G1 PHASE	The retinoblastoma susceptibility gene (RB) product, the retinoblastoma protein (pRb), functions as a regulator of cell proliferation. Introduction of the RB gene into SAOS-2 osteosarcoma cells, which lack functional pRb, prevents cell cycle progression. Such growth-suppressive functions can be modulated by phosphorylation of pRb, which occurs via cell cycle-regulated kinases. We show that constitutively expressed cyclins A and E can overcome pRb-mediated suppression of proliferation. pRb becomes hyperphosphorylated in cells overexpressing these cyclins, and this phosphorylation is essential for cyclin A- and cyclin E-mediated rescue of pRb-blocked cells. This suggests that G1 and S phase cyclins can act as regulators of pRb function in the cell cycle by promoting pRb phosphorylation.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; MASSACHUSETTS GEN HOSP, ENDOCRINE UNIT, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02114 USA	Scripps Research Institute; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	HINDS, PW (corresponding author), WHITEHEAD INST, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.			Dulic, Vjekoslav/0000-0003-1201-3901	NATIONAL CANCER INSTITUTE [R01CA055909] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038328, R01GM038328, P01GM046006] Funding Source: NIH RePORTER; NCI NIH HHS [CA55909] Funding Source: Medline; NIGMS NIH HHS [GM38328, GM46006] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BUENO A, 1991, CELL, V66, P149, DOI 10.1016/0092-8674(91)90147-Q; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHERINGTON V, 1988, MOL CELL BIOL, V8, P1380, DOI 10.1128/MCB.8.3.1380; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DULIC V, 1992, IN PRESS SCIENCE; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FURUKAWA Y, 1991, ONCOGENE, V6, P1343; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; IMAI Y, 1991, J VIROL, V65, P4966, DOI 10.1128/JVI.65.9.4966-4972.1991; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; Maller JL, 1991, CURR OPIN CELL BIOL, V3, P269; MENDENHALL MD, 1987, CELL, V50, P927, DOI 10.1016/0092-8674(87)90519-8; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MITTNACHT S, 1991, COLD SPRING HARB SYM, V56, P197; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MOTOKURA T, 1992, IN PRESS J BIOL CHEM; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; Nigg E A, 1991, Semin Cell Biol, V2, P261; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; REED SI, 1980, GENETICS, V95, P561; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SHEW JY, 1989, ONCOGENE RES, V4, P205; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SMITH DH, 1988, MOL CELL BIOL, V8, P3882, DOI 10.1128/MCB.8.9.3882; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VARLEY JM, 1989, ONCOGENE, V4, P725; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WILLIAMS RT, 1992, ONCOGENE, V7, P423; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WITTENBERG C, 1988, CELL, V54, P1061, DOI 10.1016/0092-8674(88)90121-3; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	68	1007	1022	0	24	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 18	1992	70	6					993	1006		10.1016/0092-8674(92)90249-C	http://dx.doi.org/10.1016/0092-8674(92)90249-C			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JN781	1388095				2022-12-28	WOS:A1992JN78100014
J	SMITH, AP				SMITH, AP			HOW TO DO IT - DESIGN A CLINICAL INFORMATION-SYSTEM	BRITISH MEDICAL JOURNAL			English	Article											SMITH, AP (corresponding author), LLANDOUGH HOSP,PENARTH GP6 1XX,S GLAM,WALES.		Smith, Adam/GPS-8322-2022						0	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 15	1992	305	6850					415	417		10.1136/bmj.305.6850.415	http://dx.doi.org/10.1136/bmj.305.6850.415			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK314	1392927	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992JK31400024
J	WILSON, RG; MACINTYRE, IMC; NIXON, SJ; SAUNDERS, JH; VARMA, JS; KING, PM				WILSON, RG; MACINTYRE, IMC; NIXON, SJ; SAUNDERS, JH; VARMA, JS; KING, PM			LAPAROSCOPIC CHOLECYSTECTOMY AS A SAFE AND EFFECTIVE TREATMENT FOR SEVERE ACUTE CHOLECYSTITIS	BRITISH MEDICAL JOURNAL			English	Article							EXPERIENCE	Objective-To evaluate the feasibility and safety of laparoscopic cholecystectomy in severe acute cholecystitis. Design-Analysis of data collected prospectively from a consecutive series of 350 laparoscopic operations. Setting-Two general surgical units in a teaching hospital. Subjects-31 patients with a diagnosis of severe acute cholecystitis based on clinical examination, investigation results, and operative findings. Interventions-Initial intravenous fluids and broad spectrum antibiotics followed by laparoscopic cholecystectomy within 72 hours of presentation. Main outcome measures-Failure to complete the operation laparoscopically, length of postoperative stay in hospital, early postoperative morbidity, interval from operation to full activity, and return to work. Results-Laparoscopic cholecystectomy was attempted in 19 patients with empyema of the gall bladder and 12 who had severe cholecystitis which failed to settle on medical management. A total of 29 operations were successfully completed with two conversions to open surgery. Two minor postoperative complications occurred, and one case of retained common bile duct stones with jaundice was treated by endoscopic retrograde cholangio-pancreatography and papillotomy. Median postoperative hospital stay was two days, with return to normal activity in seven days and to work in two weeks. There were no deaths related to the operation. Conclusions-In the presence of severe acute cholecystitis laparoscopic cholecystectomy is feasible in most patients, with minimal risk of injury to surrounding structures and considerable benefits. It is recommended that laparoscopic cholecystectomy should be attempted in these patients when appropriate surgical skill is available.			WILSON, RG (corresponding author), WESTERN GEN HOSP,DEPT SURG,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.			Macintyre, Iain/0000-0003-2716-8500				Cooperman A M, 1990, J Laparoendosc Surg, V1, P37, DOI 10.1089/lps.1990.1.37; CUSCHIERI A, 1991, AM J SURG, V161, P385, DOI 10.1016/0002-9610(91)90603-B; DUBOIS F, 1990, ANN SURG, V211, P60, DOI 10.1097/00000658-199001000-00010; FLOWERS JL, 1991, AM J SURG, V161, P388, DOI 10.1016/0002-9610(91)90604-C; HOLOHAN TV, 1991, LANCET, V338, P801, DOI 10.1016/0140-6736(91)90678-I; MCARTHUR P, 1975, BRIT J SURG, V62, P850, DOI 10.1002/bjs.1800621025; MEYERS WC, 1991, NEW ENGL J MED, V324, P1073; REDDICK EJ, 1989, SURG ENDOSC-ULTRAS, V3, P1333; REISS R, 1990, WORLD J SURG, V14, P567, DOI 10.1007/BF01658790; Unger S W, 1991, Surg Laparosc Endosc, V1, P14; WILSON P, 1991, LANCET, V338, P795, DOI 10.1016/0140-6736(91)90674-E; ZUCKER KA, 1991, AM J SURG, V161, P36, DOI 10.1016/0002-9610(91)90358-K	12	101	103	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 15	1992	305	6850					394	396		10.1136/bmj.305.6850.394	http://dx.doi.org/10.1136/bmj.305.6850.394			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK314	1392919	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JK31400014
J	AUBRY, JP; POCHON, S; GRABER, P; JANSEN, KU; BONNEFOY, JY				AUBRY, JP; POCHON, S; GRABER, P; JANSEN, KU; BONNEFOY, JY			CD21 IS A LIGAND FOR CD23 AND REGULATES IGE PRODUCTION	NATURE			English	Article							HUMAN LYMPHOCYTES-B; MHC CLASS-II; C3D RECEPTOR; SOLUBLE CD23; MONOCLONAL-ANTIBODIES; SEQUENCE HOMOLOGY; EBV/C3D RECEPTOR; INTERFERON-ALPHA; CELLS EXPRESS; ANTIGEN	THE molecule CD23, a low-affinity receptor for IgE (Fc-epsilon-R2)1,2, is a type II transmembrane molecule expressed on many haemopoietic cell types3,4. CD23 has pleiotropic roles in the control of lymphocyte behaviour5-9, suggesting that CD23 may interact with another ligand in addition to IgE. To identify such a CD23 ligand, we expressed and purified full-length recombinant CD23, incorporated it into fluorescent liposomes and used these as a probe. We report here that fluorescent liposomes carrying CD23 interact specifically with the cell-surface protein CD21, identified as the receptor for Epstein-Barr virus and the complement receptor-2 on B cells, some T cells and follicular dendritic cells. In addition, fluorescent CD23-liposomes were shown to bind to hamster kidney cells (BHK-21) transfected with CD21 complementary DNA. The interaction between fluorescent CD23-liposomes and B cells or CD21-transfected BHK-21 cells was specifically inhibited by anti-CD21 and anti-CD23 monoclonal antibodies. Western blotting analysis revealed that C-14-labelled liposomes carrying CD23, in contrast to anti-CD21 antibodies, reacted with a subtype of CD21 molecules. Triggering of CD21 either with an anti-CD21 antibody or with recombinant soluble CD23 was shown to increase specifically interleukin-4-induced IgE production from blood mononuclear cells. These results demonstrate that the cell-surface protein CD21 is a ligand for CD23 and that the pairing of these molecules may participate in the control of IgE production.	GLAXO INST MOLEC BIOL,14 CHEMIN AULX,CH-1228 PLAN LES OUATES,SWITZERLAND	GlaxoSmithKline								BILLAUD M, 1989, J VIROL, V63, P4121, DOI 10.1128/JVI.63.10.4121-4128.1989; BONNEFOY JY, 1987, J IMMUNOL, V138, P2970; BONNEFOY JY, 1988, J EXP MED, V167, P57, DOI 10.1084/jem.167.1.57; BONNEFOY JY, 1990, EUR J IMMUNOL, V20, P139, DOI 10.1002/eji.1830200120; CAIRNS J, 1990, EUR J IMMUNOL, V20, P534; CANTALOUBE JF, 1990, EUR J IMMUNOL, V20, P409, DOI 10.1002/eji.1830200226; DELCAYRE AX, 1991, EMBO J, V10, P919, DOI 10.1002/j.1460-2075.1991.tb08025.x; DELESPESSE G, 1989, IMMUNOL TODAY, V10, P159, DOI 10.1016/0167-5699(89)90173-4; DORKEN B, 1989, LEUCOCYTE TYPING, V4, P99; FISCHER E, 1991, J IMMUNOL, V146, P865; FLORESROMO L, 1990, EUR J IMMUNOL, V20, P2465, DOI 10.1002/eji.1830201116; FRADE R, 1985, P NATL ACAD SCI USA, V82, P1490, DOI 10.1073/pnas.82.5.1490; GORDON J, 1986, EUR J IMMUNOL, V16, P1075, DOI 10.1002/eji.1830160908; GORDON J, 1989, IMMUNOL TODAY, V10, P153, DOI 10.1016/0167-5699(89)90171-0; GRABER P, 1992, J IMMUNOL METHODS, V149, P215, DOI 10.1016/0022-1759(92)90253-P; HUTTFLECHER LM, 1987, J VIROL, V651, P774; IKUTA K, 1987, P NATL ACAD SCI USA, V84, P819, DOI 10.1073/pnas.84.3.819; JANSEN KU, 1991, J RECEPTOR RES, V11, P507, DOI 10.3109/10799899109066424; KOLB JP, 1990, J IMMUNOL, V145, P429; LIU YJ, 1991, EUR J IMMUNOL, V21, P1107, DOI 10.1002/eji.1830210504; MELCHERS F, 1985, NATURE, V317, P264, DOI 10.1038/317264a0; MOSSALAYI MD, 1990, BLOOD, V75, P1924; MOSSALAYI MD, 1990, J EXP MED, V171, P959, DOI 10.1084/jem.171.3.959; NADLER LM, 1981, J IMMUNOL, V126, P1941; NEMEROW GR, 1987, J VIROL, V61, P1416, DOI 10.1128/JVI.61.5.1416-1420.1987; PENE J, 1988, EUR J IMMUNOL, V18, P929, DOI 10.1002/eji.1830180615; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; POCHON S, IN PRESS J EXP MED; REYNES M, 1985, J IMMUNOL, V135, P2687; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; TANNER J, 1987, CELL, V50, P203, DOI 10.1016/0092-8674(87)90216-9; TEW JG, 1979, IMMUNOLOGY, V37, P69; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; WEIS JJ, 1984, P NATL ACAD SCI-BIOL, V81, P881, DOI 10.1073/pnas.81.3.881; WILSON BS, 1985, BLOOD, V66, P824; YOUNG LS, 1986, LANCET, V1, P240; YUKAWA K, 1987, J IMMUNOL, V138, P2576	37	450	467	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 6	1992	358	6386					505	507		10.1038/358505a0	http://dx.doi.org/10.1038/358505a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG739	1386409				2022-12-28	WOS:A1992JG73900050
J	ALDOUS, J; HICKMAN, M; ELLAM, A; GAZZARD, B; HARGREAVES, S				ALDOUS, J; HICKMAN, M; ELLAM, A; GAZZARD, B; HARGREAVES, S			IMPACT OF HIV-INFECTION ON MORTALITY IN YOUNG MEN IN A LONDON HEALTH AUTHORITY	BRITISH MEDICAL JOURNAL			English	Article							AIDS; EPIDEMIC; ENGLAND; DEATHS; WALES	Objective-To determine the number of deaths attributable to HIV infection among men aged 15-64 in a geographically defined population in the United Kingdom. Design-Retrospective review of death certificates and linkage with local and national HIV and AIDS surveillance data. Setting-Riverside District Health Authority, London. Main outcome measures-Numbers of deaths attributed to HIV infection in male residents of Riverside aged 15-64 and 15-44 over a six month period. Proportion of attributed deaths were (i) identified from death certificates by the Office of Population Censuses and Surveys as being due to HIV infection and (ii) reported as cases of AIDS or HIV related deaths to the Public Health Laboratory Service Communicable Disease Surveillance Centre Results-34 of 213 (16%) deaths in men aged 15-64 and 27 of 69 (39%) deaths in men aged 15-44 were attributed to HIV infection. Six of 33 (18%) attributed deaths were identified by the Office of Population Censuses and Surveys and 32/34 (94%) were reported to the Communicable Disease Surveillance Centre. Conclusions-HIV infection was the leading cause of death in male residents of Riverside aged 15-44 and the third commonest cause of death in those aged 15-64. Most individuals dying of known HIV infection were reported to the Communicable Disease Surveillance Centre but identification of the true cause of death from the process of death certification was poor. Measures to improve the certification of HIV and AIDS or the use of AIDS surveillance information correctly to code the cause of death needs to be considered to ensure that the true impact of HIV infection is reflected in routine mortality statistics.	RIVERSIDE HLTH AUTHOR,DEPT PUBL HLTH,LONDON SW6 4UL,ENGLAND; WESTMINSTER MED SCH & HOSP,HIV GENITOURINARY MED UNIT,LONDON SW1P 2AP,ENGLAND	Imperial College London			Hickman, Matthew/Y-2400-2019	Hickman, Matthew/0000-0001-9864-459X				BOBBY JJ, 1988, PUBLIC HEALTH, V102, P519, DOI 10.1016/S0033-3506(88)80020-9; DECOCK KM, 1990, SCIENCE, V249, P793, DOI 10.1126/science.2167515; EVANS GE, 1991, BMJ, V302, P1351; FENNA D, 1984, COMPUT PROG BIOMED, V19, P31, DOI 10.1016/0010-468X(84)90035-7; HICKMAN M, 1990, LANCET, V336, P1328, DOI 10.1016/0140-6736(90)93020-P; HICKMAN M, 1991, BRIT MED J, V302, P1376, DOI 10.1136/bmj.302.6789.1376; MCCORMICK A, 1989, PHILOS T ROY SOC B, V325, P163, DOI 10.1098/rstb.1989.0081; MCCORMICK A, 1991, BRIT MED J, V302, P1365, DOI 10.1136/bmj.302.6789.1365; MCCORMICK A, 1988, BRIT MED J, V296, P1289, DOI 10.1136/bmj.296.6632.1289; MCCORMICK A, 1991, BRIT MED J, V302, P1375, DOI 10.1136/bmj.302.6789.1375; 1991, Q SURVEILLANCE TABLE; 1990, STATE PUBLIC HLTH YE; 1991, MMWR, V40, P41; 1987, MMWR S1, V36, P3; 1986, MMWR S2, V35, P1	15	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1992	305	6847					219	221		10.1136/bmj.305.6847.219	http://dx.doi.org/10.1136/bmj.305.6847.219			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG112	1392823	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JG11200020
J	GISHIZKY, ML; WITTE, ON				GISHIZKY, ML; WITTE, ON			INITIATION OF DEREGULATED GROWTH OF MULTIPOTENT PROGENITOR CELLS BY BCR-ABL INVITRO	SCIENCE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE-ACTIVITY; MYELOID-LEUKEMIA; MICE; TRANSFORMATION; INDUCTION; CULTURES; PROTEIN; BCR/ABL; REGION	Expression of the bcr-abl oncogene in multipotent progenitor cells (MPPCs) is implicated as a key event in the development of chronic myelogenous leukemia. Bone marrow enriched for MPPCs was infected with a retrovirus that carried bcr-abl. The mixed-lineage colonies that resulted were responsive to growth factors and could differentiate. These cells later became growth factor-independent but, when injected into severe combined immunodeficient mice, were not leukemogenic. Thus, the presence of bcr-abl alone does not cause growth factor independence, although it initiates a stepwise process. This system may prove useful in the study of other oncogenes that cause leukemia.	UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024	Howard Hughes Medical Institute; University of California System; University of California Los Angeles	GISHIZKY, ML (corresponding author), UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024, USA.							AHUJA H, 1991, J CLIN INVEST, V87, P2042, DOI 10.1172/JCI115234; BODINE DM, 1991, BLOOD, V78, P914; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; COLLINS LS, 1987, J IMMUNOL, V138, P1082; COLLINS SJ, 1990, CHRONIC MYELOGENOUS, P253; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEVRIES P, 1991, J EXP MED, V173, P1205, DOI 10.1084/jem.173.5.1205; EARLY P, 1980, CELL, V19, P981, DOI 10.1016/0092-8674(80)90089-6; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; EPSTEIN J, 1990, NEW ENGL J MED, V322, P664, DOI 10.1056/NEJM199003083221005; FEINSTEIN E, 1991, P NATL ACAD SCI USA, V88, P6293, DOI 10.1073/pnas.88.14.6293; FIALKOW PJ, 1981, BLOOD, V58, P158, DOI 10.1182/blood.V58.1.158.158; GISHIZKY ML, 1991, ONCOGENE, V6, P1299; GISHIZKY ML, UNPUB; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; Hariharan I K, 1988, Oncogene Res, V3, P387; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; KEINANEN M, 1988, NEW ENGL J MED, V318, P1153, DOI 10.1056/NEJM198805053181803; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LIU E, 1988, P NATL ACAD SCI USA, V85, P1952, DOI 10.1073/pnas.85.6.1952; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MCCARTHY DM, 1984, LANCET, V2, P1362; MIGLIACCIO G, 1991, P NATL ACAD SCI USA, V88, P7420, DOI 10.1073/pnas.88.16.7420; NOWELL PC, 1960, SCIENCE, V132, P1497; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; TOWATARI M, 1991, BLOOD, V78, P2178, DOI 10.1182/blood.V78.9.2178.bloodjournal7892178; YOUNG JC, 1988, MOL CELL BIOL, V8, P4079, DOI 10.1128/MCB.8.10.4079; YOUNG JC, 1991, MOL CELL BIOL, V11, P854, DOI 10.1128/MCB.11.2.854; [No title captured]	36	155	160	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 8	1992	256	5058					836	839		10.1126/science.1375394	http://dx.doi.org/10.1126/science.1375394			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT235	1375394				2022-12-28	WOS:A1992HT23500045
J	NICOLAIDES, KH; AZAR, G; BYRNE, D; MANSUR, C; MARKS, K				NICOLAIDES, KH; AZAR, G; BYRNE, D; MANSUR, C; MARKS, K			FETAL NUCHAL TRANSLUCENCY - ULTRASOUND SCREENING FOR CHROMOSOMAL DEFECTS IN 1ST TRIMESTER OF PREGNANCY	BRITISH MEDICAL JOURNAL			English	Article							CYSTIC HYGROMA; 1ST-TRIMESTER DIAGNOSIS; RECURRENCE	Objective-To examine the significance of fetal nuchal translucency at 10-14 weeks' gestation in the prediction of abnormal fetal karyotype. Design-Prospective screening study. Setting-The Harris Birthright Research Centre for Fetal Medicine, King's College Hospital, London. Subjects-827 fetuses undergoing first trimester karyotyping by aminocentesis or chorionic villus sampling. Main outcome measure-Incidence of chromosomal defects. Results-The incidence of chromosomal defects was 3% (28 of 827 cases). In the 51 (6%) fetuses with nuchal translucency 3-8 mm thick the incidence of chromosomal defects was 35% (18 cases). In contrast, only 10 of the remaining 776 (1%) fetuses were chromosomally abnormal. Conclusion-Fetal nuchal translucency greater-than-or-equal-to 3 mm is a useful first trimester marker for fetal chromosomal abnormalities.			NICOLAIDES, KH (corresponding author), UNIV LONDON KINGS COLL HOSP,SCH MED,HARRIS BIRTHRIGHT RES CTR FETAL MED,LONDON SE5 8RX,ENGLAND.			Nicolaides, Kypros/0000-0003-1266-0711				AZAR GB, IN PRESS FETAL DIAGN; BRONSHTEIN M, 1989, AM J OBSTET GYNECOL, V161, P78, DOI 10.1016/0002-9378(89)90237-8; BYRNE D, 1991, ULTRASOUND OBSTETRIC, V1, P234; CULLEN MT, 1990, PRENATAL DIAG, V10, P643, DOI 10.1002/pd.1970101004; DALLAPICCOLA B, 1984, PRENATAL DIAG, V4, P383, DOI 10.1002/pd.1970040510; GUSTAVII B, 1984, ACTA OBSTET GYN SCAN, V63, P377, DOI 10.3109/00016348409155537; NICOLAIDES KH, 1985, BRIT J OBSTET GYNAEC, V92, P671, DOI 10.1111/j.1471-0528.1985.tb01446.x; NICOLAIDES KH, IN PRESS FETAL DIAGN; PONS JC, 1989, EUR J OBSTET GYN R B, V33, P141, DOI 10.1016/0028-2243(89)90206-2; REUSS A, 1987, EUR J OBSTET GYN R B, V26, P271, DOI 10.1016/0028-2243(87)90079-7; REUSS A, 1987, PRENATAL DIAG, V7, P299, DOI 10.1002/pd.1970070412; VANDERPUTTE SCJ, 1977, VIRCHOWS ARCH A, V376, P233	12	707	766	0	29	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1992	304	6831					867	869		10.1136/bmj.304.6831.867	http://dx.doi.org/10.1136/bmj.304.6831.867			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM835	1392745	Bronze, Green Published			2022-12-28	WOS:A1992HM83500020
J	RECKER, RR; DAVIES, KM; HINDERS, SM; HEANEY, RP; STEGMAN, MR; KIMMEL, DB				RECKER, RR; DAVIES, KM; HINDERS, SM; HEANEY, RP; STEGMAN, MR; KIMMEL, DB			BONE GAIN IN YOUNG-ADULT WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ORAL-CONTRACEPTIVE USE; MOTHER-DAUGHTER PAIRS; BIRTH-CONTROL PILLS; MINERAL CONTENT; PHYSICAL-ACTIVITY; LUMBAR SPINE; GENETIC-DETERMINANTS; PREMENOPAUSAL WOMEN; CALCIUM BALANCE; NORMAL-CHILDREN	Objective.-To test whether bone mass increases in healthy nonpregnant white women during early adult life after cessation of linear growth; and to test whether various self-chosen levels of physical activity and nutrient intake or use of oral contraceptives influences this increase in bone mass. Design.-Longitudinal prospective study of up to 5 years of 156 healthy college-aged women full-time students attending professional schools in universities in the Omaha, Neb, area. Setting.-University medical center. Participants.-A convenience sample of healthy women students from Omaha-area professional schools. Any candidate with an illness, condition, or medication (except oral contraceptives) thought to affect general health or bone mass was excluded. Interventions.-None. Outcome Measures.-Clinical and family histories of disease, particularly osteoporosis; oral contraceptive use; bone mineral densities of the spine, forearm, and total body by dual- and single-photon absorptiometry; estimates of nutrient intake by repeated 7-day diet diaries; and measures of physical activity using a physical activity monitor. Results.-The median gain in bone mass for the third decade of life, expressed as a percentage per decade, was 4.8% for the forearm, 5.9% for lumbar bone mineral content, 6.8% for lumbar bone mineral density, and 12.5% for total body bone mass (P<.0001 in all cases). By both bivariate and multiple regression analysis the rate of gain in bone density of the spine was negatively correlated with age and positively correlated with calcium/protein intake ratio and physical activity (multiple r=.31; P=.004). Bivariate analysis showed that use of oral contraceptives was associated with greater gain in total body bone mass (r=.31, P=.01). The estimated age when mineral acquisition ceased ranged from 28.3 years to 29.5 years at the several study sites. Conclusions.-Gain in bone mass occurs in healthy young women during the third decade of life. Physical activity and dietary calcium intake both exert a positive effect on this bone gain. Use of oral contraceptives exerts a further independent positive effect. Changes in life-style among college-aged women, involving relatively modest increases in physical activity and calcium intake, may significantly reduce the risk of osteoporosis late in life.			RECKER, RR (corresponding author), CREIGHTON UNIV,SCH MED,CTR HARD TISSUE RES,601 N 30TH ST,OMAHA,NE 68131, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR032462] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-32462] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALOIA JF, 1985, J LAB CLIN MED, V106, P630; BLACK DM, 1992, J BONE MINER RES, V7, P639; BONJOUR JP, 1991, J CLIN ENDOCR METAB, V73, P555, DOI 10.1210/jcem-73-3-555; BUCHANAN JR, 1988, J BONE MINER RES, V3, P673, DOI 10.1002/jbmr.5650030613; BUCHANAN JR, 1988, J BONE MINER RES, V3, P583; CAMERON J, 1964, SCIENCE, V142, P27; COOPER C, 1992, J BONE MINER RES, V7, P221, DOI 10.1002/jbmr.5650070214; CUMMINGS SR, 1989, ARCH INTERN MED, V149, P2445, DOI 10.1001/archinte.149.11.2445; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; CUMMINGS SR, 1990, CLIN ORTHOPAEDICS, V252, P163; DAVEE AM, 1990, J BONE MINER RES, V5, P245, DOI 10.1002/jbmr.5650050307; DEQUEKER J, 1987, BONE, V8, P207, DOI 10.1016/8756-3282(87)90166-9; ELDERS PJM, 1989, BONE MINER, V7, P289, DOI 10.1016/0169-6009(89)90085-8; EPKER B. N., 1965, CLIN ORTHOP RELAT RES, V41, P198; EVANS RA, 1988, ANN INTERN MED, V109, P870, DOI 10.7326/0003-4819-109-11-870; Garn S.M., 1970, EARLIER GAIN LATER L; GEUSENS P, 1986, J NUCL MED, V27, P1540; GILSANZ V, 1988, CALCIFIED TISSUE INT, V43, P260, DOI 10.1007/BF02555144; GLASTRE C, 1990, J CLIN ENDOCR METAB, V70, P1330, DOI 10.1210/jcem-70-5-1330; HEANEY RP, 1982, J LAB CLIN MED, V99, P46; HRESHCHYSHYN MM, 1988, AM J OBSTET GYNECOL, V159, P318, DOI 10.1016/S0002-9378(88)80075-9; Hui S L, 1990, Osteoporos Int, V1, P30, DOI 10.1007/BF01880413; HUI SL, 1985, GROWTH, V49, P34; JOHANSEN JS, 1989, BONE MINER, V6, P77, DOI 10.1016/0169-6009(89)90025-1; KANDERS B, 1988, J BONE MINER RES, V3, P145; Kelly P J, 1990, Osteoporos Int, V1, P56, DOI 10.1007/BF01880417; KLESGES RC, 1985, AM J EPIDEMIOL, V122, P400, DOI 10.1093/oxfordjournals.aje.a114121; KROLNER B, 1982, CLIN SCI, V62, P329, DOI 10.1042/cs0620329; LANDIN L, 1981, ACTA PAEDIATR SCAND, V70, P919, DOI 10.1111/j.1651-2227.1981.tb06251.x; LINDSAY R, 1986, CONTRACEPTION, V34, P333, DOI 10.1016/0010-7824(86)90086-7; LLOYD T, 1989, AM J OBSTET GYNECOL, V160, P402, DOI 10.1016/0002-9378(89)90457-2; LUTZ J, 1986, AM J CLIN NUTR, V44, P99, DOI 10.1093/ajcn/44.1.99; LUTZ J, 1990, AM J CLIN NUTR, V52, P872, DOI 10.1093/ajcn/52.5.872; MALLETTE LE, 1989, J BONE MINER RES, V4, P143; MATKOVIC V, 1990, AM J CLIN NUTR, V52, P878, DOI 10.1093/ajcn/52.5.878; MATKOVIC V, 1979, AM J CLIN NUTR, V32, P540, DOI 10.1093/ajcn/32.3.540; MAZESS RB, 1991, AM J CLIN NUTR, V53, P132, DOI 10.1093/ajcn/53.1.132; MELTON LJ, 1986, AM J EPIDEMIOL, V124, P254, DOI 10.1093/oxfordjournals.aje.a114383; MELTON LJ, 1989, AM J EPIDEMIOL, V129, P1000, DOI 10.1093/oxfordjournals.aje.a115204; MELTON LJ, 1988, J CLIN EPIDEMIOL, V41, P985; MILER J, 1991, J BONE MINER RES S, V6, P136; MOLLER M, 1978, CALC TISS RES, V25, P197, DOI 10.1007/BF02010768; MONTOYE HJ, 1983, MED SCI SPORT EXER, V15, P403; NILAS L, 1988, BONE MINER, V4, P95; PICARD D, 1988, BONE MINER, V4, P299; POCOCK NA, 1988, J BONE MINER RES, V3, P601; POCOCK NA, 1987, J CLIN INVEST, V80, P706, DOI 10.1172/JCI113125; POLLITZER WS, 1989, AM J CLIN NUTR, V50, P1244, DOI 10.1093/ajcn/50.6.1244; Recker R R, 1990, J Bone Miner Res, V5, P307; RECKER RR, 1992, J BONE MINER RES, V7, P857; RIGGS BL, 1986, J CLIN INVEST, V77, P1487, DOI 10.1172/JCI112462; RIGGS BL, 1981, J CLIN INVEST, V67, P326; RODIN A, 1990, BONE, V11, P1, DOI 10.1016/8756-3282(90)90064-6; SANDLER RB, 1985, AM J CLIN NUTR, V42, P270, DOI 10.1093/ajcn/42.2.270; SLEMENDA CW, 1991, J BONE MINER RES, V6, P561; SNOWHARTER C, 1990, J BONE MINER RES, V5, P589; STEGMAN M, IN PRESS OSTEOPOROSI; TYLAVSKY FA, 1989, CALCIFIED TISSUE INT, V45, P265, DOI 10.1007/BF02556017; WAHNER HW, 1985, RADIOLOGY, V156, P203, DOI 10.1148/radiology.156.1.4001406; WASHBURN RA, 1988, RES Q EXERCISE SPORT, V59, P83, DOI 10.1080/02701367.1988.10605479	60	599	612	0	28	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 4	1992	268	17					2403	2408		10.1001/jama.268.17.2403	http://dx.doi.org/10.1001/jama.268.17.2403			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV694	1404797				2022-12-28	WOS:A1992JV69400026
J	GUAN, JL; SHALLOWAY, D				GUAN, JL; SHALLOWAY, D			REGULATION OF FOCAL ADHESION-ASSOCIATED PROTEIN TYROSINE KINASE BY BOTH CELLULAR ADHESION AND ONCOGENIC TRANSFORMATION	NATURE			English	Article							PHOSPHORYLATION; PP60C-SRC; CELLS; ANTIBODIES; SITES	INCREASING evidence indicates that the integrin family of cell adhesion receptors can transduce biochemical signals from the extracellular matrix to the cell interior to modulate cell growth and differentiation1. We have shown that integrin/ligand interactions can trigger tyrosine phosphorylation of a protein of M(r) 120,000 (pp120), so it is possible that signal transduction by integrins might involve activation of intracellular protein tyrosine kinases as an early event in cell binding to the extracellular matrix2. Here we report that pp120 is identical to the focal adhesion-associated protein tyrosine kinase pp125FAK (refs 3,4). We show that tyrosine phosphorylation of this protein is modulated both by cell adhesion and transformation by pp60v-src, and that these changes in phosphorylation are correlated with increased pp125FAK tyrosine kinase activity. A model is proposed to relate these findings to the molecular basis of anchorage-independent growth of transformed cells.	CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853	Cornell University	GUAN, JL (corresponding author), CORNELL UNIV,COLL VET MED,DEPT PATHOL,CANC BIOL LABS,ITHACA,NY 14853, USA.							GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TUCKER R W, 1981, Journal of Supramolecular Structure and Cellular Biochemistry, V15, P29, DOI 10.1002/jsscb.1981.380150104; WANG JYJ, 1985, MOL CELL BIOL, V5, P3640, DOI 10.1128/MCB.5.12.3640; WITTELSBERGER SC, 1981, CELL, V24, P859, DOI 10.1016/0092-8674(81)90111-2	14	791	804	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 20	1992	358	6388					690	692		10.1038/358690a0	http://dx.doi.org/10.1038/358690a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ882	1379699				2022-12-28	WOS:A1992JJ88200061
J	KABUKOBA, JJ; YOUNG, P				KABUKOBA, JJ; YOUNG, P			MIDWIFERY AND BODY-FLUID CONTAMINATION	BRITISH MEDICAL JOURNAL			English	Article							PRIMARY TARGET; HIV		ALL ST HOSP,OBSTET & GYNAECOL,CHATHAM,KENT,ENGLAND									BRAATHEN LR, 1987, LANCET, V2, P1094; CHAMBERLAIN G, 1991, LANCET, V337, P1219; JESSOP JH, 1990, BRIT MED J, V300, P49, DOI 10.1136/bmj.300.6716.49-a; NIEDECKEN H, 1987, LANCET, V2, P519; 1987, REPORT RCOG SUBCOMMI	5	18	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1992	305	6847					226	226		10.1136/bmj.305.6847.226	http://dx.doi.org/10.1136/bmj.305.6847.226			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG112	1392828	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JG11200025
J	INABA, T; ROBERTS, WM; SHAPIRO, LH; JOLLY, KW; RAIMONDI, SC; SMITH, SD; LOOK, AT				INABA, T; ROBERTS, WM; SHAPIRO, LH; JOLLY, KW; RAIMONDI, SC; SMITH, SD; LOOK, AT			FUSION OF THE LEUCINE ZIPPER GENE HLF TO THE E2A GENE IN HUMAN ACUTE B-LINEAGE LEUKEMIA	SCIENCE			English	Article							DNA-BINDING PROTEIN; PRE-B; TRANSCRIPTION FACTOR; ONCOGENE; AP-1; PRODUCT; DOMAIN; REGION; MOTIF	A t(17;10) chromosomal translocation in early B-lineage acute leukemia was shown to result in chimeric transcripts that contain sequences from the E2A basic helix-loop-helix transcription factor gene on chromosome 19, fused to sequences from a previously unidentified gene (HLF) on chromosome 17 that encodes a hepatic leukemia factor. The chimeric protein consisted of the amino-terminal transactivation domain of E2A linked to the carboxyl-terminal basic region-leucine zipper domain of HLF. HLF was normally expressed in liver and kidney, but not in lymphoid cells, and was found to be closely related to the leucine zipper-containing transcription factors DBP (albumin D-box binding protein) and TEF (thyrotroph embryonic factor), which regulate developmental stage-specific gene expression.	ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT PATHOL & LAB MED, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT PATHOL, MEMPHIS, TN 38163 USA; UNIV CHICAGO, DEPT PEDIAT, CHICAGO, IL 60637 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Chicago			Raimondi, Susana C/N-8166-2018		NCI NIH HHS [CA-20180, CA-21765, CA-42804] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765, P01CA020180, R01CA042804] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; DROLET DW, 1991, GENE DEV, V5, P1739, DOI 10.1101/gad.5.10.1739; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOPE IA, 1985, CELL, V43, P177, DOI 10.1016/0092-8674(85)90022-4; INABA T, UNPUB; INABA T, UNPUBL; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LANDAU NR, 1987, MOL CELL BIOL, V7, P3237, DOI 10.1128/MCB.7.9.3237; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MELLENTIN JD, 1990, GENE CHROMOSOME CANC, V2, P239, DOI 10.1002/gcc.2870020313; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, COMMUNICATION; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PRIVITERA E, 1992, BLOOD, V79, P1781; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RAIMONDI SC, 1991, BLOOD, V77, P2016; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; ROTH DB, 1989, MOL CELL BIOL, V9, P3049, DOI 10.1128/MCB.9.7.3049; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; van Tuinen P, 1987, Genomics, V1, P374, DOI 10.1016/0888-7543(87)90042-5	31	264	269	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 24	1992	257	5069					531	534		10.1126/science.1386162	http://dx.doi.org/10.1126/science.1386162			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE755	1386162				2022-12-28	WOS:A1992JE75500029
J	KOHLSTAEDT, LA; WANG, J; FRIEDMAN, JM; RICE, PA; STEITZ, TA				KOHLSTAEDT, LA; WANG, J; FRIEDMAN, JM; RICE, PA; STEITZ, TA			CRYSTAL-STRUCTURE AT 3.5 ANGSTROM RESOLUTION OF HIV-1 REVERSE-TRANSCRIPTASE COMPLEXED WITH AN INHIBITOR	SCIENCE			English	Article							DNA-POLYMERASE-I; HUMAN IMMUNODEFICIENCY VIRUS; AREA DETECTOR DIFFRACTOMETER; ESCHERICHIA-COLI; KLENOW FRAGMENT; MACROMOLECULAR CRYSTALLOGRAPHY; PHASE AMBIGUITY; RIBONUCLEASE-H; IDENTIFICATION; PROTEIN	A 3.5 angstrom resolution electron density map of the HIV-1 reverse transcriptase heterodimer complexed with nevirapine, a drug with potential for treatment of AIDS, reveals an asymmetric dimer. The polymerase (pol) domain of the 66-kilodalton subunit has a large cleft analogous to that of the Klenow fragment of Escherichia coli DNA polymerase I. However, the 51-kilodalton subunit of identical sequence has no such cleft because the four subdomains of the pol domain occupy completely different relative positions. Two of the four pol subdomains appear to be structurally related to subdomains of the Klenow fragment, including one containing the catalytic site. The subdomain that appears likely to bind the template strand at the pol active site has a different structure in the two polymerases. Duplex A-form RNA-DNA hybrid can be model-built into the cleft that runs between the ribonuclease H and pol active sites. Nevirapine is almost completely buried in a pocket near but not overlapping with the pol active site. Residues whose mutation results in drug resistance have been approximately located.	YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06511; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06511	Yale University; Howard Hughes Medical Institute; Yale University	KOHLSTAEDT, LA (corresponding author), YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511, USA.		Steitz, Thomas A./C-6559-2009	friedman, jonathan/0000-0001-6908-5928	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM039546] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 39546] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGOS P, 1988, NUCLEIC ACIDS RES, V16, P9909, DOI 10.1093/nar/16.21.9909; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; BASU A, 1987, BIOCHEMISTRY-US, V26, P1704, DOI 10.1021/bi00380a032; BASU A, 1989, J BIOL CHEM, V264, P8746; BASU A, 1992, BIOCHEMISTRY-US, V31, P616, DOI 10.1021/bi00117a045; BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946; BEESE L, UNPUB; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CASTAGNOLI L, 1989, EMBO J, V8, P621, DOI 10.1002/j.1460-2075.1989.tb03417.x; COHEN KA, 1991, J BIOL CHEM, V266, P14670; CONNOLLY ML, 1985, J MOL GRAPHICS, V3, P19, DOI 10.1016/0263-7855(85)80009-6; DAQUILA RT, 1989, J ACQ IMMUN DEF SYND, V2, P579; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; FRIEDMAN J, UNPUB; FURFINE ES, 1991, J BIOL CHEM, V266, P406; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; HARRISON SC, 1978, TRENDS BIOCHEM SCI, V3, P3, DOI 10.1016/S0968-0004(78)92447-7; Hendrickson W. A., 1970, Acta Crystallographica, Section B (Structural Crystallography and Crystal Chemistry), Vb26, P136, DOI 10.1107/S0567740870002078; HOSTOMSKA Z, 1991, J BIOL CHEM, V266, P14697; HOSTOMSKY Z, 1992, J VIROL, V66, P3179, DOI 10.1128/JVI.66.5.3179-3182.1992; HOSTOMSKY Z, 1991, P NATL ACAD SCI USA, V88, P1148, DOI 10.1073/pnas.88.4.1148; JACOBOMOLINA A, 1991, P NATL ACAD SCI USA, V88, P10895, DOI 10.1073/pnas.88.23.10895; JACOBOMOLINA A, 1991, BIOCHEMISTRY-US, V30, P6351, DOI 10.1021/bi00240a001; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; JOYCE CM, 1987, TRENDS BIOCHEM SCI, V12, P288, DOI 10.1016/0968-0004(87)90143-5; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KOHLSTAEDT LA, IN PRESS P NATL ACAD; LARDER BA, 1989, P NATL ACAD SCI USA, V86, P4803, DOI 10.1073/pnas.86.13.4803; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; LINGNER J, 1991, NATURE, V354, P496, DOI 10.1038/354496a0; LLOYD LF, 1991, J MOL BIOL, V217, P19, DOI 10.1016/0022-2836(91)90607-8; LOWE DM, 1988, BIOCHEMISTRY-US, V27, P8884, DOI 10.1021/bi00425a002; LUNDBLAD V, 1990, CELL, V60, P529; MCKAY DB, 1981, NATURE, V290, P744, DOI 10.1038/290744a0; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; OLLIS DL, 1985, NATURE, V313, P818, DOI 10.1038/313818a0; OYAMA F, 1989, J BIOL CHEM, V264, P18808; PANDEY VN, 1988, J BIOL CHEM, V263, P6068; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; POLESKY AH, 1990, IN PRESS J BIOL CHEM, V265; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; RAABE T, 1991, NATURE, V353, P229, DOI 10.1038/353229a0; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; RUSH J, 1990, J BIOL CHEM, V265, P4821; SHIH CK, 1991, P NATL ACAD SCI USA, V88, P9878, DOI 10.1073/pnas.88.21.9878; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; STEITZ TA, 1976, J MOL BIOL, V104, P197, DOI 10.1016/0022-2836(76)90009-7; SYGUSCH J, 1985, METHOD ENZYMOL, V115, P15; TAKEUCHI Y, 1988, J VIROL, V62, P3900, DOI 10.1128/JVI.62.10.3900-3902.1988; UNGE T, 1990, AIDS RES HUM RETROV, V6, P1297, DOI 10.1089/aid.1990.6.1297; VARMUS H, 1987, SCI AM, V257, P56, DOI 10.1038/scientificamerican0987-56; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEISS R, 1989, RNA TUMOR VIRUSES; WONDRAK EM, 1986, J GEN VIROL, V67, P2791, DOI 10.1099/0022-1317-67-12-2791; WU JC, 1991, BIOCHEMISTRY-US, V30, P2022, DOI 10.1021/bi00222a003; XUONG NH, 1985, ACTA CRYSTALLOGR B, V41, P267, DOI 10.1107/S0108768185002105; XUONG NH, 1985, J APPL CRYSTALLOGR, V18, P342, DOI 10.1107/S0021889885010433; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648	70	1779	1846	2	134	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 26	1992	256	5065					1783	1790		10.1126/science.1377403	http://dx.doi.org/10.1126/science.1377403			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA434	1377403				2022-12-28	WOS:A1992JA43400026
J	JIANG, H; ZHANG, SL; PERNIS, B				JIANG, H; ZHANG, SL; PERNIS, B			ROLE OF CD8+ T-CELLS IN MURINE EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS	SCIENCE			English	Article							MYELIN BASIC-PROTEIN; AUTOIMMUNE ENCEPHALOMYELITIS; IMMUNOREGULATION; SUPPRESSION; CLONES; INVIVO	The course of experimental allergic encephalomyelitis (EAE), an animal model for multiple sclerosis, is affected by immunoregulatory T lymphocytes. When animals are immunized with encephalitogenic peptide of myelin basic protein and recover from the first episode of EAE, they become resistant to a second induction of this disease. Animals depleted of CD8+ T cells by antibody-mediated clearance were used to examine the role of CD8+ T cells in EAE. These cells were found to be major participants in the resistance to a second induction of EAE but were not essential for spontaneous recovery from the first episode of the disease.			JIANG, H (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032, USA.							ANDO DG, 1989, CELL IMMUNOL, V124, P132, DOI 10.1016/0008-8749(89)90117-2; EICHELBERGER M, 1991, J EXP MED, V174, P857; ELLERMAN KE, 1988, NATURE, V331, P265, DOI 10.1038/331265a0; KARPUS WJ, 1989, J IMMUNOL, V143, P3942; KOH DR, 1992, SCIENCE, V256, P1210, DOI 10.1126/science.256.5060.1210; LECLERC C, 1990, J IMMUNOL, V145, P1343; SAKAI K, 1986, J IMMUNOL, V137, P1527; SEDGWICK JD, 1988, EUR J IMMUNOL, V18, P495, DOI 10.1002/eji.1830180402; SUN D, 1988, NATURE, V332, P843, DOI 10.1038/332843a0; SUN DM, 1991, CELL IMMUNOL, V137, P292, DOI 10.1016/0008-8749(91)90080-U; WILLENBORG DO, 1986, J IMMUNOL, V136, P1676; ZAMVIL SS, 1985, J EXP MED, V162, P2107, DOI 10.1084/jem.162.6.2107; ZAMVIL SS, 1986, NATURE, V324, P258, DOI 10.1038/324258a0	13	312	324	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 22	1992	256	5060					1213	1215		10.1126/science.256.5060.1213	http://dx.doi.org/10.1126/science.256.5060.1213			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV192	1375398				2022-12-28	WOS:A1992HV19200039
J	SAKMANN, B				SAKMANN, B			ELEMENTARY STEPS IN SYNAPTIC TRANSMISSION REVEALED BY CURRENTS THROUGH SINGLE ION CHANNELS	SCIENCE			English	Article							ACETYLCHOLINE-RECEPTOR CHANNEL; PATCH-CLAMP TECHNIQUES; ACTIVATED CHANNELS; OPERATED CHANNELS; MESSENGER-RNAS; SPINAL NEURONS; AMINO-ACIDS; MUSCLE; MEMBRANE; SUBUNIT				SAKMANN, B (corresponding author), MAX PLANCK INST MED RES, W-6900 HEIDELBERG 1, GERMANY.							ANDERSON CR, 1973, J PHYSIOL-LONDON, V235, P655, DOI 10.1113/jphysiol.1973.sp010410; ASCHER P, 1988, J PHYSIOL-LONDON, V399, P227; ATKINS PW, 1983, PRINCIPLES PHYSICAL; AXELSSON J, 1959, J PHYSIOL-LONDON, V147, P178, DOI 10.1113/jphysiol.1959.sp006233; BETZ H, 1990, BIOCHEMISTRY-US, V29, P3591, DOI 10.1021/bi00467a001; BETZ W, 1973, J PHYSIOL-LONDON, V230, P673, DOI 10.1113/jphysiol.1973.sp010211; BORMANN J, 1987, J PHYSIOL-LONDON, V385, P243, DOI 10.1113/jphysiol.1987.sp016493; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; BUSCH C, 1990, COLD SH Q B, V55, P69; COLQUHOUN D, 1981, NATURE, V294, P464, DOI 10.1038/294464a0; COLQUHOUN D, 1982, PHILOS T ROY SOC B, V300, P1, DOI 10.1098/rstb.1982.0156; COLQUHOUN D, 1985, J PHYSIOL-LONDON, V369, P501, DOI 10.1113/jphysiol.1985.sp015912; COLQUHOUN D, 1977, PROC R SOC SER B-BIO, V199, P231, DOI 10.1098/rspb.1977.0137; COLQUHOUN D, IN PRESS J PHYSL LON; CULLCANDY SG, 1987, NATURE, V325, P525, DOI 10.1038/325525a0; DELCASTILLO J, 1957, PROC R SOC SER B-BIO, V146, P369; ECCLES JC, 1963, PRIX NOBEL 1963, P261; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; FRANKE C, 1987, NEUROSCI LETT, V77, P199, DOI 10.1016/0304-3940(87)90586-6; HAMILL OP, 1983, NATURE, V305, P805, DOI 10.1038/305805a0; HAMILL OP, 1981, NATURE, V294, P462, DOI 10.1038/294462a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hille B, 1984, IONIC CHANNELS EXCIT; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; IMOTO K, 1986, NATURE, V324, P670, DOI 10.1038/324670a0; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; JONAS P, 1992, J PHYSIOL-LONDON, V446, pP515; KARLIN A, 1991, HARVEY LECT, V85, P71; KATZ B, 1972, J PHYSIOL-LONDON, V224, P665, DOI 10.1113/jphysiol.1972.sp009918; Katz B., 1969, RELEASE NEURAL TRANS; Katz B., 1966, NERVE MUSCLE SYNAPSE; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KHODOROVA A, 1992, J PHYSIOL-LONDON, V446, pP516; KONNO T, 1991, P ROY SOC B-BIOL SCI, V244, P69, DOI 10.1098/rspb.1991.0053; MAGLEBY KL, 1972, J PHYSIOL-LONDON, V223, P173, DOI 10.1113/jphysiol.1972.sp009840; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; MICHLER A, 1980, DEV BIOL, V80, P1, DOI 10.1016/0012-1606(80)90494-7; Miledi R., 1989, FIDIA RES FDN NEUROS, VVolume 3, P57; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; MISHINA M, 1985, NATURE, V313, P364, DOI 10.1038/313364a0; NEHER E, 1976, J PHYSIOL-LONDON, V258, P705, DOI 10.1113/jphysiol.1976.sp011442; NEHER E, 1978, PFLUG ARCH EUR J PHY, V375, P219, DOI 10.1007/BF00584247; NEHER E, 1976, NATURE, V260, P799, DOI 10.1038/260799a0; NEHER E, IN PRESS PRIX NOBEL; NUMA S, 1989, HARVEY LECT, V83, P121; NUMBERGER M, 1991, EMBO J, V10, P2957, DOI 10.1002/j.1460-2075.1991.tb07846.x; SAKMANN B, 1978, NATURE, V276, P401, DOI 10.1038/276401a0; SAKMANN B, 1980, NATURE, V286, P71, DOI 10.1038/286071a0; SAKMANN B, 1985, NATURE, V318, P538, DOI 10.1038/318538a0; SAKMANN B, 1989, Q J EXP PHYSIOL CMS, V74, P1107, DOI 10.1113/expphysiol.1989.sp003336; SAKMANN B, 1983, J NEURAL TRANSM, P83; SAKMANN B, 1978, FED PROC, V37, P2654; SAKMANN B, 1992, FIDIA RES F NEUROSCI, V6, P53; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; STERN P, 1992, J PHYSIOL-LONDON, V449, P247, DOI 10.1113/jphysiol.1992.sp019085; TRUSSELL LO, 1989, NEURON, V3, P209, DOI 10.1016/0896-6273(89)90034-2; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; VERDOORN TA, 1990, NEURON, V4, P919, DOI 10.1016/0896-6273(90)90145-6; VILLARROEL A, 1991, P ROY SOC B-BIOL SCI, V243, P69, DOI 10.1098/rspb.1991.0012; VILLARROEL A, IN PRESS BIOPHYS J; WITZEMANN V, 1987, FEBS LETT, V223, P104, DOI 10.1016/0014-5793(87)80518-5; WITZEMANN V, 1989, FEBS LETT, V242, P419, DOI 10.1016/0014-5793(89)80514-9; WITZEMANN V, 1991, J CELL BIOL, V114, P125, DOI 10.1083/jcb.114.1.125; WITZEMANN V, 1991, FEBS LETT, V282, P259, DOI 10.1016/0014-5793(91)80490-T; WITZEMANN V, 1990, EUR J BIOCHEM, V194, P437, DOI 10.1111/j.1432-1033.1990.tb15637.x	71	54	54	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 24	1992	256	5056					503	512		10.1126/science.1373907	http://dx.doi.org/10.1126/science.1373907			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ187	1373907				2022-12-28	WOS:A1992HQ18700059
J	SHARIFF, A; LUNA, EJ				SHARIFF, A; LUNA, EJ			DIACYLGLYCEROL-STIMULATED FORMATION OF ACTIN NUCLEATION SITES AT PLASMA-MEMBRANES	SCIENCE			English	Article							PROTEIN KINASE-C; DICTYOSTELIUM-DISCOIDEUM; HUMAN-NEUTROPHILS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; POLYMORPHONUCLEAR LEUKOCYTES; AMEBOID CELLS; SHAPE CHANGES; POLYMERIZATION; INHIBITOR; CYTOSKELETON	Diacylglycerols, which are generated during phospholipase-catalyzed hydrolysis of phospholipids, stimulated actin polymerization in the presence of highly purified plasma membranes from the cellular slime mold Dictyostelium discoideum. The increased rate of actin polymerization apparently resulted from de novo formation of actin nucleation sites rather than uncapping of existing filament ends, because the membranes lacked detectable endogenous actin. The increased actin nucleation was mediated by a peripheral membrane component other than protein kinase C, the classical target of diacylglycerol action. These results indicate that diacylglycerols increase actin nucleation at plasma membranes and suggest a mechanism whereby signal transduction pathways may control cytoskeletal assembly.			SHARIFF, A (corresponding author), WORCESTER FDN EXPTL BIOL INC,CELL BIOL GRP,SHREWSBURY,MA 01545, USA.		Luna, Elizabeth/B-4364-2012		NIGMS NIH HHS [GM-33048, R01 GM033048] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033048] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APGAR JR, 1991, J CELL BIOL, V112, P1157, DOI 10.1083/jcb.112.6.1157; BELL RM, 1991, J BIOL CHEM, V266, P4661; BENGTSSON T, 1988, J BIOL CHEM, V263, P17385; CARRAWAY KL, 1989, BIOCHIM BIOPHYS ACTA, V988, P147, DOI 10.1016/0304-4157(89)90017-8; CARSON M, 1986, J CELL BIOL, V103, P2707, DOI 10.1083/jcb.103.6.2707; CHIA CP, 1991, CELL MOTIL CYTOSKEL, V18, P164, DOI 10.1002/cm.970180303; CONDEELIS J, 1990, DEV GENET, V11, P333, DOI 10.1002/dvg.1020110504; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; DADABAY CY, 1991, J CELL BIOL, V112, P1151, DOI 10.1083/jcb.112.6.1151; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; DOWNEY GP, 1990, J CELL BIOL, V110, P1975, DOI 10.1083/jcb.110.6.1975; EBERLE M, 1990, J BIOL CHEM, V265, P16725; EXTON JH, 1990, J BIOL CHEM, V265, P1; FRIEDEN C, 1983, P NATL ACAD SCI-BIOL, V80, P6513, DOI 10.1073/pnas.80.21.6513; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; HALL AL, 1989, J CELL BIOL, V109, P2207, DOI 10.1083/jcb.109.5.2207; HALL AL, 1988, J CELL BIOCHEM, V37, P285, DOI 10.1002/jcb.240370304; HOWARD TH, 1984, J CELL BIOL, V98, P1265, DOI 10.1083/jcb.98.4.1265; KELLER HU, 1989, J CELL SCI, V93, P457; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; LAL AA, 1984, J BIOL CHEM, V259, P8794; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LUDERUS MEE, 1989, FEBS LETT, V253, P71, DOI 10.1016/0014-5793(89)80932-9; LUNA EJ, 1984, J CELL BIOL, V99, P58, DOI 10.1083/jcb.99.1.58; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OMANN GM, 1989, J BIOL CHEM, V264, P16355; OOSAWA F, 1962, J MOL BIOL, V4, P10, DOI 10.1016/S0022-2836(62)80112-0; PHATAK PD, 1988, J IMMUNOL, V141, P2929; REIBMAN J, 1988, J BIOL CHEM, V263, P6322; SHARIFF A, 1990, J CELL BIOL, V110, P681, DOI 10.1083/jcb.110.3.681; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TRANTER MP, 1989, J CELL BIOL, V109, P2833, DOI 10.1083/jcb.109.6.2833; WUESTEHUBE LJ, 1987, J CELL BIOL, V105, P1741, DOI 10.1083/jcb.105.4.1741; YAMAMOTO K, 1982, J CELL BIOL, V95, P711, DOI 10.1083/jcb.95.3.711; YIN HL, 1987, BIOESSAYS, V7, P176, DOI 10.1002/bies.950070409; ZIMMERMANN A, 1988, J CELL SCI, V90, P657	37	135	135	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 10	1992	256	5054					245	247		10.1126/science.1373523	http://dx.doi.org/10.1126/science.1373523			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM896	1373523				2022-12-28	WOS:A1992HM89600037
J	HASSEL, B				HASSEL, B			ACUTE HYPOTHERMIA DUE TO PENICILLIN	BRITISH MEDICAL JOURNAL			English	Letter											HASSEL, B (corresponding author), NORWEGIAN DEF RES ESTAB,DIV ENVIRONM TOXICOL,N-2007 KJELLER,NORWAY.							HASSEL B, 1991, ANN INTERN MED, V115, P69, DOI 10.7326/0003-4819-115-1-69_2; REULER JB, 1978, ANN INTERN MED, V89, P519, DOI 10.7326/0003-4819-89-4-519	2	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1992	304	6831					882	882		10.1136/bmj.304.6831.882-b	http://dx.doi.org/10.1136/bmj.304.6831.882-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM835	1392751	Bronze, Green Published			2022-12-28	WOS:A1992HM83500030
J	GORDON, LI; HARRINGTON, D; ANDERSEN, J; COLGAN, J; GLICK, J; NEIMAN, R; MANN, R; RESNICK, GD; BARCOS, M; GOTTLIEB, A; OCONNELL, M				GORDON, LI; HARRINGTON, D; ANDERSEN, J; COLGAN, J; GLICK, J; NEIMAN, R; MANN, R; RESNICK, GD; BARCOS, M; GOTTLIEB, A; OCONNELL, M			COMPARISON OF A 2ND-GENERATION COMBINATION CHEMOTHERAPEUTIC REGIMEN (M-BACOD) WITH A STANDARD REGIMEN (CHOP) FOR ADVANCED DIFFUSE NON-HODGKINS-LYMPHOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LARGE-CELL LYMPHOMA; DOSE INTENSITY; HISTIOCYTIC LYMPHOMA; INTERMEDIATE-GRADE; RANDOMIZED TRIAL; ONCOLOGY-GROUP; METHOTREXATE; SUPERIORITY; LEUCOVORIN; SURVIVAL	Background. In 1984, the Eastern Cooperative Oncology Group began a randomized controlled clinical trial of patients with advanced (stage III or IV) diffuse mixed or diffuse large-cell lymphoma to determine whether complete-remission rates, survival, and toxicity differed when patients were treated with a chemotherapeutic regimen containing cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), as compared with a regimen containing bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone, methotrexate, and leucovorin (m-BACOD). Methods. From July 1984 through January 1988, 392 patients were enrolled, 325 of whom (83 percent) were eligible for the analysis and capable of being evaluated. The extent of disease was defined according to standard staging techniques, including bilateral bone-core biopsies in 88 percent of patients. Randomization was stratified according to age (<60 or greater-than-or-equal-to 60 years), performance status (0, 1, or other), stage (III or IV), and histologic presentation (diffuse mixed or diffuse large-cell lymphoma). Results. After a median follow-up of four years, there were no significant differences in rates of complete remission, time to treatment failure, disease-free survival, or overall survival in the patients treated with CHOP as compared with those treated with m-BACOD. However, there was more severe and life-threatening pulmonary, infectious, and hematologic toxicity associated with the m-BACOD regimen. In an attempt to measure the importance of dose intensity in the 325 patients who could be analyzed, we retrospectively calculated dose intensity (measured in milligrams per square meter of body-surface area per week) and normalized dose intensity (defined as a percentage of the prescribed dose) for all drugs. The median normalized dose intensity for both cyclophosphamide and doxorubicin was found to be greater in the patients treated with CHOP than in those treated with m-BACOD. Conclusions. For patients with stage III or IV diffuse mixed or diffuse large-cell lymphoma, CHOP is superior to m-BACOD, but the role of dose intensity is not yet clear.	ROBERT F LURIE CANC CTR, CHICAGO, IL USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; MAYO CLIN & MAYO FDN, ROCHESTER, MN 55905 USA; INDIANA UNIV, MED CTR, INDIANAPOLIS, IN 46204 USA; NEW YORK STATE DEPT HLTH, ROSWELL PK MEM INST, BUFFALO, NY 14263 USA; UNIV PENN, CTR CANC, PHILADELPHIA, PA 19104 USA; JOHNS HOPKINS UNIV HOSP, CTR ONCOL, BALTIMORE, MD 21205 USA; CORNELL UNIV, MED CTR, NEW YORK HOSP, NEW YORK, NY 10021 USA; SUNY HOSP SYRACUSE, UPSTATE MED CTR, SYRACUSE, NY USA	Robert H. Lurie Comprehensive Cancer Center; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Mayo Clinic; Indiana University System; Indiana University-Purdue University Indianapolis; Roswell Park Cancer Institute; University of Pennsylvania; Johns Hopkins University; Johns Hopkins Medicine; Cornell University; NewYork-Presbyterian Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	GORDON, LI (corresponding author), NORTHWESTERN UNIV, SCH MED, DEPT MED, DIV HEMATOL ONCOL, 303 E CHICAGO AVE, CHICAGO, IL 60611 USA.			Gordon, Leo/0000-0003-1666-7064	NCI NIH HHS [CA 13650, CA 23318, CA 17145] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA013650, U10CA023318, U10CA017145] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOYD DB, 1988, J CLIN ONCOL, V6, P425, DOI 10.1200/JCO.1988.6.3.425; CARDE P, 1991, ANN ONCOL, V2, P431, DOI 10.1093/oxfordjournals.annonc.a057979; Coltman CA, 1986, ADV CHEMOTHERAPY UPD, P71; Cox DR., 1989, ANAL BINARY DATA; DANA BW, 1990, J CLIN ONCOL, V8, P1155, DOI 10.1200/JCO.1990.8.7.1155; DEVITA VT, 1975, LANCET, V1, P248; DEVITA VT, 1987, CANCER RES, V47, P5810; DEVITA VT, 1989, CANCER PRINCIPLES PR, V2, P1741; FISHER RI, 1983, ANN INTERN MED, V98, P304, DOI 10.7326/0003-4819-98-3-304; FREI E, 1980, AM J MED, V69, P585, DOI 10.1016/0002-9343(80)90472-6; GAYNOR ER, 1985, J CLIN ONCOL, V3, P1596, DOI 10.1200/JCO.1985.3.12.1596; GREEN JA, 1980, BRIT J CLIN PHARMACO, V9, P511, DOI 10.1111/j.1365-2125.1980.tb05847.x; HRYNIUK W, 1984, J CLIN ONCOL, V2, P1281, DOI 10.1200/JCO.1984.2.11.1281; HRYNIUK WM, 1990, J CLIN ONCOL, V8, P1935, DOI 10.1200/JCO.1990.8.12.1935; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KLIMO P, 1985, ANN INTERN MED, V102, P596, DOI 10.7326/0003-4819-102-5-596; KWAK LW, 1990, J CLIN ONCOL, V8, P963, DOI 10.1200/JCO.1990.8.6.963; LONGO, 1991, J CLIN ONCOL, V9, P710, DOI 10.1200/JCO.1991.9.4.710; LONGO DL, 1991, J CLIN ONCOL, V9, P25, DOI 10.1200/JCO.1991.9.1.25; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MEHTA CR, 1984, BIOMETRICS, V40, P819, DOI 10.2307/2530927; MEYER RM, 1991, J CLIN ONCOL, V9, P339, DOI 10.1200/JCO.1991.9.2.339; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; ROSENBERG SA, 1982, CANCER, V49, P2112; SHIPP MA, 1986, ANN INTERN MED, V104, P757, DOI 10.7326/0003-4819-104-6-757; SHIPP MA, 1990, J CLIN ONCOL, V8, P84, DOI 10.1200/JCO.1990.8.1.84; SKARIN AT, 1983, J CLIN ONCOL, V1, P91, DOI 10.1200/JCO.1983.1.2.91; SKARIN AT, 1986, ADV CANCER CHEMOTHER, P23; Skipper H E, 1990, Important Adv Oncol, P43; SWEET DL, 1980, ANN INTERN MED, V92, P785, DOI 10.7326/0003-4819-92-6-785; 1966, TUMORS HEMATOPOIETIC, P91	31	292	304	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 5	1992	327	19					1342	1349		10.1056/NEJM199211053271903	http://dx.doi.org/10.1056/NEJM199211053271903			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW077	1383819				2022-12-28	WOS:A1992JW07700003
J	AMOS, CI; SHAW, GL; TUCKER, MA; HARTGE, P				AMOS, CI; SHAW, GL; TUCKER, MA; HARTGE, P			AGE AT ONSET FOR FAMILIAL EPITHELIAL OVARIAN-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROPHYLACTIC OOPHORECTOMY; BREAST; CARCINOMA; LINKAGE; PRONE	Objective.-To provide age-specific risks for ovarian cancer for relatives of ovarian cancer case patients. To characterize the age at onset for ovarian cancer for women with a single relative vs several relatives affected with ovarian cancer. Design.-Three previous studies were reexamined. The cumulative probability of ovarian cancer in first-degree relatives of women with histologically confirmed epithelial ovarian cancer and matched control subjects who participated in the Cancer and Steroid Hormone (CASH) Study was determined. The age of onset of ovarian cancer in women with and without relatives with ovarian cancer in a Washington, DC, case-control study was contrasted with that of women with at least two first-degree relatives studied at the National Cancer Institute (NCI). Results.-The CASH Study data showed that first-degree relatives of women with ovarian cancer had an increased risk for ovarian cancer, especially at older ages, when compared with relatives of control subjects. However, the median age at onset was the same among women in the Washington, DC, study with and without an affected relative. Among the women with an extensive family history of ovarian cancer studied at the NCI, the age at onset was considerably younger (47 years) than is typical for this disease (59 years). Of these, 17% had been diagnosed as having primary ovarian cancer by age 40 years. Conclusions.-Women who have one first-degree relative affected by ovarian cancer are at greater risk for ovarian cancer but not at an age earlier than the general population. The small proportion of women who have several affected relatives are, however, at a greater risk of early onset of ovarian cancer. Prophylactic oophorectomy may be reasonable for these women.	NCI, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	AMOS, CI (corresponding author), NIAMSD, LSB, GENET STUDIES SECT, BLDG 6, ROOM 249, BETHESDA, MD 20892 USA.		Tucker, Margaret A/B-4297-2015		PHS HHS [3-Y01-8-1037] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMOS CI, IN PRESS CANCER; BERLIN NI, 1966, ANN INTERN MED, V64, P403, DOI 10.7326/0003-4819-64-2-403; Cox DR, 1984, ANAL SURVIVAL DATA, P48; CREASMAN WT, 1991, AM J OBSTET GYNECOL, V165, P7, DOI 10.1016/0002-9378(91)90213-B; DOZOIS RR, 1970, ANN SURG, V172, P233, DOI 10.1097/00000658-197008000-00009; FERRELL RE, 1989, CANCER GENET CYTOGEN, V38, P241, DOI 10.1016/0165-4608(89)90665-1; FRAUMENI JF, 1975, CANCER-AM CANCER SOC, V36, P364, DOI 10.1002/1097-0142(197508)36:2<364::AID-CNCR2820360211>3.0.CO;2-C; GREGGI S, 1990, GYNECOL ONCOL, V39, P300, DOI 10.1016/0090-8258(90)90256-K; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Harrel F, 1986, SUGI SUPPLEMENTAL LI, P437; HARTGE P, 1989, AM J OBSTET GYNECOL, V161, P10, DOI 10.1016/0002-9378(89)90221-4; JACOBS I, 1989, BRIT J OBSTET GYNAEC, V96, P510, DOI 10.1111/j.1471-0528.1989.tb03248.x; LURAIN JR, 1979, GYNECOL ONCOL, V8, P185, DOI 10.1016/0090-8258(79)90024-6; LURAIN JR, 1991, JAMA-J AM MED ASSOC, V266, P3343; LYNCH HT, 1991, CANCER, V67, P1460, DOI 10.1002/1097-0142(19910301)67:5<1460::AID-CNCR2820670534>3.0.CO;2-S; LYNCH HT, 1985, BRIT J CANCER, V52, P271, DOI 10.1038/bjc.1985.187; LYNCH HT, 1982, OBSTET GYNECOL, V59, P589; LYNCH HT, 1981, JAMA-J AM MED ASSOC, V245, P261, DOI 10.1001/jama.245.3.261; NAROD SA, 1991, LANCET, V338, P82; PIVER MS, 1982, OBSTET GYNECOL, V60, P397; PIVER MS, 1991, SEMIN ONCOL, V18, P177; SCHILDKRAUT JM, 1989, AM J HUM GENET, V45, P521; SCHILDKRAUT JM, 1988, AM J EPIDEMIOL, V128, P456, DOI 10.1093/oxfordjournals.aje.a114994; SPEROFF T, 1991, AM J OBSTET GYNECOL, V164, P165, DOI 10.1016/0002-9378(91)90649-C; TETER J, 1967, CANCER-AM CANCER SOC, V20, P1301, DOI 10.1002/1097-0142(196708)20:8<1301::AID-CNCR2820200814>3.0.CO;2-4; TOBACMAN JK, 1982, LANCET, V2, P795; WINGO PA, 1988, AM J EPIDEMIOL, V128, P206, DOI 10.1093/oxfordjournals.aje.a114942; [No title captured]	28	55	55	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1992	268	14					1896	1899		10.1001/jama.268.14.1896	http://dx.doi.org/10.1001/jama.268.14.1896			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR439	1404714				2022-12-28	WOS:A1992JR43900039
J	WING, RR; MATTHEWS, KA; KULLER, LH; SMITH, D; BECKER, D; PLANTINGA, PL; MEILAHN, EN				WING, RR; MATTHEWS, KA; KULLER, LH; SMITH, D; BECKER, D; PLANTINGA, PL; MEILAHN, EN			ENVIRONMENTAL AND FAMILIAL CONTRIBUTIONS TO INSULIN LEVELS AND CHANGE IN INSULIN LEVELS IN MIDDLE-AGED WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; CARDIOVASCULAR RISK-FACTORS; BODY-MASS INDEX; BLOOD-PRESSURE; PREMENOPAUSAL WOMEN; PLASMA-INSULIN; ESSENTIAL-HYPERTENSION; GLUCOSE-INTOLERANCE; DIABETES-MELLITUS; PHYSICAL-ACTIVITY	Objective.-To examine familial and environmental variables associated with elevated insulin levels and changes in insulin levels in healthy, premenopausal women. Methods.-A population-based sample of 518 women (aged 42 to 50 years) completed baseline assessments of weight, cardiovascular risk factors, exercise behaviors, and glucose and insulin levels (fasting and 2 hours after a glucose load); 495 of the women were reevaluated after 3 years. Results.-Plasma insulin levels were related to weight, activity level, race, body fat distribution, and weight gain since age 20 years. Parental history of either diabetes or hypertension was also related to elevated insulin levels, independent of body mass index, with the highest insulin levels occurring in those women with a parental history of both diseases. Increases in plasma insulin levels over the years of follow-up were related to weight gain. Conclusions.-This study suggests the importance of using family history to identify women who may have elevated insulin levels and of intervening to prevent weight gain during middle age.	CHILDRENS HOSP PITTSBURGH, DIV ENDOCRINE, PITTSBURGH, PA USA; UNIV PITTSBURGH, DEPT PSYCHIAT, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, GRAD SCH PUBL HLTH, DEPT EPIDEMIOL, PITTSBURGH, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			West, Delia Smith/GWV-5839-2022	West, Delia Smith/0000-0002-4375-2785	NHLBI NIH HHS [HL28266] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028266] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAIN CC, 1974, CLIN CHEM, V20, P470; BOGARDUS C, 1989, DIABETES, V38, P1423, DOI 10.2337/diabetes.38.11.1423; BUCOLO G, 1973, CLIN CHEM, V19, P476; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; DISCHINGER P, 1986, CONTROL CLIN TRIALS, V7, pS137; DONAHUE RP, 1987, AM J EPIDEMIOL, V125, P650, DOI 10.1093/oxfordjournals.aje.a114578; DONAHUE RP, 1990, AM J EPIDEMIOL, V132, P827, DOI 10.1093/oxfordjournals.aje.a115725; DUCIMETIERE P, 1980, DIABETOLOGIA, V19, P205, DOI 10.1007/BF00275270; ERIKSSON J, 1989, NEW ENGL J MED, V321, P337, DOI 10.1056/NEJM198908103210601; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; FOURNIER AM, 1986, AM J MED, V80, P861, DOI 10.1016/0002-9343(86)90629-7; FUH MMT, 1987, ARCH INTERN MED, V147, P1035, DOI 10.1001/archinte.147.6.1035; GARCIAWEBB P, 1983, SCAND J CLIN LAB INV, V43, P677; GIDEZ JI, 1978, HIGH DENSITY LIPOPRO, P328; HAFFNER SM, 1988, NEW ENGL J MED, V319, P1297, DOI 10.1056/NEJM198811173192001; HERBERT V, 1965, J CLIN ENDOCR METAB, V25, P1375, DOI 10.1210/jcem-25-10-1375; HOLBROOK TL, 1989, INT J OBESITY, V13, P723; HORTON E S, 1986, Diabetes Metabolism Reviews, V2, P1; KAPLAN NM, 1989, ARCH INTERN MED, V149, P1514, DOI 10.1001/archinte.149.7.1514; KOLTERMAN OG, 1980, J CLIN INVEST, V65, P1272, DOI 10.1172/JCI109790; KROTKIEWSKI M, 1979, METABOLISM, V28, P650, DOI 10.1016/0026-0495(79)90018-0; LESLIE RDG, 1986, BRIT MED J, V293, P840, DOI 10.1136/bmj.293.6551.840; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MARKOVITZ JH, 1991, J HYPERTENS, V9, P399, DOI 10.1097/00004872-199105000-00003; MATTHEWS KA, 1989, AM J EPIDEMIOL, V129, P1132, DOI 10.1093/oxfordjournals.aje.a115235; MODAN M, 1985, J CLIN INVEST, V75, P809, DOI 10.1172/JCI111776; ORCHARD TJ, 1983, AM J EPIDEMIOL, V118, P326, DOI 10.1093/oxfordjournals.aje.a113639; OWENS JF, 1990, PREV MED, V19, P147, DOI 10.1016/0091-7435(90)90016-D; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; Pyorala K, 1979, Diabetes Care, V2, P131, DOI 10.2337/diacare.2.2.131; REAVEN GM, 1991, DIABETES CARE, V14, P195, DOI 10.2337/diacare.14.3.195; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; SAAD MF, 1991, NEW ENGL J MED, V324, P733, DOI 10.1056/NEJM199103143241105; SINGER P, 1985, HYPERTENSION, V7, P182, DOI 10.1161/01.HYP.7.2.182; WARNICK GR, 1978, J LIPID RES, V19, P65; Welborn T A, 1979, Diabetes Care, V2, P154, DOI 10.2337/diacare.2.2.154; WING RR, 1989, ARTERIOSCLEROSIS, V9, P479, DOI 10.1161/01.ATV.9.4.479; ZAVARONI I, 1990, DIABETIC MED, V7, P494, DOI 10.1111/j.1464-5491.1990.tb01430.x; ZIMMET P, 1989, DIABETIC MED, V6, P728, DOI 10.1111/j.1464-5491.1989.tb01266.x	39	44	44	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1992	268	14					1890	1895		10.1001/jama.268.14.1890	http://dx.doi.org/10.1001/jama.268.14.1890			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR439	1404713				2022-12-28	WOS:A1992JR43900038
J	SIEBERT, PD; LARRICK, JW				SIEBERT, PD; LARRICK, JW			COMPETITIVE PCR	NATURE			English	Article							POLYMERASE CHAIN-REACTION; MESSENGER-RNA; GENE-EXPRESSION; ACTIN GENE; CELL-LINE; QUANTITATION; AMPLIFICATION; SEQUENCES; DNA		PALO ALTO INST MOLEC MED,MT VIEW,CA 94043		SIEBERT, PD (corresponding author), CLONTECH LABS INC,4030 FABIAN WAY,PALO ALTO,CA 94303, USA.							BECKERANDRE M, 1989, NUCLEIC ACIDS RES, V17, P9437, DOI 10.1093/nar/17.22.9437; BRENNER CA, 1989, BIOTECHNIQUES, V7, P1096; BYRNE BC, 1988, NUCLEIC ACIDS RES, V16, P4165, DOI 10.1093/nar/16.19.9342; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; ELDER PK, 1988, MOL CELL BIOL, V8, P480, DOI 10.1128/MCB.8.1.480; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; KAWASAKI ES, 1991, PCR PROTOCOLS GUIDE, P21; LARRICK JW, 1992, TRENDS BIOTECHNOL, V10, P146, DOI 10.1016/0167-7799(92)90202-7; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MOCHARLA H, 1990, GENE, V93, P271, DOI 10.1016/0378-1119(90)90235-J; MURPHY LD, 1990, BIOCHEMISTRY-US, V29, P10351, DOI 10.1021/bi00497a009; NEDELMAN J, 1992, COMPUT APPL BIOSCI, V8, P65; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; SCHMIDT EE, 1991, MOL CELL BIOL, V11, P3726, DOI 10.1128/MCB.11.7.3726; SIEBERT PD, 1985, J BIOL CHEM, V260, P3868; SIEBERT PD, IN PRESS BIOTECHNIQU; Uberla K, 1991, PCR Methods Appl, V1, P136; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	20	657	684	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 8	1992	359	6395					557	558		10.1038/359557a0	http://dx.doi.org/10.1038/359557a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR859	1383831				2022-12-28	WOS:A1992JR85900067
J	MORTON, C; HICKEYDWYER, M				MORTON, C; HICKEYDWYER, M			CORTICAL BLINDNESS AFTER NIFEDIPINE TREATMENT	BRITISH MEDICAL JOURNAL			English	Letter											MORTON, C (corresponding author), ST PAULS EYE HOSP,LIVERPOOL L3 9PF,ENGLAND.							BULLING M, 1988, MED J AUSTRALIA, V148, P266, DOI 10.5694/j.1326-5377.1988.tb99445.x; NOBILEORAZIO E, 1981, BRIT MED J, V283, P948, DOI 10.1136/bmj.283.6297.948; SCHWARTZ M, 1990, ARCH INTERN MED, V150, P686, DOI 10.1001/archinte.150.3.686; SORKIN EM, 1985, DRUGS, V30, P182, DOI 10.2165/00003495-198530030-00002	4	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 19	1992	305	6855					693	693		10.1136/bmj.305.6855.693-b	http://dx.doi.org/10.1136/bmj.305.6855.693-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP511	1393116	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992JP51100026
J	STINSON, J; WALSH, M; FEELY, J				STINSON, J; WALSH, M; FEELY, J			VENTRICULAR ASYSTOLE AND OVERDOSE WITH ATENOLOL	BRITISH MEDICAL JOURNAL			English	Letter											STINSON, J (corresponding author), ST JAMES HOSP,DUBLIN 8,IRELAND.							CRITCHLEY JAJH, 1989, MED TOXICOL ADV DRUG, V4, P32; PRICHARD BNC, 1984, ADVERSE DRUG REACT T, V3, P91; ZACHARIAS FJ, 1977, POSTGRAD MED J, V53, P111; 1980, LANCET, V1, P803	4	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 19	1992	305	6855					693	693		10.1136/bmj.305.6855.693-c	http://dx.doi.org/10.1136/bmj.305.6855.693-c			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP511	1393118	Green Submitted, Bronze, Green Published			2022-12-28	WOS:A1992JP51100027
J	NIGHTINGALE, SL				NIGHTINGALE, SL			WIDE ACCESS PROTOCOLS FOR BREAST IMPLANTS APPROVED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	8	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 16	1992	268	11					1390	1390						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM849	1380995				2022-12-28	WOS:A1992JM84900005
J	ATKINSON, SW; YOUNG, Y; TROTTER, GA				ATKINSON, SW; YOUNG, Y; TROTTER, GA			TREATMENT WITH ACTIVATED-CHARCOAL COMPLICATED BY GASTROINTESTINAL OBSTRUCTION REQUIRING SURGERY	BRITISH MEDICAL JOURNAL			English	Article									LEWISHAM HOSP,GEN SURG ANAESTHET,LONDON SE13,ENGLAND									NEUVONEN PJ, 1980, EUR J CLIN PHARMACOL, V17, P51, DOI 10.1007/BF00561677; POLACK MM, 1981, ANN EMERG MED, V10, P528; POND SM, 1986, MED TOXICOL ADV DRUG, V1, P3, DOI 10.1007/BF03259824; WATSON W A, 1986, Journal of Emergency Medicine, V4, P401, DOI 10.1016/0736-4679(86)90219-2; 1992, BRIT NATIONAL FORMUL, V23, P17	5	19	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 5	1992	305	6853					563	563		10.1136/bmj.305.6853.563	http://dx.doi.org/10.1136/bmj.305.6853.563			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM495	1393038	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JM49500020
J	JONGENS, TA; HAY, B; JAN, LY; JAN, YN				JONGENS, TA; HAY, B; JAN, LY; JAN, YN			THE GERM CELL-LESS GENE-PRODUCT - A POSTERIORLY LOCALIZED COMPONENT NECESSARY FOR GERM-CELL DEVELOPMENT IN DROSOPHILA	CELL			English	Article							MEDIATED ENHANCER DETECTION; MATERNAL-EFFECT MUTATIONS; POLAR GRANULES; SEQUENCE SIMILARITY; DETERMINANT NANOS; CYCLIN-B; MELANOGASTER; EMBRYOS; PROTEIN; RNA	The first cell fate specification process in the Drosophila embryo, formation of the germline precursors, requires posteriorly localized germ plasm. We have cloned a gene, germ cell-less (gcl), required for germline formation. Posterior localization of the gcl messenger RNA (mRNA) requires the function of those genes essential for the localization of both nanos RNA, which specifies the abdomen, and the germ cell determinants. Mothers with reduced gcl function give rise to sterile adult progeny that lack germ cells. In embryos with reduced maternal gcl product, the germ cell precursors fail to form properly. Consistent with this phenotype, gcl protein specifically associates with those nuclei that later become the nuclei of the germ cell precursors. These observations suggest that gcl functions in the germ cell specification pathway.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT BIOCHEM,SAN FRANCISCO,CA 94143; UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC CELLULAR & DEV BIOL,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California Berkeley	JONGENS, TA (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT PHYSIOL,SAN FRANCISCO,CA 94143, USA.			Jan, Lily/0000-0003-3938-8498; Jan, Yuh Nung/0000-0003-1367-6299	NIGMS NIH HHS [GM PHS2271] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BEAMS HW, 1974, INT REV CYTOL, V39, P413, DOI 10.1016/S0074-7696(08)60944-4; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BODMER R, 1987, ROUX ARCH DEV BIOL, V196, P69, DOI 10.1007/BF00402027; BOSWELL RE, 1985, CELL, V43, P97, DOI 10.1016/0092-8674(85)90015-7; BOULAY JL, 1987, NATURE, V330, P395, DOI 10.1038/330395a0; CABRERA CV, 1987, CELL, V50, P659, DOI 10.1016/0092-8674(87)90039-0; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Davidson E. H., 1986, GENE ACTIVITY EARLY; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; ENGSTROM E, 1982, DEV BIOL, V91, P163; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; FOE VE, 1983, J CELL SCI, V61, P31; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GROSSNIKLAUS U, 1989, DEVELOPMENT, V107, P189; HAY B, 1988, DEVELOPMENT, V103, P625; HAY B, 1990, DEVELOPMENT, V109, P425; HAY B, 1988, CELL, V55, P577, DOI 10.1016/0092-8674(88)90216-4; ILLMENSEE K, 1976, DEV BIOL, V49, P40, DOI 10.1016/0012-1606(76)90257-8; ILLMENSEE K, 1974, P NATL ACAD SCI USA, V71, P1016, DOI 10.1073/pnas.71.4.1016; JOWETT T, 1986, DROSOPHILA PRACTICAL; KALFAYAN L, 1982, CELL, V29, P91, DOI 10.1016/0092-8674(82)90093-9; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; King R. C., 1970, OVARIAN DEV DROSOPHI; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LEHMANN R, 1987, NATURE, V329, P167, DOI 10.1038/329167a0; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LINDSLEY DL, 1968, CARNEGIE I WASH PUBL, V627; Mahowald A.P., 1980, Genetics and Biology of Drosophila, V2d, P141; MAHOWALD AP, 1983, DEV BIOL, V98, P437, DOI 10.1016/0012-1606(83)90373-1; MAHOWALD AP, 1968, J EXP ZOOL, V167, P237, DOI 10.1002/jez.1401670211; MAHOWALD AP, 1962, J EXP ZOOL, V151, P201, DOI 10.1002/jez.1401510302; MAHOWALD AP, 1979, DEV BIOL, V69, P118, DOI 10.1016/0012-1606(79)90279-3; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MOHLER J, 1986, GENETICS, V112, P803; NIKI Y, 1984, DEV BIOL, V103, P182, DOI 10.1016/0012-1606(84)90019-8; NIKI Y, 1986, DEV BIOL, V113, P255, DOI 10.1016/0012-1606(86)90127-2; OLIVER B, 1987, GENE DEV, V1, P913, DOI 10.1101/gad.1.9.913; PIRROTTA V, 1986, DROSOPHILA PRACTICAL; RAFF JW, 1990, DEVELOPMENT, V110, P1249; ROBERTSON HM, 1988, GENETICS, V118, P461; ROSENBERG UB, 1985, NATURE, V313, P703, DOI 10.1038/313703a0; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; SUTER B, 1989, GENE DEV, V3, P1957, DOI 10.1101/gad.3.12a.1957; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TECHNAU GM, 1986, ROUX ARCH DEV BIOL, V195, P489, DOI 10.1007/BF00375889; THERKAUF WE, 1992, IN PRESS J CELL BIOL, V116; UNDERWOOD EM, 1980, DEV BIOL, V77, P303, DOI 10.1016/0012-1606(80)90476-5; VAESSIN H, 1987, EMBO (European Molecular Biology Organization) Journal, V6, P3431; VANDERKROL AR, 1988, BIOTECHNIQUES, V6, P958; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; WHITFIELD WGF, 1989, NATURE, V338, P337, DOI 10.1038/338337a0	63	147	151	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 21	1992	70	4					569	584		10.1016/0092-8674(92)90427-E	http://dx.doi.org/10.1016/0092-8674(92)90427-E			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1380406				2022-12-28	WOS:A1992JJ88600007
J	SCHREIBER, SL				SCHREIBER, SL			IMMUNOPHILIN-SENSITIVE PROTEIN PHOSPHATASE ACTION IN CELL SIGNALING PATHWAYS	CELL			English	Review							SACCHAROMYCES-CEREVISIAE; RAPAMYCIN				SCHREIBER, SL (corresponding author), HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138, USA.							BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BOREL JF, 1976, IMMUNOLOGY, V31, P631; CALVO V, 1992, IN PRESS P NATL ACAD, V89; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; KOLTIN Y, 1991, MOL CELL BIOL, V11, P1718, DOI 10.1128/MCB.11.3.1718; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; MCKEON F, 1991, CELL, V66, P823, DOI 10.1016/0092-8674(91)90426-Y; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MUMBY MC, 1991, CELL REGUL, V2, P589, DOI 10.1091/mbc.2.8.589; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PRICE DJ, 1992, IN PRESS SCIENCE; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SEGHAL SN, 1975, J ANTIBIOT, V28, P727; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; SPITZFADEN C, 1992, FEBS LETT, V300, P291, DOI 10.1016/0014-5793(92)80866-F; TANAKA H, 1987, J AM CHEM SOC, V109, P5031, DOI 10.1021/ja00250a050; VANDUYNE GD, 1991, J AM CHEM SOC, V113, P7433, DOI 10.1021/ja00019a057; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302	26	321	339	2	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 7	1992	70	3					365	368		10.1016/0092-8674(92)90158-9	http://dx.doi.org/10.1016/0092-8674(92)90158-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1379518	Bronze			2022-12-28	WOS:A1992JH12400001
J	RELMAN, DA; SCHMIDT, TM; MACDERMOTT, RP; FALKOW, S				RELMAN, DA; SCHMIDT, TM; MACDERMOTT, RP; FALKOW, S			IDENTIFICATION OF THE UNCULTURED BACILLUS OF WHIPPLES DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHYLOGENETIC ANALYSIS; INFECTION; GRANULOMAS; ORGANISMS; EVOLUTION; BACTERIA; AGENT; AIDS	Background. Whipple's disease is a systemic disorder known for 85 years to be associated with an uncultured, and therefore unidentified, bacillus. Methods. We used a molecular genetic approach to identify this organism. The bacterial 16S ribosomal RNA (rRNA) sequence was amplified directly from tissues of five unrelated patients with Whipple's disease by means of the polymerase chain reaction, first with broad-range primers and then with specific primers. We determined and analyzed the nucleotide sequence of the amplification products. Results. A unique 1321-base bacterial 16S rRNA sequence was amplified from duodenal tissue of one patient. This sequence indicated the presence of a previously un characterized organism. We then detected this sequence in tissues from all 5 patients with Whipple's disease, but in none of those from 10 patients without the disorder. According to phylogenetic analysis, this bacterium is a gram-positive actinomycete that is not closely related to any known genus. Conclusions. We have identified the uncultured bacillus associated with Whipple's disease. The phylogenetic relations of this bacterium, its distinct morphologic characteristics, and the unusual features of the disease are sufficient grounds for naming this bacillus Tropheryma whippelii gen. nov. sp. nov. Our findings also provide a basis for a specific diagnostic test for this organism.	STANFORD UNIV, DEPT MED, STANFORD, CA 94305 USA; STANFORD UNIV, CTR DIGEST DIS, STANFORD, CA 94305 USA; STANFORD UNIV, DEPT MICROBIOL & IMMUNOL, STANFORD, CA 94305 USA; MIAMI UNIV, DEPT MICROBIOL, OXFORD, OH 45056 USA; UNIV PENN, DEPT MED, DIV GASTROENTEROL, PHILADELPHIA, PA 19104 USA	Stanford University; Stanford University; Stanford University; University System of Ohio; Miami University; University of Pennsylvania				Relman, David A./0000-0001-8331-1354; Schmidt, Thomas/0000-0002-8209-6055	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK038707, R01DK021474, R37DK021474] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-26195] Funding Source: Medline; NIDDK NIH HHS [DK-38707, DK-21474] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAUER HM, 1991, JAMA-J AM MED ASSOC, V265, P472, DOI 10.1001/jama.265.4.472; CHEARS WC, 1961, GASTROENTEROLOGY, V41, P129; CHO C, 1984, GASTROENTEROLOGY, V87, P941; CIMPRICH RE, 1977, VET PATHOL, V14, P95, DOI 10.1177/030098587701400201; CLANCY RL, 1975, BRIT MED J, V3, P568, DOI 10.1136/bmj.3.5983.568; Clark JB, 1972, CRIT REV MICROBIOL, V1, P521; COLLINS MD, 1989, INT J SYST BACTERIOL, V39, P1, DOI 10.1099/00207713-39-1-1; DOBBINS WO, 1981, GASTROENTEROLOGY, V80, P1468; DOBBINS WO, 1987, WHIPPLES DISEASE; EDEN PA, 1991, INT J SYST BACTERIOL, V41, P324, DOI 10.1099/00207713-41-2-324; FELDMAN M, 1989, GASTROENTEROLOGY, V96, P1207, DOI 10.1016/0016-5085(89)91643-0; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FLEMING JL, 1988, MAYO CLIN PROC, V63, P539, DOI 10.1016/S0025-6196(12)64884-8; FOX GE, 1992, INT J SYST BACTERIOL, V42, P166, DOI 10.1099/00207713-42-1-166; GILLIN JS, 1983, GASTROENTEROLOGY, V85, P1187; GOODFELLOW M, 1989, BERGEYS MANUAL SYSTE, V4, P2333; GUPTA S, 1986, GASTROENTEROLOGY, V90, P1286, DOI 10.1016/0016-5085(86)90398-7; Jukes T., 1969, MAMMALIAN PROTEIN ME, P21; KHAVARI PA, 1991, ARCH DERMATOL, V127, P543, DOI 10.1001/archderm.127.4.543; LUSCOMBE BM, 1974, J GEN MICROBIOL, V82, P213, DOI 10.1099/00221287-82-2-213; OLSEN GJ, 1991, NUCLEIC ACIDS RES, V19, P2017, DOI 10.1093/nar/19.suppl.2017; OLSEN GJ, 1987, COLD SPRING HARB SYM, V52, P825, DOI 10.1101/SQB.1987.052.01.090; OLSEN GJ, 1986, ANNU REV MICROBIOL, V40, P337, DOI 10.1146/annurev.mi.40.100186.002005; RELMAN DA, 1990, NEW ENGL J MED, V323, P1573, DOI 10.1056/NEJM199012063232301; ROTH RI, 1983, NEW ENGL J MED, V309, P1324; SILVA MT, 1985, J GEN MICROBIOL, V131, P1001; SOUTHERN JF, 1989, JAMA-J AM MED ASSOC, V261, P1467, DOI 10.1001/jama.261.10.1467; SPAPEN HDM, 1989, DIGEST DIS SCI, V34, P640, DOI 10.1007/BF01536345; STACKEBRANDT E, 1983, J GEN MICROBIOL, V129, P1831; STAHL DA, 1990, J BACTERIOL, V172, P116, DOI 10.1128/JB.172.1.116-124.1990; STROM RL, 1983, NEW ENGL J MED, V309, P1323; TRACY TE, 1991, BIOTECHNIQUES, V11, P68; WANG HH, 1986, NEW ENGL J MED, V314, P1577; Whipple GH, 1907, B JOHNS HOPKINS HOSP, V18, P382; WILLIAMS ST, 1989, BERGEYS MANUAL SYSTE; WILSON KH, 1991, LANCET, V338, P474, DOI 10.1016/0140-6736(91)90545-Z; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; YARDLEY JH, 1961, B JOHNS HOPKINS HOSP, V109, P80	39	903	924	0	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 30	1992	327	5					293	301		10.1056/NEJM199207303270501	http://dx.doi.org/10.1056/NEJM199207303270501			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF655	1377787				2022-12-28	WOS:A1992JF65500001
J	LEROITH, D; CLEMMONS, D; NISSLEY, P; RECHLER, MM				LEROITH, D; CLEMMONS, D; NISSLEY, P; RECHLER, MM			INSULIN-LIKE GROWTH-FACTORS IN HEALTH AND DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						ACROMEGALY; INSULIN-LIKE GROWTH FACTORS; GROWTH DISORDERS; DIABETES-MELLITUS; SOMATOMEDINS; HYPOGLYCEMIA	FACTOR-BINDING-PROTEIN; SOMATOMEDIN-C LEVELS; FACTOR IGF BINDING; EXTRAPANCREATIC TUMOR HYPOGLYCEMIA; NONISLET CELL TUMORS; FACTOR-II; SHORT STATURE; RAT-HEART; HORMONE; SERUM	The insulin-like growth factor (IGF) family of peptides, binding proteins, and receptors are ubiquitous and important for normal human growth and development. Modern techniques including specific radioimmunoassays, radioreceptor assays and recombinant DNA technology have improved our understanding of the role of IGFs in growth and development. In addition to enhancing our understanding of normal physiology, these techniques assess changes in these hormones, binding proteins, and receptors in pathologic conditions including growth retardation, acromegaly, malnutrition, diabetes, and malignancy. Further, these studies have led to improvement in the assessment of responses to certain therapies used in the treatment of these diseases and may lead to improvements in these therapies.	NCI, BETHESDA, MD 20892 USA; UNIV N CAROLINA, DIV ENDOCRINOL, CHAPEL HILL, NC 27599 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of North Carolina; University of North Carolina Chapel Hill	LEROITH, D (corresponding author), NIDDKD, DIABET BRANCH, ROOM 8S423, BLDG 10, BETHESDA, MD 20892 USA.							BAHAUDDIN MH, 1987, J LAB CLIM MED, V109, P346; BAR RS, 1990, ENDOCRINOLOGY, V127, P1078, DOI 10.1210/endo-127-3-1078; BAR RS, 1990, ENDOCRINOLOGY, V127, P497, DOI 10.1210/endo-127-1-497; BARKAN AL, 1988, J CLIN ENDOCR METAB, V67, P69, DOI 10.1210/jcem-67-1-69; BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BAXTER RC, 1991, J CLIN ENDOCR METAB, V73, P696, DOI 10.1210/jcem-73-4-696; BAXTER RC, 1989, P NATL ACAD SCI USA, V86, P6898, DOI 10.1073/pnas.86.18.6898; BAXTER RC, 1990, J CLIN ENDOCR METAB, V70, P1347, DOI 10.1210/jcem-70-5-1347; BENN JJ, 1990, CLIN ENDOCRINOL, V32, P769, DOI 10.1111/j.1365-2265.1990.tb00924.x; BIERICH JR, 1984, EUR J PEDIATR, V142, P186, DOI 10.1007/BF00442446; BLUM WF, 1990, J CLIN ENDOCR METAB, V70, P1292, DOI 10.1210/jcem-70-5-1292; BLUM WF, 1989, ENDOCRINOLOGY, V125, P766, DOI 10.1210/endo-125-2-766; BRISMAR K, 1988, J ENDOCRINOL INVEST, V11, P599, DOI 10.1007/BF03350189; CARA JF, 1987, AM J DIS CHILD, V141, P562, DOI 10.1001/archpedi.1987.04460050104041; CASCIERI MA, 1989, J CELL PHYSIOL, V139, P181, DOI 10.1002/jcp.1041390125; CLEMMONS DR, 1979, NEW ENGL J MED, V301, P1138, DOI 10.1056/NEJM197911223012102; CLEMMONS DR, 1985, AM J CLIN NUTR, V41, P191, DOI 10.1093/ajcn/41.2.191; CLEMMONS DR, 1991, J CLIN ENDOCR METAB, V73, P727, DOI 10.1210/jcem-73-4-727; CLEMMONS DR, 1990, TRENDS ENDOCRIN MET, V1, P412, DOI 10.1016/1043-2760(90)90102-9; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DAUGHADAY WH, 1988, NEW ENGL J MED, V319, P1434, DOI 10.1056/NEJM198812013192202; DAUGHADAY WH, 1989, P NATL ACAD SCI USA, V86, P6778, DOI 10.1073/pnas.86.17.6778; DAUGHADAY WH, 1980, J CLIN ENDOCR METAB, V51, P781, DOI 10.1210/jcem-51-4-781; ELGIN RG, 1987, P NATL ACAD SCI USA, V84, P3254, DOI 10.1073/pnas.84.10.3254; FURLANETTO RW, 1977, J CLIN INVEST, V60, P648, DOI 10.1172/JCI108816; GULER HP, 1989, ACTA ENDOCRINOL-COP, V121, P753, DOI 10.1530/acta.0.1210753; HEATHMONNIG E, 1987, J CLIN ENDOCR METAB, V64, P501, DOI 10.1210/jcem-64-3-501; ISLEY WL, 1983, J CLIN INVEST, V71, P175, DOI 10.1172/JCI110757; KADOWAKI T, 1990, J CLIN INVEST, V86, P254, DOI 10.1172/JCI114693; KAHN CR, 1980, CLIN ENDOCRINOL META, V9, P335, DOI 10.1016/S0300-595X(80)80037-5; KAWAI K, 1990, ENDOCRINOL JAPON, V37, P867; KNIGHT AB, 1981, P NATL ACAD SCI-BIOL, V78, P2554, DOI 10.1073/pnas.78.4.2554; LAMBERTS SWJ, 1987, J CLIN ENDOCR METAB, V65, P703, DOI 10.1210/jcem-65-4-703; LAMBERTS SWJ, 1988, CLIN ENDOCRINOL, V29, P411, DOI 10.1111/j.1365-2265.1988.tb02890.x; LEE P D K, 1987, Pediatrician, V14, P154; LEROITH D, 1991, TRENDS ENDOCRIN MET, V2, P134, DOI 10.1016/1043-2760(91)90003-6; LINDHOLM J, 1987, CLIN ENDOCRINOL, V27, P553, DOI 10.1111/j.1365-2265.1987.tb01185.x; LOWE WL, 1989, J CLIN ENDOCR METAB, V69, P1153, DOI 10.1210/jcem-69-6-1153; MCCUSKER RH, 1990, J CELL PHYSIOL, V144, P244, DOI 10.1002/jcp.1041440210; MERIMEE TJ, 1986, METABOLISM, V35, P360, DOI 10.1016/0026-0495(86)90155-1; MOLLER N, 1991, DIABETOLOGIA, V34, P17, DOI 10.1007/BF00404019; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; Nissley P, 1991, Growth Factors, V5, P29, DOI 10.3109/08977199109000269; NISSLEY P, 1991, INSULIN LIKE GROWTH, P111; OOI GT, 1990, MOL ENDOCRINOL, V4, P321, DOI 10.1210/mend-4-2-321; OOI GT, 1992, IN PRESS 74TH ANN M; ORLOWSKI CC, 1991, MOL ENDOCRINOL, V5, P1180, DOI 10.1210/mend-5-8-1180; POWELL DR, 1987, AM J KIDNEY DIS, V10, P287, DOI 10.1016/S0272-6386(87)80024-0; RANKE MB, 1988, ACTA PAEDIATR SCAND, P114; RECHLER MM, 1990, HDB EXPT PHARM, V95, P263; RECHLER MM, 1992, IN PRESS GROWTH REGU; RIEU M, 1982, J CLIN ENDOCR METAB, V55, P147, DOI 10.1210/jcem-55-1-147; ROBACK EW, 1991, AM J MED GENET, V38, P74, DOI 10.1002/ajmg.1320380117; RON D, 1989, J CLIN ENDOCR METAB, V68, P701, DOI 10.1210/jcem-68-4-701; ROSENFELD RG, 1986, J PEDIATR-US, V109, P428, DOI 10.1016/S0022-3476(86)80112-3; SALMON WD, 1957, J LAB CLIN MED, V49, P825; SHAPIRO ET, 1990, J CLIN INVEST, V85, P1672, DOI 10.1172/JCI114619; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SUIKKARI AM, 1989, J CLIN ENDOCR METAB, V68, P135, DOI 10.1210/jcem-68-1-135; TOLLEFSEN SE, 1991, J CLIN INVEST, V87, P1241, DOI 10.1172/JCI115125; TREADWAY JL, 1991, P NATL ACAD SCI USA, V88, P214, DOI 10.1073/pnas.88.1.214; UNDERWOOD L E, 1985, P155; UNTERMAN TG, 1985, AM J MED, V78, P228, DOI 10.1016/0002-9343(85)90431-0; VANOBBERGHENSCHILLING EE, 1981, J CLIN INVEST, V68, P1356, DOI 10.1172/JCI110383; VANVLIET G, 1983, NEW ENGL J MED, V309, P1016; WASS JAH, 1982, CLIN ENDOCRINOL, V17, P369, DOI 10.1111/j.1365-2265.1982.tb01602.x; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZAPF J, 1990, J CLIN INVEST, V86, P952, DOI 10.1172/JCI114797; ZAPF J, 1990, J BIOL CHEM, V265, P14892	70	148	152	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1992	116	10					854	862		10.7326/0003-4819-116-10-854	http://dx.doi.org/10.7326/0003-4819-116-10-854			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT802	1373590				2022-12-28	WOS:A1992HT80200012
J	SIMON, SM; BLOBEL, G				SIMON, SM; BLOBEL, G			SIGNAL PEPTIDES OPEN PROTEIN-CONDUCTING CHANNELS IN ESCHERICHIA-COLI	CELL			English	Article							SYNTHESIZING SECRETORY PROTEIN; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; RECOGNITION PARTICLE; PHOSPHOLIPID-VESICLES; NASCENT PREPROLACTIN; MICROSOMAL-MEMBRANES; PLANAR MEMBRANE; PLASMA-MEMBRANE; TRANSLOCATION	Plasma membrane vesicles and protoplasts of Escherichia coli were fused to planar lipid bilayers and studied with electrophysiological techniques. Large transmembrane aqueous channels were opened when 0.2 nM LamB signal peptide was added to the cytoplasmic side of the membrane. These aqueous pores are similar in conductance to those previously observed in mammalian endoplasmic reticulum when puromycin is used to release and thus unplug nascent translocating chains. Signal sequences have been previously shown to be necessary and sufficient for targeting proteins to cellular membranes. These results demonstrate that signal peptides are sufficient for opening the protein-conducting channels. We suggest that they are the physiological ligands that open protein-conducting channels at the initiation of protein translocation across prokaryotic plasma membrane and mammalian endoplasmic reticulum.	ROCKEFELLER UNIV, CELL BIOL LAB, NEW YORK, NY 10021 USA	Rockefeller University	SIMON, SM (corresponding author), ROCKEFELLER UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA.			Simon, Sanford/0000-0002-8615-4224	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047005] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM47005-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON K, 1991, J EXP MED, V174, P489, DOI 10.1084/jem.174.2.489; BIRDSELL DC, 1967, J BACTERIOL, V93, P427, DOI 10.1128/JB.93.1.427-437.1967; BLIGHT MA, 1990, MOL MICROBIOL, V4, P873, DOI 10.1111/j.1365-2958.1990.tb00660.x; BRIGGS MS, 1986, SCIENCE, V233, P206, DOI 10.1126/science.2941862; COBET WWE, 1989, J BIOL CHEM, V264, P10169; COHEN FS, 1989, J GEN PHYSIOL, V93, P201, DOI 10.1085/jgp.93.2.201; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; DIERSTEIN R, 1985, J BIOL CHEM, V260, P5919; EMR SD, 1983, P NATL ACAD SCI-BIOL, V80, P4599, DOI 10.1073/pnas.80.15.4599; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; FRANK G, 1978, FEBS LETT, V96, P183, DOI 10.1016/0014-5793(78)81090-4; FRIEDLANDER M, 1985, NATURE, V318, P338, DOI 10.1038/318338a0; GAROFF H, 1978, J MOL BIOL, V124, P587, DOI 10.1016/0022-2836(78)90173-0; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GILSON L, 1990, EMBO J, V9, P3875, DOI 10.1002/j.1460-2075.1990.tb07606.x; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; JOSEFSSON LG, 1983, METHOD ENZYMOL, V97, P77; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KILLIAN JA, 1990, EMBO J, V9, P815, DOI 10.1002/j.1460-2075.1990.tb08178.x; KORONAKIS V, 1989, EMBO J, V8, P595, DOI 10.1002/j.1460-2075.1989.tb03414.x; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LUBBEN TH, 1987, SCIENCE, V238, P1112, DOI 10.1126/science.238.4830.1112; MEYER DI, 1980, J CELL BIOL, V87, P498, DOI 10.1083/jcb.87.2.498; MILLER C, 1976, J MEMBRANE BIOL, V30, P283, DOI 10.1007/BF01869673; MOSTOV KE, 1981, NATURE, V292, P87, DOI 10.1038/292087a0; MUELLER P, 1962, NATURE, V194, P979, DOI 10.1038/194979a0; MULLER M, 1984, P NATL ACAD SCI-BIOL, V81, P7421, DOI 10.1073/pnas.81.23.7421; NGUYEN M, 1987, J BIOL CHEM, V262, P3929; PARK SH, 1988, SCIENCE, V239, P1033, DOI 10.1126/science.3278378; RANDALL LL, 1989, SCIENCE, V243, P1156, DOI 10.1126/science.2646712; ROBERTS RB, 1963, STUDIES BIOSYNTHESIS; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SIMON SM, 1989, P NATL ACAD SCI USA, V86, P6176, DOI 10.1073/pnas.86.16.6176; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; VONHEIJNE G, 1979, EUR J BIOCHEM, V97, P175; WALTER P, 1979, P NATL ACAD SCI USA, V76, P1795, DOI 10.1073/pnas.76.4.1795; WALTER P, 1981, J CELL BIOL, V91, P551, DOI 10.1083/jcb.91.2.551; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WATANABE M, 1989, CELL, V58, P695, DOI 10.1016/0092-8674(89)90104-9; ZIMMERBERG J, 1980, J GEN PHYSIOL, V75, P241, DOI 10.1085/jgp.75.3.241; ZIMMERMANN R, 1990, BIOCHIMIE, V72, P95, DOI 10.1016/0300-9084(90)90134-3	43	199	201	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 15	1992	69	4					677	684		10.1016/0092-8674(92)90231-Z	http://dx.doi.org/10.1016/0092-8674(92)90231-Z			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HV089	1375130				2022-12-28	WOS:A1992HV08900012
J	KREIDER, BL; BENEZRA, R; ROVERA, G; KADESCH, T				KREIDER, BL; BENEZRA, R; ROVERA, G; KADESCH, T			INHIBITION OF MYELOID DIFFERENTIATION BY THE HELIX-LOOP-HELIX PROTEIN ID	SCIENCE			English	Article							DNA-BINDING; NEGATIVE REGULATOR; SEX DETERMINATION; PROGENITOR-CELL; DROSOPHILA; GENE; TRANSCRIPTION; DAUGHTERLESS; MOTIF; EXTRAMACROCHAETAE	Id is a helix-loop-helix (HLH) protein that represses activity of several basic helix-loop-helix (bHLH) proteins involved in cell type-specific transcription and cell lineage commitment. The myeloid precursor cell line 32DC13(G) expressed Id messenger RNA, which was transiently decreased when cells were induced to terminally differentiate with granulocyte-colony-stimulating factor. Concomitant with the decrease of Id messenger RNA was the appearance in nuclear extracts of DNA binding proteins that recognized a canonical E-box motif, a DNA binding site for some bHLH proteins. Constitutive expression of an Id complementary DNA in 32DC13(G) cells blocked their ability to differentiate and to induce E-box-binding activity. These results suggest that Id and, hence, bHLH proteins function in the process of myeloid differentiation.	UNIV PENN,SCH MED,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT HUMAN GENET,PHILADELPHIA,PA 19104; WISTAR INST,PHILADELPHIA,PA 19104; FRED HUTCHINSON CANC RES CTR,DEPT GENET,SEATTLE,WA 98104	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; The Wistar Institute; Fred Hutchinson Cancer Center					NCI NIH HHS [CA 21124, CA 10815, CA 25875] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA010815, P01CA025875, P01CA021124] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; CABRERA CV, 1987, CELL, V50, P425, DOI 10.1016/0092-8674(87)90496-X; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; CRONMILLER C, 1988, GENE DEV, V2, P1666, DOI 10.1101/gad.2.12a.1666; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KHALILI K, 1984, J MOL BIOL, V180, P1007, DOI 10.1016/0022-2836(84)90268-7; KREIDER B, UNPUB; KREIDER BL, 1990, MOL CELL BIOL, V10, P4846, DOI 10.1128/MCB.10.9.4846; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; OHTA M, 1989, PATHOL IMMUNOPATH R, V8, P1, DOI 10.1159/000157134; PONGUBALA JMR, 1991, MOL CELL BIOL, V11, P1040, DOI 10.1128/MCB.11.2.1040; RUEZINSKY D, 1991, GENE DEV, V5, P29, DOI 10.1101/gad.5.1.29; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; VALTIERI M, 1987, J IMMUNOL, V138, P3829; WALKER MD, 1990, NUCLEIC ACIDS RES, V18, P1159, DOI 10.1093/nar/18.5.1159; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185	31	242	246	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 27	1992	255	5052					1700	1702		10.1126/science.1372755	http://dx.doi.org/10.1126/science.1372755			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HK812	1372755				2022-12-28	WOS:A1992HK81200036
J	WEISSMAN, JS; KIM, PS				WEISSMAN, JS; KIM, PS			THE PRO REGION OF BPTI FACILITATES FOLDING	CELL			English	Article							PANCREATIC TRYPSIN-INHIBITOR; PROTEIN-DISULFIDE-ISOMERASE; NUCLEAR-MAGNETIC-RESONANCE; INTERMEDIATE; SEQUENCES; PATHWAY; DITHIOTHREITOL; POLYPEPTIDE; REQUIREMENT; MICROSOMES	The in vitro folding pathway of bovine pancreatic trypsin inhibitor (BPTI) has been described previously in terms of the disulfide-bonded intermediates that accumulate during folding of the protein. Folding is slow, occurring in hours at pH 7.3, 25-degrees-C. In addition, approximately half of the BPTI molecules become trapped as a dead-end, native-like intermediate. In vivo, BPTI is synthesized as a precursor protein that includes a 13 residue amino-terminal pro region. This pro region contains a cysteine residue. We find that, in vitro, both the rate of formation and the yield of properly folded BPTI are increased substantially in a recombinant model of pro-BPTI. The cysteine residue is necessary for this effect. Moreover, a single cysteine residue, tethered to the carboxy-terminal end of BPTI with a flexible linker of repeating Ser-Gly-Gly residues, is sufficient to assist in disulfide formation. Thus, the pro region appears to facilitate folding by providing a tethered, solvent-accessible, intramolecular thiol-disulfide reagent.	MIT, WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; MIT, DEPT PHYS, CAMBRIDGE, MA 02142 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	WEISSMAN, JS (corresponding author), MIT, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02142 USA.				NIAID NIH HHS [T32AI07348] Funding Source: Medline; NIGMS NIH HHS [GM41307] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041307] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; BEDOWS E, 1992, J BIOL CHEM, V267, P8880; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; CHAU MH, 1991, FEBS LETT, V291, P296, DOI 10.1016/0014-5793(91)81305-R; CREIGHTON TE, 1980, J MOL BIOL, V142, P43, DOI 10.1016/0022-2836(80)90205-3; CREIGHTON TE, 1984, METHOD ENZYMOL, V107, P305; CREIGHTON TE, 1977, J MOL BIOL, V113, P275, DOI 10.1016/0022-2836(77)90142-5; CREIGHTON TE, 1987, J MOL BIOL, V194, P11, DOI 10.1016/0022-2836(87)90711-X; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; CREIGHTON TE, 1975, J MOL BIOL, V95, P167, DOI 10.1016/0022-2836(75)90389-7; CREIGHTON TE, 1988, BIOPHYS CHEM, V31, P155, DOI 10.1016/0301-4622(88)80021-8; DARBY NJ, 1992, J MOL BIOL, V224, P905, DOI 10.1016/0022-2836(92)90458-V; DEISENHOFER J, 1975, ACTA CRYSTALLOGR B, V31, P238, DOI 10.1107/S0567740875002415; DOERING D, 1992, THESIS MIT CAMBRIDGE; EIGENBROT C, 1990, PROTEIN ENG, V3, P591, DOI 10.1093/protein/3.7.591; FIELDS C G, 1991, Peptide Research, V4, P95; FREEDMAN RB, 1991, CONFORMATIONS FORCES, P204; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GOLDENBERG DP, 1992, TRENDS BIOCHEM SCI, V17, P257, DOI 10.1016/0968-0004(92)90405-X; GOLDENBERG DP, 1989, NATURE, V338, P127, DOI 10.1038/338127a0; GRAY AM, 1990, SCIENCE, V247, P1328, DOI 10.1126/science.2315700; GROSJEAN H, 1982, GENE, V18, P199, DOI 10.1016/0378-1119(82)90157-3; HURLE MR, 1992, PROTEIN SCI, V1, P91; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; KAISER CA, 1987, SCIENCE, V235, P312, DOI 10.1126/science.3541205; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KOSEN PA, 1992, BIOCHEMISTRY-US, V31, P5705, DOI 10.1021/bi00140a004; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LIN TY, 1991, P NATL ACAD SCI USA, V88, P10573, DOI 10.1073/pnas.88.23.10573; NADERI HM, 1991, CONFORMATIONS FORCES, P86; OAS TG, 1988, NATURE, V336, P42, DOI 10.1038/336042a0; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROTHWARF DM, 1992, P NATL ACAD SCI USA, V89, P7944, DOI 10.1073/pnas.89.17.7944; ROTHWARF DM, 1991, J AM CHEM SOC, V113, P6293, DOI 10.1021/ja00016a068; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; STALEY JP, 1992, P NATL ACAD SCI USA, V89, P1519, DOI 10.1073/pnas.89.5.1519; STALEY JP, 1990, NATURE, V344, P685, DOI 10.1038/344685a0; STASSINOPOULOU CI, 1984, EUR J BIOCHEM, V145, P423, DOI 10.1111/j.1432-1033.1984.tb08571.x; STATES DJ, 1987, J MOL BIOL, V195, P731, DOI 10.1016/0022-2836(87)90192-6; STATES DJ, 1984, J MOL BIOL, V174, P411, DOI 10.1016/0022-2836(84)90345-0; STEINER DF, 1968, P NATL ACAD SCI USA, V60, P622, DOI 10.1073/pnas.60.2.622; VANMIERLO CPM, 1992, P NATL ACAD SCI USA, V89, P6775, DOI 10.1073/pnas.89.15.6775; VANMIERLO CPM, 1991, J MOL BIOL, V222, P373, DOI 10.1016/0022-2836(91)90217-T; VANMIERLO CPM, 1991, J MOL BIOL, V222, P353, DOI 10.1016/0022-2836(91)90216-S; VERWEIJ CL, 1987, EMBO J, V6, P2885, DOI 10.1002/j.1460-2075.1987.tb02591.x; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WEISSMAN JS, 1992, P NATL ACAD SCI USA, V89, P9900, DOI 10.1073/pnas.89.20.9900; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; WINTHER JR, 1991, P NATL ACAD SCI USA, V88, P9330, DOI 10.1073/pnas.88.20.9330; WLODAWER A, 1984, J MOL BIOL, V180, P301, DOI 10.1016/S0022-2836(84)80006-6; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	57	133	139	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 27	1992	71	5					841	851		10.1016/0092-8674(92)90559-U	http://dx.doi.org/10.1016/0092-8674(92)90559-U			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JZ633	1384990				2022-12-28	WOS:A1992JZ63300013
J	WELCH, HG; FISHER, ES				WELCH, HG; FISHER, ES			LETS MAKE A DEAL - NEGOTIATING A SETTLEMENT BETWEEN PHYSICIANS AND SOCIETY	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HEALTH-CARE; UNITED-STATES; MORTALITY; EDUCATION; OUTCOMES		DARTMOUTH COLL,HANOVER,NH 03755	Dartmouth College	WELCH, HG (corresponding author), VET AFFAIRS MED CTR,WHITE RIVER JCT,VT 05009, USA.							BLANE D, 1990, BRIT MED J, V301, P429, DOI 10.1136/bmj.301.6749.429; BLENDON RJ, 1991, CLIN NEUR, V37, P225; EVANS RG, 1990, J HEALTH POLIT POLIC, V15, P101, DOI 10.1215/03616878-15-1-101; Fisher R., 2011, GETTING YES NEGOTIAT; GINSBURG PB, 1991, ACAD MED, V66, P20, DOI 10.1097/00001888-199101000-00005; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; HUGHES RG, 1991, NEW ENGL J MED, V325, P404, DOI 10.1056/NEJM199108083250606; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; MARTIKAINEN PT, 1990, BMJ-BRIT MED J, V301, P407, DOI 10.1136/bmj.301.6749.407; NAVARRO V, 1990, LANCET, V336, P1238, DOI 10.1016/0140-6736(90)92846-A; PETERSDORF RG, 1985, NEW ENGL J MED, V312, P1322, DOI 10.1056/NEJM198505163122011; PINCUS T, 1987, J CHRON DIS, V40, P865, DOI 10.1016/0021-9681(87)90186-X; REINHARDT UE, 1987, MILBANK Q, V65, P153, DOI 10.2307/3350018; WENNBERG JE, 1990, NEW ENGL J MED, V323, P1202, DOI 10.1056/NEJM199010253231710; WENNBERG JE, 1991, JAMA-J AM MED ASSOC, V265, P1306, DOI 10.1001/jama.265.10.1306; 1991, ECONOMIST       0810, V320, P13; 1990, HLTH CARE FINANC REV, V11, P1	17	12	12	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 29	1992	327	18					1312	1315		10.1056/NEJM199210293271813	http://dx.doi.org/10.1056/NEJM199210293271813			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JV259	1406823				2022-12-28	WOS:A1992JV25900013
J	CLANCY, CM; MASSION, CT				CLANCY, CM; MASSION, CT			AMERICAN WOMENS HEALTH-CARE - A PATCHWORK QUILT WITH GAPS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PSYCHOTROPIC-DRUG USE; SEX-DIFFERENCES; INSURANCE; DISEASE; ABUSE				CLANCY, CM (corresponding author), AGCY HLTH CARE POLICY & RES,CTR GEN HLTH SERV EXTRAMURAL RES,DIV PRIMARY CARE,EOC 502,ROCKVILLE,MD 20852, USA.							AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BACHMANN GA, 1988, OBSTET GYNECOL, V71, P631; BARTMAN BA, 1991, CLIN RES, V39, pA595; BERK ML, 1984, AM J PUBLIC HEALTH, V74, P1276, DOI 10.2105/AJPH.74.11.1276; BERNSTEIN B, 1981, MED CARE, V19, P600, DOI 10.1097/00005650-198106000-00004; BERRY PL, 1990, OBSTET GYN CLIN N AM, V17, P837; BICKELL NA, 1992, ANN INTERN MED, V116, P791, DOI 10.7326/0003-4819-116-10-791; BOLEN J, 1992, WOM HLTH FORUM, V1, P3; CAFFERATA GL, 1990, MED CARE, V28, P285; COHEN MM, 1992, MED CARE, V30, P514, DOI 10.1097/00005650-199206000-00005; COOPERSTOCK R, 1976, CAN MED ASSOC J, V115, P760; DROSSMAN DA, 1990, ANN INTERN MED, V113, P828, DOI 10.7326/0003-4819-113-11-828; FARLEY PJ, 1985, MILBANK FUND Q, V63, P476, DOI 10.2307/3349844; GIFFIN R, 1992, COMMUNICATION   0210; Gray J, 1982, J R Coll Gen Pract, V32, P167; GREENFIELD S, 1985, ANN INTERN MED, V102, P520, DOI 10.7326/0003-4819-102-4-520; HARVEY B, 1990, NEW ENGL J MED, V323, P1216, DOI 10.1056/NEJM199010253231726; HEALY B, 1991, JAMA-J AM MED ASSOC, V266, P566, DOI 10.1001/jama.266.4.566; JECKER NS, 1991, JAMA-J AM MED ASSOC, V266, P3012, DOI 10.1001/jama.266.21.3012; Johnson K, 1990, J Am Med Womens Assoc (1972), V45, P222; JOHNSON K, 1991, MS               NOV, P68; KIRCHSTEIN RL, 1991, AM J PUBLIC HEALTH, V81, P291; KRUMHOLZ HM, 1992, ANN INTERN MED, V116, P785, DOI 10.7326/0003-4819-116-10-785; Lempert L B, 1986, Health Care Women Int, V7, P255; LOOKER P, 1992, COMMUNICATION   0302; LUTZ ME, 1989, WOMEN HEALTH, V15, P21, DOI 10.1300/J013v15n01_03; MAKUC DM, 1989, AM J PUBLIC HEALTH, V79, P21, DOI 10.2105/AJPH.79.1.21; MANDELBLATT J, 1986, JAMA-J AM MED ASSOC, V256, P367, DOI 10.1001/jama.256.3.367; MARINIER RL, 1985, DRUG INTEL CLIN PHAR, V19, P40, DOI 10.1177/106002808501900111; MONTGOMERY K, 1992, WOM HLTH FORUM, V1, P1; POLLNER F, 1989, MED WORLDS NEWS 0424, P42; ROTER D, 1991, MED CARE, V29, P1083; SOFAER S, 1990, WOMEN HEALTH, V16, P47, DOI 10.1300/J013v16n03_04; SPENCER G, 1989, CURRENT POPULATI P25, V1018; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; STONE R, 1986, CAREGIVERS FRAAIL EL; Woods N F, 1985, Health Care Women Int, V6, P193; WOOLHANDLER S, 1988, JAMA-J AM MED ASSOC, V259, P2872; YAFFE MJ, 1984, CAN MED ASSOC J, V131, P1225; 1990, 104 EMPL BEN RES I I; 1989, GPO017022010666 NAT; 1992, JAMA-J AM MED ASSOC, V267, P3184; 1991, JAMA-J AM MED ASSOC, V266, P559; 1990, WOMEN MED DATA SOURC; 1988, GPO003001915430 US D; 1992, JAMA-J AM MED ASSOC, V267, P3190; 1988, WOMEN HLTH, V14, P53	47	94	95	1	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1992	268	14					1918	1920		10.1001/jama.268.14.1918	http://dx.doi.org/10.1001/jama.268.14.1918			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JR439	1404719				2022-12-28	WOS:A1992JR43900044
J	HENDEY, B; KLEE, CB; MAXFIELD, FR				HENDEY, B; KLEE, CB; MAXFIELD, FR			INHIBITION OF NEUTROPHIL CHEMOKINESIS ON VITRONECTIN BY INHIBITORS OF CALCINEURIN	SCIENCE			English	Article							FREE CALCIUM; POLYMORPHONUCLEAR LEUKOCYTES; CELLULAR-REGULATION; CYCLOSPORINE-A; PROTEIN; DOMAIN; FIBRONECTIN; RECEPTORS; CELLS; IDENTIFICATION	Migration of human polymorphonuclear neutrophils on vitronectin is dependent on repeated transient increases in the concentration of intracellular free calcium ([Ca2+]i). A specific peptide inhibitor of the Ca2+-calmodulin-dependent phosphatase calcineurin was introduced into the cytoplasm of neutrophils. The peptide inhibited neutrophil migration on vitronectin by interfering with the release of the cells from sites of attachment. A similar reduction in motility on vitronectin occurred when cells were treated with the immunosuppressant FK506, which also inhibits calcineurin when bound to its binding protein, FKBP. These results indicate that a rise in [Ca2+]i reduces integrin-mediated adhesion to vitronectin by a mechanism that requires calcineurin activity.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT PHYSIOL,NEW YORK,NY 10032; NCI,BIOCHEM LAB,BETHESDA,MD 20892	Columbia University; Columbia University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Maxfield, Fred/A-1718-2011; Maxfield, Fred/M-6747-2019	Maxfield, Fred/0000-0003-4396-8866	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014150, R01GM034770] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34770, GM14150] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHANTLER PD, 1985, J CELL BIOL, V101, P207, DOI 10.1083/jcb.101.1.207; CHATILA TA, 1989, J CELL BIOL, V109, P3435, DOI 10.1083/jcb.109.6.3435; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; GRESHAM HD, 1989, J CELL BIOL, V108, P1935, DOI 10.1083/jcb.108.5.1935; GUERINI D, 1989, P NATL ACAD SCI USA, V86, P9183, DOI 10.1073/pnas.86.23.9183; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HAYMAN EG, 1985, J CELL BIOL, V100, P1948, DOI 10.1083/jcb.100.6.1948; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; HUBBARD MJ, 1991, MOL NEUROBIOL, P135; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P255, DOI 10.1111/j.1432-1033.1983.tb07357.x; JACONI MEE, 1991, J CELL BIOL, V112, P1249, DOI 10.1083/jcb.112.6.1249; KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8983, DOI 10.1073/pnas.85.23.8983; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; LO SK, 1989, J EXP MED, V169, P1779, DOI 10.1084/jem.169.5.1779; MARKS PW, 1990, J CELL BIOL, V110, P43, DOI 10.1083/jcb.110.1.43; MARKS PW, 1991, J CELL BIOL, V112, P149, DOI 10.1083/jcb.112.1.149; OSTERGAARD HL, 1991, SCIENCE, V253, P1423, DOI 10.1126/science.1654595; RATAN RR, 1986, P NATL ACAD SCI USA, V83, P5136, DOI 10.1073/pnas.83.14.5136; RECHSTEINER M, 1987, METHOD ENZYMOL, V149, P42; SIEKIERKA JJ, 1989, J IMMUNOL, V143, P1580; SINGER II, 1989, J CELL BIOL, V109, P3169, DOI 10.1083/jcb.109.6.3169; TOMASINI BR, 1990, PROG HEMOSTASIS THRO, V10, P269; WRIGHT SD, 1986, J IMMUNOL, V136, P1759; WRIGHT SD, 1988, J CELL SCI S, V9, P99; YAMASHIRO DJ, 1983, J CELL BIOL, V97, P929, DOI 10.1083/jcb.97.3.929	29	183	183	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 9	1992	258	5080					296	299		10.1126/science.1384129	http://dx.doi.org/10.1126/science.1384129			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JR860	1384129				2022-12-28	WOS:A1992JR86000033
J	ANDERSON, MP; WELSH, MJ				ANDERSON, MP; WELSH, MJ			REGULATION BY ATP AND ADP OF CFTR CHLORIDE CHANNELS THAT CONTAIN MUTANT NUCLEOTIDE-BINDING DOMAINS	SCIENCE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC-FIBROSIS GENE; MULTIDRUG RESISTANCE; R-DOMAIN; EXPRESSION; MUTATIONS; IDENTIFICATION; TRANSPORT; CELLS; PHOSPHORYLATION	Regulation of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel is unusual in that phosphorylated channels require cytosolic adenosine triphosphate (ATP) to open. The CFTR contains two regions predicted to be nucleotide-binding domains (NBDs); site-directed mutations in each NBD have now been shown to alter the relation between ATP concentration and channel activity, which indicates that ATP stimulates the channel by direct interaction with both NBDs. The two NBDs are not, however, functionally equivalent: adenosine diphosphate (ADP) competitively inhibited the channel by interacting with NBD2 but not by interacting with NBD1. Four cystic fibrosis-associated mutations in the NBDs reduced absolute chloride channel activity, and one mutation also decreased the potency with which ATP stimulates channel activity. Dysfunction of ATP-dependent stimulation through the NBDs may be the basis for defective CFTR chloride channel activity in some cystic fibrosis patients.	UNIV IOWA, COLL MED, HOWARD HUGHES MED INST, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa	ANDERSON, MP (corresponding author), UNIV IOWA, COLL MED, HOWARD HUGHES MED INST, DEPT INTERNAL MED, IOWA CITY, IA 52242 USA.			Anderson, Matthew/0000-0003-4602-1811; Welsh, Michael/0000-0002-1646-6206				AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BEAUDET A, COMMUNICATION; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; BLACK ME, 1990, J BIOL CHEM, V265, P17584; BLOXMAN DP, 1973, ENZYMES, P262; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; DEVOTO M, 1991, AM J HUM GENET, V48, P1127; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; HARTMAN J, 1992, J BIOL CHEM, V267, P6455; HORN R, 1991, BIOPHYS J, V60, P433, DOI 10.1016/S0006-3495(91)82069-0; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; LISSENS W, COMMUNICATION; NEET KE, 1983, CONT ENZYME KINETICS, P267; PASTAN I, 1991, FASEB J, V5, P2523, DOI 10.1096/fasebj.5.11.1868977; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; Smith R.M., 1975, CRITICAL STABILITY C; STRONG TV, 1991, NEW ENGL J MED, V325, P1630, DOI 10.1056/NEJM199112053252307; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; Tsui L C, 1991, Adv Hum Genet, V20, P153; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	37	202	208	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 18	1992	257	5077					1701	1704		10.1126/science.1382316	http://dx.doi.org/10.1126/science.1382316			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JN501	1382316				2022-12-28	WOS:A1992JN50100036
J	BERGIN, PS; HARVEY, P				BERGIN, PS; HARVEY, P			LESSON OF THE WEEK - WERNICKES ENCEPHALOPATHY AND CENTRAL PONTINE MYELINOLYSIS ASSOCIATED WITH HYPEREMESIS GRAVIDARUM	BRITISH MEDICAL JOURNAL			English	Article							EXTRAPONTINE MYELINOLYSIS		ROYAL FREE HOSP,LONDON NW3 2QG,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School								BLASS JP, 1977, NEW ENGL J MED, V297, P1367, DOI 10.1056/NEJM197712222972503; DAVIS RE, 1983, ADV CLIN CHEM, V23, P93, DOI 10.1016/S0065-2423(08)60399-6; DEWITT LD, 1984, NEUROLOGY, V34, P570, DOI 10.1212/WNL.34.5.570; FLANNELLY G, 1990, IRISH J MED SCI, V159, P82, DOI 10.1007/BF02946676; FRASER D, 1988, BRIT J OBSTET GYNAEC, V95, P621, DOI 10.1111/j.1471-0528.1988.tb09496.x; GOCHT A, 1987, CLIN NEUROPATHOL, V6, P262; GOEBEL HH, 1976, HDB CLIN NEUROLOGY 2, V28, P285; Henderson DK, 1914, B JOHNS HOPKINS HOSP, V25, P261; LAURENO R, 1988, LANCET, V1, P1439; LEVIN P, 1983, OBSTET GYNECOL, V62, pS13; MILLER GM, 1988, RADIOLOGY, V168, P795, DOI 10.1148/radiology.168.3.3406409; NORENBERG MD, 1982, ANN NEUROL, V11, P128, DOI 10.1002/ana.410110204; THOMPSON PD, 1986, BRIT MED J, V292, P684, DOI 10.1136/bmj.292.6521.684; WILSON JD, 1991, HARRISONS PRINCIPLES, P434; WOOD P, 1983, BRIT J OBSTET GYNAEC, V90, P583, DOI 10.1111/j.1471-0528.1983.tb08974.x; 1980, RECOMMENDED DIETARY	16	61	64	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 29	1992	305	6852					517	518		10.1136/bmj.305.6852.517	http://dx.doi.org/10.1136/bmj.305.6852.517			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL609	1393001	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992JL60900025
J	MORI, H; MASAKI, H; YAMAKURA, T; MISHINA, M				MORI, H; MASAKI, H; YAMAKURA, T; MISHINA, M			IDENTIFICATION BY MUTAGENESIS OF A MG2+-BLOCK SITE OF THE NMDA RECEPTOR CHANNEL	NATURE			English	Article							METHYL-D-ASPARTATE; EXCITATORY AMINO-ACIDS; MOUSE CENTRAL NEURONS; SPINAL-CORD NEURONS; ANTICONVULSANT MK-801; ACTIVATED CHANNELS; CORTICAL-NEURONS; RESPONSES; ZINC; PERMEABILITY	THE N-methyl-D-aspartate (NMDA) receptor channel is highly permeable to Ca2+ but is blocked by Mg2+ in a voltage-dependent manner1-4. These characteristics are essential for the NMDA receptor channel to mediate the induction of long-term potentiation of synaptic efficacy, a form of activity-dependent synaptic plasticity thought to underlie memory, learning and development5-8. Recent studies have revealed the molecular and functional diversity of the NMDA receptor channel subunits, which are classified into the epsilon and zeta families according to the amino-acid sequence homology9-12. Here we report that replacement by glutamine of asparagine 598 in putative transmembrane segment M2 of the zeta-1 subunit, strongly reduces the sensitivity of the heteromeric epsilon-2/zeta-1 NMDA receptor channel to Mg2+ block. The corresponding mutation of the epsilon-2 subunit has a similar effect. Furthermore, the heteromeric epsilon-2/zeta-1 NMDA receptor channel with the mutation on both subunits shows greatly reduced sensitivity to MK-801, a channel blocker of the NMDA receptor channel13,14, but is still susceptible to inhibition by Zn2+ 15,16. These findings suggest that the conserved asparagine residue in segment M2 constitutes a Mg2+-block site of the NMDA receptor channel, and that the MK-801 site overlaps the Mg2+ site.	NIIGATA UNIV, BRAIN RES INST, DEPT NEUROPHARMACOL, ASAHIMACHI 1, NIIGATA 95021, JAPAN	Niigata University								ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; ASHCER P, 1986, J PHYSIOL-LONDON, V377, pP35; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; CHRISTINE CW, 1990, J NEUROSCI, V10, P108; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; HERRON CE, 1986, NATURE, V322, P265, DOI 10.1038/322265a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUETTNER JE, 1988, P NATL ACAD SCI USA, V85, P1307, DOI 10.1073/pnas.85.4.1307; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LEGENDRE P, 1990, J PHYSIOL-LONDON, V429, P429, DOI 10.1113/jphysiol.1990.sp018266; LEONARD JP, 1990, NEURON, V4, P53, DOI 10.1016/0896-6273(90)90443-J; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MISHINA M, 1991, BIOCHEM BIOPH RES CO, V180, P813, DOI 10.1016/S0006-291X(05)81137-4; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; PETERS S, 1987, SCIENCE, V236, P589, DOI 10.1126/science.2883728; SAKIMURA K, 1990, FEBS LETT, V272, P73, DOI 10.1016/0014-5793(90)80452-O; WESTBROOK GL, 1987, NATURE, V328, P640, DOI 10.1038/328640a0; WONG EHF, 1986, P NATL ACAD SCI USA, V83, P7104, DOI 10.1073/pnas.83.18.7104; YAMAZAKI M, 1992, FEBS LETT, V300, P39, DOI 10.1016/0014-5793(92)80160-I	25	218	220	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 20	1992	358	6388					673	675		10.1038/358673a0	http://dx.doi.org/10.1038/358673a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ882	1386653				2022-12-28	WOS:A1992JJ88200055
J	LAWRENCE, M				LAWRENCE, M			PARTNERS IN PRACTICE .4. CARING FOR THE FUTURE	BRITISH MEDICAL JOURNAL			English	Article							SATISFACTION; CONTRACT				LAWRENCE, M (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,OXFORD OX2 6HE,ENGLAND.							BAKER R, 1990, BRIT J GEN PRACT, V40, P487; Balint M., 1957, DOCTOR; Byrne P.S., 1976, DOCTORS TALKING PATI; COLLINGS JS, 1950, LANCET, V1, P555; DALE J, 1991, PROVIDING PRIMARY CA; Griffiths R, 1988, COMMUNITY CARE AGEND; Jones R.V.H., 1986, 33 ROYAL COLL GEN PR; Magee B, 1971, MODERN BRIT PHILOS; MAHONEY FI, 1964, MED J, V14, P61; MANT D, 1990, BMJ-BRIT MED J, V300, P1053, DOI 10.1136/bmj.300.6731.1053; MORRELL DC, 1986, BRIT MED J, V292, P870; Pendleton D., 1984, CONSULTATION APPROAC; PERKINS ER, 1991, BRIT J GEN PRACT, V41, P382; PRITCHARD P, 1981, PATIENT PARTICIPATIO; Qureshi K N, 1974, Age Ageing, V3, P152, DOI 10.1093/ageing/3.3.152; RICHARDSON A, 1987, PROMOTING HLTH PARTI; Tuckett D., 1985, M BETWEEN EXPERTS; WILKIN D, 1992, MEASURES NEED OUTCOM; 1965, CHARTER FAMILY DOCTO; 1991, ASK PATIENT; 1989, GENERAL PRACTICE NAT; 1991, INTEGRATING PRIMARY; 1986, PRIMARY HLTH CARE AG; 1987, PROMOTING BETTER HLT; 1986, NEIGHBOURHOOD NURSIN; 1991, MEAUSREMENT PATIENT; 1990, CMND555; 1990, HCFP908 DEP HLTH HLT; 1991, CM1523 SECR STAT HLT	29	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 15	1992	305	6850					400	402		10.1136/bmj.305.6850.400	http://dx.doi.org/10.1136/bmj.305.6850.400			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK314	1392923	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JK31400018
J	HALL, SM				HALL, SM			REGULAR REVIEW - CONGENITAL TOXOPLASMOSIS	BMJ-BRITISH MEDICAL JOURNAL			English	Review							FOLLOW-UP; PREGNANCY; DIAGNOSIS; GONDII; INFECTION				HALL, SM (corresponding author), PUBL HLTH LAB SERV, CTR COMMUNICABLE DIS SURVEILLANCE, LONDON NW9 5EQ, ENGLAND.							ADES AE, 1991, EPIDEMIOL INFECT, V107, P527, DOI 10.1017/S0950268800049220; ADLAM L, 1992, READERS DIGEST   FEB, P139; [Anonymous], 1990, LANCET, V336, P346, DOI 10.1016/0140-6736(90)91883-C; APARECIDA GP, 1968, ARCH DIS CHILD, V43, P705; ASBELI PA, 1982, AM J OPHTHALMOL, V94, P656, DOI 10.1016/0002-9394(82)90011-3; BALFOUR AH, 1988, J CLIN PATHOL, V41, P1135, DOI 10.1136/jcp.41.10.1135-b; BENENSON MW, 1982, NEW ENGL J MED, V307, P666, DOI 10.1056/NEJM198209093071107; BUXTON D, 1991, VET REC, V129, P89, DOI 10.1136/vr.129.5.89; CONYNVANSPAENDO.MA, 1991, PREVENTION CONGENITA; DAFFOS F, 1988, NEW ENGL J MED, V318, P271, DOI 10.1056/NEJM198802043180502; DESMONTS G, 1990, PRESSE MED, V19, P1445; FORTIER B, 1991, LANCET, V338, P444, DOI 10.1016/0140-6736(91)91064-2; HALL SM, 1983, BRIT MED J, V287, P453, DOI 10.1136/bmj.287.6390.453; HALL SM, 1986, J SMALL ANIM PRACT, V27, P705, DOI 10.1111/j.1748-5827.1986.tb03770.x; HERMENTIN K, 1988, ZBL BAKT-INT J MED M, V269, P423; HOFF R, 1990, ALB BIR DEF, P169; HOHLFELD P, 1989, J PEDIATR-US, V115, P765, DOI 10.1016/S0022-3476(89)80660-2; HOLLIMAN RE, 1991, BRIT J OPHTHALMOL, V75, P353, DOI 10.1136/bjo.75.6.353; HOLLIMAN RE, 1991, BRIT J OBSTET GYNAEC, V98, P832, DOI 10.1111/j.1471-0528.1991.tb13492.x; HOLLIMAN RE, 1990, SERODIAG IMMUN INF D, V4, P83, DOI 10.1016/0888-0786(90)90031-I; JEANNEL D, 1990, LANCET, V336, P359, DOI 10.1016/0140-6736(90)91890-M; JOSS AWL, 1990, PUBLIC HEALTH, V104, P9, DOI 10.1016/S0033-3506(05)80340-3; JOYNSON DHM, 1990, J CLIN PATHOL, V43, P1032, DOI 10.1136/jcp.43.12.1032; JOYNSON DHM, 1988, LANCET, V2, P795; JOYNSON DHM, 1991, CONT REV OBSTET GYNA, V3, P61; KOPPE JG, 1989, INT OPHTHALMOL, V13, P387, DOI 10.1007/BF02306486; MANT D, 1990, BRIT MED J, V300, P916, DOI 10.1136/bmj.300.6729.916; MARTEAU TM, 1989, BRIT MED J, V299, P527, DOI 10.1136/bmj.299.6698.527; MASON MC, 1990, INDEPENDENT     1106, P15; MCCABE R, 1988, NEW ENGL J MED, V318, P313, DOI 10.1056/NEJM198802043180509; MITCHELL CD, 1990, PEDIATR INFECT DIS J, V9, P512, DOI 10.1097/00006454-199007000-00012; NEWTON RW, 1979, BRIT MED J, V2, P411, DOI 10.1136/bmj.2.6187.411; PALMER J, 1989, DAILY MIRROR    0904, P13; Remington JS., 1990, INFECT DIS FETUS NEW, V3, P89; Richards M P M, 1989, J Reprod Infant Psychol, V7, P171; RUOSS CF, 1972, J OBSTET GYN BR COMM, V79, P1115; SACKETT DL, 1975, LANCET, V2, P357, DOI 10.1016/S0140-6736(75)92790-7; SKINNER LJ, 1990, SCAND J INFECT DIS, V22, P359, DOI 10.3109/00365549009027060; SMITH R, 1992, BMJ-BRIT MED J, V304, P370; TEUTEN B, 1990, LANCET, V336, P819; THORP JM, 1988, NEW ENGL J MED, V319, P372, DOI 10.1056/NEJM198808113190615; Tymstra T, 1989, Int J Technol Assess Health Care, V5, P207; WALKER J, 1992, EPIDEMIOL INFECT, V108, P99, DOI 10.1017/S0950268800049542; WILSON CB, 1980, PEDIATRICS, V66, P767; Wilson J JG, 1968, PUBLIC HLTH PAPERS, V34; YEN DOH, IN PRESS HUMAN TOXOP; 1991, WHILE YOU ARE PREGNA; 1987, BMJ, V295, P1551; 1992, PRENATAL SCREENING T; 1991, BMJ, V302, P973	50	45	45	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 1	1992	305	6848					291	297		10.1136/bmj.305.6848.291	http://dx.doi.org/10.1136/bmj.305.6848.291			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG740	1392863	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JG74000023
J	LIN, HC; SUDHOF, TC; ANDERSON, RGW				LIN, HC; SUDHOF, TC; ANDERSON, RGW			ANNEXIN-VI IS REQUIRED FOR BUDDING OF CLATHRIN-COATED PITS	CELL			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; LOW-DENSITY LIPOPROTEIN; ANTICOAGULANT PROTEIN; MEMBRANE-FUSION; CALCIUM; CALPACTIN; BINDING; KINASE; CELLS; PHOSPHOLIPASE-A2	Isolated plasma membranes attached to a solid substratum at 4-degrees-C have numerous clathrin-coated pits. These pits initially are flat but become deeply invaginated after warming to 37-degrees-C. The pits remain tethered to the membrane in this rounded condition unless supplied with ATP, Ca2+, and cytosol. We now show that when cytosol is treated to remove the Ca2+-dependent, phospholipid-binding protein annexin VI, coated pit budding no longer takes place. Addition of purified annexin VI back to the annexin VI-depleted cytosol restores budding activity to normal. Purified annexin VI alone shows only a modest budding activity, suggesting that the cytosol contains a factor(s) in addition to annexin VI that is required for full activity. Cytosol-dependent activation of annexin VI requires both ATP and Ca2+. Annexin VI appears to be not only an active component in the detachment of coated pits from the membrane but also a site for regulating the formation of coated vesicles.	UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	LIN, HC (corresponding author), UNIV TEXAS, SW MED CTR, DEPT CELL BIOL & NEUROSCI, DALLAS, TX 75235 USA.				NHLBI NIH HHS [HL39644, HL20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948, R01HL039644] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALI SM, 1989, NATURE, V340, P313, DOI 10.1038/340313a0; Anderson R G, 1986, Methods Enzymol, V129, P201; ANDERSON RGW, 1977, CELL, V10, P351, DOI 10.1016/0092-8674(77)90022-8; Anderson RM, 1991, INFECT DIS HUMANS DY, P13; BARTON GJ, 1991, EUR J BIOCHEM, V198, P749, DOI 10.1111/j.1432-1033.1991.tb16076.x; BLUMENTHAL R, 1987, CURR TOP MEMBR TRANS, V29, P203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODSKY FM, 1988, SCIENCE, V242, P1396, DOI 10.1126/science.2904698; BRODSKY FM, 1985, J CELL BIOL, V101, P2047, DOI 10.1083/jcb.101.6.2047; BURGOYNE RD, 1989, CELL CALCIUM, V10, P1, DOI 10.1016/0143-4160(89)90038-9; COMERA C, 1990, EUR J BIOCHEM, V188, P139, DOI 10.1111/j.1432-1033.1990.tb15381.x; Darnell J., 1990, MOL CELL BIOL; ERNST JD, 1991, J IMMUNOL, V146, P3110; ERNST JD, 1991, J BIOL CHEM, V266, P6670; ERNST JD, 1990, J CLIN INVEST, V85, P1065, DOI 10.1172/JCI114537; GENGE BR, 1990, J BIOL CHEM, V265, P4703; GLENNEY J, 1986, P NATL ACAD SCI USA, V83, P4258, DOI 10.1073/pnas.83.12.4258; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HAZARIKA P, 1991, J CELL BIOCHEM, V46, P78, DOI 10.1002/jcb.240460112; HAZARIKA P, 1991, J CELL BIOCHEM, V46, P86, DOI 10.1002/jcb.240460113; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HUANG KS, 1986, CELL, V46, P191, DOI 10.1016/0092-8674(86)90736-1; HUBER R, 1992, J MOL BIOL, V223, P683, DOI 10.1016/0022-2836(92)90984-R; HUBER R, 1990, EMBO J, V9, P3867, DOI 10.1002/j.1460-2075.1990.tb07605.x; JOHNSTON PA, 1990, BIOCHEM SOC T, V18, P1097, DOI 10.1042/bst0181097; KRAUS FN, 1990, CELL CALCIUM, V11, P625; KWIATKOWSKA K, 1991, EXP CELL RES, V196, P255, DOI 10.1016/0014-4827(91)90259-W; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARKIN JM, 1986, J CELL BIOL, V103, P2619, DOI 10.1083/jcb.103.6.2619; LIN HC, 1991, J CELL BIOL, V114, P881, DOI 10.1083/jcb.114.5.881; MAHAFFEY DT, 1990, J BIOL CHEM, V265, P16514; MEERS P, 1991, BIOCHEMISTRY-US, V30, P2903, DOI 10.1021/bi00225a025; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MOORE MS, 1987, SCIENCE, V236, P558, DOI 10.1126/science.2883727; NEWMAN R, 1989, J MOL BIOL, V206, P213, DOI 10.1016/0022-2836(89)90534-2; OHALLORAN TJ, 1992, IN PRESS J CELL BIOL; OSHRY L, 1991, BIOCHIM BIOPHYS ACTA, V1066, P239, DOI 10.1016/0005-2736(91)90192-B; PAPAHADJOPOULOS D, 1990, J BIOENERG BIOMEMBR, V22, P157, DOI 10.1007/BF00762944; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; ROJAS E, 1990, J BIOL CHEM, V265, P21207; ROSS TS, 1990, SCIENCE, V248, P605, DOI 10.1126/science.2159184; SARAFIAN T, 1991, J CELL BIOL, V114, P1135, DOI 10.1083/jcb.114.6.1135; SARIS CJM, 1986, CELL, V46, P201, DOI 10.1016/0092-8674(86)90737-3; SEKIMOTO S, 1991, J NEUROCHEM, V56, P1774, DOI 10.1111/j.1471-4159.1991.tb02080.x; SUDHOF TC, 1982, EMBO J, V1, P1167, DOI 10.1002/j.1460-2075.1982.tb00008.x; SUDHOF TC, 1984, BIOCHEMISTRY-US, V23, P1103; SUDHOF TC, 1988, P NATL ACAD SCI USA, V85, P664, DOI 10.1073/pnas.85.3.664; THIAGARAJAN P, 1990, J BIOL CHEM, V265, P17420; VANDEURS B, 1989, INT REV CYTOL, V117, P131; ZAKS WJ, 1990, J BIOENERG BIOMEMBR, V22, P97, DOI 10.1007/BF00762942; ZAKS WJ, 1991, BIOCHEMISTRY-US, V30, P9607, DOI 10.1021/bi00104a007	52	129	129	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 24	1992	70	2					283	291		10.1016/0092-8674(92)90102-I	http://dx.doi.org/10.1016/0092-8674(92)90102-I			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JE757	1386288				2022-12-28	WOS:A1992JE75700011
J	MACCHIARINI, P; FONTANINI, G; HARDIN, MJ; SQUARTINI, F; ANGELETTI, CA				MACCHIARINI, P; FONTANINI, G; HARDIN, MJ; SQUARTINI, F; ANGELETTI, CA			RELATION OF NEOVASCULARIZATION TO METASTASIS OF NON-SMALL-CELL LUNG-CANCER	LANCET			English	Note							ANGIOGENESIS; VESSELS	The growth of a tumour beyond a certain size requires angiogenesis. We assessed whether intensity of angiogenesis correlates with metastasis of non-small-cell lung cancer by counting microvessels and grading their density within the initial carcinomas in 87 T1N0M0 patients. After radical surgery, metastases developed in 22. Both microvessel count and density grades correlated significantly with metastatic disease as well as tumour size and proliferative activity. The likelihood of metastasis increased as the vessel count increased. On multivariate analysis, the microvessel density count was the only independent predictor of metastasis.	UNIV PISA,INST PATHOL ANAT & HISTOL,I-56100 PISA,ITALY; UNIV ALABAMA,DEPT BIOSTAT,BIRMINGHAM,AL 35294; UNIV PISA,SERV THORAC SURG,I-56100 PISA,ITALY	University of Pisa; University of Alabama System; University of Alabama Birmingham; University of Pisa			Macchiarini, Paolo/E-6878-2013; Fontanini, Gabriella/O-7636-2015	Fontanini, Gabriella/0000-0003-1957-2052				EAVES G, 1972, J PATHOL, V109, P233; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1980, NATURE, V288, P551, DOI 10.1038/288551a0; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; FONTANINI G, IN PRESS CANCER; Hsu S.M., 1984, ADV IMMUNOHISTOCHEMI, P31; LIOTTA LA, 1974, CANCER RES, V34, P997; NAGY J A, 1988, Biochimica et Biophysica Acta, V948, P305; SRIVASTAVA A, 1988, AM J PATHOL, V133, P19; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101	10	788	853	0	19	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 18	1992	340	8812					145	146		10.1016/0140-6736(92)93217-B	http://dx.doi.org/10.1016/0140-6736(92)93217-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE382	1378165				2022-12-28	WOS:A1992JE38200005
J	KOURI, YH; BASCH, RS; KARPATKIN, S				KOURI, YH; BASCH, RS; KARPATKIN, S			B-CELL SUBSETS AND PLATELET COUNTS IN HIV-1 SEROPOSITIVE SUBJECTS	LANCET			English	Note								A subset of B lymphocytes positive for the CD5 antigen have been implicated in several autoimmune disorders. To investigate their role in human immunodeficiency virus type 1 (HIV-1) infection, we studied peripheral-blood B and T lymphocytes from HIV-1-positive patients with (n = 13) and without (n = 18) thrombocytopenia, 8 patients with classic autoimmune thrombocytopenia, and 16 healthy controls. The proportion of CD5-positive B cells was significantly higher in the HIV-1-positive thrombocytopenic patients than in the healthy controls, as a result of both higher numbers of CD5-positive B cells and lower numbers of CD5-negative B cells. Platelet count was positively correlated with CD5-negative B-cell count (r = 0.6, P < 0.001) and negatively correlated with proportion of B cells that were CD5 positive (r = -0.5, p < 0.01) among the HIV-1-positive patients. The high concentrations of IgM-containing immune complexes in HIV-1-positive patients with autoimmune disorders may be due to changes in the CD5-positive B-cell subset.	NYU MED CTR, DEPT MED, 550 1ST AVE, NEW YORK, NY 10016 USA; NYU MED CTR, DEPT PATHOL, NEW YORK, NY 10016 USA; NYU MED CTR, KAPLAN CANC CTR, NEW YORK, NY 10016 USA	New York University; New York University; New York University				Basch, Ross/0000-0001-6666-2718	NHLBI NIH HHS [HL133336] Funding Source: Medline; NIA NIH HHS [AGO48660] Funding Source: Medline; NIDA NIH HHS [DADA04315] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL133336, R01HL133336] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004315] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ARAUJO PMF, 1987, SCAND J IMMUNOL, V25, P497, DOI 10.1111/j.1365-3083.1987.tb02221.x; BOUMSELL L, 1980, J EXP MED, V152, P229, DOI 10.1084/jem.152.1.229; Burastero S E, 1989, Contrib Microbiol Immunol, V11, P231; HARDY RR, 1987, SCIENCE, V236, P81, DOI 10.1126/science.3105057; KARPATKIN S, 1988, P NATL ACAD SCI USA, V85, P9763, DOI 10.1073/pnas.85.24.9763; KARPATKIN S, 1992, J CLIN INVEST, V89, P356, DOI 10.1172/JCI115593; KIPPS TJ, 1989, ADV IMMUNOL, V47, P117, DOI 10.1016/S0065-2776(08)60663-X; KOPELMAN RG, 1988, AM J MED, V84, P82, DOI 10.1016/0002-9343(88)90012-5; PAINTER CJ, 1988, J EXP MED, V167, P1137, DOI 10.1084/jem.167.3.1137; ZAULI G, 1991, J ACQ IMMUN DEF SYND, V4, P1251	10	19	19	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 13	1992	339	8807					1445	1446		10.1016/0140-6736(92)92033-C	http://dx.doi.org/10.1016/0140-6736(92)92033-C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY317	1376384	hybrid			2022-12-28	WOS:A1992HY31700006
J	GOODFIELD, MJD; ANDREW, L; EVANS, EGV				GOODFIELD, MJD; ANDREW, L; EVANS, EGV			SHORT-TERM TREATMENT OF DERMATOPHYTE ONYCHOMYCOSIS WITH TERBINAFINE	BRITISH MEDICAL JOURNAL			English	Article							KETOCONAZOLE; GRISEOFULVIN; LAMISIL; AGENTS	Objective - To evaluate the effect of short term treatment with terbinafine on dermatophytosis. Design - Multicentre, randomised, double blind placebo controlled trial of 250 mg/day terbinafine for 12 weeks in dermatophyte onychomycosis. Setting - Eight dermatology centres in the United Kingdom. Patients - 112 patients (mean age 44, range 19-78), 99 with mycologically proved toenail infections and 13 with fingernail infections, of whom eight were subsequently excluded and 19 failed to complete the study. Intervention - Terbinafine 250 mg daily or placebo for 12 weeks. Follow up for 36 weeks after stopping treatment. Main outcome measures - Mycological cure (negative results on microscopy and culture) and clinical cure at the end of follow up, adverse events, and biochemical and haematological variables at monthly intervals during treatment. Results - After follow up 82% (37/45) (95% confidence interval 68% to 92%) mycological cure and 69% clinical cure' were recorded for evaluable patients treated with terbinafine for toenail infection and 71% (5/7) (30% to 96%) mycological cure and clinical cure for those treated for fingernail infection. The corresponding values for those treated with placebo were 12% (3% to 31%) mycological cure and no clinical cure for toenail infections and 33% (1% to 91%) mycological cure and no clinical cure for fingernail infections. On an intention to treat basis for toenail infections the figures were 73% (38/52) (58% to 85%) mycological cure for terbinafine compared with 6% (0% to 30%) for placebo (p < 0.007). Two withdrawals were related to adverse events with terbinafine, and there were no significant abnormal laboratory test results. Conclusion - 12 weeks' terbinafine is effective and safe treatment for nail dermatophytosis.	DATA ANAL & RES,CARNWATH,LANARK,SCOTLAND; UNIV LEEDS,REG MYCOL LAB,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND	University of Leeds	GOODFIELD, MJD (corresponding author), GEN INFIRM,DEPT DERMATOL,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND.							BACK DJ, 1989, BRIT J CLIN PHARMACO, V28, P166, DOI 10.1111/j.1365-2125.1989.tb05410.x; BLANK H, 1959, ARCH DERMATOL, V79, P259, DOI 10.1001/archderm.1959.01560150001001; DAVIES RR, 1967, BMJ-BRIT MED J, V3, P464, DOI 10.1136/bmj.3.5563.464; EVANS EGV, 1990, J DERMATOLOGICAL S2, V1, P47; GOODFIELD MJD, 1989, BRIT J DERMATOL, V121, P753, DOI 10.1111/j.1365-2133.1989.tb08217.x; HARLAND CC, 1990, BRIT J DERMATOL, V123, P31; HAY RJ, 1988, BRIT J DERMATOL, V119, P359, DOI 10.1111/j.1365-2133.1988.tb03229.x; HAY RJ, 1987, CLIN EXP DERMATOL, V12, P175, DOI 10.1111/j.1365-2230.1987.tb01888.x; HEIBERG JK, 1981, BRIT MED J, V283, P825, DOI 10.1136/bmj.283.6295.825; PETRANYI G, 1984, SCIENCE, V224, P1239, DOI 10.1126/science.6547247; ROBERTS DT, 1990, FUNGAL NAIL INFECTIO; SAVIN R, 1989, CLIN EXP DERMATOL, V14, P116, DOI 10.1111/j.1365-2230.1989.tb00906.x; Stutz A, 1988, Ann N Y Acad Sci, V544, P46, DOI 10.1111/j.1749-6632.1988.tb40388.x; VANDENBOSSCHE H, 1978, CHEM-BIOL INTERACT, V21, P59, DOI 10.1016/0009-2797(78)90068-6; Villers V, 1990, J DERMATOL TREAT S2, V1, P33; ZAIAS N, 1983, J AM ACAD DERMATOL, V9, P912, DOI 10.1016/S0190-9622(83)70208-2; ZAIAS N, 1989, CLIN EXP DERMATOL, V14, P120, DOI 10.1111/j.1365-2230.1989.tb00907.x	17	102	106	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 2	1992	304	6835					1151	1154		10.1136/bmj.304.6835.1151	http://dx.doi.org/10.1136/bmj.304.6835.1151			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT232	1392793	Green Published, Bronze			2022-12-28	WOS:A1992HT23200021
J	MITCHELL, IC; TURK, JL; MITCHELL, DN				MITCHELL, IC; TURK, JL; MITCHELL, DN			DETECTION OF MYCOBACTERIAL RIBOSOMAL-RNA IN SARCOIDOSIS WITH LIQUID-PHASE HYBRIDIZATION	LANCET			English	Article							DNA; IDENTIFICATION; HYBRIDIZATION; TUBERCULOSIS	Because sarcoidosis resembles tuberculosis clinically and histologically, it has been suggested that mycobacteria might have a role in the pathogenesis of the disorder. Mycobacteria have not been found in sarcoid tissues by conventional culture techniques, so we have used a liquid-phase hybridisation method to see whether we could detect mycobacterial rRNA in such tissues. RNA was extracted from five sarcoid and five normal spleens. Extracts were assayed by liquid-phase DNA/RNA hybridisation with a DNA probe specific for the rRNA of the Mycobacterium tuberculosis complex. Hybridisation obtained with the sarcoid spleens, from which mycobacteria were neither seen on microscopy nor cultured with standard methods, was 4.8 times higher than that with normal spleens (p < 0.001). Our demonstration of mycobacterial nucleic-acid components in sarcoid splenic tissues supports the notion that mycobacteria play a part in the cause of sarcoidosis.	ROYAL COLL SURG ENGLAND,HUNTERIAN INST,DEPT PATHOL,LONDON WC2A 3PN,ENGLAND; ROYAL BROMPTON HOSP,LONDON,ENGLAND	Royal College of Surgeons of England; University of London; Royal Brompton Hospital								BERCOVIER H, 1986, BIOCHEM BIOPH RES CO, V136, P1136, DOI 10.1016/0006-291X(86)90452-3; BURNET FM, 1959, CLONAL SELECTION THE, P160; GONZALEZ R, 1987, DIAGN MICR INFEC DIS, V8, P69, DOI 10.1016/0732-8893(87)90152-0; Graham D, 1988, SARCOIDOSIS OTHER GR, P161; HANCE AJ, 1989, MOL MICROBIOL, V3, P843, DOI 10.1111/j.1365-2958.1989.tb00233.x; HANNGREN A, 1987, SARCOIDOSIS, V4, P104; KIRBY KS, 1968, METHOD ENZYMOL, P87; KOHNE DE, 1981, J GEN VIROL, V56, P223, DOI 10.1099/0022-1317-56-2-223; KOHNE DE, 1986, AM CLIN PROD REV, V5, P20; KOHNE DE, 1971, PROCEDURES NUCLEIC A, V2, P500; MCFADDEN JJ, 1987, BIOCHEM SOC T, V15, P548, DOI 10.1042/bst0150548; MITCHELL DN, 1983, 9TH INT C SARC OTH G, P132; PARKES SA, 1987, THORAX, V42, P420, DOI 10.1136/thx.42.6.420	13	96	99	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 25	1992	339	8800					1015	1017		10.1016/0140-6736(92)90536-C	http://dx.doi.org/10.1016/0140-6736(92)90536-C			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ435	1373786				2022-12-28	WOS:A1992HQ43500004
J	BRADBURY, NA; JILLING, T; BERTA, G; SORSCHER, EJ; BRIDGES, RJ; KIRK, KL				BRADBURY, NA; JILLING, T; BERTA, G; SORSCHER, EJ; BRIDGES, RJ; KIRK, KL			REGULATION OF PLASMA-MEMBRANE RECYCLING BY CFTR	SCIENCE			English	Article							CYSTIC-FIBROSIS; PROTEIN-KINASE; CHLORIDE; CONDUCTANCE; CELLS	The gene that encodes the cystic fibrosis transmembrane conductance regulator (CFTR) is defective in patients with cystic fibrosis. Although the protein product of the CFTR gene has been proposed to function as a chloride ion channel, certain aspects of its function remain unclear. The role of CFTR in the adenosine 3',5'-monophosphate (cAMP)-dependent regulation of plasma membrane recycling was examined. Adenosine 3',5'-monophosphate is known to regulate endocytosis and exocytosis in chloride-secreting epithelial cells that express CFTR. However, mutant epithelial cells derived from a patient with cystic fibrosis exhibited no cAMP-dependent regulation of endocytosis and exocytosis until they were transfected with complementary DNA encoding wild-type CFTR. Thus, CFTR is critical for cAMP-dependent regulation of membrane recycling in epithelial tissues, and this function of CFTR could explain in part the pleiotropic nature of cystic fibrosis.	UNIV ALABAMA,GREGORY FLEMING JAMES CYST FIBROSIS RES CTR,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT MED,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham				Sorscher, Eric J./0000-0001-9341-3354; Jilling, Tamas/0000-0002-6200-3851				ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BAE HR, 1990, NATURE, V348, P637, DOI 10.1038/348637a0; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BERTA G, UNPUB; BRADBURY NA, 1992, AM J PHYSIOL, V262, pC752, DOI 10.1152/ajpcell.1992.262.3.C752; BRADBURY NA, UNPUB; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; GASSER KW, 1988, AM J PHYSIOL, V254, pG93, DOI 10.1152/ajpgi.1988.254.1.G93; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; JILLING T, 1990, AM J PHYSIOL, V259, pC1010, DOI 10.1152/ajpcell.1990.259.6.C1010; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; POLLARD HB, 1984, J BIOL CHEM, V259, P1114; QUINTON PM, 1983, NATURE, V301, P421, DOI 10.1038/301421a0; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; SORSCHER EJ, 1991, LANCET, V337, P1115, DOI 10.1016/0140-6736(91)92785-Z; SORSCHER EJ, 1992, AM J PHYSIOL, V262, pC136, DOI 10.1152/ajpcell.1992.262.1.C136; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC233	21	329	330	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 24	1992	256	5056					530	532		10.1126/science.1373908	http://dx.doi.org/10.1126/science.1373908			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HQ187	1373908				2022-12-28	WOS:A1992HQ18700066
J	VETTER, NJ; LEWIS, PA; FORD, D				VETTER, NJ; LEWIS, PA; FORD, D			CAN HEALTH VISITORS PREVENT FRACTURES IN ELDERLY PEOPLE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED TRIAL; FEMUR	Objectives-To assess whether intervention by a health visitor could reduce the number of fractures, over a four year period, in those aged 70 and over. Design-Randomised, controlled trial; randomisation by household. Setting-General practice in a market town. Subjects-Of 863 patients aged 70 and over on the practice records, 674 were traced and successfully interviewed; 350 were assigned to the intervention group, 324 as controls. Intervention-The people in the intervention group were allocated to the care of a health visitor. The approach was four pronged: assessment and correction of nutritional deficiencies, including reducing smoking and alcohol intake; assessment and referral of medical conditions such as heart block or inappropriate medication; assessment and correction of environmental hazards in the home such as poor lighting; assessment and improvement of fitness- for example, exercise classes for the moderately fit. The intervention continued for four years. Main outcome measure-Fracture rate over four years. Results-The incidence of fractures was 5% (16/350) in the intervention group and 4% (14/324) in the control group (difference not significant). Conclusions-A health visitor visiting a group of people aged 70 and over and using simple preventive measures had no effect on the incidence of fractures.	UNIV WALES COLL CARDIFF, COLL MED, DEPT MED COMP & STAT, CARDIFF CF1 3NN, WALES	Cardiff University	VETTER, NJ (corresponding author), UNIV WALES COLL CARDIFF, COLL MED, DEPT EPIDEMIOL & COMMUNITY MED, CARDIFF CF1 3NN, WALES.							ARMITAGE P, 1987, STATISTICAL METHODS; BOYCE WJ, 1985, LANCET, V1, P150; CLARK ANG, 1968, GERONTOL CLIN, V10, P257, DOI 10.1159/000245191; GREATOREX IF, 1988, COMMUNITY MED, V10, P203; HENDRIKSEN C, 1984, BMJ-BRIT MED J, V289, P1522, DOI 10.1136/bmj.289.6457.1522; Inc S. P. S. S., 1988, SPSS X USERS GUIDE; LEWIS AF, 1981, BMJ-BRIT MED J, V283, P1217, DOI 10.1136/bmj.283.6301.1217; LUKER KA, 1982, EVALUATING HLTH VISI; Prudham D, 1981, Age Ageing, V10, P141; Townsend P., 1979, POVERTY UK; Tulloch A J, 1979, J R Coll Gen Pract, V29, P733; VETTER NJ, 1984, BRIT MED J, V288, P369, DOI 10.1136/bmj.288.6414.369; VETTER NJ, 1986, LANCET, V2, P30; 1982, HOME ACCIDENT SURVEI	14	116	117	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 4	1992	304	6831					888	890		10.1136/bmj.304.6831.888	http://dx.doi.org/10.1136/bmj.304.6831.888			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HM835	1392755	Green Published, Bronze			2022-12-28	WOS:A1992HM83500033
J	MCCLELLAND, RJ; WATSON, DR; LAWLESS, V; HOUSTON, HG; ADAMS, D				MCCLELLAND, RJ; WATSON, DR; LAWLESS, V; HOUSTON, HG; ADAMS, D			RELIABILITY AND EFFECTIVENESS OF SCREENING FOR HEARING-LOSS IN HIGH-RISK NEONATES	BRITISH MEDICAL JOURNAL			English	Article							INFANTS; NEWBORNS	Objective - To establish the reliability and effectiveness of screening for hearing loss by brainstem auditory evoked potential testing in high risk neonates. Design - Seven year investigation of newborn babies admitted to a special care baby unit and monitored through a regional children's audiology unit. Setting - Special care baby unit and children's audiology department, Belfast. Subjects - 405 neonates admitted to the baby unit, during 1 October 1982 to 31 March 1987. Main outcome measures - Presence of hearing impairment, type and severity of hearing impairment, mortality. Results - 85 children failed the screening test, 62 of whom were followed up. Five children had severe bilateral sensorineural impairment and 12 had conductive impairment requiring surgical intervention. A further 18 had severe neurological disorder detected. The sensitivity of screening was 100% and specificity was 88%. If the procedure was introduced into routine clinical practice the mean age at diagnosis for all children with severe perinatal hearing impairment would be 11 (median 1) months. The mean age at diagnosis with the health visitor screening service was 23 (19) months (difference 10 months, 95% confidence interval 6 to 16 months; p < 0-0001). Conclusion - Screening for hearing loss in high risk neonates is highly reliable and cost effective. It also provides valuable neurophysiological information. Routine testing of these infants would result in over half of all children with severe bilateral perinatal sensorineural hearing impairment being identified by 2 months of age. This would make an important contribution to the habilitation of this socially, emotionally, and educationally vulnerable group.	QUEENS UNIV BELFAST,DEPT OTORHINOLARYNGOL,BELFAST BT9 7BL,ANTRIM,NORTH IRELAND; ROYAL BELFAST HOSP SICK CHILDREN,CHILDRENS AUDIOL UNIT,BELFAST,NORTH IRELAND	Queens University Belfast	MCCLELLAND, RJ (corresponding author), QUEENS UNIV BELFAST,DEPT MENTAL HLTH,BELFAST BT9 7BL,ANTRIM,NORTH IRELAND.							DURIEUXSMITH A, 1987, AUDIOLOGY, V26, P284; GALAMBOS R, 1982, EAR HEARING, V3, P87, DOI 10.1097/00003446-198203000-00007; GERBER SE, 1978, EARLY DIAGNOSIS HEAR; HALLIDAY HL, 1989, HDB NEONATAL INTENSI; JACOBSON JT, 1986, NEONATAL HEARING SCR, P67; MARTIN JAM, 1988, DILEMMAS OTORHINOLAR, P164; MASON S M, 1988, British Journal of Audiology, V22, P211, DOI 10.3109/03005368809076454; McAllister H G, 1983, Br J Audiol, V17, P275, DOI 10.3109/03005368309081489; McClelland R J, 1983, Br J Audiol, V17, P263, DOI 10.3109/03005368309081487; MENCHER GT, 1976, EARLY IDENTIFICATION; MURRAY AD, 1985, AM J OTOLARYNG, V6, P120, DOI 10.1016/S0196-0709(85)80050-8; Northern J.L., 1984, HEARING CHILDREN, Vthird, P89; RAPIN I, 1979, ANN OTO RHINOL LARYN, V88, P3, DOI 10.1177/00034894790880S502; SIMMONS FB, 1980, LARYNGOSCOPE, V90, P448, DOI 10.1002/lary.5540900311; STEPHENS JC, 1989, ARCH DIS CHILD, V64, P1105; STEWARTBROWN S, 1987, BRIT MED J, V294, P1386, DOI 10.1136/bmj.294.6584.1386; SWIGONSKI N, 1987, EAR HEARING, V8, P26, DOI 10.1097/00003446-198702000-00005; WILD NJ, 1990, BRIT MED J, V301, P903, DOI 10.1136/bmj.301.6757.903	18	21	22	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1992	304	6830					806	809		10.1136/bmj.304.6830.806	http://dx.doi.org/10.1136/bmj.304.6830.806			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL827	1392707	Bronze, Green Accepted, Green Published			2022-12-28	WOS:A1992HL82700019
J	EDDY, DM				EDDY, DM			APPLYING COST-EFFECTIVENESS ANALYSIS - THE INSIDE STORY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OF-CONTRAST-MEDIA; ADVERSE REACTIONS; OSMOLALITY; AGENTS; CANCER		DUKE UNIV,DURHAM,NC 27706	Duke University								[Anonymous], 1992, MANUAL ASSESSING HLT; CARO JJ, 1991, AM J ROENTGENOL, V156, P825, DOI 10.2214/ajr.156.4.1825900; CURRY NS, 1991, RADIOLOGY, V178, P361, DOI 10.1148/radiology.178.2.1987593; Eddy D, 1990, JAMA-J AM MED ASSOC, V263, P389; EDDY DM, 1990, JAMA-J AM MED ASSOC, V264, P1737, DOI 10.1001/jama.264.13.1737; EDDY DM, 1992, JAMA-J AM MED ASSOC, V267, P1669, DOI 10.1001/jama.267.12.1669; EDDY DM, 1992, JAMA-J AM MED ASSOC, V267, P3342, DOI 10.1001/jama.267.24.3342; EDDY DM, 1989, ANN INTERN MED, V111, P389, DOI 10.7326/0003-4819-111-5-389; EDDY DM, 1991, JAMA-J AM MED ASSOC, V265, P105, DOI 10.1001/jama.265.1.105; EDDY DM, 1990, ANN INTERN MED, V113, P214, DOI 10.7326/0003-4819-113-3-214; EDDY DM, 1992, JAMA-J AM MED ASSOC, V268, P132, DOI 10.1001/jama.268.1.132; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P1839, DOI 10.1001/jama.263.13.1839; EDDY DM, 1992, JAMA-J AM MED ASSOC, V267, P1674; EVENS RG, 1987, RADIOLOGY, V162, P267, DOI 10.1148/radiology.162.1.3786775; GERSTMAN BB, 1991, RADIOLOGY, V178, P787, DOI 10.1148/radiology.178.3.1994419; HALL MA, 1991, L CONT PROBS, V54, P119; HIRSHFELD EB, 1990, JAMA-J AM MED ASSOC, V263, P1556; KATAYAMA H, 1990, RADIOLOGY, V175, P621, DOI 10.1148/radiology.175.3.2343107; KENT B, UNPUB IONIC NONIONIC; LASSER EC, 1987, NEW ENGL J MED, V317, P845, DOI 10.1056/NEJM198710013171401; PALMER F J, 1988, Australasian Radiology, V32, P426, DOI 10.1111/j.1440-1673.1988.tb02770.x; WOLF GL, 1989, AM J ROENTGENOL, V152, P939, DOI 10.2214/ajr.152.5.939; 1990, RESOLUTION REGARDING; 1988, ARCH INTERN MED, V148, P36	24	62	62	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1992	268	18					2575	2582		10.1001/jama.268.18.2575	http://dx.doi.org/10.1001/jama.268.18.2575			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW616	1404827				2022-12-28	WOS:A1992JW61600033
J	GRINSPOON, SK; BILEZIKIAN, JP				GRINSPOON, SK; BILEZIKIAN, JP			CURRENT CONCEPTS - HIV DISEASE AND THE ENDOCRINE SYSTEM	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; IMMUNE-DEFICIENCY-SYNDROME; HORMONE-RELATED PROTEIN; TUMOR NECROSIS FACTOR; VIRUS INFECTION; SYNDROME AIDS; INTERLEUKIN-1; MEN; HYPONATREMIA; HYPOCALCEMIA		COLUMBIA UNIV COLL PHYS & SURG, DEPT MED 9410, 630 W 168TH ST, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT PHARMACOL, NEW YORK, NY 10032 USA	Columbia University; Columbia University								ADAMS JS, 1989, BLOOD, V73, P235; AGARWAL A, 1989, NEPHRON, V53, P317, DOI 10.1159/000185774; ARON DC, 1989, ARCH INTERN MED, V149, P330, DOI 10.1001/archinte.149.2.330; AXELROD L, 1989, TXB RHEUMATOLOGY, P845; AXELROD L, 1990, PRINCIPLES PRACTICE, P613; BATTAN R, 1991, J CLIN ENDOCR METAB, V72, P724, DOI 10.1210/jcem-72-3-724; BEUTLER B, 1985, J EXP MED, V161, P984, DOI 10.1084/jem.161.5.984; BRIVET F, 1987, LANCET, V2, P570; CALKINS JH, 1988, ENDOCRINOLOGY, V123, P1605, DOI 10.1210/endo-123-3-1605; CONNOLLY KJ, 1991, AM J MED, V91, P471, DOI 10.1016/0002-9343(91)90182-W; CROXSON TS, 1989, J CLIN ENDOCR METAB, V68, P317, DOI 10.1210/jcem-68-2-317; CUSANO AJ, 1990, J ACQ IMMUN DEF SYND, V3, P949; DESAI TK, 1988, AM J MED, V84, P209, DOI 10.1016/0002-9343(88)90415-9; DINARELLO CA, 1990, ANN NY ACAD SCI, V587, P332, DOI 10.1111/j.1749-6632.1990.tb00174.x; DOBS AS, 1988, AM J MED, V84, P611, DOI 10.1016/0002-9343(88)90144-1; DODD RC, 1985, CANCER RES, V45, P2501; Donovan D, 1991, ENDOCRINOLOGIST, V1, P227; EVELY RS, 1991, J BONE MINER RES, V6, P85; GLASGOW BJ, 1985, AM J CLIN PATHOL, V84, P594, DOI 10.1093/ajcp/84.5.594; GLASS AR, 1988, J CLIN ENDOCR METAB, V66, P934, DOI 10.1210/jcem-66-5-934; GREENBERG RE, 1987, POSTGRAD MED J, V63, P677, DOI 10.1136/pgmj.63.742.677; GREENE LW, 1984, ANN INTERN MED, V101, P497, DOI 10.7326/0003-4819-101-4-497; GRIFFIN JE, 1985, AM J MED SCI, V289, P76, DOI 10.1097/00000441-198502000-00008; GRUNFELD C, 1989, AM J MED, V86, P27, DOI 10.1016/0002-9343(89)90225-8; GRUNFELD C, 1992, J CLIN ENDOCR METAB, V74, P1045, DOI 10.1210/jc.74.5.1045; GRUNFELD C, 1991, AM J MED, V90, P154, DOI 10.1016/0002-9343(91)80154-E; GRUNFELD C, 1992, NEW ENGL J MED, V327, P329, DOI 10.1056/NEJM199207303270506; HOMMES MJT, 1990, METABOLISM, V39, P1186, DOI 10.1016/0026-0495(90)90092-Q; JACOBSON MA, 1991, J CLIN ENDOCR METAB, V72, P1130, DOI 10.1210/jcem-72-5-1130; KALIN MF, 1987, AM J MED, V82, P1035, DOI 10.1016/0002-9343(87)90171-9; KOTLER DP, 1985, AM J CLIN NUTR, V42, P1255, DOI 10.1093/ajcn/42.6.1255; LAHDEVIRTA J, 1988, AM J MED, V85, P289, DOI 10.1016/0002-9343(88)90576-1; LAMBERT M, 1990, AM J MED, V89, P748, DOI 10.1016/0002-9343(90)90216-Z; LOPRESTI JS, 1989, ANN INTERN MED, V110, P970, DOI 10.7326/0003-4819-110-12-970; MEMBRENO L, 1987, J CLIN ENDOCR METAB, V65, P482, DOI 10.1210/jcem-65-3-482; MERENICH JA, 1990, J CLIN ENDOCR METAB, V70, P566, DOI 10.1210/jcem-70-3-566; MERRILL JE, 1989, J VIROL, V63, P4404, DOI 10.1128/JVI.63.10.4404-4408.1989; MEYER WJ, 1987, J CLIN ENDOCR METAB, V64, P98, DOI 10.1210/jcem-64-1-98; MORLEY JE, 1979, METABOLISM, V28, P1051, DOI 10.1016/0026-0495(79)90010-6; MOTOKURA T, 1989, ANN INTERN MED, V111, P484, DOI 10.7326/0003-4819-111-6-484; NORBIATO G, 1992, J CLIN ENDOCR METAB, V74, P608, DOI 10.1210/jc.74.3.608; OSULLIVAN P, 1985, J AM DIET ASSOC, V85, P1483; PARKER LN, 1985, J CLIN ENDOCR METAB, V60, P947, DOI 10.1210/jcem-60-5-947; PERRONNE C, 1990, DIABETIC MED, V7, P585, DOI 10.1111/j.1464-5491.1990.tb01453.x; PORETSKY L, 1990, MT SINAI J MED, V57, P236; SALIM YS, 1988, APMIS, V96, P889, DOI 10.1111/j.1699-0463.1988.tb00956.x; SAPOLSKY R, 1987, SCIENCE, V238, P522, DOI 10.1126/science.2821621; SCHWARTZ MS, 1989, AM J GASTROENTEROL, V84, P459; STRAUSS KW, 1991, ARCH INTERN MED, V151, P1441, DOI 10.1001/archinte.151.7.1441; SZEBENI J, 1991, J VIROL, V65, P6362, DOI 10.1128/JVI.65.11.6362-6364.1991; TANG WW, 1989, WESTERN J MED, V151, P627; TRACEY KJ, 1990, ANN NY ACAD SCI, V587, P325, DOI 10.1111/j.1749-6632.1990.tb00173.x; VERGES B, 1989, ACTA ENDOCRINOL-COP, V121, P633, DOI 10.1530/acta.0.1210633; VILLETTE JM, 1990, J CLIN ENDOCR METAB, V70, P572, DOI 10.1210/jcem-70-3-572; VITTING KE, 1990, JAMA-J AM MED ASSOC, V263, P973, DOI 10.1001/jama.263.7.973; WELCH K, 1984, JAMA-J AM MED ASSOC, V252, P1152, DOI 10.1001/jama.252.9.1152; WHITCOMB RW, 1988, J CLIN ENDOCR METAB, V66, P33, DOI 10.1210/jcem-66-1-33; WOLOSKI BMRNJ, 1985, SCIENCE, V230, P1035, DOI 10.1126/science.2997929; WOOLF PD, 1985, J CLIN ENDOCR METAB, V60, P444, DOI 10.1210/jcem-60-3-444; ZAKALIK D, 1991, J BONE MINER RES  S1, V1, pS234; ZALOGA GP, 1987, ANN INTERN MED, V107, P36, DOI 10.7326/0003-4819-107-1-36; 1990, MED LETT DRUGS THER, V32, P59	62	202	204	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 5	1992	327	19					1360	1365						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW077	1406838				2022-12-28	WOS:A1992JW07700006
J	BURGARD, M; MAYAUX, MJ; BLANCHE, S; FERRONI, A; GUIHARDMOSCATO, ML; ALLEMON, MC; CIRARUVIGNERON, N; FIRTION, G; FLOCH, C; GUILLOT, F; LACHASSINE, E; VIAL, M; GRISCELLI, C; ROUZIOUX, C				BURGARD, M; MAYAUX, MJ; BLANCHE, S; FERRONI, A; GUIHARDMOSCATO, ML; ALLEMON, MC; CIRARUVIGNERON, N; FIRTION, G; FLOCH, C; GUILLOT, F; LACHASSINE, E; VIAL, M; GRISCELLI, C; ROUZIOUX, C			THE USE OF VIRAL CULTURE AND P24-ANTIGEN TESTING TO DIAGNOSE HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION IN NEONATES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; INFANTS BORN; HIV-1 INFECTION; CHILDREN; TYPE-1; ANTIBODIES; PROTEINS; MOTHERS; ASSAY; FETUS	Background. Early diagnosis of human immunodeficiency virus (HIV) infection in infants born to infected mothers is important for the infants' medical care, but the presence of maternal antibodies makes serologic tests uninformative. Methods. In a cohort study of 181 infants born to HIV-infected mothers, we assessed the diagnostic value of HIV viral culture and testing for the presence of p24 antigen. The infants were tested at birth, again during the first 3 months, then followed and tested at the age of at least 18 months. Results. Of the 181 infants, 3 died of HIV infection and 37 were seropositive after the age of 18 months. Viral cultures at birth were positive in 19 of the 40 infected infants and in none of the uninfected infants, yielding a sensitivity of 48 percent (95 percent confidence interval, 32 to 63 percent) and a specificity of 100 percent (95 percent confidence interval, 97 to 1 00 percent). By the age of three months, 30 of the 40 infants (75 percent) had positive cultures; again, there were no false positive results among the infants who were tested a second time, of the 141 who remained uninfected. The sensitivity of testing for p24 antigen at birth was only 18 percent, with a specificity of 100 percent. The presence of p24 antigen at birth was associated with the development of early and severe HIV-related disease (P<0.04). Conclusions. Viral culture at birth can correctly identify about half of newborns with HIV infection. The fact that this usually sensitive technique fails to identify about half the ultimately infected neonates suggests that vertical transmission of HIV may occur late in pregnancy or during delivery.	HOP NECKER ENFANTS MALAD,MICROBIOL LAB,PARIS,FRANCE; HOP NECKER ENFANTS MALAD,IMMUNOL & HEMATOL UNIT,PARIS,FRANCE; HOP NECKER ENFANTS MALAD,INSERM,U132,PARIS,FRANCE; HOP BICETRE,INSERM,U292,F-94270 LE KREMLIN BICETR,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)								AMADORI A, 1988, LANCET, V1, P852; ARCHIBALD DW, 1990, AIDS, V4, P417, DOI 10.1097/00002030-199005000-00006; AUGER I, 1988, NATURE, V336, P575, DOI 10.1038/336575a0; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; BLANCHE S, 1990, AM J DIS CHILD, V144, P1210, DOI 10.1001/archpedi.1990.02150350042021; CANDOTTI D, 1991, AIDS, V5, P1003, DOI 10.1097/00002030-199108000-00012; CHIN J, 1990, LANCET, V336, P221, DOI 10.1016/0140-6736(90)91743-T; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; CZERKINSKY C, 1988, J IMMUNOL METHODS, V115, P31, DOI 10.1016/0022-1759(88)90306-7; DEROSSI A, 1991, AIDS, V5, P15, DOI 10.1097/00002030-199101000-00002; FEORINO P, 1987, J CLIN MICROBIOL, V25, P2344, DOI 10.1128/JCM.25.12.2344-2346.1987; GOEDERT JJ, 1991, LANCET, V338, P1471, DOI 10.1016/0140-6736(91)92297-F; JOVAISAS E, 1985, LANCET, V2, P1129; LAURE F, 1988, LANCET, V2, P538; MAINLAND D, 1956, STATISTICAL TABLES U; MARTIN NL, 1991, J PEDIATR-US, V118, P354, DOI 10.1016/S0022-3476(05)82146-8; MOK JQ, 1987, LANCET, V1, P1164; PEUCHMAUR M, 1991, AIDS, V5, P741, DOI 10.1097/00002030-199106000-00015; ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503; ROUZIOUX C, 1992, AIDS, V6, P373, DOI 10.1097/00002030-199204000-00003; ROUZIOUX C, 1991, VIRAL QUANTITATION IN HIV INFECTION, P187; SCOTT GB, 1989, NEW ENGL J MED, V321, P1791, DOI 10.1056/NEJM198912283212604; SPRECHER S, 1986, LANCET, V2, P288; WEIBLEN BJ, 1990, LANCET, V335, P988, DOI 10.1016/0140-6736(90)91061-E; WILLIAMS P, 1990, AIDS, V4, P393, DOI 10.1097/00002030-199005000-00003; 1987, MMWR MORB MORTAL WKL, V36, P225	26	167	168	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 22	1992	327	17					1192	1197		10.1056/NEJM199210223271702	http://dx.doi.org/10.1056/NEJM199210223271702			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JU393	1406792				2022-12-28	WOS:A1992JU39300002
J	GORMLEY, GJ; STONER, E; BRUSKEWITZ, RC; IMPERATOMCGINLEY, J; WALSH, PC; MCCONNELL, JD; ANDRIOLE, GL; GELLER, J; BRACKEN, BR; TENOVER, JS; VAUGHAN, ED; PAPPAS, F; TAYLOR, A; BINKOWITZ, B; NG, J				GORMLEY, GJ; STONER, E; BRUSKEWITZ, RC; IMPERATOMCGINLEY, J; WALSH, PC; MCCONNELL, JD; ANDRIOLE, GL; GELLER, J; BRACKEN, BR; TENOVER, JS; VAUGHAN, ED; PAPPAS, F; TAYLOR, A; BINKOWITZ, B; NG, J			THE EFFECT OF FINASTERIDE IN MEN WITH BENIGN PROSTATIC HYPERPLASIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							5-ALPHA-REDUCTASE INHIBITOR; MALE PSEUDOHERMAPHRODITISM; VOLUNTEERS; RESECTION; ANDROGENS; MK-906	Background. Benign prostatic hyperplasia is a progressive, androgen-dependent disease resulting in enlargement of the prostate gland and urinary obstruction. Preventing the conversion of testosterone to its tissue-active form, dihydrotestosterone, by inhibiting the enzyme 5alpha-reductase could decrease the action of androgens in their target tissues; in the prostate the result might be a decrease in prostatic hyperplasia and therefore in symptoms of urinary obstruction. Methods. In a double-blind study, we evaluated the effect of two doses of finasteride (1 mg and 5 mg) and placebo, each given once daily for 12 months, in 895 men with prostatic hyperplasia. Urinary symptoms, urinary flow, prostatic volume, and serum concentrations of dihydrotestosterone and prostate-specific antigen were determined periodically during the treatment period. Results. As compared with the men in the placebo group, the men treated with 5 mg of finasteride per day had a significant decrease in total urinary-symptom scores (P<0.001), an increase of 1.6 ml per second (22 percent, P<0.001) in the maximal urinary-flow rate, and a 19 percent decrease in prostatic volume (P<0.001). The men treated with 1 mg of finasteride per day did not have a significant decrease in total urinary-symptom scores, but had an increase of 1.4 ml per second (23 percent) in the maximal urinary-flow rate, and an 18 percent decrease in prostatic volume. The men given placebo had no changes in total urinary-symptom scores, an increase of 0.2 ml per second (8 percent) in the maximal urinary-flow rate, and a 3 percent decrease in prostatic volume. The frequency of adverse effects in the three groups was similar, except for a higher incidence of decreased libido, impotence, and ejaculatory disorders in the finasteride-treated groups. Conclusions. The treatment of benign prostatic hyperplasia with 5 mg of finasteride per day results in a significant decrease in symptoms of obstruction, an increase in urinary flow, and a decrease in prostatic volume, but at a slightly increased risk of sexual dysfunction.	UNIV WISCONSIN,MADISON,WI 53706; NEW YORK HOSP,NEW YORK,NY 10021; JOHNS HOPKINS UNIV HOSP,BALTIMORE,MD 21205; WASHINGTON UNIV,ST LOUIS,MO 63130; MERCY HOSP & MED CTR,SAN DIEGO,CA 92103; UNIV CINCINNATI,MED CTR,CINCINNATI,OH 45267; UNIV WASHINGTON,HARBORVIEW MED CTR,SEATTLE,WA 98104; UNIV TEXAS,DALLAS,TX 75230	University of Wisconsin System; University of Wisconsin Madison; NewYork-Presbyterian Hospital; Johns Hopkins University; Johns Hopkins Medicine; Washington University (WUSTL); University System of Ohio; University of Cincinnati; Harborview Medical Center; University of Washington; University of Washington Seattle; University of Texas System; University of Texas Dallas	GORMLEY, GJ (corresponding author), MERCK RES LABS,POB 2000,RAHWAY,NJ 07065, USA.							BIRKHOFF JD, 1983, BENIGN PROSTATIC HYP, P5; BOSCH RJLH, 1989, J UROLOGY, V141, P68, DOI 10.1016/S0022-5347(17)40591-X; Boyarsky S, 1976, Trans Am Assoc Genitourin Surg, V68, P29; BRUSKEWITZ RC, 1990, PROSTATE S, V3, P27; DRACH GW, 1979, J UROLOGY, V122, P210, DOI 10.1016/S0022-5347(17)56333-8; GLYNN RJ, 1985, AM J EPIDEMIOL, V121, P78; GORMLEY GJ, 1990, J CLIN ENDOCR METAB, V70, P1136, DOI 10.1210/jcem-70-4-1136; GORMLEY GJ, 1991, PROBLEMS UROLOGY, V5, P436; IMPERATO.J, 1974, SCIENCE, V186, P1213, DOI 10.1126/science.186.4170.1213; LEPOR H, 1990, J UROLOGY, V143, P533, DOI 10.1016/S0022-5347(17)40012-7; LEVINE AC, 1989, UROLOGY, V34, P10, DOI 10.1016/0090-4295(89)90147-7; PETERS CA, 1987, NEW ENGL J MED, V317, P599, DOI 10.1056/NEJM198709033171004; RASMUSSON GH, 1987, PHARM CLIN USES INHI, P308; RITTMASTER RS, 1989, J ANDROL, V10, P259; ROOS NP, 1989, NEW ENGL J MED, V320, P1120, DOI 10.1056/NEJM198904273201705; ROTKIN ID, 1983, BENIGN PROSTATIC HYP, P10; STONER E, 1992, J UROLOGY, V147, P1298, DOI 10.1016/S0022-5347(17)37547-X; STONER E, 1990, J STEROID BIOCHEM, V37, P375, DOI 10.1016/0960-0760(90)90487-6; SUSSET JG, 1983, BENIGN PROSTATIC HYP, P528; WALSH PC, 1974, NEW ENGL J MED, V291, P944, DOI 10.1056/NEJM197410312911806	20	910	931	0	25	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 22	1992	327	17					1185	1191		10.1056/NEJM199210223271701	http://dx.doi.org/10.1056/NEJM199210223271701			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JU393	1383816				2022-12-28	WOS:A1992JU39300001
J	HERRMANN, N				HERRMANN, N			NO BETTER OR WISER, JUST BRAVER AND SICKER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 21	1992	268	15					2102	2102						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT520	1404750				2022-12-28	WOS:A1992JT52000038
J	RUBINOW, DR				RUBINOW, DR			THE PREMENSTRUAL-SYNDROME - NEW VIEWS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PLASMA BETA-ENDORPHIN; MENSTRUAL-CYCLE; MOOD DISORDER; WOMEN; TENSION; OVARIECTOMY; DEPRESSION; RESPONSES; SYMPTOMS; PHASE		NIMH,BIOL PSYCHIAT BRANCH,BEHAV ENDOCRINOL SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)								ASHBY CR, 1988, BIOL PSYCHIAT, V24, P225, DOI 10.1016/0006-3223(88)90277-6; BANCROFT J, 1991, PSYCHOL MED, V21, P305, DOI 10.1017/S0033291700020407; CASPER RF, 1990, AM J OBSTET GYNECOL, V162, P105, DOI 10.1016/0002-9378(90)90831-Q; CASSON P, 1990, AM J OBSTET GYNECOL, V162, P99, DOI 10.1016/0002-9378(90)90830-Z; CHUONG CJ, 1985, FERTIL STERIL, V44, P760; FACCHINETTI F, 1987, FERTIL STERIL, V47, P570; FACCHINETTI F, 1990, PSYCHONEUROENDOCRINO, V15, P269, DOI 10.1016/0306-4530(90)90077-M; HAMILTON JA, 1988, PSYCHONEUROENDOCRINO, V13, P505, DOI 10.1016/0306-4530(88)90036-4; LEE KA, 1990, SLEEP, V13, P403; MALMGREN R, 1987, NEUROPSYCHOBIOLOGY, V18, P83, DOI 10.1159/000118398; MUSE KN, 1984, NEW ENGL J MED, V311, P1345, DOI 10.1056/NEJM198411223112104; PADDISON PL, 1990, PSYCHOSOMATICS, V31, P265, DOI 10.1016/S0033-3182(90)72162-7; PARRY BL, 1989, PSYCHIAT RES, V30, P285, DOI 10.1016/0165-1781(89)90020-6; PARRY BL, 1990, ARCH GEN PSYCHIAT, V47, P1139; PORRINO LJ, 1987, 26TH ANN M AM COLL N, P18; RABIN DS, 1990, J CLIN ENDOCR METAB, V71, P1158, DOI 10.1210/jcem-71-5-1158; REAME NE, IN PRESS PSYCHONEURO; REID RL, 1986, FERTIL STERIL, V46, P738; RIVERATOVAR AD, 1990, AM J PSYCHIAT, V147, P1634; ROSENSTEIN DL, 1982, 145TH ANN M AM PSYCH; ROYBYRNE PP, 1987, AM J PSYCHIAT, V144, P480, DOI 10.1176/ajp.144.4.480; RUBINOW DR, 1988, AM J OBSTET GYNECOL, V158, P5, DOI 10.1016/0002-9378(88)90765-X; RUBINOW DR, 1984, AM J PSYCHIAT, V141, P684; SCHACHTER S, 1962, PSYCHOL REV, V69, P379, DOI 10.1037/h0046234; SCHMIDT PJ, 1990, J CLIN PSYCHIAT, V51, P434; SCHMIDT PJ, 1991, NEW ENGL J MED, V324, P1174, DOI 10.1056/NEJM199104253241705; Schnurr PP, 1989, PSYCHOL ASSESSMENT, V1, P277; SHERWOOD RA, 1986, ANN CLIN BIOCHEM, V23, P667, DOI 10.1177/000456328602300607; STONE AB, 1990, PSYCHOPHARMACOL BULL, V26, P331; TAYLOR DL, 1984, NEUROPSYCHOBIOLOGY, V12, P16, DOI 10.1159/000118103; TULENHEIMO A, 1987, BRIT J OBSTET GYNAEC, V94, P26, DOI 10.1111/j.1471-0528.1987.tb02247.x; VEENINGA AT, IN PRESS PSYCHOPHARM; WEISS SRB, 1989, PHARMACOL BIOCHEM BE, V34, P655, DOI 10.1016/S0091-3057(89)80001-2; 1987, DIAGNOSTIC STATISTIC; 1983, NIMH PREMENSTRUAL SY	35	26	27	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1992	268	14					1908	1912		10.1001/jama.268.14.1908	http://dx.doi.org/10.1001/jama.268.14.1908			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR439	1404717				2022-12-28	WOS:A1992JR43900042
J	NIGHTINGALE, SL				NIGHTINGALE, SL			DRUG APPROVED TO TREAT BENIGN PROSTATIC HYPERPLASIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	8	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 16	1992	268	11					1390	1390						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM849	1380995				2022-12-28	WOS:A1992JM84900004
J	POPE, C				POPE, C			CUTTING QUEUES OR CUTTING CORNERS - WAITING LISTS AND THE 1990 NHS REFORMS	BRITISH MEDICAL JOURNAL			English	Article											POPE, C (corresponding author), ST THOMAS HOSP,DEPT PUBL HLTH MED,CONFERENCE JOINT MED ROYAL COLL & THEIR FAC,LONDON SE1 7EH,ENGLAND.			Pope, Catherine/0000-0002-8935-6702				Amos D, 1989, Health Serv J, V99, P788; [Anonymous], 1992, BMJ-BRIT MED J, V304, P57; BUTTERY RB, 1979, BRIT MED J, V2, P403, DOI 10.1136/bmj.2.6186.403; BUTTERY RB, 1980, HLTH TRENDS, V12, P57; Frankel S, 1989, Health Trends, V21, P56; FROST CEB, 1979, SOC SCI MED-MED SOC, V13, P193; Maynard A, 1984, Br Med J (Clin Res Ed), V288, P1849; POPE C, 1991, SOC HLTH ILLNESS, V13, P194; ROLAND M, 1989, BMJ, V297, P599; WENNBERG JE, 1982, SOC SCI MED, V16, P811, DOI 10.1016/0277-9536(82)90234-9; YATES J, 1991, BRIT MED J, V303, P802, DOI 10.1136/bmj.303.6806.802; 1992, BMJ, V304, P705; 1991, PATIENTS CHARTER; 1986, HOSPITAL MED STAFFIN; 1992, BMJ, V304, P1385; 1990, NHS REFORMS 1ST 6 MO; 1985, ORTHOPAEDIC SERVICES; 1991, GUIDE HOSPITAL WAITI	18	12	13	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 5	1992	305	6853					577	579		10.1136/bmj.305.6853.577	http://dx.doi.org/10.1136/bmj.305.6853.577			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM495	1393041	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992JM49500025
J	CHIPEV, CC; KORGE, BP; MARKOVA, N; BALE, SJ; DIGIOVANNA, JJ; COMPTON, JG; STEINERT, PM				CHIPEV, CC; KORGE, BP; MARKOVA, N; BALE, SJ; DIGIOVANNA, JJ; COMPTON, JG; STEINERT, PM			A LEUCINE-]PROLINE MUTATION IN THE H1 SUBDOMAIN OF KERATIN-1 CAUSES EPIDERMOLYTIC HYPERKERATOSIS	CELL			English	Article							1/KERATIN-10 INTERMEDIATE FILAMENTS; COILED-COIL; BULLOSA SIMPLEX; INVITRO; GENE; PHOSPHORYLATION; ABNORMALITIES; ORGANIZATION; HETERODIMER; ICHTHYOSES	Epidermolytic hyperkeratosis is an autosomal dominant disorder affecting the structural integrity of the suprabasal layers of human epidermis. We have recently documented in one family linkage of the disease phenotype to the cluster of type II keratins. We have now identified a leucine-->proline amino acid substitution in the conserved H1 subdomain of keratin 1 that is present only in affected family members. Using a quantitative assay and electron microscopy with synthetic peptides, we show that, whereas the wild-type H1 peptide rapidly disassembles preformed keratin filaments in vitro, the mutant peptide does this far less efficiently. Therefore the mutation in keratin 1 is likely to cause defective keratin filaments and hence a defective cytoskeleton in the epidermal cells in vivo.	NCI,DERMATOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	CHIPEV, CC (corresponding author), NIAMSD,SKIN BIOL BRANCH,BETHESDA,MD 20892, USA.			DiGiovanna, John J./0000-0002-2750-2313				AEBI U, 1983, J CELL BIOL, V97, P1131, DOI 10.1083/jcb.97.4.1131; ANTONLAMPRECHT I, 1983, J INVEST DERMATOL, V81, pS149, DOI 10.1111/1523-1747.ep12540961; BONIFAS JM, 1991, SCIENCE, V254, P1202, DOI 10.1126/science.1720261; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; COMPTON JG, 1992, NAT GENET, V1, P301, DOI 10.1038/ng0792-301; COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FUCHS E, 1992, CELL, V69, P899, DOI 10.1016/0092-8674(92)90607-E; GAN SQ, 1990, BIOCHEMISTRY-US, V29, P9432, DOI 10.1021/bi00492a018; HATZFELD M, 1992, J CELL BIOL, V116, P157, DOI 10.1083/jcb.116.1.157; HATZFELD M, 1985, J CELL BIOL, V101, P1826, DOI 10.1083/jcb.101.5.1826; HATZFELD M, 1990, J CELL BIOL, V110, P1199, DOI 10.1083/jcb.110.4.1199; HOHL D, 1991, J BIOL CHEM, V266, P6626; ISHIDAYAMAMOTO A, 1992, J INVEST DERMATOL, V99, P19, DOI 10.1111/1523-1747.ep12611391; JOHNSON LD, 1985, P NATL ACAD SCI USA, V82, P1896, DOI 10.1073/pnas.82.7.1896; KORGE BP, 1992, P NATL ACAD SCI USA, V89, P910, DOI 10.1073/pnas.89.3.910; LANE EB, 1992, NATURE, V356, P244, DOI 10.1038/356244a0; MACK JW, 1988, BIOCHEMISTRY-US, V27, P5418, DOI 10.1021/bi00415a006; OGAWA H, 1979, ARCH DERMATOL RES, V266, P109, DOI 10.1007/BF00694618; PARRY D A D, 1992, Current Opinion in Cell Biology, V4, P94, DOI 10.1016/0955-0674(92)90064-J; PETER M, 1991, EMBO J, V10, P1535, DOI 10.1002/j.1460-2075.1991.tb07673.x; Resing K.A., 1991, PHYSL BIOCH MOL BIOL, V1, P148; SAMBROOK E, 1989, MOL CLONING LABORATO; SOMMER SS, 1992, BIOTECHNIQUES, V12, P82; STEINERT PM, 1976, J MOL BIOL, V108, P547, DOI 10.1016/S0022-2836(76)80136-2; STEINERT PM, 1991, J STRUCT BIOL, V107, P175, DOI 10.1016/1047-8477(91)90020-W; STEINERT PM, 1990, J BIOL CHEM, V265, P8766; STEINERT PM, 1990, CELL, V60, P521, DOI 10.1016/0092-8674(90)90651-T; STEINERT PM, 1988, J BIOL CHEM, V263, P13333; STEINERT PM, 1991, J STRUCT BIOL, V107, P157, DOI 10.1016/1047-8477(91)90019-S; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STEINERT PM, 1991, INT J BIOL MACROMOL, V13, P130, DOI 10.1016/0141-8130(91)90037-U; STEINERT PM, 1975, BIOCHEM J, V151, P603, DOI 10.1042/bj1510603; STEINERT PM, 1985, J BIOL CHEM, V260, P7442; SUN TT, 1984, CANCER CELL TRANSFOR, P167; Wanner R, 1992, PCR Methods Appl, V1, P193; WILLIAMS ML, 1987, DERMATOL CLIN, V5, P155, DOI 10.1016/S0733-8635(18)30772-1	37	253	267	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 4	1992	70	5					821	828		10.1016/0092-8674(92)90315-4	http://dx.doi.org/10.1016/0092-8674(92)90315-4			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JL663	1381288				2022-12-28	WOS:A1992JL66300013
J	MALMBERG, AB; YAKSH, TL				MALMBERG, AB; YAKSH, TL			HYPERALGESIA MEDIATED BY SPINAL GLUTAMATE OR SUBSTANCE-P RECEPTOR BLOCKED BY SPINAL CYCLOOXYGENASE INHIBITION	SCIENCE			English	Article							ASPIRIN-LIKE DRUGS; EXCITATORY AMINO-ACIDS; PROSTAGLANDIN SYNTHESIS; ARACHIDONIC-ACID; NEURONS; RAT; ACTIVATION; CORD; SENSITIZATION; STIMULATION	Inhibition of cyclooxygenase by nonsteroidal anti-inflammatory drugs (NSAIDs) in the periphery is commonly accepted as the primary mechanism by which these agents produce a selective attenuation of pain (analgesia). NSAIDs are now shown to exert a direct spinal action by blocking the excessive sensitivity to pain (hyperalgesia) induced by the activation of spinal glutamate and substance P receptors. These findings demonstrate that the analgesic effects of NSAIDs can be dissociated from their anti-inflammatory actions. Spinal prostanoids are thus critical for the augmented processing of pain information at the spinal level.			MALMBERG, AB (corresponding author), UNIV CALIF SAN DIEGO, DEPT ANESTHESIOL 0818, LA JOLLA, CA 92093 USA.		Yaksh, Tony/D-4119-2009		NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002110] Funding Source: NIH RePORTER; NIDA NIH HHS [DA02110] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AANONSEN LM, 1990, PAIN, V41, P309, DOI 10.1016/0304-3959(90)90008-2; AANONSEN LM, 1991, PAIN, V131, P71; BRUNE K, 1991, EXPERIENTIA, V47, P257, DOI 10.1007/BF01958153; CODERRE TJ, 1991, NEUROSCI LETT, V131, P71, DOI 10.1016/0304-3940(91)90339-U; DICKENSON AH, 1987, NEUROSCI LETT, V83, P207, DOI 10.1016/0304-3940(87)90242-4; DOUGHERTY PM, 1991, BRAIN RES, V542, P15, DOI 10.1016/0006-8993(91)90991-4; DROWER EJ, 1987, EUR J PHARMACOL, V133, P249, DOI 10.1016/0014-2999(87)90020-3; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; FERREIRA SH, 1973, BRIT J PHARMACOL, V49, P86, DOI 10.1111/j.1476-5381.1973.tb08270.x; GUZMAN F, 1964, ARCH INT PHARMACOD T, V149, P571; HAGEN AA, 1977, STROKE, V8, P672, DOI 10.1161/01.STR.8.6.672; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; HEAPY C G, 1987, British Journal of Pharmacology, V90, p164P; Janis RA, 1987, ADV DRUG RES, V16, P309; KURAISHI Y, 1989, NEUROSCIENCE, V30, P241, DOI 10.1016/0306-4522(89)90369-2; Lim R K, 1970, Annu Rev Physiol, V32, P269, DOI 10.1146/annurev.ph.32.030170.001413; LIM RKS, 1964, ARCH INT PHARMACOD T, V152, P25; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MALMBERG AB, 1977, PAIN, V4, P161; MALMBERG AB, IN PRESS J PHARM EXP; MARRIOTT D, 1991, ADV PROSTAG THROMB L, V21, P739; MCCORMACK K, 1991, DRUGS, V41, P533, DOI 10.2165/00003495-199141040-00003; MONCADA S, 1979, INFLAMMATION HDB EXP, P588; NICOL GD, 1992, J NEUROSCI, V12, P1917; PELLERIN L, 1991, NEUROCHEM RES, V16, P983, DOI 10.1007/BF00965841; RAMWELL PW, 1966, AM J PHYSIOL, V211, P998, DOI 10.1152/ajplegacy.1966.211.4.998; SCHAIBLE HG, 1988, J PHYSIOL-LONDON, V403, P91, DOI 10.1113/jphysiol.1988.sp017240; SKILLING SR, 1988, J NEUROCHEM, V51, P127, DOI 10.1111/j.1471-4159.1988.tb04845.x; SORKIN LS, UNPUB; TAIWO YO, 1986, BRAIN RES, V373, P81, DOI 10.1016/0006-8993(86)90317-3; TALLARIDA RJ, 1987, MANUAL PHARM CALCULA, P137; UDA R, 1990, BRAIN RES, V510, P26, DOI 10.1016/0006-8993(90)90723-O; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; WOOD PL, 1984, ANALGESICS NEUROCHEM, P175; WOOLF CJ, 1991, PAIN, V44, P293, DOI 10.1016/0304-3959(91)90100-C; YAKSH TL, 1976, PHYSIOL BEHAV, V17, P1031, DOI 10.1016/0031-9384(76)90029-9; YAKSH TL, 1982, ACETYLSALICYLIC ACID, P137; YAMAMOTO T, 1991, LIFE SCI, V49, P1955, DOI 10.1016/0024-3205(91)90637-Q; YAMAMOTO T, IN PRESS ANESTHESIOL	39	520	532	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 28	1992	257	5074					1276	1279		10.1126/science.1381521	http://dx.doi.org/10.1126/science.1381521			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1381521				2022-12-28	WOS:A1992JL05000033
J	SNOWISE, NG				SNOWISE, NG			GENERAL-PRACTICE PARTNERSHIPS - TILL DEATH US DO PART	BRITISH MEDICAL JOURNAL			English	Article							PRACTITIONERS; APPOINTMENT; MOBILITY	Objectives-To investigate applications for general practice partnership vacancies by established general practitioner principals, the reasons for changing partnerships, and the disincentives to these moves. Design-Confidential Postal questionnaire. Subjects-Applicants to 367 general practices in the United Kingdom advertising for a new full time partner. Main outcome measures-The proportion of job applications containing at least one application from established principals, proportion of principals appointed as new partners, incentives and disincentives to changing partnership. Results-Of 325 replies (89% response rate) received, 292 were suitable for further analysis. 210/241 (87%) of all applications contained some applications from at least one established principal. 12% of all applications were made by principals. 41/296 (14%) of the newly appointed partners had previously been an established principal. The main reasons for leaving the previous partnership were a desire to move locality or not getting on with previous partners. The disincentives to changing partnerships were largely financial, including the cost of the move and loss of income. Conclusions-It is possible for established principals in general practice to overcome the disincentives and to change partnerships. There did not seem to be any overall prejudice against appointing principals, in contrast to previously published views.					Snowise, Neil/AAX-7339-2021					KEY I, 1985, BRIT MED J, V291, P451, DOI 10.1136/bmj.291.6493.451; KING J, 1990, BRIT MED J, V301, P1258, DOI 10.1136/bmj.301.6763.1258; MACLEOD JAJ, 1987, BRIT MED J, V295, P54, DOI 10.1136/bmj.295.6589.54-a; RICHARDS C, 1991, BMJ, V30, P827; SIDE CD, 1987, BRIT MED J, V294, P1265, DOI 10.1136/bmj.294.6582.1265	5	6	6	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 15	1992	305	6850					398	400		10.1136/bmj.305.6850.398	http://dx.doi.org/10.1136/bmj.305.6850.398			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK314	1392922	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JK31400017
J	KOCH, MC; STEINMEYER, K; LORENZ, C; RICKER, K; WOLF, F; OTTO, M; ZOLL, B; LEHMANNHORN, F; GRZESCHIK, KH; JENTSCH, TJ				KOCH, MC; STEINMEYER, K; LORENZ, C; RICKER, K; WOLF, F; OTTO, M; ZOLL, B; LEHMANNHORN, F; GRZESCHIK, KH; JENTSCH, TJ			THE SKELETAL-MUSCLE CHLORIDE CHANNEL IN DOMINANT AND RECESSIVE HUMAN MYOTONIA	SCIENCE			English	Article							GENERALIZED MYOTONIA; CL CONDUCTANCE; DYSTROPHY; EXPRESSION; ASSIGNMENT; POTASSIUM; LINKAGE; BECKER; SODIUM; CDNA	Autosomal recessive generalized myotonia (Becker's disease) (GM) and autosomal dominant myotonia congenita (Thomsen's disease) (MC) are characterized by skeletal muscle stiffness that is a result of muscle membrane hyperexcitability. For both diseases, alterations in muscle chloride or sodium currents or both have been observed. A complementary DNA for a human skeletal muscle chloride channel (CLC-1) was cloned, physically localized on chromosome 7, and linked to the T cell receptor-beta (TCRB) locus. Tight linkage of these two loci to GM and MC was found in German families. An unusual restriction site in the CLC-1 locus in two GM families identified a mutation associated with that disease, a phenylalanine-to-cysteine substitution in putative transmembrane domain D8. This suggests that different mutations in CLC-1 may cause dominant or recessive myotonia.	UNIV HAMBURG,CTR MOLEC NEUROBIOL,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY; UNIV MARBURG,HUMAN GENET MED CTR,W-3550 MARBURG,GERMANY; UNIV WURZBURG,W-8700 WURZBURG,GERMANY; UNIV GOTTINGEN,INST HUMAN GENET,W-3400 GOTTINGEN,GERMANY; TECH UNIV MUNICH,W-8000 MUNICH 2,GERMANY	University of Hamburg; Philipps University Marburg; University of Wurzburg; University of Gottingen; Technical University of Munich				Jentsch, Thomas/0000-0002-3509-2553				BAUER CK, 1991, P NATL ACAD SCI USA, V88, P11052, DOI 10.1073/pnas.88.24.11052; Becker PE, 1977, MYOTONIA CONGENITA S; BRETAG AH, 1987, PHYSIOL REV, V67, P618, DOI 10.1152/physrev.1987.67.2.618; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; EIBERG H, 1983, CLIN GENET, V24, P159; FRANKE C, 1990, J PHYSIOL-LONDON, V425, P391, DOI 10.1113/jphysiol.1990.sp018110; FRANKE C, 1991, MUSCLE NERVE, V14, P762, DOI 10.1002/mus.880140811; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; GISSELMANN G, 1989, EMBO J, V8, P2359, DOI 10.1002/j.1460-2075.1989.tb08364.x; HARLEY HG, 1991, AM J HUM GENET, V49, P68; Iaizzo P A, 1991, Neuromuscul Disord, V1, P47, DOI 10.1016/0960-8966(91)90042-Q; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; JOBS A, 1990, HUM GENET, V84, P147; LEHMANNHORN F, 1990, MUSCLE NERVE, V13, P528, DOI 10.1002/mus.880130609; LIPICKY RJ, 1971, J CLIN INVEST, V50, P2091, DOI 10.1172/JCI106703; RICKER K, 1990, ARCH NEUROL-CHICAGO, V47, P268, DOI 10.1001/archneur.1990.00530030034012; RUDEL R, 1989, MUSCLE NERVE, V12, P281; RUDEL R, 1988, MUSCLE NERVE, V11, P202, DOI 10.1002/mus.880110303; RUDEL R, 1985, PHYSIOL REV, V65, P310, DOI 10.1152/physrev.1985.65.2.310; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; STEINMEYER K, 1991, NATURE, V354, P304, DOI 10.1038/354304a0; STEINMEYER K, UNPUB; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; Thomsen, 1876, ARCH PSYCHIAT NERVEN, V6, P702, DOI DOI 10.1007/BF02164912; YANAGI Y, 1984, NATURE, V308, P145, DOI 10.1038/308145a0	25	628	638	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 7	1992	257	5071					797	800		10.1126/science.1379744	http://dx.doi.org/10.1126/science.1379744			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG851	1379744				2022-12-28	WOS:A1992JG85100035
J	LINDBERG, G; RASTAM, L; GULLBERG, B; EKLUND, GA				LINDBERG, G; RASTAM, L; GULLBERG, B; EKLUND, GA			LOW SERUM-CHOLESTEROL CONCENTRATION AND SHORT-TERM MORTALITY FROM INJURIES IN MEN AND WOMEN	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; ALCOHOL-CONSUMPTION; DEATH; RISK	Objective-To determine whether total serum cholesterol concentration predicts mortality from injuries including suicide. Design-Cohort study of men and women who had their serum cholesterol concentration measured as part of a general health survey in Varmland, Sweden in 1964 or 1965 and were followed up for an average of 20.5 years. Subjects-Adults participating in health screening in 1964-5 (26 693 men and 27 692 women). The study sample was restricted to subjects aged 45-74 years during any of the 20.5 years of follow up. Main outcome measures-Serum cholesterol concentration. Deaths from all injuries and suicides during three periods of follow up (0-6 years, 7-13 years, and 14-21 years) according to the Swedish mortality register in subjects aged 45-74. Adjustment was made for prevalent cancer (identified from the Swedish cancer register) at the time of a suicide. Results-A strong negative relation between cholesterol concentration and mortality from injuries was found in men during the first seven years of follow up. The relative risk in the lowest 25% of the cholesterol distribution was 2.8 (95% confidence interval 1.52 to 4.96) compared with the top 25%. Most of the excess risk was caused by suicide with a corresponding relative risk of 4.2 (p for trend=0.001). Correction for prevalent cancer did not change the results. Events occurring during the latter two thirds of the 20.5 years of follow up were not predicted. In women no relation between cholesterol concentration and mortality from injuries was found. Conclusions-Together with observations from intervention trials the findings support the existence of a relation between serum cholesterol concentration and suicide. The causality of such a relation is, however, not resolved.	UNIV LUND,DEPT COMMUNITY HLTH SCI,S-21401 MALMO,SWEDEN; KAROLINSKA HOSP,RADIUM HEMMET,DEPT CANC EPIDEMIOL,S-10401 STOCKHOLM,SWEDEN	Lund University; Karolinska Institutet; Karolinska University Hospital	LINDBERG, G (corresponding author), CTR PUBL HLTH RES,S-65182 KARLSTAD,SWEDEN.							BOLANDER AM, 1981, MED ASPECTS MORTALIT; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FRIEDMAN LA, 1986, AM J EPIDEMIOL, V124, P481, DOI 10.1093/oxfordjournals.aje.a114418; GORDON T, 1986, ARCH INTERN MED, V146, P262, DOI 10.1001/archinte.146.2.262; HATCH FT, 1966, CIRCULATION, V33, P679, DOI 10.1161/01.CIR.33.5.679; JENKINS CD, 1969, PSYCHOSOM MED, V31, P115; KAPLAN JR, 1990, PSYCHOSOM MED, V52, P226; LINDBERG G, 1991, BRIT MED J, V302, P143, DOI 10.1136/bmj.302.6769.143; LINDBERG G, 1992, INT J EPIDEMIOL, V21, P253, DOI 10.1093/ije/21.2.253; MATTSSON B, 1984, ACTA RADIOL ONCOL, V23, P305, DOI 10.3109/02841868409136026; McCullagh P., 1989, GENERALIZED LINEAR M, DOI DOI 10.1007/978-1-4899-3242-6; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; PEKKANEN J, 1989, ARCH INTERN MED, V149, P1589, DOI 10.1001/archinte.149.7.1589; SMITH GD, 1992, BMJ-BRIT MED J, V304, P431, DOI 10.1136/bmj.304.6824.431; SMITH GD, 1990, BRIT MED J, V301, P552; TORNBERG SA, 1989, JNCI-J NATL CANCER I, V81, P1917, DOI 10.1093/jnci/81.24.1917; VIRKKUNEN M, 1979, NEUROPSYCHOBIOLOGY, V5, P27, DOI 10.1159/000117660; VIRKKUNEN M, 1984, BIOL PSYCHIAT, V19, P435; ZAK B, 1954, AM J CLIN PATHOL, V24, P1307, DOI 10.1093/ajcp/24.11_ts.1307; 1967, MANUAL INT STATISTIC; 1984, JAMA-J AM MED ASSOC, V251, P351	22	197	198	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1992	305	6848					277	279		10.1136/bmj.305.6848.277	http://dx.doi.org/10.1136/bmj.305.6848.277			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG740	1392858	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JG74000015
J	TUNSTALLPEDOE, H				TUNSTALLPEDOE, H			VALUE OF THE DUNDEE CORONARY RISK-DISK - A DEFENSE	BRITISH MEDICAL JOURNAL			English	Article							HEART-DISEASE; MANAGEMENT; MORTALITY; MEN				TUNSTALLPEDOE, H (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,CARDIOVASC EPIDEMIOL UNIT,DUNDEE DD1 9SY,SCOTLAND.							Gore, 1987, HLTH LIFESTYLE SURVE; JARRETT RJ, 1982, BRIT MED J, V285, P535, DOI 10.1136/bmj.285.6341.535; KANNEL WB, 1986, AM HEART J, V112, P825, DOI 10.1016/0002-8703(86)90481-3; POULTER N, 1991, AM HEART J, V121, P246, DOI 10.1016/0002-8703(91)90851-8; Shaper A G, 1987, Health Trends, V19, P37; SMITH WCS, 1989, SCOT MED J, V34, P550, DOI 10.1177/003693308903400603; TUNSTALLPEDOE H, 1989, BMJ-BRIT MED J, V298, P1593, DOI 10.1136/bmj.298.6688.1593; TUNSTALLPEDOE H, 1991, BRIT MED J, V303, P744, DOI 10.1136/bmj.303.6805.744; WILSON PWF, 1987, AM J CARDIOL, V59, P91; 1991, BMJ, V303, P748; 1991, BMJ, V302, P1057; 1990, DIETARY NUTRITIONAL	12	6	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1992	305	6847					231	232		10.1136/bmj.305.6847.231	http://dx.doi.org/10.1136/bmj.305.6847.231			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG112	1392830	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992JG11200028
J	RENWICK, DS; CHANDRAKER, A; BANNISTER, P				RENWICK, DS; CHANDRAKER, A; BANNISTER, P			LESSON OF THE WEEK - MISSED NEUROLEPTIC MALIGNANT SYNDROME	BRITISH MEDICAL JOURNAL			English	Article							HYPERTHERMIA				RENWICK, DS (corresponding author), MANCHESTER ROYAL INFIRM,ROBERT BARNES MED UNIT,MANCHESTER M13 9WL,LANCS,ENGLAND.		Chandraker, Anil/L-3908-2019	Chandraker, Anil/0000-0001-9729-7717				ADNET PJ, 1989, ACTA ANAESTH SCAND, V33, P676, DOI 10.1111/j.1399-6576.1989.tb02990.x; CAROFF S, 1983, LANCET, V1, P244; EBADI M, 1990, GEN PHARMACOL-VASC S, V21, P367, DOI 10.1016/0306-3623(90)90685-F; GUZE BH, 1985, NEW ENGL J MED, V313, P163, DOI 10.1056/NEJM198507183130306; HENDERSON VW, 1981, NEUROLOGY, V31, P132, DOI 10.1212/WNL.31.2.132; KELLAM AMP, 1987, BRIT J PSYCHIAT, V150, P752, DOI 10.1192/bjp.150.6.752; LEVENSON JL, 1985, AM J PSYCHIAT, V142, P1137; ROSENBERG MR, 1989, ARCH INTERN MED, V149, P1927, DOI 10.1001/archinte.149.9.1927	8	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1992	304	6830					831	832		10.1136/bmj.304.6830.831	http://dx.doi.org/10.1136/bmj.304.6830.831			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HL827	1392715	Green Published, Bronze			2022-12-28	WOS:A1992HL82700030
